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ABSTRACT 
 
SYNTHESIS OF SUBTYPE SELECTIVE Bz/GABAA RECEPTOR LIGANDS FOR THE 
TREATMENT OF ANXIETY, EPILEPSY AND NEUROPATHIC PAIN, AS WELL AS 
SCHIZOPHRENIA AND ASTHMA 
 
by 
Michael M. Poe 
The University of Wisconsin-Milwaukee, 2016 
Under the Supervision of Professor James M. Cook 
 
 The α2/α3 subtype selective Bz/GABAA receptor positive allosteric modulator HZ-166 (3) 
has been shown to be a nonsedating anxiolytic with anticonvulsant and antihyperalgesic activity. 
However, instability in vitro and in vivo has hindered its advancement into clinical trials. A series 
of ligands based on HZ-166 (3) were synthesized. Many of these ligands were designed to increase 
metabolic stability, while others were synthesized to study the effects that electronics and sterics 
have on the efficacy exerted when bound to the GABAA receptor. The α3 subtype selective methyl 
ester MP-III-024 (19) was shown to have increased resistance to metabolism in in vitro liver 
microsomal studies and exhibited significant anxiolytic and antihyperalgesic effects in mice 
iii 
 
without showing signs of sedation. However, pharmacokinetic studies indicated that esters as a 
functional group may not be suitable for extensive preclinical studies. 
 A series of heterocyclic bioisosteres were synthesized to specifically overcome short half-
lives in vivo. The oxadiazole MP-III-080 (34) and oxazole KRM-II-81 (36) underwent 
pharmacokinetic studies and were both found to exist in plasma and brain samples at high levels. 
These results indicated these and related heterocycles would be stable in vivo to undergo extensive 
preclinical trials. A dozen ligands were assessed in vivo in an anxiolytic marble burying assay as 
well as a rotarod assay designed to measure ataxic effects. The results from these studies and other 
in vitro protocols led to additional studies using KRM-II-81 (36). This oxazole 36 was found to 
exhibit significant anxiolytic and anticonvulsant properties, including reducing network firing rate 
frequency in human brain tissue from a patient suffering from resistance epilepsy. In addition, 
KRM-II-81 (36) was found to be more efficacious than gabapentin in reversing the effects of 
hyperalgesia in a neuropathic pain model at a lower dose than gabapentin in rats, as well as 
exhibiting antidepressant-like effects. 
 The α5 GABAA receptor subtype has been linked to cognitive disorders in such diseases 
as schizophrenia, bipolar I disorder and major depressive disorder. The enantiomers SH-053-2'F-
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S-CH3 (51) and SH-053-2'F-R-CH3 (52) have been shown to be α2/α3/α5- and α5- subtype 
selective agonists, respectively. Both ligands (S)-51 and (R)-52 have been shown to reduce some 
positive symptoms of schizophrenia; the S-enantiomer 51 was active in the poly(I:C) model of 
schizophrenia, while the R-enantiomer 52 was active in the MAM-model of schizophrenia. Due to 
the high rate of comorbidity of schizophrenia with anxiety, epilepsy and depression, the S-
enantiomer (51) was shown herein to be useful in these instances because it exhibited both 
anxiolytic and anticonvulsant properties. In addition, work on analogs of 52 produced MP-III-004 
(63), an α5 subtype selective ligand with reduced efficacy at the α1, α2 and α3 subtypes as 
compared to 52, as well as the very potent α5 positive allosteric modulator MP-III-022 (65). This 
methyl amide 65 was shown to activate α5 subtypes in vivo in rats at low concentrations, providing 
a valuable tool to study the α5 GABAA receptor subtype. Recent work has shown that R-(52) and 
MP-III-022 (65) exert antidepressant-like effects in mice, indicating a new use for α5 subtype 
selective ligands. Moreover, work by Emala et al. has discovered a use for α5 subtype selective 
ligands outside of the central nervous system. Numerous ligands, especially the α5 subtype 
selective acid 73, presented herein have been shown to relax precontracted human and guinea pig 
airway smooth muscle and could provide a novel treatment for those who suffer from asthma. 
v 
 
TABLE OF CONTENTS 
LIST OF FIGURES .................................................................................................................... xv 
LIST OF TABLES .................................................................................................................... xxv 
LIST OF SCHEMES .............................................................................................................. xxvii 
LIST OF ABBREVIATIONS ............................................................................................... xxviii 
1 INTRODUCTION................................................................................................................. 1 
1.1 The GABAA Receptor ......................................................................................................... 1 
1.2 Benzodiazepines .................................................................................................................. 4 
1.3 Pharmacology of the GABAAR and Agonistic Effects at Various Subtypes ................. 6 
2 MOLECULAR MODELING ............................................................................................ 11 
2.1 Background ....................................................................................................................... 11 
2.2 Halogen-Acetylene Switch ................................................................................................ 13 
3 DESIGN OF α2/α3 SUBTYPE SELECTIVE LIGANDS AND THEIR USE IN 
EPILEPSY, ANXIETY AND NEUROPATHIC AND INFLAMMATORY PAIN .............. 16 
3.1 Introduction ....................................................................................................................... 16 
3.2 Background ....................................................................................................................... 19 
3.3 Chemistry and Results ...................................................................................................... 23 
3.3.1 The Synthesis of HZ-166 (3) ...................................................................................... 23 
3.3.2 The Synthesis of Esters to Characterize the LDi Pocket ......................................... 25 
vi 
 
3.3.3 Further Alterations of the C(3) Ester Position of Antinociceptive/ Anxiolytic 
Agent HZ-166 (3)................................................................................................................. 45 
3.3.4 The Synthesis of Heterocyclic Bioisosteres .............................................................. 59 
3.3.5 The In Vitro Analysis of HZ-166 (3) and its Analogs .............................................. 69 
3.3.6 Determination of Ataxic and Anxiolytic Effects in Preclinical Models ................ 73 
3.3.7 In Vivo Characterization of New Lead Compound, KRM-II-81 (36) (CRO) ....... 81 
3.4 Discussion......................................................................................................................... 103 
3.5 Methods ............................................................................................................................ 106 
3.5.1 Liver microsomal assay (Revathi Kodali at UWM) .............................................. 106 
3.5.2 Liver microsomal assay (CRO)............................................................................... 107 
3.5.3 Time-plasma concentration pharmacokinetic studies (CRO) ............................. 107 
3.5.4 Efficacy data determined by electrophysiology using Xenopus laevis oocytes (Dr. 
Margot Ernst at the Medical University of Vienna) 172-175 ............................................ 108 
3.5.5 The activity of MP-III-024 (19) in the anxiolytic Vogel conflict assay (Dr. 
Bradford Fischer at Rowan University) ......................................................................... 110 
3.5.6 The activity of MP-III-024 (19) in the zymosan A model of inflammatory pain 
using von Frey filaments (Dr. Bradford Fischer at Rowan University) ...................... 110 
3.5.7 The activity of MP-III-024 (19) tested for effects in locomotor activity (Dr. 
Bradford Fischer at Rowan University) ......................................................................... 111 
3.5.8 The activity of MP-III-024 (19) assessment for operant behavior (Dr. Bradford 
Fischer at Rowan University) .......................................................................................... 111 
vii 
 
3.5.9 Efficacy data for MP-II-064 (27) using the IonFlux automated patch-clamp (Nina 
Yuan at UWM) .................................................................................................................. 111 
3.5.10 FLIPR functional assay (CRO)180, 181 ................................................................... 113 
3.5.11 Assessment of anxiolytic effects in the marble burying assay (CRO) ............... 116 
3.5.12 Assessment for ataxic effects in the rotarod paradigm (CRO) 152 ..................... 117 
3.5.13 Assessment for muscle relaxation in the inverted screen test (CRO) ............... 117 
3.5.14 Assessment for anxiolytic-like effects in the Vogel conflict assay (CRO) 182 .... 118 
3.5.15 Anticonvulsant activity in the MES protocol (CRO) .......................................... 119 
3.5.16 Anticonvulsant activity in the scMET protocol (CRO) ...................................... 120 
3.5.17 Human epileptic cerebral cortex electrophysiology (CRO) ............................... 121 
3.5.18 Antihyperalgesic activity in the SNL model of neuropathic pain (CRO) ......... 122 
3.5.19 Antihyperalgesic activity in the CFA-model of inflammatory pain (Dr. Jun-Xu 
Li at the University at Buffalo) ........................................................................................ 123 
3.5.20 Depression activity in the forced swim test (CRO) ............................................. 124 
3.6 Experimental Details ...................................................................................................... 125 
3.6.1 (2-Amino-5-bromophenyl)(pyridin-2-yl)methanone (6)91 .................................... 125 
3.6.2 7-Bromo-5-(pyridin-2-yl)-1H-benzo[e][1,4]diazepin-2(3H)-one (7)91.................. 125 
3.6.3 Ethyl-8-bromo-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-
carboxylate (8)91 ................................................................................................................ 127 
3.6.4 Ethyl-6-(pyridin-2-yl)-8-((trimethylsilyl)ethynyl)-4H-benzo[f]imidazo [1,5a]-
[1,4]diazepine-3-carboxylate (9)91 .................................................................................... 128 
viii 
 
3.6.5 Ethyl-8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4] diazepine-3-
carboxylate (HZ-166, 3)91 ................................................................................................. 128 
3.6.6 tert-Butyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-
carboxylate (MP-II-067, 10) ............................................................................................. 129 
3.6.7 Isopropyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-
carboxylate (MP-II-068, 11) ............................................................................................. 130 
3.6.8 Cyclopropylmethyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxylate (MP-II-069, 12) ............................................................. 131 
3.6.9 Propyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-
carboxylate (MP-II-070, 13) ............................................................................................. 132 
3.6.10 sec-Butyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-
carboxylate (MP-II-071, 14) ............................................................................................. 133 
3.6.11 Isobutyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-
carboxylate (MP-II-072, 15) ............................................................................................. 134 
3.6.12 2-Methoxyethyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxylate (MP-II-073, 16) ............................................................. 134 
3.6.13 Benzyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-
carboxylate (MP-II-075, 17) ............................................................................................. 135 
3.6.14 1-Phenyl, ethyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxylate (MP-II-076, 18) ............................................................. 136 
3.6.15 Methyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-
carboxylate (MP-III-024, 19) ........................................................................................... 137 
ix 
 
3.6.16 8-Ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-
carboxylic acid (SR-II-54, 20) .......................................................................................... 138 
3.6.17 2d-Ethyl-8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4] diazepine-3-
carboxylate (MP-III-068, 21) ........................................................................................... 139 
3.6.18 (8-Ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-
yl)methanol (MP-II-023, 22) ............................................................................................ 139 
3.6.19 8-Ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-
carbaldehyde (MP-II-050, 23) .......................................................................................... 140 
3.6.20 N-Ethyl-8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-
carboxamide (MP-II-037, 25) ........................................................................................... 141 
3.6.21 N-Cyclopropyl-8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxamide  (MP-II-046, 26) .......................................................... 141 
3.6.22 8-Ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-
carbonitrile (MP-II-064, 27) ............................................................................................. 142 
3.6.23 8-Ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-
carboxamide (MP-II-065, 28) ........................................................................................... 143 
3.6.24 5-(8-Ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-yl)-3-
methyl-1,2,4-oxadiazole (MP-III-085, 33) ....................................................................... 144 
3.6.25 3-Ethyl-5-(8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-
yl)-1,2,4-oxadiazole (MP-III-080, 34) .............................................................................. 145 
3.6.26 5-(8-Ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-
yl)oxazole (KRM-II-81, 36). ............................................................................................. 147 
x 
 
4 CHIRAL α5 LIGANDS AND THEIR USES IN COGNITIVE DISORDERS AND 
ASTHMA ................................................................................................................................... 148 
4.1 Introduction ..................................................................................................................... 148 
4.2 Background ..................................................................................................................... 151 
4.3 Chemistry and Results .................................................................................................... 157 
4.3.1 Synthesis of SH-053-2'F-S-CH3 (51) and SH-053-2'F-R-CH3 (52) ...................... 157 
4.3.2 Properties and Pharmacokinetics of SH-053-2'F-S-CH3 (51) and SH-053-2'F-R-
CH3 (52).............................................................................................................................. 160 
4.3.3 Pharmacological Differences between the Enantiomers, SH-053-2'F-S-CH3 (51) 
and SH-053-2'F-R-CH3 (52) and their Potential to Treat Schizophrenia. ................... 167 
4.3.4 Synthesis of Analogs ................................................................................................ 175 
4.3.5 MP-III-004, a Superior α5 Bz/GABAAergic Subtype Selective Ligand .............. 182 
4.3.6 MP-III-022 ................................................................................................................ 192 
4.3.7 The Antidepressant Effects of α5 Subtype Selective Ligands .............................. 200 
4.3.8 The Use of α5 Subtype Selective Ligands as Bronchodilators for Asthma ......... 203 
4.4 Discussion......................................................................................................................... 213 
CONCLUSION / FINAL REMARKS .................................................................................... 216 
4.5 Methods ............................................................................................................................ 218 
4.5.1 Liver microsomal study (CRO) .............................................................................. 218 
4.5.2 Cytotoxicity (Kelly Teske at the University of Wisconsin-Milwaukee) .............. 218 
xi 
 
4.5.3 Time-concentration (plasma and brain) pharmacokinetic studies (Dr. Miroslav 
Savić at University of Belgrade)275 .................................................................................. 219 
4.5.4 Rat brain metabolism assay .................................................................................... 220 
4.5.5 Seizure protection in the 6 Hz electroshock assay (ASP at NINDS) ................... 220 
4.5.6 Ataxic assessment in the rotorod assay (ASP at NINDS) ..................................... 221 
4.5.7 Prepulse inhibition and the assessment for the development of catalepsy (Dr. 
David Baker and Nick Raddatz at Marquette University) ........................................... 221 
4.5.8 FLIPR functional assay (CRO)180, 181 ..................................................................... 223 
4.5.9 Efficacy data determined by electrophysiology using Xenopus laevis oocytes (Dr. 
Margot Ernst at the Medical University of Vienna)172-175 ............................................. 224 
4.5.10 Seizure protection against the maximal electroshock (MES) assay (ASP at 
NINDS)280-282 ...................................................................................................................... 224 
4.5.11 Seizure protection against the scMET-induced assay (ASP at NINDS) ........... 224 
4.5.12 Determination of plasma and brain concentrations ........................................... 225 
4.5.13 Ataxic assessment in the rotarod assay (Dr. Miroslav Savić at the University of 
Belgrade) ............................................................................................................................ 225 
4.5.14 Seizure protection against the scMET-induced assay (Dr. Miroslav Savić at the 
University of Belgrade) ..................................................................................................... 225 
4.5.15 Effects in memory and learning in the Morris water maze (Dr. Miroslav Savić 
at the University of Belgrade) .......................................................................................... 226 
xii 
 
4.5.16 Effects in the social novelty discrimination (SND) procedure (Dr. Miroslav Savić 
at the University of Belgrade) .......................................................................................... 227 
4.5.17 Antidepressant effects in the unpredictable chronic mild stress (UCMS) assay 
(Dr. Etienne Sibille and Sean Piantadosi at the University of Pittsburgh and University 
of Toronto) ......................................................................................................................... 227 
4.5.18 Immunohistochemistry of human ASM for α5-containing GABAAR subunit 
protein expression217 ......................................................................................................... 229 
4.5.19 Force measurements in human airway smooth muscle strips ........................... 230 
4.5.20 Force measurements in guinea pig tracheal rings .............................................. 231 
4.6 Experimental ................................................................................................................... 233 
4.6.1 Tert-butyl (S)-(1-((4-bromo-2-(2-fluorobenzoyl)phenyl)amino)-1-oxopropan-2-
yl)carbamate (54) .............................................................................................................. 233 
4.6.2 (S)-7-Bromo-5-(2-fluorophenyl)-3-methyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-
2-one (55)............................................................................................................................ 233 
4.6.3 Ethyl (S)-8-bromo-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxylate (56) ................................................................................. 234 
4.6.4 Ethyl (S)-6-(2-fluorophenyl)-4-methyl-8-((trimethylsilyl)ethynyl)-4H-
benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate (57) .............................................. 235 
4.6.5 Ethyl (S)-8-ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxylate (SH-053-2'F-S-CH3, 51) ............................................... 236 
xiii 
 
4.6.6 Tert-butyl (R)-(1-((4-bromo-2-(2-fluorobenzoyl)phenyl)amino)-1-oxopropan-2-
yl)carbamate (58) .............................................................................................................. 236 
4.6.7 (R)-7-Bromo-5-(2-fluorophenyl)-3-methyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-
2-one (59)............................................................................................................................ 237 
4.6.8 Ethyl (R)-8-bromo-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxylate (60) ................................................................................. 237 
4.6.9 Ethyl (R)-6-(2-fluorophenyl)-4-methyl-8-((trimethylsilyl)ethynyl)-4H-
benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate (61) .............................................. 238 
4.6.10 Ethyl (R)-8-ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxylate (SH-053-2'F-R-CH3, 52) .............................................. 238 
4.6.11 (S)-Methyl 8-ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxylate (MP-III-021, 62) ........................................................... 239 
4.6.12 (R)-Methyl 8-ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxylate (MP-III-004, 63) ........................................................... 239 
4.6.13 (S)-8-Ethynyl-6-(2-fluorophenyl)-N,4-dimethyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxamide (MP-III-023, 64) ......................................................... 240 
4.6.14 (R)-8-Ethynyl-6-(2-fluorophenyl)-N,4-dimethyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxamide (MP-III-022, 65) ......................................................... 241 
4.6.15 (S)-8-Ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carbonitrile (MP-III-018.A, 66) ....................................................... 241 
4.6.16 (S)-8-Ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxamide (MP-III-018.B, 67)...................................................... 243 
xiv 
 
4.6.17 (R)-8-Ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carbonitrile (MP-III-019.A, 68) ....................................................... 243 
4.6.18 (R)-8-Ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxamide (MP-III-019.B, 69)...................................................... 244 
4.6.19 (R)-Isopropyl 8-ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxylate (MP-III-050, 70) ........................................................... 244 
4.6.20 (R)-Tert-butyl 8-ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxylate (MP-III-051, 71) ........................................................... 245 
4.6.21 (R)-Cyclopropylmethyl 8-ethynyl-6-(2-fluorophenyl)-4-methyl-4H-
benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate (MP-III-052, 72) ........................ 246 
4.6.22 (R)-8-ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxylic acid (SH-053-2'F-R-CH3-Acid, 73) ............................... 247 
4.6.23 (R)-5-(8-ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepin-3-yl)-3-methyl-1,2,4-oxadiazole (MP-IV-004, 74) ................................ 247 
4.6.24 (R)-3-Ethyl-5-(8-ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepin-3-yl)-1,2,4-oxadiazole (MP-IV-005, 75) ................................................ 248 
4.6.25 (R)-5-(8-Ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepin-3-yl)-3-isopropyl-1,2,4-oxadiazole (MP-IV-010, 76) ............................ 249 
4.6.26 (R)-Methyl 8-bromo-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxylate (MP-III-058, 78) ........................................................... 250 
REFERENCES .......................................................................................................................... 252 
xv 
 
 
 
APPENDIX A. Characterization of HZ-166 and YT-III-31 (CRO)………………………...289 
APPENDIX B. Oocyte Efficacy and Binding Data of BZDs and β-Carbolines…………….309 
APPENDIX C. Ester Breakdown of Compounds in Biological Matrices……………….….312 
APPENDIX D. ADME Evaluation of Test Agents………………………………………...…329 
APPENDIX E. A Review of the Updated Pharmacophore for the Alpha 5 GABA(A) 
Benzodiazepine Receptor Model.........................................................................................338 
APPENDIX F. Manuscript Prepared by Miroslav M. Savic, et al. on the behavioral 
characterization of MP-III-022…………………………………………………………...394 
APPENDIX G. Manuscript Prepared by Etienne Sibille, et al. on the Anti-Depressant Effects 
of SH-053-2'F-R-CH3……………………………………………………………………...445 
APPENDIX H. Manuscript Prepared by Margot Ernst, et al. on the Effects of α5-GABAAR 
Positive Allosteric Modulators in Bronchodilation……………………………………....479 
APPENDIX I. Provisional Patent on α5 GABAA Selective Agonists for the Treatment of 
Depression and Related Disorders…………………………………………………….….513 
APPENDIX J. PCT Patent on α2/α3 GABAA Selective Ligands for the Treatment of Anxiety, 
Epilepsy, Neuropathic Pain and Depression……………………………………………..548 
APPENDIX K. Crystal Structures……………………………………………………………689 
APPENDIX L. Results from the Psychoactive Drug Screening Program………………….711  
xvi 
 
 
LIST OF FIGURES 
Figure 1. γ-Aminobutyric acid, the major inhibitory neurotransmitter in the central nervous 
system. ............................................................................................................................................ 1 
Figure 2. Proposed topology of a GABAA receptor subunit. The extracellular domain begins with 
the N-terminus and M1-M4 represent the four transmembrane domains (modified from the figures 
in Burt, et al.16 and Clayton, et al.).17 ............................................................................................. 2 
Figure 3. Longitudinal (A) and cross-sectional (B) schematic representations of the ligand-gated 
ion channel. The number 1-4 refer to the M1-M4 segments. The M2 segment contributes to the 
majority of the pore lining within the membrane lipid bilayer (modified from the figures in 
Keramidas, et al18. and Clayton et al.).17 ........................................................................................ 3 
Figure 4. Absolute subunit arrangement of the 122 GABAA receptor when viewed from the 
synaptic cleft.  The GABA binding sites are located at the +- subunit interfaces and the Bz 
modulatory binding site is located at the +- subunit interface.  The part of the schematically 
drawn subunits marked by the + indicates loop C of the respective subunits (modified from the 
figures in Clayton, et al.17 and Ernst, et al.).29 ................................................................................ 4 
Figure 5. Structures of common BZDs diazepam, chlordiazepoxide, triazolobenzodiazepine 
alprazolam and imidazobenzodiazepine (IBZD) midazolam. The atoms are labeled for both BZDs 
and IBZDs. ...................................................................................................................................... 5 
Figure 6. Structures of diazepam, which binds only to the DS sites, and flumazenil, which can 
bind to both the DS and DI sites. .................................................................................................... 8 
xvii 
 
Figure 7. Membrane potential over time during the transmission of a nerve signal. A 
hyperpolarized state represents a potential further away from the threshold potential (modified 
from the figure in Clayton Ph.D thesis).73 .................................................................................... 10 
Figure 8. Relative locations of the descriptors and regions of the unified pharmacophore/ receptor 
model.  The pyrazolo[3,4-c]quinolin-3-one CGS-9896 (dotted line), a diazadiindole (thin line), 
and diazepam (thick line) aligned within the unified pharmacophore/receptor model for the Bz BS.  
H1 and H2 represent hydrogen bond donor sites within the Bz BS while A2 represents a hydrogen 
bond acceptor site necessary for potent inverse agonist activity in vivo.  L1, L2, L3 and LDi are four 
lipophilic regions and S1, S2, and S3 are regions of negative steric repulsion. LP = lone pair of 
electrons on the ligands (modified from the figure in Clayton, et al.). 17 ..................................... 13 
Figure 9. In vitro Bz/GABAA receptor binding data of diazepam and QH-II-066.
75, 94 .............. 14 
Figure 10.  Comparison of BZD receptor binding data at α1 and α5 GABAA receptors which 
illustrates increased selectivity at α5 subtypes, as compared to α1 subtypes; where change in 
selectivity = (Acetyleneα1/α5) / (Halogenα1/α5). ........................................................................ 15 
Figure 11. Anticonvulsants pregabalin and gabapentin, opioids morphine and methadone, and the 
COX-2 inhibitor celecoxib, which are used for treatment of neuropathic pain. ........................... 17 
Figure 12. Structure, binding affinity, and oocyte efficacy of XHe-II-053 (1). .......................... 20 
Figure 13. Structures, binding affinities, and oocyte efficacies of JY-XHe-053 (2) and HZ-166 
(SH-053-2'N, 3). ........................................................................................................................... 21 
Figure 14. Plasma concentration-time profile of SR-II-54 (20) when given IV (1 mg/kg) and P.O. 
(10 mg/kg); n = 3 per time point. .................................................................................................. 32 
Figure 15. Preliminary oocyte efficacy concentration curve of SR-II-54 (20) on GABAA receptors 
using an EC3 GABA concentration (n = 2). .................................................................................. 34 
xviii 
 
Figure 16. Preliminary oocyte efficacy concentration curve of MP-III-024 (19) on GABAA 
receptors using an EC3 GABA concentration (n = 3). .................................................................. 35 
Figure 17. Comparison of a dose-response (DR) curve at EC3 and EC20. ................................... 37 
Figure 18. Effects of diazepam and MP-III-024 (19) in the Vogel conflict procedure. Male 
C57BL/6 mice (n = 6) were pretreated i.p. with vehicle (0.5% methyl cellulose, 0.9% sodium 
chloride), diazepam or MP-III-024 (19) 30 minutes prior to testing. Mice were then placed in a 
chamber and the amount of licks of water was recorded over a 6 minute time period. ............... 39 
Figure 19. Effects of MP-III-024 (19) on inflammatory pain the in von Frey filament test. 
Zymosan A (0.06 mg in 20 µL 0.9% sodium chloride) was injected subcutaneously into the plantar 
surface of the right hindpaw 24 hours prior to testing. Male C57BL/6 mice (n = 6) were then dosed 
with MP-III-024 (19) and mechanical sensitivity was assessed using von Frey filaments. The paw 
withdrawal threshold was recorded. Open symbols represent the left (non-injured) hindpaw and 
the closed symbols represent the right (injured) hindpaw. “BL” represents predrug baseline. .... 41 
Figure 20. Effects of diazepam and MP-III-024 (19) on locomotor activity. Male C57BL/6 mice 
(n = 6) were dosed i.p. with vehicle (0.5% methyl cellulose, 0.9% sodium chloride), diazepam or 
MP-III-024 (19). Mice were then assessed for locomotor activity and the total distance traveled 
was recorded. “V” represents distance traveled after vehicle administration. .............................. 43 
Figure 21. Effects of MP-III-024 (19) on operant behavior. Male C57BL/6 mice (n = 6) were 
dosed i.p. with MP-III-024 (19) and were placed on a fixed ratio of liquid food. Training and test 
sessions consisted of multiple cycle components, and each culminated in a 5 minute response 
period. ........................................................................................................................................... 44 
Figure 22. Previously synthesized amides, HJ-I-040 (24), ZJW-II-61 and ZJW-II-60 and the 
oocyte efficacy data of N-methyl amide HJ-I-040 (24). Concentration curve of 24 on GABAA 
xix 
 
receptors suing an EC3 GABA concentration (n = 4, modified from the figure in Namjoshi, et 
al.).117 ............................................................................................................................................ 48 
Figure 23. Efficacy testing of MP-II-064 (27) in the IonFlux high-throughput patch-clamp 
instrument. Nitrile MP-II-064 was run against HZ-166 (3) to determine how the efficacy profiles 
compared in parallel experiments. ................................................................................................ 52 
Figure 24. Preliminary oocyte efficacy results of MP-II-064 (27) by two-electrode voltage clamp 
technique (Margot Ernst). Concentration curve of 27 on GABAA receptors suing an EC3 GABA 
concentration (n = 2-3). ................................................................................................................ 53 
Figure 25. Proposed structure of a nitrile with an increased degree of freedom at C(3) to interact 
at H1 than MP-II-064 (27). ............................................................................................................ 54 
Figure 26. Structure of imidazenil. .............................................................................................. 55 
Figure 27. Structure and efficacy of ZJW-II-65 (29). Concentration curve of 29 on GABAA 
receptors using an EC3 GABA concentration (n = 3). .................................................................. 57 
Figure 28. Efficacy comparisons of 19, 24 and 29 at 1 μM. Efficacy determined on GABAA 
receptors using an EC3 GABA concentration (n = 2 – 4). ............................................................ 58 
Figure 29. Structures of a thionoester 30 and thioamide 31. ....................................................... 59 
Figure 30. Common heterocyclic ester bioisosteres. ................................................................... 60 
Figure 31. Structure and oocyte efficacy data of ZJW-II-40. Concentration curve of 32 on GABAA 
receptors using an EC3 GABA concentration (n = 3), as reported in Namjoshi, et al.
117 ............. 62 
Figure 32. Structure and oocyte efficacy of SH-I-85 (35), displaying very low efficacy at the α1 
subtype. Concentration curve of 35 on GABAA receptors using an EC3 GABA concentration (n = 
3). .................................................................................................................................................. 66 
xx 
 
Figure 33. Structures of oxazoles (37 – 40) and methyl oxazoles (41 – 46). These were synthesized 
based on the pharmacophore/receptor model of Clayton, Poe, et al.74 in collaboration with Dr. 
Methuku. The synthesis of these can be found in Appendix J. ..................................................... 68 
Figure 34. Analysis of the anxiolytic effects exerted by HZ-166 (3) and other ligands. 
....................................................................................................................................................... 80 
Figure 36. Structure and oocyte efficacy of KRM-II-81 (36) and HZ-166 (3) ............................ 83 
Figure 37. Plasma concentration-time plot of KRM-II-81 (36). Male Sprague-Dawley rats (n = 3 
per time point) were dosed i.p. (10 mg/kg) or I.V. (1 mg/kg) and the plasma concentration was 
analyzed at varying time points for up to 12 hours. ...................................................................... 84 
Figure 38. Inverted screen assessment of diazepam, HZ-166 (3) and KRM-II-81 (36) .............. 86 
Figure 39. HZ-166 (3) and KRM-II-81 (36) in the Vogel conflict procedure. ............................ 88 
Figure 40. Diazepam, HZ-166 (3) and KRM-II-81 (36) in the MES anticonvulsant activity assay
....................................................................................................................................................... 91 
Figure 41. Diazepam, HZ-166 (3) and KRM-II-81 (36) in the blockage (A) and threshold (B) 
measurement against scMET-induced seizures. ........................................................................... 92 
Figure 42.  Network Firing Rate. Dampening effects of KRM-II-81 (36) on firing rate frequency 
(Hz) in tissue resected from a human with epilepsy.   .................................................................. 94 
Figure 43. Antihyperalgesic effects of HZ-166 (3) in wild-type (left) and α2 knock-in (right) 
mice50 ............................................................................................................................................ 96 
Figure 44. KRM-II-81 (36) and gabapentin in the SNL model of neuropathic pain.. ................. 97 
Figure 45. Assessment of antihyperalgesic effects of midazolam, 3, 36 and 38 in CFA-induced 
inflammatory pain ......................................................................................................................... 99 
xxi 
 
Figure 46. Antagonism of BZD effects using flumazenil. The benzodiazepine site antagonist 
flumazenil shifted the dose-effect curves of PAMs rightward, indicating the effect is modulated by 
the benzodiazepine receptor. ....................................................................................................... 100 
Figure 47. The antidepressant effects of KRM-II-81 (36). ........................................................ 102 
Figure 48. Typical (haloperidol, chlorpromazine) and atypical (clozapine, olanzapine) 
antipsychotics. ............................................................................................................................. 149 
Figure 49. Fast-acting (salbutamol) and long-term control (salmeterol, beclomethasone 
dipropionate) medications for asthma. ........................................................................................ 150 
Figure 50. Structures of α5 negative allosteric modulators, RY-23, RY-24, RY-79 and RY-80.
..................................................................................................................................................... 151 
Figure 51. Structure and binding affinity of α5 antagonist XLi-093 (47). ................................ 152 
Figure 52. Structure and oocyte efficacy of PWZ-029 (48)74 .................................................... 153 
Figure 53. PWZ-029 docked within α5γ2 BzR binding site (BS). Modified from the figure in 
Clayton, et al.74 ........................................................................................................................... 153 
Figure 54. PWZ-029 docked with amino acid residues. Modified from the figure in Clayton, et 
al.74 .............................................................................................................................................. 154 
Figure 55. PWZ-029 docked with A.A. residue interactions. Modified from the figure in Clayton, 
et al.74 .......................................................................................................................................... 154 
Figure 56. PWZ-029 docked with interactions74 ....................................................................... 154 
Figure 57. Structures and oocyte efficacy data of SH-053-S-CH3 (49) and SH-053-R-CH3 (50)
..................................................................................................................................................... 155 
Figure 58. Structures and oocyte efficacy data of SH-053-2'F-S-CH3 (51) and SH-053-2'F-R-CH3 
(52) .............................................................................................................................................. 157 
xxii 
 
Figure 59. Plasma and brain concentration-time profile of SH-053-2'F-S-CH3 (51) after 10 mg/kg 
i.p. administration in male Wistar rats (n = 3) for up 6 hours..................................................... 163 
Figure 60. Plasma and brain concentration-time profile of SH-053-2'F-R-CH3 (52) after 10 mg/kg 
i.p. administration in male Wistar rats (n = 3) for up to 6 hours ................................................ 164 
Figure 61. Results of 51 and 52 in a rat brain metabolism assay (n = 12) ................................. 166 
Figure 62. Assessment of SH-053-2'F-S-CH3 (51) and SH-053-2'F-R-CH3 (52) to protect mice 
from electroshock-induced convulsions. .................................................................................... 171 
Figure 64. Assessment of SH-053-2'F-S-CH3 (51) and SH-053-2'F-R-CH3 (52) to reverse the PPI 
deficits induced by PCP .............................................................................................................. 172 
Figure 65. Assessment of the development of catalepsy of SH-053-2'F-S-CH3 (51) and SH-053-
2'F-R-CH3 (52). ........................................................................................................................... 174 
Figure 66. Structure, binding affinity and oocyte efficacy profile of SH-I-75 (77). Binding affinity 
at αxβ3γ2 GABAA/benzodiazepine site subtypes using [3H]-flumazenil displacement studies from 
two separate experiments.. .......................................................................................................... 183 
Figure 67. Structures and oocyte efficacy profiles of SH-053-2'F-R-CH3 (52) and MP-III-004 (63). 
Concentration curves on GABAA receptors using an EC3 GABA concentration (n = 3 – 5)..... 184 
Figure 68. Assessment of MP-III-004 (63) in reversing the PPI deficits induced by MK-801.. 186 
Figure 69. Assessment of the development of catalepsy of MP-III-004 (63).. .......................... 187 
Figure 70. Assessment of MP-III-004 for protection against 6 Hz electroshock-induced seizures 
alongside enantiomers 51 and 52.. .............................................................................................. 189 
Figure 71. Assessment of MP-III-004 (63) against seizures when given i.p. or p.o.. ................ 190 
Figure 72. Structure, binding affinity and oocyte efficacy profile for MP-III-022 (65). ........... 192 
xxiii 
 
Figure 73. Plasma and brain concentration-time profile of MP-III-022 (65) after 2.5 mg/kg i.p. 
administration in male Wistar rats (n = 3) for up to 3 hours....................................................... 194 
Figure 74. The effects on MP-III-022 (65) in basic behavioral tests. ........................................ 195 
Figure 75. The effects of 2 mg/kg diazepam and 1, 2 and 10 mg/kg MP-III-022 on (a) distance in 
the target zone (m) and (b) distance in the peripheral ring (%) during probe trial in the water maze.
..................................................................................................................................................... 197 
Figure 76. The effects of 1.5 mg/kg diazepam (DZP 1.5) and 1, 2.5 and 10 mg/kg MP-III-022 on 
discrimination index (a) and the time exploring the familiar and the novel juvenile rat in T2 (b) in 
the social novelty discrimination procedure. .............................................................................. 199 
Figure 77. Effect of SH-053-2'F-R-CH3 (52; α5-PAM) on anxiety- and depressive-like behavior 
induced by UCMS in female and male mice. ............................................................................. 201 
Figure 78. Structures of the α4 selective ligands, CMD-45 and XHe-III-74. ............................ 204 
Figure 79. Protein expression of the GABAA α5 subunit in intact human trachea-bronchial airway 
smooth muscle.217 ....................................................................................................................... 205 
Figure 80. SH-053-2’F-R-CH3 (52) mediated activation of α5 subunits containing GABAA 
channels induces relaxation of pre-contracted airway smooth muscle217 ................................... 206 
Figure 81. Structures of α5 selective ligands assessed in an organ bath for the relaxation of 
precontracted airway smooth muscle; as well as the route to the methyl ester MP-III-058 (78).
..................................................................................................................................................... 207 
Figure 82. Oocyte efficacy of the α5 selective ligand, SH-053-2'F-R-CH3 (52), MP-III-004 (63), 
MP-III-058 (78) and SH-053-2'F-R-CH3-Acid (73) ................................................................... 208 
xxiv 
 
Figure 83. Oocyte efficacy of the super-agonist SH-I-048A (55). Concentration curves on GABAA 
receptors using an EC3 GABA concentration (n = 3 – 5). Modified from the figure in Obradovic, 
et al.272......................................................................................................................................... 210 
Figure 84. Assessment of α5 ligands, HZ-166 and SH-I-048A in airway smooth muscle force 
relaxation..................................................................................................................................... 211 
 
  
xxv 
 
LIST OF TABLES 
Table 1. Action of benzodiazepines at CNS GABAA α1-6β1-3γ2 receptor subtypes. Presented at 
the Mona Symposium (2014), University of the West Indies……………………………………7 
Table 2. Metabolic stability of esters and the carboxylic acid (20)……………………….……..29 
Table 3. Time-plasma concentration of 3, 21 and 20 in IV and P.O. dosing in rats (n = 3 per time 
point)……………………………………………………………………………………………..32 
Table 4. Brain concentrations at the 2 hour time point of the parent compound which was dosed 
and 20 after a 10 mg/kg P.O. of either 3, 21, or 20 in rats (n = 3 per time point)………………..33 
Table 5. In vitro metabolic stability, α3 Bz/GABAAR EC50’s and clogP’s of ligands…………71 
Table 6. Plasma and brain concentrations of HZ-166 (3) and KRM-II-81 (36) after a 10 mg/kg 
P.O. dose in rats…………………………………………………………………………………85 
Table 7. Quantification of Antiseizure Activity: ED50 MES, ED50 scMET, TD50 TOX, and 
Therapeutic Index (TI) via i.p. and P.O. Routes.a Modified from the table in Rivas, et al.115......90 
Table 8. Liver microsomal stability and cytotoxicity of 51 and 52…………………………….161 
Table 9. Pharmacokinetic data of SH-053-2'F-S-CH3 (51) and SH-053-2'F-R-CH3 (52) after 10 
mg/kg i.p. administration in male Wistar rats (n = 3) ………………………………………….164 
Table 10. In vitro metabolic stability, α3 Bz/GABAAR EC50 values and clogP’s of the SH-053-
2'F-S-CH3 (51) and SH-053-2'F-R-CH3 (52) and their analogs…………………………………180 
Table 11. Plasma and brain concentrations of MP-III-022 (65) and SH-053-2'F-R-CH3 (52) taken 
20 minutes after an i.p. (10 mg/kg) dose, n = 3…………………………………………………193 
xxvi 
 
Table 12. Plasma and brain concentrations taken 20 minutes after an i.p. (10 mg/kg) injection of 
α5 selective ligands, n = 3…………………………………………………………....................209 
 
 
 
 
 
 
 
 
 
 
 
 
  
xxvii 
 
LIST OF SCHEMES 
Scheme 1. Synthesis of HZ-166 (3). Amounts listed are the greatest scale for each reaction. They 
do not correspond to the product which resulted from the previous reaction. ............................. 24 
Scheme 2. Synthesis of esters from HZ-166 (3) using lithium and the corresponding alcohols. 26 
Scheme 3. Synthesis of the methyl ester MP-III-024 (19). .......................................................... 27 
Scheme 4. Synthesis of the deuterated ethyl ester, MP-III-068 (21)............................................ 28 
Scheme 5. Synthesis of the alcohol MP-II-023 (22) and aldehyde MP-II-050 (23). ................... 46 
Scheme 6. Synthesis of amides, MP-II-037 (25) and MP-II-046 (26). ........................................ 49 
Scheme 7. Synthesis of nitrile MP-II-064 (27) and the byproduct MP-II-065 (28) ..................... 50 
Scheme 8. Improved route to the carboxamide MP-II-065 (28). ................................................. 56 
Scheme 9. Synthesis of the oximes and methyl (MP-III-085, 33) and ethyl (MP-III-080, 34) 
oxadiazoles. ................................................................................................................................... 63 
Scheme 10. Route to SH-I-85 (35) as a byproduct. ...................................................................... 64 
Scheme 11. Proposed mechanism for the formation of 5-(isocyanomethyl)oxazole. .................. 65 
Scheme 12. The synthesis of oxazole KRM-II-81 (36). ............................................................... 67 
Scheme 13. Synthesis of SH-053-2'F-S-CH3 (51). .................................................................... 159 
Scheme 14. Synthesis of SH-053-2'F-R-CH3 (52). .................................................................... 160 
Scheme 15. Synthesis of methyl esters as well as methyl amides .............................................. 176 
Scheme 16. Synthesis of nitriles (MP-III-018.A, 66 and MP-III-019.A, 68) and carboxamides 
(MP-III-018.B, 67 and MP-III-019.B, 69). ................................................................................. 177 
Scheme 17. Synthesis of esters (70 – 72) and SH-053-2'F-R-CH3-Acid (73). .......................... 178 
Scheme 18. Synthesis of oxadiazoles (74 – 76). ........................................................................ 179 
 
xxviii 
 
LIST OF ABBREVIATIONS 
ASM  airway smooth muscle 
ASP  Anticonvulsant Screening Program 
BBB  blood-brain-barrier 
BQL  below quantification limit 
BZD  benzodiazepine 
BzR  benzodiazepine binding site 
CCI  chronic constriction injury 
CFA  complete Freund’s adjuvant 
CMC  carboxymethyl cellulose 
CNS  central nervous system 
CRO  contracted research organization 
DI  diazepam-insensitive 
DLM  dog liver microsomes 
DS  diazepam-sensitive 
FLIPR  fluorescence imaging plate reader 
GABA  gamma-aminobutyric acid 
GABAAR gamma-aminobutyric acid type A receptors 
HLM  human liver microsomes 
xxix 
 
IBZD  imidazobenzodiazepine 
IP  intraperitoneal 
IV  intravenously 
LR  Lawesson’s reagent 
MAM  methylazoxymethanol acetate 
MES  maximal electroshock 
MLM  mouse liver microsomes 
MPE  maximum possible effect 
NAM  negative allosteric modulator 
NINDS National Institute for Neurological Disorders and Stroke 
PAM  positive allosteric modulator 
PCP  phencyclidine 
PPI  prepulse inhibition 
PTZ  pentylenetetrazole 
PWT  paw withdrawal threshold 
PO  oral administration 
RLM  rat liver microsomes 
SAR  structure-activity relationship 
scMET subcutaneous pentylenetetrazole 
xxx 
 
SEM  standard error of the mean 
SNL  sciatic nerve ligation 
SSRI  selective serotonin reuptake inhibitors 
  
xxxi 
 
ACKNOWLEDGEMENTS 
 I would like to first thank my advisor Professor James M. Cook for the opportunity and 
support to complete my doctorate in synthetic medicinal chemistry. In addition, Dr. Cook allowed 
me to gain experience in grant and patent writing to further my development during my time at 
UW-Milwaukee. I would also like to thank the Cook research group for their helpful discussions 
and the members of my doctoral committee, Professor’s Arnold, Pacheco, Schwabacher and 
Silvaggi, for their suggestions and instructive discussions. 
 It was a pleasure working with our numerous collaborators. I have benefitted greatly and 
gained significant knowledge in various fields through the insightful discussions with each 
individual, especially Drs. Miroslav Savić (University of Belgrade) and Margot Ernst (Medical 
University of Vienna). I would also like to thank Professor Robert Carlson, who allowed me to do 
undergraduate research at the University of Minnesota-Duluth under his supervision. I credit my 
interest in organic chemistry to this work and experience. 
 Thank you to my family. To my parents, to which this is dedicated to for all their support 
and encouragement through my life. To my sister Sarah and her husband Muris, who have offered 
suggestions and their knowledge regarding the transition out of graduate school.  
 Finally, I would like to thank my amazing fiancé Kelly Teske, who has made my time in 
Milwaukee one of the best times of my life. 
1 
 
1 INTRODUCTION 
1.1 The GABAA Receptor 
 Gamma (γ)-amino butyric acid (GABA; Figure 1) is the major inhibitory neurotransmitter 
of the central nervous system (CNS) in the mammalian body. When GABA binds to the GABA 
type A receptor (GABAAR), a transmembrane heteropentameric ion channel,
1, 2 the result is an 
induction of chloride ions through the pore, which can affect a wide variety of pharmacological 
actions including anxiety,3 epilepsy,4 insomnia,5 depression,6 bipolar disorder,7, 8 schizophrenia9 
and Alzheimer’s disease.10 The response is dependent on the specific composition of the GABAA 
subunits which make up the GABAAR.
11 To date, there are 19 individual GABAAR subunits which 
have been positively identified; α1-6, β1-3, γ1-3, δ, ε, θ, π, and ρ1-312 with additional unidentified 
subunits plausible. These subunits can arrange in either a hetero- or homo- pentameric ring. 
Currently, only a small handful of subunit formations have been positively identified to form a 
functional receptor, with many others highly likely or plausible.13, 14 The most common and 
intensively studied arrangement of the GABAAR consists of α1-6β1-3γ2 in a 2:2:1 stoichiometric 
ratio.2 
 
Figure 1. γ-Aminobutyric acid, the major inhibitory neurotransmitter in the central nervous system. 
 
 The GABAAR protein is a polypeptide which possesses an approximate mass of ~50 kD, 
and each subunit is structurally related. The homology between separate classes (i.e. α versus β) is 
about 20% sequence identity or 50% sequence similarity, while the homology within a single class 
is about 70%.15 A large portion of the N-terminal end of each subunit exists in the extracellular 
2 
 
region and contains sites for potential glycosylation and a “Cys-loop” formed by a covalent bond 
between two conserved cysteines. The protein then proceeds to cross the lipid bilayer four times, 
with a large intracellular loop located between the M3 and M4 transmembrane regions (Figure 2). 
Five individual subunits then combine to form the chloride ion pore (Figure 3). 
 
 
Figure 2. Proposed topology of a GABAA receptor subunit. The extracellular domain begins with the N-
terminus and M1-M4 represent the four transmembrane domains (modified from the figures in Burt, et al.16 
and Clayton, et al.).17 
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Figure 3. Longitudinal (A) and cross-sectional (B) schematic representations of the ligand-gated ion channel. 
The number 1-4 refer to the M1-M4 segments. The M2 segment contributes to the majority of the pore lining 
within the membrane lipid bilayer (modified from the figures in Keramidas, et al18. and Clayton et al.).17 
 
 The GABAAR has numerous binding sites located at the synaptic cleft and also within the 
pore. Activation of the GABAAR complex can occur due to the binding of a variety of compound 
classes at these various sites including β-carbolines, barbiturates, ethanol and benzodiazepines, as 
well as endogenous steroids, among others.2, 19 Located at the synaptic cleft of the abundant α1-6β1-
3γ2, which are arranged αβαβγ clockwise when viewed from the extracellular region (Figure 4), 
are the GABA binding sites at the two α-β+ interfaces, the benzodiazepine binding site (BzR) at 
the γ-α+ interface,3, 20 and the more recently discovered CGS 9895 binding site at the β-α+ 
interface.21, 22 A number of pyrazoloquinolines have been shown to bind to and activate this 
GABAAR site by Ernst, Sieghart, Cook, et al. This is based on the seminal work of Sieghart
2 and 
Sigel.23 In addition, neurosteroids,24 ethanol25, 26 and other compounds may also bind in the interior 
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of the pore. Research on the interactions of ethanol at the Bz/GABAAergic subtypes has been 
reported by Olsen,27 Platt28 and others. 
 
 
Figure 4. Absolute subunit arrangement of the 122 GABAA receptor when viewed from the synaptic cleft.  
The GABA binding sites are located at the +- subunit interfaces and the Bz modulatory binding site is located 
at the +- subunit interface.  The part of the schematically drawn subunits marked by the + indicates loop C 
of the respective subunits (modified from the figures in Clayton, et al.17 and Ernst, et al.).29 
 
1.2 Benzodiazepines 
 Traditional benzodiazepines (BZDs), such as diazepam (Valium) which contain the 
pendent phenyl C ring (Figure 5), tend to bind non-selectively to the α1-3,5β1-3γ2 GABAA receptors3, 
17, 20 at the BzR site. This class of compounds has been frequently prescribed as a medication for 
various CNS disorders such as anxiety and convulsions30, 31 for over half a century. They offer 
many advantages in drug therapy32 as they are rapidly absorbed though the gastrointestinal tract 
when taken orally and generally reach maximum blood concentrations within a couple hours of 
ingestion. In addition, BZDs are privileged structures, which are able to readily cross the blood-
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brain-barrier (BBB) and are rapidly distributed throughout the brain. When used as an emergency 
anticonvulsant, certain BZDs can reach levels of detection within five minutes when given 
intravenously (IV),33-35 but these do develop tolerance in humans after 3 – 5 days which limits 
their use to status epilepticus in emergency rooms. Other advantages include minimal liver 
microsomal enzyme inhibition which can cause drug-drug interactions,36 and a lack of serious 
toxicity concerns even at high concentrations.37 Unfortunately, there are also a number of adverse 
effects that can be produced by BZDs such as drowsiness, sedation, ataxia, muscle-relaxation, 
amnesia, dependence, withdrawal issues and tolerance to the anticonvulsant and antinociceptive 
effects limiting their use for the chronic treatment of convulsions and chronic pain syndromes.19, 
38, 39 These adverse effects are a result of the non-selective efficacy of BZDs at multiple GABAAR 
subtypes simultaneously. 
 
 
Figure 5. Structures of common BZDs diazepam, chlordiazepoxide, triazolobenzodiazepine alprazolam and 
imidazobenzodiazepine (IBZD) midazolam. The atoms are labeled for both BZDs and IBZDs. 
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1.3 Pharmacology of the GABAAR and Agonistic Effects at Various Subtypes 
 The pharmacological response to the activation of the α1-6β1-3γ2-GABAAR’s is dependent 
on the composition of the subunits that form the receptor (Table 1), with the presence of different 
α substituents as the key factor. Over the past couple decades, studies using GABAAR mutated 
single-point knock-in mice have been used to identify the actions of different α subunits located 
within the brain by rendering the BzR insensitive to modulation with BZDs14 pioneered by 
Seeburg, Möhler and Rudolph. These studies have been done by replacing a single histidine amino 
acid of the α subunit with an arginine. In both α1 and α2 subunits, the replacement is an H101R, 
while the replacements are H126R for α3 and H105R in α5 subunits.40  
GABAA receptors containing the α1 subunit have been shown to mediate anterograde 
amnesia, motor impairment, addiction and sedative effects, as well as part of the anticonvulsant 
action.41, 42 Anxiolytic action and some anticonvulsant activity stems from the activation of the α2 
subunits,43, 44 while contribution to the anxiolytic-like effects and possible muscle relaxation at 
higher receptor occupancy are reported to be mediated by the α3 subunit.45, 46 Memory and spatial 
learning, as well as other cognitive effects, are influenced by the α5 subtype.47 Antihyperalgesic 
effects also stem from the α2 subunit;48 however, the site of this action appears to occur from 
activation of the GABAAR that are located primarily in the spinal cord
49 as opposed to the brain. 
A recent triple-point knock-in mutation study was done and shown to confirm which specific α 
subunit was the source of these pharmacological responses.50 However, earlier work from this 
laboratory with the α3 subtype selective ligand YT-III-31 (Poe, Cook, et al., unpublished results; 
see Appendix A) provided evidence that the agonist efficacy at α3 receptors can contribute to the 
anxiolytic and antinociceptive effects of these ligands. This work, however, may be confounded 
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by some sedative actions, consequently, unambiguous determination of the processes mediated by 
the α3β3γ2 subtypes remains to be carried out. 
Table 1. Action of benzodiazepines at CNS GABAA α1-6β1-3γ2 receptor subtypes. Presented at the Mona 
Symposium (2014), University of the West Indies.51 
Subtype Associated Effect 
 Sedation, anterograde amnesia, some anticonvulsant action, 
ataxia, some addiction at higher doses and muscle relaxation  
 Anxiolytic, perhaps hypnotic (EEG) at higher doses, perhaps 
some muscle relaxation at higher doses, and antihyperalgesic effects 
 Some anxiolytic action, anticonvulsant action at higher doses,  
maybe some muscle relaxation at higher doses 
 Diazepam-insensitive (DI) site, a sedative in the CNS;  
important in lung disorders in the periphery  
 Cognition, temporal and spatial memory  
(Maybe memory component of anxiety) 
 Diazepam-insensitive (DI) site 
 
 The abundance of specific α subtypes in α1-6β2/3γ2 GABAA receptors is not equal 
throughout the brain. Various studies have been completed by using [3H]-muscimol binding in 
conjunction with immunoprecipitation using subunit specific antibodies3, 14 in rat brains, 
immunohistochemistry,52, 53 or by monitoring the total decrease in GABAA receptors after 
knockout studies in mice.3 The seminal work by Wisden, et al.54 was key in this regard. The α1 
subtype is the most abundant throughout the brain and accounts for 40-50% of the α GABAA 
subtypes.55, 56 The α2 and α3 subtype assemblies account for up to, but not more than, 35% and 
8 
 
14%, respectively3 and are located mainly in the limbic region. Receptors containing the α5 
subtype are the least abundant of the diazepam-sensitive (DS) GABAAR accounting for about 5% 
of all α subtypes within the brain, the majority of which are located in the hippocampus.52, 57 There 
are some that have been found in the spinal cord.58 
In addition to the DS GABAA receptor subtypes (α1-3,5β2/3γ2), there are also two diazepam-
insensitive (DI) sites in which the binding pocket cannot tolerate the C ring of various 
benzodiazepines. BZDs, such as flumazenil (Figure 6), which lack the pendent C ring can bind to 
both the DS and DI GABAAR binding sites. These two (DI) subtypes are the α4 and α6 subtypes 
and they account for a smaller percentage of functional GABAA receptors than the DS subtypes. 
The α4 makes up 6% of all subtypes59 and the α6 subtype is found principally in the cerebellum 
and olfactory bulb.60 Although these have been studied, the pharmacological effects associated 
with these two subtypes are still not fully understood. GABAA receptors are also found in the 
peripheral nervous system.61, 62 A major effect of GABA here involves tonic inhibition,63 but 
potential uses of BZDs targeting GABAAR in the peripheral nervous system have been noted 
within the lungs64-66 and spleen.67, 68 
 
 
Figure 6. Structures of diazepam, which binds only to the DS sites, and flumazenil, which can bind to both the 
DS and DI sites. 
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 The pharmacological response due to the modulation of BZDs is dependent not only on 
which α receptor subtype the BZD binds to, but ultimately the in vivo effect it has on the influx of 
chloride ions through the receptor pore. Under normal physiological conditions, a neuron may 
become hyperpolarized leading to an action potential and a signal is fired (Figure 7). As GABA 
binds to the GABAA receptor and causes a conformational change in the receptor, chloride ions 
are allowed to travel through the pore. These chloride ions flow into the postsynaptic area and 
lower the membrane potential, which decreases the likelihood of an action potential being reached 
and further inhibits neuronal signaling. Benzodiazepines can influence the chloride ion flux in 
three separate ways; however, GABA must also be present as BZDs alone cannot induce a channel 
opening.69-71 A positive allosteric modulator (PAM) alters the conformation of the GABAAR 
which results in an increase flux of chloride ions, further inhibiting neuronal firing. PAMs are 
different from agonists such as muscimol, as agonists bind to the GABA binding site (orthosteric) 
while all allosteric modulators bind at a separate site by definition. Negative allosteric modulators 
(NAM) have the opposite effect, termed “inverse agonists”, in that the influx of chloride ions is 
reduced, increasing the chance of an action potential and neuronal firing. The third class of 
benzodiazepines are null modulators, more commonly referred to as antagonists, which have no 
discernable effect on the influx of chloride ions. Instead, these antagonists generally have a strong 
binding affinity for one or more specific BzR sites and limit the ability for other BZDs (such as 
diazepam, alprazolam, midazolam) to bind and influence the membrane potential.72 In essence, 
antagonists occupy the binding site but do not elicit a pharmacological response.17 
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Figure 7. Membrane potential over time during the transmission of a nerve signal. A hyperpolarized state 
represents a potential further away from the threshold potential (modified from the figure in Clayton Ph.D 
thesis).73 
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2 MOLECULAR MODELING 
2.1 Background 
 The ability to use BZDs clinically to effectively target various pharmacological diseases is 
severely hampered by the fact that BZDs generally target multiple α subtypes. This leads to 
numerous adverse effects including drowsiness, sedation, ataxia, muscle-relaxation, amnesia, 
dependence, withdrawal issues and tolerance to the anticonvulsant and antinociceptive effects 
limiting their use for chronic treatment of convulsions.19, 38, 39 Research in other fields have 
benefitted from the crystallization of a target receptor protein which allows ligands to be designed 
based on the binding pocket. Unfortunately for the GABAAR, transmembrane proteins are difficult 
to crystallize because the removal of the protein from the lipid bilayer destabilizes the protein. 
Attempts to crystallize a functional α1-6β2/3γ2 GABAAR protein have been unsuccessful. Recently, 
a homopentameric β3 receptor has been crystallized at a 3 Å resolution.49 Since the BzR is located 
at the γ-α+ interface, this does not give any insight into the binding pocket for benzodiazepines; 
however, it does provide hope that a fully functional α1-6β2/3γ2 may be crystallized in the near 
future. Certainly, the topology of the β3 receptor can be used to improve homology models 
reported in the past by Cromer, et al.,1 Sieghart, et al.29 and Clayton, et al.17, 74 
 Currently, molecular modeling and structure-activity relationship (SAR) studies are two of 
the best tools for the study of the activity of benzodiazepines and the design of subtype-selective 
ligands. Over the past couple decades, extensive work on the BzR pharmacophore has been carried 
out in Milwaukee17, 74-76 based on rigid ligands pioneered by Trudell, Diaz, He, Huang and Cook, 
et al.75-77 This unified Milwaukee-based pharmacophore/receptor model has been built based on 
the in vitro binding affinities of over 150 various ligands which bind to the BzR as PAMs, NAMs 
or antagonists. These ligands come from over a dozen different classes of compounds including 
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benzodiazepines,78, 79 β-carbolines,80-82 triazolopyrimidines,83 pyridodiindoles,84, 85 imidazo-
pyridines86 and pyrazoloquinolines.87 The predicted binding pocket is created by superimposing 
ligands from the different compound classes at each individual α1-3,5β2/3γ2 GABAAR and aligning 
them in a way wherein specific elements of the ligands interact with the key descriptors of the 
pharmacophore model which are used as anchor points. After compounds are docked at these 
positions, subtle changes in orientation are used around additional lipophilic and steric descriptors. 
Analysis of these data show that the binding pocket of the DS benzodiazepine binding sites (α1-
3,5β2/3γ2) have very similar topology, and a two-dimensional representation has been produced 
(Figure 8) with compounds from three separate classes (a quinolinone, a diazadiindole and a 
benzodiazepine) depicted within. The key descriptors consist of two hydrogen bond donors (H1 
and H2, corresponding to Y210 and H102, respectively), one hydrogen bond acceptor (A2, 
corresponding to T142) and a single, large lipophilic region (L1) near the center of the binding 
pocket. Additional descriptors include lipophilic regions (L2, L3, and LDi), and regions of negative 
steric repulsion (S1, S2 and S3). Other lipophilic interactions between the ligand and receptor 
include van der Waals interactions and π – π stacking between aromatic regions of the ligand and 
groups within the receptor protein. Each one of these interactions play an important role in binding 
affinity, efficacy, potency, and subtype selectivity.17, 74 
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Figure 8. Relative locations of the descriptors and regions of the unified pharmacophore/ receptor model.  The 
pyrazolo[3,4-c]quinolin-3-one CGS-9896 (dotted line), a diazadiindole (thin line), and diazepam (thick line) 
aligned within the unified pharmacophore/receptor model for the Bz BS.  H1 and H2 represent hydrogen bond 
donor sites within the Bz BS while A2 represents a hydrogen bond acceptor site necessary for potent inverse 
agonist activity in vivo.  L1, L2, L3 and LDi are four lipophilic regions and S1, S2, and S3 are regions of negative 
steric repulsion. LP = lone pair of electrons on the ligands (modified from the figure in Clayton, et al.). 17 
 
2.2 Halogen-Acetylene Switch 
 Two lipophilic regions that have been found to be key in the development of ligands for 
the benzodiazepine binding site of the GABAAR are the L2 and LDi regions. A comparison of 
diazepam and QH-II-066 (Figure 9) shows that switching the chlorine in diazepam to an acetylene 
in QH-II-066 in the L2 pocket significantly increased the α5 to α1 selectivity from 1.27 to 11.22, 
respectively for diazepam and QH-II-066.75 In terms of selectivity, the switch from a chloride to 
an acetylene produced an 8.83 selectivity factor for the α5 subtype over the α1 subtype. This was 
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important for the reduction of the adverse effects commonly exhibited by BZDs.41, 42 In addition, 
tolerance has been shown to develop from the coupling of the α1 and α5 subtypes by Möhler, et 
al.88 Reduction of agonist efficacy at both the α1 and α5 subtypes, disproportionately as compared 
to other subtypes, has resulted in ligands with little or no development of tolerance.89-93 This 
selectivity has been seen in many other cases as well, a few of which are depicted in Figure 10. 
Two compounds, the data from which in vitro and in vivo studies, have greatly shaped the 
development of future ligands, XHe-II-053 (1) and JY-XHe-053 (2). These two ligands will be 
discussed in further detail in the next section. The LDi pocket has also been seen as critical in 
developing new ligands. Based on the molecular modeling,17, 74 this region appears to be located 
near the extracellular region of the receptor binding cleft and may be the key to fine tuning ligands. 
 
 
Figure 9. In vitro Bz/GABAA receptor binding data of diazepam and QH-II-066.75, 94 
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Figure 10.  Comparison of BZD receptor binding data at α1 and α5 GABAA receptors which illustrates 
increased selectivity at α5 subtypes, as compared to α1 subtypes; where change in selectivity = (Acetyleneα1/α5) 
/ (Halogenα1/α5). 
 
 In addition to the synthesis of a library of ligands, which bind to the BzR site of the 
GABAAR, to be used for the study of the basic neuroscience behind the receptor subtype, the goal 
of this research was to design ligands which can potentially be used in the treatment of epilepsy, 
anxiety, neuropathic pain and cognition disorders. Because the adverse side effects of BZD ligands 
are mediated by α1 subtypes and tolerance is effected by the coupling of the α1 subtypes to the α5 
subtypes, the goal here is reduced agonist efficacy at α1 subtypes for all ligands, and reduced 
agonist efficacy at the α1 and α5 subtypes for ligands targeting epilepsy, anxiety, neuropathic and 
inflammatory pain. 
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3 DESIGN OF α2/α3 SUBTYPE SELECTIVE LIGANDS AND 
THEIR USE IN EPILEPSY, ANXIETY AND NEUROPATHIC AND 
INFLAMMATORY PAIN 
3.1 Introduction 
 Anxiety disorders as a group are among the most common mental disorders afflicting over 
18% of the US population.95 These disorders include generalized anxiety disorder (GAD), 
obsessive-compulsive disorder (OCD) and panic disorder among others. These disorders can 
significantly lower a patient’s quality of life. Classical BZDs, such as diazepam, and selective 
serotonin reuptake inhibitors (SSRIs) are two common treatments; however, BZDs are often the 
drugs of choice since many SSRIs can increase anxiety before becoming effective, and can cause 
sexual dysfunction and generally take three to four weeks to reach an effect.96, 97 Diazepam is one 
classical BZD that has been prescribed for over 50 years for anxiety, but the adverse effects limit 
its long-term effectiveness and improved treatments are needed that are devoid of sedation, ataxia, 
amnesia and addiction. 
 Neuropathic pain is a disease that affects the somatosensory nervous system and is 
characterized by increased sensitivity to pain (hyperalgesia), or the sensation of pain from stimuli 
that is, in the absence of neuropathic pain, non-painful (allodynia). Anticonvulsants pregabalin and 
gabapentin (Figure 11) are two of the first-line treatments for neuropathic pain, but have, in many 
patients, serious adverse effects including drowsiness, ataxia and an increased risk of suicide in 
some cases. In addition, they are synergistic with alcohol, which presents a dangerous driving 
situation. Opioids, such as morphine, fentanyl, dihydrocodiene and methadone, are some of the 
most effective forms of treatment against neuropathic pain, including in chronic conditions, and 
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act upon the µ-opioid receptor. These are generally only used in severe cases and never as first-
line treatment as the adverse effects include constipation, tolerance, physical dependence and 
addiction among others.98 In some cases, they can result in dysphoria. Pain syndromes are also 
treated with COX-2 inhibitors, such as celecoxib (Celebrex); however, some of these have 
increased the risk of non-fatal heart attacks and strokes.99, 100 
 
Figure 11. Anticonvulsants pregabalin and gabapentin, opioids morphine and methadone, and the COX-2 
inhibitor celecoxib, which are used for treatment of neuropathic pain. 
  
 Recently in the pain area, the analogs of salvinorin A by Prisinizano, et al.101 and the 
enantiomer of (+)-Naloxone by Rice, Hutchinson, Watkins, et al.102 have been found to reduce 
nociception without tolerance or withdrawal. The enantiomer of Naloxone (marketed, opioid 
antagonist for overdose) work on toll-like receptor 4 (TLR4)103 and not opioid receptors. Intense 
research in these agents are underway and one idea is to mix them with α2/α3 Bz/GABAA agonists 
to determine if the effects are synergistic, addictive or neither in the treatment of pain.  
 Over the years, there have been a number of promising leads for the treatment of anxiety 
and neuropathic pain that have fallen out of favor for various reasons. A series of 
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triazolopyridazines, which are partial agonists at the benzodiazepine binding site, were withdrawn 
from the clinic for various reasons. The L-838417, a partial α2-, α3-, and α5-PAM with 
antagonistic effects at the α1 subtype promoted anxiolytic properties in rodents42 and was effective 
against inflammatory and neuropathic pain;48 however, the pharmacokinetic profile halted the 
development.104 The agent TPA-023, a non-sedating, anticonvulsant, anxiolytic in humans,105 
made it into Phase II clinical trials where long term dosing studies found the formation of 
cataracts.106 The ligand MRK-409 (MRK-0343) produced anxiolytic effects in both rodents and 
primates void of sedation but when given to humans, pronounced sedation was observed at 2 
mg/kg.107 TP023B showed a similar profile to MRK-409 in both rodents and primates, but also 
displayed sedation and significant ataxia at 2 mg/kg in humans.108 A benzimidazole, NS11394, 
exhibited antinociceptive effects in rodents;109, 110 however, learning and memory impairment has 
been observed, likely resulting from the high efficacy at the α5 subtype.111 
Over the past decade there has been growing evidence that an α2 GABAAR subtype 
selective ligand can be used in the treatment of neuropathic pain. Molecular modeling17, 74 has 
shown that the α2 and α3 binding pockets are nearly identical, which results in ligands that can 
target both anxiety and neuropathic pain with reduced adverse effects, that exhibit agonist efficacy 
at α2/α3 Bz/GABAA subtypes. One of the problems of the Merck compounds was the extremely 
potent affinity at the DS subtypes (α1, α2, α3 and α5), even though they were reported as 
antagonists at the α1 and α5 subtypes. This high potency at all four DS subtypes may have led to 
potent off target effects at other receptor populations and may have resulted in the adverse effects. 
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3.2 Background 
 The ligand XHe-II-053 (1) was one of the first new generation of ligands which contained 
the C(8) acetylene in place of a halogen atom in ring A. This halogen-acetylene switch provided a 
series of BzR/GABAA ligands with either reduced potency or efficacy at the undesired α1 subtype. 
In addition, an imidazo-fragment was added to these ligands to further separate them from 
diazepam and other classical benzodiazepines. Ligands of this type were found to be selective for 
the α2 and α3 GABAARs in both binding affinity and the oocyte efficacy (Figure 12).112, 113 
Anxiolytic XHe-II-053 was in Phase I clinical trials (Bristol-Myers Squibb) and was active as an 
anticonvulsant and anxiolytic, but the metabolism of the ethyl ester function in the liver kept 1 
from progressing to Phase II. 
 Two related ligands were made replacing the 2'-H atom with a fluorine and nitrogen to 
obtain JY-XHe-053 (2) and HZ-166 (3), as depicted in Figure 13. Increased electron density is 
known to increase the potency in classical 1,4-BZDs,114 and the reason for this may be due to the 
ability of the fluorine or nitrogen at the 2'-position to form a three-centered hydrogen bond with 
the hydrogen bond donor H2 and the N(5) imine lone pair of electrons (see Clayton, Clayton and 
He for details)17, 74, 75 While 2'-F ligand 2 was found to be more potent in binding affinity and a 
more potent anticonvulsant,89, 90, 115 this trend was seen at all subtypes including an increase at the 
α1 subtype. This led to minimal sedation at 10 mg/kg in primates112 which was likely due to the 
efficacy of the 2'-F compound 2 at the α1 subtype. However, 2'-N ligand HZ-166 (3) was found to 
have a weaker binding affinity at all subtypes, including the greatest decrease at the α1 subtype. 
However, examining the efficacy profiles of 2 and 3 show that HZ-166 retains the α2/α3 selectivity 
with reduced efficacy at both the α1 and α5 subtypes, as compared to lead ligand 1.112, 113 
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Figure 12. Structure, binding affinity, and oocyte efficacy of XHe-II-053 (1). 
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Figure 13. Structures, binding affinities, and oocyte efficacies of JY-XHe-053 (2) and HZ-166 (SH-053-2'N, 3).  
 
 The ligand HZ-166, as well as JY-XHe-053 and others, were sent to the Anticonvulsant 
Screening Program (ASP) at the National Institutes for Neurological Disorders and Stroke 
(NINDS) and were evaluated to determine their anticonvulsant activity. In both rat and mouse in 
vivo experiments, 3 was able to protect the test subjects from subcutaneous pentylenetetrazole 
(scMET)-induced seizures with ED50’s of 16.3 in rats and 98.5 mg/kg in mice when given an i.p. 
administration.115 Chronic dosing of 3 for five days at NINDS did not lead to the development of 
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tolerance in the scMET assay.116 In addition, HZ-166 was shown to be a non-sedating anxiolytic 
in the Vogel conflict procedure in rhesus monkeys at 1 mg/kg. Ligand JY-XHe-053 (2), on the 
other hand, was able to protect rodents from seizures and had significant anxiolytic activity at 0.3 
mg/kg in monkeys, but the increased efficacy at the α1 subtype likely led to partial sedation in the 
monkeys at 3 mg/kg; whereas HZ-166 did not exhibit sedation at 10 mg/kg, the highest dose 
tested.112 
 The 2'-N analog HZ-166 has also been shown to be active in mouse93 and rat89, 90 models 
of inflammatory and neuropathic pain, which exhibited an antihyperalgesic effect without 
producing general analgesia.93 A dose-dependent comparison revealed a lower ED50 for ligand 3 
(5.3 mg/kg) than for gabapentin (6.2 mg/kg), without signs of sedation (ED50 = 97 mg/kg) or ataxia 
(no significant rotarod performance reduction at 160 mg/kg) at the therapeutically relevant dose.93 
A 17-day study of tolerance (chronic versus acute) employing the von Frey filament test in the 
chronic constriction injury (CCI) paradigm indicated HZ-166 (3) performed equally well in the 
chronic study as it did when naïve mice were treated after 17 days.93 This lack of tolerance to the 
antihyperalgesic effects is in agreement with the findings that targeting the α2 subunit will not 
result in the development of tolerance,50 as well as the lack of tolerance to the anticonvulsant 
effects of HZ-166. 
 In addition to behavioral studies, lead ligands were tested by SRI International in vitro for 
stability on human liver microsomes (HLMs).117 As expected, based on Phase I clinical trials of 
the initial lead ligand 1, XHe-II-053 (1) was rapidly metabolized with only 1.5% of the parent 
compound remaining after a one hour incubation with HLMs while JY-XHe-053 (3) exhibited a 
similar metabolic profile with 0.3% of the parent compound remaining after incubation for one 
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hour. The more polar 2'-N analog, HZ-166, on the other hand, proved to have an increased 
resistance to metabolism in HLMs with 80.2% of the parent compound remaining after one hour.117 
Despite these positive results for HZ-166 (3), it was found that rodent metabolism still 
degraded the compound too rapidly due to the high level of esterases in rodents based on the time-
of-effect of HZ-166 in anticonvulsant115 and antihyperalgesia93 studies. This was a major problem 
as many preclinical trials are performed in rodents and evaluation of ligands might be halted due 
to the metabolic instability. The chemistry and biology that follows focuses on new ligands that 
are structurally based to HZ-166 and its privileged scaffold. The goal of the development of these 
ligands was to retain the α2/α3 subtype selectivity, while increasing the metabolic stability in 
rodents while stability in HLMs remained high.  
 
3.3 Chemistry and Results  
3.3.1 The Synthesis of HZ-166 (3) 
 The synthesis of HZ-166 (3) was undertaken on a large scale, as illustrated in Scheme 1. 
The commercially available 2-amino-5-bromobenzoic acid 5 was condensed with the anion of 2-
bromopyridine 4 to give the 2'-N ketone 6 in 74% yield on a 100 gram scale. The amine 6 was 
acetylated with bromoacetyl bromide in the presence of sodium bicarbonate, followed by the 
cyclization by treatment of a saturated solution of ammonia (gas) in methanol at reflux to form the 
1,4-benzodiazepine 7 in 78% overall yield for the two steps. The imidazole ring was prepared 
using an improved method118 by treating amide 7 with potassium tert-butoxide and 
diethylchlorophosphate at -35 oC before the addition of ethyl isocyanate at -78 oC with potassium 
tert-butoxide to provide imidazobenzodiazepine 8 in 81% yield. The previous method employed 
sodium hydride as a base at higher temperatures, and yields were consistently below 40%. A Heck-
24 
 
type coupling reaction with the bromide 8 and trimethylsilylacetylene provided 9, which was 
deprotected using tetrabutylammonium fluoride to provide the HZ-166 3 in 81% overall yield over 
two steps on a 20 gram scale. 
 
 
Scheme 1. Synthesis of HZ-166 (3). Amounts listed are the greatest scale for each reaction. They 
do not correspond to the product which resulted from the previous reaction. 
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The synthesis of HZ-166 (3) on large scale was developed to prepare related analogs for 
SAR/efficacy at Bz/GABAA receptors, as well as to send to collaborators for their in vivo studies 
of efficacy, anxiolytic activity, antinociceptive activity and metabolism. Some of these ligands 
have been found in vivo to have clinical potential.93, 112, 115 
 
3.3.2 The Synthesis of Esters to Characterize the LDi Pocket 
 A series of esters were synthesized which were designed to explore the effects of size 
within the LDi pocket, as well as effects on metabolism. The majority of these reactions were 
carried out by stirring small freshly cut pieces of lithium rod in an alcohol at 40 oC, before adding 
HZ-166 (3) which had been dissolved in THF (Scheme 2). The reaction was monitored by TLC 
(silica gel), and must be closely monitored. This is because the small changes in polarity and size 
between the parent ethyl ester 3 with the new esters, especially the isopropyl 11 and n-propyl 13 
esters, resulted in such similar structures, it was important to make sure all the starting material 
was consumed so the use of a small wash column could be employed for purification. Additionally, 
when the reaction was allowed to proceed for longer periods of time after the starting material was 
consumed, additional byproducts that began to develop would complicate purification. It was also 
discovered that this reaction was best performed in a dryer atmosphere as moisture and CO2/O2 in 
the air quickly oxidized the freshly cut lithium. To balance this in times of high humidity, the 
lithium rod was cut while submerged in oil and then transferred to the reaction flask; this, however, 
resulted in a longer reaction time and also led to longer chromatography (column, silica gel, 
pressure) during purification to remove all the oil.  
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Scheme 2. Synthesis of esters from HZ-166 (3) using lithium and the corresponding alcohols. 
 
 
 
 The methyl ester was also desired for this series of esters because of the possibility of beta-
oxidation in the liver during the metabolism of ester 3 (HZ-166) to the carboxylic acid SR-II-54 
(20). This was completed by dissolving 3 in methanol, adding sodium methoxide and refluxing for 
30 minutes, as depicted in Scheme 3. It was known (Rowlett, et al., unpublished results) that while 
the ester 3 was an anxiolytic in the Vogel conflict procedure in monkeys, the acid was not active. 
This was presumably because the acid does not readily cross the BBB. This was proven earlier for 
the acid metabolite of 1 which did not cross the BBB (Lelas, et al., BMS, unpublished results). 
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Scheme 3. Synthesis of the methyl ester MP-III-024 (19). 
 
 
 It has been previously shown that the additional mass from the deuterium isotope can 
extend the half-life of a compound.119 The strength of a C-D bond is about 9 times that of a C-H 
bond.120 The deuterated ethyl ester 21 was designed and synthesized in an attempt to utilize this 
technique to increase the half-life of HZ-166. Unlike the synthesis of other esters (10 – 19) which 
were synthesized in one reaction, MP-III-068 (21) required preparation in the absence of ethanol, 
including the ethyl ester function, which could result in a mixture of 3 and 21. To avoid this mixture 
of products, HZ-166 was first converted into the acid (SR-II-54, 20) by saponification with sodium 
hydroxide at reflux and a subsequent acidification with hydrochloric acid.121 The d2-ethyl ester 21 
was then synthesized by stirring 20 with 1,1-dideuterated ethyl bromide in the presence of cesium 
carbonate, as shown in Scheme 4. 
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Scheme 4. Synthesis of the deuterated ethyl ester, MP-III-068 (21). 
 
 
 
 
3.3.2.1 Analysis of the In vitro Metabolic Stability of the Esters 
 To analyze the effect of the ester on stability, liver microsomal studies were completed 
(Table 2); some of which were tested by a contract research organization (CRO) and others by 
Revathi Kodali at the University of Wisconsin-Milwaukee (UWM). The two assays were both run 
using liver microsomes from either human (HLM) or mouse (MLM) liver microsomes, while the 
CRO also ran the compounds in dog (DLM) and rat (RLM) microsomes. Although both assays 
used microsomes along with NADPH as an energy source at 37 oC, they were run under different 
conditions, with the CRO incubating the compound at a 4 μM final concentration for 30 minutes. 
The assays from UWM were run at a 10 μM final concentration for 60 minutes. In the comparison 
between the two assays, compounds 3 and 19 were the only ones run in both assays and gave 
similar results. The results for HZ-166 (3) also agree well with previously published data117 in both 
assays.  
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Table 2. Metabolic stability of esters and the carboxylic acid (20). 
CRO Results Metabolic stability in liver microsomes (reported in 
%-remaining) 
Conditions: 4 µM compound, 37 oC, 30 minutes 
clogPa 
 
Species Human 
(HLM)b 
Dog 
(DLM)b 
Mouse 
(MLM)b 
Rat 
(RLM)b 
(Diazepam = 
2.96) 
XHe-II-053 (1) 40 83.7 9.9 8.7 3.11 
JY-XHe-053 (2) 8.9 83.8 5.1 0.7 2.91 
HZ-166 (3) 80.4 97.2 54.1 50.2 1.71 
MP-III-068 (21) 95.1 100 63.1 76.6 1.71 
MP-III-024 (19) 92.2 72.6 73.3 92.7 1.18 
SR-II-54 (20) 95.9 100 92.7 99.3 1.82 
UWM Results Conditions: 10 µM compound, 37 oC, 60 minutes  
Species HLM  MLM   
HZ-166 (3) 69  45  1.71 
MP-III-024 (19) 80  75  1.18 
MP-II-067 (10) 66  46  2.42 
a This was calculated used clogP on the ChemDraw 13.0 software; as compared to diazepam 
b Human liver microsomes (HLM), dog liver microsomes (DLM), mouse liver microsome (MLM) and rat liver 
microsomes (RLM). 
 
 Analysis of the data on the ethyl esters 1 – 3 from the CRO indicated that, as previously 
shown, HZ-166 (3) was more stable than either 1 or 2 in all species. Rodent microsomes degraded 
all compounds more rapidly than either human or dog, and this is likely due to a higher 
concentration of esterases in rodents that in humans or dogs. The short time-of-effect for HZ-166 
(3) in studies of anticonvulsant115 and antihyperalgesia93 may also be explained by this rapid 
metabolism by esterases in rodents. This low rodent stability of 3 was also seen in MLM’s in the 
results from UWM at 45% remaining after one hour. 
30 
 
 Currently, only two additional (non-deuterated) esters have been tested, the methyl ester 
19 and the tert-butyl ester 10. The methyl ester (MP-III-024, 19) was tested in both assays and 
shows a consistent increase in stability in comparison 3 in all species except DLM, which 
decreased from 97% to 73%. In rodents, the stability of methyl ester 19 compared to the ethyl ester 
3 increased from 45% to 75% and 54% to 73% in the UWM and CRO results, respectively. In 
addition, 19 exhibited little degradation against RLMs at 93% remaining after 30 minutes. This 
supports the hypothesis that some of the metabolism of 3 was effected by oxidation in the liver of 
the ethyl group to acetaldehyde. Compound 10 displays almost no change from 3. The increased 
metabolic stability of the methyl ester 19 in rodents led to the decision to test MP-III-024 (19) in 
anxiolytic and antihyperalgesic assays, the positive results of which are presented in Section 
3.3.2.3. 
 The incorporation of deuterium into the ethyl ester functionality, as seen in MP-III-068 
(21), was successful in decreasing metabolism of the ethyl ester in all species. Slight increases in 
stability of 21 compared to 3 were exhibited in DLMs, which was already highly stable, and MLMs 
rose from 54% to 63% remaining. The greatest increase in stability of MP-III-068 (21) was seen 
in RLMs which increased from 50% to 77%. At this juncture it appeared beta oxidation was, in 
some part, responsible for the metabolism of the ethyl ester in HZ-166 (3). This is the reason an in 
vivo pharmacokinetic study on MP-III-068 (21) and HZ-166 (3) was carried out, and is discussed 
in Section 3.3.2.2.  
 One trend that can be seen to occur is that the more polar compounds have an increased 
resistance to liver microsomes. This of course agrees entirely with the function of liver microsomes 
since they are there to convert nonpolar ligands into polar metabolites which can be conjugated 
and excreted more readily via the kidneys. Of the ethyl esters, 3 was the most polar and the most 
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stable. The varying ester functionalities of 3, 19, and 10 also display this trend; it should be noted, 
however, that the size of the ester could play a role, at least in the case of the methyl ester MP-III-
024 (19).   
 
3.3.2.2 The In vivo Pharmacokinetics of HZ-166 (3), MP-III-068 (21) and SR-II-54 (20) 
 The replacement of the ethyl (-CH2CH3) group in HZ-166 (3) to a deuterated ethyl (-
CD2CH3) group in 21 was able to increase the amount of parent compound remaining after an 
incubation in RLMs for 30 minutes from 50% to 77%. In addition, the carboxylic acid 20 was 
shown to have very little degradation across all species and was a predicted metabolite of the result 
of the degradation of the ethyl esters 3 and 21. This was shown earlier by a CRO clearly, that the 
acid 20 was the principle metabolite of HZ-166 (3), see Appendix A. A pharmacokinetic study 
was completed using the three compounds in rats. The compounds were given intravenously (IV) 
at a 1 mg/kg dose and oral administration (per os; P.O.) at a 10 mg/kg dose. Plasma samples (n = 
3/time point) were taken at time points ranging from 0 hours to 16 hours.  
Examination of the results found that neither HZ-166 (3) nor the deuterated analog (21) 
was stable in the assay in vivo as each was below the quantification limit (BQL) at every time point 
(Table 3). The acid 20, which showed only a 0.7% degradation in the RLMs, was able to be 
quantified and the time-plasma concentration curve is depicted in Figure 14. Because neither 3 nor 
21 was stable enough in the in vivo assay to be quantified, this still does not rule out beta oxidation 
in part, as a mechanism for conversion of 3 or 21 into the acid 20 and in fact the more stable d2-
analogs 21 is consistent with this pathway, in part. 
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Table 3. Time-plasma concentration of 3, 21 and 20 in IV and P.O. dosing in rats (n = 3 per time point). 
 Total Time Concentrations (time in h.; concentration in nM) 
IV (1 mg/kg)a 0.25 0.5 1.0 2.0 
3 BQL BQL BQL BQL 
21 BQL BQL BQL BQL 
20 450 148 33.5 3.5 
P.O. (10 mg/kg)b 0.25 0.5 1.0 2.0 
3 BQL BQL BQL BQL 
21 BQL BQL BQL BQL 
20 248 293 161 37.5 
BQL – below quantification limit 
a Quantifiable limit < 2.81 nM in IV samples. 
b Quantifiable limit < 12.2 nM in PO samples. 
 
 
 
 
Figure 14. Plasma concentration-time profile of SR-II-54 (20) when given IV (1 mg/kg) and P.O. (10 mg/kg); n 
= 3 per time point. 
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 Despite the fact that the acid 20 was metabolically stable in vivo in this system, it is very 
far from a useful compound. In a separate experiment, examination of Table 4 shows that 20 was 
unable to be detected in the brain at the two hour time point when given at a 10 mg/kg P.O. dose. 
When taken with the plasma concentration-time profile, it can be concluded that 20 was unable to 
readily penetration the BBB. When the ethyl ester 3 was given, which was not detected in plasma 
in the initial pharmacokinetic study, analysis of the brain samples found the metabolite 20, albeit 
in concentrations just about the quantifiable limit (12.2 nM). This suggests that 3 may be able to 
rapidly penetrate the brain upon dosing, and it was slowly metabolized to the carboxylic acid 20. 
This is consistent with the anxiolytic, anticonvulsant and antinociceptive activity in vivo of 3. 
 
Table 4. Brain concentrations at the 2 hour time point of the parent compound which was dosed and 20 after a 
10 mg/kg P.O. of either 3, 21, or 20 in rats (n = 3 per time point). 
 3 21 20 
Concentration of Parent compound BQLa BQL BQL 
Concentration of 20 10b BQL BQL 
a BQL = below quantification limit; Quantification limit < 12.2 nM 
b The three samples averaged 10 nM; individual samples were BQL, 12.5, and 17.5 nM. 
 
Since the parent ethyl ester 3 was BQL in brain samples after two hours but the acid 20 
was detected, it is plausible that 20 may be the compound that is, either in part or in full, producing 
the pharmacological effects seen when 3 is given; or for that matter, any ester or other compound 
that may be metabolized to the acid 20. The oocyte efficacy of 20 is depicted in Figure 15. SR-II-
54 (20), compared to 3 (Figure 13), is much more potent and less selective. Examination of this 
oocyte efficacy profile of the acid 20 exhibited potent efficacy at the α1, α3 and α5 subtypes at 
500 nM, although α1 was very weak at 100 nM. This does not look like the efficacy profile of a 
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non-sedating anxiolytic nor anticonvulsant nor antinociceptive agent. It appears HZ-166 (3) gets 
into the brain rapidly and is metabolized into the acid 20, as mentioned previously. 
 
 
Figure 15. Preliminary oocyte efficacy concentration curve of SR-II-54 (20) on GABAA receptors using an EC3 
GABA concentration (n = 2). 
 
3.3.2.3 The Efficacy and Behavioral Studies on MP-III-024 (19) 
 The methyl ester MP-III-024 (19), related to HZ-166 (3), was found to have significant 
increased resistance to metabolism by rodent microsomes, as previously mentioned, and has been 
evaluated further for efficacy to determine the subtype selectivity (Dr. Margot Ernst, Medical 
University of Vienna) and in behavioral tests to measure the pharmacological effects (Dr. Bradford 
Fischer, Cooper Medical School of Rowan University). 
 The methyl ester MP-III-024 (19) was tested in Xenopus laevis oocytes individually 
expressing a GABAA receptor subunit (α1-3,5β3γ2) for efficacy by Margot Ernst, et al. The test 
consisted of the measurement of chloride currents using a two-electrode voltage clamp at GABA 
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3% effective concentration (EC3). Analysis of the results in Figure 16 show that the methyl ester 
19 was an α3 subtype selective ligand that is nearly silent at the α1, α2 and α5 subtypes. Within 
the generally accepted therapeutic range (100 – 300 nM), 19 positively modulated the α3 subtype 
with low potency. Some researchers have made the case that low potency modulators, sometimes 
called partial agonists, which stimulate the receptor in the 150 – 200% range are preferred over 
full agonists which modulate the receptor over 400%. The reasoning is that full agonists which 
strongly activate receptors can cause desensitization of the receptor. This can lead to the 
development of tolerance to drug effects (private communication with Dr. Werner Sieghart). It 
should be noted that the ligands presented here which have been pursued for therapeutic potential 
are partial agonists in the therapeutic range. In addition, methyl ester 19 should exhibit low risk of 
the common adverse effects associated with activation of the α1 subtype, especially sedation, 
tolerance, ataxia and addiction 
 
Figure 16. Preliminary oocyte efficacy concentration curve of MP-III-024 (19) on GABAA receptors using an 
EC3 GABA concentration (n = 3). 
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 There have been opposing views on which effective concentration to use when performing 
these electrophysiology experiments. Dr. Werner Sieghart (Medical University of Vienna), in a 
private communication, has outlined the complex matter of using EC3 or EC20. One of the 
arguments in favor of employing EC3 in these experiments is that at this concentration the assay 
is generally stable and exhibits low variability if the concentration is slightly off, since it is not in 
the steep linear portion of the dose response curve such as the EC20 would be, as depicted in Figure 
17. In addition, because of a low GABA concentration, the effect seen by a modulator is more 
clearly visible and generally produces a stronger response by percentage. The EC20 was initially 
chosen because the researchers were in favor of using a dose in the linear range of the dose 
response curve; however, this high concentration is rarely encountered in physiological situations. 
For this reason, most of the oocyte efficacy for Bz modulation of GABAA receptors is run at an 
EC3 of GABA in this research. 
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Figure 17. Comparison of a dose-response (DR) curve at EC3 and EC20. 
 
 The α3 subtype selectivity of MP-III-024 (19), with little or no activation of the α1 or α5 
subtypes, indicated that this ligand 19 could be a valuable therapeutic agent. The partial agonism 
at the α3 subtype indicated that 19 is an important ligand to study the α3 subtype; as other previous 
α3 subtype selective ligands were more similar to full agonists. In addition, since the adverse 
effects generally stem from activation of the α1 subunit and tolerance is due to the coupling of the 
α1 and α5 subunits,88 methyl ester 19 should be devoid of these adverse effects. 
 An assessment of MP-III-024 (19) for anxiolytic activity was completed in the operant-
based Vogel conflict procedure in mice by Dr. Bradford Fischer at Rowan University (B. Fischer, 
M. Poe, unpublished results). This procedure first positively reinforces behavior with a food 
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reinforcement before suppressing this response with a noxious stimulus, such as a mild shock.122-
124 Anxiolytic drugs are able to increase the rate of suppressed responding in spite of the noxious 
stimulus. BZDs have been shown to reduce the anxiety of test subjects, including HZ-166 (3) in 
rhesus monkeys.112, 124 One other aspect of the Vogel conflict procedure is that it is also able to 
test for possible signs of sedation. This is observed when the subjects stop responding in the non-
suppressed assay, or when an anxiolytic response is observed in the suppressed portion but 
decreases at higher doses, as seen previously with 2'-F analog JY-XHe-053 (2).112 
 The anxiolytic effects of MP-III-024 (19) in the Vogel conflict procedure are illustrated in 
Figure 18. The C57BL/6 mice (n = 6) were first deprived of water for 24 hours before being placed 
in a chamber with water access for 6 minutes, which created the vehicle data point. Mice were then 
deprived of water a second time before being given access to water for another 6 minutes for the 
suppressed testing session. On the second day of testing, mice were given either vehicle, diazepam 
(1, 3, or 10 mg/kg) or 19 (10, 32, or 100 mg/kg) 30 minutes prior to testing by intraperitoneal (i.p.) 
injection. During the 6 minutes of measured response time, a 0.14-mA shock (0.5 sec) was 
administered for the completion of every 20 consecutive licks from the water spout. Compared to 
vehicle, diazepam was able to increase the suppressed responding rate at all three doses given, 
with a further increase seen between the 3 mg/kg and 10 mg/kg doses. Methyl ester 19 produced 
similar increases, albeit at higher concentrations of 10 and 33 mg/kg.; however, 19 was not tested 
at lower doses and may still be active in the 1 – 3 mg/kg range. At 100 mg/kg of ester 19, the 
response rate of the mice significantly decreased to below vehicle. This indicated that ester 19 may 
appear to exhibit sedation at high doses. Alternatively, since 19 has a low activation of α1, it is 
also possible this decrease in responding is due to muscle relaxation, which may occur at higher 
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receptor occupancy of the α3 subtype. This was observed with α3 subtype selective agonist YT-
III-31 at a CRO in mice (M. Poe, et al., unpublished results. See Appendix A). 
 
 
 
Figure 18. Effects of diazepam and MP-III-024 (19) in the Vogel conflict procedure. Male C57BL/6 mice (n = 
6) were pretreated i.p. with vehicle (0.5% methyl cellulose, 0.9% sodium chloride), diazepam or MP-III-024 
(19) 30 minutes prior to testing. Mice were then placed in a chamber and the amount of licks of water was 
recorded over a 6 minute time period. 
 
 The selectivity of MP-III-024 (19) for the α2 and α3 subtypes and similar efficacy profile 
to HZ-166 (3) resulted in the evaluation of 19 in the mouse model (zymosan A assay) for 
inflammatory pain (Dr. Bradford Fischer). Zymosan A, a yeast extract, was subcutaneously 
injected into a test subject’s right hindpaw which induced inflammation, consequently, the test 
subject becomes more sensitive to mechanical force. Von Frey filaments are then used in 
increasing force to determine the paw withdrawal threshold (PWT). This standard assay has been 
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used to determine the ability of drugs to reduce this hypersensitivity, and HZ-166 (3) has 
previously been shown to reverse these effects in mice by Zeilhofer, et al.93 
 The reversal of hyperalgesia of MP-III-024 (19) was evaluated and the results are depicted 
in Figure 19. The C57BL/6 mice (n = 6) were given a 0.06 mg dose of zymosan A subcutaneously 
into the plantar surface of the right hindpaw 24 hours prior to testing. On the day of testing, mice 
were given a 3.2, 10 or 32 mg/kg dose of 19 i.p. and evaluated for the protection against 
inflammatory pain using a mechanical sensitivity assay. Von Frey filaments were used and 
increasing force was applied at a rate of 1 gram per second until the paw was withdrawn and the 
PWT was recorded. Time points consisted of 10, 20, 40, 80, 160 and 320 minutes after injection 
of methyl ester 19. The left paw, which was not injected with zymosan A, acted as the control paw 
and was also assessed for the PWTs. Mice given a dose of 3.2 mg/kg of 19 show a very slight 
increase in PWT compared to vehicle, while the 10 and 32 mg/kg doses displayed the 
inflammation-sensitive right paw able to withstand more force beginning at the 20 minute time 
point. The inflamed paw which was treated with methyl ester 19 was able to withstand nearly as 
much force as the non-inflamed left paw (control) at time points 40, 80 and 160 in both the 10 and 
32 mg/kg doses. Both higher doses given underwent a significant decrease in antinociceptive effect 
at the 320 minute time point. This was a significant antinociceptive effect. 
 
41 
 
 
Figure 19. Effects of MP-III-024 (19) on inflammatory pain the in von Frey filament test. Zymosan A (0.06 mg 
in 20 µL 0.9% sodium chloride) was injected subcutaneously into the plantar surface of the right hindpaw 24 
hours prior to testing. Male C57BL/6 mice (n = 6) were then dosed with MP-III-024 (19) and mechanical 
sensitivity was assessed using von Frey filaments. The paw withdrawal threshold was recorded. Open symbols 
represent the left (non-injured) hindpaw and the closed symbols represent the right (injured) hindpaw. “BL” 
represents predrug baseline. 
 
 The ethyl ester HZ-166 (3) was previously tested in the zymosan A model of inflammatory 
pain in C57BL/6 mice using von Frey filaments under different, albeit, similar conditions.93 The 
major differences were that 3 was used at a 16 mg/kg dose, zymosan A was injected 48 hours prior 
to the assessment of 3, but the inflamed paw was still the right paw. Examination of this test 
indicated that 3 began to exhibit a decreased antinociceptive effect at the 150 minute time point. 
The study on HZ-166 (3) also indicated an increase in PWT; however, the maximum possible 
effect (MPE) was slightly over 50%, which occurred at the 1 hour time point. It can be speculated 
that the longer time-of-effect of MP-III-024 (19) over 3 could be due to the decreased degradation 
of 3 seen in the in vitro liver metabolism studies presented above (Table 2), and the improved 
efficacy profile of 19 over 3 lead to an MPE of nearly 100% at 10 mg/kg for methyl ester 19. 
However, because these ligands were tested under slightly different conditions, the conclusions 
need to be verified with further experiments with the methyl ester 19 under the same conditions 
that HZ-166 (3) was evaluated before an accurate direct comparison can be made. Nevertheless, it 
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is clear that MP-III-024 (19) is a more potent antinociceptive agent with a longer duration of action 
in the mice employed here. 
 As previously mentioned, traditional BZDs come with a host of adverse effects including 
sedation, muscle relaxation, ataxia, addiction and amnesia, which primarily originate from 
interaction at the α1 subtype. Methyl ester 19 and diazepam were assessed in the locomotor activity 
assay which does evaluate the occurrence of some of these adverse effects (Figure 20). In the 
locomotor activity test, C57BL/6 mice were dosed with either vehicle, diazepam (0.32, 1, 3.2 or 
10 mg/kg), or ester 19 (3.2, 10 or 32 mg/kg) and monitored for 60 minutes; the total amount of 
distance traveled was tracked. Diazepam, which is known to cause sedation and muscle relaxation, 
began showing an immediate decrease in distance traveled at the lower dose (0.32 mg/kg) as 
compared to vehicle. The 1 and 3.2 mg/kg doses of diazepam exhibited similar results to that of 
0.32 mg/kg, while the mice dosed with 10 mg/kg were nearly inactive in comparison to the vehicle. 
Ester MP-III-024 (19) showed no significant decrease at any dose test (3.2 – 32 mg/kg). All three 
doses with 19 performed on par with vehicle, indicating that methyl ester 19 does not affect mice 
in this assay up to 32 mg/kg, a highly effective dose in both the Vogel conflict and zymosan A 
models from above. This is a dose of 32 mg/kg at which the therapeutic index of methyl ester 19 
is at least 10-fold or more. 
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Figure 20. Effects of diazepam and MP-III-024 (19) on locomotor activity. Male C57BL/6 mice (n = 6) were 
dosed i.p. with vehicle (0.5% methyl cellulose, 0.9% sodium chloride), diazepam or MP-III-024 (19). Mice were 
then assessed for locomotor activity and the total distance traveled was recorded. “V” represents distance 
traveled after vehicle administration. 
 
 The response rate on operant behavior is another model designed to measure a compounds 
adverse effects. In many cases, if a subject is given a large enough dose, it should suppress general 
behavior and is used as an important benchmark to reveal behavioral specificity. If the general 
behavior is changed at a specific dose, it is possible that other assays may be effected by this 
suppression of normal behavior at said dose. In this case, MP-III-024 (19) was assessed for the 
change in operant behavior to determine whether the results in the Vogel conflict procedure and 
antihyperalgesia were true results, or were affected by this suppression. 
 In the operant behavioral model, C57BL/6 mice (n = 6) were dosed i.p. with vehicle or 
methyl ester 19 (10, 32 or 100 mg/kg) and examined for a response rate. At all doses, ester 19 
performed comparably to vehicle with times ranging from 10 minutes after injection to 160 
minutes. These results indicate that MP-III-024 (19) has no effect on operant behavior. 
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Figure 21. Effects of MP-III-024 (19) on operant behavior. Male C57BL/6 mice (n = 6) were dosed i.p. with MP-
III-024 (19) and were placed on a fixed ratio of liquid food. Training and test sessions consisted of multiple 
cycle components, and each culminated in a 5 minute response period. 
  
 Taken together, the efficacy and behavioral results of ester MP-III-024 (19) presented here 
indicate 19 could be a useful tool to study anxiety and pain and has clinical potential for the 
treatment of anxiety and neuropathic pain. The oocyte efficacy profile indicated that ester 19 would 
have very few concerns in regard to adverse effects given the low activation at α1 subtypes, as 
well as little chance for the development of tolerance which stems from the coupling of the α1 and 
α5 subtypes as reported by Möhler, et al.88 In the anxiolytic Vogel conflict procedure, MP-III-024 
(19) displayed an increased response rate during the suppressed session at 10 and 32 mg/kg, but a 
decreased response rate at 100 mg/kg. This is likely not a concern as the 100 mg/kg dose would 
be well above the pharmacologically relevant dose. Examination of the efficacy indicated that MP-
III-024 (19) would not be active in neuropathic pain due to the very little positive modulation of 
the α2 subtype; however, the results in the in vivo zymosan A assay have shown the opposite. The 
antinociceptive inflammation assay indicated 19 was effective in reversing the zymosan A-induced 
hyperalgesia at the effective doses of 10 and 32 mg/kg. Low activation of the α1 subtype at these 
effective doses was indicated by the results of the locomotor activity test. Finally, the results of 
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the Vogel conflict procedure and the zymosan A assay for inflammatory pain can confidently be 
attributed to anxiolysis and antihyperalgesic actions exerted by the imidazobenzodiazepine (IBZD) 
19 because ester 19 did not reduce the responding rate in the operant behavior test even at 100 
mg/kg. The high resistance to rodent liver metabolism is also encouraging; however, the ester 
functionality may still be too readily metabolized as the time-of-effect is shown to be between 160 
and 320 minutes ( > 5 hours) based on the zymosan A model of inflammatory pain. It should be 
noted however, that an effect which lasts 2 hours in mice/rats will be about 4 hours in dogs, 8 hours 
in primates and 12 hours in humans. Because MP-III-024 (19) exerted an antihyperalgesic effect 
as an α3 selective ligand, this agent bears further preclinical trials. 
 
3.3.3 Further Alterations of the C(3) Ester Position of Antinociceptive/ Anxiolytic Agent HZ-
166 (3) 
3.3.3.1 The Synthesis of Oxygen-Containing Analogs 
 In addition to the esters, which were designed to explore the effect the alkyl chain would 
have on affinity at the binding pocket and efficacy, the alcohol MP-II-023 (22) and aldehyde MP-
II-050 (23) were synthesized to determine the effects of electronics on receptor binding. The 
alcohol, 22, was synthesized by dissolving 3 in dry THF at room temperature and adding lithium 
aluminum hydride, as depicted in Scheme 5. The alcohol 22 which resulted was then oxidized 
using Dess-Martin periodinane in methylene chloride to afford the aldehyde, MP-II-050 (23) in 
good yield.  
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Scheme 5. Synthesis of the alcohol MP-II-023 (22) and aldehyde MP-II-050 (23). 
 
 
 The synthesis of the alcohol went through several stages of development before the 
determination of the best reaction conditions, illustrated here. Initially, milder reducing agents, 
such as lithium and sodium borohydride, were used but these were unable to reduce the ester at 
room temperature or higher temperatures. When lithium aluminum hydride was employed, the 
N(5)-C(6) imine bond was reduced in some molecules, even when one equivalent was used at low 
temperatures. This also complicated the purification process as the two alcohols were difficult to 
separate by column chromatography (streaking occurred). Diisobutylaluminium hydride (DIBAL) 
was also used in attempts to directly convert ethyl ester 3 to the aldehyde 23. These attempts were 
either unsuccessful, or successful in low yields, again with the reduced imine bond at the N(5)-
C(6) position. It should also be noted that during oxidation of the alcohol 22 to the aldehyde 23, a 
mixture of the imine at N(5)-C(6) with the C(3) alcohol along with the reduced imine with the C(3) 
alcohol were used, the imine would also be oxidized to recover product. However, the imine bond 
also isomerized to the C(4)-N(5) position. 
 Based on the pharmacophore/receptor model,17, 74 it is unlikely that the alcohol, MP-II-023 
(22), would result in a compound active for anxiety or neuropathic pain. The reason for this is that 
the loss of the ester function creates a molecule 22 with fewer hydrogen-bond acceptors in the LDi 
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region limiting interaction with the H1 (Y210) descriptor. This descriptor has been shown to be an 
important interaction for positive allosteric modulation.17, 74 
 
3.3.3.2 The Synthesis of Nitrogen-Containing Analogs at C(3) 
 Previously the synthesis of nitrogen-containing analogs of HZ-166 (3) at C(3) included the 
methyl (24), dimethyl, and diethyl amides, illustrated in Figure 22. Ligand HJ-I-040 (24) has been 
tested in oocytes for efficacy and was found to be a potent α3 subtype selective PAM.117 In relation 
to the methyl ester MP-III-024 (19), ligand 24 was much more selective for the α3 subtype; 
however, the potency at the α1 and α5 subtypes are greater for 24 as well as exhibiting a weaker 
potency at the α2 subtype. Based solely on the efficacy profile, methyl ester 19 appeared more 
likely to be useful for the treatment of anxiety and neuropathic pain, although N-methyl amide 24 
remains a great research tool for the study of the physiological effects of selective efficacy at the 
α3 subtype. 
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Figure 22. Previously synthesized amides, HJ-I-040 (24), ZJW-II-61 and ZJW-II-60 and the oocyte efficacy 
data of N-methyl amide HJ-I-040 (24). Concentration curve of 24 on GABAA receptors suing an EC3 GABA 
concentration (n = 4, modified from the figure in Namjoshi, et al.).117 
 
 To expand the scope of the amides, the ethyl amide, MP-II-037 (25) and cyclopropyl 
amide, MP-II-046 (26), were synthesized, as depicted in Scheme 6. The acid SR-II-54 (20) was 
stirred in methylene chloride with thionyl chloride and then heated to reflux. The conversion to 
the acid chloride was complete when the solution became homogeneous, since acid 20 is insoluble 
in CH2Cl2 and was initially suspended in the mixture. The reaction was cooled to room temperature 
and the solvent was removed under reduced pressure. Methylene chloride was added and flash 
evaporated three times to eliminate any excess hydrochloric acid and thionyl chloride. The residue 
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was redissolved in CH2Cl2, cooled to 0 
oC and the required amine was added. This solution was 
slowly allowed to warm to room temperature and monitored for the appearance of the amide on 
TLC (silica gel). The reactions were worked up in the usual manner (see Experimental for details) 
and purified by column chromatography. The structures were determined by 1H and 13C NMR and 
compared to the spectrum of HZ-166 (3). The high resolution mass spectroscopy was in complete 
agreement with the structure determination.  
 
Scheme 6. Synthesis of amides, MP-II-037 (25) and MP-II-046 (26). 
 
 
 
 The ethyl amide 25 was chosen as a direct comparison to 3 to further evaluate an SAR 
between esters and amides because of the structural similarity at C(3) to 3. The cyclopropyl amide 
26 was chosen to substitute an amide with an alkyl group which was similar in size to the ethyl 
ester function, but less prone to hydrolysis by peptidases or hydrolases in vivo. The synthesis of a 
larger number of amides was initially reduced until the ester series had been screened in regard to 
binding or efficacy data. This data would then be analyzed to determine the effects of the size of 
the alkyl chain and the corresponding amides would subsequently be synthesized. Currently, the 
esters are awaiting oocyte efficacy evaluation and binding affinity. 
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 The nitrile, MP-II-064 (27), was designed to help determine how the degrees of freedom 
of the hydrogen-bond acceptor H1 in the binding site play a role in binding and efficacy because 
of the linearity of the nitrile function. This synthesis is illustrated in Scheme 7 where HZ-166 (3) 
was stirred in xylene and heated to 80 oC, followed by the addition of dimethylaluminum amine.125 
The dimethylaluminum amine was made fresh126 immediately prior to its use by saturating CH2Cl2 
with ammonia gas and adding trimethylaluminum. The nitrile reaction was stirred at 80 oC for two 
hours before cooling the solution to room temperature and working up. The reaction mixture 
contained two products, the desired nitrile 27 and the carboxamide MP-II-065 (28). Additional 
dimethylaluminum amine was added in attempts to produce only the nitrile 27, since the 
carboxamide 28 was an intermediate, but these were unsuccessful. Repeated reaction attempts 
resulted in no consistent trend when the temperature or equivalents of dimethylaluminum amine 
were varied in the production of the nitrile 27 over the carboxamide 28. The side-by-side reactions 
of two enantiomers, seen and discussed further in Section 4.3, resulted in different yields of each 
product. 
 
Scheme 7. Synthesis of nitrile MP-II-064 (27) and the byproduct MP-II-065 (28); as well as 
the preparation of dimethylaluminum amine. 
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 Preliminary efficacy using human embryonic kidney (HEK) 293T cells was evaluated on 
nitrile MP-II-064 (27) using the high-throughput patch-clamp IonFlux instrument (Nina Yuan, 
Alexander “Leggy” Arnold, et al., unpublished results) and the results are depicted in Figure 23. 
The two-electrode voltage clamp technique has been the standard method for collecting efficacy 
data, but has its drawbacks. The primary hindrance is the time-consuming nature of the assay. 
Assays are performed one oocyte at a time for each individual subunit, creating a large number of 
experiments to reach n-values great enough to verify a compounds’ effects confidently. In 
comparison, the automated patch-clamp averages the general response of 20 parallel cell currents 
to form into a single data point. Transiently transfected cells were produced and 27 was tested in 
the preliminary stages of development. It is noteworthy that the % of control current exerted by a 
compound in the IonFlux cannot be directly compared to the results reported in the oocyte two-
electrode voltage clamp technique. For the preliminary results of the IonFlux technique, the assay 
was designed to run a test compound along with a control compound to determine whether or not 
the test compound exerted a greater or lesser potency at each subtype. 
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Figure 23. Efficacy testing of MP-II-064 (27) in the IonFlux high-throughput patch-clamp instrument. Nitrile 
27 was run against HZ-166 (3) to determine how the efficacy profiles compared in parallel experiments.  
 
 The results of the IonFlux assay indicated that MP-II-064 (27) was an α3 preferring subtype 
selective ligand with weak efficacy at α1 and α5 subtypes compared to control HZ-166 (3). 
Examination of the data in Figure 23A illustrates 27 has a lower potency at the α1 subtype than 3, 
which was used as a control compound. Similar results at the α2 subtype are shown in Figure 23B. 
At the α3 subtype in Figure 23C, 27 was shown to have a greater potency than HZ-166 (3). 
Examination of the data from the α5 subtype indicates that 27 was less potent than 3 at that subtype. 
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To test the accuracy of the IonFlux patch-clamp technique, the Ernst group in Austria agreed to 
assess the efficacy of nitrile 27 in the two-electrode voltage clamp technique, and the results are 
depicted in Figure 24. 
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Figure 24. Preliminary oocyte efficacy results of MP-II-064 (27) by two-electrode voltage clamp technique 
(Margot Ernst). Concentration curve of 27 on GABAA receptors suing an EC3 GABA concentration (n = 2-3). 
 
 Examination of the data from the oocyte assay in the two-electrode voltage clamp 
technique indicated of MP-II-064 (27) has no selectivity at all in oocytes, as well as very little 
potency. When compared to the predicted IonFlux results, nitrile 27 showed no selectivity for the 
α3 subtype in oocytes; however, nitirle 27 does show lower potency at the α1, α2 and α5 subtypes, 
as predicted. It is also worth mentioning that the two-electrode voltage clamp technique commonly 
assesses a ligands’ efficacy in the 1 nM – 10 µM range, while the IonFlux patch-clamp technique 
assessed 27 in the high nanomolar range to 100 µM, and these concentration differences could 
reveal different results. Since the two-electrode voltage clamp technique is currently the ‘gold-
standard’ for efficacy evaluation, it was concluded that the methodology for generating the 
different subtypes for the IonFlux patch-clamp technique needed more investigation and have 
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targeted stable cell lines now in place of transiently transfected cell lines. However, it must be 
emphasized the oocyte efficacy experiments are now within statistical significance at n = 2. More 
oocytes are required for accurate analysis of the efficacy in Figure 24. 
In regard to the results of the two-electrode voltage clamp technique, it can be hypothesized 
that the lack of significant potency at any subtype below a high concentration (10 μM) by MP-II-
064 (27) likely results from the lack of interaction of the C(3) substituent with the H1 (Y210) 
descriptor, or possibly the lack of lipophilic-lipophilic interactions in the LDi pocket. This LDi 
pocket is a lipophilic pocket and the polar nitrile may have been incompatible. Because the nitrile 
(Ar-C≡N:) is a linear molecule with much of the electron density projecting straight out, this may 
have hindered the ability of the N: lone pair to interact with the hydrogen bond donor H1. One way 
that may be able to overcome this lack of interaction at H1 would be to add a methylene function 
between the C(3) aromatic ring and the nitrile, as shown in Figure 25. This would provide more 
flexibility for the lone pair of electrons on the -C≡N: bond to interact with H1. Further work in the 
series is ongoing. 
 
Figure 25. Proposed structure of a nitrile with an increased degree of freedom at C(3) to interact at H1 than 
MP-II-064 (27). 
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 The byproduct of the nitrile reaction, MP-II-065 (28), is also of interest. The C(3) 
carboxamide functional group is the same as imidazenil, shown in Figure 26. Imidazenil has been 
thoroughly studied and has been shown to be a non-sedating anticonvulsant and anxiolytic, without 
developing tolerance to the anticonvulsant effects.127 It has been suggested that 
imidazobenzodiazepine carboxamides, such as 28, possess these properties as a class of 
compounds.128 Imidazenil has also shown the ability to alleviate withdrawal symptoms that has 
been associated with long-term BZD usage.129 
 
 
Figure 26. Structure of imidazenil. 
 
 An improved route was needed to synthesize the carboxamide because the route depicted 
in Scheme 7, which provided MP-II-065 (28) as a byproduct, was unacceptable. An improved 
route to 28 employed stirring HZ-166 (3) in a saturated ammonia (gas)/methanol solution with 
calcium chloride in a sealed tube and then heated at 65 oC for 18 hours,130 as illustrated in Scheme 
8. The calcium chloride was necessary and served as a Lewis acid130 for the transformation from 
an ester to the carboxamide. In the absence of calcium chloride, the product which resulted was 
the methyl ester MP-III-024 (19). Heating 3 in the presence or absence of ammonia (g) under these 
conditions did not result in a higher yield of 19 than previously described (Scheme 3). With its 
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similarities to imidazenil and therapeutic potential, MP-II-065 (28) has been assessed for 
anxiolytic activity and the data is described in Section 3.3.6. 
 
Scheme 8. Improved route to the carboxamide MP-II-065 (28). 
 
 
 
3.3.3.3 Attempts to Synthesize the Thionoester (30) and Thioamide (31) 
 Previously, the methyl thioester, ZJW-II-65 (29), had been synthesized by Wang, et al. and 
is shown with the efficacy data in Figure 27. This thioester ligand 29 exhibited low potency with 
almost no efficacy at α1 subtypes, even at 10 μM (log[-5]), but did exhibit a slight agonist 
preference at the α3 subtype.  A comparison of the efficacy data at 1 μM of the methyl ester (19), 
methyl amide (24) and methyl thioester (29) is illustrated in Figure 28. Here, the influence of the 
heteroatom next to the carbonyl can be examined. The 1 μM concentration was chosen to be 
evaluated because this concentration has the greatest degree of selectivity. 
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Figure 27. Structure and efficacy of ZJW-II-65 (29). Concentration curve of 29 on GABAA receptors using an 
EC3 GABA concentration (n = 3). 
 
 Analysis of the data in Figure 28 show that methyl ester 19 and methyl amide 24 are both 
more potent in oocytes than the corresponding methyl thioester 29, espeically at the α2 and α3 
subtypes. One hypothesis for this is that both the oxygen and nitrogen are more electronegative 
than the sulfur, and may have stronger interactions with the pharmacophore descriptor at H1. The 
amide 24 is the only compound of the three which contains a hydrogen-bond donor group, which 
could interact with A2, as well as the H-bond donor H1. This may result in higher potency at the 
α1 and α3 subtypes. Overall, one trend that can be seen by comparison of the efficacy of these 
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three compounds was the necessity for strong hydrogen-bond interactions in the binding site; 
however, this hypothesis is based on a the three examples presented in Figure 28 at C(3) and must 
be explored more thoroughly to see if the pattern continues. 
 
Figure 28. Efficacy comparisons of 19, 24 and 29 at 1 μM. Efficacy determined on GABAA receptors using an 
EC3 GABA concentration (n = 2 – 4). 
 
 Attempts were made to synthesize the thionoester 30, as well as the thioamide 31 
(structures shown in Figure 29), to examine whether replacing the carbonyl oxygen with sulfur 
would affect the same decrease in potency as replacing the carboxylic oxygen did, as seen in 29 
compared 19. Initial attempts to complete this conversion employed Lawesson’s reagent (LR),131 
which is a reagent that is commonly used to replace a carbonyl oxygen with a sulfur atom. Ligand 
HZ-166 (3) was first stirred in benzene at room temperature with LR with no conversion observed, 
as indicated by mass spectrometry. The reaction was repeatedly attempted heating incrementally 
up to reflux for up to 48 hours with no success. Similar reaction conditions were carried out using 
toluene, xylene, dimethylformamide and dimethylsulfoxide with no conversion, which was 
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monitored by mass spectrometry. Other conditions were attempted to no avail.132, 133 Although the 
carbonyl oxygen in esters has been replaced with sulfur in many cases, it is reportedly one of the 
more difficult carbonyl oxygens to replace133 and generally requires harsher conditions than other 
molecules. Conversion of MP-II-065 (28) to a thioamide 31 was also attempted to determine the 
compatibility of the BZD scaffold to undergo thionation. Initial attempts used reaction conditions 
as described above. Another route reported quantitative yields using LR in 
hexamethylphosphoramide,134 but these conditions failed to work with amide 28. 
 
Figure 29. Structures of a thionoester 30 and thioamide 31. 
 
 Attempts to thionate the carbonyl oxygen of esters and amides were unsuccessful. There 
have been reports of the synthesis of newer generation fluorous LRs135 and conditions using a 
microwave;136, 137 however, these were not attempted due to lack of material. 
 
3.3.4 The Synthesis of Heterocyclic Bioisosteres 
 The isostere concept has been around since the early 1900’s. It initially referred to the octet 
theory of valence electrons and if two compounds existed, which had the same number of atoms 
and electrons, the electrons would arrange themselves in the same fashion.138 The initial Group 2 
of isosteres identified by Langmuir consisted of O2-, F-, Ne, Na+, Mg2+ and Al.3+ Through the years, 
60 
 
the terms and meaning expanded and eventually evolved into a new concept of bioisosteres which 
was defined by compounds exerting a similar biological effect. More recently, bioisosteres have 
been defined by Burger as, “Compounds or groups that possess near-equal molecular shapes and 
volumes, approximately the same distribution of electrons, and which exhibit similar physical 
properties”.139 
 Classical bioisosteres consisted of simple replacements such as switching a hydrogen for 
fluorine or deuterium, or a phenyl ring for a thiophene ring.140 Nonclassical bioisosteres are 
generally structurally distinct and contain a different number of atoms. Changes also include 
different electronic and steric properties. One subclass of nonclassical bioisosteres includes cyclic 
versus noncyclic compounds. 
Ligand HZ-166 (3) has previously been shown to be an important non-sedating anxiolytic, 
with anticonvulsant and antihyperalgesic properties; however, the metabolism of the ester function 
in rodents in vivo hinders the ability to study the ADME toxicity for a clinical candidate due to the 
short half-life in rodents. The use of a bioisostere to replace the ester function could increase the 
in vivo stability of the ligand, while retaining its pharmacological properties. Esters have a number 
of bioisosteres, and some of the heterocyclic bioisosteres are depicted in Figure 30. 
 
 
Figure 30. Common heterocyclic ester bioisosteres. 
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3.3.4.1 The Synthesis of Oxadiazoles 
 An oxadiazole is a common ester bioisostere.141 It has been previously utilized with HZ-
166 (3) to provide the isopropyl oxadiazole ZJW-II-40 (32; Namjoshi, et al.),117 depicted in Figure 
31. The replacement of the ester function was able to significantly increase the stability in a one-
hour human liver microsomal assay over HZ-166 (3) by SRI, and it increased the stability of 
bioisostere 32 over the parent compound HZ-166 (3) in vitro from 76% to 95%, respectively.117 
Analysis of the efficacy data of 3 and 32 indicated that the isopropyl oxadiazole lost efficacy at 
the α2 subtype, while retaining potency at the α5 subtype. The activation of the α1 and α3 subtypes 
remained about the same as in 3. The results indicated that the bioisostere replacement of the ethyl 
ester with an isopropyl oxadiazole has a negative effect of the efficacy profile. However, it should 
be noted that the isopropyl function of the oxadiazole would more similarly correspond to an 
isobutyl ester group in reference to sterics. Instead, a methyl oxadiazole would be a better 
replacement of the ethyl ester in this respect and was synthesized, along with the ethyl oxadiazole.  
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Figure 31. Structure and oocyte efficacy data of ZJW-II-40. Concentration curve of 32 on GABAA receptors 
using an EC3 GABA concentration (n = 3), as reported in Namjoshi, et al.117 
  
 The methyl oxadiazole, MP-III-085 (33), and the ethyl oxadiazole, MP-III-080 (34), were 
synthesized to expand the scope of the bioisosteres and this work is illustrated in Scheme 9. The 
oxime was first synthesized by refluxing an alkyl nitrile and hydroxylamine hydrochloride with 
potassium carbonate in water and methanol.142 This oxime was then stirred with sodium hydride 
in the presence of 3 Å molecular sieves before adding HZ-166 (3) and permitting the solution, 
which resulted, to stir at room temperature for two hours to produce the corresponding oxadiazoles. 
We thank Dr. Merle Johnson and Dr. Ranjit Verma for earlier work on the synthesis of oxadiazoles. 
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Scheme 9. Synthesis of the oximes and methyl (MP-III-085, 33) and ethyl (MP-III-080, 34) 
oxadiazoles.  
 
 
 
 The methyl oxadiazole MP-III-085 (33) is a good bioisostere for the ethyl ester 3 and 
should display a similar efficacy profile. This, along with the ethyl oxadiazole 34 are awaiting 
evaluation of their efficacy in oocytes or via HTPS on a stable human cell lines. However, they 
have been characterized through in vitro metabolic stability studies and in vivo on the rotarod 
assay. In addition, they have been evaluated in the marble burying assay for anxiolytic activity. 
These studies are discussed in Sections 3.3.5 and 3.3.6, respectively. 
 
3.3.4.2 Ligand SH-I-85 and the Synthesis of Oxazoles 
 During the synthesis of JY-XHe-053 (2), Shengming Huang isolated SH-I-85 (35) as am 
18% byproduct143 while building on the imidazole ring in going from benzodiazepine JYI-31 to 
imidazobenzodiazepine JYI-32, as shown in Scheme 10. The use of sodium hydride was utilized 
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in an earlier route to prepare ethyl ester JYI-32, prior to the development of the improved route to 
imidazobenzodiazepines using potassium tert-butoxide at low temperature.118 This earlier route 
was carried out by stirring the ethyl isocyanate in dimethylformamide with sodium hydride for one 
hour. This resulted in the formation of a byproduct which ultimately led to 1,3-oxazole 35 when 
the benzodiazepine JYI-31 was added to the mixture. Attempts to increase the yield by stirring the 
ethyl isocyanate with sodium hydride for three hours resulted in the isocyanate attacking another 
isocyanate molecule and eventually forming the 5-(isocyanomethyl)oxazole, illustrated in Scheme 
11.143 The methyl (CH2) group was then deprotonated and reacted with the BZD JYI-32 to form 
the imidazobenzodiazepine SH-I-85 (35) with a 1,3-oxazole at the C(3) position. 
Scheme 10. Route to SH-I-85 (35) as a byproduct. 
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Scheme 11. Proposed mechanism for the formation of 5-(isocyanomethyl)oxazole. 
 
 
 The 1,3-oxazole found in byproduct 35 was not a common bioisosteric replacement for an 
ester, but has been used before.144 The five-membered ring relates to a methyl ester in size, but the 
electronics are less similar to an ester than those of the oxadiazole. The two-electrode voltage-
clamp technique was performed to attain the oocyte efficacy profile, shown in Figure 32. Agonist 
(PAM) SH-I-85 (35) was found to be a potent α2/α3/α5 subtype selective agonist with very low 
α1 agonist efficacy. The concentration at which the ligand 35 begins to increase the chloride flux 
began around 10 nM which means byproduct 35 was able to affect the chloride current at lower 
concentrations than most compounds, although this is similar to 2, another 2'-fluoro compound. 
Although there is no direct comparison to the bromo, ethyl ester ligand JYI-32, a discussion 
resulted in the exploration of the oxazole as a C(3) ester replacement in HZ-166 (3) and other 
compounds in order to increase the half-life in vivo and in vitro in rodents and humans. 
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Figure 32. Structure and oocyte efficacy of SH-I-85 (35), displaying very low efficacy at the α1 subtype. 
Concentration curve of 35 on GABAA receptors using an EC3 GABA concentration (n = 3). 
 
 In collaboration with a coworker, Dr. Kashi Reddy Methuku was tasked to find an 
improved route to the synthesis of ligands with the 1,3-oxazole ester replacement at C(3) based on 
the pharmacophore/receptor model.74 Initial reactions attempted to improve the yield of the 
byproduct in a similar reaction sequence, as depicted in Scheme 10 by stirring the ethyl isocyanate 
with a base (potassium tert-butoxide) before combining this solution with JYI-31. Replacement of 
sodium hydride with potassium tert-butoxide did increase the yield slightly, but this route was still 
unacceptable. Attempts to synthesize 5-(isocyanomethyl)oxazole were unsuccessful. Eventually, 
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a route through the aldehyde using toluenesulfonylmethyl isocyanide (TosMIC) and potassium 
carbonate145, 146 was developed by Methuku, Cook, et al.147 The synthesis using this new route was 
employed to produce the oxazole (KRM-II-81, 36) of HZ-166 (3) and is depicted in Scheme 12. 
A number of other related 1,3-oxazoles, based on modeling,74 were also synthesized by Dr. 
Methuku in the 2'-H and 2'-F series to obtain KRM-II-82 (37) and KRM-II-18B (38), respectively, 
and are shown in Figure 33. After preliminary testing of oxazoles 36 – 38 indicated they exhibited 
anxiolytic activity in a marble burying assay (see Section 3.3.6), Dr. Methuku, myself and others 
worked together to synthesize these three (36 – 38) compounds on large scale, with a heavy focus 
on the 2'-N analog of HZ-166, KRM-II-81 (36). In addition, the 2'-N 8-bromo analogs (39) and 2'-
H (40) versions of 35 were synthesized as well as six methyl oxazole compounds, 41 – 46, by Dr. 
Methuku. All of these were designed based on the fit into the LDi pocket of the 
pharmacophore/receptor model by Clayton, Poe, et al.74 These methyl oxazoles were synthesized 
by replacing TosMIC with 1-((1-isocyanoethyl)sulfonyl-4-methylbenzene.147 The synthesis and 
characterization of these oxazoles and methyl oxazoles 37 – 46 can be found in Appendix J. 
 
 Scheme 12. The synthesis of oxazole KRM-II-81 (36). 
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Figure 33. Structures of oxazoles (37 – 40) and methyl oxazoles (41 – 46). These were synthesized based on the 
pharmacophore/receptor model of Clayton, Poe, et al.74 in collaboration with Dr. Methuku. The synthesis of 
these can be found in Appendix J. 
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3.3.5 The In Vitro Analysis of HZ-166 (3) and its Analogs 
 Many of the compounds were tested by a big pharma CRO (under a Confidential 
Disclosure Agreement) for affinity at α1 and α3 GABAAR subtypes on the fluorescence imaging 
plate reader (FLIPR) functional assay, as shown in Table 5. Examination of the data at the α1 
subtype in the FLIPR assay indicated that all ligands tested had an EC50 greater than 20 µM, which 
was the highest concentration tested. This illustrated they have little to no affinity at the sedating, 
ataxic, amnesic, addictive α1 subtype. In contrast, they exhibited good affinity at the α3 subtypes, 
indicating they have significant selectivity for the α3 subtype over the α1 subtype. Because α2 and 
α3 subtypes are very similar in binding topology74 this indicated they should exhibit efficacy at 
the key α2 subtypes as well. Based on data by Möhler, Zeilhofer, Cook and others on ligand HZ-
166 (3); agonist efficacy at the α2 subtypes is the most important in treating anxiety and pain. This 
indicated that all compounds should have a high likelihood of being active against anxiety and 
possibly hyperalgesia with a low risk of adverse effects. This was a key breakthrough in 
Bz/GABAA receptor studies with worldwide importance. 
Analysis of ethyl esters 1 – 3 and oxazoles 36 – 38 indicated that the 2'-F compounds 2 and 
38 showed a greater affinity for the α3 subtype (0.0346 and 0.0112 µM, respectively) than their 
2'-H (1 and 37; 0.146 and 0.0321 µM, respectively) or 2'-N (3 and 36; 0.844 and 0.937 µM, 
respectively) counterparts, with the more polar 2'-N compounds 3 and 36 were the least potent of 
the three in each series. Examination of the metabolic stability of these compounds indicated that 
the 2'-N containing ligands are much more stable than either of the other two series in vitro on 
MLMs and RLMs. Analysis of each species shows that, other than DLMs, replacing the ethyl ester 
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with the atypical bioisosteric oxazole significantly increased the resistance to metabolism by liver 
microsomes. 
 The metabolism and clogP of the esters 3, 21 and 19 were previously discussed in Section 
3.3.2.1. Examination of the data from the FLIPR assay indicated that a smaller alkyl side chain 
exhibited a more potent EC50 value at the α3 subtype. This general trend in sterics can be seen 
throughout the series of compounds analyzed. The two compounds with the largest C(3) 
substituents, oxadiazoles 33 and 34, displayed two of the poorest EC50 values at 5.15 and 3.02 µM, 
respectively at the α3 subtype. Although it may be that lipophilic-lipophilic interactions of the 
larger alkyl substituent prevented the rotation of the bioisostere to interact at H1. On the other hand, 
the low potency could be just the result of repulsive lipophilic-lipophilic interactions with the 
receptor protein. The only other compound with an EC50 greater than 2 µM was the nitrile 27 
which we classify as inactive at Bz/GABAA receptors. This may be due to the lack of degree of 
freedom to interact with hydrogen-bond donor H1, as discussed previously in Section 3.3.3.2. 
Although the C(3)-nitrile was not active, the four 2'-N compound (methyl ester 19, methyl amide 
24, carboxylic acid 20 and carboxamide 28), displayed the most potent EC50’s at the α3 subtype: 
0.461, 0.757, 0.47 and 0.166 µM, respectively. Of all the 2'-N compounds, carboxamide 28 
displayed the strongest affinity towards the α3 subtype. This may be due to the fact that it contained 
two hydrogen-bond acceptors, as well as two hydrogen-bond donor groups in the –NH2 group. 
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Table 5. In vitro metabolic stability, α3 Bz/GABAAR EC50’s and clogP’s of ligands. 
a The α1 subtype was also examined for all compounds (except 23), and the EC50 > 20 µM was very poor for all 
compounds. 
b This was calculated used clogP on the ChemDraw 13.0 software; as compared to diazepam 
c Human liver microsomes (HLM), dog liver microsomes (DLM), mouse liver microsome (MLM) and rat liver 
microsomes (RLM). 
c Aldehyde 23 was tested by Revathi Kodali at UWM under separate conditions (10 µM, 37 oC, 60 minutes). 
Analysis of all compounds that were assayed by both places exhibited similar results. 
  
CRO Results Metabolic stability in liver microsomes 
(reported in %-remaining) 
Conditions: 4 µM compound, 37 oC, 30 
minutes 
α3 
FLIPR 
assaya 
clogPb 
Compound and C(3) 
substituent 
HLM c DLM c MLM c RLM c 
EC50 
(µM) 
(Diazepam 
= 2.96) 
1 Ethyl ester (2'H) 
XHe-II-053 
40 83.7 9.9 8.7 0.146 3.11 
2 Ethyl ester (2'F) 
JY-XHe-053 
8.9 83.8 5.1 0.7 0.0346 2.91 
3 Ethyl ester (2'N) 
HZ-166 
80.4 97.2 54.1 50.2 0.844 1.71 
21 2d-Ethyl ester (2'N) 95.1 100 63.1 76.6 1.17 1.71 
19 Methyl ester 92.2 72.6 73.3 92.7 0.461 1.18 
20 Acid 95.9 100 92.7 99.3 0.47 1.82 
23 Aldehyded 70  56   1.41 
24 Me. amide 95.3 70.6 82.7 87.6 0.757 1.32 
27 Nitrile 87.8 65.6 77.2 76.6 5 1.29 
28 Carboxamide 94.1 89.4 90.6 71.4 0.166 0.99 
33 Methyl Oxadiazole 80.8 92.5 85.4 92.9 5.15 1.50 
34 Ethyl Oxadiazole 90.6 96.9 91.6 94.2 3.02 2.03 
36 1,3-Oxazole (2'N) 91.4 94.1 89.9 90.4 0.937 1.58 
37 1,3-Oxazole (2'H) 73.5 85.5 73.1 72.2 0.0321 2.98 
38 1,3-Oxazole (2'F) 77.6 86.5 78.5 67.9 0.0112 2.78 
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 There does not seem to be a general trend when replacing an oxygen atom with an –NH 
group, as seen from methyl ester 19 to methyl amide 24 and carboxylic acid 20 to carboxamide 
28. The results in the HLMs are nearly identical, while the DLMs and MLMs show up to 10% 
changes, but with no particular trend. The largest discrepancy is seen from the acid 20 to 
carboxamide 28 in RLMs, with %-parent compound decreasing from 99.3% to 71.4%, 
respectively. The carboxamide 28 also has decreased stability in DLMs, decreasing from 100% 
remaining in the acid 20 to 89.4% remaining in 28; however, this may not be statistically 
significant. In addition, the methyl amide 24 increased in stability from 73.3% in the methyl ester 
19 to 82.7% in MLMs, which indicated the methyl amide is worthy of preclinical assays on 
sedation, anxiety as well as neuropathic and inflammatory pain. 
 The heterocyclic 2'-N oxadiazoles 33 and 34, as well as 1,3-oxazole 36 (KRM-II-81), were 
designed to combat rodent degradation and all show significant increases in metabolic stability in 
MLMs and RLMs. This is very important. Lead ligand HZ-166 (3) was degraded to about 50% of 
the parent HZ-166 remaining in both rodent species after a 30 minute incubation, whereas the 
methyl oxadiazole 33, which exhibited the greatest degradation of the heterocycles, was still much 
more stable as compared to lead ester HZ-166 (3) with 85.4% of 33 remaining in mouse 
microsomes after 30 minutes. This clearly shows that the replacement of an ethyl ester function at 
C(3) was effective in reducing metabolism in rodent liver microsomes, as anticipated. Increased 
stability in HLMs was also seen in 36 (91.4% remaining) and 34 (90.6%) as compared to 3 
(80.4%). These are extremely important findings since most preclinical studies in drug design are 
carried out in rodents. 
 Although tested under different conditions, the aldehyde 23 exhibited the least resistance 
to degradation in human and mouse liver microsomes at 70% and 56% of the parent 23 remaining, 
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respectively, of the compounds containing the 2'-nitrogen. Analysis of the results shown in Table 
2 illustrated that the same compounds 3 and 19 assayed, which had similar profiles, indicated that 
the results on the aldehyde 23 shown in Table 4 can be roughly compared to all other results. It is 
reasonable to assume the aldehyde 23 would be metabolically more stable in HLM than in MLM 
because of the increase in metabolic activity in mice as compared to humans. 
 
 
3.3.6 Determination of Ataxic and Anxiolytic Effects in Preclinical Models 
 The increased stability of the heterocyclic oxadiazoles 33 and 34 as well as the 1,3-oxazoles 
36 – 38 in rodent liver microsomes resulted in in vivo testing in search of a clinical candidate for 
the treatment of anxiety disorders, epilepsy and pain syndromes in collaboration with the same 
CRO that did the in vitro testing on the ligands. The initial round of testing included HZ-166 (3) 
as a standard because it is a non-sedating anxiolytic and antinociceptive agent that does not develop 
tolerance to the anticonvulsant and antinociceptive effects. These initial in vivo experiments 
consisted of a marble burying assay to test the ligands’ anxiolytic effects148 and a rotarod assay to 
determine whether or not the compounds induced ataxia.149 After the positive initial results, a 
second round of testing assessed the methyl 1,3-oxazoles 41 – 46, due to their heterocyclic 
replacement of the ester function at C(3), and the carboxamide 28, due to its potent affinity at the 
α3 subtype in the FLIPR assay while still not interacting at the sedating α1 subtype (EC50 > 20 
µM). Despite the potent affinity and metabolic affinity of the acid 20 in HLMs, DLMs, MLMs and 
RLMs, it was not tested due to the poor brain penetration, as described in Section 3.3.2.1. The 
methyl ester, or any other ester, were also excluded from testing due to the high concentration of 
esterases found in rodents, which would likely hinder the esters from future development. 
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3.3.6.1 The Results from the Marble Burying Assay for Anxiolytic-like Effects 
 The marble burying assay was designed to measure the anxiolytic effect a ligand exerts on 
a test subject.148, 150 This assay has been an effective way to assess traditional BZDs, such as 
diazepam,151 and analysis of the imidazobenzodiazepines (1,3-oxazoles, oxadiazoles, etc.) is 
illustrated in Figure 34. The male Swiss mice (n = 10) were dosed i.p. with either vehicle (1% 
carboxymethyl cellulose (CMC; a surfactant) or a test compound (10 or 30 mg/kg) 30 minutes 
prior to testing. During testing, mice were set inside a box with 20 marbles placed throughout the 
container in a bed of shredded paper. When dosed with vehicle, mice begin to ‘nest’, or bury the 
marbles for fear of them being taken.152 A ligand which exhibited anxiolytic effects will reduce 
this urge, resulting in a fewer number of marbles buried over a 30 minute time period. 
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Figure 34. Analysis of the anxiolytic effects exerted by HZ-166 (3) and other ligands. Male Swiss mice (n = 10) 
were given an i.p. 30 minute pretreatment of vehicle (1% CMC) or a test ligand (10 or 30 mg/kg) and were then 
placed in a chamber with 20 marbles, and were observed for 30 minutes and the number of marbles buried was 
recorded. Analyzed using ANOVA (Dunnet’s test: * P < 0.05). a Sedation-like effects observed at 30 mg/kg. b 
Sedation-like effects observed at 10 and 30 mg/kg. c Modest sedation-like effects observed at 30 mg/kg. 
Structures depicted in (G). 
77 
 
 Analysis of the results in Figures 34A-F indicated each ligands (Figure 34G) ability to 
reduce the anxiety-driven behavior of marble burying. All compounds exhibited a significant 
anxiolytic-like effect when compared to vehicle after a 30 mg/kg dose. Only the ethyl oxadiazole 
(34), carboxamide (28), and one of the methyl oxazoles (46) exhibited a significant decrease in 
marble burying at 10 mg/kg. It has been noted in the past that the reduction in buried marbles is 
sometimes a results of sedation,151 and observers reported sedation-like effects in both 28 and 46 
at the both the 10 and 30 mg/kg doses. Sedation-like effects were also observed in 34, but only at 
30 mg/kg which indicated the results seen at 10 mg/kg may be a true anxiolytic-like effect exerted 
by the ligand. Other compounds that were noted for signs of sedation at 30 mg/kg were methyl 
oxadiazoles 41 – 45. 
 A closer look at the methyl oxazoles show that compounds with the C(8)-bromide (44 – 
46) display greater signs of sedation then the corresponding methyl oxazoles with an acetyleno- 
functionality (41 – 43) in keeping with the Milwaukee hypothesis.17, 74-76 Although these ligands 
display sedative effects, the 2'-N bromide 44 was noted to display sedative-like effects at 30 mg/kg 
(Figure 34C), while the 2'-N acetylene 41 was noted to elicit only modest sedation at 30 mg/kg 
(Figure 34F). The similar result is seen in the 2'-fluoro compounds, with the bromide 46 displaying 
sedation at 10 and 30 mg/kg (Figure 34D) and the acetylene 43 only having modest sedation at 30 
mg/kg (Figure 34E). On the other hand, the 2'-H compounds 43 and 42 were reported to exhibit 
the same degree of sedation (Figures 34E and 34F, respectively). This is not unexpected and 
follows the trend that replacing the C(8) halogen with an acetylene can reduce the binding affinity 
and/or efficacy at the α1 subtype by interaction in the L2 pocket, as previously discussed in Section 
2.2. This is based on the pharmacophore/receptor model17, 75, 76 which was designed employing 
rigid ligands as a template and the use of 12 other families overlaid in this model. 
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It was also interesting to note that in comparison between corresponding oxazoles (36 – 
38) and methyl oxazoles (41 – 43), all the methyl oxazoles were reported to have sedative-like 
effects. It is possible that the methyl functions increase the potency at the α1 subtype. However, 
because testing of the oxazoles and methyl oxazoles occurred at different times, it may also be 
possible that the observers were different, as observation of sedation-like effects can be considered 
subjective. That said, the oxazoles 36 – 38 and methyl oxadiazole 33 were the only compounds 
that were reported to have significant reduction in marble burying at 30 mg/kg without the 
observation of sedative-like effects. 
3.3.6.2 Assessment for the Presence of Ataxia by the Rotarod Protocol 
 The ligands which were tested in the marble burying assay were also assessed for ataxic 
effects in the rotarod paradigm and the results are depicted in Figure 35A-F. Ataxia, or the partial 
or full loss of control of body movements, has been observed in many patients when given 
traditional BZDs41, 153, 154 such as diazepam, alprazolam and midazolam, and is an adverse effect 
that stems from the activation of the α1 subtype. The male Swiss mice (n = 10) were dosed i.p. 
with either vehicle (1% CMC) or one of the test compounds (10 or 30 mg/kg) 30 minutes prior to 
testing. The testing consisted of placing the mice on a rotating rod at 4 r.p.m. Any mouse that was 
able to stay on for the two minute testing period were called a ‘Success’, while mice that fell once 
were given a ‘Partial’ designation. Mice that fell off twice during the two minute time period failed 
the test. 
 The ethyl ester HZ-166 (3) has previously been shown to complete a rotarod trial 
comparably to vehicle at 48 mg/kg,93 therefore there was no sedation nor ataxia. Ligand HZ-166 
(3) is shown here in Figure 35A to have no change at 10 mg/kg in relation to vehicle, but one 
failure occurred as well as a few additional ‘Partial’ trials at 30 mg/kg. However, in mice and rats 
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by Stables et al., showed 3 elicited no sedation up to 500 mg/kg.115 The oxazole KRM-II-81 (36) 
performed the best of the oxazoles 36 – 38, as both the 2'-H (37) and 2'-F (38) oxazoles had no 
‘Success’ trials as 30 mg/kg. Both the oxadiazoles 33 and 34 and carboxamide 37 performed 
similarly to 3, with the ethyl oxadiazole 34 undergoing a few more successful trials than its methyl 
counterpart 33. All methyl oxazoles 41 – 46 performed comparable to its corresponding vehicle 
with the exception of the 2'-F, C(8)-bromo methyl oxazole 46. These results indicated that 1,3-
oxazoles 37 and 38 have the greatest risk of exerting ataxic-like effects. However, it is important 
to note that these ataxic-like symptoms were observed in some mice dosed with vehicle as some 
mice trained on a rotating rod were unable to successfully complete the task. 
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Figure 35. Results of BzR ligands in the rotarod assay. Male Swiss mice (n = 10) were given a 30 minute i.p. 
pretreatment of either vehicle (1% CMC) or a test ligand (10 or 30 mg/kg) and were then run for two minutes 
on a rotarod at 4 revolutions per minute. Mice that did not fall were designated a “Success”, while mice that 
fell once during the timing were given a “Partial” designation. Mice that fell twice “Fail” the testing.  
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 It is interesting to note that with the exception of KRM-III-59 (46), all compounds which 
were observed to induce sedation-like effects in Figures 34C-F did not perform significantly worse 
than vehicle on the rotarod assay, shown in Figures 35C-F. This was initially an odd finding as 
both adverse effects stem from the activation of the α1 subtype. Arguably, 1,3-oxazoles 37 and 38 
performed the worst in the rotarod paradigm, and neither were reported to induce sedation. 
However, this could be attributed to the subjectiveness of observing sedation-like effects described 
above in Section 3.3.6.1. Alternatively, it is possible that the sedation-like effects could be 
attributed to muscle relaxation, which can occur from activation of the α3 subtype at higher 
receptor occupancy. Although sedation and muscle relaxation may appear to result in the same 
observation in some assays, others protocols have been able to distinguish between the two; 
however, these are not explored here. 
 
3.3.7 In Vivo Characterization of New Lead Compound, KRM-II-81 (36) (CRO) 
 A new lead ligand was chosen to further characterize in anticonvulsant, anxiolytic and 
neuropathic pain assays as a potential clinical candidate. The oxazole KRM-II-81 (36) was chosen 
for a number of reasons. In the in vitro metabolic analysis, KRM-II-81 (36) was highly stable in 
all species tested, with the greatest degradation occurring in mice, however, only 10.1% of the 
parent compound was metabolized over a 30 minute time period. Ligand 36 also exhibited potent 
affinity at the α3 subtype, with a sub-micromolar EC50 at 0.937 nM. Of all the compounds analyzed 
in Table 4, the only other ligand to display these characteristics was the acid 20, which had already 
been shown to have poor BBB penetration. The two oxadiazoles 33 and 34 displayed a high 
resistance to degradation as well, but the micromolar EC50’s of 5.15 and 3.02 μM, respectively, 
were slighter higher than desired, but this did not immediately exclude them from consideration. 
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On the other hand, the carboxamide 27, the 2'-H (37) and 2'-F (38) oxazoles displayed good affinity 
for the α3 subtype (0.166, 0.0321 and 0.0112 µM, respectively), but also had lower stability against 
rodent microsomes, particularly in RLMs at 71.4%, 72.2% and 67.9% of the parent compound 
remaining, respectively, over 30 minutes. 
 Analysis of the in vitro data alone promoted moving forward with KRM-II-81 (36). In the 
marble burying assay, all mice dosed with a methyl oxazole, 41 – 46, showed some degree of 
sedative-like effects, as reported in the marble burying assay by the observer; however, this was 
subjective and requires further characterization on the matter. This, along with the lack of in vitro 
data excluded the methyl oxazoles from being considered further as the lead compound. Oxazole 
36 and the two oxadiazoles 33 and 34 performed well in the marble burying assay at 30 mg/kg. 
Ethyl oxazole 34 also exerted anxiolytic-like effects in mice at 10 mg/kg; however, sedative-like 
effects were observed at 30 mg/kg. In the rotarod assay, 36 performed comparable to 3 and vehicle 
at both 10 and 30 mg/kg, whereas mice dosed with methyl oxadiazole 33 only had two successful 
trials at 30 mg/kg. Because of the higher likelihood of α1 activation by the oxadiazoles, it was 
decided that oxazole KRM-II-81 (36) would be investigated in greater detail, as mentioned above. 
 
3.3.7.1 Oocyte Efficacy Data 
 The efficacy for KRM-II-81 (36) was investigated by Dr. Margot Ernst in a direct 
comparison against HZ-166 (3). Examination of the results have shown that the two compounds 
have similar efficacies at all subtypes α1-3,5β3γ2 subtypes at 100 nM and 1 μM when tested, as 
depicted in Figure 36. At a 10 μM concentration, KRM-II-81 was shown to have increased efficacy 
at the α1 and α5 subtypes in comparison to HZ-166; however, it is highly unlikely to reach this 
high of a concentration within the brain. Gratifyingly, analysis of all these results indicate that 
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KRM-II-81 (36) should perform as well or better than HZ-166 (3). This circumstance is due to the 
fact that KRM-II-81 (36) is less rapidly metabolized in mouse and rat liver microsomes than HZ-
166 (3). The low activation at the α1 and α5 subtypes also indicated that 1,3-oxazole 36 should be 
devoid of adverse effects such as sedation, muscle relaxation, dependence and tolerance issues. 
 
Figure 36. Structures and oocyte efficacy comparison of KRM-II-81 (36) and HZ-166 (3). Dose-dependent 
modulation of GABA (EC3-6 concentration) by ligands 9 and 2 on Xenopus laevis oocytes expressing GABAAR 
subtypes α1-3,5β3γ2S was determined by two-electrode voltage clamp current recordings. Data represents mean 
± SEM. 
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3.3.7.2 Pharmacokinetic Data 
 The plasma concentration-time profile was next examined to evaluate the pharmacokinetic 
properties of PAM 36, and is depicted in Figure 37. Male rats (n = 3 for each data point) were 
dosed with oxazole 36 (1 mg/kg I.V., or 10 mg/kg i.p.) and the concentration in the rat plasma was 
determined at various time points up to 24 hours. Analysis of the data from the IV injection 
indicated a half-life of 1.36 hours with a plasma Cmax of 2480 nM at the first measured time point 
of 5 minutes. The i.p. dosing resulted in a half-life of 3.1 hours and a plasma Cmax of 3090 nM at 
the two-hour time point. This is important for it indicated that oxazole 36 is stable in vivo whereas 
HZ-166 (3) was metabolized immediately upon administration. Comparison of the results of the 
I.V. injections of 36 and 3 (Table 3) show that the oxazole 36 is incredibly more stable in rats since 
the analysis of HZ-166 (3) was found to be below the quantifiable limit. 
 
Figure 37. Plasma concentration-time plot of KRM-II-81 (36). Male Sprague-Dawley rats (n = 3 per time 
point) were dosed i.p. (10 mg/kg) or I.V. (1 mg/kg) and the plasma concentration was analyzed at varying 
time points for up to 12 hours. 
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 The analysis of the results from oral dosing in rats also provided similar results, as shown 
in Table 6. The ethyl ester 3 went similarly undetected in the oral dosing as it did in the I.V. dosing 
because of hydrolysis to the acid which prevented penetration through the BBB, with the parent 
compound HZ-166 undetected in plasma at 1 hour, and brain samples at 2 hours. The 1,3-oxazole 
36 had a 3910 nM concentration found in the plasma at one hour and 3640 nM in brain samples. 
This is a terrific level for KRM-II-81 (36). Although HZ-166 (3) went undetected, it was still able 
to produce pharmacological effects in anxiolytic, convulsant, and hyperalgesic assays. As 
mentioned previously, this may be due to the ester immediately entering the brain and being 
converted to the acid 20 very rapidly. The acid 20 may then exert some anxiolytic and 
anticonvulsant effects on its own. 
Table 6. Plasma and brain concentrations of HZ-166 (3) and KRM-II-81 (36) after a 10 mg/kg P.O. dose in rats. 
 3 36 
Plasma concentration at 1 h. (nM) BQLa 3910 ± 1870 
Brain concentration (nM) BQLa,b 3640 ± 1680 
BQL = below quantification limit 
a Quantifiable limit < 12.2 nM 
b Brain concentration for 3 taken at 2 hour time point 
 
3.3.7.3 Assessment for Motor Impairment in the Inverted Screen Paradigm 
 In addition to the rotarod paradigm, the inverted screen assay was carried out to further 
assess the levels of motor impairment exerted by KRM-II-81 (36). The inverted screen test has 
been used for years to measure whether a compound induced muscle relaxation,155 which can stem 
from the α1 subtype, and possibly the α3 subtype at higher receptor occupancy. Muscle relaxation 
can be observed in the inverted screen test where the rats were placed on a wire screen which was 
subsequently inverted and suspended a few centimeters above a soft bedding. The reaction of the 
test subject was to climb to the opposite side of the screen so that they are no longer hanging upside 
86 
 
down. If a compound induced muscle relaxation, the test subject will either be unable to hold onto 
the screen while upside down and fall, or hang onto the screen without successfully climbing to 
the other side. The male Sprague-Dawley rats (n = 5) were dosed i.p. with vehicle (1% CMC), 
diazepam (3, 10 or 30 mg/kg), 3 (30 mg/kg) or 36 (10, 30 or 60 mg/kg) 25 minutes prior to testing. 
The rats were then placed on the screen which was then inverted and observed for one minute and 
scored (0 = climbed over; 1 = hanging upside down; 2 = fell off).  
 
Figure 38. Inverted screen assessment of diazepam, HZ-166 (3) and KRM-II-81 (36). Vehicle scored 0.1. Male 
Sprague-Dawley rats (n = 5) were dosed i.p. with vehicle (1% carboxymethyl cellulose), diazepam (3, 10 or 30 
mg/kg), KRM-II-81 (10, 30 or 60 mg/kg) or HZ-166 (30 mg/kg) 30 minutes prior to testing. Analyzed using 
ANOVA (Dunnett’s test: * P < 0.05). 
 
 Diazepam was shown to induce signs of muscle relaxation at 3 mg/kg, with significant 
results at 10 and 30 mg/kg. This was not unexpected since diazepam notably has many of the 
common adverse effects that are associated with traditional BZDs and binds non-selectively to α1, 
α2, α3 and α5 subtypes.17 Rats dosed with 3 exhibited some signs of muscle relaxation at 30 mg/kg. 
Oxazole KRM-II-81 (36) was shown to induce no signs of muscle relaxation at the 10 and 30 
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mg/kg doses, while it begins to show some mild signs at 60 mg/kg. If the pharmacological effects 
seen after dosing of 3 are in fact from the ethyl ester, and not the acid 20, it might be possible that 
the muscle relaxation was due to activation of the α3 subtype, which would indicate that KRM-II-
81 (36) may have a lower efficacy activation of the α3 subtype, which resulted in 36 interacting 
more at the α2 subtype selective ligand rather than a α2/α3. Because there are no α2 subtype 
selective ligands known, to date, this could be an extremely valuable compound. Alternatively, if 
the pharmacological effects are due to the acid 20, than the oxazole top of 36 is very effective in 
combating the degradation that was seen in ethyl ester 3. Nevertheless, the lack of muscle relaxant 
effects of KRM-II-81 (36) as compared to the lead anxiolytic/antinociceptive agent HZ-166 (3) 
are exciting and provide the impetus for further evaluation of 1,3-oxazole 36 below. 
 
3.3.7.4 Assessment of Anxiolytic Activity in the Vogel Conflict Procedure 
 The marble burying assay was a good general anxiolytic test, but did not do a great job in 
distinguishing which ligands in the oxazole or oxadiazole series are the best clinical candidates. 
The Vogel conflict protocol (previously described in Section 3.3.2.3) is the gold standard for 
anxiolytic activity and was employed as a second assay with KRM-II-81 (36) for anxiolytic 
activity,112, 124 illustrated in Figure 39. In this, male Sprague-Dawley rats (n = 6 – 8) were dosed 
with vehicle (1% CMC), 3 (30 mg/kg), 36 (3, 10, 30 or 60 mg/kg) or the positive control 
chlordiazepoxide (CDAP; 20 mg/kg). CDAP is a traditional BZD which is commonly prescribed 
as a short-term anxiolytic, but tolerance is a concern limiting its long-term use,156 especially as an 
anticonvulsant or antinociceptive agent. 
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Figure 39. HZ-166 (3) and KRM-II-81 (36) in the Vogel conflict procedure. After a baseline is established using 
a vehicle (1% 2-hydroxyethyl cellulose), male Sprague-Dawley rats (n = 6-8) were dosed i.p. with either KRM-
II-81 (3, 10, 30, or 60 mg/kg) or chlordiazepoxide (20 mg/kg) 30 minutes prior to testing. Analyzed using 
ANOVA (Dunnett’s test: * P < 0.05; Student t-test: ** P < 0.05). 
 
 HZ-166 (3) was shown to be ineffective in increasing the response in the punished session 
at 30 mg/kg (Figure 39A), whereas KRM-II-81 (36) showed a significant increase in responses at 
10 mg/kg (Figure 39B). Oxazole 36 also produced increased response rates at 30 and 60 mg/kg, 
but these did not reach significance. In examination of the inverted screen test, the 60 mg/kg dose 
did produce slight muscle relaxation; however, muscle relaxation should not play a major role in 
the Vogel conflict procedure and the test subjects could remain at the water source with little 
movement required. Muscle relaxation should not influence the Vogel conflict at 30 mg/kg dose 
either since there was none observed in the inverted screen with oxazole 36 at the same dose. 
 Ethyl ester 3 had previously been shown to perform well in the Vogel conflict procedure 
in rhesus monkeys at 1 mg/kg112 where esterase levels are much lower than in rodents; but the 30 
mg/kg dose of 3 in this test had no effect. It is highly possible that the high concentration of 
esterases in rats may degrade 3 too rapidly to have an effect as mentioned above. Alternatively, 
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these results cannot be directly compared because rats and monkeys are significantly different 
species. Regardless, because KRM-II-81 (36) performed well in rats at 10 mg/kg, it can be assumed 
that the 1,3-oxazole 36 would also exhibit non-sedating anxiolytic properties in monkeys. This 
work is currently underway. 
 
3.3.7.5 Evaluation of Anticonvulsant Activity in the MES and scMET Procedures 
 Epilepsy is a common neurological disease that is often treated with BZDs157 in status 
epilepticus in emergency rooms. The seizures that are associated can range from nearly 
undetectable, to mild or severe uncontrollable shaking for an extended period of time. BZDs elicit 
anticonvulsant activity from both the α1 and α2 subtypes. Ligands which target the α1 subtype 
also come with the adverse effects of sedation, ataxia, amnesia, addiction, tolerance, etc. The 
development of tolerance is the greatest drawback of the use of BZDs to treat convulsions as the 
prescribed ligands become ineffective with continued use158 due to the development of tolerance. 
BZDs which target only the α2 subtype can avoid these concerns while also being effective in the 
management of seizures, especially since these ligands would avoid the coupling of the α1 and α5 
subtypes which have been shown to be the source of the development of tolerance by Möhler, et 
al.88 and demonstrated by Cook et al.89, 90, 93 
 Ligand HZ-166 (3) was previously characterized by ASP at NINDS. It was found to be 
inactive when mice were given a 100 mg/kg i.p. dose in the maximal electroshock (MES) assay, 
which was designed to evaluate a compounds ability to prevent seizures in a generalized tonic-
clonic response, when all neuronal circuits in the brain are firing. Tonic seizures generally set in 
first, and are characterized by the stiffening of muscles. These are commonly followed by the 
clonic phase, which is the uncontrollable spasming of muscles. Alternatively, 3 was active in the 
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scMET assay for antiseizure activity115. In mice, 3 had an ED50 of 16.28 mg/kg when given i.p., 
and an ED50 of 98.5 mg/kg when dosed P.O. in rats, as depicted in Table 7. Both of these ED50’s 
are better than has been reported for carbamazepine and phenytoin, both of which are commonly 
prescribed for epileptic seizures, in similar assays. 
Table 7. Quantification of Antiseizure Activity: ED50 MES, ED50 scMET, TD50 TOX, and Therapeutic Index 
(TI) via i.p. and P.O. Routes.
a Modified from the table in Rivas, et al.115 
  Mouse 
i.p. 
  Rat P.O.  TI Mouse 
i.p. 
 TI Rat 
P.O. 
entry ED50 
MESd 
ED50 
scMETd 
TD50 
TOXd 
 ED50 
MESd 
ED50 
scMETd 
TD50 
TOXd 
 TD50/ED
50 
(scMET) 
 TD50/ED50 
(scMET) 
3 >300 16.28 >500  >250 98.5 >500  >30.2  >>5c 
Cbzb 7.81 >50 45.4  5.35 >250 364  <0.9  1.5 
Clb 25.6 0.02 0.26  7.86 0.61 2.38  13  3.9 
Pnb 5.64 >50 41.0  28.1 >500 >1000  <0.82  2.0 
a MES, maximal electroshock induced seizures; scMET, subcutaneous pentylenetetrazole induced seizures; 
TOX, observed minimal muscular or neurological impairment as indicated by rotarod paradigm (mice) or 
abnormal, uncoordinated gait (rats); TI, therapeutic index = TD50/ED50; ED50, median effective dose; TD50, 
median toxic dose; i.p., intraperitoneal; P.O., oral. 
b Refer to reference.159  
c A higher dose was not tested, since 500 mg/kg was clearly not sedating. dAll values are in mg/kg; Cbz, 
carbamazepine; Cl, clonazepam; Pn, Phenytoin 
 
The maximal electroshock (MES) assay is a common choice in search of new antiepileptic 
drugs160 and KRM-II-81 (36) was evaluated, along with diazepam and HZ-166 (3) for comparison. 
Male CD-1 mice (n = 10) were dosed i.p. with vehicle (1% CMC), diazepam (1, 3 or 6 mg/kg), 3 
(3, 10 or 30 mg/kg) or 36 (3, 10 or 30 mg/kg) 30 minutes prior to testing. During the testing, mice 
were given a 7mA electroshock for 0.2 seconds and observed for tonic and/or clonic seizures and 
the results are illustrated in Figure 40. 
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Figure 40. Diazepam, HZ-166 (3) and KRM-II-81 (36) in the MES anticonvulsant activity assay. Male CD-1 
mice (n = 10) were dosed i.p. 30 minutes prior to being tested with either vehicle (1% CMC), diazepam (1, 3 or 
6 mg/kg), KRM-II-81 (3, 10 or 30 mg/kg) or HZ-166 (3, 10 or 30 mg/kg). Analyzed using ANOVA (Dunnett’s 
test versus vehicle: * P < 0.05). 
 
 Examination of the results indicated that HZ-166 (3) produced little to no protection against 
MES-induced seizures at 3, 10 or 30 mg/kg. This was consistent with the findings at ASP (NINDS, 
Stables, et al.), which had seen no protection at 100 mg/kg, albeit under somewhat different 
conditions 115. Diazepam, which is a potent anticonvulsant, was able to significantly reduce the 
percent of seizure outcomes to about 10% at 3 mg/kg and provided full protection at 6 mg/kg. The 
1 mg/kg dose did reduce the number of seizures to 60% of the total number of outcomes, but this 
was not a significant effect. Oxazole 36 performed comparably to 3 at 3 mg/kg and exerting little 
effect, but began to show activity in reducing convulsions at 10 mg/kg and protected all test 
subjects at 30 mg/kg. This was exciting and long-lived in vivo. 
 KRM-II-81 (36) was also evaluated for its anticonvulsant activity against scMET-induced 
clonic seizures. Male Sprague-Dawley rats (n = 5) were dosed i.p. with either vehicle (1% CMC), 
diazepam (3 or 10 mg/kg), 3 (30 mg/kg) or 36 (10, 30 or 60 mg/kg). Thirty minutes post 
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administration of a test compound, the convulsant pentylenetetrazole (in saline), was then given 
i.p. at a 35 mg/kg dose and the rats were observed for convulsions, as depicted in Figure 41A. 
Another assessment of the protection from scMET-induced seizures is shown in Figure 41B. This 
assay consisted of first dosing rats i.p. with either vehicle (1% CMC), diazepam (0.1, 0.3 or 1 
mg/kg), 3 (3, 10, 30 or 60 mg/kg), 36 (3, 10, 30 or 60 mg/kg), or valproic acid (300 mg/kg) before 
determining the concentration of metrazole that was needed to induce a seizure. Thirty minutes 
after administration of a test compound, pentylenetetrazole (PTZ) was infused I.V. at a rate of 0.5 
mL/minute (10 mg/mL) until the appearance of a clonic seizure. 
 
 
Figure 41. Diazepam, HZ-166 (3) and KRM-II-81 (36) in the blockage (A) and threshold (B) measurement 
against scMET-induced seizures. In the blockage procedure (A), mice were dosed i.p. with either diazepam (3 
or 10 mg/kg), KRM-II-81 (10, 30 or 60 mg/kg) or HZ-166 (30 mg/kg) 30 minutes prior to testing. The threshold 
procedure (B) dosed diazepam, KRM-II-81, HZ-166 or valproic acid 30 minutes prior to an I.V. infusion of the 
convulsant pentylenetetrazole until convulsions were observed. Analyzed using ANOVA (Dunnett’s test: * P < 
0.05). 
 
 
 The ability of diazepam, 3 and 36 to prevent convulsions is shown in Figure 41A. 
Diazepam was able to produce some reduction of scMET-induced seizures at 3 mg/kg, and offered 
93 
 
full protection at 10 mg/kg. At a 30 mg/kg, ethyl ester 3 was able to protect rats from some seizures, 
but not significantly different than vehicle. Oxazole 36 showed some reduction at 10 mg/kg, and 
full protection at 30 and 60 mg/kg. These results are in alignment with the results from the MES-
induced seizure assay. 
 The follow-up study to determine the threshold limit of protection of the test compounds 
is shown in Figure 41B. At 1 mg/kg, diazepam was able to increase the required dose of PTZ to 
49 mg/kg, which was significantly different than vehicle (PTZ threshold = 37.1 ± 1.9 mg/kg). 
Ligand HZ-166 (3) was unable to increase the amount of PTZ required to induce seizures up to 60 
mg/kg, whereas KRM-II-81 (36) began to require a significant increase of PTZ at 10 mg/kg, 
requiring a 71 mg/kg dose of PTZ to induce seizures. When rats were given a 60 mg/kg dose of 
KRM-II-81 (36), the amount of PTZ required to induce a convulsion rose to 108 mg/kg. This was 
greater than the 81 mg/kg of PTZ required when given a 300 mg/kg of the antiepileptic drug 
valproic acid at a fifth of the dose. 
 Analysis of the anticonvulsant data indicated that 36 was better at protecting rodents from 
seizures than the known anticonvulsant 3. In the threshold test (Figure 41B), oxazole 36 was able 
to significantly increase the amount of PTZ required to induce a seizure at 10 mg/kg, which was a 
sixth of the dose that 3 was unable to produce a significant effect. It is interesting that HZ-166 (3) 
was unable to produce significant effects at 60 mg/kg here in rats when given i.p. Earlier in a 
scMET mouse study by ASP, an ED50 of 16.28 mg/kg resulted when dosed i.p. The rat P.O. study 
by ASP also showed HZ-166 (3) performed well with an ED50 of 98.5 mg/kg.
115 However, these 
test conditions are not identical, along with the species of animals and cannot be directly compared. 
The most important finding is that KRM-II-81 (36) was effective against convulsions at a fifth of 
the dose to achieve the same effect with the known anticonvulsant valproic acid. 
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3.3.7.5.1 Assessment of Seizure Protection in Resistant Epileptic Human Brain Tissue 
 Recently, human brain tissue from a patient suffering from intractable, or resistance, 
epilepsy was obtained and KRM-II-81 (36) was assessed to determine if it would reduce the firing 
rate in epileptic brain tissue after surgical treatment, as illustrated in Figure 42. The slice was first 
monitored while in a picrotoxin solution which determined that the tissue was active while 
recording over a one-hour time period (open circles) and resulted in an average firing rate of 0.05 
Hz ± 0.01. The oxazole 36 was then added (30 µM) which inhibited the firing rate activity (closed 
circles) and resulted in a firing rate of 0.01 Hz ± 0.005. Data was collected for 1 hour under each 
condition. 
 
Figure 42.  Network Firing Rate. Dampening effects of KRM-II-81 (36) on firing rate frequency (Hz) in tissue 
resected from a human with epilepsy.  Data was collected for 1 hour under each condition (circle/baseline 
EACSF) (filled circle EACSF + 30uM 36).  KRM-II-81 (36) significantly reduced the firing rate frequency 
(paired t-test: P < 0.05). 
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 These results indicated that KRM-II-81 (36) was able to significantly reduce the firing rate 
of epileptic seizures that were resistant to other forms of treatment. This data is a very important 
step forward for 36 and the treatment of epileptic seizures! 
 
3.3.7.6 Reversal of Hyperalgesia in Neuropathic and Inflammatory Pain Models 
 The use of BZDs for the treatment of neuropathic pain is one study that has become a topic 
of growing interest over the past few years. It has been shown by Zeilhofer, et al. with HZ-166 
and a triple knock-in mouse that the positive activation of the α2 subtype is responsible for most 
of the antihyperalgesic effects161 exerted by BZDs. More recently, instead of being effected in the 
brain, it appears that the action stems from the α2 Bz/GABAAR subunits that are located 
supraspinal region of the CNS (Paul, Cook, Zeilhofer, et al.).162 As previously discussed, HZ-166 
(3) has been shown to be active in inflammatory pain models and the CCI model of neuropathic 
pain93 by Zeilhofer, Cook, et al. More recently, 3 was used in a knock-in CCI model of mechanical 
sensitization in which the α2 subtype was rendered insensitive with a H101R replacement.50 Here, 
ethyl ester 3 exerted an antihyperalgesic effect in wild-type mice using von Frey filaments, but the 
α2 knock-in mice showed little difference from vehicle, as illustrated in Figure 43. This indicated 
that most of the antihyperalgesic effects do stem from the α2 subtype. In a different study, the α3 
subtype selective agent YT-III-31117 did show some antinociceptive activity but sedation 
confounded the results of this study; a sedative effect would slow down paw withdrawal (M. Poe, 
J. Cook, unpublished results; see Appendix A). Oxazole 3 was investigated for its antihyperalgesic 
effects to further assess its pharmacological profile. 
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Figure 43. Antihyperalgesic effects of HZ-166 (3) in wild-type (left) and α2 knock-in (right) mice. Mice (n = 7-
8) were dosed with 3 (16 mg/kg) and assessed in the CCI antihyperalgesic procedure using von Frey filaments. 
Analyzed using the unpaired t-test: ** P < 0.01. Modified from the figure in Ravlenius, et al.50 
 
3.3.7.6.1 The Potential Treatment of Neuropathic Pain 
 The oxazole KRM-II-81 (36) was assessed in a neuropathic pain model in which the sciatic 
nerve ligation (SNL) model was used. The SNL model induces hypersensitivity to pain by tying 
spinal nerves163 and is similar to the CCI model. It can be measured by mechanical sensitization 
or thermal methods. This model employed male Sprague-Dawley rats (n = 5) that went through 
SNL 90 days prior to testing. After determining a baseline for the study, rats were injected i.p. with 
either vehicle (1% CMC), gabapentin (50 mg/kg) or 36 (30 mg/kg). Every hour for 4 hours, rats 
were subjected to mechanical sensitization using von Frey filaments to determine the paw 
withdrawal threshold (PWT) and the results are shown in Figure 44. Gabapentin was chosen as a 
positive control as it is commonly used for neuropathic pain, as discussed in Section 3.1. 
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Figure 44. KRM-II-81 (36) and gabapentin in the SNL model of neuropathic pain. Male Sprague-Dawley rats 
(n = 5) were dosed i.p. either vehicle, KRM-II-81 (30 mg/kg), or gabapentin (50 mg/kg) and tested in the von 
Frey filament assay after undergoing SNL 90 days prior. Analyzed using ANOVA (Dunnett’s test: * P < 0.05). 
It is clear that KRM-II-81 is more potent than gabapentin in this model of neuropathic pain. KRM-II-81 in von 
Frey filament assay for antihyperalgesia. 
 
 The results of the SNL model of neuropathic pain show that oxazole 36 and gabapentin 
were able to significantly reverse the effects of hyperalgesia at the one-hour time point after dosing. 
The PWT of rats dosed with KRM-II-81 (36) produced the same medium value at the one- and 
two-hour time points, but the results at two hours were not significant due to a slightly higher 
vehicle PWT and a greater SEM. It should be noted that in addition to the mediation of a greater 
antihyperalgesic effect at a lower dose than gabapentin, although not significantly so, the more 
than double molecular weight of KRM-II-81 (36) also indicates that it is acting at a lower 
respective concentration than gabapentin. This corresponds to 36 exerting a greater reversal of 
hyperalgesia than gabapentin at about a third of the concentration which would further help reduce 
the concerns of adverse effects which could result in doses of higher concentrations that would 
result in the activation of off-target GABAAR subtypes or other receptors. These interactions were 
assessed by the National Institute for Mental Health (Psychoactive Drug Screening Program, Dr. 
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Bryan Roth, UNC) and screened against a panel of cloned human and rodent CNS receptors 
determine any off-target effects. The oxazole 36 was found to have little to no binding affinity for 
a wide-array of receptors, including dopamine, histamine, opioid, adrenergic, and serotonin 
receptors among other. In addition, KRM-II-81 had no hERG activity,164 which is involved in 
coordinating the electrical activity associated with the heart’s beating, decreasing the risk of 
inducing heart arrhythmias.165 
 
3.3.7.6.2 The Activity of KRM-II-81 (36) and KRM-II-18B (38) in a Model of Inflammatory 
Pain 
 The antihyperalgesic effects of KRM-II-81 (36) and KRM-II-18B (38) were assessed in an 
assay which uses the complete Freund’s adjuvant (CFA) model of inflammatory pain by Dr. Jun-
Xu Li (University at Buffalo). CFA contains Mycobacterium butyricum which induces 
inflammation.166 Male Sprague-Dawley rats (n = 6) were injected with 0.1 mL of CFA into the 
right hind paw. Three days post injection, rats were injected with either midazolam, 3, 36 or 38 
and tested for antihyperalgesic activity using von Frey filaments. The results are illustrated in 
Figure 45. Von Frey filaments were used slowly increasing the pressure on the left hind paw 
(control). Once the left paw was withdrawn, the amount of force applied was recorded as 100% 
maximum possible effect (MPE), with a maximum of 26 g. 
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Figure 45. Assessment of antihyperalgesic effects of midazolam, 3, 36 and 38 in CFA-induced inflammatory 
pain. GABAA receptor PAMs, Midazolam (nonselective PAM), HZ166, KRM-II-18B, and KRM-II-81 dose-
dependently attenuated mechanical hyperalgesia in a CFA-induced inflammatory pain rat model. Raw data 
(paw withdrawal threshold, expressed in g of von Frey filament) was converted to a maximal possible effect 
value according the following equation:  
% MPE = [(test threshold (g)- control threshold (g) / (pre-CFA threshold – control threshold)] x 100 
 
 
 HZ-166 (3) had been previously shown to reverse the antihyperalgesia in the zymosan A 
model of inflammatory pain.93 Here in the CFA model, 3 was able to reduce hypersensitivity; 
however, it only reached 50% MPE at 17.8 mg/kg, and did not offer full protection until rats were 
given a 56 mg/kg dose. This was much higher than midazolam, which was used as a positive 
control, which was shown to offer 80% MPE at 5.6 mg/kg, and full protection at 10 mg/kg. 
However, it must be remembered that sedation caused by midazolam may seriously confound these 
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results. KRM-II-81 (36) on the other hand elicited very similar results to midazolam, with an MPE 
near 80% at the 5.6 mg/kg dose but there was no sedation to confound the results. Ligand KRM-
II-18B appeared to be much more potent at lower concentrations, for it showed a 57% MPE at 3.2 
mg/kg, but at the 5.6 mg/kg dose it offered the same protection as 36. 
 The antihyperalgesic effects of ligands 3, 36 and 38 were examined to verify the source of 
the pharmacological effect. This was done by using flumazenil, which is a GABAAR antagonist 
which tightly binds to all GABAAR subtypes and blocks the effect of DS BzR ligands. Rats were 
dosed with 3, 36 and 38 at the same doses as was completed previously, but an additional 
pretreatment of flumazenil (1, 3.2 or 10 mg/kg) 10 minutes prior to the test compound was given. 
These results are shown in Figure 46.  
 
Figure 46. Antagonism of BZD effects using flumazenil. The benzodiazepine site antagonist flumazenil shifted 
the dose-effect curves of PAMs rightward, indicating the effect is modulated by the benzodiazepine receptor. 
 
 The GABAAR antagonist, flumazenil, was able to dose-dependently right-shift the 
antihyperalgesic effects, which resulted in a lower MPE at each concentration of a given test 
compound. With increasing flumazenil doses, the greater the concentration was needed to reach 
the pre-CFA level, or 100% MPE. This key result indicated clearly that HZ-166 (3), KRM-II-81 
101 
 
(36) and the 2'-F analog (38) exerted their effects through benzodiazepine receptors and not some 
other receptor system. 
 
3.3.7.7 The Treatment of Depression in the Forced Swim Test 
A hypothesis that predicts depression can be treated through a GABAergic pathway has 
been proposed,6 and some clinical studies have seen BZDs alprazolam and adinazolam exert some 
antidepressant nature similar to marketed antidepressants;167, 168 however the Bz/GABAAR 
subtype is unknown. The forced swim test is used as a primary screen for the antidepressant nature 
of a test compound. One knockout study has suggested that the α2 subunit may be the source of 
the activity169 and KRM-II-81 (36) was assessed for antidepressant activity. Mice NIH Swiss mice 
were dosed i.p. with vehicle (1% CMC), 36 (3, 10 or 30 mg/kg) or positive control imipramine (15 
mg/kg) 30 minutes prior to being placed in a cylinder filled with a small amount of water, and the 
results are illustrated in Figure 47. Mice that were more mobile during the test were determined to 
be less depressed as they continued to search for an escape, opposed to treading water.  
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Figure 47. The antidepressant effects of KRM-II-81. Male NIH Swiss mice (n = 7 – 8) were dosing i.p. with 
vehicle (1% HEC, 0.25% Tween 80, 0.05% antifoam), KRM-II-81 (3, 10 or 30 mg/kg) or imipramine (15 mg/kg) 
and assessed in the forced swim test. Analyzed using ANOVA (Dunnett’s test * P < 0.05). 
 
 The results indicated that KRM-II-81 (36) was able induce an antidepressant effect at 10 
and 30 mg/kg, characterized by the decreased immobility time as compared to vehicle. Because 
the majority of antidepressants, which have their drawbacks, act upon the serotonergic and/or 
noradrenergic systems,170 there is a need for agents that target different pathways.171 The data 
presented here is exciting and encouraging that nonsedating nor addicting BZDs could be used in 
the treatment of depression by targeting GABAA receptors. 
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3.4 Discussion 
 Prior to this work, lead compound ethyl ester HZ-166 (3) had been shown to be a very good 
non-sedating anxiolytic,112 anticonvulsant,115 and it was also active against inflammatory and 
neuropathic pain.50, 93, 162 It was shown by Stables (NINDS) and Zeilhofer that 3 did not develop 
tolerance to the anticonvulsant and antinociceptive effects. This lack of tolerance by low efficacy 
at α1 and α5 subtypes indicated HZ-166 (3) was in a very special class of ligands which target the 
benzodiazepine binding site of GABAA receptors. It was shown to be stable when incubated with 
human liver microsomes;117 however, the short time-of-effect seen in the in vivo assays in 
rodents93, 115 led to the realization that 3 was not stable enough in rodents required for extensive 
preclinical trials. The research in this thesis was designed to address the stability issues, in regard 
to preclinical testing, as well as to design better subtype selective ligands to understand the 
physiological effects of α2 and/or α3 subtype Bz/GABAAR ligands. This work has led to a number 
of important findings. 
 Pharmacokinetic studies of 3 (Table 3) show that the ethyl ester was not detected in plasma 
or brain of rodents when dosed I.V. or orally; however, the acid 20 was found in the brain in very 
small amounts. This indicated that 3 was possibly a prodrug of the pharmacologically active acid 
20 or the ester 3 enters the brain very rapidly and is hydrolyzed to 20 in the brain. The acid 20 
itself, however, was also dosed in PK studies and it was shown that 20 has very poor BBB 
penetration, indicated by the absence of 20 in brain samples. The deuterated ethyl ester 21 of 3 
was designed and synthesized, which was successful in combating degradation when incubated in 
vitro with liver microsomes, but was still metabolized in vivo in rodents. 
 The methyl ester 19 was also found to have an increased resistance to metabolism by liver 
microsomes in vitro. We believe that the metabolism of 3 is effected by esterases and β-oxidation 
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of the ethyl group in MLMs, whereas the methyl ester would not undergo β-oxidation in the liver. 
This is speculation at the moment but is in agreement with the longer half-life of the methyl ester 
19 when compared to the ethyl ester 3. This compound was tested in vivo for anxiolytic and 
antihyperalgesic activity by Dr. Bradford Fischer. It was found to be active in both assays and 
appeared to have a longer time-of-effect than 3 when tested in similar experiments. Because of 
poor metabolic results with other esters described above, it was concluded that esters as a group, 
although active, were too metabolically unstable in vivo to be regarded as promising preclinical 
candidates. 
 A series of heterocyclic bioisosteres were designed using the pharmacophore/receptor 
model74 and synthesized, including various oxazoles and oxadiazoles, to resist rodent metabolic 
degradation. The 2'-N compounds which are more polar were found to have increased stability in 
in vitro rodent and human liver microsomes. KRM-II-81 (36) was found to be the most promising 
of the heterocyclic compounds based on an α3 FLIPR assay, liver microsomal stability, anxiolytic 
marble burying assay and a rotarod assay which indicated no ataxia at the therapeutic dose. Further 
studies on KRM-II-81 were carried out with HZ-166 employed as a comparison ligand. Oxazole 
36 was found to be a better anticonvulsant, anxiolytic and more active against neuropathic and 
inflammatory pain than published lead non-sedating anxiolytic 3. This includes two critical pieces 
of data which indicate that 36 was able to reduce network firing in resistant human epileptic brain 
tissue and was able to decrease depression. Moreover, KRM-II-81 had much greater BBB 
penetration, as indicated by the high concentration of compound found within brain samples two 
hours after oral administration whereas 3 was below the quantifiable limit ( < 12 nM). Additional 
studies on 36, as well as other heterocycles and amides, are currently being completed to further 
characterize these compounds. The results of these studies indicate that KRM-II-81 or its analogs 
105 
 
have great potential to advance to clinical trials as non-sedating anxiolytic, anticonvulsant and 
antinociceptive agents which do not develop tolerance to the anticonvulsant or antinociceptive 
effects.  
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3.5 Methods 
3.5.1 Liver microsomal assay (Revathi Kodali at UWM) 
Chemicals and Reagents 
Test compound (1 mM in DMSO), Verapamil HCl (1 µM in Acetonitrile), phosphate buffer (0.5 
M) pH 7.4, 18 mΩ water, NADPH Regenerating System Solution A (BD Bioscience Cat. No. 
451220), NADPH Regenerating System Solution B (BD Bioscience Cat. No. 451200), Human 
pooled liver microsome (BD Gentest, Cat. No. 452156), Mouse liver microsomes (Life 
Technologies, Cat. No. MSMC-PL). 
Microsomal stability assay 
Test compounds (10 µM) were incubated with human and mouse liver microsomes at a protein 
concentration of 0.5 mg/mL in a total volume of 400 µL containing 282 µL of water, 80 µL of 
phosphate buffer (0.5 M) pH 7.4, 20 µL of NADPH Solution A, 4 µL of NADPH Solution B, 4 
µL of test compound (1 mM in DMSO) and 8.8 µL of liver microsomes. After preincubation at 37 
°C for 5 minutes, the reaction was initiated by addition of microsomes and vials were stirred using 
a digital heat-shaking dry bath (Fischer Scientific, Cat. No. S08040). Aliquots of 50 µL were taken 
at time intervals of 0 (without microsomes), 10, 20, 30, 40, 50 and 60 min. Each aliquot was added 
to 100 µL of cold acetonitrile solution containing 1 µM of the internal standard verapamil, 
followed by sonication for 10 seconds and centrifugation at 10,000 rpm for 5 minutes. The 100 µL 
of the supernatant was transferred into Spin-X HPLC filter tubes and centrifuged at 13,000 rpm 
for 5 min. The filtrate was diluted and subsequently analyzed by LC-MS/MS (Shimadzu LCMS 
8040). The ratio of the peak areas of the internal standard and test compound was calculated for 
every time point and the natural log of this ratio was plotted against the time to determine the linear 
slope (k). The metabolic rate (k*C0/C), half-life (0.693/k), and internal clearance (V*k) were 
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calculated, where k is the slope, C0 is the initial concentration of test compound (µM), C is the 
concentration of microsomes (mg/mL), and V is the volume of incubation (µL)/protein in the 
incubation (mg). All incubations throughout the study were performed in three experiments carried 
out in duplicate and the data was presented as the average value with the standard deviation. 
3.5.2 Liver microsomal assay (CRO) 
The compounds were incubated in hepatic microsomes (human, dog, mouse and rat) over a 30-
minute incubation period at 37ºC. Incubations both with and without NADPH (2 mM) were 
performed in a 96-well plate format. The reaction was initiated with the addition of substrate and 
was terminated by protein precipitation with acetonitrile. All incubations are performed using a 
final substrate concentration of 4 μM in 50 mM sodium phosphate buffer, pH 7.4. The final organic 
solvent content was 0.5 % acetonitrile and 0.02% DMSO. The amount of enzyme present was 
fixed at 1.11mg/mL protein irrespective of the species of microsomes used. Samples were analyzed 
by LC/MS-MS to determine the percent loss in the NAPDH incubations relative to the NADPH 
free incubations. 
3.5.3 Time-plasma concentration pharmacokinetic studies (CRO) 
The single-dose pharmacokinetics were determined in femoral artery/vein cannulated Sprague-
Dawley rats. The rats received a 1mg/kg intravenous and 10 mg/kg oral gavage dose of compound 
in individual experiments, respectively. Blood samples were collected at 0.08 (I.V. only), 0.25, 
0.5, 1, 2, 4, 8, 12 and 24 hrs after initiation of compound administration.  Plasma was obtained via 
centrifugation. Plasma samples were then analyzed by LC-MS, and pharmacokinetic parameters 
calculated using Watson (version 7.4; Thermo Fisher Scientific). Calculated parameters included 
clearance (CL), volume of distribution (Vdss), area-under-the-curve (AUC), half-life (T1/2), 
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maximum plasma concentration (Cmax), time of maximum concentration (Tmax), and bioavailability 
(%F). 
3.5.4 Efficacy data determined by electrophysiology using Xenopus laevis oocytes (Dr. 
Margot Ernst at the Medical University of Vienna) 172-175 
Ligand effects on GABAA receptors were tested by two-electrode voltage clamp experiments in 
cRNA injected Xenopus oocytes that functionally expressed several subtype combinations of 
GABAA receptors. 
Preparation of cloned mRNA 
Cloning of GABAA receptor subunits α1, β3 and γ2 into pCDM8 expression vectors (Invitrogen, 
CA) has been described elsewhere.176 The cDNAs for subunits α2, α3 and α5 were gifts from P. 
Malherbe and were subcloned into a pCI-vector. After linearizing the cDNA vectors with 
appropriate restriction endonucleases, capped transcripts were produced using the mMessage 
mMachine T7 transcription kit (Ambion, TX). The capped transcripts were polyadenylated using 
yeast poly(A) polymerase (USB, OH) and were diluted and stored in diethylpyrocarbonate-treated 
water at –70 °C. 
Functional expression of GABAA receptors 
The methods used for isolating, culturing, injecting and defolliculating of the oocytes were 
identical as described previously.173, 177, 178 Briefly, mature female Xenopus laevis (Nasco, WI) 
were anaesthetized in a bath of ice-cold 0.17 % Tricain (Ethyl-m-aminobenzoate, Sigma, MO) 
before decapitation and removal of the frog ovary. Stage 5 to 6 oocytes with the follicle cell layer 
around them were singled out of the ovary using a platinum wire loop. Oocytes were stored and 
incubated at 18 °C in modified Barths medium [MB, containing 88 mM NaCl, 10 mM HEPES-
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NaOH (pH 7.4), 2.4 mM NaHCO3, 1 mM KCl, 0.82 mM MgSO4, 0.41 mM CaCl2, 0.34 mM 
Ca(NO3)2] that was supplemented with 100 units/mL penicillin and 100 μg/mL streptomycin. 
Oocytes with follicle cell layers still around them were injected with a total of 2.25 ng of cRNA. 
This solution contained the transcripts for the different α subunits and the β 3 subunit at a 
concentration of 0.0065 ng/nL as well as the transcript for the γ2 subunit at 0.032 ng/nL. After 
injection of the cRNA, oocytes were incubated for at least 36 h before the enveloping follicle cell 
layers were removed. To this end, oocytes were incubated for 20 min at 37 °C in MB that contained 
1 mg/mL collagenase type IA and 0.1 mg/mL trypsin inhibitor I-S (both Sigma). This was followed 
by osmotic shrinkage of the oocytes in doubly concentrated MB medium supplied with 4 mM Na-
EGTA. Finally, the oocytes were transferred to a culture dish containing MB and were gently 
pushed away from the follicle cell layer which stuck to the surface of the dish. After removal of 
the follicle cell layer, oocytes were allowed to recover for at least 4 h before being used in 
electrophysiological experiments. 
Electrophysiological experiments112, 115, 175 
For electrophysiological recordings, oocytes were placed on a nylon-grid in a bath of Xenopus 
Ringer solution (XR, containing 90 mM NaCl, 5 mM HEPES NaOH (pH 7.4), 1 mM MgCl2, 1 
mM KCl and 1 mM CaCl2). The oocytes were constantly washed by a flow of 6 mL/min XR which 
could be switched to XR containing GABA and/or drugs. Drugs were diluted into XR from DMSO 
solutions resulting in a final concentration of 0.1 % DMSO perfusing the oocytes. Drugs were 
preapplied for 30 sec before the addition of GABA, which was coapplied with the drugs until a 
peak response was observed. Between the two applications, oocytes were washed in XR for up to 
15 min to ensure full recovery from desensitization. For current measurements the oocytes were 
impaled with two microelectrodes (2–3 mΩ) which were filled with 2 mM KCl. All recordings 
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were performed at rt at a holding potential of –60 mV using a Warner OC-725C two-electrode 
voltage clamp (Warner Instruments, Hamden, CT). Data were digitized, recorded and measured 
using a Digidata 1322A data acquisition system (Axon Instruments, Union City, CA). Results of 
concentration response experiments were fitted using GraphPad Prism 3.00 (GraphPad Software, 
San Diego, CA). The equation used for fitting the concentration response curves was Y=Bottom 
+ (Top-Bottom)/(1+10^((LogEC50-X)*HillSlope)); X represents the logarithm of the 
concentration, Y represents the response; Y starts at the Bottom and goes to the Top with a sigmoid 
shape. 
3.5.5 The activity of MP-III-024 (19) in the anxiolytic Vogel conflict assay (Dr. Bradford 
Fischer at Rowan University) 
Experimentally naive adult male C57BL/6 mice (n = 6) were used as subjects. Water was withheld 
for 24 h prior to the first training session (habituation period). After 30 min, mice were placed in 
an experimental chamber for 6 min with water access. The mice went through a second 24 h water 
deprivation period before an i.p. pretreatment of either vehicle (0.5% methyl cellulose, 0.9% 
NaCl), diazepam or MP-III-024. The mice were then placed in the chamber after 30 min for another 
6 min test period (suppressed session). During the suppressed session, every completion of 20 
consecutive licks from the water spout was suppressed by a 0.14-mA shock (0.5 sec) to the tongue. 
The number of licks was recorded. 
3.5.6 The activity of MP-III-024 (19) in the zymosan A model of inflammatory pain using 
von Frey filaments (Dr. Bradford Fischer at Rowan University) 
Experimentally naive adult male C57BL/6 mice (n = 6) were used as subjects. Zymosan A (0.06 
mg) was suspended in 20 µL of 0.9% NaCl solution and injected subcutaneously into the plantar 
surface of the right hindpaw. Mechanical sensitivity was assessed 24 h after the zymosan A 
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injection with a Dynamic Plantar Aesthesiometer (Ugo Basile, Varese, Italy). A pretreatment of 
MP-III-024 was given 30 minutes prior to testing. Von Frey filaments were used in increasing 
force (1 gram per second) until the paw withdrawal threshold had been reached. The left hindpaw 
served as the non-injured paw for a baseline (control). 
3.5.7 The activity of MP-III-024 (19) tested for effects in locomotor activity (Dr. Bradford 
Fischer at Rowan University) 
Experimentally naive adult male C57BL/6 mice (n = 6) were used as subjects. Mice were dosed 
i.p. with either vehicle, diazepam or MP-III-024 and the ambulatory behavior was assessed in a 
locomotor activity chamber (Med Associates, St Albans, VT). The total distance was recorded 
over a 60 min span, and expressed in 5-min bins. 
3.5.8 The activity of MP-III-024 (19) assessment for operant behavior (Dr. Bradford Fischer 
at Rowan University) 
Experimentally naive adult male C57BL/6 mice (n = 6) were used as subjects. Mice were on a 
fixed ratio 3 (FR3) schedule of liquid food (Ensure) and observed in an experimental operant 
chamber (Med Associates, St Albans, VT). Training and test sessions consisted of multiple cycle 
components, each culminating with a 5 minute response period. Predrug response rate was 
recorded over 160 minutes and used as a 100% baseline. Mice were injected i.p. with MP-III-024 
and observed for 160 minutes and the response rates were expressed as a percent control relative 
to the pre-drug baseline value. 
3.5.9 Efficacy data for MP-II-064 (27) using the IonFlux automated patch-clamp (Nina Yuan 
at UWM) 
Patch Clamp Solutions 
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The intracellular solution (ICS) contained (mM): 60 KCl, 15 NaCl, 70 KF, 5 EGTA, 5 HEPES, 
pH 7.25 with KOH. The extracellular solution (ECS) contained (mM): 138 NaCl, 4 KCl, 1 MgCl, 
1.8 CaCl2, 5.6 D-glucose monohydrate, and 10 HEPES, pH 7.4 with NaOH. EC10 was 
approximated to be 0.25uM GABA.  
 Automated patch-clamp electrophysiology 
Measurements were performed with the IonFlux instrument (Molecular Devices, Sunnyvale, CA), 
which utilizes microfluidic compound delivery on timescales below 100 ms, facilitating the 
recording of fast activating ligand gated ion channels. Using this platform, a large number of cells 
(20 per ensemble) can be held under voltage clamp and exposed to a series of concentrations of 
compound within a short time period in parallel across a plate. Continuous recording coupled with 
fast solution exchange enables high-throughput. The IonFlux 16 plate layout consists of units of 
twelve wells; two wells contain intracellular solution (cytosolic), one contains cells diluted in 
extracellular solution, eight contain the compounds of interest diluted in extracellular solution, and 
one well is for waste collection. Cells are captured from suspension by applying suction to 
microscopic channels in ensemble recording arrays. Once the array is fully occupied, the applied 
suction breaks the cell membranes of captured cells, establishing whole cell voltage clamp. For 
compound applications, pressure is applied to the appropriate compound wells, introducing the 
compound into the extracellular solution rapidly flowing over the cells. For recording GABAA 
currents, cell arrays were voltage clamped at a holding potential of -80 mV. IonFlux software 
(IonFlux App) was used for data acquisition and exported to an Excel file (Microsoft) for 
organization. The data was uploaded to GraphPad Prism 5 (GraphPad Software) for automated 
analysis of the concentration dose-response curves. 
Plasmid Propagation Reagents 
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Plasmids containing the genes for α1-6, β3, and γ2 were generously donated by Dr. Werner 
Sieghart’s Lab in Vienna, Austria.   
 Cell Culture Reagents and Instrumentation 
A commercially available, stably transfected, human embryonic kidney (HEK 293T) cell 
containing the simian vacuolating (SV) virus 40 T-antigen origin of replication 179 was used in all 
the stable cell lines. The HEK 293T cells were purchased (ATCC) and cultured in 75 cm2 flasks 
(CellStar) coated in Matrigel (BD Bioscience, #354234), a gelatinous protein secreted by mouse 
sarcoma that facilitates cell adhesion to the flask. Cells are grown in DMEM/High Glucose 
(Hyclone, SH3024301) media to which non-essential amino acids (Hyclone, SH30238.01), 10 mM 
HEPES (Hyclone, SH302237.01), 5 x 106 units of penicillin and streptomycin (Hyclone, 
SV30010), and 10% of heat-inactivated premium US-sourced fetal bovine serum (FBS) (Biowest, 
SO1520HI) were added. Cells were rinsed with phosphate buffered saline (Hyclone SH30256.01) 
without calcium or magnesium. Cells are harvested using 0.05% Trypsin (Hyclone, SH3023601) 
or Detachin (Genlantis T100100) which both disrupts the cell monolayer and proteolytically 
cleaves the bonds between the cells and flask; the latter more gently for patch-clamp study. The 
media utilized in transient transfections contains the same components only the FBS was heat-
inactivated and dialyzed FBS (Atlanta Bio, S12650H), then cells were rinsed and shaken in Serum 
Free Media (Hyclone, SH30521.01).Cell transfection was conducted by lipid-based methods using 
Lipofectamine with PLUS reagent (Life Technologies, #15338020).  
3.5.10 FLIPR functional assay (CRO)180, 181 
Compounds 
Compounds tested were synthesized internally and solubilized in DMSO at a 10 mM 
concentration. GABA was purchase from Sigma (#A2129) and prepared at 100 mM in water. 
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Cells expressing the GABAA receptor 
HEK-293 cells stably transfected with the α1, β3, γ2 GABA A receptor subunits (GenBank 
accession numbers NM_000806.3, NM_000814.5, and NM_198904.1, respectively) or α3, β3, γ2 
(NM_000808 for α3) where obtained from ChanTest Co. (Catalog # CT6216 and CT6218, 
respectively). 
Cells were cultivated in Dulbeco’s Modified Eagle’s Medium (DMEM, Sigma D5796) 
supplemented with 10 % Fetal Bovine Serum (FBS, Gibco 16000), 0.5 mg/ml Geneticin (Gibco), 
0.04 mg/ml Hygromycin B (Gibco), 0.1 mg/ml Zeocin (Gibco) and 20 mM HEPES (Sigma). Cells 
were grown at 37 ºC in a humidified atmosphere of 5% CO2. In the experiments described here 
frozen cells were used. For this purpose, cells were gown and maintained under confluency during 
2-3 weeks and then frozen down at different cell densities using Recovery™ Cell Culture Freezing 
Medium (Gibco). 
FLIPR assays in 384 format 
18 hours prior to the experiment, cells were quickly thawed at 37 ºC and seeded on Poly-D-Lys 
384 plates (Corning 356663) at a density of 25,000 cells/well and in 25 uL of complete cell medium 
as described above. 
Membrane potential changes induced by the flux of ions through the receptor were measured as 
relative fluorescence units (RFU) using the Fluorometric Imaging Plate Reader (FLIPR Tetra®, 
Molecular Devices) and the FLIPR Membrane Potential Blue Assay kit (Molecular Devices). Prior 
to the addition of the compounds, the medium was removed and cells were loaded with 20 µL of 
dye prepared in assay buffer composed of Hank’s Balanced  Salt Solution (HBSS with Ca+2 and 
Mg+2; Gibco 14025) with 20 mM Hepes. After 1 hour of incubation at room temperature (RT), the 
115 
 
plate was placed into the FLIPR instrument and experiments were run adding first 10 uL from the 
1st addition plate (compound plate) and after a 3 min incubation adding 20 uL of the 2nd addition 
or agonist plate. The response to this last GABA addition was monitored for another 3 min. 
1st Addition plates or compound plates.  
First addition plates containing the compounds to be tested were prepared as follows: compounds 
in 10 mM dimethyl sulfoxide (DMSO) stock were serially diluted from column 3 to 12 and 13 to 
22 in 100 % DMSO using Corning 3657 plates and a Tecan Freedom Evo ® platform. Then, 
compounds were further diluted 1:100 in assay buffer. A GABA EC0 (assay buffer alone) and 
EC100 (150 or 100 uM final GABA concentration after 1
st addition for α1 or α3-containing receptor 
cell lines, respectively) were also included in these plates and used as minimum and maximum 
response controls, respectively, to analyze any possible compound agonist response.  
2nd Addition plate or agonist plate.  
Second addition plates were generated using a GABA EC20 to test the potentiation profile of the 
compounds. EC20 and EC100 GABA (final assay concentrations) were used as minimum and 
maximum response controls, respectively. EC20 was 2 or 1.2 uM final GABA concentration for α1 
or α3-containing receptor cell lines, respectively. 
Data analysis.  
The difference between the maximum and the minimum (Max-Min) fluorescence reached during 
the first addition or read interval and the second read interval were used for data analysis (agonist 
and potentiation, respectively). Data was normalized according to the following formula: 
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% activation = 100 ×   (
Test well − Median EC0 or EC20 Control
Median EC100 Control − Median EC0 or EC20 Control
) 
Where Test well refers to those that contain test compounds. 
 
EC50 and maximum stimulation values were determined from concentration-response curves at 10 
distinct concentrations. The four-parameter logistic model was used to fit each data set. 
3.5.11 Assessment of anxiolytic effects in the marble burying assay (CRO) 152 
Animals 
Experimentally naïve, male NIH Swiss mice (Harlan Sprague–Dawley, Indianapolis, IN) were 
allowed to acclimate to a vivarium for at least 3 days prior to testing. They weighed between 28 
and 32 g and were housed in groups of 10 to 12 in plastic cages (24 x 45 x 15 cm high) with 
sawdust bedding in a temperature-controlled vivarium with a 12-h light dark cycle (lights on: 
0600–1800 hours). Experiments were conducted during the light phase of this cycle. The facilities 
in which the animals were maintained are fully accredited by the American Association for the 
Accreditation of Laboratory Animal Care (AAALAC) and the studies described herein were 
conducted in accordance with the Guide for Care and Use of Laboratory Animals under protocols 
approved by a local animal care and use committee. 
Protocol 
Mice were dosed i.p. with either vehicle (1% CMC) or a test compound 30 min prior to testing. 
Mice were placed in a 17 x 28 x 12 cm high plastic tub with 5 mm sawdust shavings (Harlan Sani-
Chips, Harlan-Teklad, Indianapolis, IN) on the floor that were covered with 20 blue marbles (1.5 
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cm diameter) placed in the center. Mice were left in the tub for 30 min. The number of marbles 
buried (2/3 covered with sawdust) were counted and recorded. 
3.5.12 Assessment for ataxic effects in the rotarod paradigm (CRO) 152 
Animals 
See 3.5.11 for description 
Protocol 
Mice were dosed i.p. with either vehicle (1% CMC) or a test compound 30 min prior to testing. 
Mice were then placed on a rotarod (Ugo Basile 7650) operating at a speed of 4 revolutions/minute 
and observed for falling. Mice that did not fall during the 2 minutes of testing were given a 
“Success” designation. Mice that fell once were given a “Partial” score, while the mice that fell 
twice failed the test. 
3.5.13 Assessment for muscle relaxation in the inverted screen test (CRO) 
Animals 
Male Sprague Dawley rats, (from Harlan Sprague Dawley. Indianapolis, IN), weighing 90-110 
grams at time of test were employed. The animals were housed 5 per cage with ad libitum food 
and water in a large colony room with a standard light cycle (lights on 6am, lights off 6pm).  
Animals were maintained in the colony room for at least 3 days before testing.  Animals were 
moved to the quiet room 1 h prior to the start of the test. 
Equipment 
The apparatus for the inverted screen is made of six 13 cm x 16 cm squares or round holes, 
perforated stainless steel mesh (18 holes/square inch; 3/16 inch diameter, ¼ inch staggered centers, 
50% open area) which are mounted 15 cm apart on a metal rod, 42 cm above the table top. 
118 
 
Procedure 
Male Sprague-Dawley rats (n = 5) were dosed i.p. (vehicle = 1% carboxymethyl cellulose) with 
diazepam (3, 10 or 30 mg/kg), KRM-II-81 (10, 30 or 60 mg/kg) or HZ-166 (30 mg/kg) 30 min 
prior to testing. Rats were then placed onto the top of a wire screen, which was then inverted 180o 
over a 2 – 3 second time span, so that the rats were hanging upside down. Rats were observed for 
60 seconds, at which point they were scored (0 = climbed over; 1 = hanging onto screen; 2 = fell 
off). 
3.5.14 Assessment for anxiolytic-like effects in the Vogel conflict assay (CRO) 182 
Animals 
Experimentally naive adult male Sprague-Dawley rats (Harlan Industries, Indianapolis, IN), 
weighing between 200 and 300 g, were used as subjects. The rats were housed in Plexiglas cages 
(4 per cage), and given free access to Lab Diet #5001 for rodents (PMI Nutrition International Inc., 
St. Louis, MO). Water was withheld for 20 – 24 h prior to the first training session. A 12-h 
light/dark cycle was maintained, and all experimental sessions were conducted during the light 
phase of the cycle at about the same time each day. All experiments were conducted in accordance 
with the NIH regulations of animal care covered in “Principles of Laboratory Animal Care”, NIH 
Publication 85-23, and were approved by the Institutional Animal Care and Use Committee. 
Apparatus 
The experiments were conducted using operant behavior test chambers ENV-007 (Med Associates 
Inc., Georgia, Vermont, USA), 30.5 x 24.1 x 29.2 cm. The test chambers were contained within 
light and sound attenuating shells. On the front wall of the chamber, a food trough was mounted 2 
cm off the grid floor on the centerline. Two response levers were centered 8 cm off the centerline 
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and 7 cm off the grid floor. Three lights were located above each response lever at 15 cm off the 
grid floor. Responding on the levers was without consequences for all sessions. On the rear of the 
chamber, a sipping tube was mounted 3 cm off the grid floor and 3 cm from the door. The sipping 
tube was wrapped with electrical tape to prevent the circuit from being completed if the animals 
were holding/touching the tube. All events were controlled and licking data were recorded by a 
Compaq computer running MED-PC Version IV (Med Associates Inc., Georgia, Vermont, USA). 
Sipper tube training 
Rats were put into the chamber on day 1 and 2 with white noise and the houselight illuminated, 
and allowed to drink for a total of 6 min after the first lick was made. The 6 min was broken into 
two components, the first 3 min was recorded as the unpunished component and the second 3 min 
was recorded as the punished component. During the 2 training days no shock was delivered in 
the punished component. After training, animals were returned to the home cage and given access 
to water for 30 min. For the second and third tests for each group, water was withheld for 24 h 
before the training session. Animals were re-trained for 1 day. After training, animals were 
returned to the home cage and given access to water for 30 min. 
Sipper tube testing, conflict session 
On day 3, animals were weighed and injected with either vehicle or compound and returned to the 
home cage. Thirty minutes after injection, animals were placed into the test chamber. The session 
was identical to the training session except that during the punishment component the sipper tube 
delivered a brief electric shock (100 ms, 0.5 mA) after every 20th lick (FR20). 
3.5.15 Anticonvulsant activity in the MES protocol (CRO) 
Animals 
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Experimentally naive adult male CD mice (Harlan Industries, Indianapolis, IN), weighing between 
20 and 30 g, were used as subjects. The mice were housed in Plexiglas cages (4 per cage), and 
given free access to Lab Diet #5001 for rodents (PMI Nutrition International Inc., St. Louis, MO). 
Protocol  
Male CD mice (n = 10) were pretreated i.p. with vehicle (1% CMC), KRM-II-81 (3, 10, 30 mg/kg) 
or HZ-166 (3, 10, 30 mg/kg) and examined for anticonvulsant effects at 30 minutes after treatment. 
Mice were then given a 7mA electroshock (using a Wahlquist Model H) for 0.2 seconds, and 
observed for the presence or absence of seizure activity. Each mouse was tested only once, and 
euthanized immediately following the test. 
3.5.16 Anticonvulsant activity in the scMET protocol (CRO) 
Animals 
Male Sprague Dawley rats, (from Harlan Sprague Dawley. Indianapolis, IN), weighing 90-110 
grams at time of test were employed.  Animals were housed 5 per cage with ad libitum food and 
water in a large colony room with a standard light/dark cycle (lights on 6am, lights off 6pm).  
Animals were maintained in the colony room for at least 3 days before testing.  Animals were 
moved to a quiet room 1 h prior to the start of the test. 
Protocol (scMET blockade) 
Male Sprague-Dawley rats (n = 5) were dosed i.p. (vehicle = 1% CMC) with either diazepam (3 
or 10 mg/kg), KRM-II-81 (10, 30 or 60 mg/kg), or HZ-166 (30 mg/kg) 30 min prior to testing and 
placed in an observation cage covered with ¼ inch of woodchips. After 30 min pentylenetetrazole 
(in saline) in a volume of 1 mL/kg was then injected i.p. at 35 mg/kg, and rats were observed for 
30 min for signs of seizures, demonstrated by loss of righting reflex.  
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Protocol (scMET threshold) 
Male Sprague-Dawley rats (n = 8) were dosed i.p. (vehicle = 1% CMC) with diazepam (0.1, 0.3 
or 1 mg/kg) or a test compound (3, 10, 30 or 60 mg/kg) 30 min prior to testing. After the 30 min, 
pentylenetetrazole was administered IV to each group (10 mg/mL at 0.5 mL/min) until each animal 
exhibited a clonic convulsion, or for four min. Each animal was used only once, and was 
euthanized post testing. 
3.5.17 Human epileptic cerebral cortex electrophysiology (CRO) 
Tissue preparation and recording:  
The block of tissue from the patient described above was then sliced into coronal sections with a 
thickness of 250 µm using a vibratome tissue slicer.  Coronal sections were cut using white matter 
as landmark. After cutting, slices were bathed for ~1hr at room temperature in Artificial 
cerebrospinal fluid (ACSF), with 125 mM NaCl to restore Na+ and allow cells to fire action 
potentials again.  
In preparation for recording, slices were adhered to microelectrode arrays (MEA; Multichannel 
Systems, Reutlingen, Germany) with a solution of 0.1% polyethelinamine that had been previously 
applied and let dry for 2 hrs.183 We attempted to place the tissue so that neocortical layers I-V 
covered the array.  Slices were maintained thermostatically at 37° C and were perfused at 1.0 
ml/min first with normal ACSF (NACSF) for one hour to see if the tissue was spontaneously 
active.  If spontaneous activity did not develop after one hour the tissue was bathed in excitable 
ACSF (EACSF) solution containing 5 mM KCl and 0 mM Mg+2.  These external ionic 
concentrations are known to produce robust local field potential (LFP) activity in cortical brain 
slices.184-186 Tissue was then recorded in EACSF with a concentration of 10 M of picrotoxin for 
more than 1 hour.  Subsequently, tissue was recorded in EACSF with a concentration of 10M of 
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picrotoxin with perampanel and recorded for 1 hour.  Following the perampanel addition, tissue 
was recorded in a washout solution of EACSF and 10 M picrotoxin for 1 hour. 
Electrode arrays.  
Recordings were performed on microelectrode arrays purchased from Multichannel Systems 
(Reutlingen, Germany). Each array had 60 electrodes, and each electrode was 30 µm in diameter, 
and 30 µm high.  Electrodes were arranged in a square grid with 200 µm spacing between 
electrodes.      
Local field potential (LFP) detection. 
Extracellular activity from slices was recorded in the same manner as previously reported.187 
Activity was sampled from all 60 electrodes (Fig. 3B) at 1 kHz and amplified before being stored 
to disk for offline analysis. Local field potentials (LFPs) that showed sharp negative peaks below 
a threshold set at 3 standard deviations of the signal were marked, and the time of the maximum 
excursion was recorded as the time of that LFP. Time points were binned at 4 ms resolution, as 
this was previously shown to match the average time between successive LFP events across 
electrodes.188 
In characterizing network activity, we closely followed the methods as previously described.188, 189 
An avalanche is a sequence of consecutively active frames that is preceded by a blank frame and 
terminated by a blank frame. The length of an avalanche is given by the total number of active 
frames and the size of an avalanche is given by the total number of electrodes activated during the 
avalanche. 
3.5.18 Antihyperalgesic activity in the SNL model of neuropathic pain (CRO) 
Animals 
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Experimentally naive adult male Sprague-Dawley rats (Harlan Industries, Indianapolis, IN), 
weighing between 200 and 300 g, were used as subjects. The rats were housed in Plexiglas cages 
(4 per cage), and given free access to Lab Diet #5001 for rodents (PMI Nutrition International Inc., 
St. Louis, MO). Rats underwent SNL at least 90 days prior to testing. 
Protocol 
Rats were first tested without given an injection to determine a baseline. Following baseline 
establishment, rats (n = 5 for all groups) were dosed i.p. with either vehicle (1% CMC), KRM-II-
81 (30 mg/kg), or gabapentin (50 mg/kg). Subjects were then tested every hour for four hours to 
determine the antihyperalgesic effect of the test compounds; for testing, pressure using von Frey 
filaments was applied to the forelimb of the rat, increasing in pressure until the limb was withdrawn 
and the amount of pressure recorded versus the control (opposite unaffected forelimb). 
3.5.19 Antihyperalgesic activity in the CFA-model of inflammatory pain (Dr. Jun-Xu Li at 
the University at Buffalo) 
Model of Pain 
Complete Freund’s adjuvant (CFA) contains Mycobacterium butyricum, inducing inflammation 
and an increase in paw thickness. The 0.1 mL of CFA was injected in the right hind paw of Sprague 
Dawley male rats under isoflurane anaesthesia.  
Drugs 
The following drugs were used: HZ-166 (3), KRM-II-81 (36), and KRM-II-18B (38), and were 
dissolved in a mixture containing 20% dimethyl sulfoxide (DMSO), 10% Emulphor-620 (Rhodia 
Inc.), and 70% of 0.9% saline. Flumazenil (purchased from Cayman Chemical Company, MI) was 
dissolved in a mixture containing 10% ethanol, 40% propylene glycol, and 50% sterile water. 
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Midazolam (Akorn, Inc.) was dissolved in 0.9% saline. Doses were expressed as the weight of the 
drug in milligrams per kilogram of body weight and drugs were administered intraperitoneally.  
Mechanical hyperalgesia 
Mechanical hyperalgesia was measured 3 days after CFA treatment.  Rats (n=6) were placed in 
elevated boxes with a mesh floor. Von Frey filaments (expressed in g) were applied 
perpendicularly to the hindpaws, starting with the lowest filament (1.4 g) then increased until 
hindpaw withdrawal was observed. After each measurement, rats received the next dose of drug 
(every 20 min) until the maximum threshold (26 g) was observed. For the antagonist study, rats 
were pretreated with the benzodiazepine site antagonist flumazenil (10 min), then received the 
next dose of drug (every 20 min) until the pre-CFA threshold was observed.   
3.5.20 Depression activity in the forced swim test (CRO) 
Full experimental details are described by Porsolt et al.190 Mice were placed individually in clear 
plastic cylinders (10 cm in diameter x 25 cm in height) filled to 6 cm with 22 – 25 oC water for 6 
minutes. The duration of immobility was recorded during the last 4 minutes of a 6-min trial. A 
mouse was regarded as immobile when floating motionless or making only those movements 
necessary to keep its head above the water. 
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3.6 Experimental Details 
3.6.1 (2-Amino-5-bromophenyl)(pyridin-2-yl)methanone (6)91 
To a stirred solution of 2-bromopyridine 4 (295.5 g, 1.9 mol) in dry diethyl ether under an argon 
atmosphere at -40 °C was added dropwise a solution of 2.5 M n-butyl lithium in hexanes (815 mL, 
2.04 mol). The temperature was maintained at -40 °C during the addition. The resultant dark 
orange solution which resulted was stirred further for 1 h at -40 °C. In a separate flask, a solution 
of 2-amino-5-bromobenzoic acid 2 (100 g, 0.5 mol) in dry THF under a nitrogen atmosphere at 0 
°C (ice bath) was transferred by cannula in one portion into the former bromopyridine solution. 
The mixture was stirred for 4 h at 0 °C and then treated with Me3SiCl (75.5 g, 0.7 mol) while the 
stirring was continued. The reaction mixture was allowed to warm to rt and hydrolyzed with a 
solution of 1N aq HCl (2.3 L). The two-phase system which resulted was separated. The aq phase 
was neutralized with an aq solution of 3N NaOH under ice cold conditions and extracted with Et2O 
(3 x 150 mL). The combined organic extracts were dried (Na2SO4) and the solvent was removed 
under reduced pressure. The yellow oil, which resulted, was purified by flash chromatography 
using ethyl acetate/hexanes (2 : 3) as eluent to give the title compound 3 as yellow needles (101 g, 
79%): 1H NMR (300 MHz, CDCl3)  8.73 (ddd, J = 4.8, 1.6, 1.0 Hz, 1H), 7.93 – 7.87 (m, 2H), 
7.81 (dt, J = 7.8, 1.0 Hz, 1H), 7.48 (ddd, J = 7.5, 4.8, 1.3 Hz, 1H) 7.37 (dd, J = 8.8, 2.4 Hz, 1H), 
6.65 (d, J = 8.8 Hz, 1H), 6.31 (br s, 1H). This material was used in the next step without any further 
characterization. 
3.6.2 7-Bromo-5-(pyridin-2-yl)-1H-benzo[e][1,4]diazepin-2(3H)-one (7)91 
Benzophenone 6 (40 g, 144 mmol) was dissolved in dry CH2Cl2 (300 mL) in a 3-neck flask and 
stirred using an overhead mechanical stir until a homogenous solution was obtained. Then solid 
NaHCO3 (24.3 g, 289 mmol) was slowly added to the solution and the mixture was cooled to 0
oC 
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(ice bath). Using an addition funnel, the bromoacetyl bromide (35.0 g, 173 mmol; dissolved in 100 
mL dry CH2Cl2) was added dropwise at 0
oC . The reaction mixture was allowed to stir overnight 
at ambient temperature or until the the starting material was consumed as indicated by TLC 
(EtOAc/hexanes, 2:1). Ice-water (400 mL) was then added to the reaction mixture to quench the 
reaction. The organic layer was separated, and the water layer was extracted with CH2Cl2 (3 x 120 
mL). The organic layers were combined, and washed (200 mL each) sequentially with a sat’d aq 
NaHCO3 solution, water, 10% HCl, brine and then dried (Na2SO4). The organic solution was then 
concentrated to 1/3 of its original volume under reduced pressure and employed in the following 
step without further purification. 
Methanol (800 mL) was cooled to -10oC using an ice-brine mixture in the cooling bath and 
saturated with anhydrous ammonia gas. The former organic solution from above was added to the 
solution of saturated methanolic-ammonia at 0oC. The mixture was allowed to warm to rt and 
slowly heated to reflux overnight or until the starting material was consumed, as indicated by 
analysis by TLC (silica gel). The reaction mixture was then cooled to rt and the solvent was 
removed under reduced pressure. The solid which remained was washed with water as well as 
EtOAc and filtered to give the amide 7 as an off-white colored solid (32.4 g, 71% yield over the 
two steps): 1H NMR (300 MHz, CDCl3)  8.65 (ddd, J = 4.8, 1.7, 09 Hz, 1H), 8.02 (dt, J = 7.9, 
0.9 Hz, 1H), 7.85 (td, J = 7.7, 1.8 Hz, 1H), 7.59 (dd, J = 8.6, 2.3 Hz, 1H), 7.50 (d, J = 2.2 Hz, 1H), 
7.41 (ddd, J = 7.5, 4.8, 1.2 Hz, 1H), 7.02 (d, J = 8.6 Hz, 1H), 4.39 (s, 2H); HPLC-MS (ESI) m/z 
(M+H) 316.00. This material was used in the next step without any further characterization. 
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3.6.3 Ethyl-8-bromo-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-
carboxylate (8)91 
 Amide 7 (30 g, 94.9 mmol) was dissolved in dry THF (1500 mL), and cooled to -20oC, after which 
potassium tert-butoxide (13.8 g, 123.3 mmol) was added in one portion. The reaction mixture was 
stirred until it reached 0oC and then stirred for 0.5h at 0oC. The mixture was then cooled to -50oC 
after which diethyl chlorophosphate (22.9 g, 132.8 mmol) was added and the stirring continued. 
Upon reaching 0oC, after which it was allowed to stir for 0.5h, the solution was then cooled to -
78oC and ethyl isocyanoacetate (14.0 g, 123.3 mmol) was added, immediately followed by a 
second portion of potassium tert-butoxide (13.8 g, 123.3 mmol). This solution was allowed to stir 
overnight, during which it was allowed to warm to rt. The reaction was quenched by addition of a 
cold sat’d aq solution of NaHCO3 (2 L) and extracted with EtOAc. The organic layers were 
combined and washed with brine (2 x 200 mL), dried (Na2SO4) and the solvent was removed under 
reduced pressure to afford a dark brown solid. The solid was washed with Et2O/EtOAc (9:1) to 
remove some of the impurities and the remaining solid was purified by column chromatography 
(silica gel, EtOAc/hexanes 2:1) to afford the pure imidazobenzodiazepine 8 as an off-white solid 
(30.4 g, 78% yield): 1H NMR (300 MHz, CDCl3)  8.57 (d, J = 4.11 Hz, 1H), 8.09 (d, J = 7.9 Hz, 
1H), 7.90 (s, 1H), 7.83 (td, J = 7.7, 1.8 Hz, 2H), 7.60 (d, J = 2.2 Hz, 1H), 7.55 (d, J = 31 Hz, 1H), 
7.28 (t, J = 7.7, 2.1 Hz. 1H), 6.11 (d, J = 10.4 Hz, 1H), 4.45 (m, 2H), 4.13 (d, J = 10.0 Hz, 1H), 
1.44 (t, J = 7.1 Hz, 3H); 13C NMR (75 MHz, CDCl3)  167.0, 162.8, 156.1, 148.6, 138.3, 136.8, 
135.2, 134.9, 134.5, 134.3, 128.4, 124.8, 124.2, 123.9, 120.5, 60.7, 44.9, 14.3; HPLC-MS (ESI) 
m/z (M+H) 411.04. 
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3.6.4 Ethyl-6-(pyridin-2-yl)-8-((trimethylsilyl)ethynyl)-4H-benzo[f]imidazo [1,5a]-
[1,4]diazepine-3-carboxylate (9)91 
Imidazobenzodiazepine 8 (20 g, 48.6 mmol) from the above step was dissolved in triethylamine 
(650 mL) and acetonitrile (800 mL). Trimethylsilylacetylene (7.2 g, 72.9 mmol) and 
bis(triphenylphosphine)-palladium (II) acetate (2.0 g, 2.7 mmol) were added. A reflux column was 
attached and the mixture was degassed under vacuum and argon; the process was repeated four 
times. The solution was then heated to reflux under argon and stirred overnight. The reaction 
mixture was cooled to rt, filtered through celite and the celite washed with EtOAc. The filtrate was 
concentrated under reduced pressure. The black residue which resulted was purified by a wash 
column (silica gel, EtOAc/hexanes 2:1 with 1% each E3N and CH3OH) to afford 9 as an off-white 
solid (18.1 g, 87% yield): 1H NMR (300 MHz, CDCl3)  8.56 (d, J = 4.11 Hz, 1H), 8.06 (d, J = 
7.9 Hz, 1H), 7.92 (s, 1H), 7.83 (td, J = 7.7, 1.8 Hz, 2H), 7.55 (dd, J = 8.6, 1.8 Hz, 2H), 7.38 (ddd, 
J = 7.5, 4.8, 1.1 Hz, 1H), 6.13 (d, J = 10.4 Hz, 1H), 4.45 (m, 2H), 4.17 (d, J = 10.0 Hz, 1H), 1.45 
(t, J = 7.1 Hz, 3H), 0.25 (s, 9H); 13C NMR (75 MHz, CDCl3)  167.7, 162.8, 156.4 148.7, 138.4, 
136.8, 135.6, 135.1, 135.0, 134.4, 126.9, 124.7, 123.9, 122.6, 122.2, 102.7, 97.0, 60.7, 44.9, 14.3, 
-0.3, (one quaternary carbon atom is embedded in one of the above peaks); HPLC-MS (ESI) m/z 
(M+H) 429.17. 
3.6.5 Ethyl-8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4] diazepine-3-
carboxylate (HZ-166, 3)91 
Intermediate 9 (18 g, 42 mmol) was dissolved in THF (1 L) and cooled to -78oC. This was treated 
with tetrabutylammonium fluoride hydrate (1 M solution in THF, 50 mmol), followed by water 
(18 mL). The reaction mixture was stirred at -78 oC until the starting material was consumed as 
indicated by TLC (silica gel), in about 0.5h. The reaction mixture was allowed to warm to -20 oC 
129 
 
and quenched by a slow addition of water (500 mL), followed by extraction with EtOAc (5 x 500 
mL). The combined organic extracts were washed with brine (2 x 500 mL), dried (Na2SO4), and 
the solvent was removed under reduced pressure. The residue which resulted was purified by a 
wash column (silica gel, EtOAc/hexanes 4:1 with 1% each Et3N and CH3OH) to afford pure 3 as 
a white powder (13.6 g, 91% yield): 1H NMR (300 MHz, CDCl3)  8.56 (d, J = 4.11 Hz, 1H), 8.06 
(d, J = 7.9 Hz, 1H), 7.92 (s, 1H), 7.83 (td, J = 7.7, 1.8 Hz, 2H), 7.55 (dd, J = 8.6, 1.8 Hz. 2H), 7.38 
(ddd, J = 7.5, 4.8, 1.1 Hz, 1H), 6.13 (d, J = 10.4 Hz, 1H), 4.45 (m, 2H), 6.13 (d, J = 10.4 Hz, 1H), 
4.17 (d, J = 10.0 Hz, 1H), 3.17 (s, 1H), 1.45 (t, J = 7.1 Hz, 2H); 13C NMR (75 MHz, CDCl3)  
167.68, 162.94, 156.43, 148.75, 138.47, 136.91, 136.22, 135.45, 135.28, 134.52, 129.34, 127.08, 
124.82, 124.03, 122.86, 121.2, 81.68, 79.52, 60.81, 45.04, 14.44; HRMS (LCMS-IT-TOF) Calc. 
for C21H17N4O2 (M + H)
+ 357.1307, found 357.1321.  
HRMS (LCMS-IT-TOF) Calc. for C22H17FN4O (M + H)
+ 373.1459, found: 373.1462. 
3.6.6 tert-Butyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-
carboxylate (MP-II-067, 10) 
Ethyl ester HZ-166 3 (200 mg, 0.56 mmol) was stirred in dry THF (10mL) in an oven-dried flask 
under argon at 40 oC; while anhydrous tert-butanol (3mL) was stirred in a separate oven-dried 
flask under an argon atmosphere at 40 oC. Small pieces of freshly cut Li rod (~50mg) were quickly 
added to tert-butanol and the suspension was stirred for 10 min under argon. The ethyl ester 
solution was then added to tert-butanol and it was monitored by TLC (silica gel) until most of the 
starting material was consumed, about 30 min. The reaction mixture was then quenched with 
sodium bicarbonate (sat’d aq solution, 5 mL) and the product was extracted with EtOAc. The 
organic layers were combined, washed with brine, dried (Na2SO4) and the solvent was removed 
under reduced pressure. The solid which resulted was purified by flash chromatography (3:2 
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EtOAc:hexanes with 1% each of Et3N and CH3OH added to the eluent) to afford pure t-butyl ester 
10 as a white solid (132 mg, 61%): 1H NMR (300 MHz. CDCl3) δ 8.58 (d, J = 4.6 Hz, 1H), 8.07 
(d, J = 7.9 Hz, 1H), 7.91 (s, 1H), 7.88 – 7.78 (m, 1H), 7.75 (dd, J = 8.3, 1.6 Hz, 1H), 7.54 (d, J = 
8.6 Hz, 2H), 7.37 (dd, J = 7.0, 5.2 Hz, 1H), 6.10 (d, J = 11.7 Hz, 1H), 4.14 (d, J = 7.9 Hz, 1H), 
3.17 (s, 1H), 1.65 (s, 9H); 13C NMR (75 MHz. CDCl3) δ 167.64, 162.18, 156.50, 148.78, 138.02, 
136.90, 136.16, 135.61, 135.26, 134.27, 130.50, 127.07, 124.78, 124.07, 122.87, 121.09, 81.72, 
81.54, 79.43, 45.16, 28.38; HRMS (LCMS-IT-TOF) Calc. for C23H21N4O2 (M + H)
+ 385.1620, 
found 385.1614. 
3.6.7 Isopropyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-
carboxylate (MP-II-068, 11) 
Ethyl ester HZ-166 3 (500 mg, 1.403 mmol) was stirred in dry THF (10mL) in an oven-dried flask 
under an argon atmosphere at 40 oC; while anhydrous isopropanol (3mL) was stirred in a separate 
oven-dried flask under argon at 40 oC. Small pieces of freshly cut Li rod (~50mg) were quickly 
added to isopropanol at 40 oC and the suspension was stirred for 10 min under argon. The ethyl 
ester solution was then added to isopropanol and the mixture monitored by analysis of TLC (silica 
gel) until most of the starting material had been consumed (TLC, silica gel), about 30 min. The 
reaction solution was then quenched with sodium bicarbonate (sat’d aq solution, 5 mL) and the 
product was extracted with EtOAc. The organic layers were combined, washed with brine, dried 
(Na2SO4), and the solvent was removed under reduced pressure. The solid which resulted was 
purified by flash chromatography (3:2 EtOAc:hexanes with 1% each of Et3N and CH3OH added 
to the eluent) to afford pure iso-propyl ester 11 as a white solid (439.4 mg, 84.6%): 1H NMR (300 
MHz. CDCl3) δ 8.59 (d, J = 4.5 Hz, 1H), 8.08 (d, J = 8.0 Hz, 1H), 7.93 (s, 1H), 7.83 (t, J = 7.7 Hz, 
1H), 7.76 (dd, J = 8.3, 1.5 Hz, 1H), 7.55 (d, J = 8.5 Hz, 2H), 7.38 (dd, J = 7.3, 5.0 Hz, 1H), 6.12 
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(s, 1H), 5.43 – 5.24 (m, 1H), 4.18 (s, 1H), 3.17 (s, 1H), 1.43 (d, J = 5.6 Hz, 6H); 13C NMR (75 
MHz. CDCl3) δ 167.64, 162.55, 156.45, 148.76, 138.44, 136.90, 136.20, 135.51, 135.26, 134.44, 
129.64, 127.09, 124.80, 124.04, 122.85, 121.17, 81.70, 79.47, 68.32, 45.07, 22.01; HRMS 
(LCMS-IT-TOF) Calc. for C22H19N4O2 (M + H)
+ 371.1463, found 371.1476. 
3.6.8 Cyclopropylmethyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxylate (MP-II-069, 12) 
Ethyl ester HZ-166 3 (600 mg, 1.683 mmol) was stirred in dry THF (10mL) in an oven-dried flask 
under argon at 40 oC; while anhydrous cyclopropylmethyl alcohol (3mL) was stirred in a separate 
oven-dried flask under an argon atmosphere at 40 oC. Small pieces of freshly cut Li rod (~50mg) 
were quickly added to cyclopropylmethyl alcohol and the suspension was stirred for 10 min under 
argon. The ethyl ester solution was then added to cyclopropylmethyl alcohol at 40 oC and 
monitored by analysis by TLC (silica gel) until most of the starting material had been consumed 
(TLC, silica gel), about 30 min. The reaction was then quenched with sodium bicarbonate (sat’d 
aq solution, 5 mL) and the product was extracted with EtOAc. The organic layers were combined, 
washed with brine, dried (Na2SO4), and the solvent was removed under reduced pressure. The 
solid which resulted was purified by flash chromatography (3:2 EtOAc:hexanes with 1% each of 
Et3N and CH3OH added to the eluent) to afford pure cyclopropyl methyl ester 12 as a white solid 
(508.6 mg, 79.0%): 1H NMR (300 MHz. CDCl3) δ 8.60 (d, J = 4.8 Hz, 1H), 8.09 (d, J = 7.9 Hz, 
1H), 7.95 (s, 1H), 7.84 (t, J = 7.7 Hz, 1H), 7.77 (dd, J = 8.4, 1.3 Hz, 1H), 7.57 (dd, J = 4.9, 3.3 Hz, 
2H), 7.39 (dd, J = 7.3, 4.9 Hz, 1H), 6.13 (s, 1H), 4.15 (dd, J = 19.0, 11.8 Hz, 3H), 3.18 (s, 1H), 
1.41 – 1.24 (m, 1H), 0.63 (q, J = 5.2 Hz, 2H), 0.40 (q, J = 5.0 Hz, 2H); 13C NMR (75 MHz. CDCl3) 
δ 167.69, 163.06, 156.43, 148.76, 138.50, 136.93, 136.20, 135.48, 135.29, 134.56, 129.38, 127.09, 
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124.82, 124.03, 122.86, 121.21, 81.69, 79.50, 69.69, 45.07, 10.03, 3.55; HRMS (LCMS-IT-TOF) 
Calc. for C23H19N4O2 (M + H)
+ 383.1463, found 383.1451. 
3.6.9 Propyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-
carboxylate (MP-II-070, 13) 
Ethyl ester HZ-166 3 (200 mg, 0.56 mmol) was stirred in dry THF (10mL) in an oven-dried flask 
under an argon atmosphere at 40 oC; while anhydrous propanol (3mL) was stirred in a separate 
oven-dried flask under Argon at 40 oC. Small pieces of freshly cut Li rod (~50mg) were quickly 
added to the propanol and the suspension was stirred for 10 min under argon. The ethyl ester 
solution was then added to propanol at 40 oC and monitored by analysis of the TLC (silica gel) 
until most of the starting material had been consumed, about 30 min. The reaction mixture was 
then quenched with sodium bicarbonate (sat’d aq solution, 5 mL) and the product was extracted 
with EtOAc. The organic layers were combined, washed with brine, dried (Na2SO4), and the 
solvent was removed under reduced pressure. The solid which resulted was purified by flash 
chromatography (3:2 EtOAc:hexanes with 1% each of Et3N and CH3OH added to the eluent) to 
afford pure propyl ester 13 as a white solid (128 mg, 61.5%): 1H NMR (300 MHz. CDCl3) δ 8.59 
(d, J = 4.6 Hz, 1H), 8.08 (d, J = 7.9 Hz, 1H), 7.93 (s, 1H), 7.89 – 7.73 (m, 2H), 7.57 (t, J = 4.2 Hz, 
2H), 7.38 (dd, J = 6.8, 5.5 Hz, 1H), 6.12 (d, J = 9.4 Hz, 1H), 4.34 (d, J = 6.0 Hz, 2H), 4.23 – 4.10 
(m, 1H), 3.17 (d, J = 1.2 Hz, 1H), 1.94 – 1.78 (m, 2H), 1.05 (dd, J = 8.0, 6.8 Hz, 3H); 13C NMR 
(75 MHz. CDCl3) δ 167.66, 163.03, 156.42, 148.76, 138.44, 136.91, 136.22, 135.47, 135.28, 
134.55, 129.37, 127.09, 124.81, 124.02, 122.86, 121.20, 81.69, 79.49, 66.40, 45.08, 22.12, 10.52; 
HRMS (LCMS-IT-TOF) Calc. for C22H19N4O2 (M + H)
+ 371.1463, found 371.1455. 
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3.6.10 sec-Butyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-
carboxylate (MP-II-071, 14) 
Ethyl ester HZ-166 3 (200 mg, 0.561 mmol) was stirred in dry THF (10mL) in an oven-dried flask 
under an argon atmosphere at 40 oC; while anhydrous sec-butanol (3mL) was stirred in a separate 
oven-dried flask under argon at 40 oC. Small pieces of freshly cut Li rod (~50mg) were quickly 
added to sec-butanol and the suspension was stirred for 10 min under argon. The ethyl ester 
solution was then added to sec-butanol at 40 oC and monitored by analysis by TLC (silica gel) 
until most of the starting material had been consumed (TLC, silica gel), about 30 min. The reaction 
solution was then quenched with sodium bicarbonate (sat’d aq solution, 5 mL) and the product 
was extracted with EtOAc. The organic layers were combined, washed with brine, dried (Na2SO4), 
and the solvent was removed under reduced pressure. The solid which resulted was purified by 
flash chromatography (3:2 EtOAc:hexanes with 1% each of Et3N and CH3OH added to the eluent) 
to afford pure racemic sec-butyl ester 14 as a white solid (145 mg, 67.1%): 1H NMR (300 MHz. 
CDCl3) δ 8.59 (d, J = 4.8 Hz, 1H), 8.09 (d, J = 7.9 Hz, 1H), 7.93 (s, 1H), 7.83 (t, J = 7.7 Hz, 1H), 
7.76 (dd, J = 8.3, 1.0 Hz, 1H), 7.56 (d, J = 8.6 Hz, 2H), 7.38 (dd, J = 7.4, 4.9 Hz, 1H), 6.12 (s, 
1H), 5.25 – 5.08 (m, 1H), 4.16 (d, J = 9.0 Hz, 1H), 3.17 (s, 1H), 1.84 (dd, J = 13.9, 6.8 Hz, 1H), 
1.76 – 1.64 (m, 1H), 1.39 (d, J = 5.7 Hz, 3H), 1.07 – 0.91 (m, 3H); 13C NMR (75 MHz. CDCl3) δ 
167.55, 162.63, 156.29, 148.66, 138.40, 137.03, 136.18, 135.50, 135.32, 134.48, 129.56, 127.04, 
124.85, 124.11, 122.89, 121.22, 81.69, 79.50, 72.94, 45.07, 28.92, 19.68, 10.01; HRMS (LCMS-
IT-TOF) Calc. for C23H21N4O2 (M + H)
+ 385.1620, found 385.1613. 
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3.6.11 Isobutyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-
carboxylate (MP-II-072, 15) 
Ethyl ester HZ-166 3 (200 mg, 0.56 mmol) was stirred in dry THF (10mL) in an oven-dried flask 
under an argon atmosphere at 40 oC; while anhydrous iso-butanol (3mL) was stirred in a separate 
oven-dried flask under argon at 40 oC. Small pieces of freshly cut Li rod (~50mg) were quickly 
added to iso-butanol and the suspension was stirred for 10 min under argon. The ethyl ester 
solution was then added to iso-butanol at 40 oC and the mixture was monitored by analysis by TLC 
(silica gel) until most of the starting material had been consumed (TLC, silica gel), about 30 min. 
The reaction was then quenched with sodium bicarbonate (sat’d aq solution, 5 mL) and the product 
was extracted with EtOAc. The organic layers were combined, washed with brine, dried (Na2SO4), 
and the solvent was removed under reduced pressure. The solid which resulted was purified by 
flash chromatography (3:2 EtOAc:hexanes with 1% each of Et3N and CH3OH added to the eluent) 
to afford pure iso-butyl ester 15 as a white solid (173 mg, 80.1%): 1H NMR (300 MHz. CDCl3) δ 
8.58 (d, J = 4.3 Hz, 1H), 8.08 (d, J = 7.9 Hz, 1H), 7.93 (s, 1H), 7.82 (td, J = 7.8, 1.5 Hz, 1H), 7.76 
(dd, J = 8.3, 1.7 Hz, 1H), 7.56 (d, J = 8.6 Hz, 2H), 7.37 (dd, J = 6.5, 5.0 Hz, 1H), 6.11 (d, J = 10.5 
Hz, 1H), 4.17 (s, 3H), 3.17 (s, 1H), 2.17 (dp, J = 13.4, 6.7 Hz, 1H), 1.05 (d, J = 6.7 Hz, 6H); 13C 
NMR (75 MHz. CDCl3) δ 167.64, 163.01, 156.41, 148.75, 138.40, 136.91, 136.21, 135.48, 135.27, 
134.62, 129.38, 127.09, 124.81, 124.01, 122.86, 121.20, 81.70, 79.49, 70.89, 45.13, 27.84, 19.32; 
HRMS (LCMS-IT-TOF) Calc. for C23H21N4O2 (M + H)
+ 385.1620, found 385.1611. 
3.6.12 2-Methoxyethyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-
3-carboxylate (MP-II-073, 16) 
Ethyl ester HZ-166 3 (200 mg, 0.56 mmol) was stirred in dry THF (10mL) in an oven-dried flask 
under an argon atmosphere at 40 oC; while 2-methoxyethanol (3mL) was stirred in a separate oven-
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dried flask under argon at 40 oC. Small pieces of freshly cut Li rod (~50mg) were quickly added 
to the 2-methoxyethanol and the suspension was stirred for 10 min under argon. The ethyl ester 
solution was then added to 2-methoxyethanol at 40 oC under argon and monitored by analysis by 
TLC (silica gel) until most of the starting material had been consumed, about 30 min. The reaction 
was then quenched with sodium bicarbonate (sat’d aq solution, 5 mL) and the product was 
extracted with EtOAc. The organic layers were combined, washed with brine, dried (Na2SO4), and 
the solvent was removed under reduced pressure. The solid which resulted was purified by flash 
chromatography (3:2 EtOAc:hexanes with 1% each of Et3N and CH3OH added to the eluent) to 
afford pure 2-methoxyethyl ester 16 as a white solid (94 mg, 43.4%): 1H NMR (300 MHz. CDCl3) 
δ 8.57 (d, J = 4.3 Hz, 1H), 8.06 (d, J = 7.9 Hz, 1H), 7.93 (s, 1H), 7.81 (td, J = 7.8, 1.5 Hz, 1H), 
7.75 (dd, J = 8.4, 1.5 Hz, 1H), 7.55 (dd, J = 4.8, 3.3 Hz, 2H), 7.36 (dd, J = 6.9, 5.3 Hz, 1H), 6.10 
(d, J = 11.1 Hz, 1H), 4.51 (s, 2H), 4.15 (d, J = 10.9 Hz, 1H), 3.76 (t, J = 4.9 Hz, 2H), 3.42 (s, 3H), 
3.17 (s, 1H); 13C NMR (75 MHz. CDCl3) δ 167.56, 162.73, 156.16, 148.63, 138.63, 137.11, 
136.19, 135.43, 135.38, 134.68, 129.03, 127.01, 124.92, 124.13, 122.90, 121.30, 81.65, 79.57, 
70.37, 63.53, 59.00, 45.05; HRMS (LCMS-IT-TOF) Calc. for C22H19N4O3 (M + H)
+ 387.1412, 
found 387.1426. 
3.6.13 Benzyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-
carboxylate (MP-II-075, 17) 
Ethyl ester HZ-166 3 (200 mg, 0.56 mmol) was stirred in dry THF (10mL) in an oven-dried flask 
under an argon atmosphere at 40 oC; while anhydrous benzyl alcohol (3mL) was stirred in a 
separate oven-dried flask under argon at 40 oC. Small pieces of freshly cut Li rod (~50mg) were 
quickly added to the benzyl alcohol and the suspension was stirred for 10 min under argon. The 
ethyl ester solution was then added to benzyl alcohol at 40 oC under argon and monitored by 
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analysis by TLC (silica gel) until most of the starting material had been consumed (TLC, silica 
gel), about 30 min. The reaction was then quenched with sodium bicarbonate (sat’d aq solution, 5 
mL) and the product was extracted with EtOAc. The organic layers were combined, washed with 
brine, dried (Na2SO4), and the solvent was removed under reduced pressure. The solid which 
resulted was purified by flash chromatography (3:2 EtOAc:hexanes with 1% each of Et3N and 
CH3OH added to the eluent) to afford pure benzyl ester 17 as a white solid (138 mg, 58.8%): 1H 
NMR (300 MHz. CDCl3) δ 8.61 – 8.56 (m, 1H), 8.08 (d, J = 7.9 Hz, 1H), 7.94 (s, 1H), 7.82 (td, J 
= 7.8, 1.7 Hz, 1H), 7.76 (dd, J = 8.3, 1.8 Hz, 1H), 7.57 (s, 2H), 7.55 – 7.47 (m, 2H), 7.42 – 7.31 
(m, 4H), 6.11 (d, J = 11.7 Hz, 1H), 5.43 (d, J = 20.8 Hz, 2H), 4.15 (d, J = 11.4 Hz, 1H), 3.17 (s, 
1H); 13C NMR (75 MHz. CDCl3) δ 167.66, 162.71, 156.34, 148.73, 138.76, 136.94, 136.19, 
136.05, 135.38, 135.30, 134.69, 129.02, 128.54, 128.48, 128.16, 127.07, 124.84, 124.02, 122.88, 
121.25, 81.67, 79.60, 66.42, 45.05; HRMS (LCMS-IT-TOF) Calc. for C26H19N4O2 (M + H)
+ 
419.1463, found 419.1466. 
3.6.14 1-Phenyl, ethyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-
3-carboxylate (MP-II-076, 18) 
Ethyl ester HZ-166 3 (205 mg, 0.57 mmol) was stirred in dry THF (10mL) in an oven-dried flask 
under an argon atmosphere at 40 oC; while anhydrous 1-phenylethanol (5 mL) was stirred in a 
separate oven-dried flask under argon at 40 oC. Small pieces of freshly cut Li rod (~50mg) were 
quickly added to 1-phenylethanol and the suspension was stirred for 10 min under argon. The ethyl 
ester solution was then added to 1-phenylethanol at 40 oC under argon and the reaction mixture 
was stirred and monitored by analysis by TLC (silica gel) until most of the starting material had 
been consumed, about 30 min (TLC, silica gel). The reaction solution was then quenched with 
sodium bicarbonate (sat’d aq solution, 5 mL) and the product was extracted with EtOAc. The 
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organic layers were combined, washed with brine, dried (Na2SO4), and the solvent was removed 
under reduced pressure. The solid which resulted was purified by flash chromatography (3:2 
EtOAc:hexanes with 1% each of Et3N and CH3OH added to the eluent) to afford pure 1-phenyl, 
ethyl ester 18 as a white solid (173 mg, 71.6%): 1H NMR (300 MHz. CDCl3) δ 8.58 (d, J = 4.5 
Hz, 1H), 8.08 (d, J = 7.7 Hz, 1H), 8.01 (s, 1H), 7.84 (dd, J = 11.0, 4.5 Hz, 1H), 7.76 (dd, J = 8.4, 
1.6 Hz, 1H), 7.56 (t, J = 7.7 Hz, 2H), 7.50 (d, J = 7.2 Hz, 2H), 7.37 (dd, J = 14.2, 7.5 Hz, 3H), 7.28 
(dd, J = 8.1, 6.3 Hz, 1H), 6.17 (dd, J = 13.2, 6.6 Hz, 2H), 4.15 (s, 1H), 3.17 (s, 1H), 1.72 (d, J = 
5.8 Hz, 3H); 13C NMR (75 MHz. CDCl3) δ 167.44, 161.98, 155.93, 148.49, 141.69, 138.60, 
137.29, 136.11, 135.45, 135.35, 134.74, 128.95, 128.52, 127.83, 126.95, 126.27, 125.00, 124.22, 
123.00, 121.39, 81.62, 79.66, 72.96, 44.97, 22.43; HRMS (LCMS-IT-TOF) Calc. for C27H21N4O2 
(M + H)+ 433.1586, found 433.1592. 
3.6.15 Methyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-
carboxylate (MP-III-024, 19) 
Ethyl ester HZ-166 3 (500 mg, 1.40 mmol) was dissolved in methanol (40 mL). Sodium methoxide 
(303 mg, 5.61 mmol) was added in one portion and the solution was heated to reflux. The reaction 
mixture was monitored by analysis by TLC (silica gel, 4:1 EtOAc:hexanes) until the starting 
material had been consumed; approximately 30 min. The reaction solution was then cooled to rt 
and then quenched with a saturated aq solution of sodium bicarbonate (10 mL). Water (30 mL) 
was then added to the solution and the methanol was removed under reduced pressure. The product 
was then extracted with EtOAc (3 x 100 mL) and the organic layers were combined, washed with 
brine, and as well as dried (Na2SO4). The solution was concentrated under reduced pressure. The 
solid which resulted was purified via a wash column (silica gel, 4:1 EtOAc:hexanes with 1% each 
of Et3N and CH3OH added to the eluent) which provided pure methyl ester 19 as an off-white solid 
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(374 mg, 78.0% yield): 1H NMR (300 MHz, CDCl3) δ 8.60 (d, J = 4.7 Hz, 1H), 8.09 (d, J = 7.9 
Hz, 1H), 7.99 (s, 1H), 7.90 – 7.81 (m, 1H), 7.78 (dd, J = 8.4, 1.6 Hz, 1H), 7.59 – 7.54 (m, 1H), 
7.41 (dd, J = 6.9, 5.4 Hz, 1H), 7.28 (s, 1H), 6.10 (s, 1H), 4.20 (s, 1H), 3.96 (s, 3H), 3.18 (s, 1H); 
13C NMR (75 MHz, CDCl3) δ 167.51, 163.15, 155.92, 148.49, 138.36, 137.36, 136.16, 135.49, 
135.37, 134.69, 128.94, 126.94, 125.04, 124.25, 122.97, 121.41, 81.59, 79.67, 51.94, 44.94; 
HRMS (LCMS-IT-TOF) Calc. for C20H15N4O2 (M + H)
+ 343.1150, found 343.1146. 
3.6.16 8-Ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylic 
acid (SR-II-54, 20) 
Ethyl ester HZ-166 3 (4 g, 11.22 mmol) was stirred in ethanol (100 mL) and sodium hydroxide (3 
M, 44 mL) was added and the solution was heated at reflux for one h. The reaction solution was 
then cooled to rt and diluted with water (100 mL). The solution was evaporated under reduced 
pressure until half the solvent remained. The remaining reaction mixture was stirred at rt and 
aqueous hydrochloric acid (1 M) was added dropwise until the product precipitated out. The 
product was filtered, rinsed with water and dried to afford pure acid 20 as a white solid (2.63 g, 
71.3%):  1H NMR (300 MHz, DMSO-d6)  8.51 (d, J = 4.3 Hz, 1H), 8.41 (s, 1H), 8.06 (d, J = 7.8 
Hz, 1H), 7.94 (t, J = 7.7 Hz, 1H), 7.86 (q, J = 8.5 Hz, 2H), 7.48 (dd, J = 7.1, 5.8 Hz, 2H), 5.84 (d, 
J = 9.8 Hz, 1H), 4.34 (s, 1H), 4.20 (d, J = 9.7 Hz, 1H).; 13C NMR (75 MHz, DMSO-d6)  167.68, 
164.42, 156.64, 148.77, 138.43, 137.60, 136.23, 135.92, 135.57, 135.15, 129.12, 127.19, 125.47, 
124.20, 123.86, 120.35, 82.98, 82.42, 45.10; HRMS (LCMS-IT-TOF) Calc. for C19H13N4O2 (M + 
H)+ 329.1033, found 329.1032. 
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3.6.17 2d-Ethyl-8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4] diazepine-3-
carboxylate (MP-III-068, 21) 
Carboxylic acid SR-II-54 20 (2.3 g, 7.01 mmol) and cesium carbonate (4.5 g, 14 mmol) were 
dissolved in dry DMF (dry, 25 mL) at rt. The 1,1-dideuterated bromoethane was added and the 
reaction was stirred for two hr at rt. The reaction mixture was then filtered, and the solid CsBr 
rinsed with EtOAc. The organic layers were combined and the solvent was removed under reduced 
pressure. The residue that resulted was purified by flash chromatography (4:1 EtOAc:hexanes with 
1% each of Et3N and CH3OH added to the eluent) which provided pure C(3) subtituted d
2-ethyl 
ester 21 as a white solid (1.34 g, 61.2%): 1H NMR (300 MHz, CDCl3) δ 8.57 (d, J = 4.2 Hz, 1H), 
8.06 (d, J = 7.9 Hz, 1H), 7.95 (s, 1H), 7.82 (dd, J = 10.7, 4.8 Hz, 1H), 7.75 (d, J = 8.3 Hz, 1H), 
7.61 – 7.52 (m, 1H), 7.41 – 7.33 (m, 1H), 7.28 (d, J = 1.9 Hz, 1H), 6.09 (s, 1H), 4.16 (s, 1H), 3.16 
(d, J = 1.7 Hz, 1H), 1.40 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 167.59, 162.79, 156.16, 148.62, 
138.36, 137.11, 136.15, 135.40, 135.37, 134.61, 129.16, 126.98, 124.91, 124.12, 122.94, 121.28, 
81.62, 79.61, 60.25, 44.98, 14.20 (-CD2 carbon does barely appears at 60.25); HRMS (LCMS-IT-
TOF) Calc. for C21H15D2N4O2 (M + H)
+ 359.1462, found 359.1468. 
3.6.18 (8-Ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-yl)methanol 
(MP-II-023, 22) 
Ethyl ester HZ-166 3 (1.0 g, 2.81 mmol) was dissolved in dry THF (100 mL). The LiAlH4 (181 
mg, 4.77 mmol) was added in one portion and the mixture was stirred at rt for 90 min. Once the 
starting the material was consumed, as indicated by analysis by TLC (silica gel), ice-cold water 
(50 mL) was slowly added to quench the excess LiAlH4, and the product was extracted with EtOAc 
(3 x 100 mL). The organic layers were combined, washed with brine, dried (Na2SO4), and the 
solvent was removed under reduced pressure. The solid, which resulted, was purified by flash 
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chromatography (basic alumina, EtOAc with 3% each Et3N and CH3OH added to the eluent) to 
afford the alcohol 22 as an off-white powder (0.56 g, 63%): 1H NMR (300 MHz, DMSO) δ 8.50 
(d, J = 4.6 Hz, 1H), 8.24 (s, 1H), 8.03 (d, J = 7.9 Hz, 1H), 7.94 (td, J = 7.7, 1.7 Hz, 1H), 7.79 (s, 
2H), 7.51 – 7.44 (m, 1H), 7.38 (s, 1H), 5.31 (d, J = 9.7 Hz, 1H), 4.47 (d, J = 5.5 Hz, 2H), 4.31 (s, 
1H), 4.16 (s, 1H); 13C NMR (75 MHz, DMSO) δ 167.13, 159.96, 157.12, 148.73, 138.22, 137.52, 
136.49, 134.89, 129.96, 126.82, 125.28, 123.75, 119.49, 100.07, 82.58, 72.54, 56.56, 50.42, 44.71; 
HRMS (ESI) m/z calc’d for C19H15N4O (M+H)+ 315.1246, found 315.1216. 
3.6.19 8-Ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carbaldehyde 
(MP-II-050, 23) 
Alcohol MP-II-023 22 (200 mg, 0.636 mmol) was dissolved in dry DCM (50 mL) under argon and 
cooled to 0oC with an ice bath. Dess-Martin periodinane (405 mg, 0.954 mmol) was added and the 
reaction was stirred for 30 min at 0oC. The ice bath was then removed and the reaction was allowed 
to stir for an additional 1.5 hours. The reaction was quenched by adding Na2S2O3 (sat’d aq solution, 
10 mL) and NaHCO3 (sat’d aq solution, 10 mL), and the product was extracted with EtOAc (3 x 
50 mL). The organic layers were combined, washed with brine, dried (Na2SO4), and the solvent 
was removed under reduced pressure. The solid which resulted was purified by flash 
chromatography (silica gel, EtOAc with 1% each Et3N and CH3OH added to the eluent) to afford 
the aldehyde 23 as a white powder (151 mg, 76%): 1H NMR (300 MHz. CDCl3) δ 10.08 (s, 1H), 
8.60 (d, J = 4.2 Hz, 1H), 8.11 (d, J = 7.9 Hz, 1H), 7.99 (s, 1H), 7.86 (t, J = 7.1 Hz, 1H), 7.79 (d, J 
= 8.4 Hz, 1H), 7.59 (d, J = 7.9 Hz, 2H), 7.44 – 7.38 (m, 1H), 6.04 (s, 1H), 4.21 (s, 1H), 3.19 (s, 
1H); 13C NMR (75 MHz, CDCl3) δ 186.92, 167.50, 155.91, 148.38, 137.66, 137.47, 136.71, 
136.19, 135.51, 127.09, 125.09, 125.06, 124.22, 122.92, 122.89, 121.59, 81.54, 79.78, 44.44; 
HRMS (ESI) m/z calc’d for C19H13N4O (M+H)+ 313.1089, found 313.1060. 
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3.6.20 N-Ethyl-8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-
carboxamide (MP-II-037, 25) 
The carboxylic acid SR-II-54 20 (200 mg, 0.609 mmol) was suspended and stirred in CH2Cl2 (dry, 
15 mL), after which thionyl chloride (2 mL) was added and the reaction mixture was heated to 
reflux. After the conversion of the acid to the acid chloride was complete, as observed by the 
conversion into a  homogeneous solution (about 2 h.), the reaction was cooled to rt and the solvent 
was removed under reduced pressure. The residue which resulted was redissolved in CH2Cl2 (dry, 
15 mL) and the solution was cooled to 0 oC. Ethyl amine was added and the reaction mixture was 
allowed to stir until the amide product formed, as indicated by analysis by TLC (silica gel). The 
solvent was removed under reduced pressure and the mixture was purified by flash column 
chromatography (3:1 EtOAc/hex with 1% each of methanol and trimethylamine added to the 
eluent) to afford pure cyclopropyl amide 25 (103.9 mg, 48%): 1H NMR (300 MHz. CDCl3) δ 8.61 
– 8.53 (m, 1H), 8.16 (d, J = 7.9 Hz, 1H), 7.90 – 7.79 (m, 2H), 7.76 (dd, J = 8.3, 1.8 Hz, 1H), 7.58 
(d, J = 1.7 Hz, 1H), 7.53 (d, J = 8.4 Hz, 1H), 7.41 – 7.30 (m, 2H), 6.34 (s, 1H), 4.14 (dd, J = 14.3, 
7.1 Hz, 1H), 3.17 (s, 1H), 2.94 – 2.82 (m, 2H), 0.88 – 0.78 (m, 3H); 13C NMR (75 MHz. CDCl3) 
δ 167.48, 161.34, 155.72, 148.39, 138.27, 136.84, 136.05, 135.36, 135.18, 134.49, 129.98, 126.82, 
124.76, 123.94, 122.75, 121.06, 81.51, 79.40, 44.86, 34.12, 14.76; HRMS (LCMS-IT-TOF) Calc. 
for C21H18N5O (M + H)
+ 356.1467, found 356.1476. 
3.6.21 N-Cyclopropyl-8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-
3-carboxamide  (MP-II-046, 26) 
The carboxylic acid SR-II-54 20 (200 mg, 0.609 mmol) was suspended and stirred in CH2Cl2 (dry, 
15 mL) and thionyl chloride (2 mL) was added, after which the reaction mixture was heated to 
reflux. After the conversion of the acid to the acid chloride was complete, observed by the 
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conversion to a homogeneous solution (about 2 h.), the reaction mixture was cooled to rt and the 
solvent was removed under reduced pressure. The residue which resulted was redissolved in 
CH2Cl2 (dry, 15 mL) and the solution was cooled to 0 
oC. The cyclopropyl amine was added and 
the reaction mixture was allowed to stir until the amide product formed, as indicated by analysis 
by TLC (silica gel). The solvent was removed under reduced pressure and the residue was purified 
by flash column chromatography (3:1 EtOAc:hexanes with 1% each of methanol and 
trimethylamine added to the eluent) to afford pure cyclopropyl amide 26 (82.8 mg, 37%): 1H NMR 
(300 MHz. CDCl3) δ 8.56 (d, J = 4.7 Hz, 1H), 8.14 (d, J = 7.9 Hz, 1H), 7.83 (dd, J = 7.7, 1.6 Hz, 
1H), 7.78 (s, 1H), 7.74 (dd, J = 8.4, 1.7 Hz, 1H), 7.57 (d, J = 1.6 Hz, 1H), 7.51 (d, J = 8.3 Hz, 1H), 
7.35 (dd, J = 6.8, 5.0 Hz, 1H), 7.19 (s, 1H), 6.30 (s, 1H), 4.14 (s, 1H), 3.16 (s, 1H), 2.88 (dt, J = 
10.7, 3.6 Hz, 1H), 1.43 (t, J = 7.3 Hz, 2H), 0.84 (dd, J = 12.2, 6.9 Hz, 2H); 13C NMR (75 MHz. 
CDCl3) δ 167.39, 161.48, 155.83, 148.45, 138.21, 136.77, 136.01, 135.42, 135.17, 134.56, 130.10, 
126.71, 124.65, 124.06, 122.81, 120.98, 81.54, 79.32, 44.78, 26.14, 7.81; HRMS (LCMS-IT-TOF) 
Calc. for C22H18N5O (M + H)
+ 369.1433, found 369.1441. 
3.6.22 8-Ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carbonitrile 
(MP-II-064, 27) 
Ethyl ester HZ-166 3 (500 mg, 1.40 mmol) was stirred in dry xylene (35 mL) at rt; while an oil 
bath was heated to 80 oC. Using a glass syringe and metal needle, dimethylaluminum amine (0.67 
M, 12.5 mL, 8.42 mmol) was carefully added to the starting material. Caution: Do not breathe 
this amine or get it on you! The reaction was then heated to 80oC in the oil bath and the solution 
was monitored by analysis by TLC (silica gel) until the starting material had been consumed, about 
2h. Once the reaction was complete, the mixture was cooled to rt, and quenched with cold water 
(15 mL). The product was extracted with EtOAc (5 x 50 mL) and the organic layers were 
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combined, washed with brine, dried (Na2SO4), and the solvent was removed under reduced 
pressure. The solid which resulted was purified by flash chromatography (Gradient elution; Step 
1: remove excess xylene with 1:4 EtOAc:hexanes eluent; Step 2: collect the nitrile product with 
1:1 EtOAc:hexanes; Step 3: collect the amide product, 4:1 EtOAc:hexanes with 1% each Et3N and 
CH3OH added to the eluent) which afforded the nitrile 27 as a white solid (208 mg, 48%) and the 
amide 28 (124 mg, 27%). The spectral data for nitrile 27: 1H NMR (300 MHz, CDCl3) δ 8.59 (d, 
J = 4.7 Hz, 1H), 8.09 (d, J = 7.9 Hz, 1H), 7.94 (s, 1H), 7.86 (td, J = 7.8, 1.7 Hz, 1H), 7.79 (dd, J = 
8.3, 1.8 Hz, 1H), 7.57 (dd, J = 7.1, 5.1 Hz, 2H), 7.45 – 7.38 (m, 1H), 5.45 (s, 1H), 4.26 (d, J = 12.0 
Hz, 1H), 3.20 (s, 1H); 13C NMR (75 MHz, CDCl3) δ 167.64, 155.98, 148.64, 140.92, 137.23, 
136.49, 135.80, 135.57, 134.77, 126.93, 125.13, 124.00, 122.70, 121.79, 113.72, 112.22, 81.41, 
79.96, 44.56; HRMS (LCMS-IT-TOF) Calc. for C19H12N5 (M + H)
+ 310.1048, found 310.1053. 
Preparation of 0.67 M dimethylaluminum amine solution, CAUTION 
You begin by stirring 20 mL of methylene chloride (dry) at 0 oC . You then bubble NH3 (g) through 
the CH2Cl2 until the solution is saturated, about 10-15 min. The 10 mL trimethylaluminum (2.0 M 
in toluene) was then added while avoiding contact with air (use glass/metal syringe and needle). 
The solution was stirred at rt for 5 min and transferred directly for use in the reaction above using 
a glass syringe and metal needle. DO NOT BREATHE OR GET ON YOU! 
3.6.23 8-Ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxamide 
(MP-II-065, 28) 
Ethyl ester HZ-166 3 (1 g, 2.81 mmol) and calcium chloride (311 mg, 2.81 mmol) were placed 
inside a sealable vessel with a stir bar. Methanol (dry, 20 mL) was added and a septum was placed 
on the top to seal the vessel. In a separate flask, ammonia (g) was bubbled into methanol (dry, 20 
mL) until saturated; this took about 10 min. The ammonia-methanol solution was then added to 
144 
 
the vessel containing HZ-166 3 and the vessel was sealed with a screw cap. The reaction mixture 
was heated and stirred at 85 oC for 18 hours. The reaction solution was allowed to cool to rt and 
the methanol was removed under reduced pressure. The solid which remained was dissolved in 
EtOAc and filtered to remove the calcium chloride. The filtrate was washed with brine, dried 
(Na2SO4), and the solvent removed under reduced pressure. The residue which remained was 
purified using flash column chromatography (EtOAc with 1% methanol and 1% trimethylamine 
added to the eluent) to afford the pure carboxamide 28 as a white solid (661 mg, 72%): 1H NMR 
(300 MHz, CDCl3) δ 8.57 (d, J = 4.6 Hz, 1H), 8.14 (d, J = 8.0 Hz, 1H), 7.84 (s, 2H), 7.81 – 7.73 
(m, 1H), 7.61 – 7.51 (m, 2H), 7.42 – 7.32 (m, 1H), 7.01 (s, 1H), 6.26 (s, 1H), 5.38 (s, 1H), 4.13 (s, 
1H), 3.17 (s, 1H); 13C NMR (75 MHz, CDCl3) δ 167.38, 164.71, 156.59, 148.59, 136.87, 136.52, 
136.32, 135.53, 135.14, 133.29, 131.01, 127.14, 124.72, 124.04, 122.76, 121.07, 81.77, 79.35, 
44.80; HRMS (LCMS-IT-TOF) Calc. for C19H14N5O (M + H)
+ 328.1154, found 328.1161. 
3.6.24 5-(8-Ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-yl)-3-methyl-
1,2,4-oxadiazole (MP-III-085, 33) 
The ethyl ester HZ-166 3 (1 g, 2.8 mmol) was dissolved in dry THF (100 mL) at rt under argon. 
In a separate flask which contained 3Å molecular sieves, N-hydroxyacetimidamide (831 mg, 11.2 
mmol) was dissolved in dry THF (100 mL) under argon and treated with sodium hydride (60% 
dispersion in mineral oil, 281 mg, 7.0 mmol). The mixture which resulted was stirred for 15 min 
at which point the solution of 2'-pyridine 3 was added. The reaction mixture which resulted was 
stirred at rt for 3h or until the starting material was consumed as indicated by TLC (silica gel). The 
reaction mixture was quenched with a saturated aq NaHCO3 solution (10 mL). Water (200 mL) 
was then added and the product was extracted with EtOAc (3 x 200 mL). The organic layers were 
combined, washed with brine, dried (Na2SO4) and the solvent was removed under reduced 
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pressure. The solid which resulted was purified by flash chromatography (silica gel, 
EtOAc/hexanes 4:1 with 1% each of Et3N and CH3OH added to the eluent) to afford pure methyl 
oxadiazole 33 as a white powder (0.76 g, 74% yield): 1H NMR (300 MHz, CDCl3) δ 8.62 (d, J = 
4.2 Hz, 1H), 8.11 (d, J = 7.9 Hz, 1H), 8.07 (s, 1H), 7.89 (t, J = 7.7 Hz, 1H), 7.81 (dd, J = 8.3, 1.6 
Hz, 1H), 7.62 (d, J = 8.4 Hz, 1H), 7.57 (d, J = 1.5 Hz, 1H), 7.49 – 7.40 (m, 1H), 6.17 (s, 1H), 4.31 
(s, 1H), 3.19 (s, 1H), 2.49 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 170.77, 167.76, 167.48, 156.16, 
148.62, 137.15, 136.32, 136.15, 135.92, 135.48, 135.24, 127.08, 124.99, 124.70, 124.12, 122.85, 
121.48, 81.59, 79.70, 44.90, 11.68; HRMS (LCMS-IT-TOF) Calc. for C21H15N6O (M + H)
+ 
367.1263, found 367.1254. 
Synthesis of the methyl oxime (N-hydroxyacetimidamide) 
The hydroxylamine hydrochloride salt (9.73 g, 0.14 mol), potassium carbonate (41.5 g, 0.3 mol), 
methanol (400 mL) and water (80 mL) were mixed and stirred as well as heated to reflux. 
Acetonitirle (5.2 mL, 0.1 mol) was added dropwise and the reaction was stirred at reflux overnight.  
The next day, the reaction was cooled to 0 oC and a precipitate formed. The reaction mixture was 
filtered and the solvent of the filtrate was removed under reduced pressure. The solid which 
resulted was dissolved in EtOAc and washed with water, brine, and dried (Na2SO4). The solvent 
was then removed under reduced pressure to afford the methyl oxime (4.35 g, 59%) which was 
used in the synthesis of 33: HPLC-MS (ESI) m/z (M+H) 75.05. This was used in the previous step 
without further characterization. 
3.6.25 3-Ethyl-5-(8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-yl)-
1,2,4-oxadiazole (MP-III-080, 34) 
Ethyl ester HZ-166 3 (200 mg, 0.561 mmol) was dissolved in dry THF (20 mL) at rt under argon. 
In a separate flask which contained 3Å molecular sieves, N'-hydroxypropionimidamide (198 mg, 
146 
 
2.25 mmol) was dissolved in dry THF (20 mL) under argon and treated with sodium hydride (60% 
dispersion in mineral oil, 56 mg, 1.40 mmol). The mixture was stirred for 15 min at which point 
the solution of ethyl ester 3 was added. The reaction mixture which resulted was stirred at rt for 
2h or until the starting material was consumed as indicated by TLC (silica gel). The reaction 
mixture was quenched with a saturated aq NaHCO3 solution (5 mL). Water (50 mL) was then 
added and the product was extracted with EtOAc (3 x 100 mL). The organic layers were combined, 
washed with brine, dried (Na2SO4) and the solvent was removed under reduced pressure. The solid 
which resulted was purified by flash chromatography (silica gel, EtOAc/hexanes 4:1 with 1% each 
Et3N and CH3OH added to the eluent) to afford pure ethyl oxadiazole 34 as a white powder (130 
mg, 61.0%): 1H NMR (300 MHz, CDCl3) δ 8.63 (d, J = 3.6 Hz, 1H), 8.16 – 8.05 (m, 2H), 7.91 (t, 
J = 7.4 Hz, 1H), 7.81 (d, J = 8.0 Hz, 1H), 7.63 (d, J = 8.3 Hz, 1H), 7.57 (s, 1H), 7.47 (d, J = 5.3 
Hz, 1H), 6.20 (s, 1H), 4.32 (s, 1H), 3.19 (s, 1H), 2.86 (dd, J = 15.0, 7.5 Hz, 2H), 1.41 (t, J = 7.5 
Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 171.93, 170.64, 167.12, 155.34, 148.00, 138.11, 136.05, 
136.00, 135.89, 135.76, 135.35, 126.77, 125.33, 124.91, 124.53, 122.98, 121.64, 81.48, 79.87, 
44.96, 19.78, 11.53; HRMS (LCMS-IT-TOF) Calc. for C22H17N6O (M + H)
+ 381.1419, found 
381.1423. 
Synthesis of the ethyl oxime (N'-hydroxypropionimidamide) 
The hydroxylamine hydrochloride (9.73 g, 0.14 mol), potassium carbonate (41.5 g, 0.3 mol), 
methanol (400 mL) and water (80 mL) were mixed and stirred, after which the mixture was heated 
to reflux. The propionitrile (7.1 mL, 0.1 mol) was added dropwise and the reaction was stirred at 
reflux overnight.  The next day, the reaction mixture was cooled to 0 oC and a precipitate formed. 
The reaction mixture was filtered and the solvent from the filtrate was removed under reduced 
pressure. The solid which resulted was dissolved in EtOAc and washed with water, brine, and 
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dried (Na2SO4), after which the solvent was removed under reduced pressure to afford the ethyl 
oxime (6.03 g, 69%) which was used in the synthesis of 34: HPLC-MS (ESI) m/z (M+H) 89.06. 
This was used in the previous step without further characterization. 
3.6.26 5-(8-Ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-yl)oxazole 
(KRM-II-81, 36). 
The toluenesulfonylmethyl isocyanide (TosMIC, 750 mg, 3.84 mmol) was placed in a dry two 
neck round bottom flask and dry MeOH (100 mL) was added under an argon atmosphere. At rt, 
solid K2CO3 (1.33 g, 9.6 mmol) and the aldehyde MP-II-050 23 (1.0 g, 3.2 mmol) were added to 
the reaction solution and the mixture was heated to reflux for 3 to 4 h. After the completion of the 
reaction on analysis by TLC (silica gel, 1:10 MeOH and EtOAc), which was indicated by the 
absence of aldehyde starting material [and complete conversion to the 1,3-oxazole (lower Rf,)] the 
reaction mixture was quenched with cold water. The solution was now reduced by one-third of the 
solvent volume under reduced pressure and the product was extracted with EtOAc (3 x 30 mL). 
The combined organic layers were washed with water, brine and dried (Na2SO4). The solvent was 
then removed under reduced pressure and the residue was purified by flash chromatography (silica 
gel) to give the pure 1,3-oxazole 36 as white solid (821 mg, 73%): 1H NMR (300 MHz, CDCl3)  
8.62 (d, J = 4.2 Hz, 1H), 8.12 (s, 1H), 8.06 (d, J = 7.8 Hz, 1H), 7.96 (s, 1H), 7.85 (ddd, J = 1.8, 
6.0 Hz, 1H), 7.79 (dd, J = 1.8, 6.6 Hz, 1H), 7.62 (d, J = 8.4 Hz, 1H), 7.55 (d, J = 1.5 Hz, 1H), 7.53 
(s, 1H), 7.41 (ddd, J = 1.5, 4.8 Hz, 1H), 5.78 (d, J = 12.9 Hz, 1H), 4.31 (d, J = 12.9 Hz, 1H). 13C 
NMR (75 MHz, CDCl3)  167.9, 156.7, 149.9, 149.0, 146.6, 137.0, 136.4, 135.8, 135.5, 135.3, 
129.8, 127.5, 127.0, 124.9, 124.0, 122.8, 122.7, 121.0, 81.8.7, 79.5, 45.3; HRMS (LCMS-IT-TOF) 
Calc. for C21H14N5O (M + H)
+ 352.1188, found 352.1193. 
The synthesis of characterization of ligands 37 – 46 can be found in Appendix J. 
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4 CHIRAL α5 LIGANDS AND THEIR USES IN COGNITIVE 
DISORDERS AND ASTHMA 
4.1 Introduction 
 The α5 GABAAR subtypes account for about 5% of all BzR-modulated α subtypes within 
the brain and are located primarily in the hippocampus.53, 57 They have been implicated in cognitive 
effects, including memory and spatial learning.47 Among these cognitive disorders include 
Alzheimer’s disease,191 Huntington’s disease,192 Down syndrome,193 schizophrenia194-198 and 
possibly depression.199 
 Schizophrenia is a mental disorder that affects nearly 1% of people worldwide200, 201 and is 
characterized by positive (disorganized thought, hallucinations, delusions, psychosis) and negative 
symptoms (little emotion, social withdrawal), as well as cognitive deficits (working memory 
deficits, reversal in learning, failure in executive function).202, 203 The most common form of 
management for schizophrenia is antipsychotics. Haloperidol, chlorpromazine (Figure 48) and 
other first-generation typical antipsychotics are thought to influence schizophrenia by targeting the 
dopamine D2 receptor (D2).
204 They are effective at reducing the positive symptoms of 
schizophrenia; however, associated adverse effects include the development of catalepsy205 and a 
range of extrapyramidal symptoms such as dystonia and parkinsonism.205 Second-generation 
atypical antipsychotics, such as clozapine and olanzapine, affect the serotonin receptor 5HT-2A in 
addition to D2.206 These have been shown to mildly reduce some of the negative symptoms of 
schizophrenia207 and cause fewer extrapyramidal symptoms,208 in addition to reducing the positive 
symptoms. However, second-generation antipsychotics are thought to be only a mild improvement 
over first-generation antipsychotics,204, 207 and as many patients discontinue these forms of 
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treatment due to ineffectiveness and adverse effects,203, 209 there is a need for improved forms of 
medication. 
 
Figure 48. Typical (haloperidol, chlorpromazine) and atypical (clozapine, olanzapine) antipsychotics. 
 
 In addition to these, schizophrenia has a high rate of comorbidity,210 in which depression, 
anxiety and substance abuse are common,211, 212 along with epilepsy to a lesser extent.213, 214 The 
result of these symptoms can lead to an extremely low quality of life in which patients with 
schizophrenia have a 10% lifetime risk of attempting suicide.215, 216 
 Outside of the CNS, the α5 and α4 subtypes have been found in the peripheral nervous 
system in the lungs.66 Here, positive Bz/GABAA allosteric modulators have been shown to exhibit 
therapeutic potential as bronchodilators for the treatment of asthma.64, 217 Asthma is a chronic 
inflammatory disease of the airways characterized by airway hyper-responsiveness, increased 
inflammation and increased mucous production.218 Current treatments include beta-2 adrenoceptor 
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agonists, such as salbutamol or salmeterol (Figure 49), which act as bronchodilators, or 
corticosteroids such as beclometasonse dipropionate which acts as an anti-inflammatory agent. 
However, down sides to these forms of treatment include route-of-administration (mainly by 
inhalation), and adverse effects including cataracts and regression in stature,219 which creates a 
need for an improved form of treatment. In addition, treating patients with steroids over a long 
period of time can lead to severe side effects. 
 Targeting the GABAARs in the airway may provide an alternative approach. It is possible 
that a long-lived in vivo α4- or α5-subtype selective ligand that targets the Bz/GABAAR in the 
lungs that does not exert CNS effects may be used as an pill to dilate the airway smooth muscle 
for the treatment of asthma or may be used in an inhaler. With fewer adverse effects, compliance 
with an oral dose or an inhaler would be much improved. 
 
Figure 49. Fast-acting (salbutamol) and long-term control (salmeterol, beclomethasone dipropionate) 
medications for asthma. 
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4.2 Background 
 The α5 GABAAR subtype has been of significant interest following reports by Möhler, et 
al. using knock-in mice. In relation to this, a series of α5 negative allosteric modulators (RY-023, 
RY-024, RY-079 and RY-080, Figure 50) were synthesized in Milwaukee and were found to 
enhance memory and learning.74, 220, 221 These were based on the structure of Ro15-4513221 and 
other ligands by Roche,222 such as flumazenil, and have been shown to be important by 
Helmstetter, Cook, et al. in the involvement of hippocampal learning and anxiety.17, 74, 220  
 
Figure 50. Structures of α5 negative allosteric modulators, RY-23, RY-24, RY-79 and RY-80.  
 
 In attempts to increase the subtype selectivity, a dimer of RY-80 was prepared to provide 
XLi-093 (47). The in vitro binding affinity was completed on α1-6β3γ2-GABAARs and revealed 
that the bivalent ligand 47 binds selectively to the α5 subtype with a Ki of 15 nM, as depicted in 
Figure 51.223 The Xenopus laevis oocyte efficacy was conducted by Sieghart, et al.223, 224 and the 
analysis indicated that at concentrations up to 1 µM, XLi-093 does not trigger chloride flux though 
the α1, α2 or α3 GABAAR subtype, but slightly inhibited the flux through the α5 subtype. This 
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resulted in the development of XLi-093 (47) as a potent α5 antagonist. This useful tool has been 
shown to shift the dose-response curve of other BZDs, including diazepam, to the right and has 
been used extensively to study the effects of agonists (PAMs) and inverse agonists (NAMs) at the 
α5 subtype.76, 220, 225, 226 
 
Figure 51. Structure and binding affinity of α5 antagonist XLi-093 (47). 
 
Additional work in this area provided the nontoxic NAM PWZ-029 (48), whose structure 
is depicted in Figure 52. Electrophysiology efficacy experiments completed by Sieghart, et al. 
demonstrated that 48 was an α5 NAM with little or no effect at the α1, α2 or α3 subtypes.227 At 
physiologically relevant concentrations about 100 to 180 nM, the negative modulation can be seen 
at the α5 subtype with no effect at other subtypes. This ligand 48 has been shown to improve 
cognitive performance in the object recognition test in both rats228 and rhesus monkeys,74, 229 which 
discriminates between exploration time between familiar and novel objects. For a review of these 
ligands, and the forthcoming PAMs, refer to Clayton, et al.,74 (see Appendix E). Because of the 
importance of PWZ-029 (48), modeling studies have been carried out to provide a rendering of 48 
docked within the α5γ2 BzR subunit homology model, as depicted in Figures 53 – 56 (legend in 
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Figure 56 caption). These models illustrate the molecule interacting with specific amino acids, as 
well as π-stacking and hydrogen bonding interactions. 
 
Figure 52. Structure and oocyte efficacy of PWZ-029 (48). Concentration curve of 48 on GABAA receptors 
using an EC3 GABA concentration (n = 4, modified from the figure in Clayton, et al.).74  
 
 
Figure 53. PWZ-029 docked within α5γ2 BzR binding site (BS). Modified from the figure in Clayton, et al.74 
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Figure 54. PWZ-029 docked with amino acid residues. Modified from the figure in Clayton, et al.74 
 
Figure 55. PWZ-029 docked with A.A. residue interactions. Modified from the figure in Clayton, et al.74 
 
Figure 56. PWZ-029 docked with interactions. (1) HIS 105 π-stacking interaction with centroid of PWZ-029; 
(2) TYR 213 phenol OH hydrogen bonding to imidazole nitrogen lone pair; (3)THR 210 OH and lone pair on 
methoxy group of PWZ029; (4) α5 ribbon is green; (5) γ2 ribbon is yellow; (6) hydrogen bonding is aqua 
blue; (7) π-stacking is magenta. Modified from the figure in Clayton, et al.74 
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 While α5 negative allosteric modulators (NAMs) decrease the flux of chloride ions through 
the pore which results in an excitatory effect and enhances cognition, positive allosteric modulators 
(PAMs) increase the concentration of chloride ions and has been shown to decrease the firing rate 
of synapses controlling cognition. A series of chiral enantiomeric α5 PAMs have also been used 
to study the α5 subtype. The first of these, SH-053-S-CH3 (49) and SH-053-R-CH3 (50), were 
found to be α2-, α3-, α5-subtype selective and α5-subtype selective ligands, respectively, as 
illustrated in Figure 57. 
 
 
Figure 57. Structures and oocyte efficacy data of SH-053-S-CH3 (49) and SH-053-R-CH3 (50). Concentration 
curves of 49 and 50 on GABAA receptors using an EC3 GABA concentration (n = 3-4, modified from the 
figures in Clayton, et al.).17 These ligands were not very potent as compared to diazepam. 
 
 These ligands both target the α5 subtype, and as a result they have been tested in a number 
of behavioral assays. These included the elevated plus maze, spontaneous locomotor activity and 
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the rotarod for anxiolytic, sedative and ataxic properties, respectively.230 These studies revealed 
that while the S-enantiomer 49 exerted anxiolytic-like properties, likely due to the activation of the 
α2 and α3 subtypes, both ligands decreased locomotor activity at 30 mg/kg in rats. Because both 
these ligands are α1-sparing, this indicated that sedation may be partially dependent on the 
activation mediated by the α5 subtype. It is possible that the sedative-like effect observed is due 
to the activation of the α5 subunits located in the spinal cord.47, 57 It should be noted, however, that 
a decrease in locomotor activity can be attributed to a variety of causes other than sedation.231 
These ligands were not potent enough to observe robust pharmacological effects and work was 
discontinued. 
 A second series of ligands replaced the 2'-H in the pendant phenyl ring with a fluorine to 
produce SH-053-2'F-S-CH3 (51) and SH-053-2'F-R-CH3 (52), as shown in Figure 58. It was shown 
by Haefley many years ago that replacement of a hydrogen with an electronegative substituent at 
the 2'-position enhanced the potency of a ligand. This can be rationalized by a 3-centered 
hydrogen-bond this ligand undergoes with the receptor protein.17, 74 These, like their predecessors, 
resulted in a α2-, α3-, α5-subtype selective ligand for the S-enantiomer 51 and an α5-subtype 
selective ligand for the R-enantiomer 52. While the S-enantiomer 51 displayed an efficacy profile 
similar to 49 with increased potency, SH-053-2'F-R-CH3 (52) remained an α5 selective ligand, but 
was much more potent than its 2'-H predecessor 50. 
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Figure 58. Structures and oocyte efficacy data of SH-053-2'F-S-CH3 (49) and SH-053-2'F-R-CH3 (50). 
Concentration curves of 49 and 50 on GABAA receptors using an EC3 GABA concentration (n = 3-5). 
 
These ligands have undergone behavioral studies and have indicated that the S-enantiomer 
51 exerts anxiolytic activity in both rats113 and rhesus monkeys112 while 52 does not unless 
administered at a very high dose. This, again, was due to efficacy activation at the α2 and α3 
subtypes by the S-enantiomer 51. These ligands provided a framework of how chiral enantiomers 
can be applied for different therapeutic uses similar to many other drugs including (+)-naloxone 
versus (-)-naloxone. 
 
4.3 Chemistry and Results 
4.3.1 Synthesis of SH-053-2'F-S-CH3 (51) and SH-053-2'F-R-CH3 (52) 
 The synthesis of SH-053-2'F-S-CH3 (51) was undertaken on large scale, as illustrated in 
Scheme 13. An amidation reaction coupling commercially available (2-amino-5-bromophenyl)(2-
fluorophenyl)methanone 53 and L-Boc-alanine was performed to provide the amide 54 using N,N'-
dicyclohexylcarbodiimde at room temperature in 87% yield. The amide was then subjected to a 
Boc-deprotection in a saturated methylene chloride-ammonia (g) solution, followed by cyclization 
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to form the basic 1,4-benzodiazepine structure 55 in 75% yield. The imidazole ring was prepared 
using the improved method118 by treating amide 55 with potassium tert-butoxide and 
diethylchlorophosphate at -35 oC and this was followed by the addition of potassium tert-butoxide 
and ethyl isocyanate at -78 oC to provide 56 in 78% yield. The previous method used sodium 
hydride as a base, and yields were consistently below 40%. A Heck-type coupling reaction with 
the bromide 56 and trimethylsilylacetylene provided the TMS ligand 57, which was deprotected 
using tetrabutylammonium fluoride at -78 oC to provide SH-053-2'F-R-CH3 51 in 86% overall 
yield over the final two steps. The enantiomer, SH-053-2'F-R-CH3 52, was prepared in similar 
yields via the same route by replacing L-Boc-alanine with D-Boc alanine in the first step, and is 
shown in Scheme 14. 
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Scheme 13. Synthesis of SH-053-2'F-S-CH3 (51). Amounts listed are the largest scale for each 
reaction in the synthesis of either (S)- 51 or (R)- 52. They do not correspond to the product which 
resulted from the previous reaction. 
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Scheme 14. Synthesis of SH-053-2'F-R-CH3 (52).  
 
 
4.3.2 Properties and Pharmacokinetics of SH-053-2'F-S-CH3 (51) and SH-053-2'F-R-CH3 
(52) 
 An advantage to this synthetic route was that it provided each compound enantiomerically 
pure, as shown by analysis by chiral HPLC by Huang.143 This also confirmed these ligands do not 
undergo racemization during the synthesis. This is important because enantiomers can exert 
different pharmacological responses, as mentioned previously, and is a common occurrence with 
enantiomeric drugs. In some cases, one enantiomer has been shown to have a therapeutic use, 
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while the other causes harmful adverse effects or is toxic, as seen with thalidomide and others.232-
236 These instances require chiral resolution and is an expensive, yet necessary, added step.237 In 
other cases, a chiral pharmaceutical drug is given as a racemic mixture, when one enantiomer is 
active and the other is inactive.232 This can lead to waste that can be as high as 50%. Although 
these enantiomers 51 and 52 were made enantiomerically pure, it was still possible that they could 
undergo chiral inversion in vitro or in vivo, which can lead to the development of the unwanted 
enantiomer, as was the case with thalidomide.237 Examination of the liver microsomal studies in 
Table 8 illustrates that this does not happen. 
Table 8. Liver microsomal stability and cytotoxicity of 51 and 52. 
Ligand Liver Microsomes Stability (%-Remaining) 
Conditions: 4 µM compound, 37 oC, 30 minutes 
Cytotoxicityb 
(18 h.) 
HLMa DLMa MLMa RLMa LD50 (µM) 
SH-053-2'F-S-CH3 (51) 2.3 90.7 66.5 6 142 
SH-053-2'F-R-CH3 (52) 100 90.3 59.1 5.4 271 
a Human liver microsomes (HLM), dog liver microsomes (DLM), mouse liver microsome (MLM) and rat liver 
microsomes (RLM). 
b Ligands were incubated in HEK293T cells for 18 hours and the cell death was assessed by luminescence. 
 
 Analysis of the data on HLMs indicated that it was very unlikely that either enantiomer 51 
nor 52 underwent chiral inversion. This was clear because the S-enantiomer 51 was at nearly 0% 
of the parent ligand 51 remaining after a 30 minute incubation time and the R-enantiomer 52 was 
not degraded at all; 100% of the parent ligand 52 remained after the 30 minute incubation. If one 
of these ligands were to undergo chiral inversion, the results would not be as dramatically different 
for the S-enantiomer 51 as compared to the R-enantiomer 52. The metabolic stability would be 
similar rather than completely opposite. The results of this study have been repeated, albeit under 
slightly different conditions, and also confirmed that SH-053-2'F-S-CH3 (51) was completely 
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degraded during the HLM incubation while SH-053-2'F-R-CH3 (52) remained at 100% of the 
parent ligand 52 at the end of the study (Rahul Edwankar, Ph.D. Thesis, see reference in his 
Appendix).116 The same conclusion cannot be made in DLMs, MLMs or RLMs, as the metabolism 
of each enantiomer was nearly the same at around 90%, 63% and 6%, respectively. This may also 
not translate into the same results in vivo. However, even chemically both the S- and R-enantiomers 
were stable for the conversion of the benzodiazepine to the imidazobenzodiazepine, which 
required stirring the ligand in the presence of potassium tertbutoxide at room temperature took 
place with no racemization (Shengming Huang, Ph.D. Thesis).143 
 Benzodiazepines are widely considered to have low toxicity concerns.154 To confirm this, 
the cytotoxicity of 51 and 52 were investigated in HEK293T cells (Kelly Teske, University of 
Wisconsin-Milwaukee). As expected, the LD50 of neither SH-053-2'F-S-CH3 (51) nor SH-053-2'F-
R-CH3 (52) are a concern, at 142 µM and 271 µM, respectively, after 18 hours of incubation time. 
Moreover, they are different as expected. The assays were also run for a 48-hour time span and 
similar results were observed. These concentrations are 150- and 10,000-fold higher than the 
respective binding constants for 51 and 52.112 This was also consistent with data for 51 and 52 
from the PDSP program (B. Roth, UNC) where these two analogs did not bind to other receptors 
nor had hERG activity. 
In regard to metabolism, the concentration-time profiles of the enantiomers 51 and 52 in 
rat plasma and brain were taken following a 10 mg/kg i.p. dose, and the results are displayed in 
Figures 59 and 60, and Table 9. These studies by Dr. Miroslav Savić, et al. yielded interesting 
results. Because the in vitro rat liver microsomal studies resulted in about 6% remaining for both 
enantiomers, it was expected that the in vivo pharmacokinetic studies would also lead to similar 
results between the S-enantiomer 51 and the R-enantiomer 52. Instead, SH-053-2'F-R-CH3 (52) 
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was found to be much more stable in vivo than SH-053-2'F-S-CH3 (51), with half-lives of 5.39 and 
2.84 hours in plasma, respectively. In addition, importantly the R-enantiomer 52 had a Cmax of 
nearly 10-fold greater than the S-enantiomer 51, with 154.85 and 18.13 ng/mL, respectively. 
Interestingly, there were some similarities in brain concentrations more than what would be 
expected based on the plasma concentrations. The S-enantiomer 51 exhibited a brain Cmax greater 
than what was reached when dosed with the R-enantiomer 52, at 304.65 and 123.16 ng/mL, 
respectively. It must be remembered that the R-CH3 enantiomer 52 was synthesized by the 
employment of the unnatural D-alanine and would be expected to be metabolized in vivo at a 
slower rate than the S-CH3 enantiomer 51 which was synthesized using the natural L-alanine. 
 
 
Figure 59. Plasma and brain concentration-time profile of SH-053-2'F-S-CH3 (51) after 10 mg/kg i.p. 
administration in male Wistar rats (n = 3) for up 6 hours. 
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Figure 60. Plasma and brain concentration-time profile of SH-053-2'F-R-CH3 (52) after 10 mg/kg i.p. 
administration in male Wistar rats (n = 3) for up to 6 hours 
 
Table 9. Pharmacokinetic data of SH-053-2'F-S-CH3 (51) and SH-053-2'F-R-CH3 (52) after 10 mg/kg i.p. 
administration in male Wistar rats (n = 3) 
SH-053-2'F-S-CH3 (51) 
Plasma Mean SEM Brain Mean SEM 
Cmax (ng/ml) 18.13 6.58 Cmax (ng/g) 304.65 49.27 
Tmax (h) 1.14 0.93 Tmax (h) 0.28 0.06 
AUC0-6 
(ng*h/ml) 26.04 13.95 
AUC0-6 
(ng*h/g) 289.61 8.14 
AUC0-∞ 
(ng*h/ml) 29.96 16.61 
AUC0-∞ 
(ng*h/g) 336.35 26.05 
β 0.33 0.11 β 0.39 0.12 
t1/2 (h) 2.84 1.14 t1/2 (h) 2.22 0.76 
SH-053-2'F-R-CH3 (52) 
Plasma Mean SEM Brain Mean SEM 
Cmax (ng/ml) 154.85 3.56 Cmax (ng/ml) 234.16 9.49 
Tmax (h) 0.33 0.00 Tmax (h) 0.33 0.00 
AUC0-6 
(ng*h/ml) 215.61 28.75 
AUC0-6 
(ng*h/g) 337.62 60.46 
AUC0-∞ 
(ng*h/ml) 289.24 25.66 
AUC0-∞ 
(ng*h/g) 511.45 21.29 
β 0.30 0.12 β 0.20 0.07 
t1/2 (h) 5.39 3.73 t1/2 (h) 5.94 3.36 
165 
 
 
 
4.3.2.1 Potential Metabolism of SH-053-2'F-S-CH3 (51) and SH-053-2'F-S-CH3 (52) in the 
CNS 
Analysis of the concentration-time pharmacokinetic profiles resulted in a few theories as 
to why the brain concentration levels are similar, yet there is a significant discrepancy between the 
plasma concentrations of SH-053-2'F-S-CH3 (51) and SH-053-2'F-R-CH3 (52). One hypothesis is 
that the S-enantiomer 51 which was synthesized from the natural Boc-L-alanine underwent active 
transport into the brain at a much fast rate than the R-enantiomer 52 which was prepared from the 
unnatural Boc-D-alanine. A second hypothesis assumed that both ligands are actively transported 
into the brain; however, the R-enantiomer 52 was readily metabolized within the brain as compared 
to the S-enantiomer 51. Cytochrome P450 isozymes primarily metabolize exogenous compounds 
in the liver, but are also found in the brain,238 albeit at about 1% concentration compared to the 
liver.239 This second hypothesis has a low probability based on; 1) RLMs degrade the isomers at a 
comparable rate, and; 2) HLMs quickly degrade the S-enantiomer 51 while the R-enantiomer 52 
is completely stable over a 30 minute time span. These two factors indicated a low likelihood that 
the second hypothesis, wherein the R-enantiomer 52 was metabolized faster, was the case.  
Irregardless, a 24 hour in vitro rat brain metabolism assay was conducted and the results are 
presented in Figure 61.  The brain of a male Wistar rat was extracted and homogenized with 
phosphate buffer solution. The ligands 51 and 52 were then incubated at 37 oC for 24 hours, and 
the % of the parent compound remaining was analyzed by mass spectrometry. The results show 
that the S-isomer (50% remaining after 24 hours) was degraded at a faster rate than the R-isomer 
(84%).   
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Figure 61. Results of 51 and 52 in a rat brain metabolism assay (n = 12). Brains were extracted from male 
Wistar rats, homogenized and incubated individually with each compound (10 µM compound concentration) 
for 24 hours. Results presented as average ± SEM. 
 
 These ligands have also been sent to PDSP for screening at the multidrug-resistance 
transport (MDR-1) transporter, which is a P-glycoprotein that transports xenobiotic compounds 
out of the brain.240 It is possible that the R-enantiomer 52 is a substrate for MDR-1 which rapidly 
transports the ligand out of the brain and lowers the brain concentration while the S-enantiomer 51 
is not. These studies are currently underway. Until the MDR-1 study has been completed, the 
reason for the contrast in brain concentrations is unknown, but appears that the S-enantiomer 51 
was actively transported into the brain at a faster rate than the R-enantiomer 52. 
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4.3.3 Pharmacological Differences between the Enantiomers, SH-053-2'F-S-CH3 (51) and 
SH-053-2'F-R-CH3 (52) and their Potential to Treat Schizophrenia. 
 Recently, these ligands, 51 and 52, have been studied due to their ability to activate the α5 
GABAAR subtype while remaining near-silent at α1 reducing the risks of adverse effects. Avoiding 
activation of the α1 subtype when targeting schizophrenia is important. First, cognitive disorders 
in schizophrenia have been proposed to involve the α5 subtype and the coupling of the α1 subtypes 
to the α5 subtypes would certainly confound this study including observations in the PCP- or MK-
801-mediated prepulse inhibition of acoustic startle paradigm and also studies of catalepsy; an 
adverse effect of some antipsychotic drugs. Also, it has been predicted that increased firing of 
dopaminergic neurons can be triggered by activation of the α1 subtype and should be avoided as 
this could further exacerbate the symptoms of schizophrenia.52, 170 Hyperdopaminergic levels have 
long been correlated with the etiology of schizophrenia. 
Studies which have focused on schizophrenia have determined that SH-053-2'F-S-CH3 
(51)241 and SH-053-2'F-R-CH3 (52)
196, 197 are able to mitigate some of the positive symptoms of 
schizophrenia. The S-enantiomer 51 was studied in an immune-mediated neurodevelopmental 
disruption model in mice which resulted in abnormalities implicated in schizophrenia. This was 
done by a prenatal administration of the viral mimetic polyriboinosinic-polyribocytidilic acid 
[poly(I:C)].242, 243 This resulted in schizophrenia-like behavioral and cognitive dysfunctions, such 
as reduced social approach behavior, impaired working memory and increased amphetamine 
sensitivity.244 Administration of SH-053-2'F-S-CH3 (51) failed to correct the deficits in working 
memory and social interaction, as was also seen with both 51 and 52 by Soto et al.,245 but was 
highly effective in alleviating the poly(I:C)-induced amphetamine hypersensitivity, a positive 
symptom of schizophrenia, without causing adverse effects.241 
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Similar studies using SH-053-2'F-R-CH3 (52) in the methylazoxymethanol acetate (MAM) 
developmental disruption model of schizophrenia in rats indicated agonist activity of the selective 
R-enantiomer 52 at the α5 receptor subtype reduced the hyperactivity of amphetamine-induced 
locomotor hyperactivity.196, 197 The MAM-model of schizophrenia was derived by administering 
the DNA-methylating agent MAM to pregnant dams and the offspring exhibit schizophrenia-like 
symptoms,246-248 similar to those seen in the poly(I:C) model of schizophrenia. The results of these 
studies using 51 and 52196, 197, 241 indicated that these α5 PAMs can be used in the treatment of 
schizophrenia. 
While the α5 subtype selective SH-053-2'F-R-CH3 (52) exhibited the potential to be used 
in the treatment of schizophrenia with a low risk of exerting non-α5 subtype effects, the 
comorbidity210 of schizophrenia with other disorders created a very useful situation for the 
α2/α3/α5 agonist SH-053-2'F-S-CH3 (51). It is not uncommon for a patient to be suffering from 
both schizophrenia and anxiety.211, 212 The S-isomer 51 has previously been shown to be a non-
sedating anxiolytic in the elevated plus maze paradigm in rats230 and the Vogel conflict procedure 
in rhesus monkeys,112 which indicated that 51 could be useful in treating both these disorders in 
regard to comorbidity. Epilepsy is also known to coexist with schizophrenia in some patients,213, 
214 and with the efficacy at the α2 subtype, it is likely that SH-053-2'F-S-CH3 (51) would be useful 
in treating patients displaying symptoms from both schizophrenia and epilepsy. The prepulse 
inhibition model of schizophrenia and the assessment of the development of catalepsy were also 
investigated to determine the practicality in the treatment of schizophrenia. 
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4.3.3.1 Evaluation of SH-053-2'F-S-CH3 (51) and SH-053-2'F-R-CH3 (52) at the 
Anticonvulsant Screening Program for Seizure Protection and Signs of Ataxia 
 The enantiomers SH-053-2'F-S-CH3 (51) and SH-053-2'F-R-CH3 (52) were assessed for 
their ability to protect from epileptic seizures by the Anticonvulsant Screening Program (ASP) at 
the National Institute for Neurological Disorders and Stroke (NINDS). The treatment of epilepsy 
by BZDs has previously been discussed in Section 3.3.7.5. As pointed out, tolerance develops to 
the anticonvulsant effect of typical BZDs in 3 – 5 days. The initial screen for 51 and 52 was a low-
frequency (6 Hz), long-duration (3 sec.) electroshock test (Figure 62A). Mice (n = 4) were dosed 
i.p. with either 100 mg/kg of the S-enantiomer 51 or 150 mg/kg of the R-enantiomer 52 and 
subjected to the electroshock test to determine the ability of each compound to protect mice from 
electroshock-induced seizures. The S-enantiomer 51 offered protection at all time points, ranging 
from 15 minutes to 4 hours, as expected due to the positive modulation of the α2 subtype. The R-
enantiomer 52 had no effect at a higher dose at any time point. The ED50 of the S-enantiomer 51 
was then calculated at the time-of-peak effect, 1 hour. Doses of 5, 15, 30 and 60 mg/kg led to an 
ED50 of 14.2 mg/kg against electroshock-induced seizures (Figure 62B). These results are 
promising for the use of SH-053-2'F-S-CH3 (51) in the treatment of patients who exhibit the 
symptoms of schizophrenia comorbid with epilepsy. 
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Figure 62. Assessment of SH-053-2'F-S-CH3 (51) and SH-053-2'F-R-CH3 (52) to protect mice from 
electroshock-induced convulsions. A) Mice were dosed i.p. with either 51 (100 mg/kg) or 52 (150 mg/kg) and a 
6 Hz shock by a corneal electrode was administered at various time points and observed for convulsions and 
51 was able to protect some subjects while 52 was not; B) The dose-response of 51 in protection in the 6 Hz 
electroshock test at 1 hour post i.p. administration. 
 
 Mice were also assessed for ataxic properties in the rotorod paradigm by ASP at NINDS. 
Both compounds were dosed i.p. at 100 mg/kg in mice (n = 8) and neither had significant ataxic 
properties since only one mouse failed to complete the assay when dosed with 51, as depicted in 
Figure 63. Rudolph et al.170 predicted that activation of the α1 subtype can increase dopamine 
firing,52, 170 further increasing the schizophrenia-like symptoms. The lack of ataxia, which also 
stems from the α1 subtype,41, 42 at high doses is encouraging and important for the treatment of 
schizophrenia with S-enantiomer 51 or the N-methyl analogs as well as other N-alkyl ligands of 
51 also including C(3)-oxadiazoles. 
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Figure 63. Assessment of SH-053-2'F-S-CH3 (51) and SH-053-2'F-R-CH3 (52) in the rotarod assay. Mice were 
dosed i.p. with 51 or 52 (100 mg/kg) 30 minutes prior to being tested on a rotating rod (6 rpm). Mice that fell 
3 times during a 1-minute trial were deemed toxic (ataxic). 
 
4.3.3.2 Prepulse Inhibition of SH-053-2'F-S-CH3 (51) and SH-053-2'F-R-CH3 (52) 
 The deficits in prepulse inhibition (PPI) to acoustic startle reflex are observed in patients 
which exhibit schizophrenic-like symptoms.249 The trait that is characterized by PPI is when a 
weak prestimulus (prepulse) is able to inhibit the reaction (startle response) of a subject to a 
subsequent strong stimulus (pulse).250, 251 This can be induced by N-methyl-D-aspartate (NMDA) 
antagonists such as phencyclidine (PCP) and dizocilpine (MK-801).250 A traditional antipsychotic 
haloperidol was unable to reverse the PPI deficits induced by PCP and MK-801; however, the 
atypical antipsychotic clonzapine was able to correct the deficits.  
The enantiomers SH-053-2'F-S-CH3 (51) and SH-053-2'F-R-CH3 (52) were assessed for 
PPI (Dr. David Baker and Nick Raddatz) to further characterize the ability of these IBZDs to be 
used in the management of schizophrenia beyond the correction of amphetamine-induced 
hyperactivity previously observed.196, 197, 241 Male Sprague-Dawley rats (n = 6 – 8) were trained in 
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a sound-attenuating chamber which rested on a motion sensing plate to determine the magnitude 
of the startle response. The sessions consisted of a 50 dB pulse above a 60 dB background noise 
which determined the baseline. Rats where then given a 60 minute pretreatment of vehicle 
(DMSO), 51 or 52 (30 mg/kg), followed by a subcutaneous injection of either PCP-hydrochloride 
(1.5 mg/kg) or saline 10 minutes prior to testing. Subjects were then tested for PPI with the 50 dB 
pulse immediately preceded (100 ms) by a 5, 10 or 15 dB prepulse to determine the ability of 51 
and 52 to reverse the effects of PCP, as depicted in Figure 64. 
 
Figure 64. Assessment of SH-053-2'F-S-CH3 (51) and SH-053-2'F-R-CH3 (52) to reverse the PPI deficits 
induced by PCP. SH-053-2’F-S-CH3, but not SH-053-2’F-R-CH3, (30 mg/kg, dosed i.p.) antagonized deficits in 
prepulse inhibition produced by phencyclidine when given one hour before testing.  The data are expressed as 
the mean (+SEM) percent prepulse inhibition of the startle response to an auditory stimulus (50 dB above a 
60 dB background) when preceded by a nonstartle-eliciting auditory cue at 5, 10, and 15 decibels above a 60 
dB background.  Disruption of prepulse inhibition was obtained in rats by an acute injection of phencyclidine 
(PCP.HCl, 1.5 mg/kg, subcutaneous) ten minutes prior to testing. *p<0.05, difference from controls receiving 
phencyclidine with 0 mg/kg drug pretreatment. The R-enantiomer 52 was trending towards significance in 
this protocol but would have required many more animals to reach significance and logistics prevented the 
completion of this study with 52. 
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 Analysis of the results indicated that the S-isomer 51, which activated the α2, α3 and α5 
subtypes, significantly reversed the schizophrenic-like symptoms induced by PCP when using a 5 
and 15 dB prepulse (over 60 dB background) prior to a pulse (50 dB over 60 dB background). The 
R-enantiomer 52, which activated only the α5 subtype, was unable to reach a significant effect, but 
did show improvement over the vehicle that was treated with PCP. The use of more animals would 
have reached significance with 52 but was not executed due to cost. Although the α5 subtype has 
been implicated as a target for the treatment of schizophrenia, it is possible that the anxiolytic 
effect exerted by the α2 subtype may have aided in the ability of 51 to reduce the startle response. 
However, there are protocols which separate out these two processes. The results may be more 
accurate by a shorter pretreatment time as the concentration-time profile in Section 4.3.2 displayed 
that the maximum brain concentration was reached around 20 minutes after injection rather than 
the 60 minutes employed here. It is reasonable to assume much of 51 and some of 52 were already 
metabolized when the PPI test was carried out. 
4.3.3.3 Catalepsy of SH-053-2'F-S-CH3 (51) and SH-053-2'F-R-CH3 (52) 
 Catalepsy, which is defined as a failure to correct an externally imposed posture,252 is 
associated with drugs that treat schizophrenia because of the effects on dopamine levels.253 
Unfortunately, some antipsychotics, such as haloperidol, have been found to cause catalepsy,254 
limiting their use in the treatment of schizophrenia. While BZDs are currently a first-line treatment 
for catalepsy,255 SH-053-2'F-S-CH3 (51) and SH-053-2'F-R-CH3 (52) were assessed against 
haloperidol to measure the development of catalepsy. 
 Male Sprague-Dawley rats were dosed i.p. with vehicle (DMSO), haloperidol (0.1 mg/kg), 
51 or 52 (30 mg/kg) and their front paws were placed on a bar that was positioned 12.5 cm above 
the floor. The time from the placement of the paws until one paw was moved or slipped from the 
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bar was measured at 30, 60 and 90 minutes post treatment, as illustrated in Figure 65. As expected, 
haloperidol significantly increased the amount of time in between the placement of the paws and 
the first movement as compared to vehicle, which indicated the development of catalepsy. Neither 
51 nor 52 displayed signs of catalepsy as both ligands performed comparable to vehicle. Moreover, 
the observer noted that neither animal appeared sedated, as mentioned by Nick Raddatz (private 
communication). 
 
 
Figure 65. Assessment of the development of catalepsy of SH-053-2'F-S-CH3 (51) and SH-053-2'F-R-CH3 (52). 
Haloperidol, but not 51 nor 52 (30 mg/kg, i.p.) produced a significant cataleptic response at 30, 60, and 120 
minutes post-injection.  The data are expressed as the mean (+SEM) time (sec) subjects spent with both front 
paws on an elevated bar. *p<0.001, difference from controls receiving vehicle alone. 
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 The results of these studies indicated that SH-053-2'F-S-CH3 (51), which has been shown 
to be an anxiolytic,112, 230 active against electroshock-induced seizures and reversed the PCP-
induced deficits of acoustic startle in the PPI paradigm, as well as reducing amphetamine-induced 
hyperactivity,241 would be useful in the management of the positive symptoms of schizophrenia 
which are comorbid with either anxiety, epilepsy or both. In addition, SH-053-2'F-R-CH3 (52) has 
been shown to reduce amphetamine-induced hyperactivity196, 197 and was nearly able to reverse the 
effects of PCP in the PPI test, which make it a strong candidate for further evaluation as well. 
 Along with the positive results for targeting schizophrenia with the S-enatiomer 51 and the 
R-enantiomer 52, these ligands provided a framework from which new analogs were made to 
improve the current pharmacokinetic and pharmacodynamic characteristics. The results of this 
research are presented in the following sections.  
 
4.3.4 Synthesis of Analogs 
 It was well known by examination of the pharmacophore/receptors model17, 74 and SAR73 
that drastic changes in a subtype selective ligand in the Bz/GABAA system will alter the subtype 
selectivity. Consequently, a few selected analogs of SH-053-2'F-S-CH3 (51) and SH-053-2'F-R-
CH3 (52) were synthesized to minimize changes in the sterics and electronics of the ligands as 
compared to those in 51 and 52. The methyl esters MP-III-021 (62) and MP-III-004 (63) and 
methyl amides MP-III-023 (64) and MP-III-022 (65) were synthesized (Scheme 15) since the 
corresponding ligands in the 2'-N series, MP-III-024 (19) and HJ-I-040 (24), respectively, retained 
similar efficacy profiles as the parent. On analysis of preliminary data on the efficacy of 19, it 
appears to be an α2/α3 subtype selective ligand, while 24 became more selective towards the α3 
subtype. It was thought that the related ligands in the enantiomic series would exhibit a similar 
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profile to their parents 51 or 52. The oocyte efficacy of MP-III-004 (63) and MP-III-022 (65) were 
investigated and the data are presented in Sections 4.3.5 and 4.3.6, respectively. 
Scheme 15. Synthesis of methyl esters (MP-III-021, 62 and MP-III-004, 63) as well as methyl 
amides (MP-III-023, 64 and MP-III-022, 65). 
 
 
 
 Dimethylaluminum amine was prepared, as described in Section 3.3.3.2, and utilized to 
convert the ethyl esters 51 and 52 into the nitriles MP-III-018.A (66) and MP-III-019.A (68) as 
well as the carboxamides MP-III-018.B (67) and MP-III-019.B (69), as illustrated in Scheme 16. 
Caution: Do not breathe or get trimethylaluminum or dimethylaluminum amide on you! These 
nitriles were prepared before the nitrile in the 2'-N series (27) was found to lose all potency, likely 
due to the linearity of the nitrile which in turn, presumably, loses the ability to interact with H1. 
These two reactions on the enantiomers were run side-by-side under identical conditions and 
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resulted in different yields. The overall conversion of the starting material to the combined 
products were high, at 92% and 89% overall for the S- and R-enantiomers, respectively; however, 
the ratio of the resulting nitriles and carboxamides were not similar, for the S-enantiomer 51 series 
produced a 4:1 nitrile to carboxamide ratio while the R-enantiomer 52 series produced a 1:1 ratio. 
It is possible the sterics of the chiral C(4) methyl group impacted the reactions because the 
preferred conformation of the seven membered BZD ring is different depending on whether you 
have the S-CH3 enantiomer 51 or the R-CH3 enantiomer 52. This has been clearly shown in at least 
two cases, wherein two rotomers were observed in the NMR spectrum which collapsed to a single 
set of signals when the NMR spectrum was run at higher temperature. This was observed often in 
chiral BZDs. 
 
Scheme 16. Synthesis of nitriles (MP-III-018.A, 66 and MP-III-019.A, 68) and carboxamides 
(MP-III-018.B, 67 and MP-III-019.B, 69). 
 
 
 
 
 The α5 selectivity seen in MP-III-004 (63), discussed in Section 4.3.5, prompted the 
synthesis of additional esters and the predicted carboxylic acid metabolite, SH-053-2'F-R-CH3-
Acid (73), as shown in Scheme 17. The esters which were afforded by a transesterification process 
with lithium metal and the corresponding alcohol, were restricted to i-propyl (MP-III-050, 70), t-
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butyl (MP-III-051, 71) and methylcyclopropyl (MP-III-052, 72) until more analysis could be 
completed. 
Scheme 17. Synthesis of esters (70 – 72) and SH-053-2'F-R-CH3-Acid (73). 
 
 
 Additionally, the methyl (MP-IV-004, 74), ethyl (MP-IV-005, 75) and i-propyl (MP-IV-
010, 76) oxadiazoles were synthesized with the corresponding oximes, as illustrated in Scheme 
18. These were synthesized in attempts to increase the metabolic stability in rodent microsomes, 
which had clearly been seen with the heterocycles in the 2'-N (HZ-166, 3) series (see Section 
3.3.5). 
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Scheme 18. Synthesis of oxadiazoles (74 – 76). 
 
 
 
 Additional analogs of both SH-053-2'F-S-CH3 (51) and SH-053-2'F-R-CH3 (52) have been 
synthesized by Guanguan Li. 
 
4.3.4.1 In Vitro Analysis of the Analogs of SH-053-2'F-S-CH3 (51) and SH-053-2'F-R-CH3 (52) 
 The analogs of SH-053-2'F-S-CH3 (51) and SH-053-2'F-R-CH3 (52) were investigated in 
vitro by a CRO to assess the metabolic stability and efficacy at the α3 subtype in the FLIPR 
functional assay, the results of which are reported in Table 10. As previously discussed in Section 
4.3.2, the R-enantiomer 52 was not degraded in HLMs, while the S-enantiomer 51 was completely 
metabolized at the end of a 30 minute incubation time. The α3 FLIPR EC50 values which are 
reported indicated that the S-enantiomer analogs all have greater efficacy at this subtype. This was 
expected as it had been the case in previously investigated compounds such as 49 and 50,230 as 
well as 51 and 52.112, 113 Based on molecular modeling, the S-enantiomer analogs would also have 
a greater efficacy at the α2 subtype.17, 74 For a review on the subject, see Clayton, et al. (Appendix 
E).74 
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Table 10. In vitro metabolic stability, α3 Bz/GABAAR EC50 values and clogP’s of the SH-053-2'F-S-CH3 (51) 
and SH-053-2'F-R-CH3 (52) and their analogs 
 
a The α1 subtype was also examined for all compounds, and the EC50 > 20 µM for all compounds. 
b This was calculated used clogP on the ChemDraw 13.0 software; as compared to diazepam 
c Human liver microsomes (HLM), dog liver microsomes (DLM), mouse liver microsome (MLM) and rat liver 
microsomes (RLM) 
d Methyl ester 63 was tested by Revathi Kodali at UWM under similar conditions (10 µM, 37 oC, 60 minutes) 
 
 Similar to the 2'-N series presented in Section 3.3.5, the S-enantiomer amides 64 and 67 
displayed greater affinity for the α3 subtype as compared to ethyl ester 52, perhaps due to 
containing a hydrogen bond donator which can interact with A2. Unlike the 2'-N nitrile 28, nitrile 
CRO Results Metabolic stability in liver microsomes 
(reported in %-remaining) 
Conditions: 4 µM compound, 37 oC, 30 
minutes 
α3 
FLIPR 
assaya 
clogPb 
Compound 
HLMc DLMc MLMc RLMc 
EC50 
(µM) 
(Diazepam 
= 2.96) 
51 Ethyl ester (S) 2.3 90.7 66.4 6 0.427 
3.42 
52 Ethyl ester (R) 100 90.3 59.1 5.4 0.973 
63 Methyl ester (R)d 64.5  68.0    
64 Methyl amide (S)     0.048 
3.04 
65 Methyl amide (R) 89.6 53.7 47.7 2.7 2.54 
67 Carboxamide (S)     0.0505 
2.71 
69 Carboxamide (R) 86.9 65.1 71.2 30.3 0.316 
66 Nitrile (S)     0.353 
3.00 
68 Nitrile (R) 86.9 6.3 49.6 38.3 20 
74 Me. oxadiazole (R) 86.4 65.3 74.3 46.4 2.37 3.21 
75 Et. oxadiazole (R) 89.3 57.5 50.3 49 20 3.74 
76 i-Pr. Oxadiazole (R) 74.3 51.9 26.6 30.9 14.6 4.14 
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(S) 66 displayed greater affinity than the parent ethyl ester 51 at 0.353 and 0.427 µM, respectively. 
In the 2'-N series, it was believed that the lack of degree of freedom of the linear nitrile hindered 
its ability to interact with H1. It is plausible to suggest that the chiral methyl group of 66 altered 
the conformation of the C(3) functional group to interact with H1. In the R-enantiomer series, it 
was interesting to note that the methyl amide 65 has decreased efficacy at the α3 subtype, whereas 
increased efficacy has occurred in other cases. Similar to the 2'-N series, the oxadiazoles 74 – 76 
have decreased efficacy at the α3 subtype, likely due to the increased size of the C(3) functional 
group. It is possible that the larger size hinders rotation as compared to the parent and does not 
permit as effective of an interaction of the heteroatoms with H1. 
 The R-enantiomers were analyzed for their resistance to metabolism in liver microsomes.  
The R-enantiomer ethyl ester 52 was not degraded over the 30 minute incubation time in HLMs, 
and all analogs exhibited good resistance, ranging from 74 – 90% of the parent remaining. All 
analogs significantly were metabolized more rapidly in DLMs, with the majority of analogs 
exhibiting 50 – 65% remaining; the exception being the nitrile 68 which was severely degraded to 
6% remaining. It was interesting to note that the metabolic behavior of the S-enantiomer ethyl ester 
51. It was nearly completely metabolized in HLM but was very stable in DLMs (90%). Moreover, 
it was much more stable in MLMs (66%) as compared to RLMs (6% remaining). Most of the 
analogs exhibited similar resistance to MLMs compared to 52, while the low initial stability in 
RLMs of 52 (5% remaining) was the same as S-51 and R-65 but the other analogs 68 and 74 – 76 
were moderately more stable. The methyl and ethyl oxadiazoles 74 and 75 performed similarly to 
52 in HLMs, DLMs and MLMs but exhibited moderately increased stability when incubated in 
RLMs. In contrast, the isopropyl oxadiazole 76 was less stable than the other oxadiazoles in all 
species with the most significant drop in rodent liver microsomes. 
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 The methyl ester 63, which was tested under slightly different conditions, exhibited lower 
resistance to HLMs as compared to the ethyl ester 52, at 64.5% and 100%, respectively. In MLMs, 
methyl ester 63 displayed a similar resistance to liver microsomes as the ethyl ester 52, at 68% of 
the parent 63 remaining after a one-hour incubation time. It should be noted that although the 
comparison made between 52 and 63 were tested under different conditions, ligands which were 
assessed in both experiments had similar results, as mentioned in Section 3.3.5. 
 
4.3.5 MP-III-004, a Superior α5 Bz/GABAAergic Subtype Selective Ligand 
 One of the goals of this research was to discover superior α5 subtype selective ligands as 
compared to SH-053-2'F-R-CH3 (52). Analysis of previous data found SH-I-75 (77),
143 a low 
potency, α5 selective ligand in regards to efficacy, as well as an α5 selective binding ligand, as 
depicted in Figure 66. The binding data was tested twice. Although the α5 affinities are more than 
1000-fold different, both sets indicate that 77 was more potent at α5 subtypes as compared to non-
α5 subtypes. 
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Figure 66. Structure, binding affinity and oocyte efficacy profile of SH-I-75 (77). Binding affinity at αxβ3γ2 
GABAA/benzodiazepine site subtypes using [3H]-flumazenil displacement studies from two separate 
experiments. Efficacy concentration curve on GABAA receptors using an EC3 GABA concentration (n = 3). 
 
 There were two subtle differences between 52 and 77. Ligand 52 contained a 2'-F and a 
C(3) ethyl ester while 77 had a 2'-H and methyl ester as the C(3) functional group. The combination 
of these resulted in a 2'-F and C(3) methyl ester ligand, MP-III-004 (63), which was predicted to 
be an α5 subtype selective GABAAR ligand. These data were relayed to Dr. Margot Ernst who 
agreed to examine the oocyte efficacy on 63, and the results are presented in a side-by-side 
comparison to SH-053-2'F-R-CH3 (52) in Figure 67. 
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Figure 67. Structures and oocyte efficacy profiles of SH-053-2'F-R-CH3 (52) and MP-III-004 (63). 
Concentration curves on GABAA receptors using an EC3 GABA concentration (n = 3 – 5). 
 
 As predicted based on the α5 selectivity of 52 and 77, the combined structural changes in 
MP-III-004 (63) resulted in an α5 subtype selective ligand. Comparison of the efficacy data in 
oocytes of the methyl ester 63 and ethyl ester 52 indicated that while both compounds exerted 
similar efficacy at the α5 subtype, MP-III-004 (63) had significantly reduced efficacy at the α1, α2 
and α3 subtypes as compared to 52. At 1 µM, ethyl ester 52 modulated GABA currents to 150 – 
200% at non-α5 subtypes; while the methyl ester modulated currents at less than 150% for the 
same subtypes. This resulted in an excellent tool for studying GABAARs containing the α5 subtype 
since it has reduced efficacy at non-α5 receptors which decreased the chances of adverse effects. 
This finding prompted the work on additional esters, as described in Section 4.3.4, as well as the 
investigation of the oocyte efficacy of MP-III-022 (65), which is presented in Section 4.3.6.  
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4.3.5.1 Prepulse Inhibition and Catalespy of MP-III-004 
 Because of the α5 subtype selectivity of MP-III-004 (63), it was tested for the effect in 
prepulse inhibition and catalepsy by Dr. David Baker and Nick Raddatz at Marquette University. 
The assays were performed as described in Sections 4.3.3.2 and 4.3.3.3. However, complications 
with consistency using phencyclidine (PCP) led to the use of MK-801 to induce PPI deficits.256 
The ethyl ester SH-053-2'F-S-CH3 (51) was assessed using MK-801 (unpublished results) to first 
validate the switch from PCP to MK-801 and was found to significantly reverse the deficits of PPI, 
as was seen earlier using PCP. Similar to the protocol with 51 and 52, rats (n = 11 – 12) were dosed 
i.p. with MP-III-004 (63) sixty minutes prior to testing, with a subcutaneous injection of MK-801 
(0.1 mg/kg) and the results are depicted in Figure 68. Additionally, MP-III-004 (63) was assessed 
for the development of catalepsy, as illustrated in Figure 69. 
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Figure 68. Assessment of MP-III-004 (63) in reversing the PPI deficits induced by MK-801. MP-III-004 (30 
mg/kg, dosed i.p.) was unable to antagonize deficits in prepulse inhibition produced by MK-801 when given 
one hour before testing.  The data are expressed as the mean (+SEM) percent prepulse inhibition of the 
startle response to an auditory stimulus when preceded by a nonstartle-eliciting auditory cue at 5, 10, and 15 
decibels.  Disruption of prepulse inhibition was obtained in rats by an acute injection of MK-801 (0.1 mg/kg, 
sc) ten minutes prior to testing. *p<0.05, difference from controls receiving MK-801 with 0 mg/kg drug 
pretreatment. 
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Figure 69. Assessment of the development of catalepsy of MP-III-004 (63). Haloperidol and MP-III-004 at 2 
hours (30 mg/kg, i.p.) post administration produced a significant cataleptic response. The data are expressed 
as the mean (+SEM) time (sec) subjects spent with both front paws on an elevated bar. *p<0.001, difference 
from controls receiving vehicle alone. 
 
The results indicated that methyl ester MP-III-004 (63) did not exert a noticeable effect in 
the reversal of the MK-801-induced deficits of PPI as compared to vehicle. This was similar to the 
results seen with the related α5 selective ethyl ester SH-053-2'F-R-CH3 (52); however, a shorter 
pretreatment time is clearly necessary to produce superior results. This is based on numerous 
concentration-time profiles which indicate the Cmax of related ligands was at 20 minutes. In the 
assessment for the development of catalepsy, MP-III-004 (63) was found to induce catalepsy at 
two-hours after administration as compared to vehicle, but not at 30 or 60 minutes. 
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Although catalepsy did not reach significance at 60 minutes post administration, a slight 
catalepsy was observed during testing. This is the time point at which the PPI was tested and it is 
possible that it had an effect on the PPI results; however, the n-value was high at 11 rats. It was 
also discouraging to find that MP-III-004 (63) induced catalepsy, but the dose may be too high. 
Many prescribed antipsychotics elicit their effects acting upon D2 (dopamine receptor 2) receptors, 
which has been shown to be involved in catalepsy using knock-out mice.257 Because the GABAA 
and dopamine pathways are linked,258 it is possible that the potent activation of α5-containing 
GABAARs by MP-III-004 may cause a down-stream effect that activates the dopamine pathway 
at too high a level which caused catalepsy. Although unfortunate in terms of the elucidation of 
catalepsy, it is possible that the strong modulation of α5 GABAARs could engender MP-III-004 
(63) as a very good therapeutic agent for cognitive disorders since it may play a role in multiple 
pathways which could ultimately lead to a better pharmaceutical drug. Further studies on PPI 
employing MP-III-004 are to be carried out with a shorter pretreatment time. 
 
4.3.5.2 The Unexpected Anticonvulsant Data of MP-III-004 
 It was known that the α1 and perhaps α2 GABAAR subtypes play a role in the 
anticonvulsant nature of BZDs.41, 42 Because the R-enantiomer MP-III-004 (63) exerted a similar 
modulation of chloride currents upon activation of the GABAAR as SH-053-2'F-R-CH3 (52), 
preferring the α5 subtype, it was not expected that 63 would have any anticonvulsant effects. 
Nevertheless, 63 was sent to ASP and assessed in the 6 Hz seizure test, as described in Section 
4.3.3.1. The results were expected to be similar to R-enantiomer ethyl ester 52 and are depicted 
alongside 52 as well as the S-enantiomer SH-053-2'F-S-CH3 (51) in Figure 70. 
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Figure 70. Assessment of MP-III-004 for protection against 6 Hz electroshock-induced seizures alongside 
enantiomers 51 and 52. Mice were dosed i.p. with a test compound (100 or 150 mg/kg) and a 6 Hz shock by a 
corneal electrode was administered at various time points and observed for convulsions. MP-III-004 offered 
the greatest protection against convulsions. 
 
 Examination of the results were quite exciting and indicated that MP-III-004 (63) did 
protect mice from the development of seizures in the 6 Hz test. At 15, 30 and 60 minutes post 
administration, all four mice tested were protected. Only one mouse was protected at 2 hours and 
all mice exhibited convulsions at 4 hours. This was unexpected since no mice were protected with 
the R-enantiomer ethyl ester 52 at any time point. Moreover, 63 was able to protect more mice 
than the α2/α3/α5 selective SH-053-2'F-S-CH3 (51) at 15 and 30 minutes; however, the time of 
effect of R-63 appeared shorter than S-51 since the S-enantiomer ethyl ester 51 protected two of 
the four mice at both 2 and 4 hours post administration. These unexpected results led to further 
characterization of the anticonvulsant effects of MP-III-004 (63) by ASP at NINDS in the maximal 
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electroshock (MES) assay and scMET (subcutaneous pentylenetetrazole) both by i.p. and oral 
administration of 63. 
 The MES assay is a more powerful electroshock assay than the 6 Hz electroshock, where 
60 Hz of alternating current at 50 mA are delivered by corneal electrodes for 2 seconds. Mice (n 
= 4) were dosed i.p. with R-63 (30, 100 or 300 mg/kg) and subjected to the electroshock to 
determine each compounds ability to protect mice from these seizures and the results are presented 
in Figure 71A. The scMET procedure dosed mice (n = 8) i.p. with 63 (13, 25, 45 or 75) prior to a 
subcutaneous 85 mg/kg IV infusion of pentylenetetrazole (PTZ or MET) was administered and the 
number of mice protected from seizures was counted (Figure 71B). Oral dosing was conducted in 
each test and the ED50 values were reported. 
 
Figure 71. Assessment of MP-III-004 (63) against seizures when given i.p. or p.o. A) Mice were dosed i.p. with 
63 (30, 100 or 300 mg/kg) and observed for convulsions in the MES assay; the oral dosing provided an ED50 of 
93.8 mg/kg. B) Mice were dose with 63 (13, 25, 45 or 75) in the scMET seizure assay to determine both the i.p. 
and p.o. ED50 values, which were found to be 33.56 and 68.3 mg/kg, respectively. 
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 The MES results indicated that MP-III-004 (63) was able to provide protection against 
these seizures at 100 and 300 mg/kg, but not at 30 mg/kg. The MES oral dosing produced an ED50 
of 93.8 mg/kg at 30 minutes post administration. In the scMET assay, methyl ester 63 produced 
an ED50 of 33.56 and 68.3 mg/kg when dosed i.p. or orally, respectively. This lower ED50 which 
resulted when dosed i.p. was expected since it is not subjected to first-pass metabolism while oral 
dosing is. These results indicated that, unexpectedly, MP-III-004 (63) has robust anticonvulsant 
effects and further studies are underway at ASP, including testing in rats. 
 It is unknown as to why MP-III-004 (63) was able to protect mice from electroshock- and 
pentylenetetrazole-induced seizures. Further studies on anticonvulsant effects are necessary 
including the use of XLi-093 (47) to antagonize the α5 Bz/GABAA effects. Additionally, the low 
modulation of the non-α5 GABAARs tested for efficacy are unlikely to play a role in the behavioral 
effects seen in these studies. Examination of the Tables 11 (Section 4.3.6) and 12 (Section 4.3.8.2) 
show that MP-III-004 (63) had very good brain penetration and was somewhat better than MP-III-
022 (65) at 1696 and 1031 nmol/kg, respectively. The methyl amide 65 was tested in a separate 
PTZ-infusion test (Section 4.3.6.1) and did not protect from seizures; taken together with the fact 
that 65 has a higher potency at all GABAARs (discussed below), this data suggests that a different 
receptor site not described is responsible for the effects. However, the anticonvulsant studies on 
the methyl amide 65 were not done in the same animals; moreover, the full metabolic stability of 
the methyl ester 63 must be completed and compared to the results of the methyl amide 65. The 
methyl amide 65 is currently being tested at ASP (NINDS) to obtain a better comparison of the 
anticonvulsant activities. The fact that Uwe Rudolph, et al. in a triple knock in mouse just reported 
that α5 subtypes exhibit anxiolytic activity259 indicated that the anticonvulsant effects of MP-III-
004 (63) are possibly via an α5 Bz/GABAAergic pathway. Through private discussions with Drs. 
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Werner Sieghart, Margot Ernst and Miroslav Savic, it is also possible that the anticonvulsant 
effects are due to a yet untested, functional GABAAR. 
 
4.3.6 MP-III-022 
 The findings from MP-III-004 (63) led directly to the investigation of MP-III-022 (65) in 
Xenopus laevis oocytes for efficacy (Dr. Margot Ernst) and binding affinity (Dr. Petra Scholze) 
and is illustrated in Figure 72. 
 
Figure 72. Structure, binding affinity and oocyte efficacy profile for MP-III-022 (65). Binding affinity at 
αxβ3γ2 GABAA/benzodiazepine site subtypes using [3H]-flumazenil displacement studies. Efficacy 
concentration curve on GABAA receptors using an EC3 GABA concentration (n = 3 – 4). 
 
 
 Examination of the results from Ernst and Scholze indicated that MP-III-022 (65) was a 
very potent α5-GABAAR subtype selective agonist. At concentrations as low as 10 nM, R-65 
exerted a 154% control current at the α5 subtype, while the α2 subtype displayed the next greatest 
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efficacy at 109%. In addition, the binding data indicated a strong affinity for R-65 for the α5 
subtype at 55 nM. The ligand 65 selectively bound to the α5 subtype at a 5:1 ratio over the α2 
subtype and greater than a 10:1 ratio over both the α1 and α3 subtypes. Analysis of both the binding 
and efficacy data indicated the methyl amide 65 should have a low potential for the development 
of tolerance since 65 only very slightly modulated the α1 subtype at high concentrations. 
 The brain and plasma concentrations of both total and free MP-III-022 (65) and SH-053-
2'F-R-CH3 (52) were measured 20 minutes after a 10 mg/kg i.p. injection in male Wistar rats (Dr. 
Miroslav Savić), and are depicted in Table 11. With the exception of the free plasma 
concentrations, dosing of the two compounds resulted in similar concentrations, all within 2.5-
fold. The major discrepancy in dosing between the ligands was seen in conjunction with the 
efficacy data. The 10 mg/kg dose of the parent R-52 resulted in a 29 nM free brain concentration 
which correlated to a 135% modulation of the α5 subtype; while the more potent methyl amide 65 
when dosed resulted in a 68 nM free brain concentration which correlated to a 314% modulation 
of the α5 subtype. 
Table 11. Plasma and brain concentrations of MP-III-022 (65) and SH-053-2'F-R-CH3 (52) taken 20 minutes 
after an i.p. (10 mg/kg) dose, n = 3. 
Ligand Plasma (nmol/L) Brain (nmol/kg) 
Total Free Total Free 
MP-III-022 (65) 645 ± 166 87 ± 23 1031 ± 278 68 ± 18 
SH-053-2'F-R-CH3 (52) 406 ± 76 279 ± 52  752 ± 132 29 ± 5 
 
 These results, along with the subsequent full pharmacokinetic study at 2.5 mg/kg (Figure 
73), indicated that MP-III-022 (65) should have exceptional characteristics required to study the 
functions mediated by the α5 Bz/GABAAergic subtype at a very low dose. 
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Figure 73. Plasma and brain concentration-time profile of MP-III-022 (65) after 2.5 mg/kg i.p. administration 
in male Wistar rats (n = 3) for up to 3 hours. Statistics calculated analogous to the methods described in 
Section 4.5. 
 
 
4.3.6.1 Basic Behavioral Studies with MP-III-022 (Dr. Miroslav Savić) 
 To assess the capabilities of the potent α5 subtype selective MP-III-022 (65), a variety of 
behavioral tests were completed by Dr. Miroslav Savić (for an in-depth review, see Appendix F). 
A rotarod assay and determination of the protection from pentylenetetrazole (PTZ)-induced 
seizures were completed to evaluate the general characteristics of R-65. Because amide 65 has 
great brain penetration, it was important to determine if non-α5 subtypes were activated at a given 
dose. The rotarod assay was employed to assess whether methyl amide 65 would induce ataxia 
which would indicate activation of the α1 subtype. Male Wistar rats (n = 3 – 9) were dosed i.p. 20 
minutes prior to testing, at which point they were placed on a rotating rod at 15 r.p.m. and the 
number of falls observed over a three minute time period, as illustrated in Figure 74A. The dosing 
consisted of amide 65 (10, 15 or 20 mg/kg), or 65 (15 mg/kg) in combination with α5 antagonist 
XLi-093 (20 mg/kg) or Bz/GABAAR antagonist flumazenil (15 mg/kg). 
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Figure 74. The effects on MP-III-022 (65) in basic behavioral tests. A) Male Wistar rats (n = 3 – 9) were dosed 
i.p. with MP-III-022 (10, 15 or 20 mg/kg) 20 minutes prior to assessment on the rotarod for ataxic effects. 
Additionally, MP-III-022 (15 mg/kg) was coadministered with the α5 anatagonist XLi-093 (20 mg/kg) or the 
Bz/GABAAR antagonist flumazenil; B) Male Wistar rats (n = 11) were dosed with vehicle or MP-III-022 (1 or 
10 mg/kg) for the assessment of seizure protection in the PTZ infusion (scMET) test. *p < 0.05 compared to 
15 mg/kg MP-III-022, +p < 0.05 compared to combination of 15 mg/kg MP-III-022 and 20 mg/kg XLi-093. 
 
 Examination of the results indicated that a 10 mg/kg i.p. dose of amide MP-III-022 (65) 
does not lead to ataxia, while doses of 15 and 20 mg/kg led to failures in the rotarod assay. Co-
administration of 15 mg/kg of 65 with α5 antagonist XLi-093 (20 mg/kg) did not result in any 
change from dosing with solely 15 mg/kg of 65. This indicated that the ataxic effects which were 
observed do not stem from the α5 GABAAR subtype. The combination of 65 (15 mg/kg) with the 
non-selective Bz/GABAAR antagonist flumazenil (15 mg/kg) was able to reverse the ataxic effects 
induced by R-65. This indicated that the ataxic effects which were observed at a 15 or 20 mg/kg 
dose of 65 were a result of the activation of one or more of the α1, α2 and/or α3 GABAAR subtypes, 
most likely α1. This may have occurred because of the rapid penetration of methyl amide 65 into 
the brain. 
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 The PTZ-infusion test was to determine if MP-III-022 (65) exerted any anticonvulsant 
effects, which would be expected to originate from the α1 and α2 subtypes.41, 42 Male Wistar rats 
(n = 11) were pretreated i.p. with vehicle solvent (85% water, 14% propylene glycol, 1% Tween 
80) or 65 (1 or 10 mg/kg) 20 minutes prior to IV administration of PTZ, which was infused until 
seizures were observed, as depicted in Figure 74B). Analysis of the results indicated that 65 at 
doses up to 10 mg/kg did not offer protection from PTZ-induced seizures as compared to vehicle, 
which demonstrated that 65 at 10 mg/kg did not modulate the α1 or α2 subtypes. Taken together 
with the results from the rotarod study, it can be concluded that the effects observed in male Wistar 
rats following a 10 mg/kg dose of MP-III-022 (65) can be attributed solely to positive modulation 
of the α5 subtype; at higher doses other receptors became involved. This was taken into account 
for the following studies. 
 
4.3.6.2 In Vivo Cognition Performance of MP-III-022 
4.3.6.2.1 Morris Water Maze 
 The Morris water maze is a commonly used behavioral test to study spatial learning and 
memory260 associated with the α5 subtype. The test consists of placing a rodent into a circular pool 
of water which has a platform placed just beneath the water level. The platform is left in one 
constant spot with visual cues for orientation to aide in locating the platform.261, 262 After a rodent 
is trained to quickly locate the platform, a cognition-altering drug can be administrated to 
determine the effect it has on locating the platform.260 Because activation of the α5 Bz/GABAAR 
subtype is inhibitory in learning, it was expected that MP-III-022 (65) would decrease performance 
in the Morris water maze.245 
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 The Morris water maze was conducted using male Wistar rats (n = 6 – 7). After successful 
training, rats were given a 20 minute pretreatment i.p. injection of vehicle, diazepam (2 mg/kg) or 
R-65 (1, 2.5 or 10 mg/kg) and placed into the pool of water at varying locations to negate 
swimming patterns with a platform oriented 2 cm below the surface of the water. Rats were tracked 
to determine the distance in the target zone that was traveled, as well as the distance (in %) traveled 
outside of the target area, as illustrated in Figure 75. 
 
Figure 75. The effects of 2 mg/kg diazepam and 1, 2 and 10 mg/kg MP-III-022 on (a) distance in the target 
zone (m) and (b) distance in the peripheral ring (%) during probe trial in the water maze. *p < 0.05, **p < 
0.01 compared to solvent (SOL) group; +p < 0.05, ++p < 0.01 compared to 2 mg/kg diazepam (DZP 2) group; 
#p<0.05 compared to 1 mg/kg MP-III-022 (MP-III-022 1) group. Animals per treatment group were 6-7. SOL 
= solvent, DZP 2 = 2 mg/kg diazepam, MP-III-022 1 = 1 mg/kg MP-III-022, MP-III-022 2.5 = 2.5 mg/kg MP-
III-022, MP-III-022 10 = 10 mg/kg MP-III-022 
 
 Examination of the results indicated that a 10 mg/kg dose of 65 had similar results to a 2 
mg/kg dose of diazepam at decreasing the distance traveled in the target zone which is likely due 
to the positive activation of the α5 subtype altering spatial learning. A 1 mg/kg dose of 65 had no 
change as compared to vehicle, indicating that the α5 subtype was not significantly modulated at 
that dose to decrease cognition. However, this dose might be useful in reversing the effects which 
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occur in schizophrenia to reset the correct oscillation effect or simply decrease the number of 
signals over-stimulating the hippocampus via α5 subtypes in long-term potentiation or perhaps 
even short-term potentiation. The 2.5 mg/kg dose of 65 resulted in a decrease in the target zone, 
which implied that a 2.5 mg/kg dose of 65 was potent enough to have an effect on spatial learning 
and memory. Consequently, diazepam and the 2.5 and 10 mg/kg doses of 65 increased the % of 
distance traveled in the peripheral ring, while the 1 mg/kg dose of 65 displayed no change from 
vehicle. These results were expected as they are generally inversely correlated with the distance 
traveled in the target zone. 
 
4.3.6.2.2 Social Novelty Discrimination Procedure 
 The social novelty discrimination procedure is used to compare the social investigation 
time of an adult rat with a familiar and a novel juvenile rat.263 The first phase (T1) introduced a 
juvenile rat to an adult rat for five minutes. After a 30 minute break, the second phase (T2) 
consisted of the adult rat being placed in the cage with the same juvenile rat along with a second, 
novel juvenile rat. The time spent with each of the two rats in T2 is measured. Typically, the adult 
rat will spend more time with the familiar rat opposed to the novel rat. This procedure was 
conducted on adult male Wistar rats (n = 8) which were dosed i.p. with vehicle, diazepam (1.5 
mg/kg) or 65 (1, 2.5 or 10 mg/kg) 20 minutes prior to testing and the results are presented in Figure 
76. 
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Figure 76. The effects of 1.5 mg/kg diazepam (DZP 1.5) and 1, 2.5 and 10 mg/kg MP-III-022 on 
discrimination index (a) and the time exploring the familiar and the novel juvenile rat in T2 (b) in the social 
novelty discrimination procedure. A significant difference from zero for discrimination index is indicated 
with: (one simple t-test, ##p < 0.01). *p < 0.05 for the familiar vs. novel exploration times (paired-samples t-
test). Data are represented as mean + SEM. Number of animals per treatment group was 8. SOL = solvent, 
DZP 1.5 = 1.5 mg/kg diazepam, MP-III-022 1 = 1 mg/kg MP-III-022, MP-III-022 2.5 = 2.5 mg/kg MP-III-022, 
MP-III-022 10 = 10 mg/kg MP-III-022 
 
 Analysis of the results indicated that a 10 mg/kg dose of MP-III-022 (65) facilitated the 
adult rat to spend a significantly greater amount of time with the novel rat than the familiar rat. 
This was consistent with the observation that a 10 mg/kg dose strongly modulated the α5 subtype 
in the Morris water maze. 
 Expanded statistics can be found in the prepared manuscript by Timic, et al. in Appendix 
F. Taken together, the results of these studies present a ligand that can be given at very low doses 
(1 – 5 mg/kg) to evaluate the therapeutic significance of positively modulating the α5 GABAAR 
subtype. The importance of MP-III-022 (65) as a potential use in the treatment of schizophrenia 
has yet to be evaluated. 
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4.3.7 The Antidepressant Effects of α5 Subtype Selective Ligands 
 The α5 subtype selective SH-053-2'F-R-CH3 (52) was sent to Sean Piantadosi and Dr. 
Etienne Sibille (University of Pittsburgh) with the intention of further characterizing the ligand for 
the use in cognition disorders. Unexpectedly, 52 was found to produce antidepressant effects in 
female, but not male, C57BL/6J mice. Although there is some rationale for the role of the α2 
subtype playing a part in treating depression170 and previously supported by the results of KRM-
II-81 (36) as discussed in Section 3.3.7.7, other evidence suggests that positively modulating the 
α5 subtype which inhibits GABA could also be useful.6, 199 There is a wealth of reports in the 
scientific literature correlating decreased expression of α5 Bz/GABAA subunits in both 
schizophrenia and bipolar depression.264-266 
The effect of α5 GABAARs on schizophrenia and bipolar I disorder are genetically and 
etiology linked.264-266 The unpredictable chronic mild stress (UCMS) procedure was known to 
precipitate anxiety- and depressive-like behavior.267 The procedure exposed test subjects (male 
and female C57BL/6J mice) to multiple mild stressors each day over a 6 weeks span; these 
stressors include wet bedding, brief restraint, forced bath, no bedding and predator odor present, 
along with single-cage isolation towards the end of the 6-week period. The study evaluated both 
chronic (28 days) and acute dosing of SH-053-2'F-R-CH3 (52) given at 30 mg/kg by i.p. 
administration. The behavioral testing consisted of the elevated plus maze (EPM), open field test 
(OFT), novelty suppressed feeding test (NSF) and a cookie test. The EPM and OFT tests are 
designed to measure the movement and location of the mice, where the greater the movement 
indicated a decrease in anxiety and/or depression; while the novelty suppressed feeding test and 
cookie test measured the latency to bite food placed in an unfamiliar area, where an increased 
latency time indicated a greater level of anxiety and/or depression (for expanded descriptions, refer 
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to Section 4.5.17 in the Methods section). The results of these behavioral tests are presented in 
Figure 77 (EPM and OFT are depicted in panels A and B; NSF in panel C; cookie test in panel D). 
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Figure 77. Effect of SH-053-2'F-R-CH3 (52; α5-PAM) on anxiety- and depressive-like behavior induced by 
UCMS in female and male mice. A) Shown are significant positive correlations of Z-anxiety scores from the 
EPM and OFT. B) Female mice treated acutely and chronically with α5-PAM had reduced anxiety-like 
behavior across both tests while no effect of treatment was observed in male mice. C) Treatment with acute 
and chronic α5-PAM reduced latency to bite a food pellet in the NSF in female but not male mice. D) Chronic 
α5-PAM treatment reduced latency to bite a piece of cookie in the cookie test in female mice, while a trend in 
the same direction was observed following acute treatment. No significant effect of α5-PAM was detected in 
males. *p<.05, **p<.01, ***p<.001.  
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 Analysis of the results presented in Figure 77 indicated that female, but not male, mice 
when given SH-053-2'F-R-CH3 (52) exhibited reduced anxiety- and/or depression-like symptoms 
in both chronic and acutely dosed assays as compared to vehicle. The results from the EPM and 
OFT observed that female mice exhibited an anxiolytic-like response indicated by the increased 
time in the open arms of the EPM and the greater locomotor activity count in the OFT. A 
significant difference between sexes was observed in the NSF and cookie test as the latency to bite 
was significantly lower for females than for males as compared to an individual vehicle for each 
sex. The increased time to react in both the NSF and cookie test indicated a higher rate of 
depression. Taken together, this data indicated that treatment with SH-053-2'F-R-CH3 (52) 
reduced stress-induced emotionality in female mice; whereas administration of 52 in male mice 
had no effect as compared to the male vehicle.  
 One observation that can be seen is the increased latency to bite in the NSF (Figure 77C) 
for female vehicle as compared to male vehicle. It is known that the prevalence of major depressive 
disorders in humans is higher in females than in males; although the causes are still being 
investigated.268 This may play a role in rodents as well as humans; regardless, a significant effect 
was seen when females were dosed with 52. The results of the EPM in which males exhibited no 
difference from vehicle is in agreement with a previous study which assessed male rats in the EPM; 
females were not tested.113 Additionally, a Vogel conflict procedure using male rhesus monkeys 
(n = 4) were dosed with SH-053-2'F-R-CH3 (52) which was found to be inactrive as an anxiolytic 
unless at a very high dose.112 This data supports the possibility that targeting the α5 subtype may 
have antidepressant-like effects in females but not males, although more studies are necessary for 
this to be concluded. 
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 Expanded statistics on SH-053-2'F-R-CH3 (52) in a prepared manuscript by Piantadosi et 
al. on this topic are located in Appendix G. Additionally, this work has led to the assessment of 
the antidepressant effects of MP-III-022 (65). Preliminary data indicated that 65 is able to reduce 
the depressant effects induced by UCMS (preliminary results by Catherine Belzung, Etienne 
Sibille, M. Poe, J. Cook, et al. can be found in Appendix I).  
 
4.3.8 The Use of α5 Subtype Selective Ligands as Bronchodilators for Asthma 
 Over the past decade, research by Dr. Charles Emala, et al. have identified functional 
GABAAR ion channels containing either the α4 or α5 subunit by reverse transcription polymerase 
chain reaction (RT-PCR) studies and Western blot as well as immunohistochemistry analysis in 
airway smooth muscle (ASM).66 Initial studies found that the GABAAR agonist muscimol was 
able to induce relaxation of precontracted guinea pig tracheal rings or human bronchial ASM using 
an organ bath.269 The ability to selectively modulate GABAARs for bronchodilation would offer a 
novel new treatment for asthma beyond the current clinical bronchodilators such as 
methylxanthines, anticholinergics and β-adrenoceptor agonists.270 Because activation of all 
GABAARs can lead to numerous adverse effects, including mucus production in the lungs
271 which 
can exacerbate the symptoms of asthma, the employment of an α4- or α5-subtype selective ligand 
is needed to reduce these liabilities. Two α4 subtype selective ligands CMD-4564 and XHe-III-
74272 (Figure 78) have been shown to successfully relax precontracted guinea pig tracheal rings. 
This ability to target GABAARs for bronchorelaxation was also attempted using the α5 subtype 
selective agonist (PAM) SH-053-2'F-R-CH3 (52).
217 
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Figure 78. Structures of the α4 selective ligands, CMD-45 and XHe-III-74. 
 
4.3.8.1 Assessment of the α5 Subtype Selective Ligand SH-053-2'F-R-CH3 (52) as a 
Bronchodilator (Gallos, et. al.)217 
 The contraction of airway smooth muscle (ASM) is due, in part, to the actin-myosin 
interactions273 which results in bronchoconstriction.274 Because α5 GABAARs are known to be 
present in ASM,66 the co-localization of smooth muscle α actin and α5 GABAARs was assessed 
by immunohistochemistry in human trachea (Figure 79). The first (1st) panel shows the α5-
GABAAR subunit in an ASM section nuclear stained with DAPI (4',6-diamidino-2-phenylindole) 
and appears in fluorescent green and blue. The second (2nd) panel is the same muscle section 
stained with an anti-α-smooth muscle actin antibody, appearing in red. The third (3rd) panel is the 
overlay of the first two panels confirming the co-localization of the α5 subunit and smooth muscle 
actin in human trachea. The final (4th) panel was used as a control with DAPI staining but omitting 
primary antibodies.217 
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Figure 79. Protein expression of the GABAA α5 subunit in intact human trachea-bronchial airway smooth 
muscle.  Representative images of human tracheal airway smooth muscle sections using confocal microscopy 
are depicted following single, double, and triple immunofluorescence labeling. The antibodies employed were 
directed against the GABAA α5 subunit (green), α-smooth muscle actin (SMA; red) and/or the nucleus via 
DAPI counterstain (blue).  Panels illustrate the following staining parameters from left to right: (1st) co-
staining of DAPI and GABAA α5 subunit (2nd) α-SMA staining alone (3rd) triple-staining of GABAA α5, α-
SMA, and DAPI (4th) DAPI nucleus counterstain, with primary antibodies omitted as negative control. 
Modified from the figure in Gallos, et al.217 
 
Following the demonstration of protein expression of GABAAR containing the α5 GABAA 
subunit, the ability of SH-053-2'F-R-CH3 (52) to relax precontracted ASM in human and guinea 
pig ASM was executed. The smooth muscle was suspended in an organ bath and monitored using 
a force transducer. The ASM was first pre-contracted using acetylcholine at the predetermined 
EC50 concentration.  The induced contraction was then relaxed with a -agonist (isoproterenol) in 
the absence or presence of R-52. Examination of the results indicated that the amount of relaxation 
induced by isoproterenol (10 nM) was significantly increased when 52 was co-administered at 50 
µM, as depicted in Figure 80A. Additional studies using substance P, a contractile agent, in guinea 
pig tracheal rings measured the ability of the α5 selective 52 to relax ASM 30 minutes after 
substance P-induced contraction, as illustrated in Figure 80B. The α5 subtype selective ligand SH-
053-2'F-R-CH3 (52) was also shown to significantly decrease the amount of muscle force, which 
indicated that 52 successfully promoted relaxation of the tracheal ring.217   
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Figure 80. SH-053-2’F-R-CH3 (52) mediated activation of α5 subunits containing GABAA channels induces 
relaxation of pre-contracted airway smooth muscle. A)  SH-053-2’F-R-CH3 (labeled as SH-053) potentiated β-
agonist-mediated relaxation of human airway smooth muscle. Co-treatment of human airway smooth muscle 
strips with SH-053-2’F-R-CH3 (50 μM) significantly enhanced isoproterenol (10 nM) mediated relaxation of 
an acetylcholine EC50 contraction compared to isoproterenol alone.  (N=8/group, $$=p <0.01). B) SH-053-2’F-
R-CH3 activation of α5 containing GABAA receptors induces direct relaxation of substance P-induced airway 
smooth muscle contraction. Compiled results demonstrating enhanced spontaneous relaxation (expressed as 
% remaining force at 30 minutes following a 1 μM substance P mediated contraction) following treatment 
with SH-053-2’F-R-CH3 compared to treatment with vehicle control (n=4-5/group, $$ = p< 0.01). Modified 
from the figure in Gallos et al.217 
 
4.3.8.2 Additional Studies using α5 Ligands as Bronchodilators 
 The results from SH-053-2'F-R-CH3 (52) prompted additional studies using α5 subtype 
selective ligands as potential bronchodilators. The structurally related methyl ester MP-III-004 
(63), methyl ester, C(8)-bromide MP-III-058 (78), as well as the SH-053-2'F-R-CH3-Acid (73), 
the predicted metabolite of 52 and 63, were investigated (structures shown in Figure 81).  
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Figure 81. Structures of α5 selective ligands assessed in an organ bath for the relaxation of precontracted 
airway smooth muscle; as well as the route to the methyl ester MP-III-058 (78). 
 
As previously discussed, the methyl ester MP-III-004 (63) has an improved oocyte efficacy 
profile as compared to the ethyl ester 52 in regards to α5 selectivity. The carboxylic acid 73 and 
bromide MP-III-058 (78) were first assessed for their modulation of chloride currents in Xenopus 
laevis oocytes, as depicted in Figure 82 (note the Y-axis scale for 73 is different than the remaining 
compounds). The bromide 78 was found to have similar receptor preference as the C(8)-acetlyene 
counterpart 63, albeit higher efficacy towards non-α5 containing receptors at higher 
concentrations; although bromide 78 does appear to be more potent towards the α5 subtype 
modulating currents greater at 100 nM than MP-III-004 (63). The carboxylic acid 73 was found to 
be extremely efficacious at the α5 subtype with a modulation of ~600% above baseline at 100 nM 
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with little to no activation of non-α5 subtypes. This potentially permits strong modulation of the 
α5 subtype without off-target effects with the correct dosing.  
 
Figure 82. Oocyte efficacy of the α5 selective ligand, SH-053-2'F-R-CH3 (52), MP-III-004 (63), MP-III-058 
(78) and SH-053-2'F-R-CH3-Acid (73). Concentration curves on GABAA receptors using an EC3 GABA 
concentration (n = 3 – 5). 
 
 
 One necessary consideration when using ligands as bronchodilators in the lungs which 
target GABAARs, either selectively or non-selectively, is the possibility of CNS adverse effects. 
Many current treatments of asthma use an aerosol for the method of delivery. If this is the case for 
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acid 73, there would be a low chance for BBB penetration which would lead to a reduced risk of 
CNS effects. If CNS adverse effects were to occur, it would likely result in learning and memory 
complications in the case of α5 subtype selective ligands.192 One goal of using BZDs in the 
treatment of asthma is that they could be taken orally, eliminating the drawbacks of aerosols. For 
this to be feasible with an α5 selective ligand, there needs to be low BBB permeability. This was 
investigated by dosing male Wistar rats (n = 3) i.p. with 10 mg/kg of the test compounds and the 
plasma and brain concentrations were analyzed (Table 12) 20 minutes after treatment. 
Table 12. Plasma and brain concentrations taken 20 minutes after an i.p. (10 mg/kg) injection of α5 selective 
ligands, n = 3. 
Compound Plasma (nmol/L) Brain (nmol/kg) 
 Total Free Total Free 
52 (ethyl ester) 337 ± 145 231 ± 99 553 ± 242 21 ± 9 
63 (methyl ester) 1182 ± 546 418 ± 193 1696 ± 270 106 ± 17 
78 (methyl ester) 95 ±64 61 ±41 903 ± 395 11 ± 4 
73 (acid) 1511 ± 815 272 ± 146 BQLa BQL 
a BQL = below quantification limit 
 
 Analysis of the results in vivo indicated that the carboxylic acid 73 had very little or no 
brain penetration, with amounts undetectable in brain samples. This is in agreement with the 
expectation that the carboxylic acids of these molecules are too hydrophilic to cross the BBB, as 
seen previously with SR-II-54 (20). The acid 73 also appeared to be the most stable to degradation, 
as indicated by the greatest plasma concentration at 1511 nmol/L. It is interesting that methyl ester 
MP-III-004 (63) exhibited significantly higher brain and plasma concentrations than the similarly 
related ethyl ester 52 and methyl ester 78. However, this is completely compatible with the rapid 
hydrolysis of esters as compared to the longer half-life of some amides. Despite the low plasma 
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concentrations of bromide 78, the 10-fold increase in brain concentration indicated that 78 was 
able to readily cross the BBB, although at a low free concentration in the CNS. 
 These ligands, along with HZ-166 (3) and SH-I-048A (55) were assessed to determine their 
ability to relax precontracted guinea pig tracheal rings. HZ-166 (3) was used as a negative control 
since the α2/α3 subtype selective agonist with very low efficacy at the α1 and α5 subtypes was not 
expected to induce relaxation since only functional receptors containing α4 and α5 subtypes have 
been identified in ASM. The ligand SH-I-048A (55) has been previously reported as a super-
agonist at all DS sites (α1-3,5β2/3γ2),275 becoming extremely potent at concentrations as low as 10 
nM, as illustrated in Figure 83. Based on the in vitro electrophysiology of the ligands, it was 
expected that the acid 73 and super-agonist 55 would induce the greatest relaxation, while the 
methyl esters 63 and 78 would have similar results to ethyl ester 52. These ligands were assessed 
in the organ bath using precontracted guinea pig tracheal rings as described previously (Figure 84). 
 
 
Figure 83. Oocyte efficacy of the super-agonist SH-I-048A (55). Concentration curves on GABAA receptors 
using an EC3 GABA concentration (n = 3 – 5). Modified from the figure in Obradovic, et al.275 
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Figure 84. Assessment of α5 ligands, HZ-166 and SH-I-048A in airway smooth muscle force relaxation. 
Guinea pig tracheal rings were suspended in an organ bath and precontracted with substance P (1 µM), 
followed by vehicle (0.1% EtOH) or a test ligand (50 µM) and the force was measured. ** and *** p< 0.01 
and 0.001 compared to vehicle control, respectively; $$$ p< 0.001 compared to SH-053, n = 6-17.  (SH-053 = 
SH-053-2'F-R-CH3; SH-053 Acid = SH-053-2'F-R-CH3-Acid). 
 
 The results indicated that the α2/α3 selective HZ-166 (3) did not induce a significant 
relaxation as compared to vehicle (EtOH). The C(8)-acetylene methyl ester MP-III-004 (63) 
improved performance over ethyl ester 52 as compared to vehicle; however, the two ligands did 
not perform statistically different when compared to each other. The super-agonist 55 induced the 
greatest relaxation, causing the ASM to produce less force than what was initially measured. 
Unexpectedly, the acid 73, which had a similar α5 efficacy profile as 55, performed on par with 
ethyl (52) and methyl (63) esters. Additionally, the C(8)-bromide 78 was found to relax the ASM 
as well as the super-agonist 55. This activity of 73 which is similar to ethyl ester 52 and methyl 
ester 63 may indicate one can use them to treat asthma depending on the vehicle and route of 
administration (aerosol or oral) because these esters are metabolized to the acid 73 rapidly and 
even on first pass metabolism. 
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 These results indicated that positive modulation of the α5-containing functional GABAARs 
induce relaxation of precontracted ASM. Part of this is evidenced by the α2/α3 PAM HZ-166 (3) 
which was unable to relax the guinea pig tracheal rings as indicated before. An additional study to 
further support this conclusion would be to antagonize the α5 subtype. Unfortunately, the non-
selective diazepam-sensitive (DS) GABAAR antagonist flumazenil,
276 as well as the selective α5 
antagonist XLi-093 (47),220 both cause positive modulation of the α4 subtype. This could result in 
the relaxation of ASM through modulation of the α4 GABAAR rather than the α5 subtype. It was 
interesting to observe that the relaxation induced by 78 is as nearly as potent as the super-agonist 
55, while the carboxylic acid 73 induced relaxation similar to ethyl ester 52, despite its potency in 
vitro at the α5 subtype. It is worth mentioning that in vitro experiments do not always correlate to 
in vivo, or ex vivo in these examples since results on neuronal firing are not always consistent from 
one type of experiment to another and is not surprising.  
 Because invoking CNS effects is a concern when using IBZDs as a treatment for asthma, 
the route of administration and potential brain penetration must be taken into account. With an 
inhaler or nebulizer, although the ligand would be delivered directly into the lungs, there is still 
the risk of the compound reaching the brain. For a compound such as the super-agonist 55 which 
targets all DS sites, it could exert a number of adverse effects upon dosing; although it was not 
tested for brain concentrations, it is structurally related to diazepam and would be expected to have 
good penetration. Some of these adverse effects of 55 including ataxia and sedation have been 
reported by Savic, et al.275 The pharmacokinetic studies indicated that, regardless of route of 
administration, the acid 73 would be the preferred α5 ligand as it was not detected in brain levels. 
This would also allow 73 to potentially be given orally if lung exposure levels are deemed 
213 
 
acceptable (not yet tested). Similar to CNS adverse effects, there is also a risk of off-target effects 
within the lungs.  
 
4.4 Discussion  
 The importance of the α5-GABAAR has been of significant interest following findings by 
Möhler, et al., since it related to cognition disorders such as schizophrenia, bipolar disorder and 
Alzheimer’s disease. The enantiomers SH-053-2'F-S-CH3 (51) and SH-053-2'F-R-CH3 (52) both 
positively modulated the α5 subtype, while the S-enantiomer 51 also activated the α2 and α3 
Bz/GABAA subtypes.
112 These ligands have both been reported to mitigate the hyperactivity 
induced by amphetamine, one of the positive symptoms of schizophrenia, when studied in the 
MAM- or the poly(I:C)- model of schizophrenia.196, 197, 241 The S-enantiomer 51 was found here to 
reverse the deficits in prepulse inhibition (PPI) while the R-enantiomer 52 failed to do so; however, 
a shorter pretreatment time may provide superior results. Moreover, SH-053-2'F-R-CH3 (52) in 
PPI was trending toward significance although the pharmacologist ran into logistic problems. 
Additionally, 51 was able to protect mice from electroshock-induced seizures. These results 
indicated that while the R-enantiomer 52 may be useful in treating some positive symptoms of 
schizophrenia, the S-enantiomer 51 may be used in the comorbidity in schizophrenia which occurs 
with anxiety211, 212 and/or epilepsy.213, 214 
 The oocyte efficacy of the methyl ester MP-III-004 (63, Figure 67) and the methyl amide 
MP-III-022 (65, Figure 72) present two improved α5 ligands over SH-053-2'F-R-CH3 (52); since 
63 has reduced efficacy at α1, α2 and α3 subtypes while α5 is increased, and the amide 65 is much 
more potent at α5 receptors at low concentrations than the parent ethyl ester (R)-52. These two 
new ligands provide superior tools to study the neuroscience and behavioral aspects associated 
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with the α5 GABAAR subtype. The importance of the potent MP-III-022 (65) has been presented 
in a number of behavioral assays, which highlight the ability to modulate the α5 subtype in the 
absence of other α subtype effects at low concentrations in rats. Unexpectedly, MP-III-004 (63) 
protected mice from both electroshock- and pentylenetetrazole-induced seizures when dosed i.p. 
and orally. To date, there is no data to confirm that positive modulation of the α5β2/3γ2 can offer 
protection from seizures. Rudolph, et al. in a triple knock in mouse recently reported α5 
BzR/GABAA subtypes can mediate anxiety. This, if confirmed, would provide some evidence for 
an α5-mediated anticonvulsant effect, but much research must be done to shed light on this result. 
 The ethyl ester SH-053-2'F-R-CH3 (52) was assessed in mice that were subjected to 
unpredictable chronic mild stress (UCMS) and 52 was found to exhibit anxiolytic- and especially 
antidepressant-like effects in female, but not male mice. Although the underlying mechanisms for 
the role α5 GABAAR subtypes exhibit unequivocally in treating depression are not known, there 
have been many reports that the α5 subtype is involved6, 199 and these data here, along with 
preliminary data on 65 (see Appendix I), offer additional support. As mentioned before, the α5 
subtype is associated with schizophrenia and bipolar I depression. These two CNS disorders are 
genetically linked and the etiology is so similar that doctors misdiagnose one for the other. In 
addition, the anxiolytic-like effects of (R)-52 in the elevated plus maze and open field test may be 
due to activation of the α5 subtypes, which has just recently been reported in a model of anxiety.259, 
277 This antianxiety effect will have to be confirmed in numerous studies because a triple knock-
in mouse model may indeed have compensatory effects. 
In addition to targeting CNS disorders, the α5 GABAAR subtype had been identified in 
airway smooth muscle.66 The ethyl ester SH-053-2'F-R-CH3 (52) was found to relax precontracted 
airway smooth muscle,217 which led to the investigation of additional α5 subtype selective ligands 
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which were tested in organ baths studies. The primary concern of using α5 Bz/GABAAR subtype 
selective ligands as bronchodilators in the treatment of asthma is the possibility of CNS effects. 
Low brain penetration is necessary to avoid these adverse effects. This indicates that SH-053-2'F-
R-CH3-Acid (73) or a prodrug may be the best ligand to treat asthma. It does not go through the 
BBB, yet relaxes airway smooth muscle. Additionally, a tetrazole, which is a bioisostere of a 
carboxylic acid, may also provide desired results in organ bath studies while having low brain 
penetration.   
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CONCLUSION / FINAL REMARKS 
 
 The GABAA receptor has long been a topic of interest and has been targeted for a wide 
range of therapeutic uses, some of which include the treatment of anxiety, seizures, neuropathic 
pain, schizophrenia, bipolar disorder and Alzheimer’s disease. Despite recent advances by Miller, 
et al., the lack of a crystallized functional receptor has left researchers without definitive 
knowledge of the specific target site within the GABAAR. Through molecular modeling, the 
Milwaukee-based pharmacophore/receptor model based on binding affinities of known ligands has 
certainly aided in the design of ligands for the Bz/GABAAR site containing α1-6β2/3γ2 subtypes, 
the efficacy of a bound ligand can only be predicted with a certain level of error. 
 Seminal studies by Möhler, Rudolph, McKernan and others have greatly advanced the 
knowledge in the field of GABAAR with the use of knock-in mice to determine effects of specific 
subtypes. The exploitation of the pharmacological response evoked by the modulation of a specific 
GABAAR can be done ideally through a subtype selective ligand which activates a single subtype. 
The α2 containing GABAAR is of particular interest for anxiety and neuropathic pain; however, 
there are no α2 subtype selective ligands known to date. The similar homology of the α2 and α3 
subtypes has led to many α2/α3 subtype selective ligands, such as HZ-166 (3), to be characterized 
for their ability to treat these disorders. The work here illustrated the discovery of the oxazole 
KRM-II-81 (36), which has improved pharmacokinetic and pharmacodynamics properties over 
HZ-166. Continued assessment of KRM-II-81 is underway, as well as work on many other 
similarly related ligands in the search for a therapeutic drug with improved properties for anxiety, 
epilepsy and neuropathic pain. 
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The work presented here on α5 selective ligands has produced significant improvements. 
The methyl ester MP-III-004 (63) has been shown to have reduced efficacy towards non-α5 
subtypes over SH-053-2'F-R-CH3, which has resulted in a more subtype selective ligand with a 
decreased risk of off-target effects. Additionally, the anticonvulsant activity of MP-III-004 
discovered at ASP (NINDS) was an unexpected result that may lead to some interesting and 
important findings as it continues to be studied. The methyl amide MP-III-022 (65) is a very potent 
α5 subtype selective PAM and was found to modulate the α5 subtype at very low concentrations, 
permitting the behavioral effects to be studied with minimal dosing necessary. 
 The goal of this research was to develop ligands for the Bz/GABAA receptor to aid in the 
understanding of the GABAAR. It is hoped that the framework of this research may continue to 
shed light directly on these subjects, or provide advancements for the next generation of ligands, 
which can be used for the treatment of anxiety disorders, epilepsy, neuropathic pain, schizophrenia 
and depression, as well as asthma; to create a better quality of life to those who suffer from these 
disorders. 
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4.5 Methods 
4.5.1 Liver microsomal study (CRO) 
Refer to Section 3.5.2 for details. 
4.5.2 Cytotoxicity (Kelly Teske at the University of Wisconsin-Milwaukee) 
Human embryonic kidney (HEK) 293T cells were purchased (ATCC) and cultured in 75 cm2 flasks 
(CellStar) coated in Matrigel (BD Bioscience, #354234). Cells were grown in DMEM/High 
Glucose (Hyclone, #SH3024301) media to which  non-essential amino acids (Hyclone, 
#SH30238.01), 10 mM HEPES (Hyclone, #SH302237.01), 5 x 106  units of penicillin and 
streptomycin (Hyclone, #SV30010), and 10% of heat inactivated fetal bovine serum (Gibco, 
#10082147) were added. HEK293T cells at 70-80% confluency were harvested with 0.05% 
Trypsin (Hyclone, #SH3023601), added to 10 mL of the assay buffer, DMEM/High Modified 
buffer without phenol red (Hyclone, #SH30284.01) containing all the above mentioned additives 
plus 10 mM sodium pyruvate and 2% percent charcoal treated FBS (Invitrogen, #12676-011) 
instead of HI FBS, and spun down for 2 min at 1000 rpm. The media was removed and cells were 
resuspended in the assay buffer. Prior to adding cells to a sterile white, optical bottom 384-well 
plates, plates were treated with 20 μL per well of a 0.25% Matrigel solution. To each well, 20 μL 
of cells were added to yield a final concentration of 15,000 cells per well for the 18 h timed assay.  
Cells were further diluted for the 48 h timed assay to yield 7,000 cells per well which allowed cells 
to grow without causing their own programmed cell death due to insufficient space and resources 
in each well. Plates were incubated for 4 h at 37 oC with 5% CO2 before 100 nL of serially diluted 
(1:3 in DMSO) small molecules (final maximum concentration at 150 µM) were transferred using 
a Tecan Freedom EVO liquid handling system with a 50H hydrophobic coated pin tool.  The 
controls for the cytotoxicity assay used were 3-dibutylamino-1-(4-hexyl-phenyl)-propan-1-one 
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(150 μM in DMSO, positive) and DMSO (negative).  After 18 h, assay plates were evaluated by 
adding 20 µL of Cell Titer-Glo™ Luminescence Assay Kit (Promega, Madison, WI) to each well 
and reading luminescence on a Tecan Infinite M1000 plate reader. Controls were measured within 
each plate to determine the z' factor and to enable data normalization.  Three independent 
experiments were performed in quadruplicate and data was analyzed using nonlinear regression 
with variable slope (GraphPrism). 
4.5.3 Time-concentration (plasma and brain) pharmacokinetic studies (Dr. Miroslav Savić 
at University of Belgrade)275 
Male Wistar rats were divided into two cohorts of six groups each, which corresponded to 
predetermined time intervals (5, 10, 20, 40, 60, 180 and 360 min), each containing three animals. 
Ligands, dosed at 10 mg/kg, were administered by i.p. injection in a volume of 2 mL/kg (85% 
distilled water, 14% propylene glycol, 1% Tween 80). The blood samples were collected in 
heparinized syringes via cardiac puncture of rats anesthetized with ketamine solution (10% 
Ketamidor, Richter Pharma Ag, Wels, Austria, dosed i.p. at 100 mg/kg), and centrifuged at 2500 
rpm for 10 min to obtain plasma. Thereafter, rats were decapitated and brains were weighed, 
homogenized in 5 mL of methanol and centrifuged at 6000 rpm for 20 min. To determine the 
concentrations of the ligands in plasma and supernatants of brain tissue homogenates, compounds 
were extracted from these samples by solid phase extraction, using Oasis HLB cartridges (Waters 
Corporation, Milford, Massachusetts). Concentrations of ligands in plasma and brain tissue were 
determined by ultra-performance liquid chromatography-tandem mass spectrometry 
(UPLC/MS/MS). The sample pretreatment procedure was carried out using solid-phase extraction 
(SPE) on Oasiss HLB cartridges (Waters, Milford, MA, USA). The procedure was adapted from 
the method reported by Mercolini et al.278 Briefly, cartridges preconditioned with methanol and 
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water were loaded with samples (plasma or supernatant of brain tissue homogenate) and the 
internal standard solution. Endogenous impurities were removed by washing the cartridges with 
water and methanol. Finally, analyte elution was carried out with 1 mL of methanol for 1 minute. 
4.5.4 Rat brain metabolism assay 
Male Wistar rats (250-350 g.) were housed in pairs and kept on a 12h dark/light cycle (lights on at 
7:00 am) with food and water provided ad libitum. For testing, a single rat was euthanized 
(asphyxiated) in accordance with IACUC, and decapitated with a small animal guillotine. The top 
of the skull was removed using bone rongeurs and the brain was extracted and placed in a pre-
weighed 15 mL centrifuge tube. The tube was weighed to determine the weight of the brain, an 
equal amount of PBS was added and the mixture was homogenized. Individual centrifuge vials 
(1.5 mL) were prepared (100 μL PBS, 20 μL of a 100 μM stock solution of test compound, 80 μL 
brain homogenate) for eight (0, 10, 30, 60, 120, 240, 480, 1440 min) time points (n = 4 per time 
point) and placed in an oscillating heat-block (37 oC, 300 r.p.m.). At each time point, the reaction 
vial was quenched with cold acetonitrile (400 μL) containing a 10 μM internal standard and placed 
on ice. The vials were centrifuged (10,000 r.p.m.) for three minutes and the supernatant was 
pipetted into a spin filter centrifuge tube (0.22 micron nylon) and recentrifuged. Samples were 
diluted 20x (25 μL into 475 μL into LC-MS grade methanol) and analyzed using a Shimadzu 
LCMS-8040. Three independent experiments were performed (n = 4 for each independent 
experiment). 
4.5.5 Seizure protection in the 6 Hz electroshock assay (ASP at NINDS) 
Adult male CF1 mice (18-25 g) were pretreated intraperitoneally (i.p.) with the test compound at 
either 100 or 150 mg/kg. Each treatment group (n = 4 mice / group) was examined for 
anticonvulsive effects at one of five time points (1/4, 1/2, 1, 2, and 4 hr) after treatment with the 
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test compound. Following pretreatment, each mouse receiveed a drop of 0.5% tetracaine 
hydrochloride applied to each eye. The mouse was then challenged with the low-frequency (6 Hz) 
stimulation for 3 sec delivered through corneal electrodes. The low-frequency (6 Hz), long-
duration (3 sec) stimuli are initially delivered at 32 mA intensity. Animals are manually restrained 
and released immediately following the stimulation and observed for the presence or absence of 
seizure activity. If the test compound is effective in the 6 Hz screen, mice were assessed in a dose-
response using 5, 15, 30 and 60 mg/kg i.p. doses to determine the ED50 value 
4.5.6 Ataxic assessment in the rotorod assay (ASP at NINDS) 
Adult mice were dosed (i.p.) 30 minutes prior to being placed on a rotating rod at a speed of 6 rpm, 
as described in Dunham and Miya, 1957.279 The ligand was considered toxic (sedating) if the 
animal fell off this rotating rod three times during a 1-min period. In addition to minimal motor 
impairment, animals may exhibit a circular or zigzag gait, abnormal body posture and spread of 
the legs, tremors, hyperactivity, lack of exploratory behavior, somnolence, stupor, catalepsy, loss 
of placing response and changes in muscle tone, and are noted accordingly by the observer. 
Toxicity at NINDS equates to sedation or ataxia. 
4.5.7 Prepulse inhibition and the assessment for the development of catalepsy (Dr. David 
Baker and Nick Raddatz at Marquette University) 
Animals 
 Male Sprague Dawley rats (350-450g) were singly housed and kept on a reverse 12hr dark/light 
cycle (lights on 7:00 pm) with food and water provided ad libitum.  Behavioral testing occurred 
between the hours of 9:00 am and 4:00 pm with all animals individually handled a minimum of 
five minutes each for two days prior to the testing days. 
Drugs  
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SH-053-2’F-R-CH3 (52), SH-053-2’F-S-CH3 (51), and haloperidol (Sigma-Aldrich, St. Louis, 
MO) were dissolved in dimethyl sulfoxide to a final concentration of 30 and 0.1 mg/mL, 
respectively.  Dimethyl sulfoxide, while not an ideal vehicle for animal behavioral work, is an 
acceptable formulation for rats (Gad et al., 2006).  Phencyclidine hydrochloride or MK-801 (NIDA 
Drug Supply Program, Research Triangle, NC) was dissolved in saline at a concentration of 1.5 or 
0.1 mg/mL, respectively. 
Prepulse Inhibition 
Prepulse inhibition testing was run according to Bakshi and Geyer (1995).249  Subjects were placed 
on a platform in a sound-attenuating chamber (10.75”x14”x19.5”; Hamilton Kinder, CA) that 
rested on a motion sensing plate.  A matching session was conducted to determine the magnitude 
of the startle response for each subject.  This session consisted of a five minute habituation period 
followed by 20 trials; 17 trials involved the presentation of a single auditory stimulus (pulse 
stimulus; 50 dB above a 60 dB background noise) and three trials in which a prepulse stimulus (10 
dB above background) was presented 100 milliseconds before the pulse auditory stimulus.  
Subjects were then assigned to the various treatment groups based on the magnitude of their startle 
response.  At least one day later, an experimental session was conducted to assess sensorimotor 
gating. Subjects were given an intraperitoneal injection of SH-053-2'F-R-CH3 (30 mg/kg), SH-
053-2'F-S-CH3 (30 mg/kg), or vehicle 60 minutes before testing, followed by a subcutaneous 
injection of either phencyclidine hydrochloride (1.5 mg/kg), MK-801 (0.1 mg/kg) or saline ten 
minutes prior to testing.  In the experimental session, after a five or ten minute habituation period, 
subjects received 58 discrete trials; 26 trials during which the pulse stimulus (50 dB above 
background) was presented alone, 8 trials each in which the pulse stimulus was preceded by a 
prepulse stimulus (5, 10, or 15 dB above background) and 8 background trials with no pulse and 
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only background noise.  The first 6 pulse alone trials were not included in the average startle 
stimulus to achieve a relatively stable level of startle reactivity.  The percent of prepulse inhibition 
was determined as 100-(average prepulse startle response/average startle stimulus alone) x 100. 
Catalepsy  
Catalepsy was tested as per the methods reviewed by Sanberg et al (1988).252  In short, the subjects 
were placed in a test box that has an open top and a stainless steel floor and grey plastic walls 
(34.50 cm x 19.60 cm x 23.00 cm). The box contains a stainless steel bar 1.25 cm in diameter 
laterally mounted 12.50 cm above the floor and 8.50 cm from one end of the box. Haloperidol (0.1 
mg/kg), SH-053-2’F-S-CH3, SH-053-2’F-R-CH3 (30 mg/kg), or vehicle was administered 
intraperitoneally and subjects were tested at 30, 60, and 120 min post injection with a maximum 
of five trials per session. Time (seconds) was measured from placement of the subject’s front paws 
on the bar until one paw moves or slips from the bar. A maximum of five consecutive trials were 
attempted. Criteria time for a completed trial was between ten seconds and five minutes. After five 
trials, if the subject had not remained on the bar for a minimum of five seconds, the longest time 
of the five trials was recorded. 
Statistics  
Comparisons in each experiment were analyzed using a repeated measures analysis of variance 
(ANOVA) with drug treatment as between-subject variables and time or prepulse intensity as 
within-subjects variables for catalepsy and prepulse inhibition, respectively.  Significant 
interactions and main effects were further analyzed using a Fisher LSD post hoc test (p<0.05). 
4.5.8 FLIPR functional assay (CRO)180, 181 
Refer to Section 3.5.10 for details. 
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4.5.9 Efficacy data determined by electrophysiology using Xenopus laevis oocytes (Dr. 
Margot Ernst at the Medical University of Vienna)172-175 
Refer to Section 3.5.4 for details. 
4.5.10 Seizure protection against the maximal electroshock (MES) assay (ASP at NINDS)280-
282 
The MES is a model for generalized tonic-clonic seizures and provides an indication of a 
compound’s ability to prevent seizure spread when all neuronal circuits in the brain are maximally 
active.These seizures are highly reproducible and are electrophysiologically consistent with human 
seizures.For all tests based on MES convulsions, 60Hz of alternating current (50 mA in mice and 
150 mA in rats) is delivered for 2s by corneal electrodes which have been primed with an 
electrolyte solution containing an anesthetic agent (0.5% tetracaine HCL).In our initial screens, 
mice or rats are tested at various intervals following doses of 30, 100 and 300 mg/kg of test 
compound given by i.p. injection or through oral dosing (p.o.). An animal is considered “protected” 
from MES-induced seizures upon abolition of the hindlimb tonic extensor component of the 
seizure. 
4.5.11 Seizure protection against the scMET-induced assay (ASP at NINDS) 
Subcutaneous injection of the GABAAR antagonist convulsant Metrazol (MET, 
pentylenetetrazole, PTZ) produces clonic seizures in laboratory animals. The scMET test detects 
the ability of a test compound to raise the seizure threshold of an animal and thus protect it from 
exhibiting a clonic seizure in response to a normally convulsant dose of Metrazol. Animals are 
pretreated with various doses of the test compound given by i.p. injection or through oral dosing. 
At various times after dosing with the test compound, the dose of Metrazol which will induce 
convulsions in 97% of animals (CD97: 85 mg/kg mice or 56.4 mg/kg rats) is injected into a loose 
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fold of skin in the midline of the neck. The animals are placed in isolation cages to minimize 
stress283 and observed for the next 30 minutes for the presence or absence of a seizure. An episode 
of clonic spasms, approximately 3-5 seconds, of the fore and/or hindlimbs, jaws, or vibrissae is 
taken as the endpoint. Animals which do not meet this criterion are considered protected. 
4.5.12 Determination of plasma and brain concentrations 
Male Wistar rats (n = 3) were dosed i.p. with a test ligand at 10 mg/kg. Refer to Section 4.5.3 for 
experimental details. 
4.5.13 Ataxic assessment in the rotarod assay (Dr. Miroslav Savić at the University of 
Belgrade) 
Motor performance was assessed using an automated rotarod (Ugo Basile, Italy). Before testing, 
male Wistar rats (n = 3 – 9)  were trained for three days until they could remain for 180 s on the 
rod revolving at 15 rpm. On the fourth day, selection was made and rats fulfilling the given criteria 
were included in the experiment. Seven groups received one of the following treatments 20 
minutes before testing: solvent, MP-III-022 (10, 15 and 20 mg/kg), and 15 mg/kg MP-III-022 in 
combination with XLi-093 (20 mg/kg) or flumazenil (15 mg/kg). Latency to fall from the rotarod 
was recorded automatically. 
4.5.14 Seizure protection against the scMET-induced assay (Dr. Miroslav Savić at the 
University of Belgrade) 
A butterfly cannula (needle size 25 G, ¾ in.) attached to a 20 ml syringe prefilled with 
pentylenetetrazole (PTZ) solution was used. The syringe was held in an adjustable motor driven 
infusion pump (Stoelting Co., Wood Dale Illinois, USA). Before infusing PTZ, the rat’s tail vein 
was dilated with warm water. A single male Wistar rat was then placed in the restrainer. A butterfly 
needle was inserted into the lateral tail vein and PTZ was infused at a constant rate of 0.5 ml/min. 
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The animal was observed throughout the infusion by two trained and blind observers. The 
threshold doses of PTZ (mg/kg) required to elicit clonic and tonic seizures were calculated using 
the following formula: volume of PTZ (ml) x concentration of PTZ (mg/ml)/body weight (kg). 
4.5.15 Effects in memory and learning in the Morris water maze (Dr. Miroslav Savić at the 
University of Belgrade) 
Experiments were performed in a 2 m diameter circular pool filled to a height of 30 cm with water 
at 22 ± 1 °C. The escape platform (15 cm × 10 cm) was submerged 2 cm below the water surface. 
An indirect illumination in the experimental room was provided by white neon tubes and many 
distal cues were present. On each of the five consecutive days, rats were given one swimming 
block, consisting of four trials. For each trial the rat was placed in the water at one of four pseudo–
randomly determined starting positions. Once the rat has found and mounted the escape platform 
it was permitted to remain on the platform for 15 s. The rat was guided to the platform by the 
experimenter if it failed to locate it within 120 s. During the acquisition phase, treatments were 
applied once daily before the swimming block. On the sixth day, rats were given a treatment–free 
probe test (60 s) without the platform. In order to ensure that any spatial bias is a consequence of 
the spatial memory of escape location, rather than of a specific swim strategy, the probe test was 
started from the novel, most distant location.284 The pool was virtually divided into four quadrants, 
three concentric annuli and a target region consisting of the intersection of the platform quadrant 
and the platform (middle) annulus, as represented in Savić et al.285 The selected parameters in the 
probe test were the distance swam in the target zone (s) and % of the distance swam in the 
peripheral annulus. We tested the effects of 1, 2.5 and 10 mg/kg MP-III-022 and 2 mg/kg 
diazepam. 
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4.5.16 Effects in the social novelty discrimination (SND) procedure (Dr. Miroslav Savić at 
the University of Belgrade) 
SND experiments compared the social investigation times of an adult rat with a familiar and a 
novel juvenile rat. The procedure is replicated from previous studies.263, 286 Testing consisted of 
two consecutive juvenile presentation periods to an adult subject: test period 1 (T1) and test period 
2 (T2). At the beginning of T1, one juvenile was placed into the adult home cage and the time 
spent by the adult investigating the juvenile (anogenital sniffing, licking, close pursuing and 
pawing) was recorded manually for 5 min. During T2, the same juvenile and a second, novel 
juvenile were placed in the cage together with the adult, and the times spent by the adult 
investigating each juvenile were measured independently for 3 min. A different pair of juvenile 
rats was presented to each adult tested. Manual scoring was conducted in a blinded manner. SND 
was impaired by the parametric manipulation applied, as there was 30 min delay between T1 and 
T2, and SND was expected to be low in control rats. The influence of MP-III-022 (1, 2.5 or 10 
mg/kg) on such induced impairment in SND was examined. There were five groups of rats which 
received one of the following treatments 20 min before T1: solvent, 1.5 mg/kg diazepam and 1, 
2.5 and 10 mg/kg MP-III-022. The amount of time investigating familiar (Tf) and novel (Tn) 
juvenile during T2 was manually scored, and discrimination indexes (Tn-Tf/Tn+Tf) was 
calculated. Total exploration time during T1 and T2 was also manually recorded. 
4.5.17 Antidepressant effects in the unpredictable chronic mild stress (UCMS) assay (Dr. 
Etienne Sibille and Sean Piantadosi at the University of Pittsburgh and University of 
Toronto) 
Animals 
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C57BL/6J mice (Jackson Laboratories, Bar Harbor, Maine USA) were housed under normal 
conditions with a 12/12 light/dark cycle and ad libitum access to food and water in accordance 
with the University of Pittsburgh Institutional Animal Care and Use Committee.  
Unpredictable chronic mild stress (UCMS)  
Mice underwent 6 weeks of UCMS. Briefly, animals were exposed to multiple mild stressors a 
day, including wet bedding, brief restraint, forced bath, no bedding, and predator odor over a period 
of several weeks (for a comprehensive review of the procedure, see Lin, et al.267 and Edgar, et 
al.).287 In one experiment, UCMS was augmented with single-cage isolation starting at the fourth 
week until sacrifice. 
Drug treatment 
Beginning on the third week of UCMS and continuing for 28 days until sacrifice, mice received 
daily i.p injections of vehicle (85% ddH2O, 14% propylene glycol, 1% Tween 80) or 30 mg/kg 
SH-053-2'F-R-CH3 (α5-PAM) in a volume of 10 mg/mL.Thirty minutes prior to behavioral testing 
all animals received a second injection of either vehicle (for chronic α5-PAM treated animals and 
UCMS-vehicle treated animals) or an α5-PAM acutely.  
Behavioral testing 
After five weeks of UCMS animals were assessed in a battery of behavioral tests including (each 
test separated by 24 hours, UCMS continued throughout behavioral testing): Elevated plus maze: 
under red light, animals were placed on a plus maze with two open and two closed arms (30x5 
cm). Number of entries into all arms as well as the time spent in the open arms was recorded 
manually for 10 minutes. Open field test: The open field test was conducted in a 43x43 cm arena 
under full (800 lux) light. Using AnyMaze software (Stoelting), the center 50% of the arena was 
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identified and animals were tracked for 10 minutes. Novelty suppressed feeding test: Mice were 
food deprived for 24 hours the day before testing. Testing occurred in brightly lit (~1000 lux) open 
field arenas covered in bedding. A normal food pellet was placed into the brightly lit center and 
the latency for an animal to approach and bite the cookie was manually recorded over a 12 minute 
session. Immediately following the 12 minute session, animals were placed into their home cage 
and allowed to eat a weighed food pellet to assess hunger drive. Cookie test: The cookie test 
apparatus contains three identically sized chambers (40x20x20) separated by two offset doors. The 
walls of each chamber were clear and the only difference between each was the color of the divider 
with one divider shaded white and the other black. One week prior to experimentation, mice were 
habituated in their home cage to a piece of (2 ± 1g) Keebler Fudge Stripe Cookie (Kellogg's 
Company, Battle Creek, MI USA). On the first and second day of testing, a piece of cookie (2 ± 
1g) was placed into the chamber separated by the black wall. Mice were then placed into the white 
chamber and monitored for 10 minutes. The time it took for each mouse to bite the cookie was 
recorded.  
4.5.18 Immunohistochemistry of human ASM for α5-containing GABAAR subunit protein 
expression217 
All human airway tissue protocols were reviewed by Columbia University Institutional Board and 
were deemed not human subjects research under 45 CFR 46.  Human tracheal tissue was obtained 
from discarded airway from healthy lung donors during transplantation surgery at Columbia 
University, N.Y. The trachea and first generation bronchi of the airway were processed for 
immediate fixation in 4% paraformaldehyde (4oC overnight), then incubated in 30% sucrose in 
PBS at 4oC for an additional 24 hrs prior to processing for cryostat sectioning (6 µm). The sections 
were washed in PBS, incubated with 0.1% Triton X-100 for 10 min, blocked with 15 % goat serum 
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then incubated overnight at 4 oC in primary antisera.  The primary antibodies used were (1) anti-
GABA 5 (rabbit, polyclonal: Chemicon # AB9678, 1:300 dilution in PBS)    (2) anti-α smooth 
muscle actin (mouse, monoclonal; Sigma-Aldrich, #A2547, 1:10,000 dilution in PBS). The 
secondary antibodies consisted of FITC-conjugated goat anti-rabbit IgG (1:400 dilution), and 
Alexa Fluor 594 goat anti-mouse IgG (1:400 dilution; Invitrogen) incubated for 1 hr. Nuclear 
staining was performed using mounting medium pre-mixed with DAPI stain (Vector laboratories, 
#H-1500). Negative controls omitted all primary antibodies, but included secondary staining and 
nuclear staining steps.  All the immunofluorescence experiments were repeated on at least 3 
independent samples. Samples were viewed under confocal microscopy (Nikon A1 Eclipse, Japan) 
and images were acquired with NIS software version 4.10. 
4.5.19 Force measurements in human airway smooth muscle strips 
Human airway smooth muscle strips were dissected from trachea and mainstem bronchi and 
epithelium was removed under a dissecting microscope.  Strips were suspended at 1.5 grams 
resting tension in Krebs-Henseleit (KH) buffer as previously described in Gallos et al.64 Trachea 
and bronchi were obtained from surgical discards from healthy donor lungs incidental to lung 
transplant surgery and studies were deemed not human subjects research after review by Columbia 
University’s Institutional Review Board. The KH buffer contained in mM: 118 NaCl, 5.6 KCl, 0.5 
CaCl2, 0.24 MgSO4, 1.3 NaH2PO4, 25 NaHCO3, and 5.6 glucose, pH 7.4). 10µM indomethacin 
was added to the buffer to block endogenous release of prostanoids.  Strips were allowed to 
equilibrate for 1 hour with KH buffer exchanges every 15 minutes.  Strips underwent contractile 
challenges with acetylcholine (100nM-100 µM) for three cycles with extensive buffer exchanges 
and resetting of resting tension to 1.5 grams between cycles.  Tetrodotoxin (1 µM), pyrilamine (10 
µM), and MK501 (10 µM) were then added to the buffer to eliminate potentially confounding 
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effects of neural activation, histamine release or leukotriene release from other cell types (neurons, 
mast cells) present in the ASM strip preparation during muscle force studies.  ASM strips were 
then contracted with an EC50 concentration of acetylcholine, and after establishing a stable plateau 
of muscle force (typically ~30 min), 10 nM of isoproterenol was added with or without 50 µM 
SH-053-2'F-R-CH3 or vehicle (0.2% ethanol).  The magnitude of remaining muscle force was 
measured 15 min after the addition of isoproterenol +/- SH-053-2'F-R-CH3 and expressed as a 
percentage of the initial acetylcholine-induced force.     
4.5.20 Force measurements in guinea pig tracheal rings 
All guinea pig protocols were approved by the Columbia University Animal Care and Use 
Committee. Studies were conducted as previously described in Gallos et al.217 Briefly, male 
Hartley guinea pigs (∼400 g) were anesthetized with intraperitoneal pentobarbital (100 mg/kg) 
and their tracheas dissected free of epithelium and suspended in physiological buffer with 10uM 
indomethacin in organ baths at 37oC and continuously aerated with 95% O2/5% CO2 (bubbled). 
Tracheal rings were placed under a resting tension of 1.0 g and allowed to equilibrate for 1h with 
buffer exchanges every 15 min.  Tracheal rings were pretreated with N-vanillylnonanamide (10 
μM) to activate and then deplete nonadrenergic, noncholinergic nerves contained within the tissue. 
After buffer exchanges the tracheal rings were subjected to two cycles of increasing cumulative 
concentrations of acetylcholine (0.1 μM to 0.1 mM). Following extensive buffer exchanges, 
pyrilamine (10 μM), and tetrodotoxin (1 μM) were added to the buffers to block confounding 
effects of released histamine or nerve depolarization on endogenous airway smooth muscle 
contractile force.  Tracheal rings were then contracted with 1uM substance P. After contractions 
achieved a steady-state plateau of increased force (typically 30 min), 50 M of the indicated 
GABAA ligand or the vehicle control (0.1% ethanol) was added to the buffers.  The maintenance 
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of force was measured after 15 min and was expressed as a percent of the initial contractile 
substance P-induced force for each ring and the resultant relaxation was compared to the vehicle 
control. 
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4.6 Experimental 
4.6.1 Tert-butyl (S)-(1-((4-bromo-2-(2-fluorobenzoyl)phenyl)amino)-1-oxopropan-2-
yl)carbamate (54) 
The (2-amino-5-bromophenyl)(2-fluorophenyl)methanone 53 (60 g., 204 mmol) and Boc-L-
alanine (38.6 g., 204 mmol) were dissolved in dry CH2Cl2 (500 mL) and stirred at 0 
oC. 
Dicyclohexylcarbodiimide (DCC; 50.5 g., 249 mmol) dissolved in dry CH2Cl2 was added dropwise 
over a 30 min period at 0 oC. The solution was allowed to stir for 8 h at rt. The dicyclohexyl urea 
byproduct which was formed was filtered off and washed with CH2Cl2. The organic layers were 
combined and concentrated under reduced pressure to afford the Boc analog 54 (82.6 g., 87%): 1H 
NMR (300 MHz, CDCl3) δ 11.68 (s, 1H), 8.71 (d, J = 9.0 Hz, 1H), 7.69 (dd, J = 9.0, 2.3 Hz, 1H), 
7.55-7.62 (m, 2H), 7.46 (td, J = 7.6, 1.4 Hz, 1H), 7.30 (t, J = 7.5 Hz, 1H), 7.21 (t, J = 9.1 Hz, 1H), 
5.13 (bs, 1H), 4.37 (bs, 1H), 1.51 (d, J = 7.2 Hz, 3H), 1.45 (s, 9H); this was used in the next step 
without further characterization. The spectral data for 54 was identical to the literature.143 
4.6.2 (S)-7-Bromo-5-(2-fluorophenyl)-3-methyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one 
(55) 
Benzophenone 54 (40 g., 86 mmol) was dissolved in dry CH2Cl2 (400 mL) and cooled to -10 
oC. 
Anhydrous HCl (g) was slowly added until the solution was saturated, about 20 min, and the 
solution was allowed to stir overnight at rt. The reaction mixture was then washed with a sat’d aq 
solution of NaHCO3 (2 x 100 mL) and water (2 x 100 mL). The organic layer was concentrated 
under reduced pressure and the oil which resulted was dissolved in methanol-water (1:1, 400 mL) 
with the pH adjusted to 8.5 using a solution of 1 M aq NaOH. The reaction mixture was allowed 
stir at rt overnight. The solution was concentrated under reduced pressure and water (100 mL) was 
added. The solution was extracted with CH2Cl2 and the organic layer was washed with brine, dried 
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(Na2SO4), and concentrated under reduced pressure. The solid which resulted was purified by 
recrystallization from methanol/water to provide benzodiazepine 55 as a white solid (22.4 g., 
75%): 1H NMR (300 MHz, CDCl3)  9.50 (bs, 1 H), 7.62 - 7.65 (m, 2 H), 7.50 (q, J= 6.5 Hz, 1 
H), 7.40 (d, J=2.0 Hz, 1 H), 7.29 (t, J=7.5 Hz 1 H) 7.15 (d, J=8.6 Hz, 1 H), 7.11 (t, J=8.9 Hz, 1 
H), 3.84 (q, J= 6.5 Hz, 1 H), 1.82 (d, J=6.5 Hz, 3 H); 13C NMR (75 MHz, CDCl3)  171.87, 
162.14, 158.79, 136.68, 135.00, 132.21, 131.72, 129.73, 124.46, 124.41, 123.03, 116.53, 116.45, 
116.17, 58.69, 16.66; HPLC-MS (ESI) m/z (M+H) 347.01; [α] 26D = +168.8 (c 0.73, EtOAc). The 
spectral data for 55 were identical to the literature.143 
4.6.3 Ethyl (S)-8-bromo-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxylate (56) 
Amide 55 (20 g., 58 mmol) was dissolved in dry THF (800 mL) and cooled to -35 oC. K-t-BuO 
(8.4 g., 75 mmol) was then added in one portion and the solution was allowed to warm to rt where 
the temperature was held for 30 min. The reaction was then cooled to -50 oC and diethyl 
chlorophosphate (14.1 g., 81 mmol) was added. The solution was allowed to warm to rt and the 
temperature was held there for 1 hour. The reaction was then cooled to -78 oC and ethyl 
isocyanoacetate (8.5 g., 75 mmol) was added, followed by a second portion of K-t-BuO (8.4 g., 75 
mmol). The reaction was allowed to warm to rt and stirred overnight. The reaction was quenched 
by addition of a cold sat’d aq solution of NaHCO3 (1 L) and extracted with EtOAc. The organic 
layers were combined and washed with brine (2 x 150 mL), dried (Na2SO4) and the solvent was 
removed under reduced pressure to afford a brown solid. The solid was washed with Et2O/EtOAc 
(9:1) to remove some of the impurities and the remaining solid was purified by column 
chromatography (silica gel, EtOAc/hexanes 2:1) to afford pure imidazobenzodiazepine 56 as an 
off-white solid (19.9 g., 78%): 1H NMR (300 MHz, CDCl3)  7.92 (s, 1 H), 7.72 (dd, J= 8.5, 1.5 
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Hz, 1 H), 7.6 (t, J= 6.9 Hz, 1H), 7.48 (d, J=8.5 Hz, 1 H), 7.42-7.49 (m, 2 H), 7.23-7.29 (m,  1 H), 
7.05 (t, J= 9.3 Hz, 1H), 6.71 (q, J=7.3Hz, 1 H), 4.41 (m, 2H), 1.42 (t, J=7.1 Hz, 3H), 1.29 (d, 
J=7.2, 3H); 13C NMR (75 MHz, CDCl3)  163.38, 162.36, 158.44, 141.18, 135.35, 135.09, 133.52, 
133.26, 132.54, 131.32, 130.70, 128.91, 124.63, 124.00, 121.30, 116.45, 116.17, 61.03, 49.80, 
14.88, 14.38; HPLC-MS (ESI) m/z (M+H) 441.05; [α] 26D = +10.6 (c 0.53, EtOAc). The spectral 
data for 56 were identical to the literature.143 
4.6.4 Ethyl (S)-6-(2-fluorophenyl)-4-methyl-8-((trimethylsilyl)ethynyl)-4H-
benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate (57) 
Imidazobenzodiazepine 56 (15 g., 34 mmol) was dissolved in triethylamine (500 mL) and 
acetonitrile (600 mL). Trimethylsilylacetylene (5.0 g., 51 mmol) and bis(triphenylphosphine)-
palladium (II) acetate (1.40 g., 1.9 mmol) were added. A reflux condenser was attached and the 
mixture was degassed under vacuum with argon; this process was repeated four times. The reaction 
mixture was heated to reflux under argon and stirred for 8 hours. The solution was cooled to rt, 
filtered through celite, and the celite was washed with EtOAc. The filtrate was concentrated under 
reduced pressure. The black residue which resulted was purified by a wash column (silica gel, 
EtOAc/hexanes 2:1) to afford the TMS-analog 57 as an off-white solid (14.2 g., 91%): 1H NMR 
(300 MHz, CDCl3)  8.00 (s, 1H), 7.74 – 7.60 (m, 2H), 7.57 (d, J = 8.3 Hz, 1H), 7.47 (dd, J = 12.7, 
6.5 Hz, 1H), 7.37 (s, 1H), 7.27 (dd, J = 9.2, 5.6 Hz, 1H), 7.06 (t, J = 9.2 Hz, 1H), 6.70 (q, J = 7.1 
Hz, 1H), 4.49 – 4.31 (m, 2H), 1.41 (t, J = 7.1 Hz, 3H), 1.27 (d, J = 7.3 Hz, 3H), 0.23 (s, 9H); 13C 
NMR (75 MHz, CDCl3)  164.13, 162.69, 158.49, 141.32, 135.62, 134.96, 134.11, 133.67, 132.42, 
131.35, 129.41, 129.08, 124.51, 122.89, 122.29, 116.44, 116.17, 102.30, 97.62, 60.87, 49.82, 
14.81, 14.40, -0.48; HPLC-MS (ESI) m/z (M+H) 459.18; [α] 26D = -27.8 (c 0.46, EtOAc). The 
spectral data for 57 were identical to the literature.143 
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4.6.5 Ethyl (S)-8-ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxylate (SH-053-2'F-S-CH3, 51) 
The intermediate 57 (10 g, 21.8 mmol) was dissolved in THF (400 mL) and cooled to -78 oC. This 
was treated with tetrabutylammonium fluoride hydrate (1 M solution in THF, 25 mmol), followed 
by water (10 mL). The reaction mixture was stirred until the starting material was consumed as 
indicated by TLC (silica gel), about 30 min. The reaction mixture was allowed to warm to -20 oC, 
and water (200 mL) was slowly added. The solution was extracted with EtOAc and the organic 
extracts were combined, washed with brine, dried (Na2SO4), and the solvent was removed under 
reduced pressure. The residue which resulted was purified by a wash column (silica gel, 
EtOAc/hexanes 4:1) to afford pure 51 as a white powder (8.0 g., 95%): 1H NMR (300 MHz, 
CDCl3)  8.03 (s, 1H), 7.72 (d, J = 8.0 Hz, 1H), 7.62 (t, J = 7.9 Hz, 2H), 7.45 (dd, J = 15.0, 8.1 
Hz, 2H), 7.32 – 7.20 (m, 1H), 7.04 (t, J = 9.3 Hz, 1H), 6.70 (q, J = 7.1 Hz, 1H), 4.47 – 4.33 (m, 
2H), 3.16 (s, 1H), 1.40 (t, J = 7.1 Hz, 3H), 1.29 (d, J = 7.3 Hz, 3H).); 13C NMR (75 MHz, CDCl3) 
 163.94, 162.65, 158.43, 141.30, 135.60, 135.02, 134.48, 134.18, 132.34, 131.32, 129.39, 129.15, 
124.54, 122.42, 121.84, 116.40, 116.11, 81.27, 79.94, 60.90, 49.84, 14.91, 14.40.;  HRMS (ESI 
m/z) for C23H19FN3O2 calc’d 388.1456, found 388.1456 (M+H)+; [α] 26D = -21.5 (c 0.89, EtOAc). 
The spectral data for (S)-51 were in excellent agreement with the literature.143 
4.6.6 Tert-butyl (R)-(1-((4-bromo-2-(2-fluorobenzoyl)phenyl)amino)-1-oxopropan-2-
yl)carbamate (58) 
The amide 58 was synthesized as described in 4.6.1, by replacing Boc-L-alanine with Boc-D-
alanine to afford 58 in 87% yield: 1H NMR (300 MHz, CDCl3) δ 11.68 (s, 1H), 8.71 (d, J = 9.0 
Hz, 1H), 7.69 (dd, J = 9.0, 2.3 Hz, 1H), 7.55-7.62 (m, 2H), 7.46 (td, J = 7.6, 1.4 Hz, 1H), 7.30 (t, 
J = 7.5 Hz, 1H), 7.21 (t, J = 9.1 Hz, 1H), 5.13 (bs, 1H), 4.37 (bs, 1H), 1.51 (d, J = 7.2 Hz, 3H), 
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1.45 (s, 9H); this was used in the next step without further characterization. The spectral data for 
55 were identical to the literature.143 
4.6.7 (R)-7-Bromo-5-(2-fluorophenyl)-3-methyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-
one (59) 
The 1,4-benzodiazepine 59 was synthesized as described in 4.7.2, by using amide 58 as the starting 
material to afford 59 in 75% yield: 1H NMR (300 MHz, CDCl3)  9.50 (bs, 1 H), 7.62 - 7.65 (m, 
2 H), 7.50 (q, J= 6.5 Hz, 1 H), 7.40 (d, J=2.0 Hz, 1 H), 7.29 (t, J=7.5 Hz 1 H) 7.15 (d, J=8.6 Hz, 
1 H), 7.11 (t, J=8.9 Hz, 1 H), 3.84 (q, J= 6.5 Hz, 1 H), 1.82 (d, J=6.5 Hz, 3 H); 13C NMR (75 
MHz, CDCl3)  171.87, 162.14, 158.79, 136.68, 135.00, 132.21, 131.72, 129.73, 124.46, 124.41, 
123.03, 116.53, 116.45, 116.17, 58.69, 16.66; HPLC-MS (ESI) m/z (M+H) 347.01; [α] 26D = -
169.1 (c 0.71, EtOAc). The spectral data for 59 were identical to the literature.143 
4.6.8 Ethyl (R)-8-bromo-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxylate (60) 
The imidazobenzodiazepine 60 was synthesized as described in 4.6.3, by using 1,4-benzodiazepine 
59 as the starting material to afford 60 in 78% yield: 1H NMR (300 MHz, CDCl3)  7.92 (s, 1 H), 
7.72 (dd, J= 8.5, 1.5 Hz, 1 H), 7.6 (t, J= 6.9 Hz, 1H), 7.48 (d, J=8.5 Hz, 1 H), 7.42-7.49 (m, 2 H), 
7.23-7.29 (m,  1 H), 7.05 (t, J= 9.3 Hz, 1H), 6.71 (q, J=7.3Hz, 1 H), 4.41 (m, 2H), 1.42 (t, J=7.1 
Hz, 3H), 1.29 (d, J=7.2, 3H); 13C NMR (75 MHz, CDCl3)  163.38, 162.36, 158.44, 141.18, 
135.35, 135.09, 133.52, 133.26, 132.54, 131.32, 130.70, 128.91, 124.63, 124.00, 121.30, 116.45, 
116.17, 61.03, 49.80, 14.88, 14.38; HPLC-MS (ESI) m/z (M+H) 441.05; [α] 26D = -10.9 (c 0.53, 
EtOAc). The spectral data for 60 were identical to the literature.143 
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4.6.9 Ethyl (R)-6-(2-fluorophenyl)-4-methyl-8-((trimethylsilyl)ethynyl)-4H-
benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate (61) 
The TMS-protected acetylene 61 was synthesized as described in 4.6.4, by using 
imidazobenzodiazepine 60 as the starting material to afford 61 in 91% yield: 1H NMR (300 MHz, 
CDCl3)  8.00 (s, 1H), 7.74 – 7.60 (m, 2H), 7.57 (d, J = 8.3 Hz, 1H), 7.47 (dd, J = 12.7, 6.5 Hz, 
1H), 7.37 (s, 1H), 7.27 (dd, J = 9.2, 5.6 Hz, 1H), 7.06 (t, J = 9.2 Hz, 1H), 6.70 (q, J = 7.1 Hz, 1H), 
4.49 – 4.31 (m, 2H), 1.41 (t, J = 7.1 Hz, 3H), 1.27 (d, J = 7.3 Hz, 3H), 0.23 (s, 9H); 13C NMR (75 
MHz, CDCl3)  164.13, 162.69, 158.49, 141.32, 135.62, 134.96, 134.11, 133.67, 132.42, 131.35, 
129.41, 129.08, 124.51, 122.89, 122.29, 116.44, 116.17, 102.30, 97.62, 60.87, 49.82, 14.81, 14.40, 
-0.48; HPLC-MS (ESI) m/z (M+H) 459.18; [α] 26D = +28.2 (c 0.48, EtOAc). The spectral data for 
61 were identical to the literature.143 
4.6.10 Ethyl (R)-8-ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxylate (SH-053-2'F-R-CH3, 52) 
The ethyl ester SH-053-2'F-R-CH3 52 was synthesized as described in 4.6.5, by using the 
benzodiazepine 61 as the starting material to afford 52 in 95% yield: 1H NMR (300 MHz, CDCl3) 
 8.03 (s, 1H), 7.72 (d, J = 8.0 Hz, 1H), 7.62 (t, J = 7.9 Hz, 2H), 7.45 (dd, J = 15.0, 8.1 Hz, 2H), 
7.32 – 7.20 (m, 1H), 7.04 (t, J = 9.3 Hz, 1H), 6.70 (q, J = 7.1 Hz, 1H), 4.47 – 4.33 (m, 2H), 3.16 
(s, 1H), 1.40 (t, J = 7.1 Hz, 3H), 1.29 (d, J = 7.3 Hz, 3H).); 13C NMR (75 MHz, CDCl3)  163.94, 
162.65, 158.43, 141.30, 135.60, 135.02, 134.48, 134.18, 132.34, 131.32, 129.39, 129.15, 124.54, 
122.42, 121.84, 116.40, 116.11, 81.27, 79.94, 60.90, 49.84, 14.91, 14.40.;  HRMS (ESI m/z) for 
C23H19FN3O2 calc’d 388.1456, found 388.1456 (M+H)+; [α] 26D = +20.9 (c 0.89, EtOAc). The 
spectral data for (R)-52 were in excellent agreement with the literature.143 
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4.6.11 (S)-Methyl 8-ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxylate (MP-III-021, 62)   
Ethyl ester SH-053-2'F-S-CH3 51 (150 mg, 0.387 mmol) was dissolved in methanol (20 mL). 
Sodium methoxide (84 mg, 1.55 mmol) was added in one portion and the solution was heated to 
reflux. The reaction mixture was monitored by analysis by TLC (silica gel, 4:1 EtOAc:hexanes) 
until the starting material had been consumed; approximately 30 min. The reaction solution was 
cooled to rt and then quenched with a saturated aq solution of sodium bicarbonate (4 mL). Water 
(10 mL) was then added to the solution and the methanol was removed under reduced pressure. 
The product was then extracted with EtOAc (3 x 40 mL), and the organic layers were combined, 
washed with brine, as well as dried (Na2SO4). The solution was then concentrated under reduced 
pressure. The solid which resulted was purified via a wash column (silica gel, 4:1 EtOAc:hexanes) 
which provided pure methyl ester 62 as an off-white solid (117 mg, 80.8% yield): 1H NMR (300 
MHz, CDCl3) δ 7.96 (s, 1H), 7.71 (d, 1H, J = 8.3 Hz), 7.59 (t, 2H, J = 9.5 Hz), 7.49-7.40 (m, 2H), 
7.29-7.21 (m, 1H), 7.04 (t, 1H, J = 9.3 Hz), 6.69 (q, 1H, 7.2 Hz), 3.92 (s, 3H), 3.16 (s, 1H), 1.29 
(d, 3H, J = 7.1 Hz); 13C NMR (75 MHz, CDCl3) δ 163.17, 161.77, 158.45, 141.47, 135.49, 135.01, 
134.46, 134.13, 132.30, 131.30, 129.21, 124.58, 124.54, 122.33, 121.83, 116.40, 116.11, 81.31, 
79.90, 51.93, 49.88, 14.92; HRMS (LCMS-IT-TOF) Calc. for C22H17FN3O2 (M + H)
+ 374.1299, 
found 374.1307. 
4.6.12 (R)-Methyl 8-ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxylate (MP-III-004, 63) 
Ethyl ester SH-053-2'F-R-CH3 52 (4.0 g, 10.32 mmol) was dissolved in methanol (250 mL). 
Sodium methoxide (2.23 g, 41.3 mmol) was added in one portion and the solution was heated to 
reflux. The reaction mixture was monitored by analysis by TLC (silica gel, 4:1 EtOAc:hexanes) 
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until the starting material had been consumed; approximately 30 min. The reaction solution was 
cooled to rt and then quenched with a saturated aq solution of sodium bicarbonate (40 mL). Water 
(100 mL) was then added to the solution and the methanol was removed under reduced pressure. 
The product was then extracted with EtOAc (3 x 100 mL), and the organic layers were combined, 
washed with brine, as well as dried (Na2SO4). The solution was then concentrated under reduced 
pressure. The solid which resulted was purified via a wash column (silica gel, 4:1 EtOAc:hexanes) 
which provided pure methyl ester 63 as an off-white solid (3.66 g, 95% yield): 1H NMR (300 
MHz, CDCl3) δ 7.96 (s, 1H), 7.71 (d, 1H, J = 8.3 Hz), 7.59 (t, 2H, J = 9.5 Hz), 7.49-7.40 (m, 2H), 
7.29-7.21 (m, 1H), 7.04 (t, 1H, J = 9.3 Hz), 6.69 (q, 1H, 7.2 Hz), 3.92 (s, 3H), 3.16 (s, 1H), 1.29 
(d, 3H, J = 7.1 Hz); 13C NMR (75 MHz, CDCl3) δ 163.17, 161.77, 158.45, 141.47, 135.49, 135.01, 
134.46, 134.13, 132.30, 131.30, 129.21, 124.58, 124.54, 122.33, 121.83, 116.40, 116.11, 81.31, 
79.90, 51.93, 49.88, 14.92; HRMS (LCMS-IT-TOF) Calc. for C22H17FN3O2 (M + H)
+ 374.1299, 
found 374.1307. 
4.6.13 (S)-8-Ethynyl-6-(2-fluorophenyl)-N,4-dimethyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxamide (MP-III-023, 64) 
Ethyl ester SH-053-2'F-S-CH3 51 (200 mg, 0.516 mmol) was added to a sealed vessel fitted with 
a septum at 0 oC and treated with methyl amine (10 mL; 33% wt solution in EtOH). The vessel 
was sealed with a screw-cap and stirred at 60 oC for 18 h. The solution was then cooled to rt and 
the methyl amine and ethanol were removed under reduced pressure. The residue which resulted 
was purified by a wash column (silica gel, 4:1 EtOAc:hexanes) to afford pure amide 64 as a white 
powder (131 mg, 68.2%): 1H NMR (300 MHz, CDCl3) δ 7.88 (s, 1H), 7.67 (dd, J = 16.3, 7.8 Hz, 
2H), 7.55 (d, J = 8.3 Hz, 1H), 7.50 – 7.41 (m, 2H), 7.29 – 7.18 (m, 2H), 7.04 (t, J = 9.3 Hz, 1H), 
6.93 (q, J = 7.4 Hz, 1H), 3.16 (s, 1H), 2.97 (d, J = 5.0 Hz, 3H), 1.29 (d, J = 6.4 Hz, 3H); 13C NMR 
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(75 MHz, CDCl3) δ 162.24, 161.81, 158.48, 138.25, 137.12, 135.73, 134.41, 133.57, 132.53, 
131.57, 129.03, 125.15, 124.92, 124.58, 122.50, 116.33, 116.05, 81.25, 79.99, 49.42, 25.73, 25.27; 
HRMS (LCMS-IT-TOF) Calc. for C22H18FN4O (M + H)
+ 373.1459, found: 373.1462. 
4.6.14 (R)-8-Ethynyl-6-(2-fluorophenyl)-N,4-dimethyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxamide (MP-III-022, 65) 
Ethyl ester SH-053-2'F-R-CH3 52 (1.0 g, 2.58 mmol) was added to a sealed vessel fitted with a 
septum at 0 oC and treated with methyl amine (15 mL; 33% wt solution in EtOH). The vessel was 
sealed with a screw-cap and stirred at 60 oC for 18 h. The solution was then cooled to rt and the 
methyl amine and ethanol were removed under reduced pressure. The residue which resulted was 
purified by a wash column (silica gel, 4:1 EtOAc:hexanes) to afford pure amide 65 as a white 
powder (731 mg, 1.96 mmol, 76%): 1H NMR (300 MHz, CDCl3) δ 7.88 (s, 1H), 7.67 (dd, J = 
16.3, 7.8 Hz, 2H), 7.55 (d, J = 8.3 Hz, 1H), 7.50 – 7.41 (m, 2H), 7.29 – 7.18 (m, 2H), 7.04 (t, J = 
9.3 Hz, 1H), 6.93 (q, J = 7.4 Hz, 1H), 3.16 (s, 1H), 2.97 (d, J = 5.0 Hz, 3H), 1.29 (d, J = 6.4 Hz, 
3H); 13C NMR (75 MHz, CDCl3) δ 162.24, 161.81, 158.48, 138.25, 137.12, 135.73, 134.41, 
133.57, 132.53, 131.57, 129.03, 125.15, 124.92, 124.58, 122.50, 116.33, 116.05, 81.25, 79.99, 
49.42, 25.73, 25.27; HRMS (LCMS-IT-TOF) Calc. for C22H18FN4O (M + H)
+ 373.1459, found: 
373.1462. 
4.6.15 (S)-8-Ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-
3-carbonitrile (MP-III-018.A, 66) 
Ethyl ester SH-053-2'F-S-CH3 51 (500 mg, 1.40 mmol) was stirred in dry xylene (35 mL) at rt; 
while an oil bath was heated to 80 oC. Using a glass syringe and metal needle, dimethylaluminum 
amine (0.67 M, 12.5 mL, 8.42 mmol) was carefully added to the starting material. Caution: Do 
not breathe this amine or get it on you! The reaction was then heated to 80 oC in the oil bath and 
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the solution was monitored by analysis by TLC (silica gel) until the starting material had been 
consumed, about 2 h. Once the reaction was complete, the mixture was cooled to rt, and quenched 
with cold water (15 mL). The product was extracted with EtOAc (5 x 50 mL) and the organic 
layers were combined, washed with brine, dried (Na2SO4), and the solvent was removed under 
reduced pressure. The solid which resulted was purified by flash chromatography (Gradient 
elution; step 1: remove excess xylene with 1:4 EtOAc:hexanes as the eluent; step 2: collect the 
nitrile product with 1:1 EtOAc:hexanes; step 3: collect the amide product, 4:1 EtAOc:hexanes) 
which afforded the nitrile 66 as a white solid (331 mg, 75.4%) and the amide 67 (78.5 mg, 17.0%). 
The spectral data for nitrile 66: 1H NMR (300 MHz, CDCl3) δ 7.98 (s, 1H), 7.78 (d, J = 7.1 Hz, 
1H), 7.67 (s, 1H), 7.62 – 7.53 (m, 1H), 7.49 (s, 2H), 7.28 (s, 1H), 7.04 (t, J = 8.7 Hz, 1H), 4.36 (d, 
J = 4.8 Hz, 1H), 3.20 (s, 1H), 2.18 (d, J = 4.6 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 163.64, 
158.60, 143.66, 135.69, 133.97, 133.35, 132.89, 132.78, 131.37, 129.22, 124.73, 122.88, 122.64, 
116.50, 116.22, 114.54, 110.74, 81.13, 80.33, 51.68, 18.09; HRMS (LCMS-IT-TOF) Calc. for 
C21H14FN4 (M + H)
+ 341.1137, found 341.1142. 
Preparation of 0.67 M dimethylaluminum amine solution, CAUTION: Do not breathe this or get 
it on you! 
You begin by stirring 20 mL of methylene chloride (dry) at 0 oC. You then bubble NH3 (g) through 
the CH2Cl2 until the solution is saturated, about 10-15 min. Then, 10 mL trimethylaluminum (2.0 
M in toluene) was added while avoiding contact with air (use glass/metal syringe and needle). The 
solution was stirred at rt for 5 minutes and transferred directly for use in the reaction above using 
a glass syringe and metal needle. DO NOT BREATHE OR GET ON YOU! 
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4.6.16 (S)-8-Ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-
3-carboxamide (MP-III-018.B, 67) 
The carboxamide 67 was synthesized as a product in the experimental in Section 4.6.15 as a white 
solid in 17% yield. The spectral data for carboxamide 67: 1H NMR (300 MHz, DMSO-d6) δ 8.41 
(s, 1H), 7.94 (d, J = 8.4 Hz, 1H), 7.81 (d, J = 8.2 Hz, 1H), 7.57 (dd, J = 15.7, 7.9 Hz, 3H), 7.33 (t, 
J = 7.3 Hz, 2H), 7.22 (t, J = 9.4 Hz, 2H), 6.66 (d, J = 7.0 Hz, 1H), 4.36 (s, 1H), 1.15 (d, J = 6.8 
Hz, 3H); 13C NMR (75 MHz, . DMSO-d6) δ 164.99, 162.68, 161.44, 158.17, 138.36, 135.45, 
134.82, 133.20, 132.58, 131.84, 131.36, 129.31, 125.12, 123.86, 120.97, 116.50, 116.22, 83.35, 
82.03, 49.45, 25.24; HRMS (LCMS-IT-TOF) Calc. for C21H16FN4O (M + H)
+ 359.1227, found 
359.1231. 
4.6.17 (R)-8-Ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-
3-carbonitrile (MP-III-019.A, 68) 
The nitrile 68 was synthesized by the experimental procedure as described in 4.6.15 using SH-
053-2'F-R-CH3 52 (500 mg, 1.40 mmol) as the starting material. The products which resulted were 
the nitrile 68 (193 mg, 41.6%) and the carboxamide 69 (204 mg, 46.5%). The spectral data for the 
nitrile 68: 1H NMR (300 MHz, CDCl3) δ 7.98 (s, 1H), 7.78 (d, J = 7.1 Hz, 1H), 7.67 (s, 1H), 7.62 
– 7.53 (m, 1H), 7.49 (s, 2H), 7.28 (s, 1H), 7.04 (t, J = 8.7 Hz, 1H), 4.36 (d, J = 4.8 Hz, 1H), 3.20 
(s, 1H), 2.18 (d, J = 4.6 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 163.64, 158.60, 143.66, 135.69, 
133.97, 133.35, 132.89, 132.78, 131.37, 129.22, 124.73, 122.88, 122.64, 116.50, 116.22, 114.54, 
110.74, 81.13, 80.33, 51.68, 18.09; HRMS (LCMS-IT-TOF) Calc. for C21H14FN4 (M + H)
+ 
341.1137, found 341.1142. 
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4.6.18 (R)-8-Ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-
3-carboxamide (MP-III-019.B, 69) 
The carboxamide 69 was synthesized as a product in the experimental in Section 4.6.17 as a white 
solid in 46.5% yield. The spectral data for carboxamide 69: 1H NMR (300 MHz, DMSO-d6) δ 
8.41 (s, 1H), 7.94 (d, J = 8.4 Hz, 1H), 7.81 (d, J = 8.2 Hz, 1H), 7.57 (dd, J = 15.7, 7.9 Hz, 3H), 
7.33 (t, J = 7.3 Hz, 2H), 7.22 (t, J = 9.4 Hz, 2H), 6.66 (d, J = 7.0 Hz, 1H), 4.36 (s, 1H), 1.15 (d, J 
= 6.8 Hz, 3H); 13C NMR (75 MHz, DMSO-d6) δ 164.99, 162.68, 161.44, 158.17, 138.36, 135.45, 
134.82, 133.20, 132.58, 131.84, 131.36, 129.31, 125.12, 123.86, 120.97, 116.50, 116.22, 83.35, 
82.03, 49.45, 25.24; HRMS (LCMS-IT-TOF) Calc. for C21H16FN4O (M + H)
+ 359.1227, found 
359.1231. 
4.6.19 (R)-Isopropyl 8-ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxylate (MP-III-050, 70) 
Ethyl ester SH-053-2'F-R-CH3 52 (196 mg, 0.506 mmol) was stirred in dry THF (20 mL) in an 
oven-dried flask under an argon atmosphere at 40 oC; meanwhile, anhydrous isopropanol (4 mL) 
was stirred in a separate oven-dried flask under argon at 40 oC. Small pieces of freshly cut Li rod 
(~50 mg) were quickly added to the dry isopropanol and the suspension was stirred for 10 min 
under argon. The ethyl ester solution was then added to isopropanol and the mixture monitored by 
analysis of TLC (silica gel) until most of the starting material had been consumed (TLC, silica 
gel), about 30 min. The reaction solution was then quenched with sodium bicarbonate (sat’d aq 
solution, 5 mL) and the product was extracted with EtOAc (3 x 100 mL). The organic layers were 
combined, washed with brine, dried (Na2SO4), and the solvent was removed under reduced 
pressure. The solid which resulted was purified by flash chromatography (3:2 EtOAc:hexanes) to 
afford pure iso-propyl ester 70 as a white solid (197 mg, 97.0%): 1H NMR (300 MHz, CDCl3) δ 
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7.95 (s, 1H), 7.71 (d, J = 8.1 Hz, 1H), 7.59 (dd, J = 19.4, 7.8 Hz, 2H), 7.46 (dd, J = 14.7, 7.3 Hz, 
2H), 7.25 (d, J = 7.5 Hz, 1H), 7.05 (t, J = 9.2 Hz, 1H), 6.71 (q, J = 6.9 Hz, 1H), 5.30 (dt, J = 12.4, 
6.2 Hz, 1H), 3.16 (s, 1H), 1.41 (dd, J = 9.8, 6.4 Hz, 6H), 1.29 (d, J = 7.0 Hz, 3H); 13C NMR (75 
MHz, CDCl3) δ 163.98, 162.21, 158.44, 141.23, 135.64, 134.98, 134.53, 134.18, 132.38, 131.33, 
129.67, 129.12, 124.55, 122.47, 121.85, 116.41, 116.13, 81.28, 79.94, 68.48, 49.87, 21.94, 14.91.; 
HRMS (LCMS-IT-TOF) Calc. for C24H21FN3O2 (M + H)
+ 402.1551, found 402.1545. 
4.6.20 (R)-Tert-butyl 8-ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxylate (MP-III-051, 71) 
Ethyl ester SH-053-2'F-R-CH3 52 (207 mg, 0.535 mmol) was stirred in dry THF (20 mL) in an 
oven-dried flask under argon at 40 oC; meanwhile, anhydrous tert-butanol (3 mL) was stirred in a 
separate oven-dried flask under an argon atmosphere at 40 oC. Small pieces of freshly cut Li rod 
(~50 mg) were quickly added to tert-butanol and the suspension was stirred for 10 min under 
argon. The ethyl ester solution was then added to tert-butanol and monitored by TLC (silica gel) 
until most of the starting material was consumed, about 30 min. The reaction mixture was then 
quenched with sodium bicarbonate (sat’d aq solution, 5 mL) and the product was extracted with 
EtOAc (3 x 100 mL). The organic layers were combined, washed with brine, dried (Na2SO4) and 
the solvent was removed under reduced pressure. The solid which resulted was purified by flash 
chromatography (3:2 EtOAc:hexanes) to afford pure t-butyl ester 71 as a white solid (118 mg, 
53.1%). 1H NMR (300 MHz, CDCl3) δ 7.96 (s, 1H), 7.71 (d, J = 8.4 Hz, 1H), 7.62 (t, J = 7.4 Hz, 
1H), 7.56 (d, J = 8.3 Hz, 1H), 7.46 (dd, J = 16.9, 9.5 Hz, 2H), 7.26 (d, J = 7.7 Hz, 1H), 7.10 – 7.00 
(m, 1H), 6.73 – 6.63 (m, 1H), 3.16 (s, 1H), 1.63 (s, 9H), 1.29 (d, J = 7.2 Hz, 3H); 13C NMR (300 
MHz, CDCl3) δ 161.80, 159.91, 158.44, 139.60, 137.25, 135.40, 134.99, 134.10, 131.98, 131.82, 
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124.92, 124.82, 123.49, 122.93, 116.72, 116.44, 100.15, 83.36, 80.85, 80.12, 48.96, 28.27, 14.95; 
HRMS (LCMS-IT-TOF) Calc. for C25H23FN3O2 (M + H)
+ 416.1705, found 416.1711. 
4.6.21 (R)-Cyclopropylmethyl 8-ethynyl-6-(2-fluorophenyl)-4-methyl-4H-
benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate (MP-III-052, 72) 
Ethyl ester SH-053-2'F-R-CH3 52 (206 mg, 0.534 mmol) was stirred in dry THF (20 mL) in an 
oven-dried flask under argon at 40 oC; meanwhile, anhydrous cyclopropylmethyl alcohol (4 mL) 
was stirred in a separate oven-dried flask under an argon atmosphere at 40 oC. Small pieces of 
freshly cut Li rod (~50 mg) were quickly added to cyclopropylmethyl alcohol and the suspension 
was stirred for 10 min under argon. The ethyl ester solution was then added to cyclopropylmethyl 
alcohol and monitored by analysis by TLC (silica gel) until most of the starting material had been 
consumed (TLC, silica gel), about 30 min. The reaction was then quenched with sodium 
bicarbonate (sat’d aq solution, 5 mL) and the product was extracted with EtOAc (3 x 100 mL). 
The organic layers were combined, washed with brine, dried (Na2SO4), and the solvent was 
removed under reduced pressure. The solid which resulted was purified by flash chromatography 
(3:2 EtOAc:hexanes) to afford pure cyclopropyl methyl ester 72 as a white solid (213 mg, 96.2%): 
1H NMR (300 MHz, CDCl3) δ 7.98 (s, 1H), 7.73 (d, J = 8.4 Hz, 1H), 7.63 (t, J = 7.7 Hz, 1H), 7.58 
(d, J = 8.3 Hz, 1H), 7.53 – 7.40 (m, 2H), 7.32 – 7.24 (m, 1H), 7.06 (t, J = 9.2 Hz, 1H), 6.78 – 6.69 
(m, 1H), 4.28 – 4.10 (m, 3H), 3.17 (s, 1H), 1.30 (d, J = 7.4 Hz, 3H), 0.62 (q, J = 5.2 Hz, 2H), 0.38 
(q, J = 4.9 Hz, 2H); 13C NMR (75 MHz, CDCl3) δ 162.81, 161.77, 158.45, 141.40, 135.57, 135.05, 
134.50, 134.14, 132.31, 131.31, 129.44, 129.21, 124.53, 122.41, 121.83, 116.40, 116.11, 81.30, 
79.92, 69.75, 49.90, 14.91, 10.01.; HRMS (LCMS-IT-TOF) Calc. for C25H21FN3O2 (M + H)
+ 
414.1534, found 414.1538. 
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4.6.22 (R)-8-ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-
3-carboxylic acid (SH-053-2'F-R-CH3-Acid, 73) 
Ethyl ester SH-053-2'F-R-CH3 52 (2.0 g, 5.16 mmol) was stirred in ethanol (100 mL) and 3 M 
sodium hydroxide (20 mL, 60 mmol) was added and the solution was heated and refluxed for 1 h. 
The reaction solution was then cooled to rt and diluted with water (100 mL). The solution was 
placed under reduced pressure until half of the solvent remained. The remaining reaction mixture 
was stirred at rt and hydrochloric acid (1 M) was added dropwise at rt until the product precipitated 
out. The product was filtered, rinsed with water and dried to afford pure acid 73 as a white solid: 
1H NMR (300 MHz, DMSO-d6) δ 8.42 (s, 1H), 7.94 (d, 1H, J = 8.4 Hz), 7.82 (d, 1H, J = 8.2 Hz), 
7.56 (dt, 2H, J = 7.8, 6.5 Hz), 7.33 (t, 1H, J = 7.4 Hz), 7.22 (t, 2H, J = 9.3 Hz), 6.53 (d, 1H, J = 
7.1 Hz), 2.51 (s, 1H), 1.16 (d, 3H, J = 6.8 Hz); 13C NMR (75 MHz, DMSO-d6) δ 164.76, 162.81, 
158.19, 140.57, 136.57, 135.54, 134.74, 133.18, 132.65, 131.88, 129.88, 129.35, 125.17, 123.98, 
121.09, 116.53, 116.25, 83.42, 82.01, 49.79, 15.08; HRMS (LCMS-IT-TOF) Calc. for 
C21H15FN3O2 (M + H)
+ 360.1143, found 360.1140. 
4.6.23 (R)-5-(8-ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepin-3-yl)-3-methyl-1,2,4-oxadiazole (MP-IV-004, 74) 
Ethyl ester SH-053-2'F-R-CH3 52 (300 mg, 0.774 mmol) was dissolved in dry THF (30 mL) at rt 
under argon. In a separate flask which contained 3Å molecular sieves, N-hydroxyacetimidamide 
(273 mg, 3.01 mmol) was dissolved in dry THF (30 mL) under argon and treated with sodium 
hydride (60% dispersion in mineral oil, 77 mg, 1.94 mmol). The mixture which resulted was stirred 
for 15 min at which point the solution containing 52 was added. The reaction mixture which 
resulted was stirred at rt for 3 h or until the starting material was consumed as indicated by TLC 
(silica gel). The reaction mixture was quenched with a saturated aq NaHCO3 solution (5 mL). 
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Water (50 mL) was then added and the product was extracted with EtOAc (3 x 100 mL). The 
organic layers were combined, washed with brine, dried (Na2SO4) and the solvent was removed 
under reduced pressure. The solid which resulted was purified by flash chromatography (silica gel, 
EtOAc:hexanes 4:1) to afford pure methyl oxadiazole 74 as a white powder (141 mg, 45.8%): 1H 
NMR (300 MHz, CDCl3) δ 8.13 (s, 1H), 7.79 (dd, J = 8.4, 1.4 Hz, 1H), 7.74 – 7.61 (m, 2H), 7.51 
(dd, J = 13.9, 6.4 Hz, 2H), 7.35 – 7.26 (m, 1H), 7.13 – 7.04 (m, 1H), 6.78 (q, J = 7.1 Hz, 1H), 3.20 
(s, 1H), 2.46 (s, 3H), 1.40 (d, J = 7.3 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 170.30, 167.49, 
161.80, 158.46, 138.42, 136.46, 135.48, 134.78, 134.30, 133.29, 131.63, 128.32, 125.12, 124.67, 
122.53, 122.26, 116.52, 116.24, 80.98, 80.39, 49.58, 15.13, 11.66; HRMS (LCMS-IT-TOF) Calc. 
for C23H17FN5O (M + H)
+ 398.1347, found 398.1350. 
Synthesis of the methyl oxime (N-hydroxyacetimidamide) 
The synthesis of the methyl oxime can be found in Section 3.6.24 
4.6.24 (R)-3-Ethyl-5-(8-ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepin-3-yl)-1,2,4-oxadiazole (MP-IV-005, 75) 
Ethyl ester SH-053-2'F-R-CH3 52 (300 mg, 0.774 mmol) was dissolved in dry THF (30 mL) at rt 
under argon. In a separate flask which contained 3Å molecular sieves, N'-
hydroxypropionimidamide (273 mg, 3.10 mmol) was dissolved in dry THF (20 mL) under argon 
and treated with sodium hydride (60% dispersion in mineral oil, 77 mg, 1.94 mmol). The mixture 
which resulted was stirred for 15 min at which point the solution containing 52 was added. The 
reaction mixture which resulted was stirred at rt for 2 h or until the starting material was consumed 
as indicated by TLC (silica gel). The reaction mixture was quenched with a saturated aq NaHCO3 
solution (5 mL). Water (50 mL) was then added and the product was extracted with EtOAc (3 x 
100 mL). The organic layers were combined, washed with brine, dried (Na2SO4) and the solvent 
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was removed under reduced pressure. The solid which resulted was purified by flash 
chromatography (silica gel, EtOAc:hexanes 4:1) to afford pure ethyl oxadiazole 75 as a white 
powder (232 mg, 72.8%): 1H NMR (300 MHz, CDCl3) δ 8.09 (s, 1H), 7.76 (d, J = 7.8 Hz, 1H), 
7.63 (d, J = 8.2 Hz, 2H), 7.47 (d, J = 11.7 Hz, 2H), 7.33 – 7.24 (m, 1H), 7.06 (t, J = 9.1 Hz, 1H), 
6.76 (dd, J = 14.1, 7.0 Hz, 1H), 3.18 (s, 1H), 2.83 (q, J = 7.5 Hz, 2H), 1.40 (dd, J = 14.7, 7.1 Hz, 
6H); 13C NMR (75 MHz, CDCl3) δ 171.93, 170.51, 161.79, 158.45, 138.81, 136.34, 135.83, 
134.44, 134.29, 132.61, 131.37, 125.16, 124.63, 124.58, 122.33, 122.07, 116.46, 116.18, 81.19, 
80.11, 49.96, 19.76, 15.07, 11.52; HRMS (LCMS-IT-TOF) Calc. for C24H19FN5O (M + H)
+ 
412.1501, found 412.1497. 
Synthesis of the ethyl oxime (N'-hydroxypropionimidamide) 
The synthesis of the ethyl oxime can be found in Section 3.6.25. 
4.6.25 (R)-5-(8-Ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepin-3-yl)-3-isopropyl-1,2,4-oxadiazole (MP-IV-010, 76) 
Ethyl ester SH-053-2'F-R-CH3 52 (300 mg, 0.774 mmol) was dissolved in dry THF (30 mL) at rt 
under argon. In a separate flask which contained 3Å molecular sieves, N'-
hydroxyisobutyrimidamide (316 mg, 3.10 mmol) was dissolved in dry THF (30 mL) under argon 
and treated with sodium hydride (60% dispersion in mineral oil, 77 mg, 1.94 mmol). The mixture 
which resulted was stirred for 15 min at which point the solution containing 52 was added. The 
reaction mixture which resulted was stirred at rt for 2 h or until the starting material was consumed 
as indicated by TLC (silica gel). The reaction mixture was quenched with a saturated aq NaHCO3 
solution (5 mL). Water (50 mL) was then added and the product was extracted with EtOAc (3 x 
100 mL). The organic layers were combined, washed with brine, dried (Na2SO4) and the solvent 
was removed under reduced pressure. The solid which resulted was purified by flash 
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chromatography (silica gel, EtOAc:hexanes 4:1) to afford pure ethyl oxadiazole 34 as a white 
powder (216 mg, 65.7%): 1H NMR (300 MHz, CDCl3) δ 8.09 (s, 1H), 7.75 (d, J = 7.8 Hz, 1H), 
7.63 (d, J = 8.3 Hz, 2H), 7.46 (d, J = 12.1 Hz, 2H), 7.27 (dd, J = 9.4, 5.5 Hz, 1H), 7.06 (t, J = 9.2 
Hz, 1H), 6.74 (q, J = 7.0 Hz, 1H), 3.24 – 3.10 (m, 2H), 1.38 (t, J = 8.3 Hz, 9H); 13C NMR (75 
MHz, CDCl3) δ 175.35, 170.27, 161.77, 158.43, 138.51, 136.39, 135.58, 134.70, 134.32, 133.01, 
131.47, 128.52, 125.31, 124.67, 122.48, 122.19, 116.52, 116.23, 81.04, 80.31, 49.76, 26.76, 20.59, 
20.54, 15.13; HRMS (LCMS-IT-TOF) Calc. for C25H21FN5O (M + H)
+ 426.1663, found 
426.1659. 
Synthesis of the isopropyl oxime (N'-hydroxyisobutyrimidamide) 
The hydroxylamine hydrochloride (9.73 g, 0.14 mol), potassium carbonate (41.5 g, 0.3 mol), 
methanol (400 mL) and water (80 mL) were mixed as well as stirred and the mixture was heated 
to reflux. The isobutyronitrile (9.0 mL, 0.1 mol) was added dropwise and the reaction was stirred 
at reflux overnight.  The next day the reaction mixture was cooled to 0 oC and a precipitate formed. 
The reaction mixture was filtered and the solvent from the filtrate was removed under reduced 
pressure. The solid which resulted was dissolved in EtOAc and washed with water, brine, and 
dried (Na2SO4) and the solvent removed under reduced pressure to afford the ethyl oxime (6.03 g, 
59%) which was used in the synthesis of 76: HPLC-MS (ESI) m/z (M+H) 103.08. This was used 
in the previous step without further characterization. 
4.6.26 (R)-Methyl 8-bromo-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxylate (MP-III-058, 78) 
Ethyl ester 55 (2.0 g, 4.52 mmol) was dissolved in methanol (120 mL). Sodium methoxide (0.98 
g, 18.1 mmol) was added in one portion and the solution was heated to reflux. The reaction mixture 
was monitored by analysis by TLC (silica gel, 4:1 EtOAc:hexanes) until the starting material had 
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been consumed; approximately 30 min. The reaction solution was cooled to rt and then quenched 
with a saturated aq solution of sodium bicarbonate (20 mL). Water (50 mL) was then added to the 
solution and the methanol was removed under reduced pressure. The product was then extracted 
with EtOAc (3 x 100 mL), and the organic layers were combined, washed with brine, as well as 
dried (Na2SO4). The solution was concentrated under reduced pressure. The solid which resulted 
was purified via a wash column (silica gel, 4:1 EtOAc:hexanes) which provided pure methyl ester 
78 as an off-white solid (1.68 g, 87% yield): 1H NMR (300 MHz, CDCl3) δ 7.93 (s, 1H), 7.74 (d, 
1H, J = 8.5 Hz), 7.61 (t, 1H, J = 7.2 Hz), 7.52-7.42 (m, 3H), 7.30-7.23 (m, 1H), 7.11-7.01 (m, 1H), 
6.71 (q, 1H, J = 7.1 Hz), 3.94 (s, 3H), 1.30 (d, 3H, J = 7.4 Hz); 13C NMR (75 MHz, CDCl3) δ 
163.90, 162.64, 158.45, 141.03, 135.70, 135.20, 133.51, 132.99, 131.46, 130.32, 128.68, 127.09, 
124.69, 124.10, 121.46, 116.52, 116.24, 52.08, 49.61, 14.96; HRMS (LCMS-IT-TOF) Calc. for 
C20H16BrFN3O2 (M + H)
+ 428.0404, found 428.0400. 
 
 
  
252 
 
REFERENCES 
 
1. Cromer, B. A.; Morton, C. J.; Parker, M. W. Anxiety over GABAA receptor structure relieved 
by AChBP. Trends Biochem. Sci. 2002, 27, 280 - 287. 
2. Sieghart, W. Structure and pharmacology of g-aminobutyric acidA receptor subtypes. 
Pharmacol. Rev. 1995, 47, 181 - 234. 
3. Sieghart, W.; Ernst, M. Heterogeneity of GABAA receptors: revived interest in the 
development of subtype-selective drugs. Curr. Med. Chem. - Central Nervous System Agents 
2005, 5, 217 - 242. 
4. Bowser, D. N.; Wagner, D. A.; Czajkowski, C.; Cromer, B. A.; Parker, M. W.; Wallace, R. 
H.; Harkin, L. A.; Mulley, J. C.; Marini, C.; Berkovic, S. F.; Williams, D. A.; Jones, M. V.; 
Petrou, S. Altered kinetics and benzodiazepine sensitivity of a GABA(A) receptor subunit 
mutation [g2(R43Q)] found in human epilepsy. Proc. Natl. Acad. Sci. 2002, 99, 15170 - 
15175. 
5. Bateson, A. N. The benzodiazepine site of the GABA(A) receptor: An old target with new 
potential? Sleep Medicine 2004, 5, S9 - S15. 
6. Luscher, B. P.; Shen, Q.; Sahir, N. The GABAergic deficit hypothesis of major depressive 
disorder. Mol. Psychiatry 2011, 16, 383 - 406. 
7. Otani, K.; Ujike, H.; Tanaka, Y.; Morita, Y.; Katsu, T.; Nomura, A.; Uchida, N.; Hamamura, 
T.; Fujiwara, Y.; Kuroda, S. The GABA type A receptor alpha 5 subunit gene is associated 
with bipolar I disorder. Neuroscience Letters 2005, 381, 108 - 113. 
8. Dean, B.; Scarr, E.; McLeod, M. Changes in hippocampal GABA(A) receptor subunit 
composition in bipolar I disorder. Brain Res. Mol. Brain Res. 2005, 138, 145 - 155. 
253 
 
9. Guidotti, A.; Auta, J.; Davis, J. M.; Dong, E.; Grayson, D. R.; Veldic, M.; Zhang, X.; Costa, 
E. GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon. 
Psychopharmacol. 2005, 180, 191 - 205. 
10. Maubach, K. GABA(A) receptor subtype selective cognition enhancers. Drug Targets-CNS 
& Neuro. Disorders 2003, 2003, 233 - 239. 
11. Barnard, E. A.; Skolnick, P.; Olsen, R. W.; Mohler, H.; Sieghart, W.; Biggio, G.; Braestrup, 
C.; Bateson, A. N.; Langer, Z. International Union of Pharmacology. XV. Subtypes of g-
aminobutyric acidA receptors: Classification on the basis of subunit structure and receptor 
function. Pharmacol. Rev. 1998, 50, 291 - 313. 
12. Simon, J.; Wakimoto, H.; Fujita, N.; Lalande, M.; Barnard, E. A. Analysis of the set of 
GABAA receptor genes in the human genome. J. Biol. Chem. 2004, 279, 41422 - 41435. 
13. Olsen, R. W.; Sieghart, W. GABAA receptors: Subtypes provide diversity of function and 
pharmacology. Neuropharmacology 2009, 56, 141 - 148. 
14. Sieghart, W.; Sperk, G. Subunit composition, distribution and function of GABAA receptor 
subtypes. Curr. Topics Med. Chem. 2002, 2, 785 - 816. 
15. Olsen, R. W.; Tobin, A. J. Molecular biology of GABAA receptors. FASEB J. 1990, 4, 1469 
- 1480. 
16. Burt, D. R.; Kamatchi, G. L. GABAA receptor subtypes: from pharmacology to molecular 
biology. FASEB J. 1991, 5, 2916 - 2923. 
17. Clayton, T.; Chen, J. L.; Ernst, M.; Richter, L.; Cromer, B. A.; Morton, C. J.; Ng, H.; 
Kaczorowski, C. C.; Helmstetter, F. J.; Furtmuller, R.; Ecker, G.; Parker, M. W.; Sieghart, 
W.; Cook, J. M. An updated unified pharmacophore model of the benzodiazepine binding site 
254 
 
on g-aminobutyric acida receptors: Correlation with comparative models. Curr. Med. Chem. 
2007, 14, 2755 - 2775. 
18. Keramidas, A.; Moorhouse, A.; Schofield, P. C.; Barry, P. Ligand-gated ion channels: 
mechanisms underlying ion selectivity. Prog. Biophys. Mol. Biol. 2004, 86, 161 - 204. 
19. MacDonald, R. L. Benzodiazepine mechanisms of action. In Antiepileptic Drugs, Levy, R. 
H.; Mattson, R. H.; Meldrum, B. S.; Perucca, E., Eds. Lippincott Williams and Wilkins: 
Philadelphia, 2002; pp 179 - 186. 
20. Sigel, E.; Luscher, B. P. A closer look at the high affinity benzodiazepine binding site on 
GABA(A) receptors. Curr. Topics Med. Chem. 2011, 11, 241 - 246. 
21. Ramerstorfer, J.; Furtmuller, R.; Sarto-Jackson, I.; Varagic, Z.; Sieghart, W.; Ernst, M. The 
GABAA receptor a+b- interface: A novel target for subtype selective drugs. J. Neurosci. 2011, 
31, 870 - 877. 
22. Varagic, Z.; Ramerstorfer, J.; Huang, S.; Rallapalli, S.; Sarto-Jackson, I.; Cook, J.; Sieghart, 
W.; Ernst, M. Subtype selectivity of a+b- site ligands of GABAA receptors: identification of 
the first highly specific positive modulators at a6b2/3g2 receptors Br. J. Pharmacol. 2013, 
169, 384 - 399. 
23. Sigel, E. Mapping of the benzodiazepine recognition site of GABAA receptors. Curr. Topics 
Med. Chem. 2002, 2, 833-839. 
24. Belelli, D.; Lambert, J. J. Neurosteriods: endogenous regulators of the GABA(A) receptor. 
Nat. Rev. Neurosci. 2005, 6, 565 - 575. 
25. Harris, R. A. Ethanol actions on multiple ion channels: which are important? Alcohol Clin. 
Exp. Res. 1999, 23, 1563 - 1570. 
255 
 
26. Lobo, I. A.; Harris, R. A. GABAA receptors and alcohol. Pharmacol. Biochem. Behav. 2008, 
90, 90 - 94. 
27. Olsen, R. W.; Hanchar, H. J.; Meera, P.; Wallner, M. GABAA receptor subtypes: the "one 
glass of wine" receptors. Alcohol 2007, 41, 201 - 209. 
28. Sawyer, E.; Moran, C.; Sirbu, M. H.; Szafir, M.; Van Linn, M.; Namjoshi, O.; Tiruveedhula, 
V. V. N. P. B.; Cook, J. M.; Platt, D. M. Little evidence of a role for the a1 GABAA subunit-
containing receptor in rhesus monkey model of alcohol drinking. Alcohol Clin. Exp. Res. 
2014, 38, 1108 - 1117. 
29. Ernst, M.; Brauchart, D.; Boresch, S.; Sieghart, W. Comparative modeling of GABAA 
receptors: Limits, insights, future developments. Neurosci. 2003, 119, 933 - 943. 
30. Haefely, W. The biological basis of benzodiazepine actions. J. Psychoactive Drugs 1983, 15, 
19 - 39. 
31. Haefely, W.; Facklam, M.; Schoch, P.; Martin, J. R.; Bonetti, E. P.; Moreau, J. L.; Jenck, F.; 
Richards, J. G. Partial agonists of benzodiazepine receptors for the treatment of epilepsy, 
sleep, and anxiety disorders. Adv. Biochem. Psychopharmacol. 1992, 47, 379 - 394. 
32. Gorman, J. M. Benzodiazepines: Taking the good with the bad and the ugly. CNS Spectrums 
2005, 10, 14 - 15. 
33. Garattini, S.; Mussini, E.; Marucci, F.; Guaitani, A. Metabolic studies on benzodiazepines in 
various animal species. In The Benzodiazepines, Garattini, S.; Mussini, E.; Randall, L. O., 
Eds. Raven Press: New York, 1973; pp 75 - 97. 
34. Rutherford, D. M.; Okoko, A.; Tyrer, P. J. Plasma concentrations of diazepam and 
desmethyldiazepam during chronic diazepam therapy. Br. J. Clin. Pharmacol. 1978, 1978. 
256 
 
35. Bond, A. J.; Hailey, D. M.; Lader, M. H. Plasma concentrations of benzodiazepines. Br. J. 
Clin. Pharmacol. 1977, 4, 51 - 56. 
36. Stevenson, I. H.; Browning, M.; Crooks, J.; O'Malley, K. Changes in human drug metabolism 
after long-term exposure to hypnotics. Br. Med. Journal 1972, 4, 322 - 324. 
37. Hillestad, L.; Hansen, T.; Melsom, H.; Drivenes, A. Diazepam metabolism in normal man I. 
Serum concentrations and clinical effects after intravenous, intramuscular, and oral 
administrations. Clin. Pharmacol. Therapeutics 1974, 16, 479 - 484. 
38. Killam, E. K.; Suria, A. Benzodiazepines. In Antiepileptic Drugs: Mechanisms of Action, 
Glaser, G. H.; Penry, J. K.; Woodbury, D. M., Eds. Raven Press: New York, 1980; pp 597 - 
615. 
39. Rogawski, M. A. Principles of antiepileptic drug action. In Antiepileptic Drugs, 5th ed.; Levy, 
R. H.; Mattson, R. H.; Meldrum, B. S.; Perucca, E., Eds. Lippincott Williams and Wilkins: 
Philadelphia, 2002; pp 3 - 22. 
40. Rudolph, U.; Mohler, H. Analysis of GABAA receptor function and dissection of the 
pharmacology of benzodiazepines and general anesthetics through mouse genetics. Ann. Rev. 
Pharmacol. Toxicol. 2004, 44, 475 - 498. 
41. Rudolph, U.; Crestani, F.; Benke, D.; Brunig, I.; Benson, J. A.; Fritschy, J.-M.; Martin, J. R.; 
Bluethmann, H.; Mohler, H. Benzodiazepine actions mediated by specific g-aminobutyric 
acidA receptor subtypes. Nature 1999, 401, 796 - 800. 
42. McKernan, R. M.; Rosahl, T. W.; Reynolds, D. S.; Sur, C.; Wafford, K. A.; Atack, J. R.; 
Farrar, S.; Myers, J.; Cook, G.; Ferris, P.; Garrett, L.; Bristow, L.; Marshall, G.; Macaulay, 
A.; Brown, N.; Howell, O.; Moore, K. W.; Carling, R. W.; Street, L. J.; Castro, J. L.; Ragan, 
257 
 
C. I.; Dawson, G. R.; Whiting, P. J. Sedative but not anxiolytic properties of benzodiazepines 
are mediated by the GABAA receptor a1 subtype. Nat. Neurosci. 2000, 3, 587 - 592. 
43. Low, K.; Crestani, F.; Keist, R.; Benke, D.; Brunig, I.; Benson, J. A.; Fritschy, J.-M.; Rulicke, 
T.; Bluethmann, H.; Mohler, H.; Rudolph, U. Molecular and neuronal substrate for the 
selective attenuation of anxiety. Science 2000, 290, 131 - 134. 
44. Morris, H. V.; Dawson, G. R.; Reynolds, D. S.; Atack, J. R.; Stephens, D. N. Both a2 and a3 
GABAA receptor subtypes mediate the anxiolytic properties of benzodiazepine site ligands in 
the conditioned emotional response paradigm. Eur. J. Neurosci. 2006, 23, 2498 - 2504. 
45. Dias, R.; Sheppard, W. F. A.; Fradley, R. L.; Garrett, E. M.; Stanley, J. L.; Tye, S. J.; 
Goodacre, S.; Lincoln, R. J.; Cook, S. M.; Conley, R.; Hallett, D.; Humphries, A. C.; 
Thompson, S. A.; Wafford, K. A.; Street, L. J.; Castro, J. L.; Whiting, P. J.; Rosahl, T. W.; 
Atack, J. R.; McKernan, R. M.; Dawson, G. R.; Reynolds, D. S. Evidence for a significant 
role of a3-containing GABAA receptors in mediating the anxiolytic effects of 
benzodiazepines. J. Neurosci. 2005, 25, 10682 - 10688. 
46. Yee, B. K.; Keist, R.; von Boehmer, L.; Studer, R.; Benke, D.; Hagenbuch, N.; Dong, Y.; 
Malenka, R. C.; Fritschy, J.-M.; Bluethmann, H.; Feldon, J.; Mohler, H.; Rudolph, U. A 
schizophrenia-related sensorimotor deficit links a3-containing GABAA receptors to a 
dopamine hyperfunction. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 17154 - 17159. 
47. Crestani, F.; Keist, R.; Fritschy, J.-M.; Benke, D.; Vogt, K.; Prut, L.; Bluthmann, H.; Mohler, 
H.; Rudolph, U. Trace fear conditioning involving hippocampal a5 GABAA receptors. Proc. 
Natl. Acad. Sci. U.S.A. 2002, 99, 8980 - 8985. 
48. Knabl, J.; Witschi, R.; Hosl, K.; Reinold, H.; Zeilhofer, U. B.; Ahmadi, S.; Brockhaus, J.; 
Sergejeva, M.; Hess, A.; Brune, K.; Fritschy, J.-M.; Rudolph, U.; Mohler, H.; Zeilhofer, H. 
258 
 
U. Reversal of pathological pain through specific spinal GABAA receptor subtypes. Nature 
2008, 451, 330 - 335. 
49. Miller, P. S.; Aricescu, A. R. Crystal structure of a human GABAA receptor. Nature 2014, 
512, 270 - 275. 
50. Ralvenius, W. T.; Benke, D.; Acuna, M. A.; Rudolph, U.; Zeilhofer, H. U. Analgesia and 
unwanted benzodiazepine effects in point-mutated mice expressing only one benzodiazepine-
sensitive GABAA receptor subtype. Nat. Commun. 2015, 6. 
51. Cook, J. M.; Edwankar, R.; Poe, M. M.; Tiruveedhula, V. V. N. P. B.; Witzigmann, C. 
Synthesis of natural products and related heterocyclic compounds. Search for agents to treat 
neuropathic pain, epilepsy and anxiety disorders as well as simple molecules to treat TB and 
MRSA infections. In Mona Symposium on Natural Products and Medicinal Chemistry, 
Kingston, Jamaica, 2014. 
52. Fritschy, J. M.; Mohler, H. GABAA-receptor heterogeneity in the adult rat brain: differential 
regional and cellular distribution of seven major subunits. J. Comp. Neurol. 1995, 359, 154 - 
194. 
53. Fritschy, J. M.; Benke, D.; Mertens, S.; Oertel, W. H.; Bachi, T.; Mohler, H. Five subtypes of 
type A gamma-aminobutyric acid receptors identified in neurons by double and triple 
immunofluorescence staining with subunit-specific antibodies. Proc. Natl. Acad. Sci. 1992, 
89, 6726 - 6730. 
54. Korpi, E. R.; Mattila, M. J.; Wisden, W.; Luddens, H. GABAA-receptor subtypes: clinical 
efficacy and selectivity of benzodiazepine site ligands. Ann. Med. 1997, 29, 275 - 282. 
259 
 
55. Vicini, S.; Ferguson, C.; Prybylowski, K.; Kralic, J.; Morrow, A. L.; Homanics, G. E. GABAA 
receptor a1 subunit deletion prevents developmental changes of inhibitory synaptic currents 
in cerebellar neurons. J. Neurosci. 2001, 21, 3009 - 3016. 
56. Sur, C.; Wafford, K. A.; Reynolds, D. S.; Hadingham, K. L.; Bromidge, F.; Macaulay, A.; 
Collinson, N.; O'Meara, G.; Howell, O.; Newman, R.; Myers, J.; Atack, J. R.; Dawson, G. R.; 
McKernan, R. M.; Whiting, P. J.; Rosahl, T. W. Loss of the major GABAA receptor subtype 
in the brain is not lethal in mice. J. Neurosci. 2001, 21, 3409 - 3418. 
57. Collinson, N.; Kuenzi, F. M.; Jarolimek, W.; Maubach, K. A.; Cothliff, R.; Sur, C.; Smith, 
A.; Otu, F. M.; Howell, O.; Atack, J. R.; McKernan, R. M.; Seabrook, G. R.; Dawson, G. R.; 
Whiting, P. J.; Rosahl, T. W. Enhanced learning and memory and altered GABAergic synaptic 
transmission in mice lacking the a5 subunit of the GABAA receptor. J. Neurosci. 2002, 22, 
5572 - 5580. 
58. Bohlhalter, S.; Weinmann, O.; Mohler, H.; Fritschy, J. M. Laminar compartmentalization of 
GABAA-receptor subtypes in the spinal cord: an immunohistochemical study. J. Neurosci. 
1996, 16, 283 - 297. 
59. Bencsits, E.; Ebert, V.; Tretter, V.; Sieghart, W. A  significant part of native g-aminobutyric 
acidA receptors containing a4 subunits do not contain g or d subunits. J. Biol. Chem. 1999, 
274, 19613 - 19616. 
60. Quirk, K.; Gillard, N. P.; Ragan, I.; Whiting, P. J.; McKernan, R. M. Model of subunit 
composition of g-aminobutyric acid A receptor subtypes expressed in rat cerebellum with 
respect to their a and g/d subunits. J. Biol. Chem. 1994, 169, 16020 - 16028. 
61. Tanaka, C.; Taniyama, K. The role of GABA in the peripheral nervous system. In GABA 
Outside the CNS, Erdo, S. L., Ed. Springer: 1992; pp 3 - 17. 
260 
 
62. Magnaghi, V.; Ballabio, M.; Consoli, A.; Lambert, J. J.; Roglio, I.; Melcangi, R. C. GABA 
receptor-mediated effects in the peripheral nervous system: A cross-interaction with 
neuroactive steroids. J. Mol. Neuroscience 2006, 28, 89 - 102. 
63. Farrant, M.; Nusser, Z. Variations on an inhibitory theme: phasic and tonic activation of 
GABAA receptors. Nat. Rev. Neurosci. 2005, 6, 215 - 229. 
64. Gallos, G.; Yim, P.; Chang, S.; Zhang, Y.; Xu, D.; Cook, J. M.; Gerhoffer, W. T.; Emala Sr., 
C. W. Targeting the restricted a-subunit repertoire of airway smooth muscle GABAA receptors 
augments airway smooth muscle relaxation. Am. J. Physiol. Lung Cell Mol. Physiol. 2012, 
302, L248 - L256. 
65. Gallos, G.; Yocum, G. T.; Siviski, M. E.; Yim, P. D.; Fu, X. W.; Poe, M. M.; Cook, J. M.; 
Harrison, N.; Perez-Zoghbi, J.; Emala Sr., C. W. Selective targeting of the a5-subunit of 
GABAA receptors relaxes airway smooth msucle and inhibits cellular calcium handling. Am. 
J. Physiol. Lung Cell Mol. Physiol. 2015, 308, L931 - L942. 
66. Mizuta, K.; Xu, D.; Pan, Y.; Comas, G.; Sonett, J. R.; Zhang, Y.; Panettieri Jr., R. A.; Yang, 
J.; Emala Sr., C. W. GABAA receptors are expressed and facilitate relaxation in airway smooth 
muscle. Am. J. Physiol. Lung Cell Mol. Physiol. 2008, 294, L1206 - L1216. 
67. Bergeret, M.; Khrestchatisky, M.; Tremblay, E.; Bernard, A.; Gregoire, A.; Chany, C. GABA 
modulates cytotoxicity of immunocompetent cells expressing GABA(A) receptor subunits. 
Biomed. Pharmacother. 1998, 52, 214 - 219. 
68. Labonte, D.; Thies, E.; Kneussel, M. The kinesin KIF21B participates in the cell surface 
delivery of g2 subunit-containing GABAA receptors. Eur. J. Cell Biol. 2014, 93, 338 - 346. 
261 
 
69. Davies, M.; Bateson, A. N.; Dunn, S. M. J. Structural requirements for ligand interactions at 
the benzodiazepine recognition site of the GABA(A) receptor. J. Neurochem. 1998, 70, 2188 
- 2194. 
70. Dunn, S. M. J.; Davies, M.; Muntoni, A. L.; Lambert, J. J. Mutagenesis of the rat a1 subunit 
of the g-aminobutyric Acid(A) receptor reveals the importance of residue 101 in determining 
the allosteric effects of benzodiazepine site ligands. Mol. Pharmacol. 1999, 56, 768 - 774. 
71. Sigel, E.; Schaerer, M. T.; Buhr, A.; Baur, R. The benzodiazepine binding pocket of 
recombinant a1b2g2 g-aminobutyric acid(A) receptors: Relative orientation of ligands and 
amino acid side chains. Mol. Pharmacol. 1998, 54, 1097 - 1105. 
72. Divljakovic, J.; Milic, M.; Namjoshi, O. A.; Tiruveedhula, V. V.; Timic, T.; Cook, J. M.; 
Savic, M. M. bCCT, an antagonist selective for a1 GABAA receptors, reverses diazepam 
withdrawal-induced anxiety in rats. Brain Res. Bulletin 2013, 91, 1 - 7. 
73. Clayton, T. S. Ph.D. Thesis, Part I. Unified Pharmacophoric Protein Models of the 
Benzodiazepine Receptor Subtypes. Part II. Subtype Selective Ligands for a5 GABAA/Bz 
Receptors. University of Wisconsin-Milwaukee, 2011. 
74. Clayton, T.; Poe, M. M.; Rallapalli, S.; Biawat, P.; Savic, M. M.; Rowlett, J. K.; Gallos, G.; 
Emala, C. W.; Kaczorowski, C. C.; Stafford, D. C.; Arnold, L. A.; Cook, J. M. A review of 
the updated pharmacophore for the alpha 5 GABA(A) benzodiazepine receptor model. Intl. J. 
Med. Chem. 2015. 
75. He, X.; Huang, Q.; Ma, C.; Yu, S.; McKernan, R.; Cook, J. M. Pharmacophore/receptor 
models for GABAA/BzR a2b3g2, a3b3g2 and a4b3g2 recombinant subtypes. Included volume 
analysis and comparison to a1b3g2, a5b3g2 and a6b3g2 subtypes. Drug Des. Discov. 2000, 
17, 131 - 171. 
262 
 
76. Huang, Q.; He, X.; Ma, C.; Liu, R.; Yu, S.; Dayer, C. A.; Wenger, G. R.; McKernan, R.; 
Cook, J. M. Pharmacophore/receptor models for GABAA/BzR subtypes (a1b3g2, a5b3g2, and 
a6b3g2) via a comprehensive ligand-mapping approach. J. Med. Chem 2000, 43, 71 - 95. 
77. Martin, M.; Trudell, M. L.; Diaz-Arauzo, H.; Allen, M. S.; LaLoggia, A.; Deng, L.; Schultz, 
C. A.; Tan, T.-C.; Bi, Y.; Narayanan, K.; Dorn, L.; Koehler, K.; Skolnick, P.; Cook, J. M. 
Molecular yardsticks. Rigid planar ligands to define the spatial dimensions of the 
benzodiazepine receptor binding site. J. Med. Chem 1992, 35, 4105 - 4117. 
78. Gu, Z. Q.; Wong, G.; Dominguez, C.; de Costa, B. R.; Rice, K. C.; Skolnick, P. Synthesis and 
evaluation of imidazo[1,5a][1,4]benzodiazepine esters with high affinities and selectivities at 
diazepam insensitive (DI) benzodiazepine receptors. J. Med. Chem 1993, 36, 1001 - 1006. 
79. Wong, G.; Koehler, K. F.; Skolnick, P.; Gu, Z. Q.; Ananthan, S.; Schonholze, P.; Hunkeler, 
W.; Zhang, W.; Cook, J. M. Synthetic and computer-assisted analysis of the structural 
requirements for selective, high affinity ligand binding to 'diazepam-insensitive' 
benzodiazepine receptors. J. Med. Chem 1993, 36, 1820 - 1830. 
80. Lippke, K. P.; Schunack, W. G.; Wenning, W.; Muller, W. E. b-Carbolines as benzodiazepine 
receptor ligands. I. Synthesis and benzodiazepine receptor interactino of esters of b-carboline-
3-carboxylic acid. J. Med. Chem 1983, 26, 499 - 503. 
81. Haefely, W.; Martin, J. R.; Schoch, P. Novel anxiolytics that act as partial agonists at 
benzodiazepine receptors. Trends Pharmacol. Sci. 1990, 11, 452 - 456. 
82. Hagen, T. J.; Guzman, F.; Schultz, C.; Cook, J. M. Synthesis of 3,6-disubstituted b-carbolines 
which possess either benzodiazepine antagonist or agonist activity. Heterocycles 1986, 24, 
2845 - 855. 
263 
 
83. Gee, K. W.; Brinton, R. E.; Yamamura, H. I. CL-218872 antagonism of diazepam induced 
loss of righting reflex: Evidence for partial agonistic activity at the benzodiazepine receptor. 
Life Sci. 1983, 32, 1037 - 1040. 
84. Allen, M. S.; Hagen, T. J.; Trudell, M. L.; Codding, P. W.; Skolnick, P.; Cook, J. M. Synthesis 
of novel 3-substituted b-carbolines as benzodiazepine receptor ligands: probing the 
benzodiazepine receptor pharmacophore. J. Med. Chem 1988, 31, 1854 - 1861. 
85. Trudell, M. L.; Lifer, S. L.; Tan, Y. C.; Martin, M. J.; Deng, T.; Skolnick, P.; Cook, J. M. 
Synthesis of substituted 7,12-dihydropyrido[3,2-b:5,4-b'] diindoles: rigid planar 
benzodiazepine receptor ligands with inverse agonist/antagonist properties. J. Med. Chem 
1990, 33, 2412 - 2420. 
86. Arbilla, S.; Depoortere, H.; Geroge, P.; Langer, S. Z. Pharmacological profile of the 
imidazopyridine zolpidem at benzodiazepine receptors and electrocorticogram in rats. 
Naunym Schmiederbergs Arch. Pharmacol. 1985, 330, 248 - 251. 
87. Yokoyama, N.; Ritter, B.; Neubert, A. D. 2-Arylpyrazolo[4,3-c]quinolin-3-ones: novel 
agonist, partial agonist, and antagonist of benzodiazepines. J. Med. Chem 1982, 25, 337 - 339. 
88. van Rijnsoever, C.; Tauber, M.; Choulli, M. K.; Keist, R.; Rudolph, U.; Mohler, H.; Fritschy, 
J.-M.; Crestani, F. Requirement of a5-GABAA receptors for the development of tolerance to 
the sedative action of diazepam in mice. J. Neurosci. 2004, 24, 6785 - 6790. 
89. Cook, J.; Huang, S.; Edwankar, R.; Namjoshi, O. A.; Wang, Z.-j. Selective agents for pain 
suppression. US 2010/0317619 A1, 2010. 
90. Cook, J.; Huang, S.; Edwankar, R.; Namjoshi, O. A.; Wang, Z.-J. Selective agents for pain 
suppression. US 8,835,424 B2, Sep. 16, 2014, 2014. 
264 
 
91. Cook, J. M.; Zhou, H.; Huang, S.; Sarma, P. V. V. S.; Zhang, C. Stereospecific anxiolytic and 
anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects. US 
2006/0003995 A1, Jan. 5, 2006, 2006. 
92. Cook, J. M.; Zhou, H.; Huang, S.; Sarma, P. V. V. S.; Zhang, C. Stereospecific anxiolytic and 
anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects. US 
7,618,958 B2, Nov. 17, 2009, 2009. 
93. Di Lio, A.; Benke, D.; Besson, M.; Desmeules, J.; Daali, Y.; Wang, Z.-j.; Edwankar, R.; Cook, 
J. M.; Zeilhofer, H. U. HZ166, a novel GABAA receptor subtype-selective benzodiazepine 
site ligand, is antihyperalgesic in mouse models of inflammatory and neuropathic pain. 
Neuropharmacology 2011, 60, 626 - 632. 
94. Huang, Q.; Zhang, W.; Liu, R.; McKernan, R. M.; Cook, J. M. Benzo-fused benzodiazepines 
employed as topological probes for the study of benzodiazepine receptor subtypes. Med. 
Chem. Res. 1996, 6, 384 - 391. 
95. Kessler, R. C.; Chiu, W. T.; Demler, O.; Walters, E. E. Prevalence, severity, and comorbidity 
of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. 
Psychiatry 2005, 62, 617 - 627. 
96. Baldwin, D. S.; Polkinghorn, C. Evidence-based pharmacotherapy of generalized anxiety 
disorder. Int. J. Neuropsychopharmacol. 2005, 8, 293 - 302. 
97. Nutt, D. J. Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectrums 
2005, 10, 49 - 56. 
98. Benyamin, R.; Trescot, A. M.; Datta, S.; Buenaventura, R.; Adlaka, R.; Sehgal, N.; Glaser, S. 
E.; Vallejo, R. Opioid complications and side effects. Pain Physician 2008, 11, S105 - S120. 
265 
 
99. Antman, E. M.; Bennett, J. S.; Daugherty, A.; Furberg, C.; Roberts, H.; Taubert, K. A. Use of 
nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the 
American Heart Association. Circulation 2007, 115, 1634 - 1642. 
100. Kearney, P. M.; Baigent, C.; Godwin, J.; Halls, H.; Emberson, J. R.; Patrono, C. Do selective 
cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase 
the risk of atherothrombosis? Meta-analysis of randomised trials. Brit. Med. J. 2006, 332, 
1302 - 1308. 
101. Cunningham, C. W.; Rothman, R. B.; Prisinzano, T. E. Neuropharmacology of the naturally 
occuring kappa-opioid hallucinogen salvinorin A. Pharmacol. Rev. 2011, 63, 316 - 347. 
102. Watkins, L. R.; Hutchinson, M. R.; Rice, K. C.; Maier, S. F. The "toll" of opioid-induced glial 
activation:improving the clinical efficacy of opioids by targeting glia. Trends Pharmacol. Sci. 
2009, 30, 581 - 591. 
103. Hutchinson, M. R.; Zhang, Y.; Shridhar, M.; Evans, J. H.; Buchanan, M. M.; Zhao, T. X.; 
Slivka, P. F.; Coats, B. D.; Rezvani, N.; Wieseler, J.; Hughes, T. S.; Landgraf, K. E.; Chan, 
S.; Fong, S.; Phipps, S.; Falke, J. J.; Leinwand, L. A.; Maier, S. F.; Yin, H.; Rice, K. C.; 
Watkins, L. R. Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain, 
Behav., and Immunity 2010, 24, 83 - 95. 
104. Scott-Stevens, P.; Atack, J. R.; Sohal, B.; Worboys, P. Rodent pharmacokinetics and receptor 
occupancy of the GABAA receptor subtype selective benzodiazepine site ligand L-838417. 
Biopharm. Drug Dispos. 2005, 26, 13 - 20. 
105. Atack, J. R.; Wafford, K. A.; Tye, T. J.; Cook, S. M.; Sohal, B.; Pike, A.; Sur, C.; Melillo, D.; 
Bristow, L.; Bromidge, F.; Ragan, I.; Kerby, J.; Street, L.; Carling, R.; Castro, J. L.; Whiting, 
P.; Dawson, G. R.; McKernan, R. M. TPA023 [7-(1,1Dimethylethyl)-6-(2-ethyl-2H-1,2,4-
266 
 
triazol-3-ylmethoxy)-3-(2-fluorophneyl)-1,2,4-triazolo[4,3-b]pyridazine], an agonist 
selective for a2- and a3-containing GABAA receptors, is a nonsedating anxiolytic in rodents 
and primates. J. Pharmacol. Exp. Ther. 2006, 316, 410 - 422. 
106. Mohler, H. The rise of a new GABA pharmacology. Neuropharmacology 2011, 60, 1042 - 
1049. 
107. Atack, J. R.; Wafford, K. A.; Street, L. J.; Dawson, G. R.; Tye, S.; Van Laere, K.; Bormans, 
G.; Sanabria-Bohorquez, S. M.; De Lepeleire, I.; de Hoon, J. N.; Van Hecken, A.; Burns, H. 
D.; McKernan, R. M.; Murphy, M. G.; Hargreaves, R. J. MRK-409 (MK-0343), a GABAA 
receptor subtype-selective partial agonist, is a non-sedating anxiolytic in preclinical species 
but causes sedation in humans. J. Psychopharmacol. 2010, 25, 314 - 328. 
108. Atack, J. R.; Hallett, D. J.; Tye, S.; Wafford, K. A.; Ryan, C.; Sanabria-Bohorquez, S. M.; 
Eng, W.-s.; Gibson, R. E.; Burns, H. D.; Dawson, G. R.; Carling, R. W.; Street, L. J.; Pike, 
A.; De Lepeleire, I.; Van Laere, K.; Bormans, G.; De Hoon, J. N.; Van Hecken, A.; 
McKernan, R. M.; Murphy, M. G.; Hargreaves, R. J. Preclinical and clinical pharmacology 
of TPA023B, a GABAA receptor a2/a3 subtype-selective partial agonist. J. Psychopharmacol. 
2010, 25, 329 - 344. 
109. Mirza, N. R.; Larsen, J. S.; Mathiasen, C.; Jacobsen, T. A.; Munro, G.; Erichsen, H. K.; 
Nielsen, A. N.; Troelsen, K. B.; Nielsen, E. O.; Ahring, P. K. NS11394 [3'-[5-(1-Hydroxy-1-
methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile], a unique subtype-selective 
GABAA receptor positive allosteric modulator: In vitro actions, pharmacokinetic properties 
and in vivo anxiolytic Efficacy. J. Pharmacol. Exp. Ther. 2008, 327, 954-968. 
110. Munro, G.; Lopez-Garcia, J. A.; Rivera-Arconada, I.; Erichsen, H. K.; Nielsen, E. O.; Larsen, 
J. S.; Ahring, P. K.; Mirza, N. R. Comparison of the novel subtype-selective GABAA receptor-
267 
 
positive allosteric modulator NS11394 [3'-[5-(1-Hydroxy-1-methyl-ethyl)benzoimidazol-1-
yl]-biphenyl-2-carbonitrile] with diazepam, zolpidem, bretazenil, and gaboxadol in rat models 
of inflammatory and neuropathic pain. J. Pharmacol. Exp. Ther. 2008, 327, 969-981. 
111. Hofmann, M.; Kordas, K. S.; Gravius, A.; Bolcskei, K.; Parsons, C. G.; Dekundy, A.; Danysz, 
W.; Dezsi, L.; Wittko-Schneider, I. M.; Saghy, K.; Gyertyan, I.; Horvath, C. Assessment of 
the effects of NS11394 and L-838417, a2/3 subunit-selective GABAA receptor-positive 
allosteric modulators, in tests of pain, anxiety, memory and motor function. Behavioural 
Pharmacology 2012, 23, 790-801. 
112. Fischer, B. D.; Licata, S. C.; Edwankar, R. V.; Wang, Z.-j.; Huang, S.; He, X.; Yu, J.; Zhou, 
H.; Jr., E. M. J.; Cook, J. M.; Furtmuller, R.; Ramerstorfer, J.; Sieghart, W.; Roth, B. L.; 
Majumder, S.; Rowlett, J. K. Anxiolytic-like effects of 8-acetylene imidazobenzodiazepines 
in a rhesus monkey conflict procedure. Neuropharmacology 2010, 59, 612 - 618. 
113. Savic, M. M.; Majumder, S.; Huang, S.; Edwankar, R. V.; Furtmuller, R.; Joksimovic, S.; 
Clayton Sr., T.; Ramerstorfer, J.; Milinkovic, M. M.; Roth, B. L.; Sieghart, W.; Cook, J. M. 
Novel positive allosteric modulators of GABAA receptors: do subtle differences in activity at 
a1 plus a5 versus a2 plus a3 subunits account for dissimilarities in behavioral effects in rats? 
Prog. Neuro-Pyschopharmacology and Biol Psychiatry 2010, 2010, 376 - 386. 
114. Haefely, W.; Kyburz, E.; Gerecke, M.; Mohler, H. Recent advances in the molecular 
pharmacology of benzodiazepine receptors and in the structure-activity relationships of their 
agonists and antagonists. In Advances in Drug Research, Testa, B., Ed. Academic Press: New 
York, 1985; pp 165 - 322. 
115. Rivas, F.; Stables, J. P.; Murphree, L.; Edwankar, R. V.; Edwankar, C. R.; Huang, S.; Jain, K. 
D.; Zhou, H.; Majumder, S.; Sankar, S.; Roth, B. L.; Ramerstorfer, J.; Furtmuller, R.; Sieghart, 
268 
 
W.; Cook, J. M. Antiseizure activity of novel g-aminobutyric acid (A) receptor subtype-
selective benzodiazepine analogues in mice and rat models. J. Med. Chem 2009, 52, 1795 - 
1798. 
116. Edwankar, R. Ph.D. Thesis, I. Hz166, A Novel g-Aminobutyric Acid (A) Receptor Subtype 
Selective Ligand Active Against Neuropathic Pain; II. The First Enantiospecific, 
Stereospecific Total Synthesis Of The C-19 Methyl Substituted Sarpagine Indole Alkaloids 
19(S),20(R)-Dihydroperaksine, 19(S),20-(R)-Dihydroperaksine-17-Al And Peraksine; III. 
Application Of Metal-Carbenoid Chemistry And Brönsted Acid Mediated Cyclization Of 
Enaminones For The Rapid And Efficient Access To The Tetracyclic (Abce) Skeleton Of The 
Strychnos Alkaloids Contained In Bisindole Alkaloids. University of Wisconsin-Milwaukee, 
2010. 
117. Namjoshi, O. A.; Wang, Z.-j.; Rallapalli, S. K.; Jr., E. M. J.; Johnson, Y.-T.; Ng, H.; 
Ramerstorfer, J.; Varagic, Z.; Sieghart, W.; Majumder, S.; Roth, B. L.; Rowlett, J. K.; Cook, 
J. M. Search for a3b2/3g2 subtype selective ligands that are stable on human liver microsomes. 
Bioorg. Med. Chem. 2013, 21, 93 - 101. 
118. Yang, J.; Teng, Y.; Ara, S.; Rallapalli, S.; Cook, J. M. An improved process for the synthesis 
of 4H-imidazo[1,5a][1,4]benzodiazepines. Synthesis 2009, 40. 
119. Sharma, R.; Strelevitz, T. J.; Gao, H.; Clark, A. J.; Schildknegt, K.; Obach, R. S.; Ripp, S. L.; 
Spracklin, D. K.; Tremaine, L. M.; Vaz, A. D. N. Deuterium isotope effects on drug 
pharmacokinetics. I. System-dependent effects of specific deuteration with aldehyde oxidase 
cleared drugs. Drug Metab. Desposition 2012, 40, 625 - 634. 
120. Scheiner, S.; Martin, C. Relative stability of hydrogen and deuterium bonds. J. Am. Chem. 
Soc. 1996, 118, 1511 - 1521. 
269 
 
121. Rallapalli, S. Ph.D. Theis, Part I. The First Enantiospecific, Stereospecific Total Synthesis of 
the Indole Alkaloid Ervincidine. Part II. The Synthesis of Alpha 5 Subtype Selective Ligands 
for GABA(A)/Benzodiazepine Receptors. University of Wisconsin-Milwaukee, 2012. 
122. Geller, I.; Seifter, J. The effects of meprobamate, barbiturate, damphetamine and promazine 
on experimentally-induced conflict in the rat. Psychopharmacologia 1960, 1, 482 - 492. 
123. Cook, L.; Davidson, A. B. Effects of behaviorally active drugs in a conflict-punishment 
procedure in rats. In The Benzodiazepines, Garattini, S.; Mussini, E.; Randall, L. O., Eds. 
Raven Press: New York, 1973; pp 327 - 345. 
124. Rowlett, J. K.; Lelas, S.; Tornatzky, W.; Licata, S. C. Anti-conflict effects of benzodiazepines 
in rhesus monkeys: relationship with therapeutic doses in humans and role of GABAA 
receptors. Psychopharmacol. (Berl.) 2006, 184, 201 - 211. 
125. Theodore, L. J.; Nelson, W. L. Stereospecific synthesis of the enantiomers of verapamil and 
gallopamil. J. Org. Chem. 1987, 52, 1309 - 1315. 
126. Ndibwami, A.; Deslongchamps, P. Study on the enolization of alkylation of cis and trans 2-
tert-5-X-1,3-dioxanes (X = CO2CH3, CHO, COPh, NO2, and CN). Evidence for 
stereoelectronic control. Can. J. Chem. 1986, 9, 1788 - 1794. 
127. Auta, J.; Impagnatiello, F.; Kadriu, B.; Guidotti, A.; Costa, E. Imidazenil: A low efficacy 
agonist at a1- but high efficacy at a5-GABAA receptors fail to show anticonvulsant cross 
tolerance to diazepam or zolpidem. Neuropharmacology 2008, 55, 148 - 153. 
128. Auta, J.; Kadriu, B.; Giusti, P.; Costa, E.; Guidotti, A. Anticonvulsant, anxiolytic, and non-
sedating actions of imidazenil and other imidazo-benzodiazepine carboxamide derivatives. 
Pharmacol. Biochem. Behav. 2010, 95, 383 - 389. 
270 
 
129. Auta, J.; Costa, E.; Davi, s. J. M.; Guidotti, A. Imidazenil: An antagonist of the sedative but 
not the anticonvulsant action of diazepam. Neuropharmacology 2005, 49, 425 - 429. 
130. Bundesmann, M. W.; Coffey, S. B.; Wright, S. W. Amidation of esters assisted by 
Mg(OCH3)2 or CaCl2. Tett. Letters 2010, 51, 3879 - 3882. 
131. Cava, M. P.; Levinson, M. I. Thionation reactions of Lawesson's reagents. Tetrahedron 1985, 
41, 5061 - 5087. 
132. Curphey, T. J. Thionation with the reagent combination of phosphorus pentasulfide and 
hexamethyldisiloxane. J. Org. Chem. 2002, 67, 6461 - 6473. 
133. Jesberger, M.; Davis, T. P.; Barner, L. Applications of Lawesson's reagent in organic and 
organometallic syntheses. Synthesis 2003, 13, 1929 - 1958. 
134. Cherkasov, R. A.; Kutyrev, G. A.; Pudovik, A. N. Organothiophosphorus reagents in organic 
synthesis. Tetrahedron 1985, 41, 2567 - 2624. 
135. Kaleta, Z.; Makowski, B. T.; Soos, T.; Dembinski, R. Thionation using fluorous Lawesson's 
reagent. Org. Letters 2006, 8, 1625 - 1628. 
136. Varma, R.; Kumar, D. Microwave-accelerated solvent-free synthesis of thioketones, 
thiolactones, thioamides, thionoesters, and thioflavonoids. Org. Letters 1999, 1, 697 - 700. 
137. Pathak, U.; Pandey, L. K.; Tank, R. Expeditious microwave-assisted thionation with the 
system PSCl3/H2O/Et3N under solvent-free condition. J. Org. Chem. 2008, 73, 2890 - 2893. 
138. Langmuir, I. Isomorphism, isosterism and covalence. J. Am. Chem. Soc. 1919, 41, 1543 - 
1559. 
139. Burger, A. Isosterism and bioisosterism in drug design. Prog. Drug Res. 1991, 37, 287 - 371. 
140. Patani, G. A.; LaVoie, E. J. Bioisosterism: A rational approach in drug design. Chem. Rev. 
1996, 96, 3147 - 3176. 
271 
 
141. Bostrom, J.; Hogner, A.; Llinas, A.; Wellner, E.; Plowright, A. T. Oxadiazoles in medicinal 
chemistry. J. Med. Chem 2012, 55, 1817 - 1830. 
142. Yang, X.; Liu, G.; Li, H.; Zhang, Y.; Song, D.; Li, C.; Wang, R.; Liu, B.; Liang, W.; Jing, Y.; 
Zhao, G. Novel oxadiazole analogues derived from ethacrynic acid: Design, synthesis, and 
structure-activity relationships in inhibiting the activity of glutathione S-transferase P1-1 and 
cancer cell proliferation. J. Med. Chem 2010, 53, 1015 - 1022. 
143. Huang, S. Ph.D. Thesis, Synthesis of Optically Active Subtype Selective Benzodiazepine 
Receptor Ligands. University of Wisconsin-Milwaukee, 2007. 
144. Bach, P.; Bostrom, J.; Brickmann, K.; Burgess, L. E.; Clarke, D.; Groneberg, R. D.; Harvey, 
D. M.; Laird, E. R.; O'Sullivan, M.; Zetterberg, F. 5-Alkyl-1,3-oxazole derivatives of 6-
amino-nicotinic acids as alkyl ester bioisosteres are antagonists of the P2Y12 receptor. Future 
Med. Chem. 2013, 5, 2037 - 2056. 
145. Bull, J. A.; Balskus, E. P.; Horan, A. J.; Langner, M.; Ley, S. V. Total synthesis of potent 
antifungal marine bisoxazole natural products Bengazoles A and B. Chem. Eur. J. 2007, 13, 
5515 - 5538. 
146. Webb, M. R.; Donald, C.; Taylor, R. J. K. A general route to the Streptomyces-derived 
inthomycin family: the first synthesis of (+)-inthomycin B. Tett. Letters 2006, 47, 549 - 552. 
147. Cook, J. M.; Poe, M. M.; Methuku, K. R.; Li, G. GABAergic ligands to treat CNS disorders 
including anxiety and depression as well as neuropathic pain. March 18, 2016, 2016. 
148. Broekkamp, C. L.; Rijk, H. W.; Joly-Gelouin, D.; Lloyd, K. Major tranquillizers can be 
distinguished from minor tranquillizers on the basis of effects on marble burying and swim-
induced grooming in mice. Eur. J. Pharmacol. 1986, 126, 223 - 229. 
272 
 
149. Cendelin, J.; Voller, J.; Vozeh, F. Ataxic gait analysis in a mouse model of the olivocerebellar 
degeneration. Behav. Brain Res. 2010, 210, 8 - 15. 
150. Njung'e, K.; Handley, S. L. Evaluation of marble-burying behavior as a model of anxiety. 
Pharmacol. Biochem. Behav. 1991, 38, 63 - 67. 
151. Kinsey, S. G.; O'Neal, S. T.; Long, J. Z.; Cravatt, B. F.; Lichtman, A. H. Inhibition of 
endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay. 
Pharmacol. Biochem. Behav. 2011, 98, 21 - 27. 
152. Li, X.; Morrow, D.; Witkin, J. M. Decreases in nestlet shredding of mice by serotonin uptake 
inhibitors: Comparison with marble burying. Life Sci. 2006, 78, 1933 - 1939. 
153. Browne, T. R. Clonazepam. A review of a new anticonvulsant drug. Arch. Neurol. 1976, 33, 
326 - 323. 
154. Gaudreault, P.; Guay, J.; Thivierge, R. L.; Verdy, I. Benzodiazepine poisoning. Clinical and 
pharmacological considerations and treatment. Drug Safety 1991, 6, 247 - 265. 
155. Kondziela, W. Eine neue method zur messung der muskularen relaxation bei weissen mausen. 
Arch. Int. Pharmacodyn. 1964, 152, 277 - 284. 
156. Liljequist, R.; Palva, E.; Linnoila, M. Effects on learning and memory of 2-week treatments 
with chlordiazepoxide lactam, N-desmethyldiazepam, oxaezpam and methyloxazepam, alone 
or in combination with alcohol. Int. Pharmacopsychiatry 1979, 14, 190 - 198. 
157. Riss, J.; Cloyd, J.; Gates, J.; Collins, S. Benzodiazepines in epilepsy: pharmacology and 
pharmacokinetics. Acta Neurol. Scand. 2008, 118, 69 - 86. 
158. Rundfeldt, C.; Wlaz, P.; Honack, D.; Loscher, W. Anticonvulsant tolerance and withdrawal 
characteristics of benzodiazepine receptor ligands in different seizure models in mice. 
273 
 
Comparison of diazepam, bretazenil and abecarnil. J. Pharmacol. Exp. Ther. 1995, 275, 693 
- 702. 
159. White, S. H.; Woodhead, J. H.; Wilcox, K. S.; Stables, J. P.; Kupferberg, H. J.; Wolf, H. H. 
Discovery and Preclinical Development of Antiepileptic Drugs. In Antiepileptic Drugs, 5th 
ed.; Levy, R. H.; Mattson, R. H.; Meldrum, B. S.; Perucca, E., Eds. Lippincott Williams and 
Wilkins: Philadelphia, PA, 2002; pp 36 - 48. 
160. Castel-Branco, M. M.; Alves, G. L.; Figueiredo, I. V.; Falcao, A. C.; Caramona, M. M. The 
maximal electroshock seizure (MES) model in the preclinical assessment of potential new 
antiepileptic drugs. Methods Find. Exp. Clin. Pharmacol. 2009, 31, 101 - 106. 
161. Knabl, J.; Zeilhofer, U. B.; Crestani, F.; Rudolph, U.; Zeilhofer, H. U. Genuine 
antihyperalgesia by systemic diazepam revealed by experiments in GABAA receptor point-
mutated mice. Pain 2009, 141, 233 - 238. 
162. Paul, J.; Yevenes, G. E.; Benke, D.; Lio, A. D.; Ralvenius, W. T.; Witschi, R.; Scheurer, L.; 
Cook, J. M.; Rudolph, U.; Fritschy, J.-M.; Zeilhofer, H. U. Antihyperalgesia by a2-GABAA 
receptors occurs via a genuine spinal action and does not involve supraspinal sites. 
Neuropsychopharm. 2014, 39, 477 - 487. 
163. Chung, J. M.; Kim, H. K.; Chung, K. Segmental spinal nerve ligation model of neuropathic 
pain. Methods Mol. Med. 2004, 99, 35 - 45. 
164. Huang, X. P.; Mangano, T.; Hufeisen, S.; Setola, V.; Roth, B. L. Identification of human 
Ether-a-go-go related gene modulators by three screening platforms in an academic drug-
discovery setting. Assay Drug Dev. Technol. 2010, 8, 727 - 742. 
165. Sanguinetti, M. C.; Tristani-Firouzi, M. hERG potassium channels and cardiac arrhythmia. 
Nature 2006, 440, 463 - 469. 
274 
 
166. Gould, H. J. Complete Freund's adjuvant-induced hyperalgesia: a human perception. Pain 
2000, 85, 301 - 303. 
167. Amsterdam, J. D.; Hornig-Rohan, M.; Maislin, G. Efficacy of alprazolam in reducing 
fluoxetine-induced jitteriness in patients with major depression. J. Clin. Psychiatry 1994, 55, 
394 - 400. 
168. Petty, F.; Trivedi, M. H.; Fulton, M.; Rush, A. J. Benzodiazepines as antidepressants: does 
GABA play a role in depression? Biol. Psychiatry 1995, 38, 578 - 591. 
169. Vollenweider, I.; Smith, K. S.; Keist, R.; Rudolph, U. Antidepressant-like properties of a2-
containing GABAA receptors. Behav. Brain Res. 2011, 217, 77 - 80. 
170. Rudolph, U.; Knoflach, F. Beyond classical benzodiazepines: novel therapeutic potential of 
GABAA receptor subtypes. Nature Reviews 2011, 10, 685 - 697. 
171. Berton, O.; Nestler, E. J. New approaches to antidepressant drug discovery beyond 
monoamines. Nat. Rev. Neurosci. 2006, 7, 137 - 151. 
172. El Hadri, A.; Abouabdellah, A.; Thomet, U.; Baur, R.; Furtmuller, R.; Sigel, E.; Sieghart, W.; 
Dodd, R. H. N-substituted 4-amino-3,3-dipropyl-2(3H)-furanones: New positive allosteric 
modulators of the GABAA receptor sharing electrophysiological properties with the 
anticonvulsant Loreclezole. J. Med. Chem 2002, 45, 2824 - 2831. 
173. Li, X.; Cao, H.; Zhang, C.; Furtmuller, R.; Fuchs, K.; Huck, S.; Sieghart, W.; Deschamps, J.; 
Cook, J. M. 6,7-Dihydro-2-benzothiophen-4(5H)-ones: A novel class of GABA-A a5 receptor 
inverse agonists. J. Med. Chem 2003, 46, 5567 - 5570. 
174. Sieghart, W. Pharmacology of benzodiazepine receptors: an update. J. Psychiatry Neurosci 
1994, 19, 24 - 29. 
275 
 
175. Schreibmayer, W.; Lester, H. A.; Dascal, N. Voltage clamping of Xenopus laevis oocytes 
utilizing agarose-cushion electrodes. Pflugers Arch-Eur. J. Physiol. 1994, 426, 453 - 458. 
176. Fuchs, K.; Zezula, J.; Slany, A.; Sieghart, W. Endogenous [3H]flunitrazepam binding in 
human embryonic kidney cell line 293. Eur. J. Pharmacol. 1995, 289, 87 - 95. 
177. Sigel, E. Properties of single sodium channels translated by Xenopus oocytes after injection 
with messenger ribonucleic acid. J. Physiol. 1987, 386, 73 - 90. 
178. Sigel, E.; Baur, R.; Trube, G.; Mohler, H.; Malherbe, P. The effect of subunit composition of 
rat brain GABAA receptors on channel function. Neuron 1990, 5, 703 - 711. 
179. Huang, Z.; Li, G.; Pei, W.; Sosa, L. A.; Niu, L. Enhancing protein expression in single HEK 
293 cells. J. Neurosci. Methods 2005, 142, 159 - 166. 
180. Liu, J.; Chen, T.; Norris, T.; Knappenberger, K.; Huston, J.; Wood, M.; Bostwick, R. A high-
throughput functional assay for characterization of g-aminobutyric acid A channel 
modulators. Assay Drug Dev. Technol. 2008, 6, 781 - 786. 
181. Joesch, C.; Guevarra, E.; Parel, S. P.; Bergner, A.; Zbinden, P.; Konrad, D.; Albrecht, H. Use 
of FLIPR membrane potential dyes for validation of high-throughput screening with the 
FLIPR and microARCS technologies: identification of ion channel modulators acting on the 
GABA(A) receptor. J. Biomol. Screen. 2008, 13, 218 - 228. 
182. Alt, A.; Weiss, B.; Ornstein, P. L.; Gleason, S. D.; Bleakman, D.; Stratford Jr., R. E.; Witkin, 
J. M. Anxiolytic-like effects through a GLUK5 kainate receptor mechanism. 
Neuropharmacology 2007, 52, 1482 - 1487. 
183. Wirth, C.; Luscher, H. R. Spatiotemporal evolution of excitation and inhibition in the rat 
barrel cortex investigated with multielectrode arrays. J. Neurophysiol. 2004, 91, 1635 - 1647. 
276 
 
184. Schiff, S. J.; Jerger, K.; Duong, D. H.; Chang, T.; Spano, M. L.; Ditto, W. L. Controlling 
chaos in the brain. Nature 1994, 370, 615 - 620. 
185. Wu, Y.; Guan, L.; Tsau, Y. Propagating activation during oscillations and evoked responses 
in neocortical slices. J. Neurosci. 1999, 19, 5005 - 5015. 
186. Hobbs, J. P.; Smith, J. L.; Beggs, J. M. Aberrant neuronal avalanches in cortical tissue 
removed from juvenile epilepsy patients. J. Clin. Neurophysiol. 2010, 27, 380 - 386. 
187. Tang, A.; Jackson, D.; Hobbs, J. P.; Chen, W.; Smith, J. L.; Patel, H.; Prieto, A.; Petrusca, D.; 
Grivich, M. I.; Sher, A.; Hottowy, P.; Dabrowski, W.; Litke, A. M.; Beggs, J. M. A maximum 
entropy model applied to spatial and temporal correlations from cortical networks in vitro. J. 
Neurosci. 2008, 28, 505 - 518. 
188. Beggs, J. M.; Plenz, D. Neuronal avalanches in enocortical circuits. J. Neurosci. 2003, 23, 
11167 - 11177. 
189. Beggs, J. M.; Plenz, D. Neuronal avalanches are diverse and precise activity patterns that are 
stable for many hours in cortical slice cultures. J. Neurosci. 2004, 24, 5216 - 5229. 
190. Porsolt, R. D.; Bertin, A.; Jalfre, M. Behavioral despair in mice: a primary screening test for 
antidepressants. Arch. Int. Pharmacodyn. Ther. 1977, 229, 327 - 336. 
191. Gill, K. M.; Grace, A. A. The role of a5 GABAA receptor agonists in the treatment of cognitive 
deficits in schizophrenia. Curr. Pharm. Des. 2014, 20, 5069 - 5076. 
192. Soh, M. S.; Lynch, J. W. Selective modulators of a5-containing GABAA receptors and their 
therapeutic significance. Current Drug Targets 2015, 16, 735 - 746. 
193. Martinez-Cue, C.; Martinez, P.; Rueda, N.; Vidal, R.; Garcia, S.; Vidal, V.; Corrales, A.; 
Montero, J. A.; Pazos, A.; Florez, J.; Gasse, R.; Thomas, A. W.; Honer, M.; Knoflach, F.; 
Trejo, J. L.; Wettstein, J. G.; Hernandez, M. C. Reducing GABAA a5 receptor-mediated 
277 
 
inhibition rescues functional and neuromorphological deficits in a mouse model of down 
syndrome. J. Neurosci. 2013, 33, 3953 - 3966. 
194. Benes, F. M. A new paradigm for understanding gamma-aminobutyric acid cell pathology in 
schizophrenia? Biol. Psychiatry 2012, 72, 712 - 713. 
195. Benes, F. M.; Lim, B.; Matzilevich, D.; Walsh, J. P.; Subburaju, S.; Minns, M. Regulations 
of the GABA cell phenotype in hippocampus of schizophrenics and bipolars. Proc. Natl. 
Acad. Sci. 2007, 104, 10164 - 10169. 
196. Gill, K. M.; Cook, J. M.; Poe, M. M.; Grace, A. A. Prior Antipsychotic Drug Treatment 
Prevents Response to Novel Antipsychotic Agent in the Methylazoxymethanol Acetate Model 
of Schizophrenia. Schizophrenia Bulletin 2014, 40, 341-350. 
197. Gill, K. M.; Lodge, D. J.; Cook, J. M.; Aras, S.; Grace, A. A. A Novel a5GABAAR-Positive 
Allosteric Modulator Reverses Hyperactivation of the Dopamine System in the MAM Model 
of Schizophrenia. Neuropsychopharm. 2011, 36, 1903-1911. 
198. Lodge, D. J.; Grace, A. A. Hippocampal dysfunction and disruption of dopamine system 
regulation in an animal model of schizophrenia. Neurotox Rex. 2008, 14, 97 - 104. 
199. Papadimitriou, G. N.; Dikeos, D. G.; Karadima, G.; Avramopoulos, D.; Daskalopoulou, E. 
G.; Vassilopoulos, D.; Stefanis, C. N. Association between the GABAA receptor a5 subunit 
gene locus (GABRA5) and bipolar affective disorder. AM. J. Med. Gen. (Neuropsychiatric 
Genetics) 1998, 81, 73 - 80. 
200. McGrath, J.; Saha, S.; Welham, J.; El Saadi, O.; MacCauley, C.; Chant, D. A systematic 
review of the incidence of schizophrenia: the distribution of rates and the influence of sex, 
urbanicity, migrant status and methodology. BMC Medicine 2004, 2. 
278 
 
201. Stilo, S. A.; Murray, R. M. The epidemiology of schizophrenia: replacing dogma with 
knowledge. Dialogues Clin. Neurosci. 2010, 12, 305 - 315. 
202. Perez, S. M.; Lodge, D. J. New approaches to the management of schizophrenia: focus on 
aberrant hippocampal drive of dopamine pathways. Drug Des. Dev. Therapy 2014, 8, 887 - 
896. 
203. Lieberman, J. A.; Stroup, T. S.; McEvoy, J. P.; Swartz, M. S.; Rosenheck, R. A.; Perkins, D. 
O.; Keefe, R. S. E.; Davis, S. M.; Davis, C. E.; Lebowitz, B. D.; Severe, J.; Hsiao, J. K. 
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 
2005, 353, 1209 - 1223. 
204. Miyamoto, S.; Duncan, G. E.; Marx, C. E.; Lieberman, J. A. Treatments for schizophrenia: a 
critical review of pharmacology and mechnisms of action of antipsycotic drugs. Mol. 
Psychiatry 2005, 10, 79 - 104. 
205. Hattori, K.; Uchino, S.; Isosaka, T.; Maekawa, M.; Iyo, M.; Soato, T.; Kohsaka, S.; Yagi, T.; 
Yuasa, S. Fyn is required for haloperidol-induced catalepsy in mice. J. Biol. Chem. 2006, 281, 
7129 - 7135. 
206. Abi-Dargham, A.; Laruelle, M. Mechanisms of action of second generation antipsychotic 
drugs in schizophrenia: insights from brain imaging studies. Eur. Psychiatry 2005, 20, 15 - 
27. 
207. Leucht, S.; Pitschel-Walz, G.; Abraham, D.; Kissling, W. Efficacy and extrapyramidal side-
effects of the new antipsychotics olanzapine, quitiapine, risperidone, and sertindole compared 
to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. 
Schizophrenia Res. 1999, 35, 51 - 68. 
279 
 
208. Geddes, J.; Freemantle, N.; Harrison, P.; Bebbington, P. Atypical antipsychotics in the 
treatment of schizophrenia: systematic overview and meta-regression analysis. Br. Med. 
Journal 2000, 321, 1371 - 1376. 
209. Komossa, K.; Rummel-Kluge, C.; Hunger, H.; Schmid, F.; Schwarz, S.; Duggan, L.; Kissling, 
W.; Leucht, S. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane 
Database Syst. Rev. 2010, 3. 
210. Pincus, H. A.; Tew Jr., J. D.; First, M. B. Psychiatric comorbidity: is more less? World 
Psychiatry 2004, 3, 18 - 23. 
211. Green, A. I.; Canuso, C. M.; Brenner, M. J.; Wijcik, J. D. Detection and management of 
comorbidity in schizophrenia. Psychiatr. Clin. N. Am. 2003, 26, 115 - 139. 
212. Buckley, P. F.; Miller, B. J.; Lehrer, D. S.; Castle, D. J. Psychiatric comorbidities and 
schizophrenia. Schizophrenia Bulletin 2009, 35, 383 - 402. 
213. Perez, M. M.; Trimble, M. R. Epileptic psychosis--diagnostic comparison with process 
schizophrenia. Br. J. Psychiatry 1980, 137, 245 - 249. 
214. Cascella, N. G.; Schretlen, D. J.; Sawa, A. Schizophrenia and epilepsy: is there a shared 
susceptibility. Neurosci. Res. 2009, 63, 227 - 235. 
215. Lewis, D. A.; Lieberman, J. A. Catching up on schizophrenia: natural history and 
neurobiology. Neuron 2000, 28, 325 - 334. 
216. De Hert, M.; McKenzie, K.; Peuskens, J. Risk factors for suicide in young people suffering 
from schizophrenia: a long-term follow-up study. Schizophrenia Res. 2001, 47, 127 - 134. 
217. Gallos, G.; Yocum, G. T.; Siviski, M. E.; Yim, P. D.; Fu, X. W.; Poe, M. M.; Cook, J. M.; 
Harrison, N.; Perez-Zoghbi, J.; Emala, C. W. Selective targeting of the a5-subunit of GABAA 
280 
 
receptors relaxes airway smooth muscle and inhibits cellular calcium handling. Am J Physiol 
Lung Cell Mol Physiol 2015, 308, L931 - L942. 
218. Pascual, R. M.; Peters, S. P. Airway remodeling contributes to the progressive loss of lung 
function in asthma: an overview. J. Allergy and Clinical Immunology 2005, 116, 477 - 486. 
219. Rachelefsky, G. Inhaled corticosteroids and asthma control in children: assessing impairment 
and risk. Pediatrics 2009, 123, 353 - 366. 
220. Li, X.; Cao, H.; Zhang, C.; Furtmuller, R.; Fuchs, K.; Huck, S.; Sieghart, W.; Deschamps, J.; 
Cook, J. M. Synthesis, in Vitro Affinity, and Efficacy of a Bis 8-Ethynyl-4H-imidazo[1,5a]-
[1,4]benzodiazepine Analogue, the First Bivalent a5 Subtype Selective BzR/GABAA 
Antagonist. J. Med. Chem 2003, 46, 5567-5570. 
221. Bailey, D. J.; Tetzlaff, J. E.; Cook, J. M.; He, X.; Helmstetter, F. J. Effects of hippocampal 
injections of novel ligands selective for the a5b2g2 subunits of the GABA/benzodiazepine 
receptor on Pavlovian conditioning. Neurobiol. Learn. Mem. 2002, 78, 1 - 10. 
222. Atack, J. R.; Alder, L.; Cook, S. M.; Smith, A. J.; McKernan, R. M. In vivo labelling of a5 
subunit-containing GABAA receptors using the selecetive radioligand [
3H]L-655,708. 
Neuropharmacology 2005, 49, 220 - 229. 
223. Li, X. Ph.D. Thesis, Synthesis of Selective Ligands for GABAA/Benzodiazepine Receptors. 
University of Wisonsin-Milwaukee, Milwaukee, WI, 2004. 
224. Abadi, A. H.; Lankow, S.; Hoefgen, B.; Decker, M.; Kassack, M. U.; Lehman, J. 
Dopamine/serotonin receptor ligands, part III: synthesis and biological activities of 7,7'-
alkylene-bis-6,7,8,9,14,15-hexahydro-5H-benz[d]indolo[2,3g]azecines- application of the 
bivalent ligand approach to a novel type of dopamine receptor antagonist. Archiv. der 
Pharmazie 2002, 355, 367 - 373. 
281 
 
225. Han, D. M.; Forsterling, F. H.; Li, X.; Deschamps, J. R.; Parrish, D.; Cao, H.; Rallapalli, S.; 
Clayton, T.; Teng, Y.; Majumder, S.; Sankar, S.; Roth, B. L.; Sieghart, W.; Furtmuller, R.; 
Rowlett, J. K.; Weed, M. R.; Cook, J. M. A study of the structure-activity relationship of 
GABAA-benzodiazepine receptor bivalent ligands by conformational analysis with low 
temperature NMR and X-ray analysis. Bioorg. Med. Chem. 2008, 16, 8853 - 8862. 
226. Liu, R. Y.; Hu, R. J.; Zhang, P. W.; Skolnick, P.; Cook, J. M. Synthesis and pharmacological 
properties of novel 8-substituted imidazobenzodiazepines: high-affinity, selective porbes for 
a5-containing GABAA receptors. J. Med. Chem 1996, 39, 1928 - 1934. 
227. Savic, M. M.; Clayton, T.; Furtmuller, R.; Gavrilovic, I.; Samardzic, J.; Savic, S.; Huck, S.; 
Sieghart, W.; Cook, J. M. PWZ-029, a compound with moderate inverse agonist functional 
selectivity at GABAA receptors containing a5 subunits, improves passive, but not active, 
avoidance learning in rats. Brain Research 2008, 1208, 150-159. 
228. Milic, M.; Timic, T.; Joksimovic, S.; Biawat, P.; Rallapalli, S.; Divljakovic, J.; Radulovic, T.; 
Cook, J. M.; Savic, M. M. Pwz-029, an inverse agonist selective for a5 GABAA receptors, 
improves object recognition, but not water-maze memory in normal and scopolamine-treated 
rats. Behav. Brain Res. 2012, 241, 206-213. 
229. Rowlett, J. K.; Moran, C. A.; Clayton, T.; Rallapalli, S.; Roth, B. L.; Cook, J. M. In PWZ-
029, an inverse agonist selective for a5 subunit containing GABA(A) receptors, enhances 
performance on an executive function task in monkeys, European Behavioral Pharmacology 
Society, Rome, Italy, 2009; Rome, Italy, 2009. 
230. Savic, M. M.; Huang, S.; Furtmuller, R.; Clayton, T.; Huck, S.; Obradovic, D. I.; Ugresic, N. 
D.; Sieghart, W.; Bokonjic, D. R.; Cook, J. M. Are GABAA receptors containing a5 subunits 
282 
 
contributing to the sedative properties of benzodiazepine site agonists? Neuropharmacology 
2008, 33, 332 - 339. 
231. Porsolt, R. D.; McArthur, R. A.; Lenegre, A. Psychotropic Screening Procedures. In Methods 
in Behavioral Pharmacol., Haaren, V., Ed. Elsevier: Amsterdam, Netherlands, 1993; pp 23 - 
51. 
232. Nguyen, L. A.; He, H.; Pham-Huy, C. Chiral drugs: an overview. Int. J. Biomed. Sci. 2006, 2, 
85 - 100. 
233. Mellin, G. W.; Katzenstein, M. The saga of thalidomide: neuropathy to embryopathy, with 
case reports and congenital abnormalities. N. Engl. J. Med. 1962, 267, 1184 - 1193. 
234. Landoni, M. F.; Soraci, A. Pharmacology of chiral compounds: 2-arylpropionic acid 
derivatives. Current Drug Metabolism 2001, 2, 37 - 51. 
235. Drayer, D. E. Pharmacodynamic and pharmacokinetic differences between drug enantiomers 
in humans: an overview. Clin. Pharmacol. Therapeutics 1986, 40, 125 - 133. 
236. Patocka, J.; Dvorak, A. Biomedical aspects of chiral molecules. J. Applied Medicine 2004, 2, 
95 - 100. 
237. Izake, E. L. Chiral discrimination and enantioselective analysis of drugs: an overview. J. 
Pharmaceutical Sci. 2007, 96, 1659 - 1676. 
238. Ferguson, C. S.; Tyndale, R. F. Cytochrome P450 enzymes in the brain: emerging evidence 
for biological significance. Trends Pharmacol. Sci. 2011, 32, 708 - 714. 
239. Hedlund, E.; Gustafsson, J. A.; Warner, M. Cytochrome P450 in the brain; a review. Curr. 
Drug Metab. 2001, 2, 245 - 263. 
240. Schinkel, A. H. P-glycoprotein, a gatekeeper in the blood-brain barrier. Adv. Drug Deliv. Rev. 
1999, 36, 179 - 194. 
283 
 
241. Richetto, J.; Labouesse, M. A.; Poe, M. M.; Cook, J. M.; Grace, A. A.; Riva, M. A.; Meyer, 
U. Behavioral effects of the benzodiazepine-positive allosteric modulator SH-053-2'F-S-CH3 
in an immune-mediated neurodevolpmental disruption model. Int. J. Neuropsychopharmacol 
2015, 18, 1 - 11. 
242. Meyer, U. Prenatal poly(I:C) exposure and other devlopmental immune activation models in 
rodent systems. Biol. Psychiatry 2014, 75, 307 - 315. 
243. Meyer, U.; Feldon, J. Epidemiology-driven neurodevelopmental animal models in 
schizophrenia. Prog. Neurobiol. 2010, 90, 285 - 326. 
244. Brown, A. S.; Derkitis, E. J. Prenatal infection and schizophrenia: a review of epidemiologic 
and translational studies. Am. J. Psychiatry 2010, 167, 261 - 280. 
245. Soto, P. L.; Ator, N. A.; Rallapalli, S. K.; Biawat, P.; Clayton, T.; Cook, J. M.; Weed, M. R. 
Allosteric modulation of GABAA receptor subtypes: effects on visual recognition and 
visuospatial working memory in rhesus monkeys. Neuropsychopharm. 2013, 38, 2315 - 2325. 
246. Lodge, D. J.; Grace, A. A. Aberrant hippocampal activity underlies the dopamine 
dysregulation in an animal model of schizophrenia. J. Neurosci. 2007, 27, 11424 - 11430. 
247. Moore, H.; Jentsch, J. D.; Ghajarnia, M.; Geyer, M. A.; Grace, A. A. A neurobehavioral 
systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications 
for the neuropathology of schizophrenia. Biol. Psychiatry 2006, 60, 253 - 264. 
248. Cattabeni, F.; Di Luca, M. Developmental models of brain dysfunctions induced by targeted 
cellular ablations with methylazooxymethanol. Physiol Rev. 1997, 77, 199 - 215. 
249. Bakshi, V. P.; Geyer, M. A. Antagonism of phencyclidine-induced deficits in prepulse 
inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacol. 1995, 122, 
198 - 201. 
284 
 
250. Geyer, M. A.; Swerdlow, N. R.; Masbach, R. S.; Braff, D. L. Startle response models of 
sensorimotor gating and habituation deficits in schizophrenia. Brain Res. Bulletin 1990, 25, 
485 - 498. 
251. Swerdlow, N. R.; Braff, D. L.; Taaid, N.; Geyer, M. A. Assessing the validity of an animal 
model of deficient sensorimotor gating in schizophrenic patients. Arch. Gen. Psychiatry 1994, 
51, 139 - 154. 
252. Sanberg, P. R.; Bunsey, M. D.; Giordano, M.; Norman, A. B. The catalepsy test: its ups and 
downs. Behavioural Neuroscience 1988, 102, 748 - 759. 
253. Garver, D. L. Disease of the Nervous System: Psychiatric Disorders. In Clinical chemistry: 
Theory analysis and correlations, Kaplan, L. A.; Pesce, A. J., Eds. C.V. Mosby: St. Louis, 
MO, 1984; pp 864 - 881. 
254. Sanberg, P. R. Haloperidol-induced catalepsy is mediated by postsynaptic dopamine 
receptors. Nature 1980, 284, 472 - 473. 
255. Daniels, J. Catatonia: clinical aspects and neurobiological correlates. J. Neuropsychiatry Clin. 
Neurosci. 2009, 21, 371 - 380. 
256. Bast, T.; Zhang, W.; Feldon, J.; White, I. M. Effects of MK801 and neuroleptics on prepulse 
inhibition: re-examination in two strains of rats. Pharmacol. Biochem. Behav. 2000, 67, 647 
- 658. 
257. Boulay, D.; Depoortere, R.; Oblin, A.; Sanger, D. J.; Schoemaker, H.; Perrault, G. 
Haloperidol-induced catalepsy is absent in dopamine D2, but maintained in dopamine D3 
receptor knock-out mice. Eur. J. Pharmacol. 2000, 391, 63 - 73. 
258. Garbutt, J. C.; van Kammen, D. P. The interaction between GABA and dopamine: 
implications for schizophrenia. Schizophrenia Bulletin 1983, 9, 336 - 356. 
285 
 
259. Behlke, L. M.; Foster, R. A.; Liu, J.; Benke, D.; Benham, R. S.; Nathanson, A.; Yee, B. K.; 
Zeilhofer, H. U.; Engin, E.; Rudolph, U. A pharmaco-genetic 'restriction-of-function' 
approach reveals evidence for anxiolytic-like actions mediated by a5-containing GABAA 
receptors in mice. Neuropsychopharm. 2016. 
260. D'Hooge, R.; De Deyn, P. P. Applications of the Morris water maze in the study of learning 
and memory. Brain Res. Rev. 2001, 36, 60 - 90. 
261. Wongwitdecha, N.; Marsden, C. A. Effects of social isolation rearing on learning in the Morris 
water maze. Brain Research 1996, 715, 119 - 124. 
262. Sharma, S.; Rakoczy, S.; Brown-Borg, H. Assessment of sptial memory in mice. Life Sci. 
2010, 87, 521 - 536. 
263. Terranova, J.-P.; Chabot, C.; Barnouin, M.-C.; Perrault, G.; Depoortere, R.; Griebel, G.; 
Scatton, B. SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist, 
alleviates disturbances of novelty discrimination in a social context in rats, a putative model 
of selective attention deficit. Psychopharmacol. 2005, 181, 134 - 144. 
264. Craddock, N.; Owen, M. J. The Kraepelinian dichotomy - going, going... but still not gone. 
Br. J. Psychiatry 2010, 196, 92 - 95. 
265. Fung, S. J.; Fillman, S. G.; Webster, M. J.; Weickert, C. S. Schizophrenia and bipolar disorder 
show both common and distinct changes in cortical interneuron markers. Schizophrenia Res. 
2014, 155, 26 - 30. 
266. Lin, L. C.; Sibille, E. Reduced brain somatostatin in mood disorders: a common 
pathophysiological substrate and drug target? Front. Pharmacology 2013, 4, 110. 
267. Lin, L. C.; Sibille, E. Somatostatin, neuronal vulnerability and behavioral emotionality. Mol. 
Psychiatry 2015, 20, 377 - 387. 
286 
 
268. Seney, M. L.; Chang, L. C.; Oh, H.; Wang, X.; Tseng, G. C.; Lewis, D. A.; Sibille, E. The 
role of genetic sex in affect regulation and expression of GABA-related genes across species. 
Front. Psychiatry 2013, 4, 104. 
269. Gallos, G.; Gleason, N. R.; Zhang, Y.; Pak, S. W.; Sonett, J. R.; Yang, J.; Emala, C. W. 
Activation of endogenous GABAA channels on airway smooth muscle potentiates 
isoproterenol-mediated relaxation. Am J Physiol Lung Cell Mol Physiol 2008, 295, L1040 - 
L1047. 
270. Chu, E. K.; Drazen, J. M. Asthma: one hundred years of treatment and onward. Am. J. Respir. 
Crit. Care Med. 2005, 171, 1202 - 1208. 
271. Xiang, Y. Y.; Wang, S.; Liu, M.; Hirota, J. A.; Li, J.; Ju, W.; Fan, Y.; Kelly, M. M.; Ye, B.; 
Orser, B.; O'byrne, P. M.; Inman, M. D.; Yang, X.; Lu, W. Y. A GABAergic system in airway 
epithelium is essential for mucus overproduction in asthma. Nature Medicine 2007, 13, 862 - 
867. 
272. Yocum, G. T.; Gallos, G.; Zhang, Y.; Jahan, R.; Stephen, M. R.; Varagic, Z.; Puthenkalam, 
R.; Ernst, M.; Cook, J. M.; Emala, C. W. Targeting the g-aminobutyric acid A receptor a4 
subunit in airway smooth muscle to alleviate bronchoconstriction. Am. J. Respir. Cell Mol. 
Biol 2016, 54, 546 - 553. 
273. Fredberg, J. J.; Inouye, D. S.; Mijailovich, S. M.; Butler, J. P. Perturbed equilibrium of myosin 
binding in airway smooth muscle and its implications in bronchospasm. Am. J. Respir. Crit. 
Care Med. 1999, 159, 959 - 967. 
274. Doeing, D. C.; Solway, J. Airway smooth muscle in the pathophysiology and treatment of 
asthma. J. Appl. Physiol. 2013, 114, 834 - 843. 
287 
 
275. Obradovic, A. L.; Joksimovic, S.; Batinic, B.; Radulovic, T.; Poe, M. M.; Namjoshi, O. A.; 
Cook, J. M.; Ramerstorfer, J.; Varagic, Z.; Sieghart, W.; Karovic, B.; Roth, B.; Savic, M. M. 
SH-I-048A, an in vitro nonselective super-agonist at the benzodiazepine site of GABAA 
receptors: the approximated activation of receptor subtypes may explain behavioral effects. 
Brain Res. 2014, 1554, 36 - 48. 
276. Ramerstorfer, J.; Furtmuller, R.; Vogel, E.; Huck, S.; Sieghart, W. The point mutation gamma 
2F77I changes the potency and efficacy of benzodiazepine site ligands in different GABAA 
receptor subtypes. Eur. J. Pharmacol. 2010, 636, 18 - 27. 
277. Botta, P.; Demmou, L.; Kasugai, Y.; Markovic, M.; Xu, C.; Fadok, J. P.; Lu, T.; Poe, M. M.; 
Xu, L.; Cook, J. M.; Rudolph, U.; Sah, P.; Ferraguti, F.; Luthi, A. Regulating anxiety with 
extrasynaptic inhibition. Nat. Neurosci. 2015, 18, 1493 - 1500. 
278. Mercolini, L.; Mandrioli, R.; Iannello, C.; Matrisciano, F.; Nicoletti, F.; Raggi, M. A. 
Simultaneous analysis of diazepam and its metabolites in rat plasma and brain tissue by 
HPLC-UV and SPE. Talanta 2009, 80, 279 - 285. 
279. Dunham, M. S.; Miya, T. A. A note on a simple apparatus for detecting neurological deficit 
in rats and mice. J. Amer. Pharm. Ass. Sci. 1957, 46, 208 - 209. 
280. Swinyard, E. A.; Woodhead, J. H.; White, H. S.; Franklin, M. R. General Principles: 
Experimental Selection, Quantification, and Evaluation of Anticonvulsants. In Antiepileptic 
Drugs, 3rd ed.; Levy, R. H.; Mattson, R. H.; Melrum, B.; Penry, J. K.; Dreifuss, F. E., Eds. 
Raven Press: New York, 1989; pp 85 - 102. 
281. White, H. S.; Woodhead, J. H.; Franklin, M. R. General Principles: Experimental Selection, 
Quantification, and Evaluation of Antiepileptic Drugs. In Antiepileptic Drugs, 4th ed.; Levy, 
R. H.; Mattson, R. H.; Meldrum, B. S., Eds. Raven Press: New York, 1995; pp 99 - 110. 
288 
 
282. White, H. S.; Johnson, M.; Wolf, H. H.; Kupferberg, H. J. The early identification of 
anticonvulsant activity: role of the maximal electroshock and subcutaneous pentylenetetrazole 
seizure models. Italian Journal of Science 1995, 16, 73 - 77. 
283. Swinyard, E. A.; Clark, L. D.; Miyahara, J. T.; Wolf, H. H. Studies on the mechanism of 
amphetamine toxicity in aggregated mice. J. Physiol. 1961, 132, 97 - 102. 
284. Vorhees, C. V.; Williams, M. T. Value of water mazes for assessing spatial and egocentric 
learning and memory in rodent basic research and regulatory studies. Neurotoxicol. Teratol. 
2014, 45, 75 - 90. 
285. Savic, M. M.; Milinkovic, M. M.; Rallapalli, S.; Clayton, T.; Joksimovic, S.; Van Linn, M.; 
Cook, J. M. The differential role of alpha1- and alpha5-containing GABA(A) receptors in 
mediating diazepam effects on spontaneous locomotor activity and water-maze learning and 
memory in rats. Int. J. Neuropsychopharmacol 2009, 12, 1179 - 1193. 
286. Engelmann, M.; Wotjak, C. T.; Landgraf, R. Social discrimination procedure: an alternative 
method to investigate juvenile recognition abilities in rats. Physiol. Behav. 1995, 58, 315 - 
321. 
287. Edgar, N. M.; Touma, C.; Palme, R.; Sibille, E. Resilient emotionality and molecular 
compensation in mice lacking the oligodendrocyte-specific gene Cnp1. Transl. Psychiatry 
2011, 20. 
 
 
 289 
 
APPENDIX A. Characterization of HZ-166 and YT-III-31 (CRO). 
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APPENDIX B. Oocyte efficacy and binding of BZDs (including flumazenil) 
and β-carbolines (data from Scott Harvey). 
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APPENDIX C. Ester Breakdown of Compounds in Biological Matrices (data 
report by Mithridion, Inc.). 
Summary: Metabolic stability studies of Bz/GABAA ligands incubated in whole blood, brain, 
liver and liver microsomes. 
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 Study Objectives 
 
A. Ester breakdown in biological tissues  
 
The objective is to determine the rate of breakdown of the ester in human blood, 
brain, liver and kidney.   
 
B. Development of a bioanalytical method for parent ester compound 
 
The proteins will be precipitated using formic acid, followed by centrifugation and 
ultra-filtration; or using acetonitrile or methanol, followed by SpeedVacing and 
redissolution in LC mobile phase.  Alternatively the compounds will be extracted into 
organic phase, SpeedVaced and redissolved in LC mobile phase.  The initial choice of 
extraction method and LC method will be made based upon chemical structure, 
chemical stability and physicochemical properties of the compounds.  If the 
compounds are poorly soluble in aqueous buffers, if they are tightly protein bound, or 
if reverse-phase LC is unsatisfactory, additional work may be required. 
 
We will consult with the Cook lab on method selection and if initial standard methods 
are unsatisfactory, meaning that additional work is required.  
 
Initially, for economy, we will measure the parent compounds simply using the peak 
areas of the parent ester compounds in the MS-MS using characteristic parent and 
product ions.  The quantification may not be exact.  
  
C. Semi-quantitative test of ester breakdown 
 
The compounds will be incubated with the tissue or tissue homogenate for various 
times, the parent compound and its breakdown products will be extracted from the 
biological materials, and assayed using LC-MS-MS.   
 
The area of the parent (ester) will be determined at time zero and at various times.  
The breakdown will be expressed as follows:  
 
Fraction broken down = 1- ((Area at time t) /(Area at time 0)) 
 
Providing all samples are treated identically, the time zero sample will serve to 
normalize for extraction efficiency.  The experiment will then be repeated.  We will 
look for characteristic breakdown products, in particular the acid, though this may be 
further metabolized. 
 
D. Interim report 
 
We will produce an interim report and discuss the initial results with Prof Cook.  We 
can then decide whether further work is required.  The semi-quantitative assay should 
enable the relative susceptibilities of the compounds to breakdown to be determined.  
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 An estimate of breakdown rates will be obtained.  We may be able to detect and 
identify breakdown products other than those formed by simple de-esterification.  If 
desired, we could use inhibitors to part-characterize the enzymes responsible. 
 
Initial Setup and Evaluation 
 
A. Solubility Determination and Solution Formulation 
 
All compounds were initially dissolved in dimethyl sulfoxide (DMSO) at a 
concentration of 20 mg/mL.  Gentle heating was applied to dissolve the compound if 
necessary.  Portions of these DMSO stocks were added to phosphate buffered saline 
(PBS) in an attempt to form 2 mM solutions.  However, six out of the seven 
compounds precipitated immediately.  The six solutions that showed precipitation 
were centrifuged at 16,000 x g for 10 minutes at 4°C, and the saturated solutions were 
removed from the undissolved material.  These saturated solutions were aliquoted and 
stored at -20°C until needed for the rest of the experiments outlined herein. 
 
Compound Saturated Stock 
(uM) 
HZ166 144 
YT-TC-3 774 
JY-XHe-053 480 
EMJ-026 146 
XLi-210 1,214 
DM-II-20 147 
XHe053 199 
 
B. Sample Preparation and Compound Recovery 
 
It is necessary to use an extraction method that shows good recovery of the compound 
from all matrices used in experimentation in order to give accurate results.  Based 
upon the compounds’ high logPs, an organic extraction was the most logical choice 
for compound recovery from biological matrices.  The procedure used for sample 
preparation is outlined below. 
 
Samples were kept on ice throughout the entire preparation procedure.  Six hundred 
microliters of acetonitrile (AcN) was added to 200 uL of sample and vortexed.  The 
precipitated sample was centrifuged at 16,000 x g for 10 minutes at 4°C.  The 
supernatant was removed and transferred to a capless tube and dried overnight in 
vaccuo at room temperature by Savant SpeedVac (Model SC110).  The dried material 
was resuspended in 200 uL of 0.1% formic acid and filtered through a 0.2 um spin 
filter (Pall) at 16,000 x g for 3 minutes.  The solution was diluted 8-fold in 0.1% 
formic acid, placed in a 96-well plate with a plate seal, and analyzed by LC/MS/MS 
as described below.  The sample remained at 4°C in the LC autosampler until 
analyzed. 
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 Compound recovery was tested by performing the above sample preparation 
procedure on each compound added to 200 uL of whole blood, brain, kidney and liver 
homogenates.  These samples were immediately precipitated with 600 uL of AcN and 
prepared as above.  Control samples were prepared by substituting the matrix with an 
equal volume of water.  These matrix samples were compared to control samples to 
calculate percent recovery. 
 
C. Liquid Chromatography and Mass Spectrometry Methods 
 
Multiple Reaction Monitoring (MRM) methods were developed for each compound 
and its corresponding metabolite.  Solutions were prepared by adding 1 uL of each 
DMSO stock to 500 uL of 50% AcN + 0.1% formic acid.  Samples were infused at a 
rate of 10 uL/min by syringe pump.  Samples were analyzed on an API3200 (Applied 
Biosystems) triple quadrupole mass spectrometer.  The parent ion, product ion, and 
mass spec settings for each compound were determined automatically through 
quantitative optimization by the Analyst 1.4.2 (Applied Biosystems) software.  The 
MS/MS settings for each compound and metabolite are summarized in Table 1 below. 
 
Table 1.  Mass Spectrometer Settings 
 
Compound Name  
Q1 
Parent 
ion m/z 
Q3 
Product  
ion m/z Polarity DP EP CE CXP 
HZ166 357.1 311.0 Positive 51 9.5 23 4 
YT-TC-3 651.2 274.0 Positive 101 9.5 47 6 
JY-XHe-053 374.1 328.0 Positive 46 8 25 4 
EMJ-026 394.2 310.1 Positive 56 5 27 4 
XLi-210 631.2 264.1 Positive 111 7.5 45 6 
DM-II-20 410.1 310.1 Positive 61 7.5 29 4 
XHe053 356.1 310.1 Positive 46 10 25 4 
HZ166 acid 329.1 232.1 Positive 46 9.5 35 4 
YT-TC-3 acid 292.0 274.0 Positive 46 8.5 19 4 
JY-XHe-053 acid 346.1 249.1 Positive 41 6.5 31 4 
EMJ-026, XHe053, DM-II-20 acid 328.2 231.1 Positive 46 8.5 33 4 
XLi-210 acid 282.1 264.1 Positive 46 9.5 19 4 
 
The same LC method was used for all compounds and metabolites.  See details in 
Table 2. 
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 Table 2.  LC Settings 
 
Variable Setting 
HPLC Shimadzu Prominence 
Column Agilent Zorbax 300SB-C8, 2.1x150mm, 3.5um 
Solvent A H2O + 0.1% formic acid 
Solvent B AcN + 0.1% formic acid 
Gradient 0-100% B, 5 min; 100% B, 2 min 
Flowrate 0.3 mL/min 
Column Oven Temp. 40°C 
Injection Volume 5 uL 
 
Table 3 shows the retention times for each compound and metabolite obtained with 
this LC method. 
 
Table 3.  LC Retention Times 
 
Compound Name  tR (min) 
HZ166 5.4 
YT-TC-3 5.7 
JY-XHe-053 5.8 
EMJ-026 6.2 
XLi-210 5.5 
DM-II-20 6.0 
XHe053 5.8 
HZ166 acid 4.8 
YT-TC-3 acid 5.1 
JY-XHe-053 acid 5.5 
EMJ-026, XHe053, DM-II-20 acid 5.4 
XLi-210 acid 5.0 
 
It is important that the parent compound and its metabolite have different retention 
times, for if there is some “breakthrough” in signal for MRM methods between the 
two due to similar product ions, the two signals may be differentiated from one 
another on the basis of their retention times.  In this situation, all parent 
compound/metabolite pairs are separated by 0.3-0.8 minutes, which is more than 
adequate to distinguish between the two signals. 
 
Ester Breakdown In Vitro 
 
A. Sample Composition 
 
The composition of samples is listed in Table 4.  Each sample had a total volume of 
200 uL.  All samples were incubated at 37°C in a water bath during each experiment. 
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 Table 4.  Sample Composition 
 
Assay Component Volume (uL) 
Brain Esterase 
Brain Homogenate 80 
H2O 30 
100 mM Tris + 600 mM NaCl + 20 mM CaCl2 50 
Compound 40 
Kidney or 
Liver Esterase 
Kidney or Liver Homogenate 40 
H2O 70 
100 mM Tris + 600 mM NaCl + 20 mM CaCl2 50 
Compound 40 
Whole Blood 
Esterase 
Whole Blood 160 
Compound 40 
 
B. B.  Timecourse Studies 
 
In order to determine the appropriate incubation time for each matrix, an initial 
timecourse study was conducted.  All seven compounds were incubated in whole 
blood, brain, kidney and liver homogenates at 37°C.  Aliquots were removed at 
selected time points and enzymatic activity halted by the addition of 600 uL of AcN.  
For brain, kidney and liver homogenates, the time points were 0, 20, 40, 60, and 120 
minutes.  For whole blood, the time points were 0, 10, 20, 30, and 60 minutes.  All 
samples were kept on ice until all time points were completed.  Samples were 
prepared for analysis by LC/MS/MS as outlined above.   
 
C. Standard Curves 
 
Standard curves for each compound were prepared with a known concentration of 
compound dissolved in DMSO by serially diluting into PBS.  Parent compound 
standards were made up at the following concentrations:  62.5, 125, 250, 500, 1000, 
2000 uM.  Standards and stock solutions were diluted 1:8 or 1:80 into 0.1% formic 
acid.  These diluted solutions were analyzed by LC/MS/MS to form standard curves 
used to calculate the concentrations of each compound and metabolite. 
 
D. Comprehensive In Vitro Esterase Experiments 
 
Triplicate samples were set up as outlined in Table 4.  Brain homogenate samples 
were incubated at 37°C for 120 minutes, and kidney and liver homogenates and 
whole blood samples were incubated at 37°C for 60 minutes.  Time 0 samples for 
each compound and matrix were also prepared in triplicate.  Samples were prepared 
for MS analysis as outlined above.  The samples were quantitatively analyzed by 
LC/MS/MS for each compound and its predicted metabolite.  Any statistical outliers 
were discarded and not used in the final calculations. 
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 E. LC/MS Scans for Novel Metabolites 
 
LC/MS Scans (Q1) were performed on all samples to attempt to identify novel 
metabolites not predicted previously.  The same LC/MS settings were used as 
outlined in Table 1.  The resulting scan for each sample was compared to its 
corresponding Time 0 scan to look for the introduction of new masses.  ChemDraw 
Ultra 10.0 software was used in an attempt to elucidate the chemical structures for the 
discovered masses. 
 
Experimental Results 
 
A. Compound Recovery 
 
The recovery of the compounds from the biological matrices used in this set of 
experiments was 58-163%.  The raw data are listed in Appendix A at the end of this 
report.  This sample extraction procedure is adequate for use in further experiments. 
 
B. Timecourse Studies 
 
The optimal incubation time for each matrix is one in which the breakdown of parent 
compound has reached a steady state for all compounds of interest.  At this point, 
differences in the metabolism of each compound can be delineated.  For this set of 
experiments, the optimal incubation time was determined to be 60 minutes for kidney 
and liver homogenates, and 120 minutes for brain homogenate. 
 
C. Standard Curves 
 
The raw data for all standard curves can be found in Appendix B at the end of this 
report.  These curves were used to calculate the concentrations of stock solutions used 
in these experiments. 
 
D. Comprehensive In Vitro Esterase Experiments 
 
A summary of these experimental results can be found in Table 5 below.  The raw 
data obtained from these experiments can be found in Appendix C at the end of this 
report. 
 
Compounds YT-TC-3 and XLi-210 had similar breakdown profiles to each other, but 
different from the rest of the compounds.  YT-TC-3 was 57% broken down in the 
brain; Xli-210 was 32% broken down under the same conditions.  Both compounds 
were metabolized less in liver, and kidney and were quite stable in 80% whole blood. 
Both compounds formed their predicted acid metabolites. 
 
Compounds HZ166, JY-XHe-053, and XHe053 had similar breakdown profiles to 
each other.  These compounds were 43%, 39% and 32% broken down by liver 
homogenate, respectively.  In addition, HZ166 was susceptible to breakdown by 
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 kidney homogenate (51% breakdown), while the other two compounds were not.  All 
compounds were stable in 80% whole blood. These three compounds formed their 
predicted acid metabolites. 
 
DM-II-20 was the most susceptible to breakdown of all the compounds tested.  59% 
breakdown was observed in kidney, 99% in liver homogenates, and 25% in brain 
homogenates, forming its predicted acid metabolite.  In contrast, this compound was 
stable in 80% whole blood.  XHe053 was more stable in liver and brain that DM-II-
20, and was stable in kidney and 80% whole blood.  This outcome might be expected 
as the trifluoroethyl group of DM-II-20 is a better leaving group than the ethyl group 
of XHe053. 
 
Compounds EMJ-026 and XHe053 had similar breakdown profiles.  However, EMJ-
026 was more susceptible to brain and kidney esterase activity, than XHe053.  
XHe053 was stable in kidney and 80% whole blood.  XHe053 formed the predicted 
acid metabolite, whereas EMJ-026 did not form its predicted acid metabolite.
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Table 5.  Summary of Esterase Breakdown of Parent Compounds 
 
Structure R 
Compound 
Name 
% Compound 
Remaining Predicted 
Metabolite 
Br Ki Li WB 
 
 
YT-TC-3 42.8 80.9 69.0 78.7 + 
 
XLi-210 68.0 72.4 59.9 111.7 + 
 
 
HZ166 98.1 49.3 58.9 97.0 + 
 
JY-XHe-053 84.4 108.5 61.3 113.8 + 
 
XHe053 88.7 103.5 67.5 109.4 + 
  
DM-II-20 74.7 40.9 1.1 101.7 + 
 
XHe053 88.7 103.5 67.5 109.4 + 
 
 
EMJ-026 57.5 66.7 59.4 97.9 - 
 
XHe053 88.7 103.5 67.5 109.4 + 
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R
O
O
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 E. LC/MS Scans for Novel Metabolites 
 
Homogenates containing compounds incubated for 60 or 120 minutes at 37oC were 
scanned using LC/MS and compared to control homogenates that had not been 
incubated, to attempt to identify novel metabolites.  Ions with masses other than the 
predicted metabolites were observed.  However, none of the novel masses could be 
translated into predicted structures derived from the structures of the parent 
compounds.  Clearly EMJ-026 forms a metabolite other than the one predicted, but its 
structural identity was not elucidated through these methods.   
 
Comments on the Experimental Results 
 
These compounds were difficult to work with, because of their highly hydrophobic 
natures and relatively low aqueous solubilities. This precluded the use of LC-UV, which 
might have made it easier to track the major metabolites.  Additionally, only minute 
amounts of each compound were available to use for testing purposes.  With the 
experience gained in the current project, we could design sound quantitative evaluations, 
though it might be difficult to estimate Vmax or Km, given their low solubilities. 
 
We would recommend that in vivo PK and metabolism studies should be undertaken 
before further in vitro studies.  It would be important to establish whether the in vitro 
tests model in vivo metabolism well.  These experiments might be quite challenging, 
because formulation has proven difficult, again due to hydrophobicity and low solubility.  
This is not to suggest it is impossible, but typically, a good deal of empirical work is 
required with such compounds to establish the best formulations and dosing regimens. 
 
It is important to bear in mind that metabolism varies greatly between species.  In 
previous work in this laboratory, we found that human and rat serum (surprisingly) did 
not hydrolyze alkyl esters in a series of carboxylic acids.  However, whole blood did 
cause hydrolysis, and it was the blood cells that caused the hydrolysis.  While it is 
difficult to identify enzymes in complex tissue homogenates by inhibitor profiling, we 
had a strong suspicion that the ester hydrolysis was not caused by typical non-specific 
esterases.  
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APPENDIX D. ADME Evaluation of Test Agents (data by Apredica). 
 
Summary: Ligand HZ-166 was incubated in rabbit, guinea pig and dog liver microsomes for 
metabolic stability. 
 
Structure: 
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An updated model of the GABA(A) benzodiazepine receptor pharmacophore of the 𝛼5-BzR/GABA(A) subtype has been
constructed prompted by the synthesis of subtype selective ligands in light of the recent developments in both ligand synthesis,
behavioral studies, and molecular modeling studies of the binding site itself. A number of BzR/GABA(A) 𝛼5 subtype selective
compounds were synthesized, notably 𝛼5-subtype selective inverse agonist PWZ-029 (1) which is active in enhancing cognition
in both rodents and primates. In addition, a chiral positive allosteric modulator (PAM), SH-053-2󸀠F-R-CH
3
(2), has been shown
to reverse the deleterious effects in the MAM-model of schizophrenia as well as alleviate constriction in airway smooth muscle.
Presented here is an updated model of the pharmacophore for 𝛼5𝛽2𝛾2 Bz/GABA(A) receptors, including a rendering of PWZ-
029 docked within the 𝛼5-binding pocket showing specific interactions of the molecule with the receptor. Differences in the
included volume as compared to 𝛼1𝛽2𝛾2, 𝛼2𝛽2𝛾2, and 𝛼3𝛽2𝛾2 will be illustrated for clarity. These new models enhance the ability
to understand structural characteristics of ligands which act as agonists, antagonists, or inverse agonists at the Bz BS of GABA(A)
receptors.
1. Introduction
Thegamma-amino butyric acid A (GABAA) receptor is a het-
eropentameric chloride ion channel.This channel is generally
made up of two 𝛼-subunits, two 𝛽-subunits, and a single 𝛾-
subunit arranged in an 𝛼𝛽𝛼𝛽𝛾 fashion.TheGABAA receptors
(GABAAR) are responsible for a myriad of brain functions.
Positive allosteric modulators (PAMs) and negative allosteric
modulators (NAMs) act on the benzodiazepine (BZ) site of
the GABAAR which can change the conformation of the
receptor to inhibit or excite the neurons associated with the
ion channel. To date, researchers have been unable to get
an X-ray crystal structure of a functional Bz/GABAAR ion
channel. Recently, Miller and Aricescu [1] have reported the
crystal structure of a homopentameric GABAAR containing
the𝛽3-subunit at 3 A˚ resolution. Although this work provides
great promise that other heteropentameric GABAARs will
be crystallized in the near future, molecular modeling and
structure-activity-relationships (SARs) still remain key tools
to find better subtype-selective binding agents.
2. Subtype Selective Ligands for 𝛼5
GABA(A)/Bz Receptors
Interest in BzR/GABA(A) 𝛼5 subtypes began years ago when
it was realized that 𝛼5𝛽3𝛾2 Bz/GABA(A) subtypes are located
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Figure 1: Alpha 5 selective compounds [13]. This figure is modified from that reported in [13].
primarily in the hippocampus. More recently this interest has
been confirmed by the report of Mo¨hler et al. [2–5] on 𝛼5
“knock-in mice.” This group has provided strong evidence
that hippocampal extrasynaptic 𝛼5 GABA(A) receptors play
a critical role in associative learning as mentioned above [6–
11].
Earlier we synthesized a series of 𝛼5 subtype selective
ligands (RY-023, RY-024, RY-079, and RY-080) based on the
structure of Ro 15-4513 and reported their binding affinity [6],
as well as several ligands by Atack et al. [12]. These ligands
are benzodiazepine receptor (BzR) negative modulators in
vivo and a number of these compounds have been shown to
enhance memory and learning [13]. One of these ligands was
shown by Bailey et al. [6] to be important in the acquisition of
fear conditioning and has provided further evidence for the
involvement of hippocampal GABA(A)/BzR in learning and
anxiety [13]. This is in agreement with the work of DeLorey
et al. [7] in a memory model with a ligand closely related
to 𝛼5 subtype selective inverse agonists RY-024 and RY-079
including PWZ-029 (1).
In order to enhance the𝛼5 subtype selectivity, the bivalent
form of RY-80 (3) was prepared to provide XLi-093 (4)
[13]. The binding affinity of XLi-093 in vitro was determined
on 𝛼
1–6𝛽3𝛾2 LTK cells and is illustrated in Figure 1. This
bivalent ligand exhibited little or no affinity at 𝛼
1–4,6𝛽3𝛾2
BzR/GABA(A) subtypes, but this 𝛼5 ligand had a𝐾
𝑖
of 15 nM
at the 𝛼5𝛽3𝛾2 subtype [14]. Since this receptor binding study
indicated bivalent ligandXLi-093 bound almost exclusively to
the 𝛼5 subtype, the efficacy of this ligand onGABA(A) recep-
tor subtypes expressed in Xenopus oocytes was investigated
by Sieghart, Furtmueller, Li, and Cook [14, 15]. Analysis of the
data indicated that XLi-093 up to a concentration of 1 𝜇Mdid
not trigger chloride flux in any one of the GABA(A) subtypes
tested. At 1 𝜇M XLi-093 did not modulate GABA induced
chloride flux in 𝛼1𝛽3𝛾2, 𝛼2𝛽3𝛾2, or 𝛼3𝛽3𝛾2 receptors, but
very slightly inhibited chloride flux in 𝛼5𝛽3𝛾2 subtypes. At
1 𝜇M, XLi-093 barely influenced benzodiazepine (Valium)
stimulation of GABA-induced current in 𝛼1𝛽3𝛾2, 𝛼2𝛽3𝛾2,
Figure 2: XLi-093 (4) aligned in the included volume of the phar-
macophore receptor model for the 𝛼5𝛽3𝛾2 subtype [17, 18] (this
figure is modified from the figure in Clayton et al., 2007) [23].
and 𝛼3𝛽3𝛾2 BzR but shifted the diazepam dose response
curve to the right in 𝛼5𝛽3𝛾2 receptors in a very signifi-
cant manner [16]. Importantly, bivalent ligand XLi-093 was
able to dose dependently and completely inhibit diazepam-
stimulated currents in 𝛼5𝛽3𝛾2 receptors. This was the first
subtype selective benzodiazepine receptor site antagonist at
𝛼5 receptors. This bivalent ligand XLi-093 provided a lead
compound for all of the bivalent ligands in this research [16].
Illustrated in Figure 2 is XLi-093 (4) aligned excellently
within the pharmacophore-receptor model of the 𝛼5𝛽3𝛾2
subtype [14, 16–19]. The fit to the pharmacophore-receptor
and the binding data indicate that bivalent ligands will bind
to BzR subtypes [14, 19]. It is believed that the dimer enters
the binding pocket with one monomeric unit docking while
the other monomer tethered by a linker extends out of
the protein into the extracellular domain. If this is in fact
true that the second imidazole unit is protruding into the
extracellular domain of the BzR/GABA(A) 𝛼5 binding site,
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Table 1: Full PDSP panel receptor binding reported (Roth [138]) for XLi-093 and XLi-356.
Cook code 5ht1a 5ht1b 5ht1d 5ht1e 5ht2a 5ht2b 5ht2c 5ht3 5ht5a 5ht6 5ht7 𝛼1A 𝛽1B 𝛼2A 𝛼2B
XLi093 ∗ Repeat ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗
XLi356 ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗
Cook code 𝛼2C Beta1 Beta2 CB1 CB2 D1 D2 D3 D4 D5 DAT DOR H1 H2 H3
XLi093 ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗
XLi356 ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗
Cook code H4 Imidaz oline KOR M1 M2 M3 M4 M5 MDR MOR NET NMDA SERT 𝜎1 𝜎2
XLi093 ∗ ∗ 2,024.00 ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗
XLi356 ∗ ∗ 6,118.00 ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗
Data (“secondary binding”) are𝐾
𝑖
values.𝐾
𝑖
values are reported in nanomolar concentration, CaseWestern Reserve University. “∗” indicates “primarymissed”
(<50% inhibition at 10 𝜇M). See full data of the PDSP screen in the report of Clayton [22].
it could have a profound effect on the ligand design. This
means other homodimers or even heterodimers may bind to
BzR/GABA(A)ergic sites.
In this vein, Wenger, Li, and Cook et al. [13, 20, 21] earlier
described preliminary data that XLi-093, an 𝛼5 subtype
selective antagonist, enhances performance of C57BL/6Jmice
under a titrating delayed matching to position schedule of
cognition, as illustrated in Figure 3 [14, 16–19].This indicates,
however, that this agent does cross the blood brain barrier.
Bivalent ligands have a preferred linker of 3–5 methylene
units, between the two pharmacophores (see XLi-093). This
was established by NMR experiments run at low tempera-
tures, X-ray crystallography, and molecular modeling of the
ligands in question and will be discussed [14, 17, 18].
Based on this data, additional 𝛼5-subtype selective lig-
ands have been prepared (see Figure 4). The basic imida-
zobenzodiazepine structure has been maintained [7]; how-
ever substituents were varied in regions around the scaffold
based on molecular modeling [6]. These are now the most
𝛼5 subtype selective ligands ever reported [22]. Moreover,
the ability to increase the subtype selectivity can be done
by selecting specific substituents on these ligands to new
agents with 400–1000-fold 𝛼5-selectivity over the remaining
5 subtypes.This is an important step forward to understanding
the true, unequivocal physiological responses mediated by
𝛼5 subtypes in regard to cognition (amnesia), schizophrenia,
anxiety, and convulsions, all of which in some degree are
influenced by 𝛼5 subtypes. Based on the ligands in Figures
4 and 5, affinity has occurred principally at 𝛼5 subtypes. In
addition, since XLi-093 bound very tightly only to 𝛼5 BzR
subtypes, the bivalent nature and functionality presented here
can be incorporated into other dimeric ligands.
As shown previously in Figure 3, 𝛼5-antagonist XLi-093
(4) was shown to enhance cognition. In another study, a
reduction of the two acetylenic groups of XLi-093 resulted
in ethyl groups [14], providing a new bivalent ligand (XLi-
356, 10) which shows 𝛼5-selective binding with very low
affinity for 𝛼1 subtypes (Figure 5). Efficacy (oocyte) data
shows XLi-356 is an 𝛼5 negative allosteric modulator [7, 13].
DeLorey et al. have recently shown in mice that XLi-356
does potently reverse scopolamine induced memory deficits
[7]. This bivalent 𝛼5 inverse agonist enhanced cognition
Cognition enhancement by XLi-093 (4) 
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)
18
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S V 0.3 1 3 5.6 10 18 30
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Figure 3: XLi-093 (4) effects on cognition enhancement byWenger
et al. (data on statistical significance not shown, unpublished
results). Effects of 4 on cognition from the mean delay achieved by
C57BL/6J mice titrating delayed matching-to-position schedule.
in agreement with work reported from our laboratory on
monovalent inverse agonists RY-10 [6] and RY-23 [7].
The dimers XLi-093 (4) and XLi-356 (10) were sent to
Case Western Reserve (NIMH supported PDSP program,
Roth et al.) for full panel receptor binding and they do not
bind to other receptors at levels of concern (Table 1).
Although XLi-093 (4) was found to be an antagonist
at the 𝛼5 subtype, XLi-356 (10) was found to be a weak
agonist-antagonist. XLi-356 was found to reverse scopo-
lamine induced memory deficits in mice. When XLi-356
was looked at in audio cued fear conditioning, the results
show no activity. This suggests that the effect of XLi-356
is selective through 𝛼5 receptors which are abundant in
the hippocampus which is highly associated with contextual
memory. Audio cuedmemory instead is amygdala-based and
should not be affected by an 𝛼5 subtype selective compound
[39–42].
As illustrated in Figure 6, scopolamine (1mg/kg) reduced
freezing (i.e., impairs memory) generally due to coupling the
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context (the cage) with a mild shock. XLi-356 (10mg/kg)
attenuated the impairment of memory returning the freezing
to the levels on par with subjects dosed with vehicle. In audio
cued memory the response was activated by sound, not the
context. XLi-356 was not able to reverse this type of memory
effect which is amygdala driven. A similar effect was observed
for XLi-093 by Harris et al. [43]. XLi-093 is the most selective
antagonist for 𝛼5 subtypes reported to date [13, 43] and is a
very useful 𝛼5 antagonist used by many in vivo [22, 44, 45].
Molecular modeling combined with this knowledge was
used to generate new lead compounds aimed at the develop-
ment of 𝛼5-subtype selective positive and negative allosteric
modulators to study cognition as well as amnesia mediated
by the hippocampus. All of these compounds have been pre-
pared based on the structure of current 𝛼5-subtype selective
ligands synthesized in Milwaukee [46] (see Figures 4 and 5),
as well as the binding affinity (15 nM)/selectivity of bivalent
𝛼5 antagonist XLi-093 (4) [13].
In efforts to enhance 𝛼5-selectivity in regards to cog-
nition, Cook, Bailey, and Helmstetter et al. have employed
RY-024 to study the hippocampal involvement in the ben-
zodiazepine receptor in learning and anxiety [14, 19]. Sup-
porting this Harris, DeLorey et al. show in mice that 𝛼5
NAMs (1) and RY-10 potently reversed scopolamine-induced
memory impairment. These 𝛼5 NAMs provide insight as to
how GABAARs influence contextual memory, an aspect of
memory affected in age associated memory impairment and
especially in Alzheimer’s disease [13, 62–64]. In addition,
Savic´ et al. have used the 𝛼1 preferring antagonist, BCCt,
in passive avoidance studies, in which midazolam’s amnesic
effects are shown to be due to interaction of agonist ligands at
𝛼5 in addition to 𝛼1𝛽3𝛾2 BzR subtypes [24, 65].
3. PWZ-029: A Negative Allosteric Modulator
PWZ-029 (1) has been studied extensively as an 𝛼5-GABAAR
inverse agonist and in certain experimental models has
Table 2: Affinity of PWZ-029 (1);𝐾
𝑖
(nM)a.
Code MW 𝛼1 𝛼2 𝛼3 𝛼4 𝛼5 𝛼6
PWZ-029 (1) 291.73 >300 >300 >300 ND 38.8 >300
PWZ-029 (1) 291.73 920 ND ND ND 30 ND
PWZ-029 (1) 291.73 362 180 328 ND 6 ND
aData from three separate laboratories.
been shown to enhance cognition. The binding data from
three separate laboratories (Table 2) have all shown that it
exhibits remarkable selectivity for the 𝛼5 subunit-containing
receptors, all greater than 60-fold compared to the next
subunit.
Electrophysiological efficacy testing done by Sieghart et
al. in oocytes demonstrated that PWZ-029 (1) acts as a
negative allosteric modulator at the 𝛼5-subunit, with a very
weak agonist activity at the 𝛼1, 𝛼2, and 𝛼3 subunits (Figure 7).
At a pharmacologically relevant concentration of 0.1 𝜇M,
PWZ-029 exhibits moderate negative modulation at the 𝛼5-
subunit, while showing little or no effect at the 𝛼1, 𝛼2, or 𝛼3-
subunits.
Milic´ et al. reported on the effects of PWZ-029 in the
widely used novel object recognition test, which differentiates
between the exploration time of novel and familiar objects.
As shown by significant differences between the exploration
times of the novel and familiar object (Figure 8(a)), as well
as the respective discrimination indices (Figure 8(b)), all the
three tested doses of PWZ-029 (2, 5 and 10mg/kg) improved
object recognition in rats after the 24 h delay period. Addi-
tionally, in the procedure with the 1 h delay between training
and testing, the lowest of the tested doses of PWZ-029
(2mg/kg) successfully reversed the deficit in recognition
memory induced by 0.3mg/kg scopolamine (Figure 9) [25].
The results of the described study showed for the first
time that inverse agonism at 𝛼5-GABAA receptors may
be efficacious in both improving cognitive performance in
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Figure 8: The effects of PWZ-029 (1) (2, 5 and 10mg/kg) on (a) time exploring familiar and novel objects and (b) discrimination indices in
the novel object recognition test using a 24 h delay (mean + SEM). Significant differences are indicated with asterisks (paired-samples 𝑡-test,
novel versus familiar, ∗𝑝 < 0.05, ∗∗𝑝 < 0.01, ∗∗∗𝑝 < 0.001). A significant difference from zero is indicated with hashes (one sample 𝑡-test,
##
𝑝 < 0.01). The number of animals per each treatment group was 10. SOL = solvent [25].
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Figure 9:The effects of 0.3mg/kg scopolamine (SCOP 0.3) and combination of 0.3mg/kg scopolamine and PWZ-029 (1) (2, 5, and 10mg/kg)
on the rats’ performance in the object recognition task after a 1 h delay: (a) time exploring familiar and novel objects and (b) discrimination
index. Data are represented as mean + SEM. Significant differences are indicated with asterisks (paired-samples 𝑡-test, novel versus familiar,
∗
𝑝 < 0.05, ∗∗𝑝 < 0.01). A significant difference from zero is indicated with hashes (one sample 𝑡-test, #𝑝 < 0.05). The number of animals per
each treatment group was 12–15. SAL = saline, SOL = solvent [25].
unimpaired subjects and ameliorating cognitive deficits in
pharmacologically impaired subjects, as assessed in two
protocols of the same animal model [25].
In a recent byRowlett et al. [26], negative allostericmodu-
lator PWZ-029 was evaluated in female rhesus monkeys (𝑛 =
4) in an Object Retrieval test with Detours (ORD; Figure 10
for details). 1 was administered via i.v. catheters in ORD
trained monkeys and evaluated for cognition enhancement.
A successful trial was determined by the ability of the
subject to obtain a food reward within a transparent box
with a single open side, with varying degrees of difficulty
(“easy” or “difficult” or “mixed” as a combination of both)
based on food placement within the box. In “mixed” trials
using PWZ-029, no significant results were observed when
compared to vehicle (Figure 11(a)). “Difficult” trials, however,
exhibited an increasing dose-dependent curve for successful
trials (Figure 11(b)). These results were attenuated by a coad-
ministration 𝛼5-antagonist XLi-093 (Figure 11(c)). PWZ-029
was also shown to dose-dependently reverse the cholinergic
deficits that were induced by scopolamine (Figure 11(d)) [26].
These findings suggest that PWZ-029 can enhance per-
formance on the ORD task, only under conditions in which
baseline performance is attenuated. The effects of PWZ-
029 were antagonized in a surmountable fashion by the
selective 𝛼5-GABAA ligand, XLi-093, consistent with PWZ-
029’s effects beingmediating via the 𝛼5-GABAA receptor.The
results are consistent with the view that 𝛼5 GABAA receptors
may represent a viable target for discovery of cognitive
enhancing agents.
In addition, we have newdata showing thatmodulation of
𝛼5-GABAARs by PWZ-029 rescues Hip-dependent memory
in an AD rat model [PMID: 23634826] as evidenced by
a significant decrease in the latency to reach the hidden
platform (memory probe trials) on spatial water maze task
(Figure 12). Roche has employed a similar strategy at 𝛼5
subtypes and recently has a drug in the clinic to treat
symptoms of dementia in Down syndrome patients. It is well
known many Down syndrome patients develop Alzheimer’s
disease or a dementia with a very similar etiology. This is
aimed at treating early onset Alzheimer’s patients.
4. PWZ-029 Docking within 𝛼5𝛾2 GABAA
Receptor Subunit Homology Model
These studies with PWZ-029 led to the molecular model
rendering of the compound docked within the 𝛼5𝛾2 BzR
subtype (Figures 13–16).Themodel figures have the following
features:
The docking of PWZ-029 within the GABAA/BzR shows
the molecule bound and interacting with specific amino
acids. The A and B rings of the benzodiazepine framework
undergo a 𝜋-stacking interaction with HIS 105, indicated
by the magenta coloring. At the other end of the molecule
the methoxy lone pair and imidazole nitrogen lone pair act
as a hydrogen bond acceptors with THR 210 and TYR 213,
respectively. These interactions are shown by the aqua-blue
descriptors.
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Methods
Subjects:
ORD task examples of different types of trials
Easy-right outside Easy-right inside Difficult-right deep
Note: open side indicated with orange lines
Mixed trials
Type of
trial
Position of Position of
opening food
Difficult trials
Difficult
Difficult
Difficult
Difficult
Difficult
Difficult
Difficult
Difficult
Difficult
Difficult
Difficult
Difficult
Difficult
Difficult
Difficult
Difficult
Difficult
Difficult
Difficult
Type of
trial
Position of Position of
opening food
Easy
Easy
Easy
Easy
Easy
Easy
Easy
Easy
Easy
Easy
Easy
Left
Left
Left
Left
Left
Left
Left
Right
Left
Right
Left
Left
Left
Left
Left
Left
Left
Left
Right
Right
Right
Right
Right
Right
Right
Right
Right
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Front
Outside
Outside
Outside
Outside
Outside
Inside
Inside
Inside
Inside
Inside
Inside
Deep
Deep
Deep
Deep
Deep
Deep
Deep
Deep
Deep
Deep
Deep
Deep
Deep
Deep
Deep
Deep
Deep
Deep
Deep
Rhesus monkeys (Macaca mulatta)
N = 5
Implanted with chronic i.v. catheters
Procedure:
Object retrieval with detours (ORD)
15 trials per session
Easy, difficult, and mixed trials (see diagram)
Tests:
(i) PWZ-029 · mixed trials
(ii) PWZ-029 · difficult trials
(iv) Scopolamine · mixed trials
(v) PWZ-029 + scopolamine · mixed trials
Measurements: % correct trials—trial in which
food is obtained with the first reach
Errors: barrier reaches (hand in contact with closed
side of box) and incomplete trials (food grasped but
dropped)
(iii) PWZ-029 + XLi-093 · difficult trials
Figure 10: ORD methods and procedure [26].
5. Subtype Selective Agonists for
𝛼5 GABAA/Bz Receptors
Mo¨hler has proposed that 𝛼5 selective inverse agonists or
𝛼5 selective agonists might enhance cognition [5, 13, 16–
18, 86]. This is because of the extrasynaptic pyramidal nature
of 𝛼5𝛽3𝛾2 subtypes, located almost exclusively in the hip-
pocampus. Because of this, a new “potential agonist” which
binds solely to 𝛼5𝛽3𝛾2 subtypes was designed by computer
modeling (see Figure 17). This ligand (DM-I-81, 9) has an
agonist framework and binds only to 𝛼5𝛽3𝛾2 subtypes [13,
17, 18, 86]. The binding potency at 𝛼5 subtypes is 176 nM.
Although the 8-pendant phenyl of DM-I-81 was lipophilic
and bound to the 𝐿
2
pocket, additional work on the 8-
position of this scaffold has been abandoned and generally
left as an acetylene or halide function, with a few exceptions.
The steric bulk of the 8-phenyl moiety was felt detrimental to
activity and potency which may have led to the weak binding
affinity.
6. Alpha 5 Positive Allosteric
Modulators in Schizophrenia
In addition to inverse agonists, a number of other 𝛼5-
GABAAR positive allosteric modulators (PAMs) have been
synthesized. These compounds, such as SH-053-2󸀠F-R-CH
3
(2), have been shown to decrease the firing rate of synapses
controlling cognition and can be used to treat schizophrenia.
The following is reported by Gill, Cook, and Grace et al.
[27–38].
There are a number of novel benzodiazepine-positive
allosteric modulators (PAMs), selective for the 𝛼5 subunit
of the GABAA receptor, including SH-053-2
󸀠F-R-CH
3
(2),
which has been tested for its ability to effect the out-
put of the HPC (hippocampal) in methylazoxymethanol-
(MAM-) treated animals, which can lead to hyperactivity
in the dopamine system [27–38]. In addition, the effect of
this compounds (2) response to amphetamine in MAM-
animals on the hyperactive locomotor activity was exam-
ined. Schizophrenic-like symptoms can be induced into
rats when treated prenatally with DNA-methylating agent,
methylazoxymethanol, on gestational day (GD) 17. These
neurochemical outcomes and changes in behavior mimic
those found in schizophrenic patients. Systemic treatment
with (2) resulted in a reduced number of spontaneously active
DA (dopamine) neurons in the VTA (ventral tegmental area)
of MAM animals (Figure 18) to levels seen in animals treated
with vehicle (i.e., saline). To confirm the location of action,
2 was also directly infused into the ventral HPC (Figure 19)
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(d) Reversal of scopolamine deficit
Figure 11: Cognitive-enhancing effects of PWZ-029 in the rhesus monkey Object Retrieval with Detours (ORD) task (𝑛 = 5 monkeys). (a)
Effects of PWZ-029 on ORD tests consist of both easy and difficult trials: (b) PWZ-029 enhanced performance on the ORD task when tested
with difficult trials only; (c) enhancement of ORD performance by 0.018mg/kg of PWZ-029 was attenuated by the 𝛼5 GABAA-preferring
antagonist XLi-093 and this antagonism was surmountable by increasing the PWZ-029 dose; (d) PWZ-029 reversed performance impaired
by 0.01mg/kg of scopolamine [26]. ∗𝑝 < 0.05 versus vehicle, ∗∗𝑝 < 0.05 versus Scopolamine.
and was shown to have the same effect. Moreover, HPC
neurons in both SAL and MAM animals showed diminished
cortical-evoked responses following𝛼5-GABAARPAM treat-
ment. This study is important for it supports a treatment
of schizophrenia that targets abnormal HPC output, which
in turn normalized dopaminergic neuronal activity [27–38].
This is a novel approach to treat schizophrenia.
The pathophysiology of schizophrenia has identified
hippocampal (HPC) dysfunction as a major mediator as
reported by many including Anthony Grace [27–38]. This
included morphological changes, reduced HPC volume, and
GAD67 expression [27, 28] that have been reported after
death in the brains of patients with schizophrenia. Both HPC
activation andmorphology changes have been identified that
can precede psychotic symptoms or correlate with severity of
cognitive deficits [29–33].This has been shown in a cognitive
test during baseline and activation.
Many animal models of schizophrenia were essential to
behavioral pathology and have delivered new knowledge
about the network disturbances that contribute to CNS
disorder.This study shows that the offspring ofMAM-treated
animals showed both structural and behavioral abnormali-
ties. These were consistent with those observed in patients
with schizophrenia. The animals had reduced limbic cortical
and HPC volumes with increased cell packing density and
showed increased sensitivity to psychostimulants [34–36].
In addition, the startle response in prepulse inhibition was
reduced in MAM-treated animals and deficits in latent
inhibition were observed [35]. Furthermore, a pathological
rise in spontaneous dopamine (DA) activity by the ventral
tegmental area (VTA) was observed that can be attributed
to aberrant activation within the ventral HPC [36]. It was
suggested that reductions in parvalbumin- (PV-) stained
interneurons might be the reason for the hyperactivation of
the HPC and disruption of normal oscillatory activity in the
HPC and cortex of MAM animals [38, 61]. At least this is
the prevailing hypothesis at the moment put forth by many
investigators (see references cited in [27–38]).
Selective 𝛼5-GABAAR positive allosteric modulator (2)
was successful in reversing the pathological increase in tonic
DA transmission in methylazoxymethanol rats by targeting
abnormal hippocampal activity. In addition, the 𝛼5-PAMwas
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Figure 12: PWZ-029 rescues spatial memory deficits in AD model
as evidenced by a decrease in the latency to reach the hidden
platform (probe test) in the water maze relative to vehicle (VEH,
∗
𝑝 < 0.05).
Figure 13: PWZ-029 docked within 𝛼5𝛾2 BzR binding site (BS).
HIS 105
TYR 213
THR 210
Figure 14: PWZ-029 docked with amino acid residues.
HIS 105
TYR 213
THR 210
Figure 15: PWZ-029 docked with A.A. residue interactions.
4.09
Figure 16: PWZ-029 docked with interactions. (1) HIS 105 𝜋-
stacking interaction with centroid of PWZ-029. (2) TYR 213 phenol
OH hydrogen bonding to imidazole nitrogen lone pair. (3) THR
210 OH and lone pair on methoxy of PWZ029. (4) 𝛼5 ribbon being
green. (5) 𝛾2 ribbon being yellow. (6) Hydrogen bonding being aqua
blue. (7) 𝜋-stacking being magenta.
able to reduce the behavioral sensitivity to psychostimulants
observed in MAM rats (Figures 20 and 21). This suggests
that novel 𝛼5-partial allostericmodulators should be effective
in alleviating dopamine-mediated psychosis. However, if
this drug can also restore rhythmicity within HPC-efferent
structure, it may also affect other aspects of this disease
state such as cognitive disabilities and negative symptoms.
This study, using the MAM-model to induce symptoms of
schizophrenia, shows that the use of 𝛼5-GABAAR targeting
compounds could be an effective treatment in schizophrenic
patients. The selective targeting solely of 𝛼5𝛽3𝛾2 subunits, as
opposed to unselective BZDs such as diazepam, could pro-
vide relief from the psychotic symptoms without producing
adverse effects such as sedation [27–38].
As reported by Gill, Grace et al. [36, 38, 47–61].
Often initial antipsychotic drug treatments (APD) for
schizophrenia are ineffective, requiring a brief washout
period prior to secondary treatment. The impact of with-
drawal from initial APD on the dopamine (DA) system
is unknown. Furthermore, an identical response to APD
therapy between normal and pathological systems should not
be assumed. In another study by Gill, Grace et al., 𝛼5 positive
allosteric modulator SH-053-2󸀠F-R-CH
3
(2) was used in the
MAM neurodevelopmental model of schizophrenia which
was used to study impact of withdrawal from repeated
haloperidol (HAL) on the dopamine system [36, 38, 47–61].
The following studies were designed to provide insight as
to why a new drug to treat schizophrenia may be effective
in Phase II clinical trials but fail in Phase III because of
the large number of patients required for the study. Many
of these patients in Phase III studies have altered neuronal
pathways in the CNS because of long-term treatment with
antipsychotics (sometimes 10–20 years) [36, 38, 47–61].
Importantly, spontaneous dopamine activity reduction
was observed in saline rats withdrawn from haloperidol with
an enhanced locomotor response to amphetamine, indicating
the development of dopamine supersensitivity. In addition,
PAM treatment, as well as ventral HPC inactivation, removed
the depolarization block of DA neurons in withdrawn HAL
treated SAL rats. In contrast, methylazoxymethanol rats
withdrawn from HAL displayed a reduction in spontaneous
dopamine activity and enhanced locomotor response that
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was unresponsive to PAM treatment with SH-053-2󸀠F-R-CH
3
or ventral HPC inactivation [36, 38, 47–61].
Prior HAL treatment withdrawal can restrict the efficacy
of subsequent pharmacotherapy in the MAM model of
schizophrenia. This is an extremely important result indi-
cating that testing a new drug for schizophrenia in humans
treated for years with both typical and atypical antipsychotics
may result in a false negative with regard to treatment. Studies
that support this hypothesis follow here [36, 38, 47–61].
Novel therapeutics for the treatment of schizophrenia
that exhibit initial promise in preclinical trials often fail to
demonstrate sufficient efficacy in subsequent clinical trials. In
addition, relapse or noncompliance from initial treatments is
common, necessitating secondary antipsychotic intervention
[47, 48]. Studies have shown that between 49 and 74%
of schizophrenia patients discontinue the use of antipsy-
chotic drug (APD) treatments within 18 months due to
adverse side-effects [48, 49]. Current pharmacotherapies for
schizophrenia target the pathological increase in dopamine
system activity, as mentioned above. Common clinical prac-
tice for secondary antipsychotic application involves a brief
withdrawal period from the initial APD. Unfortunately, the
success of even secondary treatments is far from being opti-
mal with the rehospitalization of patients being a common
occurrence. The impact of repeated antipsychotic treatment
and subsequent withdrawal on the dopamine system has not
been adequately assessed [36, 38, 47–61].
As indicated above, schizophrenia is a complex chronic
psychiatric illness characterized by frequent relapses despite
ongoing treatment. The search for more effective pharma-
cotherapies for the treatment of schizophrenia continues
unabated. It is not uncommon for novel pharmaceuticals to
demonstrate promise in preclinical trials but fail to show
an adequate response in subsequent clinical trials. Indeed,
evaluating the benefits of one APD versus another is compli-
cated by clinical trials beset with high attrition rates and poor
efficacy in satisfactorily reducing rehospitalization [47, 49–
52].
Previous work from the Gill, Grace et al.’s laboratory
[36, 38, 47–61] with the MAM model of schizophrenia has
identified a potential novel therapeutic, a 𝛼5GABAAR PAM.
The dopamine system pathology in the MAMmodel is likely
the result of excessive output from the ventral HPC [36]. The
𝛼5GABAAR PAM was identified as a potential therapeutic
due to the relatively selective expression of 𝛼5GABAAR in
the ventral HPC and its potential for reducing HPC activity
[53–60]. When either administered systemically or directly
infused into the ventralHPC, the𝛼5GABAARPAM(SH-053-
2󸀠F-R-CH
3
) was effective in reducing the dopamine system
activation in MAM rats [38]. Anthony Grace, Gill et al.
showed 𝛼5GABAAR PAM treatment was also effective in
reducing the enhanced behavioral response to amphetamine
in MAM rats, as stated above. Data from the present study
sought to delineate whether the 𝛼5GABAAR PAM (SH-053-
2󸀠F-R-CH
3
) would remain effective in MAM rats withdrawn
from prior neuroleptic treatment, a common occurrence in
the patient population. In both SAL andMAM rats, there was
a reduction in the spontaneous activity of dopamine neurons
in the VTA after 7 days withdrawal from repeated HAL
treatment. However, MAM rats continued to exhibit a greater
activation of the dopamine system in comparison to SAL rats.
Treatment with the 𝛼5GABAAR PAMwas no longer effective
in reducing the activity of dopamine neurons in the VTA in
withdrawn HAL treated MAM rats. In contrast, 𝛼5GABAAR
PAM treatment in the withdrawn HAL treated SAL rats
instead increased the spontaneous activity of dopamine in the
VTA (Figures 22–25) [36, 38, 47–61].
Similar to the effects seen following 𝛼5GABAAR PAM
treatment, ventral HPC inactivation in withdrawn HAL
treated SAL rats restored normal dopamine system activity
by increasing the number of spontaneously active dopamine
neurons. The disparate effect of withdrawal from HAL on
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Figure 18: Treatment with SH-053-2󸀠F-R-CH
3
(0.1mg/kg, i.v.; patterned bars) normalizes the aberrant increase in the number of spontane-
ously firing dopamine neurons (expressed as cells/track) inmethylazoxymethanol acetate- (MAM-) treated animals (a).There was no effect of
SH-053-2󸀠F-R-CH
3
treatment in control animals (open bars, (a)–(c)) or on firing rate and burst activity in MAM animals (dark bars; (b)-(c))
(∗𝑝 < 0.05, two-way ANOVA, Holm-Sidak post hoc;𝑁 = 5–7 rats/group) [27–38].
the dopamine system between SAL and MAM rats provides
a vital clue for the inconsistencies between preclinical trials
for novel therapeutics that utilize normal subjects and subse-
quent clinical trials in a patient population [36, 38, 47–61].
Thedata suggests underlying dopamine systempathology
alters the impact of withdrawal from prior repeated HAL in
the MAM model of schizophrenia. In addition, subsequent
novel APD treatment loses efficacy following withdrawal
from repeated HAL in MAM animals. This certainly has
relevance to Phase III clinical trials of new drugs to treat
schizophrenia [36, 38, 47–61].
7. GABAA 𝛼5 Positive Allosteric Modulators
Relax Airway Smooth Muscle
Emala, Gallos, et al. [66–75] have found that novel 𝛼5-
subtype selective GABAA positive allosteric modulators relax
airway smoothmuscle from rodents and humans.The clinical
need for new classes of bronchodilators for the treatment of
bronchoconstrictive diseases such as asthma remains a major
medical issue. Few novel therapeutics have been approved
for targeting airway smoothmuscle (ASM) relaxation or lung
inflammation in the last 40 years [66]. In fact, several asthma-
related deaths are attributed, in part, to long-acting 𝛽-
agonists (LABA) [67]. Adherence to inhaled corticosteroids,
the first line of treatment for airway inflammation in asthma,
is very poor [68, 69]. Therapies that break our dependence
on 𝛽-agonism for ASM relaxation would be a novel and
substantial advancement.
These ASM studies were undertaken due to a pressing
clinical need for novel bronchodilators in the treatment
of asthma and other bronchoconstrictive diseases such as
COPA. There are only three drug classes currently in clinical
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Figure 19: Hippocampal (HPC) infusion of SH-053-2󸀠F-R-CH
3
(1 𝜇M/side; patterned bars) normalizes the aberrant increase in the number
of spontaneously firing dopamine neurons (expressed as cells/track) in methylazoxymethanol acetate- (MAM-) treated animals (a). There
was no effect of SH-053-2󸀠F-R-CH
3
treatment in control animals (open bars, (a)–(c)) or on firing rate in MAM animals (dark bars; (b)).
Hippocampal (HPC) infusion of SH-053-2󸀠F-R-CH
3
significantly reduced the percentage of spikes occurring in bursts of dopamine (DA)
neurons in MAM and control animals (c) (∗𝑝 < 0.05, two-way ANOVA, Holm-Sidak post hoc;𝑁 = 7 rats/group) [27–38].
use as acute bronchodilators in the United States (methylxan-
thines, anticholinergics, and 𝛽-adrenoceptor agonists) [70].
Thus, a novel therapeutic approach that would employ
cellular signaling pathways distinct from those used by
these existing therapies involves modulating airway smooth
muscle (ASM) chloride conductance via GABAA receptors to
achieve relaxation of precontracted ASM [71, 72]. However,
widespread activation of all GABAA receptors may lead to
undesirable side effects (sedation, hypnosis, mucus forma-
tion, etc.). Thus, a strategy that selectively targets a subset
of GABAA channels, those containing 𝛼 subunits found to
be expressed in airway smooth muscle, may be a first step
in limiting side effects. Since human airway smooth muscle
contains only 𝛼4 or 𝛼5 subunits [72], ligands with selectiv-
ity for these subunits are an attractive therapeutic option.
Concern regarding nonselective GABAA receptor activation
is not limited to the airway or other peripheral tissues.
GABAA receptor ligands are classically known for their cen-
tral nervous system effects of anxiolysis, sedation, hypnosis,
amnesia, anticonvulsion, and muscle relaxant effects. Such
indiscriminate activation of GABAA receptors in the CNS is
exemplified by the side effects of classical benzodiazepines
(such as diazepam) which were the underpinning for the
motivation of a search for benzodiazepine (BZD) ligands that
discriminate among the 𝛼 subunits of GABAA receptors [73–
75].
A novel approach to identify novel benzodiazepine
derivatives to selectively target GABAA channels containing
specific 𝛼 subunits was developed by Cook et al. in the
1980s that employed a pharmacophore receptor model based
on the binding affinity of rigid ligands to BDZ/GABAA
receptor sites (as reviewed in 2007 [23]). From this series
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Figure 20: Extracellular recording traces illustrate the reduction in evoked responses in the ventral hippocampal (HPC) to entorhinal
cortex stimulation in bothMAM- and saline-treated animals (a, b). Treatment with SH-053-2󸀠F-R-CH
3
(0.1mg/kg, i.v.) decreases the evoked
excitatory response (dashed lines) of ventral HPC neurons to entorhinal cortex stimulation in both MAM- and saline-treated animals (c)
(∗𝑝 < 0.05 for saline and +𝑝 < 0.05, two-way repeated measures ANOVA, Holm-Sidak post hoc) [27–38].
of receptor models for 𝛼
1–6𝛽3𝛾2 subtypes a robust model
for 𝛼5 subtype selective ligands emerged, the result of which
included the synthesis of a novel 𝛼5𝛽3𝛾2 partial agonist
modulator, SH-053-2󸀠F-R-CH
3
(2). The discovery of this and
related ligands selective for 𝛼5 BDZ/GABAA-ergic receptors
and the realization that only 𝛼4 and 𝛼5 subunits are expressed
inGABAA channels on human airway smoothmuscle yielded
an ideal opportunity for targeting these 𝛼5-subunit contain-
ing GABAA channels for bronchorelaxation [66–75].
The GABAA𝛼5 subunit protein was first localized to the
ASM layer of human trachea while costaining for the smooth
muscle specific protein 𝛼 actin (Figure 26). The first panel of
Figure 26 shows GABAA 𝛼5 protein stained with fluorescent
green and blue fluorescent nuclear staining (DAPI). The
second panel is the same human tracheal smooth muscle
section simultaneously stained with a protein specific for
smooth muscle, 𝛼 actin, and the third panel is a merge of
the first two panels showing costaining of smooth muscle
with GABAA 𝛼5 and 𝛼 actin proteins. The fourth panel is
a control omitting primary antibodies but including nuclear
DAPI staining [66–75].
After demonstrating the protein expression of GABAA
receptors containing the 𝛼5 subunit, functional studies of
isolated airway smooth muscle were performed in tracheal
airway smooth muscle from two species. Human airway
smooth muscle suspended in an organ bath was precon-
tracted with a concentration of acetylcholine that was the
EC
50
concentration of acetylcholine for each individual
airway smooth muscle preparation. The induced contraction
was then relaxed with a 𝛽-agonist (isoproterenol) in the
absence or presence of the GABAA 𝛼5 ligand SH-053-2
󸀠F-
R-CH
3
(2). Figure 27(a) shows that the amount of relaxation
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Figure 21: Treatment with SH-053-2󸀠F-R-CH
3
(10mg/kg, i.p.) reduced the aberrant increased locomotor response to D-amphetamine
(0.5mg/kg i.p.) observed in MAM rats (a). MAM animals demonstrated a significantly larger peak locomotor response than both saline-
treated animals and MAM animals pretreated with the alpha-5 PAM (b) (there was a significant difference between MAM-vehicle and all
other groups, ∗𝑝 < 0.05, two-way repeated measures ANOVA, Holm-Sidak post hoc) [27–38].
induced by 10 nM isoproterenol was significantly increased if
50 𝜇M SH-053-2󸀠F-R-CH
3
(2) was also present in the buffer
superfusing the airway smoothmuscle strip. Studieswere also
performed in airway smooth muscle from another species,
guinea pig, that measured direct relaxation of a different
contractile agonist, substance P. As shown in Figure 27(b),
the amount of remaining contractile force 30 minutes after
a substance P-induced contraction was significantly reduced
in airway smooth muscle tracheal rings treated with SH-053-
2󸀠F-R-CH
3
(2) [66–75].
Following these studies in intact airway smooth muscle,
cell based studies were initiated in cultured human airway
smooth muscle cells to directly measure plasma membrane
chloride currents and the effects of these currents on intracel-
lular calcium concentrations. SH-053-2󸀠F-R-CH
3
(2) induced
a Cl− current in vitro using conventional whole cell patch
clamp techniques [66–75]. These electrophysiology studies
were then followed by studies to determine the effect of these
plasma membrane chloride currents on intracellular calcium
concentrations following treatment of human airway smooth
muscle cells with a ligand whose receptor couples through a
Gq protein pathway, a classic signaling pathway thatmediates
airway smooth muscle contraction.
SH-053-2󸀠F-R-CH
3
(2) attenuated an increase in intracel-
lular calcium concentrations induced by a classic Gq-coupled
ligand, bradykinin (Figure 28(a)) [66–75]. The attenuation
by SH-053-2󸀠F-R-CH
3
(2) was significantly blocked by the
GABAA antagonist gabazine (Figure 28(b)) indicating that
SH-053-2󸀠F-R-CH
3
(2) wasmodulatingGABAA receptors for
these effects on cellular calcium [66–75].
The major findings of these studies are that human
airway smooth muscle expresses 𝛼5 subunit containing
GABAA receptors that can be pharmacologically targeted
by a selective agonist. The GABAA 𝛼5 subunit selective
ligand SH-053-2󸀠F-R-CH
3
(2) relaxed intact guinea pig
airway smooth muscle contracted with substance P and
augmented 𝛽-agonist-mediated relaxation of intact human
airway smooth muscle. The mechanism for these effects
was likely mediated by plasma membrane chloride currents
that contributed to an attenuation of contractile-mediated
increases in intracellular calcium, a critical event in the initi-
ation and maintenance of airway smooth muscle contraction
[66–75].
8. Recent Discovery of Alpha 5 Included
Volume Differences: L
4
Pocket as Compared
to Other Bz/GABAergic Subtypes
The findings in both the MAM-model of schizophrenia and
the relaxation of airway smooth muscle have led to the study
of SH-053-2󸀠F-R-CH
3
and related compounds bound within
the𝛼5-GABAA/BzR (Figure 29).The SH-053-R-CH3 (15) and
SH-053-S-CH
3
(16) isomers have been previously described
[23]. These compounds along with SH-053-2󸀠F-R-CH
3
and
SH-053-2󸀠F-S-CH
3
have been tested for binding affinity and
show selectivity for the 𝛼5-subunit (Table 3).
From examination of Figure 30 and Tables 3 and 4, it is
clear the (R)-isomers bound to the 𝛼5 subtype while the (S)-
isomers were selective for 𝛼2/𝛼3/𝛼5 subtypes.
From this data, these compounds were then used in
examining the 𝛼5-binding pocket, most specifically the
fluoroseries. In regard to molecular modeling, depicted in
Figure 30 is the included volume and ligand occupation
of the SH-053-2󸀠F-S-CH
3
(17) and SH-053-2󸀠F-R-CH
3
(2)
enantiomers in the 𝛼5 subtype as well as the 𝛼2 subtype. It
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Figure 22: Repeated haloperidol treatment caused a reduction in the number of spontaneously active dopamine neurons in both SAL and
MAM rats injected with vehicle compared to untreated control animals. Treatment with SH-053-2󸀠F-R-CH
3
(0.1mg/kg, i.v.) reversed the
haloperidol-induced reduction in cells/track in SAL, but not MAM, rats (a). Repeated haloperidol treatment had no effect on the firing rate
of dopamine neurons recorded in SAL or MAM rats treated with vehicle. However, SH-053-2󸀠F-R-CH
3
caused an increase in firing rate of
dopamine neurons in repeatedly haloperidol-treated SAL rats (b). Repeated haloperidol treatment, as well as SH-053-2󸀠F-R-CH
3
injection,
had no impact on the percentage of spikes occurring in bursts for dopamine neurons recorded in SAL and MAM rats (c) [36, 38, 47–61].
∗
𝑝 < 0.05.
is clear a new pocket (𝐿
4
) has been located in the 𝛼5 subtype
permitting 2 as well as 17 to bind to the 𝛼5 subtype. Exami-
nation of both ligands in the 𝛼2 subtype clearly illustrates the
analogous region in the 𝛼2 subtype is not present and thus
does not accommodate 2 for the pendant phenyl which lies
outside the included volume in the space allocated for the
receptor protein itself [23].
9. BzR GABA(A) Subtypes
In terms of potency, examination of the values in Table 4 [87],
it is clear the R-isomer (2) shows more selectivity towards the
𝛼5-subunit, while the S-isomer (17) is potent at the 𝛼2/3/5
subunits. It is important, as postulated earlier [23], that the
major difference in GABA(A)/Bz receptors subtypes stems
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Figure 23: Repeated haloperidol treatment caused a reduction in the number of spontaneously active dopamine neurons in both SAL and
MAMratsmicroinfusedwith vehicle in the ventral HPC compared to untreated control animals. Infusion of TTX in the ventral HPC reversed
the haloperidol-induced reduction in cells/track in SAL, but not MAM, rats (a). Repeated haloperidol treatment had no effect on the firing
rate of dopamine neurons recorded in SAL orMAM rats infused with vehicle or TTX in the ventral HPC (b). Repeated haloperidol treatment
had no effect on the percentage of spikes occurring in bursts for dopamine neurons recorded in SAL or MAM rats infused with vehicle or
TTX in the ventral HPC (c) [36, 38, 47–61]. ∗𝑝 < 0.05.
from differences in asymmetry in the lipophilic pockets 𝐿
1
,
𝐿
2
, 𝐿
3
, 𝐿
4
, and 𝐿Di in the pharmacophore/receptor model
and indicates even better functional selectivity is possible
with asymmetric BzR ligands.
The synthetic switching of chirality at the C-4 position
of imidazobenzodiazepines to induce subtype selectivity was
successful. Moreover, increase of the potency of imidazoben-
zodiazepines can be achieved by substitution of the 2󸀠-
position hydrogen atomwith an electron rich atom (fluorine)
on the pendant phenyl ring in agreement with Haefely et al.
[88], Fryer [89, 90], and our ownwork [22, 91].The biological
data on the two enantiomeric pairs of benzodiazepine ligands
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Figure 24: Administration of apomorphine (80mg/kg i.v.)
increased the number of spontaneously active dopamine neurons in
SAL rats withdrawn from repeated HAL, while having no effect on
the number of active dopamine neurons in MAM rats withdrawn
from repeated HAL [36, 38, 47–61]. ∗𝑝 < 0.05.
Table 3: Binding affinity at 𝛼𝑥𝛽2𝛾2 GABAA receptor subtypes
(values are reported in nM).
Compounda 𝛼1 𝛼2 𝛼3 𝛼4 𝛼5 𝛼6
SH-053-R-CH
3
, (15) 2026 2377 1183 >5000 949.1 >5000
SH-053-S-CH
3
, (16) 1666 1263 1249 >5000 206.4 >5000
SH-053-2󸀠F-R-CH
3
, (2) 759.1 948.2 768.8 >5000 95.17 >5000
SH-053-2󸀠F-S-CH
3
, (17) 350 141 1237 >5000 19.2 >5000
aData shown here are themeans of two determinations which differed by less
than 10%.
Table 4: Oocyte electrophysiological data of benzodiazepinesa [87].
Compound 𝛼1 𝛼2 𝛼3 𝛼5
SH-053-2󸀠F-R-CH
3
(2) 111/154 124/185 125/220 183/387
SH-053-2󸀠F-S-CH
3
(17) 116/164 170/348 138/301 218/389
aEfficacy at 𝛼𝑥𝛽3𝛾2 GABAA receptor subtypes as % of control current at
100 nM and 1𝜇M concentrations. Data presented as percent over baseline
(100) at concentrations of 100 nM/1 𝜇M.
confirm the ataxic activity of BZ site agonists is mediated by
𝛼1𝛽2/3𝛾2 subtypes, as reported in [23, 91–93].The antianxiety
activity in primates of the S isomers was preserved with
no sedation. In only one study in rodents was any sedation
observed; the confounding sedation was observed in both the
S isomer (functionally selective for 𝛼2, 𝛼3, and 𝛼5 receptor
subtypes) and R isomer (essentially selective for 𝛼5 subtype)
and may involve at least, in part, agonist activity at 𝛼5 BzR
subtypes. There are some 𝛼5 BzR located in the spinal cord
which might be the source of the decrease in locomotion
with SH-053-2󸀠F-R-CH
3
and SH-053-2󸀠F-S-CH
3
; however,
this is possibly some type of stereotypical behavior. Hence in
agreement with many laboratories including our own [23, 92,
93] the best potential nonsedative, nonamnesic, antianxiety
agents stem from ligands with agonist efficacy at 𝛼2 subtypes
essentially silent at 𝛼1 and 𝛼5 subtypes (to avoid sedation)
[91]. It must be pointed out again; however, in primates
Fischer et al. [87] observed a potent anxiolytic effect with no
sedation with the 2󸀠F-S-CH
3
(17) isomer, while the 2󸀠F-R-
CH
3
(2) isomer exhibited only a very weak anxiolytic effect.
Numerous groups have done modeling and SAR studies
on different classes of compounds which have resulted in
a few different pharmacophore models based on the ben-
zodiazepine binding site (BS) of the GABAA receptor [94].
These models are employed to gain insight in the interactions
between the BS and the ligand. These have been put forth
by Loew [7, 95, 96], Crippen [97, 98], Codding [76, 77, 99–
101], Fryer [89, 90, 94], Gilli and Borea [102–105], Tebib et al.
[106], and Gardner [107], as well as from Professors Sieghart,
Cromer, and our own laboratory [21, 39, 40, 76, 78–82, 108–
118].
The Milwaukee-based pharmacophore/receptor model
is a comprehensive building of the BzR using radioligand
binding data and receptor mapping techniques based on 12
classes of compounds [20, 23, 39, 40, 42, 111, 119–122]. This
model (Figure 31) [79] has brought together previous models
which have used data from the activity of antagonists, positive
allosteric modulators, and negative allosteric modulators and
included the newmodels for the “diazepam-insensitive” (DI)
sites [123]. Four basic anchor points,𝐻
1
,𝐻
2
,𝐴
2
, and 𝐿
1
, were
assigned, and 4 additional lipophilic regions were defined as
𝐿
2
, 𝐿
3
, 𝐿Di, and the new 𝐿4 (see captions in Figure 31 for
details); regions 𝑆
1
, 𝑆
2
, and 𝑆
3
represent negative areas of
steric repulsion. As previously reported, the synthesis of both
partial agonists and partial inverse agonists has been achieved
by using parts of this model [99, 100, 104, 105, 119, 124–127].
The cloning, expression, and anatomical localization
of multiple GABA(A) subunits have facilitated both the
identification and design of subtype selective ligands. With
the availability of binding data from different recombinant
receptor subtypes, affinities of ligands from many different
structural classes of compounds have been evaluated.
Illustrated in Figure 31 is the [3,4-c]quinolin-3-one CGS-
9896 (18) (dotted line), a diazadiindole (19) (thin line), and
diazepam (20) (thick line) fitted initially to the inclusive
pharmacophore model for the BzR. Sites 𝐻
1
(Y210) and 𝐻
2
(H102) represent hydrogen bond donor sites on the receptor
protein complex while𝐴
2
(T142) represents a hydrogen bond
acceptor site necessary for potent inverse activity in vivo. 𝐿
1
,
𝐿
2
, 𝐿
3
, 𝐿
4
, and 𝐿Di are four lipophilic regions in the binding
pharmacophore. Descriptors 𝑆
1
, 𝑆
2
, and 𝑆
3
are regions of
negative steric repulsion.
Based on SAR data obtained for these ligands at 6 recom-
binant BzR subtypes [128–132], an effort has been undertaken
to establish different pharmacophore/receptor models for
BzR subtypes.The alignment of the twelve different structural
classes of benzodiazepine receptor ligands was earlier based
on the least squares fitting of at least three points. The
coordinates of the four anchor points (𝐴
2
, 𝐻
1
, 𝐻
2
, and
𝐿
1
) employed in the alignment are outlined in Figure 32.
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Figure 25: Repeated haloperidol treatment causes an enhancement in the locomotor response to D-amphetamine (0.5mg/kg, i.p.) in
SAL animals that is reduced by pretreatment with SH-053-2󸀠F-R-CH
3
(10mg/kg, i.p.) (a). MAM rats treated repeatedly with haloperidol
exhibit a locomotor response following D-amphetamine similar to untreated MAM rats. However, repeated haloperidol treatment blocks
the effect of SH-053-2󸀠F-R-CH
3
pretreatment in decreasing the locomotor response in MAM rats (b). Untreated MAM rats demonstrated a
significantly larger peak locomotor response than untreated SAL rats. In addition, SH-053-2󸀠F-R-CH
3
pretreatment significantly reduced
the peak locomotor response in untreated MAM rats, while having no effect in repeatedly haloperidol-treated MAM rats. In contrast,
repeated haloperidol treatment enhanced the peak locomotor response to amphetamine in SAL rats that was reduced by SH-053-2󸀠F-R-CH
3
pretreatment (c) [36, 38, 47–61]. ∗𝑝 < 0.05.
Herein are described the results from ligand-mapping exper-
iments at recombinant BzR subtypes of 1,4-benzodiazepines,
imidazobenzodiazepines, 𝛽-carbolines, diindoles, pyrazolo-
quinolinones, and others [126]. Some of the differences and
similarities among these subtypes can be gleaned from this
study and serve as a guide for future drug design.
10. 𝛼1 Updates
10.1. Beta-Carbolines. A series of 3,6-disubstituted 𝛽-carbo-
lines was prepared and evaluated for their in vitro affinity
at 𝛼x𝛽3𝛾2 GABA(A)/BzRr subtypes by radioligand binding
assays in search of 𝛼1𝛽3𝛾2 subtype selective compounds
(Figure 33). A potential therapeutic application of such antag-
onist analogs is to treat alcohol abuse [133, 134]. Analogues
of 𝛽CCt (21) were synthesized via a carbonyldiimidazole-
mediated method by Yin et al. [85] and the related 6-
substituted 𝛽-carboline-3-carboxylates including WYS8 (27)
were synthesized from6-iodo𝛽CCt (29). Bivalent ligands (42
and 43) were also synthesized to increase the scope of the
structure-activity relationships (SAR) to larger ligands. An
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Figure 26: Protein expression of the GABAA 𝛼5 subunit in intact human trachea-bronchial airway smooth muscle. Representative
images of human tracheal airway smooth muscle sections using confocal microscopy are depicted following single, double, and triple
immunofluorescence labeling.The antibodies employed were directed against the GABAA 𝛼5 subunit (green), 𝛼-smoothmuscle actin (SMA;
red), and/or the nucleus via DAPI counterstain (blue). Panels illustrate the following staining parameters from left to right: (1st) costaining
of DAPI and GABAA 𝛼5 subunit; (2nd) 𝛼-SMA staining alone; (3rd) triple-staining of GABAA 𝛼5, 𝛼-SMA, and DAPI; (4th) DAPI nucleus
counterstain, with primary antibodies omitted as negative control. Modified from [66–75].
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Figure 27: SH-053-2󸀠F-R-CH
3
(2) mediated activation of 𝛼5 subunit containing GABAA channels induces relaxation of precontracted
airway smooth muscle. (a) SH-053-2󸀠F-R-CH
3
(2) (SH-053) potentiates 𝛽-agonist-mediated relaxation of human airway smooth muscle.
Cotreatment of human airway smooth muscle strips with SH-053-2󸀠F-R-CH
3
(2) (50𝜇M) significantly enhances isoproterenol (10 nM)
mediated relaxation of an acetylcholine EC
50
contraction compared to isoproterenol alone (𝑁 = 8/group, $$ = 𝑝 < 0.01). Modified from
[66–75]. (b) SH-053-2󸀠F-R-CH
3
(2) activation of 𝛼5 containing GABAA receptors induces direct relaxation of substance P-induced airway
smoothmuscle contraction. Compiled results demonstrating enhanced spontaneous relaxation (expressed as% remaining force at 30minutes
following a 1 𝜇M substance P mediated contraction) following treatment with SH-053-2󸀠F-R-CH
3
(2) compared to treatment with vehicle
control (𝑛 = 4-5/group, $$ = 𝑝 < 0.01) [66–75].
initial SARon the first analogs demonstrated that compounds
with larger side-groups at C6 were well tolerated as they
projected into the𝐿Di domain (see 42 and 43) [85].Moreover,
substituents located at C3 exhibited a conserved stereo inter-
action in lipophilic pocket 𝐿
1
, while N2 likely participated in
hydrogen bonding with 𝐻
1
. Three novel 𝛽-carboline ligands
(21, 23, and 27) permitted a comparison of the pharmaco-
logical properties with a range of classical benzodiazepine
receptor antagonists (flumazenil, ZK93426) from several
structural groups and indicated these𝛽-carbolineswere “near
GABA neutral antagonists.” Based on the SAR, the most
potent (in vitro) 𝛼1 selective ligand was the 6-substituted
acetylenyl 𝛽CCt (WYS8, 27). In a previous study both 21
and 23 were able to reduce the rate at which rats self-
administrated alcohol in alcohol preferring and HAD rats
but had little or no effect on sucrose self-administration [85].
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Figure 28: SH-053-2󸀠F-R-CH
3
(2) mediated activation of 𝛼5 containing GABAA receptors attenuates bradykinin-induced elevations in cytos-
olic Ca2+ in human airway smoothmuscle cells. (a) Representative Fluo-4 Ca2+ fluorescence (RFU) tracing illustrating pretreatment with SH-
053-2󸀠F-R-CH
3
(2) (SH-053) (10𝜇M) reduces cytosolic Ca2+ response to bradykinin (1 𝜇M).This effect is reversed in the presence of gabazine
(200 𝜇M, GABAA receptor antagonist). Modified from [66–75]. (b) Compiled results illustrating SH-053-2
󸀠F-R-CH
3
(2) pretreatment of
GABAA 𝛼5 receptors on human airway smooth muscle cells attenuates bradykinin-induced elevations in intracellular Ca
2+ compared to
levels achieved following pretreatment with vehicle control ($$ = 𝑝 < 0.01). While gabazine-mediated blockade of GABAA channels does
not significantly affect bradykinin-induced intracellular calcium increase compared to vehicle control, gabazine treatment did reverse SH-
053-2󸀠F-R-CH
3
(2) ability to attenuate bradykinin-induced elevations in intracellular calcium thereby illustrating a GABAA channel specific
effect (n.s. = not significant). Modified from [66–75].
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Figure 29: Structures of enantiomers with 2󸀠H (15, 16) and 2󸀠F (2, 17).
3-PBC (23) was also active in baboons [134]. This data has
been used in updating the pharmacophore model in the 𝛼1-
subtype.
11. The Updated Included Volume Models
Illustrated in Figure 34 is the included volume of the updated
pharmacophore receptor model of the 𝛼1𝛽3𝛾2 subtype of
Clayton [22]. The current model for the 𝛼1𝛽3𝛾2 subtype
has several new features. The cyclopropyl group of CD-214
extended 2 A˚ past the 𝐴
2
descriptor slightly increasing its
volume. The trimethylsilyl group of QH-II-82 and WYS7
illustrates how well bulky groups are tolerated near the
entrance of the binding pocket. Despite not being as potent,
dimers of beta carbolines, WYS2 and WYS6, bound to 𝛼1
subtypes at 30 nM and 120 nM, respectively. Their ability
to bind, albeit weakly, supports the location of the binding
site entrance from the extracellular domain. The included
volume of the 𝛼1𝛽3𝛾2 subtype was previously 1085.7 cubic
angstroms. The volume has now been measured as 1219.2
cubic angstroms. Volume measurements should be used
carefully as the binding site is not enclosed and the theo-
retical opening near 𝐿DI is not clearly demarcated. Dimers
were excluded from the included volume exercise because
although they bound to the receptor, they represented com-
poundswhichwere felt to extend outside the receptor binding
pocket when docked to the protein. Where appropriate,
359
22 International Journal of Medicinal Chemistry
included volume of the alpha 2 subtype
included volume of the alpha 2 subtype
included volume of the alpha 5 subtype
included volume of the alpha 5 subtype fits within the included volume
The left image of figure rotated 90∘ . It can be clearly seen that 2
fits within the included volume
The left image of figure rotated 90∘ . It can be clearly seen that 17
fits within the included volume
The left image of figure rotated 90∘ . It can be clearly seen that 17
The left image of figure rotated 90∘ . It can be clearly seen
that the conformation of 2 is such that the pendant 6-phenyl sticks
outside the included volume
L4
SH-053-2󳰀F-R-CH3 2 fits the pharmacophore in the
SH-053-2󳰀F-S-CH3 17 fits the pharmacophore in the
SH-053-2󳰀F-S-CH3 17 fits the pharmacophore in the
SH-053-2󳰀F-R-CH3 2 does not fit the pharmacophore in the
Figure 30: Included volume and ligand occupation of the SH-053-2󸀠F-S-CH
3
17 and SH-053-2󸀠F-R-CH
3
2 enantiomers in the 𝛼5 and 𝛾2
pharmacophore/receptor models. This figure was modified and reproduced from that reported by Clayton et al. in [22, 23].
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Figure 31:The two-dimensional representation of the Milwaukee-based unified pharmacophore with 3 amino acids in the binding site based
on the rigid ligand template [23, 39, 42, 76–80].This figure has beenmodified from that reported for PAMs, NAMs, and antagonists in [22, 23].
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system
of the pyrazoloquinoline 
ring system
the pyrazoloquinoline 
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A2 is on the plane of
H2 is 0.1Å below the plane
H1 is on the plane of the
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A2
H1
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a = 6.735Å; b = 9.980Å; c = 5.860Å
d = 5.734Å; e = 5.218Å; f = Å7.317
Figure 32:The schematic representation of the descriptors for the initial inclusive BzR pharmacophore based on the rigid ligands (diindoles)
[79, 81–84]. This figure has been modified from that reported in [79].
their monomers were included in the included volume
analysis. Ligands considered for the included volume in
Table 5 exhibited potent binding at 𝛼1 subtypes (𝐾
𝑖
≤ 20 nM)
but were not necessarily subtype selective. The binding
data for ligands at 𝛼
2–6-subtypes follow (Tables 6–10; struc-
tures located in Clayton [22] and Supporting Information,
Appendix III in Supplementary Material available online at
http://dx.doi.org/10.1155/2015/430248).
12. The 𝛼1𝛽3𝛾2 Receptor Subtype
The focus of this research was aimed at diazepam sensitive
receptors; additional features to the 𝛼4𝛽3𝛾2 and 𝛼6𝛽3𝛾2
receptors were not identified (see Table 5, Figures 34 and 35).
Themajor new feature identified for the 𝛼5𝛽3𝛾2 receptor was
a new 𝐿
4
pocket. This new lipophilic pocket was identified
with SH-053-R-CH
3
(15) and SH-053-S-CH
3
(16) chiral
enantionmers as well as the 2󸀠F analogs [74, 135, 136].
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TMS
TMS
TMS
H
H
O
O
S
S
Bcct Bcct
Bcct Bcct
R6 R3
N
H
N
2
1
35 4
6
7
8
9
N
H
N
BnO
MOM
ZK-93423
Ligands 𝛼1 𝛼2 𝛼3 𝛼4 𝛼5 𝛼6R6 R3
𝛽CCt)21(
22(𝛽CCE)
23(3-PBC)
24(WYB14)
25(WY-B-25)
26(WY-B-99-1)
27(WYS8)
28(WY-B-26-2)
29(iodo-𝛽CCt)
31(iodo-𝛽CCE)
32(WY-B-08)
33(WYS13)
34(WYB27-1)
35(WYS12)
36(WYB27-2)
37(WYS15)
38(WYB29-2)
39(CMA57)
40(CM-A-82a)
41(CM-A-87)
42(WY-S-2)
43(WY-S-6)
30(WY-B-20)
H 0.72 15 18.9 1000 111
H
H
I
I
I
I
F
F
C(CH3)3
CO2tBu
CO2tBu
CO2Et
CO2Et
CO2Et
OnPr
CO2tBu
CO2tBu
CO2tBu
CO2tBu
CO2tBu
CO2tBu
CO2tBu
CO2CH2CF3
CO2CH2CF3
CO2CH2CF3
CO2CH2CF3
CO2CH2CF3
COC3 7H
CO2CH2CF3
CO2CH2(CF3)2
>5,000
>1,000
1.2 4.9 5.7 ND 26.8 2,700
6.8 30 36 2000 108 1000
17 59 88 200 1444 >3000
4.4 4.5 5.58 2000 47 2000
0.972 111 102 2000 1473 1980
4.5 44.6 42.7 2000 124 2000
14.4 44.9 123 >4000 65.3 >4000
12 39 47 2000 122 3000
4.8 31 34 1000 286 1000
78 301 131 3000 681 3000
2.4 13 27.5 NA 163 5000
26 143 117 3000 127 2000
37 166 314 NA 2861 5000
9.2 13 72 2000 449 2000
3.63 2.02 44.3 NA 76.5 5000
25 137 125 2000 299 2000
3.7 27 40 NA 254 >2500
2.78 8.93 24.5 1000 7.49 1000
1.62 4.54 14.7 1000 4.61 1000
30 124 100 >300 >300 >4000
120 1059 3942 5000 5000 5000
5.3 52.3 68.8 1000 591
aAffinity of compounds at GABA(A)/BzR recombinant subtypes was measured by competition for [3H]ﬂunitrazepam or [3H] Ro-15-4513 binding to HEK cell membranes expressing human
receptors of composition 𝛼1𝛽3𝛾2, 𝛼2𝛽3𝛾2, 𝛼3𝛽3𝛾2, 𝛼4𝛽3𝛾2, 𝛼5𝛽3𝛾2, and 𝛼6𝛽3𝛾2 [85]. Data represent the average of at least three determinations with a SEM of ±5%.
CO2Et
Figure 33: aAffinities (𝐾
𝑖
= nM) of 3,6-disubstituted 𝛽-carbolines at 𝛼𝑥𝛽3𝛾2 (𝑥 = 1–3, 5, 6) receptor subtypes [85].The structures versus code
numbers of all ligands in the tables of this review can be found in the Ph.D. thesis of Terry Clayton (Ph.D. thesis, University of Wisconsin-
Milwaukee, Milwaukee, WI, December, 2011) [22] and in the Supporting Information.
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Table 5: These ligands bound with potent affinity for 𝛼1; ligands bound with 𝐾
𝑖
values <20 nM at this subtype.
Cook codea 𝛼1 𝛼2 𝛼3 𝛼4 𝛼5 𝛼6
WY-TSC-4 (WYS8) 0.007 0.99 1.63 51.04
SH-TSC-2 (BCCT) 0.03 0.0419 0.035 69.32
QH-II-090 (CGS-8216) 0.05 0.08 0.12 0.25 17
XLI-286 0.051 0.064 0.118 0.684
QH-II-077 0.06 0.08 0.05 0.12 4
QH-II-092 0.07 0.03 0.04 ND 0.17 ND
JYI-57 0.076 0.076 0.131 ND 0.036 ND
QH-II-085 0.08 0.06 0.02 ND 0.08 ND
XHE-II-024 0.09 0.18 0.32 14 0.24 11
PWZ-007A 0.11 0.1 0.09 ND 0.2 10
CGS8216 0.13 ND ND ND ND 46
SPH-121 0.14 1.19 1.72 ND 4 479
QH-II-075 0.18 0.21 0.25 ND 1.3 40
PZII-028 0.2 ND 0.2 ND 0.32 1.9
CGS9895 0.21 ND ND ND ND 9.3
PWZ-0071 0.23 0.17 0.12 ND 0.44 17.31
XHE-III-24 0.25 ND 8 222 10 328
JYI-42 0.257 0.146 0.278 ND 0.256 ND
CGS9896 0.28 ND ND ND ND 181
JYI-64 (C17H12N4FBr) 0.305 1.111 0.62 ND 0.87 5000
PZII-029 0.34 ND 0.79 ND 0.52 10
BRETAZENIL 0.35 0.64 0.2 ND 0.5 12.7
FG8205 0.4 2.08 1.16 ND 1.54 227
YT-5 0.421 0.6034 36.06 ND 1.695 ND
6-PBC 0.49 1.21 2.2 ND 2.39 1343
QH-146 0.49 ND 0.76 ND 7.7 10000
DM-II-90 (C17H12N4BrCl) 0.505 1 0.63 ND 0.37 5000
SPH-165 0.63 2.79 4.85 ND 10.4 1150
BCCt 0.72 15 18.9 ND 110.8 5000
SH-I-048A 0.774 0.1723 0.383 ND 0.11 ND
alprazolam 0.8 0.59 1.43 ND 1.54 10000
Ro15-1788 0.8 0.9 1.05 ND 0.6 148
WYS10 C14H9F3N2O2 0.88 36 25.6 ND 548.7 15.3
WY-B-15 0.92 0.83 0.58 2080 4.42 646
WY-A-99-2 (WYS8) 0.972 111 102 2000 208 1980
XHE-III-06a 1 2 1 5 1.8 37
Xli366 C22H21N3O2 1 ND ND ND ND ND
JYI-59 (C22H13N3O2F4) 1.08 2.6 11.82 ND 11.5 5000
WYSC1 C16H16N2O2 1.094 5.44 12.3 ND 69.8 21.2
MLT-I-70 1.1 1.2 1.1 ND 40.3 1000
SVO-8-30 1.1 5.3 5.3 2.8 0.6 15
BCCE 1.2 4.9 5.7 ND 26.8 2700
XHE-III-04 1.2 2 1.1 219 0.4 500
XLi350 C17H11ClN2O 1.224 1.188 ND ND 2.9 ND
XHE-III-49 1.3 5.5 4.2 38.7 11.3 85.1
PWZ-009A1 1.34 1.31 1.26 ND 0.84 2.03
DM-239 1.5 ND 0.53 ND 0.14 6.89
XLi351 C21H21ClN2OSi 1.507 0.967 ND ND 1.985 ND
XLi352 C18H13ClN2O 1.56 0.991 ND ND 1.957 ND
363
26 International Journal of Medicinal Chemistry
Table 5: Continued.
Cook codea 𝛼1 𝛼2 𝛼3 𝛼4 𝛼5 𝛼6
TG-4-39 1.6 34 24 5.6 1.4 23
TG-II-82 1.6 2.9 2.8 ND 1 1000
CM-A87 1.62 4.54 14.73 1000 4.61 1000
QH-II-082 1.7 1.8 1.6 ND 6.1 100
JYI-49 (C20H12N3O2F4Br) 1.87 2.38 ND ND 6.7 3390
LJD-III-15E 1.93 14 19 ND 70.8 1000
SPH-38 2 5.4 10.8 ND 18.5 3000
XHE-I-093 2 7.1 8.9 1107 20 1162
MSA-IV-35 2.1 16 21 ND 995 3000
JYI-19 (C23H23N3O3S) 2.176 205 ND ND 34 12.7
FLUNITRAZEPAM 2.2 2.5 4.5 ND 2.1 2000
YCT-5 2.2 11.46 16.3 ND 200 10000
TJH-IV-51 2.39 17.4 14.5 ND 316 10000
WYS13 C20H18N2O3 2.442 13 27.5 ND 163 5000
YT-III-25 2.531 5.786 5.691 ND 0.095 ND
XHE-III-14 2.6 10 13 2 7
WYS9 C16H15IN2O2 2.72 22.2 23.1 ND 562 122
JYI-47 2.759 2.282 0.511 ND 0.427 ND
CM-A82a 2.78 8.93 24.51 1000 7.49 1000
TG-4-29 2.8 3.9 2.7 2.1 0.18 3.9
XLi268 C17H13BrN4 2.8145 0.6862 ND ND 0.6243 ND
JYI-54 (C24H15N3O3F4) 2.89 172 6.7 ND 57 1890
MMB-II-74 3 24.5 41.7 500 125.7 1000
MMB-III-016 3 1.97 2 1074 0.26 211
MMB-III-16 3 1.97 2 1074 0.26 211
QH-II-080b 3 3.7 4.7 ND 24 1000
YCT-7A 3 23.8 30.5 ND 240 10000
JYI-32 (C20H15N3O2BrF) 3.07 4.96 ND ND 2.92 52.24
Ro15-4513 3.3 2.6 2.5 ND 0.26 3.8
XHE-II-017 3.3 10 7 258 17 294
XLi-JY-DMH ANX3 3.3 0.58 1.9 ND 4.4 5000
MLT-II-18 3.4 11.7 11 ND 225 10000
TJH-V-88 3.41 30 ND 140.9 10000
XLI-2TC 3.442 1.673 44.08 ND 1.121
WYS15 C22H20N2O2 3.63 2.02 44.3 ND 76.5 5000
CM-A57 3.7 27 40 ND 254 1000
XHE-II-006b 3.7 15 12 1897 144 1000
JYI-60 3.73 1.635 4.3 ND 1.7 5000
RY-008 3.75 7.2 4.14 ND 1.11 44.3
MLT-II-18 3.9 12.2 24.4 ND 210 10000
OMB-18 3.9 1.2 3.4 1733 0.8 5
WY-B-09-1 3.99 8 32 1000 461 2000
SHU-1-19 4 12 7 48 14 84
ZK 93423 4.1 4.2 6 ND 4.5 1000
WY-B-23-2 (WYS11) 4.2 37.7 39 2000 176 69.4
WY-B-23-2 (WYS11) 4.2 37.7 73 ND 176 69.4
WY-B-99-1 4.4 4.5 5.58 2000 47 2000
WY-B-26-2 4.45 44.57 42.66 2000 124 2000
XHE-II-006a 4.7 4.4 20 1876 89 3531
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Table 5: Continued.
Cook codea 𝛼1 𝛼2 𝛼3 𝛼4 𝛼5 𝛼6
CM-B01 4.8 31 34 1000 286 1000
PWZ-085 4.86 13 8.5 ND 0.55 40
MLT-II-16 5.05 10.41 18.4 ND 260 10000
3 PBC 5.3 52.3 68.8 ND 591 1000
MA-3-PROPOXYL 5.3 52.3 68.8 ND 591 1000
TJH-IV-43 5.42 30.19 48.9 ND 475 10000
DMCM 5.69 8.29 4 ND 1.04 134
DM-139 5.8 ND 169 ND 9.25 325
XHE-II-073A (R ENRICHED) 5.9 11 10 15 1.18 140
MSR-I-032 6.2 18.7 4 ND 3.3 74.9
JYI-70 (C19H13N4F) 6.3 2.1 ND ND 0.56 5000
XLi343 C20H19ClN2OSi 6.375 17.71 ND ND 150.5 ND
3 EBC 6.43 25.1 28.2 ND 826 1000
DM-146 6.44 ND 148 ND 4.23 247
DM-215 6.74 ND 7.42 ND 0.293 8.28
ZG69A 6.8 16.3 9.2 ND 0.85 54.6
ZG-69a (Ro15-1310) 6.8 16.3 9.2 ND 0.85 54.6
WY-B-14 (WYS7) 6.84 30 36 2000 108 1000
YT-II 6.932 0.8712 3.518 ND 5.119 ND
SVO-8-67 7 41 26 15 2.3 191
MLT-II-34 7.04 15.95 22.3 ND 158 1000
SPH-195 7.2 168.5 283.5 ND 271 10000
XHE-I-065 7.2 17 18 500 57 500
ZG-234 7.25 22.14 9.84 ND 0.3 5.25
SH-I-04 7.3 6.136 5.1 ND 7.664 ND
XHE-I-038 7.3 5 34 ND 132 1000
XHE-III-13 7.3 ND 7.1 880 1.6 311
WY-B-25 7.6 40 66 2000 263 2000
CM-A49 (R) 7.7 32.5 43 ND 69 1000
SVO-8-14 8 25 8 6.9 0.9 14
TG-4-29 8.3 10.2 6.9 ND 0.4 7.61
XHE-II-002 8.3 18 13 3.9 1.5 11
WY-B-14 (WYS7) 8.5 165 245 ND 1786 5000
XHE-II-011 9 60 39 3233 90 1000
WY-B-27-2 9.19 111 72 2000 449 2000
QH-II-063 9.4 9.3 31 ND 7.7 3000
JC184 C13H9BrN2OS 9.606 10.5 ND ND 6.709 ND
ZG-208 9.7 11.2 10.9 ND 0.38 4.6
RY-I-31 10 45 19 ND 6 1000
WY-B-23-1 10 33 43 1000 189 2000
RY-098 10.1 22.2 16.5 ND 1.68 100
Hz148 C18H15N3 10.98 5000 ND ND 256 5000
SVO-8-20 11 40 28 19 8.6 138
XHE-II-073B (S-ENRICHED) 11 17 12 33 2.1 269
SH-I-085 11.08 4.866 13.75 ND 0.24 ND
PWZ-096 11.1 36 16.9 ND 1.07 51.5
ZG-168 11.2 10.7 9.2 ND 0.47 9.4
CM-A77 11.51 51.9 105.16 1000 42.62 1000
WY-B-20 12 39 47 2000 122 3000
ABECARNIL 12.4 15.3 7.5 ND 6 1000
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Table 5: Continued.
Cook codea 𝛼1 𝛼2 𝛼3 𝛼4 𝛼5 𝛼6
SH-I-89S 12.78 8.562 8.145 ND 3.23 ND
ZG-213 12.8 49.8 30.2 ND 3.5 22.5
EDC-I-071 12.9 83.1 ND ND 314 5000
MMB-III-14 13 13 6.9 333 1.1 333
DM-173 13.1 ND 38.1 ND 0.78 118
XLI-348 13.56 11.17 1.578 ND 82.05 ND
EDC-I-093 13.6 423 ND ND 2912 5000
diazepam 14 20 15 ND 11 ND
XLi223 C22H20BrN3O2 14 8.7 18 1000 10 2000
WYSC2 C15H11F3N2O2 14.14 113 170 ND 518 61.2
SH-I-030 14.42 11.04 19.09 ND 1.89 ND
CM-A100 14.49 44.91 123.8 1000 65.31 1000
RY-033 14.8 56 25.3 ND 1.72 22.9
HJ-I-037 15.07 8.127 28.29 ND 0.818 ND
YT-6 15.31 87.8 60.49 ND 1.039 ND
EDC-II-044 15.4 ND 293 ND 323 1000
CM-A58 16 120 184 ND 1000 1012
QH-II-067a 16 31 52 ND 199 3000
CD-214 16.4 48.2 42.5 ND 9.8 168
JYI-06 (C23H23N3O4) 16.5 5.48 5000 ND 12.6 5000
CM-A50 (S) 17 59 88 ND 144 1000
RY-061 17 13 6.7 ND 0.3 31
ZG-224 17.1 33.7 50 ND 2.5 30.7
ZG-63A 17.3 21.6 29.1 ND 0.65 4
DM-II-30 (C20H13N3O2BrF3) 17.6 13.4 28.51 ND 7.8 5000
CM-A64 18 60 116 ND 216 1000
RY-071 19 56 91 ND 7.2 266
WZ-113 19.2 13.2 13.4 ND 11.5 300
YT-III-23 19.83 23.65 19.87 ND 1.105 ND
CM-E09b 20 22 19 55 0.45 69
MMB-II-90 20 24 5.7 9 0.25 36
aAffinity of compounds at GABAA/BzR recombinant subtypes was measured by competition for [
3H]flunitrazepam or [3H] Ro15-4513 binding to HEK cell
membranes expressing human receptors of compositions 𝛼1𝛽3𝛾2, 𝛼2𝛽3𝛾2, 𝛼3𝛽3𝛾2, 𝛼4𝛽3𝛾2, 𝛼5𝛽3𝛾2, and 𝛼6𝛽3𝛾2 [139]. Data represent the average of at least
three determinations with a SEM of ±5%. The structures of these ligands are in the Ph.D. thesis of Clayton (2011) [22] and Supporting Information.
13. The 𝛼2𝛽3𝛾2 Receptor Subtype
See Table 6 and Figures 36 and 37.
14. The 𝛼3𝛽3𝛾2 Receptor Subtype
See Table 7 and Figures 38 and 39.
15. The 𝛼4𝛽3𝛾2 Receptor Subtype
See Table 8 and Figures 40 and 41.
16. The 𝛼5𝛽3𝛾2 Receptor Subtype
The multiple volume contours displayed in Figures 34–47
were created using the mvolume function (multiple volume
contour function) in Sybyl and compounds with binding
affinity at the receptor less than or equal to 20 nM. To create
the overlays, first, the display (dsp) and contour (cnt) files
were created for the 𝛼5𝛽3𝛾2 receptor subtype and the 𝛼1𝛽3𝛾2
receptor subtype by overlaying the compounds for each of
these receptors (see Table 9 and Figures 42–45). Using the
mvolume function, a logical expression was entered to create
the surfaces making up the union as well as the included
volume for each receptor subtype itself. It is clear from the
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Table 6: Ligands with potent affinity for 𝛼2; ligands bound with 𝐾
𝑖
values <20 nM at this subtype. The structures of these ligands are in the
Ph.D. thesis of Clayton (2011) [22].
Cook codea 𝛼1 𝛼2 𝛼3 𝛼4 𝛼5 𝛼6
QH-II-092 0.07 0.03 0.04 ND 0.17 ND
SH-TSC-2 (BCCT) 0.03 0.0419 0.035 ND 69.32 ND
QH-II-085 0.08 0.06 0.02 ND 0.08 ND
XLI-286 0.051 0.064 0.118 ND 0.684 ND
JYI-57 0.076 0.076 0.131 ND 0.036 ND
QH-II-090 (CGS-8216) 0.05 0.08 0.12 ND 0.25 17
QH-II-077 0.06 0.08 0.05 ND 0.12 4
PWZ-007A 0.11 0.1 0.09 ND 0.2 10
JYI-42 0.257 0.146 0.278 ND 0.256 ND
PWZ-0071 0.23 0.17 0.12 ND 0.44 17.31
SH-I-048A 0.774 0.1723 0.383 ND 0.11 ND
XHE-II-024 0.09 0.18 0.32 14 0.24 11
QH-II-075 0.18 0.21 0.25 ND 1.3 40
XLi-JY-DMH ANX3 3.3 0.58 1.9 ND 4.4 5000
alprazolam 0.8 0.59 1.43 ND 1.54 10000
YT-5 0.421 0.6034 36.06 ND 1.695 ND
BRETAZENIL 0.35 0.64 0.2 ND 0.5 12.7
XLi268 C17H13BrN4 2.8145 0.6862 ND ND 0.6243 ND
WY-B-15 0.92 0.83 0.58 2080 4.42 646
YT-II 6.932 0.8712 3.518 ND 5.119
Ro15-1788 0.8 0.9 1.05 ND 0.6 148
XLi351 C21H21ClN2OSi 1.507 0.967 ND ND 1.985 ND
WY-TSC-4 (WYS8) 0.007 0.99 1.63 ND 51.04 ND
XLi352 C18H13ClN2O 1.56 0.991 ND ND 1.957 ND
DM-II-90 (C17H12N4BrCl) 0.505 1 0.63 ND 0.37 5000
JYI-64 (C17H12N4FBr) 0.305 1.111 0.62 ND 0.87 5000
XLi350 C17H11ClN2O 1.224 1.188 ND ND 2.9 ND
SPH-121 0.14 1.19 1.72 ND 4 479
MLT-I-70 1.1 1.2 1.1 ND 40.3 1000
OMB-18 3.9 1.2 3.4 1733 0.8 5
6-PBC 0.49 1.21 2.2 ND 2.39 1343
YT-III-271 32.54 1.26 2.35 ND 103 ND
PWZ-009A1 1.34 1.31 1.26 ND 0.84 2.03
DM-II-72 (C15H10N20BrCl) 5000 1.37 ND ND 2.02 5000
JYI-60 (C17H11N2OF) 3.73 1.635 4.3 ND 1.7 5000
XLI-2TC 3.442 1.673 44.08 ND 1.121 ND
QH-II-082 1.7 1.8 1.6 ND 6.1 100
TC-YT-II-76 101.1 1.897 5.816 ND 11.99 ND
MMB-III-016 3 1.97 2 1074 0.26 211
MMB-III-16 3 1.97 2 1074 0.26 211
XHE-III-06a 1 2 1 5 1.8 37
XHE-III-04 1.2 2 1.1 219 0.4 500
WYS15 C22H20N2O2 3.63 2.02 44.3 ND 76.5 5000
FG8205 0.4 2.08 1.16 ND 1.54 227
JYI-70 (C19H13N4F) 6.3 2.1 ND ND 0.56 5000
JYI-47 2.759 2.282 0.511 ND 0.427 ND
JYI-49 (C20H12N3O2F4Br) 1.87 2.38 ND ND 6.7 3390
FLUNITRAZEPAM 2.2 2.5 4.5 ND 2.1 2000
JYI-59 (C22H13N3O2F4) 1.08 2.6 11.82 ND 11.5 5000
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Table 6: Continued.
Cook codea 𝛼1 𝛼2 𝛼3 𝛼4 𝛼5 𝛼6
Ro15-4513 3.3 2.6 2.5 ND 0.26 3.8
SPH-165 0.63 2.79 4.85 ND 10.4 1150
YT-II-76 95.34 2.797 0.056 ND 0.04 ND
TG-II-82 1.6 2.9 2.8 ND 1 1000
QH-II-080b 3 3.7 4.7 ND 24 1000
TG-4-29 2.8 3.9 2.7 2.1 0.18 3.9
PS-1-34B C20H17N4BrO ND 4.198 3.928 ND ND ND
ZK 93423 4.1 4.2 6 ND 4.5 1000
XHE-II-006a 4.7 4.4 20 1876 89 3531
WY-B-99-1 4.4 4.5 5.58 2000 47 2000
CM-A87 1.62 4.54 14.73 1000 4.61 1000
OMB-19 22 4.6 20 3333 3.5 40
SH-I-085 11.08 4.866 13.75 ND 0.24 ND
BCCE 1.2 4.9 5.7 ND 26.8 2700
JYI-32 (C20H15N3O2BrF) 3.07 4.96 ND ND 2.92 52.24
XHE-I-038 7.3 5 34 ND 132 1000
SVO-8-30 1.1 5.3 5.3 2.8 0.6 15
SPH-38 2 5.4 10.8 ND 18.5 3000
WYSC1 C16H16N2O2 1.094 5.44 12.3 ND 69.8 21.2
JYI-06 (C23H23N3O4) 16.5 5.48 5000 ND 12.6 5000
XHE-III-49 1.3 5.5 4.2 38.7 11.3 85.1
YT-III-25 2.531 5.786 5.691 ND 0.095 ND
SH-I-04 7.3 6.136 5.1 ND 7.664 ND
XHE-I-093 2 7.1 8.9 1107 20 1162
RY-008 3.75 7.2 4.14 ND 1.11 44.3
DMH-D-053 (C43H30N6O4) 236 7.4 272 5000 194.2 5000
WY-B-09-1 3.99 8 32 1000 461 2000
HJ-I-037 15.07 8.127 28.29 ND 0.818 ND
DMCM 5.69 8.29 4 ND 1.04 134
SH-I-89S 12.78 8.562 8.145 ND 3.23 ND
XLi223 C22H20BrN3O2 14 8.7 18 1000 10 2000
CM-A82a 2.78 8.93 24.51 1000 7.49 1000
QH-II-063 9.4 9.3 31 ND 7.7 3000
9.4 9.3 31 ND 7.7 3000
XHE-II-017 3.3 10 7 258 17 294
TG-4-29 8.3 10.2 6.9 ND 0.4 7.61
MLT-II-16 5.05 10.41 18.4 ND 260 10000
JC184 C13H9BrN2OS 9.606 10.5 ND ND 6.709 ND
ZG-168 11.2 10.7 9.2 ND 0.47 9.4
XHE-II-073A (R ENRICHED) 5.9 11 10 15 1.18 140
XLI-8TC 21.52 11.01 2.155 ND 4.059 ND
SH-I-030 14.42 11.04 19.09 ND 1.89 ND
XLI-348 13.56 11.17 1.578 ND 82.05 ND
ZG-208 9.7 11.2 10.9 ND 0.38 4.6
YT-TC-3 141.4 11.43 118.1 ND 29.22 ND
YCT-5 2.2 11.46 16.3 ND 200 10000
MLT-II-18 3.4 11.7 11 ND 225 10000
XHE-II-O53-ACID 50.35 11.8 44 ND 5.9 5000
SHU-1-19 4 12 7 48 14 84
RY-067 21 12 10 ND 0.37 42
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Table 6: Continued.
Cook codea 𝛼1 𝛼2 𝛼3 𝛼4 𝛼5 𝛼6
DM-III-01 (C18H12N3O2Br) 5000 12 ND ND 4.73 5000
MLT-II-18 3.9 12.2 24.4 ND 210 10000
SH-053-2󸀠F 21.99 12.34 34.9 ND 0.671 ND
WYS13 C20H18N2O3 2.442 13 27.5 ND 163 5000
PWZ-085 4.86 13 8.5 ND 0.55 40
MMB-III-14 13 13 6.9 333 1.1 333
RY-061 17 13 6.7 ND 0.3 31
WZ-113 19.2 13.2 13.4 ND 11.5 300
YT-II-83 32.74 13.22 24.1 ND 3.548 ND
DM-II-30 (C20H13N3O2BrF3) 17.6 13.4 28.51 ND 7.8 5000
LJD-III-15E 1.93 14 19 ND 70.8 1000
YT-III-272 295.9 14.98 10.77 ND 103.3 ND
BCCt 0.72 15 18.9 ND 110.8 5000
XHE-II-006b 3.7 15 12 1897 144 1000
ABECARNIL 12.4 15.3 7.5 ND 6 1000
MLT-II-34 7.04 15.95 22.3 ND 158 1000
MSA-IV-35 2.1 16 21 ND 995 3000
JYI-04 (C21H23N3O3) 28.3 16 ND ND 0.51 1.57
PS-1-35 C23H22N5OBr ND 16.03 24.41 ND ND ND
ZG69A 6.8 16.3 9.2 ND 0.85 54.6
ZG-69a (Ro15-1310) 6.8 16.3 9.2 ND 0.85 54.6
YT-III-42 382.9 16.83 44.04 ND 9.77 ND
XHE-I-065 7.2 17 18 500 57 500
XHE-II-073B (S-ENRICHED) 11 17 12 33 2.1 269
TJH-IV-51 2.39 17.4 14.5 ND 316 10000
SH-I-047 1710 17.52 1222 ND 1519 ND
XLi343 C20H19ClN2OSi 6.375 17.71 ND ND 150.5 ND
XHE-II-002 8.3 18 13 3.9 1.5 11
YT-III-38 1461 18.21 14.63 ND 3999
JYI-72 (C22H21N4SiF) 48.5 18.5 ND ND 11.5 5000
MSR-I-032 6.2 18.7 4 ND 3.3 74.9
JC208 C15H10N2OS 22.42 18.89 ND ND 5.039 ND
diazepam 14 20 15 ND 11 ND
aAffinity of compounds at GABAA/BzR recombinant subtypes was measured by competition for [
3H]flunitrazepam or [3H] Ro15-4513 binding to HEK cell
membranes expressing human receptors of compositions 𝛼1𝛽3𝛾2, 𝛼2𝛽3𝛾2, 𝛼3𝛽3𝛾2, 𝛼4𝛽3𝛾2, 𝛼5𝛽3𝛾2, and 𝛼6𝛽3𝛾2 [22, 139]. Data represent the average of at
least three determinations with a SEM of ±5%. ND: not determined.
included volume overlay that the 𝐿
2
pocket is deeper for the
𝛼5 subtype, as determined previously [13, 21–23, 110, 119].The
new 𝐿
4
pocket can be distinguished as the new yellow region
of the 𝛼5𝛽3𝛾2 subtype which is due to recently designed R-
isomers by Huang [135], Poe and Li.
17. The 𝛼6𝛽3𝛾2 Receptor Subtype
See Table 10 and Figures 46 and 47.
18. Updates to the Previous Model
In addition to the newly discovered 𝐿
4
pocket, the updated
library of binding affinity led to two specific updates in the
previous model (Figure 48).
19. QSAR
A nontraditional quantitative structure activity relationship
(QSAR) approach was executed to observe steric and electro-
static preferences for each receptor subtype. A subset of the
compounds used in each subtype pharmacophore/receptor
model were chosen with a good cross section of scaffold
variety. The compounds used in the COMFA maps are the
imidazobenzodiazepines published previously [110, 137] and
additionally alternative scaffolds which bound with <20 nM
at the respective subtype [22].
The interest here was in creation of steric and electrostatic
maps of the comparative molecular field analyses (COMFA)
created from molecular spreadsheets. A variety of com-
pounds selective for each subtype were selected and placed
into a dataset used to build the CoMFAmodels. Activities (𝐾
𝑖
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Table 7: Ligands with potent affinity for 𝛼3; ligands bound with 𝐾
𝑖
values <20 nM at this subtype. The structures of these ligands are in the
Ph.D. thesis of Clayton (2011) [22].
Cook codea 𝛼1 𝛼2 𝛼3 𝛼4 𝛼5 𝛼6
QH-II-085 0.08 0.06 0.02 ND 0.08 ND
SH-TSC-2 (BCCT) 0.03 0.0419 0.035 ND 69.32 ND
QH-II-092 0.07 0.03 0.04 ND 0.17 ND
QH-II-077 0.06 0.08 0.05 ND 0.12 4
YT-II-76 95.34 2.797 0.056 ND 0.04 ND
PWZ-007A 0.11 0.1 0.09 ND 0.2 10
XLI-286 0.051 0.064 0.118 ND 0.684 ND
QH-II-090 (CGS-8216) 0.05 0.08 0.12 ND 0.25 17
PWZ-0071 0.23 0.17 0.12 ND 0.44 17.31
JYI-57 0.076 0.076 0.131 ND 0.036 ND
BRETAZENIL 0.35 0.64 0.2 ND 0.5 12.7
PZII-028 0.2 ND 0.2 ND 0.32 1.9
QH-II-075 0.18 0.21 0.25 ND 1.3 40
JYI-42 0.257 0.146 0.278 ND 0.256 ND
XHE-II-024 0.09 0.18 0.32 14 0.24 11
SH-I-048A 0.774 0.1723 0.383 ND 0.11 ND
JYI-55 41.39 ND 0.504 ND 24.75 ND
JYI-47 2.759 2.282 0.511 ND 0.427 ND
DM-239 1.5 ND 0.53 ND 0.14 6.89
WY-B-15 0.92 0.83 0.58 2080 4.42 646
JYI-64 (C17H12N4FBr) 0.305 1.111 0.62 ND 0.87 5000
DM-II-90 (C17H12N4BrCl) 0.505 1 0.63 ND 0.37 5000
QH-146 0.49 ND 0.76 ND 7.7 10000
PZII-029 0.34 ND 0.79 ND 0.52 10
WYS19 C26H32N2O4Si ND ND 0.89 ND ND ND
XHE-III-06a 1 2 1 5 1.8 37
Ro15-1788 0.8 0.9 1.05 ND 0.6 148
MLT-I-70 1.1 1.2 1.1 ND 40.3 1000
XHE-III-04 1.2 2 1.1 219 0.4 500
FG8205 0.4 2.08 1.16 ND 1.54 227
PWZ-009A1 1.34 1.31 1.26 ND 0.84 2.03
alprazolam 0.8 0.59 1.43 ND 1.54 10000
XLI-348 13.56 11.17 1.578 ND 82.05 ND
QH-II-082 1.7 1.8 1.6 ND 6.1 100
WY-TSC-4 (WYS8) 0.007 0.99 1.63 ND 51.04 ND
SPH-121 0.14 1.19 1.72 ND 4 479
XLi-JY-DMH ANX3 3.3 0.58 1.9 ND 4.4 5000
MMB-III-016 3 1.97 2 1074 0.26 211
MMB-III-16 3 1.97 2 1074 0.26 211
XLI-8TC 21.52 11.01 2.155 ND 4.059 ND
6-PBC 0.49 1.21 2.2 ND 2.39 1343
YT-III-271 32.54 1.26 2.35 ND 103 ND
Ro15-4513 3.3 2.6 2.5 ND 0.26 3.8
TG-4-29 2.8 3.9 2.7 2.1 0.18 3.9
TG-II-82 1.6 2.9 2.8 ND 1 1000
OMB-18 3.9 1.2 3.4 1733 0.8 5
YT-II 6.932 0.8712 3.518 ND 5.119 ND
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Table 7: Continued.
Cook codea 𝛼1 𝛼2 𝛼3 𝛼4 𝛼5 𝛼6
PS-1-34B C20H17N4BrO ND 4.198 3.928 ND ND ND
DMCM 5.69 8.29 4 ND 1.04 134
MSR-I-032 6.2 18.7 4 ND 3.3 74.9
RY-008 3.75 7.2 4.14 ND 1.11 44.3
XHE-III-49 1.3 5.5 4.2 38.7 11.3 85.1
JYI-60 (C17H11N2OF) 3.73 1.635 4.3 ND 1.7 5000
FLUNITRAZEPAM 2.2 2.5 4.5 ND 2.1 2000
XLI-317 60.24 24.05 4.562 ND 0.295 ND
QH-II-080b 3 3.7 4.7 ND 24 1000
SPH-165 0.63 2.79 4.85 ND 10.4 1150
SH-I-04 7.3 6.136 5.1 ND 7.664 ND
SVO-8-30 1.1 5.3 5.3 2.8 0.6 15
WY-B-99-1 4.4 4.5 5.58 2000 47 2000
YT-III-25 2.531 5.786 5.691 ND 0.095 ND
BCCE 1.2 4.9 5.7 ND 26.8 2700
MMB-II-90 20 24 5.7 9 0.25 36
TC-YT-II-76 101.1 1.897 5.816 ND 11.99 ND
ZK 93423 4.1 4.2 6 ND 4.5 1000
RY-061 17 13 6.7 ND 0.3 31
JYI-54 (C24H15N3O3F4) 2.89 172 6.7 ND 57 1890
TG-4-29 8.3 10.2 6.9 ND 0.4 7.61
MMB-III-14 13 13 6.9 333 1.1 333
XHE-II-017 3.3 10 7 258 17 294
SHU-1-19 4 12 7 48 14 84
XHE-III-13 7.3 ND 7.1 880 1.6 311
DM-215 6.74 ND 7.42 ND 0.293 8.28
ABECARNIL 12.4 15.3 7.5 ND 6 1000
SVO-8-14 8 25 8 6.9 0.9 14
XHE-III-24 0.25 ND 8 222 10 328
SH-I-89S 12.78 8.562 8.145 ND 3.23 ND
PWZ-085 4.86 13 8.5 ND 0.55 40
XHE-I-093 2 7.1 8.9 1107 20 1162
ZG-168 11.2 10.7 9.2 ND 0.47 9.4
ZG69A 6.8 16.3 9.2 ND 0.85 54.6
ZG-69a (Ro15-1310) 6.8 16.3 9.2 ND 0.85 54.6
ZG-234 7.25 22.14 9.84 ND 0.3 5.25
XHE-II-073A (R ENRICHED) 5.9 11 10 15 1.18 140
RY-067 21 12 10 ND 0.37 42
XHE-III-14 2.6 ND 10 13 2 7
YT-III-272 295.9 14.98 10.77 ND 103.3 ND
SPH-38 2 5.4 10.8 ND 18.5 3000
ZG-208 9.7 11.2 10.9 ND 0.38 4.6
MLT-II-18 3.4 11.7 11 ND 225 10000
DM-II-33 (C20H13N3O2BrCl3) 88.6 85 11.6 ND 26.2 5000
JYI-59 (C22H13N3O2F4) 1.08 2.6 11.82 ND 11.5 5000
XHE-II-006b 3.7 15 12 1897 144 1000
XHE-II-073B (S-ENRICHED) 11 17 12 33 2.1 269
CM-B44 (ss) 32 43 12 379 4.3 485
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Table 7: Continued.
Cook codea 𝛼1 𝛼2 𝛼3 𝛼4 𝛼5 𝛼6
WYSC1 C16H16N2O2 1.094 5.44 12.3 ND 69.8 21.2
JYI-48 75.59 90.68 12.78 ND 31.28 ND
XHE-II-002 8.3 18 13 3.9 1.5 11
RY-076 26 27 13 ND 0.7 22
WZ-113 19.2 13.2 13.4 ND 11.5 300
SH-I-085 11.08 4.866 13.75 ND 0.24 ND
CM-E10 23 26 14 215 0.51 96
TJH-IV-51 2.39 17.4 14.5 ND 316 10000
YT-III-38 1461 18.21 14.63 ND 3999 ND
CM-A87 1.62 4.54 14.73 1000 4.61 1000
diazepam 14 20 15 ND 11 ND
RY-053 49 29 15 ND 1 46
YCT-5 2.2 11.46 16.3 ND 200 10000
RY-098 10.1 22.2 16.5 ND 1.68 100
PWZ-096 11.1 36 16.9 ND 1.07 51.5
XLi223 C22H20BrN3O2 14 8.7 18 1000 10 2000
XHE-I-065 7.2 17 18 500 57 500
SH-I-02B 29.82 1315 18 ND 74.05 ND
MLT-II-16 5.05 10.41 18.4 ND 260 10000
RY-024 C19H19N3O3 26.9 26.3 18.7 ND 0.4 5.1
BCCt 0.72 15 18.9 ND 110.8 5000
LJD-III-15E 1.93 14 19 ND 70.8 1000
CM-E09b 20 22 19 55 0.45 69
RY-I-31 10 45 19 ND 6 1000
SH-I-030 14.42 11.04 19.09 ND 1.89 ND
YT-III-23 19.83 23.65 19.87 ND 1.105 ND
XHE-II-006a 4.7 4.4 20 1876 89 3531
OMB-19 22 4.6 20 3333 3.5 40
XHE-III-06b 32 33 20 299 28.6 740
aAffinity of compounds at GABAA/BzR recombinant subtypes was measured by competition for [
3H]flunitrazepam or [3H] Ro15-4513 binding to HEK cell
membranes expressing human receptors of compositions 𝛼1𝛽3𝛾2, 𝛼2𝛽3𝛾2, 𝛼3𝛽3𝛾2, 𝛼4𝛽3𝛾2, 𝛼5𝛽3𝛾2, and 𝛼6𝛽3𝛾2 [22, 139]. Data represent the average of at
least three determinations with a SEM of ±5%. ND: not determined.
values) were converted to logarithmic units for this study. A
CoMFA descriptor set was created based on the –log (𝐾
𝑖
) of
over 70 structures.The goal was to derive an alternative three-
dimensional shape of the receptor using biological activity of
the most selective compounds. Structures were determined
by crystal structurewhere available or by calculation. Charges
were provided based on the Gasteiger-Huckel model. Con-
formations were kept consistent based on previous studies of
low energy conformations [110]. It should be noted that this
was not a traditional QSAR study as nonselective compounds
were excluded. Therefore, 𝐾
𝑖
values did not cross 3 log
units. This was acceptable since the goal was not to create
a predictive QSAR predictive algorithm, rather a map of
the receptor based on sterics and electrostatics. Hydrogen
acceptor radii were set to 3.0 and the hydrogen donor radii
were set to 2.6 based on recommendations from Certara
(Tripos). Analyses were executed using PLS (partial least
squares). The details of modeling will be further discussed in
the SI.
For each of the following QSAR models (Figures 49–
64), green areas represent desirable steric bulk and yellow
represents undesirable steric bulk. Positive electrostatic con-
tributions are represented by blue and negative electrostatic
contributions are represented by red.
20. The 𝛼1𝛽3𝛾2 Receptor Subtype
See Figures 49–52.
21. The 𝛼2𝛽3𝛾2 Receptor Subtype
See Figures 53–56.
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Table 8: Ligands with potent affinity for 𝛼4; ligands bound with 𝐾
𝑖
values <20 nM at this subtype. The structures of these ligands are in
the Ph.D. thesis of Clayton (2011) [22].
Cook codea 𝛼1 𝛼2 𝛼3 𝛼4 𝛼5 𝛼6
CM-D45 C19H21N3O4 90.5 65.5 30.3 0.15 1.65 0.23
CM-D44 34.3 56.3 20.7 0.33 0.57 0.92
XHE-III-74 77 105 38 0.42 2.2 5.8
TG-4-29 2.8 3.9 2.7 2.1 0.18 3.9
SVO-8-30 1.1 5.3 5.3 2.8 0.6 15
XHE-II-002 8.3 18 13 3.9 1.5 11
XHE-III-06a 1 2 1 5 1.8 37
RY-080 C17H15N3O3 28.4 21.4 25.8 5.3 0.49 28.8
TG-4-39 1.6 34 24 5.6 1.4 23
SVO-8-14 8 25 8 6.9 0.9 14
RY-023 C22H27N3O3Si 197 142.6 255 7.8 2.61 58.6
MMB-II-90 20 24 5.7 9 0.25 36
XHE-III-14 2.6 10 13 2 7
XHE-II-024 0.09 0.18 0.32 14 0.24 11
XHE-II-073A (R ENRICHED) 5.9 11 10 15 1.18 140
SVO-8-67 7 41 26 15 2.3 191
CM-B31i (ss) 90 184 78 18 4.9 121
SVO-8-20 11 40 28 19 8.6 138
aAffinity of compounds atGABAA/BzR recombinant subtypeswasmeasured
by competition for [3H]flunitrazepamor [3H]Ro15-4513 binding toHEK cell
membranes expressing human receptors of compositions 𝛼1𝛽3𝛾2, 𝛼2𝛽3𝛾2,
𝛼3𝛽3𝛾2, 𝛼4𝛽3𝛾2, 𝛼5𝛽3𝛾2, and 𝛼6𝛽3𝛾2 [22, 139]. Data represent the average
of at least three determinations with a SEM of ±5%. ND: not determined.
22. The 𝛼3𝛽3𝛾2 Receptor Subtype
See Figures 57–60.
23. The 𝛼5𝛽3𝛾2 Receptor Subtype
From the CoMFA maps several observations (Figure 65) can
bemade.The yellow steric regions near 𝐿
3
in the 𝛼5𝛽3𝛾2map
are unique. This illustrated that, in general, benzodiazepines
lacking a pendant phenyl are more suited to targeting the 𝛼5
subtype.The 𝐿Di region of the 𝛼1 subtype is most tolerable for
compounds with steric interactions in this location while the
𝛼3 subtype receptor compounds prefer no steric interaction
in this location. Negative electrostatics are most preferred
by the 𝐿
3
pocket of the 𝛼2 and 𝛼5 receptors. In general,
the 𝛼1 subtype receptor prefers molecules without a dipole.
It should be noted that none of the analogs are ionic in
nature and the charges for this model were provided by the
Gasteiger-Huckel model. For this reason more emphasis is
placed on the steric relationships which exclude interactions
in the pharmacophores. In the future a QSAR study which
includes nonbinding benzodiazepines in the data set along
with activity data will permit the creation of a predictive
algorithm which will be very useful in lead targeting (see
Figures 61–65).
24. Conclusion
Benzodiazepines, 𝛽-carbolines, and other classes of com-
pounds readily target the GABAA receptors. The difficulty
is finding subtype selective ligands, since there is no crystal
structure of the Bz/GABAA-ergic site itself, just one com-
posed of five beta-subunits which has no Bz site to date.
The 𝛼5-BzR/GABAA subunit has recently been shown to be
important in the search to treat numerous cognition-based
illnesses including Alzheimer’s, schizophrenia, bipolar, and
depression, as well as more recently a bronchodilator, poten-
tially important in the treatment of asthma. As an inverse
agonist, PWZ-029 was able to counteract the memory-
impairing effects of scopolamine, a muscarinic antagonist,
in both object recognition tests and object retrieval tests in
rodents, and was active in primates, as well as samaritan
Alzheimer’s rats. The implications of these tests point to
a use as a possible treatment for Alzheimer’s disease. The
docking of PWZ-029 in the 𝛼5𝛾2 GABAAR-subunit details
the interactions between the pharmacophore/receptor model
binding site and this important negative allosteric modulator.
Furthermore, 𝛼5-BzR/GABAA positive allosteric modulator,
SH-053-2󸀠F-R-CH
3
, was shown to reverse deleterious effects
in the MAM-model of schizophrenia. The recent discovery
of 𝛼5-GABAAR in airway smooth muscle by Emala et al.
has also lead to the testing of SH-053-2󸀠F-R-CH
3
as a
bronchodilator. This SH-053-2󸀠F-R-CH
3
was found to be
effective in relaxing preconstricted airway smooth muscle,
as well as attenuating calcium-ion entry through the plasma
membrane. In addition, XLi-093 (an 𝛼5 receptor antagonist),
a potently binding 𝛼5-subtype selective bivalent ligand, has
been shown to inhibit the 𝛼5-cognition deficits effected by
diazepam and is a very good 𝛼5 benzodiazepine receptor site
antagonist. It has also been shown to reverse the effects of 𝛼5
PAMs and NAMs in both rodent and primate models. These
findings led to the exploration of the𝛼5-binding pocket in the
Milwaukee-based pharmacophore.
New features have been introduced to the unified phar-
macophore/receptor model based on many substance classes
that act at the diazepam sensitive and diazepam insensitive
BzR binding sites of GABAA receptors.Themajor new feature
identified for the 𝛼5𝛽3𝛾2 receptor was a new 𝐿
4
pocket which
was found by using pendant 6-phenyl benzodiazepines with
a R-CH
3
at the prochiral center at C4. Further enhance-
ment of potency was achieved by addition of 2󸀠-F or 2󸀠-N
substituent in the pendant phenyl ring at C-6. While these
changes have led to enhanced subtype selective ligands, the
overall development guided by this pharmacophore model
described here has led to new agents with varying, fascinating
pharmacological profiles, ranging from use in cognition-
based diseases such as Alzheimer’s and schizophrenia, to
use as a bronchodilator. This research on updating the
Milwaukee-based pharmacophore/receptor model can be
used in the rational design for improving the selectivity
of 𝛼5 ligands. As the library of compounds increases, the
data which follows can then be further evaluated and can
lead to more insight to the identification of the possible
roles each individual residue may have with the binding
pocket.
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Table 9: Ligands with potent affinity for 𝛼5; ligands bound with 𝐾
𝑖
values <20 nM at this subtype. The structures of these ligands are in the
Ph.D. thesis of Clayton (2011) [22].
Cook codea 𝛼1 𝛼2 𝛼3 𝛼4 𝛼5 𝛼6
JYI-57 0.076 0.076 0.131 ND 0.036 ND
YT-II-76 95.34 2.797 0.056 ND 0.04 ND
QH-II-085 0.08 0.06 0.02 ND 0.08 ND
YT-III-25 2.531 5.786 5.691 ND 0.095 ND
SH-I-048A 0.774 0.1723 0.383 ND 0.11 ND
QH-II-077 0.06 0.08 0.05 ND 0.12 4
DM-239 1.5 ND 0.53 ND 0.14 6.89
QH-II-092 0.07 0.03 0.04 ND 0.17 ND
TG-4-29 2.8 3.9 2.7 2.1 0.18 3.9
SH-I-75 1487 989.9 773 ND 0.1825 ND
PWZ-007A 0.11 0.1 0.09 ND 0.2 10
XHE-II-024 0.09 0.18 0.32 14 0.24 11
SH-I-085 11.08 4.866 13.75 ND 0.24 ND
MMB-II-90 20 24 5.7 9 0.25 36
QH-II-090 (CGS-8216) 0.05 0.08 0.12 ND 0.25 17
JYI-42 0.257 0.146 0.278 ND 0.256 ND
MMB-III-016 3 1.97 2 1074 0.26 211
MMB-III-16 3 1.97 2 1074 0.26 211
Ro15-4513 3.3 2.6 2.5 ND 0.26 3.8
DM-215 6.74 ND 7.42 ND 0.293 8.28
XLI-317 60.24 24.05 4.562 ND 0.295 ND
RY-061 17 13 6.7 ND 0.3 31
ZG-234 7.25 22.14 9.84 ND 0.3 5.25
PZII-028 0.2 ND 0.2 ND 0.32 1.9
RY-067 21 12 10 ND 0.37 42
DM-II-90 (C17H12N4BrCl) 0.505 1 0.63 ND 0.37 5000
ZG-208 9.7 11.2 10.9 ND 0.38 4.6
XHE-III-04 1.2 2 1.1 219 0.4 500
TG-4-29 8.3 10.2 6.9 ND 0.4 7.61
RY-024 C19H19N3O3 26.9 26.3 18.7 ND 0.4 5.1
JYI-47 2.759 2.282 0.511 ND 0.427 ND
PWZ-0071 0.23 0.17 0.12 ND 0.44 17.31
CM-E09b 20 22 19 55 0.45 69
ZG-168 11.2 10.7 9.2 ND 0.47 9.4
RY-080 C17H15N3O3 28.4 21.4 25.8 5.3 0.49 28.8
BRETAZENIL 0.35 0.64 0.2 ND 0.5 12.7
CM-E10 23 26 14 215 0.51 96
JYI-04 (C21H23N3O3) 28.3 16 ND ND 0.51 1.57
PZII-029 0.34 ND 0.79 ND 0.52 10
PWZ-085 4.86 13 8.5 ND 0.55 40
JYI-70 (C19H13N4F) 6.3 2.1 ND ND 0.56 5000
CM-D44 34.3 56.3 20.7 0.33 0.57 0.92
SVO-8-30 1.1 5.3 5.3 2.8 0.6 15
Ro15-1788 0.8 0.9 1.05 ND 0.6 148
XLi268 C17H13BrN4 2.8145 0.6862 ND ND 0.6243 ND
ZG-63A 17.3 21.6 29.1 ND 0.65 4
SH-053-2󸀠F 21.99 12.34 34.9 ND 0.671 ND
XLI-286 0.051 0.064 0.118 ND 0.684 ND
SH-I-S66 22.93 30.36 55.26 ND 0.69 ND
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Table 9: Continued.
Cook codea 𝛼1 𝛼2 𝛼3 𝛼4 𝛼5 𝛼6
RY-076 26 27 13 ND 0.7 22
DM-173 13.1 ND 38.1 ND 0.78 118
OMB-18 3.9 1.2 3.4 1733 0.8 5
HJ-I-037 15.07 8.127 28.29 ND 0.818 ND
PWZ-009A1 1.34 1.31 1.26 ND 0.84 2.03
ZG69A 6.8 16.3 9.2 ND 0.85 54.6
ZG-69a (Ro15-1310) 6.8 16.3 9.2 ND 0.85 54.6
JYI-64 (C17H12N4FBr) 0.305 1.111 0.62 ND 0.87 5000
SVO-8-14 8 25 8 6.9 0.9 14
JYI-03 (C21H21N3O3) 185.4 107 ND ND 0.954 3.34
TG-II-82 1.6 2.9 2.8 ND 1 1000
RY-053 49 29 15 ND 1 46
YT-6 15.31 87.8 60.49 ND 1.039 ND
DMCM 5.69 8.29 4 ND 1.04 134
PWZ-096 11.1 36 16.9 ND 1.07 51.5
MMB-III-14 13 13 6.9 333 1.1 333
YT-III-23 19.83 23.65 19.87 ND 1.105 ND
RY-008 3.75 7.2 4.14 ND 1.11 44.3
XLI-2TC 3.442 1.673 44.08 ND 1.121 ND
XHE-II-073A (R ENRICHED) 5.9 11 10 15 1.18 140
QH-II-075 0.18 0.21 0.25 ND 1.3 40
RY-054 59 44 27 ND 1.3 126
TG-4-39 1.6 34 24 5.6 1.4 23
XHE-II-002 8.3 18 13 3.9 1.5 11
RY-031 (RY-10) 20.4 27 26.1 ND 1.5 176
FG8205 0.4 2.08 1.16 ND 1.54 227
alprazolam 0.8 0.59 1.43 ND 1.54 1000
XHE-III-13 7.3 ND 7.1 880 1.6 311
CM-D45 C19H21N3O4 90.5 65.5 30.3 0.15 1.65 0.23
RY-098 10.1 22.2 16.5 ND 1.68 100
YT-5 0.421 0.6034 36.06 ND 1.695 ND
JYI-60 (C17H11N2OF) 3.73 1.635 4.3 ND 1.7 5000
RY-033 14.8 56 25.3 ND 1.72 22.9
XHE-III-06a 1 2 1 5 1.8 37
SH-I-030 14.42 11.04 19.09 ND 1.89 ND
XLi352 C18H13ClN2O 1.56 0.991 ND ND 1.957 ND
XLi351 C21H21ClN2OSi 1.507 0.967 ND ND 1.985 ND
XHE-III-14 2.6 ND 10 13 2 7
DM-II-72 (C15H10N20BrCl) 5000 1.37 ND ND 2.02 5000
XHE-II-073B (S-ENRICHED) 11 17 12 33 2.1 269
FLUNITRAZEPAM 2.2 2.5 4.5 ND 2.1 2000
XHE-III-74 77 105 38 0.42 2.2 5.8
SVO-8-67 7 41 26 15 2.3 191
6-PBC 0.49 1.21 2.2 ND 2.39 1343
RY-058 86 40 85 ND 2.4 150
ZG-224 17.1 33.7 50 ND 2.5 31.7
RY-066 83 60 48 ND 2.6 180
RY-023 C22H27N3O3Si 197 142.6 255 7.8 2.61 58.6
XLi350 C17H11ClN2O 1.224 1.188 ND ND 2.9 ND
JYI-32 (C20H15N3O2BrF) 3.07 4.96 ND ND 2.92 52.24
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Table 9: Continued.
Cook codea 𝛼1 𝛼2 𝛼3 𝛼4 𝛼5 𝛼6
SH-I-89S 12.78 8.562 8.145 ND 3.23 ND
MSR-I-032 6.2 18.7 4 ND 3.3 74.9
OMB-19 22 4.6 20 3333 3.5 40
ZG-213 12.8 49.8 30.2 ND 3.5 22.5
YT-II-83 32.74 13.22 24.1 ND 3.548 ND
RY-059 89 70 91 ND 3.7 301
SPH-121 0.14 1.19 1.72 ND 4 479
RY-047 200 124 79 ND 4 340
XLI-8TC 21.52 11.01 2.155 ND 4.059 ND
YT-I-38 945.9 326.8 245.9 ND 4.07 ND
DM-146 6.44 ND 148 ND 4.23 247
CM-B44 (ss) 32 43 12 379 4.3 485
CM-B47 32 63 34 2007 4.4 717
XLi-JY-DMH ANX3 3.3 0.58 1.9 ND 4.4 5000
WY-B-15 0.92 0.83 0.58 2080 4.42 646
ZK 93423 4.1 4.2 6 ND 4.5 1000
JYI-12 (C19H16N3O3F3) 91 39 ND ND 4.5 6.8
CM-A87 1.62 4.54 14.73 1000 4.61 1000
DM-III-01 (C18H12N3O2Br) 5000 12 ND ND 4.73 5000
RY-057 73 85 97 ND 4.8 333
JYI-15 (C19H14N3O3F3) 205 812 ND ND 4.8 22
CM-B31i (ss) 90 184 78 18 4.9 121
RY-079 121.1 141.9 198.4 159 5 113.7
JC208 C15H10N2OS 22.42 18.89 ND ND 5.039 ND
YT-II 6.932 0.8712 3.518 ND 5.119 ND
XLi270 C19H14N4 36.39 25.81 ND ND 5.291 ND
XHE-I-051 35 39 42 ND 5.3 979
MMB-II-87 200 333 107 109 5.4 333
XLI-210 231 661 2666 ND 5.4 54.22
XHE-II-O53-ACID 50.35 11.8 44 ND 5.9 5000
ABECARNIL 12.4 15.3 7.5 ND 6 1000
RY-I-31 10 45 19 ND 6 1000
QH-II-082 1.7 1.8 1.6 ND 6.1 100
SH-TSC-1 (PWZ-029) 362.4 180.3 328.2 ND 6.185 ND
XHE-II-065 1000 409 216 37 6.4 175
JYI-49 (C20H12N3O2F4Br) 1.87 2.38 ND ND 6.7 3390
JC184 C13H9BrN2OS 9.606 10.5 ND ND 6.709 ND
QH-II-066 76.3 42.1 47.4 2000 6.8 3000
XLI-381 619.9 285.6 3639 ND 7.051 ND
RY-071 19 56 91 ND 7.2 266
RY-I-28 283 318 102 ND 7.2 61
CM-A82a 2.78 8.93 24.51 1000 7.49 1000
YT-III-31 36.39 67.85 129.7 ND 7.59 ND
SH-I-04 7.3 6.136 5.1 ND 7.664 ND
QH-146 0.49 ND 0.76 ND 7.7 1000
QH-II-063 9.4 9.3 31 ND 7.7 3000
JC221 ANX1 106.175 49.405 182 ND 7.7495 362
DM-II-30 (C20H13N3O2BrF3) 17.6 13.4 28.51 ND 7.8 5000
SH-TS-CH
3
107.2 50.09 20.95 ND 8.068 ND
RY-073 156 88 122 ND 8.5 267
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Table 9: Continued.
Cook codea 𝛼1 𝛼2 𝛼3 𝛼4 𝛼5 𝛼6
SVO-8-20 11 40 28 19 8.6 138
SHU-221-1 66 41 43 3000 9 3000
YT-III-231 51.09 61.46 26.34 ND 9.124 ND
CM-E09a 176 192 122 490 9.2 718
DM-139 5.8 ND 169 ND 9.25 325
YT-III-42 382.9 16.83 44.04 ND 9.77 ND
CD-214 16.4 48.2 42.5 ND 9.8 168
XHE-III-24 0.25 ND 8 222 10 328
XLi223 C22H20BrN3O2 14 8.7 18 1000 10 2000
SPH-165 0.63 2.79 4.85 ND 10.4 1150
JYI-01 (C19H20N3O3Br) 59.2 159 96 ND 10.6 2.88
diazepam 14 20 15 ND 11 ND
XHE-III-49 1.3 5.5 4.2 38.7 11.3 85.1
WZ-113 19.2 13.2 13.4 ND 11.5 300
JYI-59 (C22H13N3O2F4) 1.08 2.6 11.82 ND 11.5 5000
JYI-72 (C22H21N4SiF) 48.5 18.5 ND ND 11.5 5000
TC-YT-II-76 101.1 1.897 5.816 ND 11.99 ND
JYI-10 (C17H13N3O3F3Br) 5000 368 ND ND 12.3 23
WZ-069 40 30.5 38.5 ND 12.6 1000
JYI-06 (C23H23N3O4) 16.5 5.48 5000 ND 12.6 5000
RY-072 220 150 184 ND 12.7 361
JYI-14 (C17H14N3O3F3) 32 25 ND ND 13 565
XHE-II-053 287 45 96 1504 13.8 1000
Xli-347 C34H28N6O7 828.05 690.2 ND ND 13.87 ND
SHU-1-19 4 12 7 48 14 84
CM-C28 (SR) 176 752 244 290 14 141
CM-E11 333 308 161 394 14 750
XHE-II-012 49 24 31 1042 14 2038
MMB-III-018 117 140 78 3500 14 976
MMB-III-18 117 140 78 3500 14 976
CM-B31c (ss) 118 319 173 37 15 137
CM-B45 230 557 336 265 15 230
XLI-093 1000 1000 858 1550 15 2000
DM-II-20 (C22H14N3O2F3) 54.3 27.14 35.68 ND 15.35 5000
XLi269 C22H22N4Si 221.8 154.2 ND ND 15.51 ND
SH-O53-S-CH
3
-2󸀠F 350 141 1237 ND 16 5000
JYI-13 (C21H16N3O4F3) 5000 63.7 ND ND 16 8.38
CM-B34 472 451 223 114 17 175
XHE-II-017 3.3 10 7 258 17 294
JC222 C16H12N2OS 86.7 45.11 ND ND 17.63 ND
SPH-38 2 5.4 10.8 ND 18.5 3000
WZ-070 72.7 30.7 53.2 ND 18.6 300
RY-069 692 622 506 ND 19 1000
SH-053-2󸀠F-S-CH
3
468.2 33.27 291.5 ND 19.2 ND
XHE-I-093 2 7.1 8.9 1107 20 1162
aAffinity of compounds at GABAA/BzR recombinant subtypes was measured by competition for [
3H]flunitrazepam or [3H] Ro15-4513 binding to HEK cell
membranes expressing human receptors of compositions 𝛼1𝛽3𝛾2, 𝛼2𝛽3𝛾2, 𝛼3𝛽3𝛾2, 𝛼4𝛽3𝛾2, 𝛼5𝛽3𝛾2, and 𝛼6𝛽3𝛾2 [22, 139]. Data represent the average of at
least three determinations with a SEM of ±5%. ND: not determined.
377
40 International Journal of Medicinal Chemistry
Table 10: Ligands with potent affinity for 𝛼6; ligands bound with𝐾
𝑖
values <20 nM at this subtype. The structures of these ligands are in
the Ph.D. thesis of Clayton (2011) [22].
Cook codea 𝛼1 𝛼2 𝛼3 𝛼4 𝛼5 𝛼6
CM-D45 C19H21N3O4 90.5 65.5 30.3 0.15 1.65 0.23
CM-D44 34.3 56.3 20.7 0.33 0.57 0.92
JYI-04 (C21H23N3O3) 28.3 16 ND ND 0.51 1.57
PZII-028 0.2 ND 0.2 ND 0.32 1.9
PWZ-009A1 1.34 1.31 1.26 ND 0.84 2.03
JYI-01 (C19H20N3O3Br) 59.2 159 96 ND 10.6 2.88
JYI-03 (C21H21N3O3) 185.4 107 ND ND 0.954 3.34
Ro15-4513 3.3 2.6 2.5 ND 0.26 3.8
TG-4-29 2.8 3.9 2.7 2.1 0.18 3.9
JYI-11 (C22H22N3O3F3Si) 5000 5000 ND ND 648 3.97
QH-II-077 0.06 0.08 0.05 ND 0.12 4
ZG-63A 17.3 21.6 29.1 ND 0.65 4
ZG-208 9.7 11.2 10.9 ND 0.38 4.6
OMB-18 3.9 1.2 3.4 1733 0.8 5
RY-024 C19H19N3O3 26.9 26.3 18.7 ND 0.4 5.1
ZG-234 7.25 22.14 9.84 ND 0.3 5.25
XHE-III-74 77 105 38 0.42 2.2 5.8
JYI-12 (C19H16N3O3F3) 91 39 ND ND 4.5 6.8
DM-239 1.5 ND 0.53 ND 0.14 6.89
XHE-III-14 2.6 ND 10 13 2 7
TG-4-29 8.3 10.2 6.9 ND 0.4 7.61
DM-215 6.74 ND 7.42 ND 0.293 8.28
JYI-13 (C21H16N3O4F3) 5000 63.7 ND ND 16 8.38
CGS9895 0.21 ND ND ND ND 9.3
ZG-168 11.2 10.7 9.2 ND 0.47 9.4
PWZ-007A 0.11 0.1 0.09 ND 0.2 10
PZII-029 0.34 ND 0.79 ND 0.52 10
XHE-II-024 0.09 0.18 0.32 14 0.24 11
XHE-II-002 8.3 18 13 3.9 1.5 11
BRETAZENIL 0.35 0.64 0.2 ND 0.5 12.7
JYI-19 (C23H23N3O3S) 2.176 205 ND ND 34 12.7
SVO-8-14 8 25 8 6.9 0.9 14
SVO-8-30 1.1 5.3 5.3 2.8 0.6 15
WYS10 C14H9F3N2O2 0.88 36 25.6 ND 548.7 15.3
QH-II-090 (CGS-8216) 0.05 0.08 0.12 ND 0.25 17
PWZ-0071 0.23 0.17 0.12 0.44 17.31
aThe affinity of compounds at GABAA/BzR recombinant subtypes was
measured by competition for [3H]flunitrazepam binding to HEK cell
membranes expressing human receptors of compositions 𝛼1𝛽3𝛾2, 𝛼2𝛽3𝛾2,
𝛼3𝛽3𝛾2, 𝛼4𝛽3𝛾2, 𝛼5𝛽3𝛾2, and 𝛼6𝛽3𝛾2 [139]. Data represent the average of
at least three determinations with a SEM of ±5%. ND: not determined.
The X-ray structure determination of the 𝛼5𝛽3𝛾2
GABA(A) receptor is eagerly awaited, while that with five
𝛽3-subunits has been reported recently (Miller and Aricescu,
Nature 2014). It is hoped that the proposed orientation may
be used by others to gain additional insight into the potential
mechanisms underlying binding and modulation at the Bz
site, all of which will lead to a better understanding of the
structure and function of GABA(A) receptors, ultimately
targeted toward treatment of diseases.
25. Synthesis of Ligands with
𝛼5 BzR Subtype Selectivity
Briefly, bromoacetyl bromide was added to 2-aminobenzo-
phenone 44, followed by treatment with methanol, which
had been saturated with ammonia (g) under the cooling
of an ice-water bath. The benzodiazepine, 45, was bromi-
nated to provide 46 and then reacted with ethyl iso-
cyanoacetate to generate the imidazobenzodiazepine, 47. A
much better one-pot process has now been devised using
KtBuO at −30∘C [140]. The bromide 48 was subjected
to a Stille-type coupling to give DM-I-81 (9) [126]. This
route (Scheme 1) can be executed on several hundred gram
scales.
The benzodiazepine monomers were prepared by the
method of Fryer and Gu [89, 141]. The isatoic anhydride was
heated with sarcosine in dimethyl sulfoxide to provide amide
49. Bromination of 49 in a mixture of acetic acid, bromine,
and sodium acetate afforded the corresponding monosubsti-
tuted bromide 50 in good yield. Deprotonation of 50 with
lithium diisopropyl amide (LDA) in THF was followed by
treatment with diethyl chlorophosphate to provide the inter-
mediate enol phosphate.The enol phosphate was stirred with
a solution of ethyl isocyanoacetate and LDA to yield the imi-
dazo congener. Again, a better one-pot procedure has been
developed using KtBuO at −30∘C in place of LDA at 0∘C. A
Heck type coupling reaction was employed with the bromide
51 with bis(acetate)bis(triphenylphosphine)palladium(II) to
provide the TMS-acetylene 52. Treatment of 52 with Bu
4
NF
removed the trimethylsilyl group. Hydrolysis of the ester
function of 53 provided the acid 54 in excellent yield and this
material was dried scrupulously and subjected to a standard
CDI-mediated coupling reaction to furnish bivalent ligand
XLi-093 (4).The imidazobenzodiazepine diethyl diester XLi-
356 (10) was obtained from XLi-093 (Scheme 2) in high yield
via catalytic hydrogenation (Pd/C, H
2
).
26. Synthesis of Bivalents
Inverse agonist 53 was synthesized via the reported proce-
dure. Hydrolysis of the ester function of 53 provided the acid
54 in excellent yield. This material was dried scrupulously
and was subjected to a standard CDI-mediated coupling
reaction to furnish bivalent ligands 4, 55, and 56 in 60% yield
(Scheme 3) [13].
The acid 57, obtained from the ester 47, which was
available from the literature [13], was stirred with CDI
in DMF, followed by stirring with the required diol and
DBU to provide bromide substituted dimers 58 or 59,
respectively. They were converted into the trimethylsily-
lacetylenyl 60 or 61, respectively, under standard conditions
(Pd-mediated, Heck-type coupling) [142]. The bisacetylene
62 or63 (individually) was easily obtained by treatment of the
trimethylsilyl ligand 60 or 61with fluoride anion, as shown in
Scheme 4.
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Figure 34: Overlay of selected compounds for 𝛼1𝛽3𝛾2 subtype from
Table 5.
Figure 35: Updated 𝛼1𝛽3𝛾2 subtype (blue solid) overlaid with the
previous model (red wire). Overlap identified where wire and solid
overlap.
Figure 36: Overlay of compounds selective for 𝛼2𝛽3𝛾2 subtype.
Figure 37: Updated 𝛼2𝛽3𝛾2 subtype (solid) overlaid with the
previous model (red wire). Overlap identified where wire and solid
overlap.
Figure 38: Overlay of compounds selective for 𝛼3𝛽3𝛾2 subtype.
Figure 39: Updated 𝛼3𝛽3𝛾2 subtype (blue solid) overlaid with the
previous model (red wire). Overlap identified where wire and solid
overlap.
Figure 40: Overlay of selected compounds selective for 𝛼4𝛽3𝛾2
subtype.
Figure 41: Updated 𝛼4𝛽3𝛾2 subtype (blue solid) overlaid with the
previous model (yellow wire). Overlap identified where wire and
solid overlap.
379
42 International Journal of Medicinal Chemistry
Figure 42: Overlay of selected compounds selective for 𝛼5𝛽3𝛾2
subtype.
L4
Figure 43: Updated 𝛼5𝛽3𝛾2 subtype (blue solid) overlaid with the
previous model (yellow wire). Overlap identified where wire and
solid overlap.
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Figure 44: Overlay of the 𝛼5𝛽3𝛾2 receptor (yellow) subtype with
the 𝛼1𝛽3𝛾2 receptor (magenta) subtype. Orange surfaces indicate
overlapping regions.
27. Materials, Methods, and Experimental
27.1. Materials and General Instrumentation. Chemicals were
purchased from Aldrich Chemical Co. or Tokyo Chemical
Industries and were used without further purification except
where otherwise noted. Anhydrous THF was distilled from
sodium/benzophenone ketyl. TLC analyses were carried out
on Merck Kieselgel 60 F
254
, and flash column chromatog-
raphy was performed on silica gel 60b purchased from
E. M. Laboratories. Melting points were taken on a Thomas-
Hoover melting point apparatus or an Electrothermal Model
IA8100 digital melting point apparatus and are reported
uncorrected. NMR spectra were recorded on a Bruker 300
or 500MHz multiple-probe spectrometer. Infrared spectra
were recorded on a Nicolet DX FTIR BX V5.07 spectrometer
or a Mattson Polaris IR-10400 instrument. Low-resolution
mass spectral data (EI/CI) were obtained on a Hewlett-
Packard 5985B GC-mass spectrometer, while high resolution
mass spectral data were taken on a VG autospectrometer
(Double Focusing High Resolution GC/Mass Spectrometer,
UK).Microanalyseswere performed on aCEElantech EA1110
elemental analyzer. Methods of specific experiments can be
found in corresponding cited works.
27.2. Competition Binding Assays. Competition binding
assays were performed in a total volume of 0.5mL of a
50mM Tris-acetate at 4∘ degree centigrade for 1 hour using
[3H]flunitrazepam as the radioligand. For these binding
assays, 20–50mg of membrane protein harvested with
hypotonic buffer (50mM Tris-acetate pH 7.4 at 4 degree)
was incubated with the radiolabel as previously described
[139, 143]. Nonspecific binding was defined as radioactivity
bound in the presence of 100 𝜇M diazepam and represented
less than 20% of total binding. Membranes were harvested
with a Brandel cell harvester followed by three ice-cold
washes onto polyethyleneimine-pretreated (0.3%) Whatman
GF/C filters. Filters were dried overnight and then soaked in
Ecoscint A liquid scintillation cocktail (National Diagnostics;
Atlanta, GA). Bound radioactivity was quantified by liquid
scintillation counting. Membrane protein concentrations
were determined using an assay kit from Bio-Rad (Hercules,
CA) with bovine serum albumin as the standard.
27.3. Radioligand Binding Assays (Drs. McKernan and Atack)
[12]. In brief, the affinity of compounds for human recom-
binant GABA(A) receptors was measured by competition
binding using 0.5 nM [3H]flunitrazepam. Transfected HEK
cells (beta2 gamma2 and desired alpha subtype) were har-
vested into phosphate-buffered saline, centrifuged at 3,000 g,
and stored at −70∘C until required. On the day of the assay,
pellets were thawed and resuspended in sufficient volume of
50mM Tris/acetate (pH 7.4 at 4∘C) to give a total binding
of approximately 1500–2000 dpm. Nonspecific binding was
defined in the presence of 100mM (final concentration)
diazepam. Test compounds were dissolved in DMSO at a
concentration of 10mM and diluted in assay buffer to give
an appropriate concentration range in the assay, such that the
final DMSO concentration in the assay was always less than
1%. Total assay volume was 0.5mL and assays were carried
out in 96-well plates and incubation time started by the
addition of 0.1mL of resuspended cell membranes. Following
incubation for 1 hour at 4∘C, assays were terminated by
filtration through GF/B filters, washed with 10mL ice cold
buffer, dried, and then counted using a liquid scintillation
counter. The percentage of inhibition of [3H]flunitrazepam
binding, the IC
50
, and the 𝐾
𝑖
values were calculated using
the Activity Base Software Package (ID Business Solutions,
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Figure 45: Overlay of the 𝛼5𝛽3𝛾2 receptor (yellow) subtype with the 𝛼1𝛽3𝛾2 receptor (magenta) subtype (Figure 44 rotated 90∘). Orange
surfaces indicate overlapping regions.
Figure 46: Overlay of selected compounds selective for 𝛼6𝛽3𝛾2 subtype.
Figure 47: Updated 𝛼6𝛽3𝛾2 subtype (blue solid) overlaid with the previous model (yellow wire). Overlap identified where wire and solid
overlap.
Guildford, UK) according to the Cheng-Prusoff equation
[143]. We have previously reported the synthesis of the
following.
1,3-Bis(8-acetyleno-5,6-dihydro-5-methyl-6-oxo-4H-imid-
azo[1,5a][1,4]benzodiazepine-3-carboxy) propyl diester 4
(XLi-093) (Procedure A), experimental details previously
reported [17].
1,5-Bis(8-acetyleno-5,6-dihydro-5-methyl-6-oxo-4H-imid-
azo[1,5a][1,4]benzodiazepine-3-carboxy) pentyl diester 56
(XLi-210), experimental details previously reported [17].
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(a) Orthogonal views of the overlap (yellow) volumes
of 𝛼1𝛽3𝛾2 (red) and 𝛼2𝛽3𝛾2 (green)
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(b) Orthogonal views of the overlap (yellow) volumes
of 𝛼2𝛽3𝛾2 (red) and 𝛼3𝛽3𝛾2 (green)
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(c) Orthogonal views of the overlap (yellow) volumes
of 𝛼4𝛽3𝛾2 (red) and 𝛼6𝛽3𝛾2 (green)
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(d) Orthogonal views of the overlap (yellow) volumes of
𝛼1𝛽3𝛾2 (red) and 𝛼6𝛽3𝛾2 (green)
L1L1
L2L2
L3L3 LDiLDi
A1A1
H2H2
H1H1
(e) Orthogonal views of the overlap (yellow) volumes
of 𝛼5𝛽3𝛾2 (red) and 𝛼1𝛽3𝛾2 (green)
(f) Diazepam and the unified
pharmacophore descriptors
Figure 48:The previous benzodiazepine subtype selective receptor pharmacophore models [23]. (1)The 𝐿
2
region in the 𝛼5 subtype is larger
than the 𝛼1 subtypes. This is a key result. It is the principle difference between 𝛼5 subtypes compared to 𝛼2 and 𝛼3 subtypes, but especially in
regard to 𝛼1 subtypes (𝐿
2
smaller in 𝛼1). (2) The 𝐿
3
region is larger in the 𝛼5 subtype as compared to the 𝛼1, 𝛼2, 𝛼3, 𝛼4, and 𝛼6 BzR sites. R
analogs of benzodiazepines with pendant phenyls had increased affinity to 𝛼5 supporting the larger 𝐿
3
pocket in this receptor subtype, while
S isomers bound to 𝛼2, 𝛼3, and 𝛼5 subtypes because of different conformational constraints.
Figure 49: Steric (left) and electrostaticmaps of the 𝛼1𝛽3𝛾2 receptor
subtype shown in the transparent mode as seen from the classic
perspective.
1,3-Bis(8-ethyl-5,6-dihydro-5-methyl-6-oxo-4H-imid-
azo[1,5a][1,4]benzodiazepine-3-carboxy) propyl diester 10
(Xli-356), experimental previously published [144].
Figure 50: Steric (left) and electrostaticmaps of the 𝛼1𝛽3𝛾2 receptor
subtype shown in the transparent mode as seen from the classic
perspective (Figure 45) rotated 90∘.
Bis(8-acetyleno-5,6-dihydro-5-methyl-6-oxo-4H-imid-
azo[1,5a][1,4]benzodiazepine-3-carboxy) dimethyl glycol dies-
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Figure 51: Steric (left) and electrostatic maps of the 𝛼1𝛽3𝛾2 receptor
subtype shown in line mode as seen from the classic perspective.
Figure 52: Steric (left) and electrostaticmaps of the 𝛼1𝛽3𝛾2 receptor
subtype shown in line mode as seen from the classic perspective
rotated 90∘.
Figure 53: Steric (left) and electrostaticmaps of the𝛼2𝛽3𝛾2 receptor
subtype shown in the transparent mode as seen from the classic
perspective.
Figure 54: Steric (left) and electrostaticmaps of the𝛼2𝛽3𝛾2 receptor
subtype shown in the transparent mode as seen from the classic
perspective rotated 90∘.
ter 55 (Xli-374), experimental details previously reported
[17].
8-Bromo-6-phenyl-4H-benzo[f]imidazo[1,5-a][1,4]diaze-
pine-3-carboxylic acid 57, experimental details previously
reported [17].
Figure 55: Steric (left) and electrostaticmaps of the𝛼2𝛽3𝛾2 receptor
subtype shown in line mode as seen from the classic perspective.
Figure 56: Steric (left) and electrostaticmaps of the𝛼2𝛽3𝛾2 receptor
subtype shown in line mode as seen from the classic perspective
rotated 90∘.
Figure 57: Steric (left) and electrostaticmaps of the𝛼3𝛽3𝛾2 receptor
subtype shown in the transparent mode as seen from the classic
perspective.
Figure 58: Steric (left) and electrostaticmaps of the𝛼3𝛽3𝛾2 receptor
subtype shown in the transparent mode as seen from the classic
perspective rotated 90∘.
Figure 59: Steric (left) and electrostaticmaps of the𝛼3𝛽3𝛾2 receptor
subtype shown in line mode as seen from the classic perspective.
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Figure 60: Steric (left) and electrostatic maps of the 𝛼3𝛽3𝛾2 receptor subtype shown in line mode as seen from the classic perspective rotated
90∘.
Figure 61: Steric (left) and electrostatic maps of the 𝛼5𝛽3𝛾2 receptor subtype shown in the transparent mode as seen from the classic
perspective.
Figure 62: Steric (left) and electrostatic maps of the 𝛼5𝛽3𝛾2 receptor subtype shown in the transparent mode as seen from the classic
perspective rotated 90∘.
Figure 63: Steric (left) and electrostatic maps of the 𝛼5𝛽3𝛾2 receptor subtype shown in line mode as seen from the classic perspective.
Figure 64: Steric (left) and electrostatic maps of the 𝛼5𝛽3𝛾2 receptor subtype shown in line mode as seen from the classic perspective rotated
90∘.
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Figure 65: Clockwise from the top left, line maps of the 𝛼1𝛽3𝛾2, 𝛼2𝛽3𝛾3, 𝛼3𝛽3𝛾2, and 𝛼5𝛽3𝛾2 CoMFA.
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Scheme 1: Synthesis of 8-substituted imidazobenzodiazepines following chemistry earlier developed by Sternbach, Fryer et al. Reagents and
Conditions. (a) Bromoacetyl bromide, sodium bicarbonate, and chloroform; (b) ammonia (anhydrous), methanol, and reflux; (c) bromine,
sulfuric acid, and acetic acid; (d) sodium hydride, diethyl chlorophosphate, and tetrahydrofuran; (e) sodium hydride, ethyl isocyanoacetate,
and tetrahydrofuran, −30∘C to r.t.; (f) tributyl(phenyl)stannane, Pd(PPh
3
)
4
.
1,3-Bis(8-bromo-6-phenyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxy) propyl diester 59 (DMH-D-070)
(Procedure B), experimental details previously reported [17].
1,3-Bis(8-trimethylsilylacetylenyl-6-phenyl-4H-ben-
zo[f]imidazo[1,5-a][1,4]-diazepine-3-carboxy) propyl diester
61 (DMH-D-048) (Procedure C), experimental details
previously reported [17].
1,3-Bis(8-acetylenyl-6-phenyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxy) propyl diester 63 (DMH-D-053):
experimental details previously reported [17].
Bis(8-bromo-6-phenyl-4H-benzo[f]imidazo[1,5-a][1,4]di-
azepine-3-carboxy) diethylene glycol diester 58 (DM-III-93),
experimental details previously reported [17].
Bis(8-trimethylsilylacetylenyl-6-phenyl-4H-benzo[f]imid-
azo[1,5-a][1,4]diazepine-3-carboxy) diethylene glycol diester
60 (DM-III-94), experimental details previously reported
[17].
Bis(8-acetylenyl-6-phenyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxy) diethylene glycol diester 62
(DM-III-96), experimental details previously reported [17].
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APD: Antipsychotic drug
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BS: Binding site
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385
48 International Journal of Medicinal Chemistry
O
H
N O
O
N
H
H
COOHH
N
H
N O
O
N
H
N
O
O
Br
N
N
O
Br
N
N
N
O
N
TMS
N
N
O
N
H
N
N
O
N
H
O
OH
N
N
O
N
H
O
O
N
N
O
N
H
O
O
+
XLi093
N
N
O
N
N
N
O
N
O
O
O
O
XLi-356
48 49 50
51 52
53
54
4
10
(a) (b) (c)
(d)
(e) (f)
(g) (h)
(i)
H3C
3CH
3CH
3CH
3CH
3CH 3CH
3CH
CO2C2H5
CO2C2H5 CO2C2H5
H3C
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GABA: Gamma amino butyric acid
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HAL: Haloperidol
HEK: Human embryonic kidney
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LTK: Leukocyte tyrosine kinase
MAM: Methylazoxymethanol
NAM: Negative allosteric modulator
QSAR: Quantitative structure-activity relationship
PAM: Positive allosteric modulator
PV: Parvalbumin
SAL: Saline
SH-053: SH-053-2󸀠F-R-CH
3
SMA: Smooth muscle actin
TTX: Tetrodotoxin
VTA: Ventral tegmental area.
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APPENDIX E. A Review of the Updated Pharmacophore for the Alpha 5 
GABA(A) Benzodiazepine Receptor Model – Supporting Information 
Supporting information can be found at: 
 
 http://www.hindawi.com/journals/ijmc/2015/430248/ 
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APPENDIX F. Manuscript prepared by Miroslav M. Savic, et al. on the 
behavioral characterization of MP-III-022. 
 
Structure: 
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ABSTRACT 
 
Selective modulation of GABAA receptors containing the α5 subunit (α5GABAARs) is 
believed to have considerable therapeutic potential in several psychiatric and neurological 
conditions characterized by cognitive dysfunction. We have synthesized and characterized 
MP-III-022 ((R)-8-ethynyl-6-(2-fluorophenyl)-N,4-dimethyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxamide) in vitro and in vivo as an affinity and especially efficacy 
selective positive allosteric modulator of α5GABAARs. By approximation of the 
electrophysiological responses which the estimated free rat brain concentrations can induce, 
we demonstrated that convenient systemic administration of MP-III-022 in the dose range 1-
10 mg/kg resulted in a selective potentiation, over a wide range from mild to moderate to 
strong, of  GABAA receptors. For eliciting a similar range of potentiation, the parent 
ligand SH-053-2′F-R-CH3 needs to be administered over a much wider dose range (10-200 
mg/kg), but at the price of activating non-α5 GABAARs as well as the desired α5GABAARs at 
the highest dose. At the dose of 10 mg/kg, which elicits a strong positive modulation of 
α5GABAARs, MP-III-022 caused mild, but significant muscle relaxation, devoid of ataxia or 
sedation characteristic for non-selective benzodiazepines. Concomitantly, the same dose 
deteriorated spatial learning and memory of rats in the Morris water maze and the animals’ 
performance in the sociability trial in the three-chamber test, but improved social recognition 
in the social discrimination test. However, a mild potentiation of  GABAA receptors, 
produced by the 1 mg/kg dose, resulted in a faster acquisition of spatial learning in the water 
maze. These results provide additional insight into graded modulation of α5GABAARs as a 
potential treatment for distinct cognition-related clinical manifestations. Moreover, MP-III-
022 may represent an improved tool to study the effects of α5GABAARs on the neuronal 
pathways related to CNS disorders such as schizophrenia, Alzheimer’s disease, Down 
syndrome or autism, aimed at finding the optimal levels of selective modulation needed for 
their amelioration. 
 
Keywords: receptor efficacy; binding assay; free brain concentration; Morris water maze; 
social novelty discrimination; three-chamber test 
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INTRODUCTION 
Gamma-aminobutyric acid (GABA) is the main inhibitory neurotransmitter in adult brain. 
GABAA receptors mediate the majority of inhibitory neurotransmission and at the same time 
represent a prominent therapeutic target for many psychiatric and neurological conditions. 
Most notably, benzodiazepines are GABAergic drugs widely used for decades in treatment of 
anxiety, insomnia, epilepsy and muscular spasms, and detailed elucidation of their mechanism 
of action has helped the understanding of the role of various GABAA receptor populations in 
normal and pathological conditions. Specifically, GABAA receptors are pentameric 
assemblies composed of five subunits recruited from a pool of 19 subunits designated as α1-6, 
β1-3, γ1-3, δ, ε, π and ρ1-3. Despite the huge number of possible subunit combinations, the 
vast majority of GABAA receptors contain an α1, α2, α3 or α5 subunits together with a 
neighboring γ2 subunit, and benzodiazepines such as diazepam act as positive allosteric 
modulators at all these receptors. An approach based on knock-in modification of α1, α2, α3 
or α5 subunits in mice, aimed at linking the distinct pharmacological effects of 
benzodiazepines with a particular receptor subtype, and thus developing selective, better-
tolerated ligands for known and novel indications, was a substantial breakthrough.1 A number 
of studies assessing the behavioral activity of diazepam in mice which harbor such point-
mutated receptors have attributed the sedative, ataxic and addictive properties of 
benzodiazepines to α1-containing GABAA receptors, the anxiolytic and antihyperalgesic 
actions to the α2- and α3-containing GABAA receptors, the muscle relaxant actions to the 
α2/α3/α5-subtypes, anterograde amnesic effects to the α1- and α5-subtypes, and 
anticonvulsant activity to all the α1/α2/α3-containing receptors.2 
Among these diazepam-sensitive target populations, α5GABAARs are the least abundant 
(<5% of total) and with the most restricted distribution,1 both of which are excellent 
characteristics for development of subtype selective ligands. Indeed, in a recent overview of 
patents in the field of benzodiazepines, it was stated that most of the analyzed patents claim 
the therapeutic usefulness of both, positive and negative selective modulators of 
α5GABAARs.3 As genetic studies revealed pro-cognitive effects by reduction of GABAergic 
neurotransmission at α5GABAARs,4,5 development of negative allosteric modulators selective 
for these receptors has been initiated firstly,6 and resulted in claims of the effectiveness of 
such ligands in cognitive symptoms of schizophrenia, Down syndrome or mood disorders.3,7 
On the other hand, development of positive allosteric modulators with selectivity for 
α5GABAARs has been recognized more recently as a potentially fruitful approach in 
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treatment of aging-related dementia8 and cognitive impairment in neurodevelopmental 
disorders such as schizophrenia9 or autism10. 
Although synthesis and discovery of ligands selective for distinct GABAA receptor subtypes 
have become a research priority,11 many encouraging preclinical results failed to translate to 
the clinical setting so far (e.g. Atack et al.12). Poor tolerability or toxicity, suboptimal 
selectivity or kinetics and lack of the needed magnitude of receptor modulation are among 
possible explanations for such failure.13-15 In the present work, we have synthesized and 
pharmacokinetically and pharmacologically characterized MP-III-022 (1), the ligand prepared 
in a one-step reaction from SH-053-2′F-R-CH3 (2), which has been characterized and widely 
studied as one of the most selective positive modulators at α5GABAARs.9,18-22 When 
compared with the published ligands, MP-III-022 demonstrated an improved selectivity for 
α5βγ2 GABAA receptors, both in binding and functional assays (cf. the recent reviews by 
Clayton et al.23 and Soh and Lynch7). Moreover, by approximation of the electrophysiological 
responses which estimated free rat brain concentrations can induce,16,17 it was demonstrated 
that systemic administration of MP-III-022 at doses between 1 and 10 mg/kg should result in 
a wide range of selective potentiation at α5GABAARs, which is not conveniently attainable 
after dosing with the parent compound SH-053-2′F-R-CH3. This was accompanied by distinct 
changes in cognitive tests, but not in overt behavioral impairments suggestive of safety issues. 
 
RESULTS AND DISCUSSION 
CHEMISTRY 
 
Synthesis of (R)-8-Ethynyl-6-(2-fluorophenyl)-N,4-dimethyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxamide (MP-III-022) was performed, as depicted in Scheme 1. 
 
Scheme 1. Synthesis of MP-III-022 (1) 
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IN VITRO CHARACTERIZATION 
Binding studies 
Membranes from HEK-293 cells transiently expressing different GABAA receptor subunit 
combinations were characterized using 3H-Flunitrazepam binding. In order to determine 
radioligand affinities to the four tested receptor subtypes (which are needed to convert the 
IC50 values of a test compound into Ki values), saturation binding experiments were 
performed. Cells were incubated with various concentrations of 3H-flunitrazepam and binding 
data were subjected to Scatchard analysis, as described in the methods section. The 
equilibrium dissociation constants of the ligand-receptor complex obtained in saturation 
binding experiments for four GABAA receptor subtypes are presented in Table S1. 
In other experiments the potency of MP-III-022 to inhibit 2 nM 3H-flunitrazepam binding to 
membranes from HEK-293 cells expressing four different receptor subtypes was studied. 
Membranes from HEK cells transfected with the four subunit combinations were incubated 
with 2 nM 3H-flunitrazepam in the absence or presence of either 5 µM diazepam (to 
determine nonspecific binding) or increasing concentrations of MP-III-022. IC50 values (i.e. 
drug concentrations resulting in half maximal inhibition of specific 3H-flunitrazepam binding) 
were converted to Ki values by using the Cheng-Prusoff relationship (for details see methods-
section). 
The determined Ki values (Table 1) of α5GABAARs differ statistically significantly from α1- 
(p=0.0011) and from α3-containing receptors (p=0.0041) (one-way ANOVA analysis 
followed by Tukey’s multiple comparison test). The Ki values demonstrate that MP-III-022 
possesses a 15, 6 and 12-fold selectivity in binding to α5GABAARs when compared to 
binding to α1, α2 and α3-containing GABAA receptors, respectively. For comparison, the Ki 
values for SH-053-2′F-R-CH3 at α1β3γ2, α2β3γ2, α3β3γ2, and α5β3γ2 GABAA receptors 
were 759.1, 948.2, 768.8 and 95.2 nM, respectively,19 which means that relative selectivity of 
the two ligands is of the same order of magnitude. However, it is clear that selectivity for α5- 
against α1-containing GABAA receptors is 15-fold for MP-III-022, and 8-fold for SH-053-
2′F-R-CH3; this approximately two-fold greater selectivity ratio may be relevant because α1-
containing GABAA receptors are the subtype predominantly connected with adverse effects of 
potentiation at GABAA receptors.
1  
 
Table 1: Binding affinities of MP-III-022 (Ki) for the different receptor subtypes  
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α1β3γ2S α2β3γ2S α3β3γ2S α5β3γ2S 
850 ± 110 nM 360 ± 56 nM 660 ± 170 nM 55 ± 17 nM 
The concentrations resulting in half maximal inhibition of radioligand binding were converted 
into Ki values by using the Cheng-Prusoff relationship and the respective KD values given in 
Table S1. Ki values are presented as mean values ± SEM from 3 independent experiments 
performed in duplicates. 
 
Ligand MP-III-022 exerted negligible activity in 50 other receptor and enzyme assays (B. 
Roth et al., NIMH Psychoactive Drug Screening Program, UNC, unpublished results). The 
only exception was the κ opioid receptor (KOR), at which the secondary binding study gave 
the Ki value of 381 nM. The value is of the same order of magnitude as that of SH-053-2′F-R-
CH3 (240 nM; B. Roth et al., NIMH Psychoactive Drug Screening Program, UNC, 
unpublished results). As these are at least 100-fold weaker affinities than that of the declared 
KOR selective ligands,24 the findings have no plausible biological relevance. However, as the 
KOR Ki for MP-III-022 is on par with that determined for α2GABAARs (360 nM), KOR-
mediated effects might be seen after the doses (15 mg/kg and above) connected with high free 
brain concentrations of this ligand, at which selectivity for α5-containing receptors was lost, 
as discussed below. 
 
Electrophysiological effects  
Two electrode voltage clamp experiments were performed as indicated in the methods 
section. Dose response curves for MP-III-022 are shown in Figure 1a, while the exact data are 
available in the Supplementary table S2. At the  GABAA receptors, MP-III-022 
elicited a significant allosteric modulatory efficacy at concentrations starting at 10 nM, and 
the potentiation values obtained at concentrations approaching 100 nM can be described as 
strong efficacy (above 300%). On the other hand, its activity tended to be weakly modulatory 
at α2- and α3-containing receptors only at concentrations of about 100 nM and above. Finally, 
MP-III-022 lacked modulatory actions at α1-containing GABAA receptors in the whole range 
of in vivo free brain concentrations which were obtained (vide infra and Table S3). For 
comparison, a concentration of 100 nM of SH-053-2′F-R-CH3 resulted in 111 ± 2%, 124 ± 
9%, 125 ± 8%, and 183 ± 7% of control current in α1β3γ2, α2β3γ2, α3β3γ2, and α5β3γ2 
GABAA receptors, respectively.
19 Analogous to the data with MP-III-022, in Figure 1b are 
presented dose response curves for SH-053-2′F-R-CH319 with approximated actions of in vivo 
obtainable free brain concentrations. The exact values of potentiation read from the curves in 
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Figure 1 (Table S3), suggest that efficacy selectivity of MP-III-022 is obtainable in the range 
from mild (below 140%) via moderate (about 160%) to strong (above 300%) potentiation at 
α5GABAARs. While SH-053-2′F-R-CH3 displays similar selectivity for mild (below 140%) 
to moderate potentiation (about 160%), its strong potentiation at α5GABAARs (below 300%) 
has been accompanied by substantial activation of all non-α5 receptors. 
 
Figure 1. The approximated electrophysiological responses elicited by the estimated free brain 
concentrations of MP-III-022 (given in Table 2) and SH-053-2′F-R-CH3 (given in Table 3), 
presented on the concentration-response curves of MP-III-022 (a) and SH-053-2′F-R-CH3 (b) 
at rat recombinant α1-, α2-, α3,- and α5β3γ2 GABAA receptors 
 
 
 
 
 
Pharmacokinetic and free fraction studies 
The concentration–time profiles of MP-III-022 and SH-053-2′F-R-CH3 in rat plasma and 
brain after intraperitoneal administration of the 2.5 mg/kg and 10 mg/kg dose, respectively, 
with the calculated pharmacokinetic parameters, are given in Figure 2. The doses chosen elicit 
a moderate degree of selective potentiation at α5GABAARs; see vertical markers in Figure 1. 
AUC values for plasma and brain were 2-fold and 1.75-fold, respectively, greater for MP-III-
022 than for SH-053-2′F-R-CH3, despite the fact that MP-III-022 was administered at a 4-
fold lower dose. In line with in vivo data of superior systemic exposure, the amide compound 
MP-III-022 displayed an excellent in vitro metabolic stability during incubation in rat plasma, 
which is in clear contrast with the values obtained with the less stable ester compound SH-
053-2′F-R-CH3 (Table S4). Analysis of these rodent data demonstrated that MP-III-022, as a 
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highly brain-bioavailable benzodiazepine, possesses a more favorable pharmacokinetic profile 
for in vivo investigation of the role of α5GABAARs than SH-053-2′F-R-CH3. 
 
 
Figure 2. Plasma and brain concentration–time profiles of MP-III-022 (a) and SH-053-2′F-R-
CH3 (b) after intraperitoneal administration of the 2.5 mg/kg and 10 mg/kg dose, respectively 
(n = 3 per time point). 
 
The concentrations of MP-III-022 in rat plasma (nmol/L) and brain tissue (nmol/kg), both 
total and free (estimated), measured 20 min after i.p. injection of MP-III-022 dosed at 1, 2.5, 
10, 15 and 20 mg/kg, are shown in Table 2. Free concentrations of MP-III-022 were 
calculated by multiplying the obtained total plasma and brain concentrations with the 
appropriate free fractions (13.51% for plasma and 6.61% for brain tissue) determined by rapid 
equilibrium dialysis. The analogous results for SH-053-2′F-R-CH3 over the same 20-fold 
dose schedule, but in the range from 10 mg/kg to 200 mg/kg, are presented in Table 3. Free 
fractions for this ester compound were 68.55% for plasma and 3.87% for brain. 
 
Table 2. Total and estimated free concentration of MP-III-022 (1, 2.5, 10, 15 and 20 mg/kg) in 
plasma and brain 20 minutes after treatment in rats. Mean ± SEM, n = 3-6 
Dose (mg/kg) 1 2.5 10 15 20 
Plasma 
(nmol/L) 
Total 
Free 
62.43  4.97 
8.47  0.67 
120.01  31.74 
16.29  4.31 
645.07  166.29 
87.57  22.57 
3709.24  2012.04 
503.51  273.13 
5378.01  1936.91 
730.04  262.93 
Brain Total 96.47  12,04 156.46  50.33 1030.52  278.03 4804.44  2821.77 8465.45  886.18 
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(nmol/kg) Free 6.38  0.80 10.34  3.33 68.12  18.38 317.57  186.52 559.57  58.58 
 
Table 3. Total and estimated free concentration of SH-053-2′F-R-CH3 (10, 20, 30, 150 and 
200 mg/kg) in plasma and brain 20 minutes after treatment in rats. Mean ± SEM, n = 2-4 
 
Dose (mg/kg) 10 20 30 150 200 
Plasma 
(nmol/L) 
Total 
Free 
406.43  76.45 
278.60  52.39 
420.63  70.01 
288.32  47.99  
555.51  68.18 
380.78  46.73  
1604.96  271.88 
1100.14  186.36 
2737.87  286.86 
1876.71  196.63 
Brain 
(nmol/kg) 
Total 
Free 
752.00  132.84 
29.10  5.14 
1003.57  87.55 
38.85  3.39  
1663.84  378.29 
64.40  14.64 
3816.79  965.21 
147.74  37.36 
8374.25  2322.03 
324.16  89.88 
 
The combined in vitro and pharmacokinetic results suggest that MP-III-022 in the dose range 
1-10 mg/kg can selectively and gradually potentiate the α5GABAARs in a wide span from 
138% to 314%. At higher doses (15 mg/kg and above), the selectivity of receptor activation 
disappears, and other, mostly α2/α3-containing GABAA receptors, would begin to 
substantially contribute to the overall pharmacological activity of MP-III-022. On the other 
hand, the estimated potentiation of GABA-mediated currents at α5GABAARs obtained with 
SH-053-2′F-R-CH3 reached the value of 280% after a huge, experimentally inconvenient 
dose of 200 mg/kg, and was accompanied with higher levels of potentiation at the respective 
non-α5GABAARs when compared with the 10 mg/kg dose of MP-III-022. In this vein, SH-
053-2′F-R-CH3 is not as applicable as MP-III-022 for in vivo studies of the role of strong 
potentiation of α5GABAARs. 
 
BASIC BEHAVIORAL TESTING 
Grip strength, rotarod test and intravenous PTZ infusion test 
MP-III-022 induced a dose-dependent decrease of muscle tension as measured by grip 
strength (Table 4). Studies in knock-in mice have suggested that all, the α2-, α3- and α5-
containing GABAA receptors, contribute to the muscle relaxant action of diazepam.
2 We have 
previously demonstrated that the α5-selective antagonist XLi-09325 can significantly diminish 
the myorelaxant actions of diazepam in rats. Consistent with these results, the first muscle 
relaxant effect of MP-III-022 was observed at a dose (10 mg/kg) postulated to elicit a 
selective strong potentiation of α5-GABAA receptors. The involvement of α2/α3-containing 
GABAA receptors at higher doses of MP-III-022 is expected to have contributed to the further 
gradual decrease of muscle tension seen in rats. 
In contrast to the grip strength results, the rats treated with 10 mg/kg MP-III-022 displayed 
normal motor coordination and balance as assessed in the rotarod test, far different from the 
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animals treated with the 15 mg/kg, and especially 20 mg/kg dose (Table 4). The ataxic effect 
of 15 mg/kg MP-III-022 was preventable by flumazenil, but not XLi-093. Namely, one-way 
ANOVA (F(2,18) = 5.05, p = 0.018) and Student–Newman–Keuls (SNK) post hoc revealed 
significant differences in performance between the rats treated with 15 mg/kg MP-III-022 
alone or in combination with 20 mg/kg of XLi-093, and the combination of 15 mg/kg MP-III-
022 and 15 mg/kg flumazenil (p = 0.021 and p = 0.019, respectively, Table 4). The rotarod 
studies in knock-in mice have suggested that the α1-, but not the α2- or α3-containing 
GABAA receptors contribute to the ataxic action of diazepam.
2 In line with this, the 
administration of L-838,417, a ligand with significant, but comparably small efficacy at α2-, 
α3- and α5-GABAARs, did not cause deficits in rotarod performance in rats26 or mice.27 
Nonetheless, the experiments using the nonselective, α1- and α5-subunit-selective antagonists 
flumazenil, βCCt and XLi-093, respectively, have suggested that an effect of diazepam 
mediated by α2- or α3-, but not α5-containing GABAA receptors may have contributed to the 
impairing influence of diazepam on the rotarod performance of rats.25 Accordingly, the 
present results imply that a pronounced modulatory action at α2/3GABAARs (the estimated 
respective potentiations at α2- and α3GABAARs were 225% and 175% after the 15 mg/kg 
dose, and 280% and 200% after the 20 mg/kg dose; for comparison, the estimated potentiation 
at α2GABAARs after the dose of 10 mg/kg was 138%) still can induce ataxia. The differences 
in dose-dependency of behavioral response in two tests demonstrate that the rotarod-ataxic 
effects of MP-III-022 may encompass, but do not solely rely on muscle relaxation. When 
testing SH-053-2′F-R-CH3 on the rotarod, the first, mild and insignificant deterioration 
(154±26 s vs. 180 s with control animals; n = 4) was noticed at the dose as high as 200 mg/kg, 
at which the estimated potentiations at α2- and α3GABAARs were 171% and 155%, 
respectively. Furthermore, even higher doses most probably required for marked 
incapacitation (for comparison, the S-isomer of this ligand, SH-053-2′F-S-CH3, displayed a 
median incapacitating dose of 219 mg/kg28) were not tested due to ethical constraints and 
irrelevancy, bearing in mind that they need to be accompanied by a distinct lack of selectivity 
of receptor subtype action. Keeping in mind the efficacy and kinetic properties of MP-III-022, 
the whole set of grip strength and rotarod results unambiguously demonstrated that the 15 
mg/kg dose of MP-III-022 is behaviorally non-selective and thus in further experiments was 
used only once more, in the spontaneous locomotor activity test. 
 
One-way ANOVA applied to the PTZ test (Table 4) did not show a statistically significant 
effect of treatment with either of two tested doses of MP-III-022 selective for α5GABAARs 
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(F(2,30) = 1.50, p = 0.239). This is consistent with the proposed contribution of the non-α5 
containing receptors to the anticonvulsant action of GABAergic drugs.2 
 
Table 4. Effect of different doses of MP-III-022 in the grip strength, rotarod, and 
pentylenetetrazole (PTZ) test; mean ± SEM. Grip strength: *p < 0.05, **p < 0.01, ***p < 
0.001 compared to SOL, +p < 0.05 compared to combination of 1 mg/kg MP-III-022. 
Rotarod: *p < 0.05 compared to 15 mg/kg MP-III-022, +p < 0.05 compared to combination of 
15 mg/kg MP-III-022 and 20 mg/kg XLi-093; SOL = solvent, FLU = flumazenil 
grip strength 
the peak force of experimenter’s pull necessary to overcome the strength of the animal’s grip 
Treatment Mean ± SEM (kg/kg) n 
SOL 2.87 ± 0.17 10 
1 mg/kg MP-III-022  2.57 ± 0.08 10 
2.5 mg/kg MP-III-022 2.41 ± 0.28 8 
10 mg/kg MP-III-022  1.94 ± 0.22**+ 8 
15 mg/kg MP-III-022 1.86 ± 0.16* 5 
20 mg/kg MP-III-022 1.78 ± 0.16***+ 11 
rotarod test 
the time remaining on the rod revolving at 15 rpm 
Treatment Mean ± SEM (s) n 
10 mg/kg MP-III-022 180 3 
20 mg/kg MP-III-022  6.67 ± 4.81 3 
15 mg/kg MP-III-022 69.09 ± 25.58 9 
15 mg/kg MP-III-022/20 mg/kg XLi-093 74.61 ± 34.03 6 
15 mg/kg MP-III-022/15 mg/kg FLU 175.17 ± 4.83*+ 6 
PTZ test 
the threshold doses of PTZ required to elicit seizures 
Treatment Mean ± SEM (mg/kg PTZ) n 
SOL 53.38 ± 1.84 11 
1 mg/kg MP-III-022  60.99 ± 6.11 11 
10 mg/kg MP-III-022  50.99 ± 3.72 11 
 
Spontaneous and amphetamine induced locomotor activity 
The spontaneous locomotor activity test was performed with the highest selective (10 mg/kg) 
and lowest non-selective (15 mg/kg) dose of MP-III-022. One-way ANOVA for total distance 
traveled revealed a significant effect of treatment (F(2,25) = 3.64, p = 0.041) and analysis of 
the SNK test showed differences between control and 15 mg/kg MP-III-022 (p = 0.029, Fig 
3a). Similarly, when the two-way repeated measures ANOVA was applied on distance 
traveled in the 5-min bins, a significant effect of treatment and time was revealed (F(2,25) = 
3.64, p = 0.041, F(8,200) = 32.90, p < 0.001, respectively), without a significant interaction of 
factors (F(16,200) = 1.63, p = 0.065, Figure 3b). The post hoc SNK test showed the 
differences between control and 15 mg/kg MP-III-022 (p = 0.032). The slight 
hyperlocomotion observed after treatment with the 15 mg/kg dose could be ascribed to a kind 
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of behavioral disinhibition induced by potentiation of α2/3-containing GABAA receptors 
unopposed by activity at α1-containing receptors.29 As an important corollary, the assertion 
that α5GABAARs may contribute to the sedative properties of benzodiazepine site 
agonists19,28 could certainly not apply to a substantial level of potentiation, such as that 
elicited by 10 mg/kg MP-III-022.  
 
 
Figure 3. The effects 10 and 15 mg/kg MP-III-022 on the total distance traveled (a) and on 
distance traveled in 5-min bins (b) during 45 min in SLA. *p < 0.05 compared to control 
(SOL/SOL) group. All data are presented as the mean +/± SEM. Number of animals per 
treatment group was 8-10. SOL = solvent, MP-III-022 10 = 10 mg/kg MP-III-022, MP-III-022 
15 = 15 mg/kg MP-III-022. 
 
Moreover, the present results lead to an assumption that activation of α5GABAARs is not 
sufficient to either enhance or decrease locomotion, as one-way ANOVA applied on data with 
three selective doses of MP-III-022 (1, 2.5 and 10 mg/kg) from the first part of the 
amphetamine-induced locomotor activity test did not show any effect of treatment (F(3,28) = 
0.08, p = 0.970, Figure 4a). The same lack of effect was observed with two-way repeated 
measures ANOVA on results of 5-min intervals: Treatment: F(3,28) = 0.08, p = 0.970; Time: 
F(3,84) = 78.36, p < 0.001: Interaction: F(9,84) = 0.49, p = 0.879. 
One-way ANOVA applied on the data from 60-min recordings after administration of 
amphetamine revealed a significant effect on total distance traveled (F(3,35) = 4.16, p = 
0.007); post hoc SNK results were given in Figure 4b. When two-way ANOVA with repeated 
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measures was applied on distance traveled in 5-min bins, the same significant effect was 
observed (Treatment: F(4,35) = 4.16, p = 0.007, Time: F(11,385) = 5.47, p < 0.001, 
Interaction: F(44,385) = 2.02, p < 0.001). The SNK test confirmed differences between 
control and all amphetamine-treated groups. Recent studies with allegedly selective positive 
as well as negative modulators of α5GABAA receptors reported a slight, but still significant 
suppression of the amphetamine-induced locomotor stimulation in the sensitized, behaviorally 
altered, animals9,30; the present data demonstrate the lack of influence of α5 receptor-selective 
doses of MP-III-022 on amphetamine’s effects in normal wild-type animals. 
 
Figure 4. The effect of 1, 2.5, and 10 mg/kg MP-III-022 on locomotor activity during 20 
minutes before amphetamine treatment (a), the influence of 1, 2.5, and 10 mg/kg MP-III-022 
on amphetamine induced hyperlocomotion during 60 min (b) and effect on distance traveled 
in 5-min bins during all testing (c) in locomotor activity test. *p < 0.05 compared to control 
(SAL/SAL) group. All data are presented as the mean + or ± SEM. Number of animals per 
treatment group was 8. SOL = solvent, SAL = vehicle, AMPH 0.5 = 0.5 mg/kg amphetamine, 
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MP-III-022 1 = 1 mg/kg MP-III-022, MP-III-022 2.5 = 2.5 mg/kg MP-III-022, MP-III-022 10 
= 10 mg/kg MP-III-022 
 
IN VIVO TESTS OF COGNITIVE PERFORMANCE 
Morris water maze 
The results of the five-day acquisition phase of the water maze test are presented in Figure 5, 
while the accompanying statistical analysis is given in Table 5. For all parameters measured, 
significant effects of factors Treatment and Days were observed. Our results demonstrated 
that at the highest dose selective for α5GABAARs (10 mg/kg), MP-III-022 elicited spatial 
learning incapacitation indistinguishable from that induced by diazepam 2 mg/kg used as a 
positive control. The effect included the percent of distance swam in the peripheral ring, as 
the parameter of thigmotaxic behavior. This is the first result which directly demonstrates that 
water maze impairments characteristic for benzodiazepines31 are achievable through positive 
modulation of α5GABAARs solely. The receptors that mediate the effect are most probably 
those located in the hippocampus,32 bearing in mind that the water maze is commonly seen as 
a hippocampal-dependent cognitive task.33 As the two-way repeated measures ANOVA for 
mean speed was not statistically significant for factor Treatment (F(4,27) = 1.112, p = 0.317), 
any sensorimotor disturbances during acquisition sessions can be excluded. 
Notably, the post hoc tests revealed that the group treated with 1 mg/kg MP-III-022 differed 
overall (for all five days) from both, 2 mg/kg diazepam and 10 mg/kg MP-III-022 group for 
all parameters: the animals receiving 1 mg/kg MP-III-022 had shorter escape latencies, shorter 
distances, swam less distance in the peripheral ring and had higher path efficiencies (Figure 
5). Moreover, post hoc analysis after one-way ANOVA on Day II revealed that rats treated 
with 1 mg/kg MP-III-022 had higher path efficiencies compared to the control and all other 
treatment groups (Day II, Figure 5d), suggesting together with the previous finding that a mild 
level of selective modulation, associated with the lowest dose of MP-III-022, tended to make 
rats faster to acquire the task. While the observation needs further investigation, we can 
hypothesize that it involves a certain degree of potentiation of α5GABAARs in the 
neocortex,32,34 which may accelerate action potential firing during up states.20 Here, it seems 
relevant to comment on our published results with 30 mg/kg SH-053-2′F-R-CH3 in the same 
MWM protocol19; a detailed presentation of those results is given in Supplementary material 
(Figures S3 and S4; Table S5). SH-053-2′F-R-CH3 at 30 mg/kg did not affect rats’ water 
maze behavior, which can be seen as analogous to the results obtained with 2.5 mg/kg MP-III-
022; both of these treatments are supposed to elicit a moderate level of positive modulation at 
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α5GABAARs. The single significant effect of SH-053-2′F-R-CH3 on distance in the 
peripheral ring (Table S5) additionally supports the notion that a much higher, experimentally 
inconvenient, dose of this ligand would be needed to exert a complete deterioration of spatial 
performance mediated by α5GABAA receptors. 
 
Table 5. The effects of 2 mg/kg DZP and 1, 2.5 and 10 mg/kg MP-III-022 administration on 
the rat’s behavior in the MWM. Two-way repeated measures ANOVA and overall post hoc 
results for latency to platform (s), total distance (m), distance swam in the peripheral annulus 
(%) and path efficiency. SOL = solvent; DZP = diazepam; MP = MP-III-022; ns = not 
significant.  
Factor 
Latency 
(s) 
Total distance 
(m) 
Distance in the 
peripheral 
ring (%) 
Path efficiency 
Treatment: F(4,27) 
p 
3.962 
0.012 
4.946 
0.004 
6.994 
< 0.001 
6.445 
< 0.001 
Days: F(4,108) 
p 
43.761 
< 0.001 
22.438 
< 0.001 
37.268 
< 0.001 
19.000 
< 0.001 
Interaction: F(16,108) 
p 
1.527 
0.103 
1.135 
0.333 
1.460 
0.128 
2.074 
0.014 
SNK post hoc for Treatment 
SOL vs. 2 mg/kg DZP ns 0.086 0.018  0.086 
SOL vs. 1 mg/kg MP ns ns ns  0.052 
SOL vs. 2.5 mg/kg MP ns 0.099 ns  ns 
SOL vs. 10 mg/kg MP ns 0.038 0.030  0.077 
2 mg/kg DZP vs. 1 mg/kg MP 0.017 0.019 0.001  0.001 
2 mg/kg DZP vs. 2.5 mg/kg MP ns ns ns  ns 
2 mg/kg DZP vs. 10 mg/kg MP ns ns ns  ns 
1 mg/kg MP vs. 2.5 mg/kg MP ns 0.036 0.018  0.022 
1 mg/kg MP vs. 10 mg/kg MP 0.026 0.007 0.002  0.002 
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Figure 5. The effects of diazepam 2 mg/kg and MP-III-022 1, 2 and 10 mg/kg on (a) latency 
to platform, (b) total distance, (c) distance in the peripheral ring (%) and (d) path efficiency 
during acquisition trials in the water maze. ***p < 0.001 compared to solvent (SOL) group; 
+p < 0.05, +++p < 0.001 compared to 2 mg/kg diazepam (DZP 2) group; #p < 0.05, ###p < 
0.001 compared to 1 mg/kg (MP-III-022 1) group. Animals per treatment group were 6-7. 
SOL = solvent, DZP 2 = 2 mg/kg diazepam, MP-III-022 1 = 1 mg/kg MP-III-022, MP-III-022 
2.5 = 2.5 mg/kg MP-III-022, MP-III-022 10 = 10 mg/kg MP-III-022 
 
One–way ANOVA applied on results from the probe test revealed a significant influence of 
MP-III-022 on both parameters analyzed: the distance swam in the target region (F(4,27) = 
6.26, p = 0.001; Figure 6a), and the percent of distance swam in the peripheral ring (F(4,27) = 
6.84, p < 0.001; Figure 6b). All groups, with the exception of 1 mg/kg MP-III-022, differed 
significantly from control animals, confirming cognitive-disruptive effects of diazepam and 
10 mg/kg, but also 2.5 mg/kg MP-III-022 on long-lasting spatial memory. The latter finding is 
at odds with the lack of action of 30 mg/kg SH-053-2′F-R-CH3 (Figure S4), and points to the 
role of expected differences in pharmacokinetic profiles of two ligands in a repeated-dose 
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study. With respect to the effects of profound deterioration of both, memory acquisition and 
retrieval, obtained with the dose of MP-III-022 eliciting a high level of potentiation of 
α5GABAARs (10 mg/kg), they demonstrate that impairments of spatial cognition elicited by 
benzodiazepines are dependent on this population of receptors. 
 
 
Figure 6. The effects of 2 mg/kg diazepam and 1, 2 and 10 mg/kg MP-III-022 on (a) distance 
in the target zone (m) and (b) distance in the peripheral ring (%) during probe trial in the 
water maze. *p < 0.05, **p < 0.01 compared to solvent (SOL) group; +p < 0.05, ++p < 0.01 
compared to 2 mg/kg diazepam (DZP 2) group; #p<0.05 compared to 1 mg/kg MP-III-022 
(MP-III-022 1) group. Animals per treatment group were 6-7. SOL = solvent, DZP 2 = 2 
mg/kg diazepam, MP-III-022 1 = 1 mg/kg MP-III-022, MP-III-022 2.5 = 2.5 mg/kg MP-III-
022, MP-III-022 10 = 10 mg/kg MP-III-022 
 
Social novelty discrimination procedure 
The effects of 1.5 mg/kg diazepam and 1, 2.5 and 10 mg/kg MP-III-022 on the rats’ behavior 
in the social novelty discrimination procedure are presented in Figure 7. One-sample t-test for 
discrimination indices revealed significant differences from zero (i.e. chance level) only for 
the 10 mg/kg MP-III-022 group (t(7) = 2.446; p = 0.023, Figure 7a). Similarly, paired t-test 
revealed significance of time spent in exploring the familiar and the novel juvenile rat during 
P2, showing that only the 10 mg/kg MP-III-022 group spent significantly more time in 
exploring the new rat (t(7) = -2.921, p = 0.022, Figure 7b). The same statistical analysis on 
exploration time revealed a statistical trend in rats treated with 1.5 mg/kg diazepam (t(7) = -
2.076, p = 0.077). The finding of facilitation of social novelty discrimination by a 
benzodiazepine that selectively potentiates α5GABAARs is novel. We can hypothesize that 
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the significant expression of α5-subunit in the olfactory bulb32,35 is associated with the 
observed effect. Namely, the primary cue for social discrimination is olfactory,36 and there is 
an intricate network of extensively connected structures involved in forming the ‘olfactory 
signature’.36,37 It is of interest to note that lesions to one of these structures, the perirhinal 
cortex, but not to the hippocampus, cause significant deficits for social odor recognition 
memory.38  
 
Figure 7. The effects of 1.5 mg/kg diazepam (DZP 1.5) and 1, 2.5 and 10 mg/kg MP-III-022 
on discrimination index (a) and the time exploring the familiar and the novel juvenile rat in P2 
(b) in social novelty discrimination procedure. A significant difference from zero for 
discrimination index is indicated with # (one sample t-test, ##p < 0.01). *p < 0.05 for the 
familiar vs. novel exploration times (paired-samples t-test). Data are represented as mean + 
SEM. Number of animals per treatment group was 8. SOL = solvent, DZP 1.5 = 1.5 mg/kg 
diazepam, MP-III-022 1 = 1 mg/kg MP-III-022, MP-III-022 2.5 = 2.5 mg/kg MP-III-022, MP-
III-022 10 = 10 mg/kg MP-III-022 
 
Three-chamber test 
The non-competitive antagonist of the NMDA receptors ketamine is widely used at 
subanesthetic doses to induce cognitive deficits and social withdrawal in rats.39 The effects of 
15 mg/kg ketamine and 10 mg/kg MP-III-022, on their own and in combination, on the rats’ 
behavior in the three chamber test are presented in Figure 8. Examination of the one-sample t-
test, for sociability indices (SI) revealed significant differences from zero (i.e. chance level) 
only for the control group (t(7) = 4.734; p = 0.002, Figure 8a). In the same way, paired t-test 
revealed significance on time spent in exploring the animal and object during T2, showing 
that only control can discriminate between object and rat group (t(7) = 4.58, p = 0.003, Figure 
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8b). The same statistical analyses on the social recognition trial (T3) showed no 
discrimination between the familiar and novel rat during testing in any treatment group 
(Figure 8c and 8d). 
It is remarkable that mice with reduced α5 subunit expression selectively in the granule cells 
of the dentate gyrus of the hippocampus showed impairments in cognitive tasks characterized 
by high interference, without any deficiencies in low-interference tasks.40 Memory 
interference refers to antagonistic processes whereby either new memories impair retrieval of 
previously learned information or earlier memories prevent future learning, and is most likely 
to occur between memories that are similar.41 Our settings of selective positive modulation of 
α5GABAARs may be seen as opposite to those with reduced expression of α5 GABAA 
receptors given by Engin and co-workers40, and hence they may be expected to favor 
facilitation in cognitive tasks characterized by high interference, but also impairment in low-
interference tasks. The results from the social novelty discrimination, exemplifying the 
former, and the Morris water maze and the sociability trial of the three-chamber test, 
exemplifying the latter kind of tasks (cf. Engin et al.40), comply with this hypothesis. 
Moreover, when looking at the results in the social novelty trial of the three-chamber test, 
which is a task characterized by high interference, it is notable that the discrimination index of 
animals exposed to 10 mg/kg MP-III-022 was 2.18, while only 1.02 in control rats, without 
reaching a statistical significance of the difference. The high rate of attrition in the three-
chamber test in all groups receiving either MP-III-022, ketamine or their combination (7, 6 
and 9 rats, respectively, did not reach the criterion in either the second or the third trial; 
Supplementary Table 6S) demonstrated that the impairing effects of ketamine,42, 43 and also 
10 mg/kg MP-III-022, on spatial orientation and memory could have substantially influenced 
the results obtainable in this paradigm. It should be emphasized that such effects are not 
pertinent for behavioral performance in the social novelty discrimination procedure. 
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Figure 8. The effects of 15 mg/kg ketamine and 10 mg/kg MP-III-022, alone and in 
combination, on sociability index (SI) (a), the time exploring the rat and the object in 
sociability trial (T2) (b), social novelty preference index (SNI) (c) and the time exploring the 
novel and the familiar rat in social recognition trial (T3) (d) in the three-chamber test. A 
significant difference from zero is indicated with # (one sample t-test, ##p < 0.01). **p < 0.01 
for the rat vs. object exploration times (paired-samples t-test). Data are represented as mean + 
SEM. Number of animals per treatment group was 8. SOL = solvent, SAL = saline, KET 15 = 
15 mg/kg ketamine, MP-III-022 1 = 1 mg/kg MP-III-022, MP-III-022 10 = 10 mg/kg MP-III-
022 
 
CONCLUSIONS 
Several sets of data unequivocally suggest that GABAA receptors containing the α5 subunit 
play a major role in modulating cognition-related behaviors. The novel ligand MP-III-022 was 
synthesized from SH-053-2′F-R-CH3, a benzodiazepine widely used in research as a positive 
allosteric modulator selective for α5GABAARs. In comparison with the starting ligand, in 
vitro studies demonstrated an improved affinity- and especially efficacy-selectivity of MP-III-
415 
 
022 for α5GABAARs, while it was mainly inactive in a standard screening panel of 50 
GPCRs, ion channels, enzymes, and transporters (PDSP, Dr Bryan Roth, UNC). The parent 
compound SH-053-2'F-R-CH3 has already permitted important insights into the role of α5βγ2 
receptors, and its improved derivative MP-III-022 enables researchers to investigate effects of 
α5βγ2 positive modulation with even lower interference from residual activity at other 
subtypes. Namely, by combining the results of electrophysiological and pharmacokinetic 
studies, we predict that the in vivo effects of MP-III-022 are solely dependent on positive 
modulation of α5GABAARs (at doses up to 10 mg/kg) and can be differentiated from those 
involving also some other diazepam-sensitive GABAA receptor subtypes, most probably the 
receptors containing α2 and/or α3 subunits (15 mg/kg and above). Moreover, when compared 
with SH-053-2′F-R-CH3, an improved applicability of MP-III-022 stems from a wide range 
of selective potentiation of α5GABAARs, from mild to moderate to strong, which can be 
accomplished by its convenient administration in the dose range 1 mg/kg to 10 mg/kg. Indeed, 
in the rotarod, pentylenetetrazole as well as spontaneous and amphetamine-induced locomotor 
activity tests, MP-III-022 at doses up to 10 mg/kg proved to be behaviorally silent in rats, and 
the only motor effect of the highest dose was a mild, though significant muscle relaxation 
expectedly observed in the grip strength test. Thus, it was possible to assess the behavioral 
consequences of eliciting a wide range of potentiation of α5GABAARs in a set of cognitive 
tests, free of safety issues such as ataxia or sedation. It was found that strong selective 
potentiation of α5GABAARs (more than three times the current level elicited by low 
concentrations of GABA) can induce at the same time both a facilitatory action on social 
recognition, and an impairing effect on spatial learning and memory, as assessed in the social 
novelty discrimination procedure and Morris water maze test, respectively. On the other hand, 
in the three-chamber test, there was impairment in the sociability trial, while an apparent 
tendency of improved social recognition in the social novelty trial for the group receiving 10 
mg/kg MP-III-022 was far from significance, possibly due to the expected concomitant 
deterioration of spatial acuity. The presented behavioral results demonstrate that MP-III-022 
may be used as an excellent experimental tool to assess protective or therapeutic potential of 
selective potentiation of α5GABAARs in various medical states putatively connected with 
pathological changes in this receptor population. 
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METHODS 
 
Chemistry 
(R)-8-Ethynyl-6-(2-fluorophenyl)-N,4-dimethyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-
carboxamide (MP-III-022) (1) was synthesized as follows.  
Ester 2 (1.0 g, 2.58 mmol)44 was added to a sealed vessel fitted with a septum at 0oC and 
treated with methyl amine (15 mL; 33% wt solution in ethanol). The vessel was sealed with a 
cap and stirred at 60oC for 18 h. The solution was then cooled to rt and the methyl amine and 
ethanol were removed under reduced pressure. The residue was purified by a wash column 
(silica column, 4:1 EtOAc:hexanes) to afford amide 1 as a white powder (731 mg, 1.96 mmol, 
76%). Characterization of compound 1: 1H NMR (300 MHz, CDCl3) δ 7.88 (s, 1H), 7.67 (dd, 
J = 16.3, 7.8 Hz, 2H), 7.55 (d, J = 8.3 Hz, 1H), 7.50 – 7.41 (m, 2H), 7.29 – 7.18 (m, 2H), 7.04 
(t, J = 9.3 Hz, 1H), 6.93 (q, J = 7.4 Hz, 1H), 3.16 (s, 1H), 2.97 (d, J = 5.0 Hz, 3H), 1.29 (d, J 
= 6.4 Hz, 3H). 13C NMR (300 MHz, CDCl3) δ 162.24, 161.81, 158.48, 138.25, 137.12, 
135.73, 134.41, 133.57, 132.53, 131.57, 129.03, 125.15, 124.92, 124.58, 122.50, 116.33, 
166.05, 81.25, 79.99, 49.42, 25.73, 25.27. HRMS (LCMS-IT-TOF) Calc. for C22H17FN4O (M 
+ H)+ 373.1459, found: 373.1462. Detailed spectra are provided in the Supporting 
Information (Figures S1  S2). 
 
 
Competition binding assays 
Materials 
3H-Flunitrazepam (specific activity 83 Ci/mmol) was purchased from Perkin Elmer NEN 
(New England Nuclear )(Waltham, Massachusetts, USA). Diazepam (7-chloro-1,3-dihydro-1-
methyl-5-phenyl-2H-1,4, benzodiazepine-2-one) from Nycomed (Opfikon, Switzerland). 
Standard chemicals came from Sigma-Aldrich (St. Louis, Missouri, USA) 
Culturing of human embryonic kidney 293 cells 
Human embryonic kidney (HEK) 293 cells (American Type Culture Collection ATCC® 
CRL-1574TM) were maintained in Dulbecco’s modified Eagle medium (DMEM, high glucose, 
GlutaMAXTM supplement, Gibco 61965-059, ThermoFisher, Waltham, Massachusetts, USA) 
supplemented with 10% fetal calf serum (Sigma-Aldrich F7524, St. Louis, Missouria, USA), 
100 U/ml Penicillin-Streptomycin (Gibco 15140-122, ThermoFisher, Waltham, 
Massachusetts, USA) and MEM (Non-Essential Amino Acids Gibco 11140-035, 
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ThermoFisher, Waltham, Massachusetts, USA) on 10cm Cell culture dishes (Cell+, Sarstedt, 
Nürnbrecht, Germany) at 37°C and 5% CO2. 
HEK293 cells were transfected with cDNAs encoding rat GABAA-receptor subunits 
subcloned into pCI expression vectors. The ratio of plasmids used for transfection with the 
calcium phosphate precipitation method45 were 3µg (1,2,3 or 5): 3µg 3 and 15 µg 2 per 10 
cm dish. Medium was changed 4-6 hours after transfection. 
Cells were harvested 72 days after transfection by scraping into phosphate buffered saline. 
After centrifugation (10 min, 12000 g, 4°C) cells were resuspended in TC50 (50 mM Tris-
Citrate pH=7.1), homogenized with an ULTRA-TURRAX® (IKA, Staufen, Germany) and 
centrifuged (20 min, 50 000g). Membranes were washed three times in TC50 as described 
above and frozen at -20°C until use. 
Radioligand binding assay 
Frozen membranes were thawed, resuspended in TC50 and incubated for 90 min at 4°C in a 
total of 500 µl of a solution containing 50 mM Tris/citrate buffer, pH=7.1, 150 mM NaCl and 
2 nM [3H]-Flunitrazepam in the absence of presence of either 5 µM diazepam (to determine 
unspecific binding) or various concentrations of receptor ligands (dissolved in DMSO, final 
DMSO-concentration 0.5%). Membranes were filtered through Whatman GF/B filters and the 
filters were rinsed twice with 4 ml of ice-cold 50mM Tris/citrate buffer. Filters were 
transferred to scintillation vials and subjected to scintillation counting after the addition of 3 
ml Rotiszint Eco plus liquid scintillation cocktail. Nonspecific binding determined in the 
presence of 5 µM Diazepam was subtracted from total [3H]-Flunitrazepam binding to result in 
specific binding. 
In order to determine the equilibrium binding constant KD of 3H-Flunitrazepam for the 
various receptor-subtypes, membranes were incubated with various concentrations of 3H-
Flunitrazepam in the absence or presence of 5 µM Diazepam.  
Data calculation 
Saturation binding experiments were analyzed using the equation Y=Bmax*X/(KD+X). 
Nonlinear regression analysis of the displacement curves used the equation: log(inhibitor) vs. 
response - variable slope with Top=100% and Bottom=0% Y=100/(1+10^((logIC50-
x)*Hillslope)). Both analyses were performed using GraphPad Prism version 5.0a for Mac OS 
X, GraphPad Software, La Jolla California USA, www. graphpad.com. 
Drug concentrations resulting in half maximal inhibition of specific 3H-Flunitrazepam 
binding (IC50) were converted to Ki values by using the Cheng-Prusoff relationship46 Ki= 
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IC50/(1+(S/KD)) with S being the concentration of the radioligand (2 nM) and the KD values 
listed in table S1. 
 
Electrophysiological experiments 
cDNAs of rat GABAA receptor subunits were used for generating the respective mRNAs that 
were then injected into Xenopus laevis oocytes (Nasco, WI) as described previously.47 For 
electrophysiological recordings, oocytes were placed on a nylon-grid in a bath of Xenopus 
Ringer solution (XR, containing 90 mM NaCl, 5 mM HEPES-NaOH (pH 7.4), 1 mM MgCl2, 
1 mM KCl and 1 mM CaCl2). The oocytes were constantly washed by a flow of 6 mL/min 
XR which could be switched to XR containing GABA or MP-III-022 and GABA. Test 
compounds were diluted into XR from DMSO-solutions resulting in a final concentration of 
0.1% DMSO perfusing the oocytes. For current measurements the oocytes were impaled with 
two microelectrodes (2–3 mΩ) which were filled with 2 mM KCl. To test for modulation of 
GABA-induced currents by MP-III-022, a concentration of GABA was used that was titrated 
to trigger 3-5% of the respective maximum GABA-elicited current of the individual oocyte 
(EC3-5). At this low GABA concentration, within-day and between-day currents are 
reproducible and effects of drugs (% of modulation) are much higher than that at higher 
GABA concentrations. GABA at EC3-5 was then coapplied with varying concentrations of 
MP-III-022 until a peak response was observed. Between two applications, oocytes were 
washed in XR for up to 15 min to ensure full recovery from desensitization. All recordings 
were performed at room temperature at a holding potential of –60 mV using Dagan TEV-200 
two-electrode voltage clamp amplifiers (Warner Instruments, Hamden, CT). Data were 
digitized, recorded and measured using Digidata 1322A and 1550 data acquisition systems 
(Axon Instruments, Union City, CA). Results of concentration response experiments were 
graphed using GraphPad Prism 4.00 (GraphPad Software, San Diego, CA). 
 
Studies in rats 
Animals 
Male outbred Wistar rats were supplied by Military Farm, Belgrade, Serbia. Rats were housed 
in groups of five and were maintained under standard laboratory conditions (21 ± 2°C, 
relative humidity 40-45%) with free access to pellet food and tap water. They were kept on 
12:12 h light/dark cycle with lights on at 07.00 h. All handling and testing took place during 
the light phase of the diurnal cycle. 
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Behavioral experiments were carried out on nine weeks old (adults weighing 200–250 g) or 
21 days old (juvenile) Wistar male rats. For social discrimination novelty procedure adults 
were isolated in individual cages two days before testing. The animals received two 
intraperitoneal (i.p.) injections, one of which was the solvent if not otherwise stated. The 
behavior was recorded by a ceiling–mounted camera and analyzed by ANY–maze Video 
Tracking System software (Stoelting Co., USA). Throughout the study, experimentally naïve 
animals were used. 
Ethics Statement 
Experiments were approved by the Ethical Commission on Animal Experimentation of the 
Faculty of Pharmacy in Belgrade and were carried out in accordance with the EEC Directive 
86/609.  
Drugs 
The ligands MP-III-022, SH-053-2′F-R-CH3 and XLi-093 were synthesized at the 
Department of Chemistry and Biochemistry, University of Wisconsin–Milwaukee, USA. XLi-
093 is an 5GABAA receptor selective antagonist. D-Amphetamine-sulfate and ketamine were 
purchased from Sigma–Aldrich, flumazenil from Feicheng BoYuan Fine Chemicals Co., Ltd, 
China, while diazepam was obtained from Galenika (Belgrade, Serbia). The ligands MP-III-
022, SH-053-2′F-R-CH3, XLi-093, flumazenil and diazepam were suspended/dissolved with 
the aid of sonication in the solvent (85% distilled water, 14% propylene glycol, and 1% 
Tween 80), while d-amphetamine and ketamine were dissolved in saline. All compounds were 
administered i.p. in a volume of 2 mL/kg, 20 min before the behavioral testing, with the 
exception of the experiment with d-amphetamine, in which the animal’s behavior was 
recorded immediately after the respective treatments. 
For determination of free fractions in plasma and brain tissue, stock solutions of MP-III-022 
and SH-053-2′F-R-CH3 were prepared in dimethyl sulfoxide (DMSO). 
Pharmacokinetic study 
Rats were divided in two cohorts of six groups which corresponded to predetermined time 
intervals (5, 10, 20, 40, 60 and 180 min), each containing three animals. MP-III-022 and SH-
053-2′F-R-CH3, dosed at 2.5 mg/kg and 10 mg/kg, respectively, were administered by i.p. 
injection in a volume of 2 mL/kg. Additional experiments were performed in order to 
determine brain and plasma concentration 20 min after i.p. injection, as well as to calculate 
free brain and plasma levels of MP-III-022 dosed at 1, 2.5, 10, 15 and 20 mg/kg, and SH-053-
2′F-R-CH3 dosed at 10, 20, 30, 150 and 200 mg/kg. The blood samples were collected in 
heparinized syringes via cardiac puncture of rats anesthetized with ketamine solution (10% 
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Ketamidor, Richter Pharma Ag, Wels, Austria, dosed i.p. at 100 mg/kg), and centrifuged at 
2500 rpm for 10 min to obtain plasma. Thereafter, rats were decapitated and brains were 
weighed, homogenized in 5 mL of methanol and centrifuged at 6000 rpm for 20 min. To 
determine the concentration of MP-III-022 and SH-053-2′F-R-CH3 in plasma and 
supernatants of brain tissue homogenates, MP-III-022 and SH-053-2′F-R-CH3 were extracted 
from these samples by solid phase extraction, using Oasis HLB cartridges (Waters 
Corporation, Milford, Massachusetts). The procedure of sample preparation and 
determination of MP-III-022 and SH-053-2′F-R-CH3 by ultraperformance liquid 
chromatography–tandem mass spectrometry (UPLC–MS/MS) with Thermo Scientific Accela 
600 UPLC system connected to a Thermo Scientific TSQ Quantum Access MAX triple 
quadrupole mass spectrometer (Thermo Fisher Scientific, San Jose, California), equipped 
with electrospray ionization (ESI) source, has been already described in detail.16 
Plasma protein and brain tissue binding studies 
The rapid equilibrium dialysis assay used to determine free fraction of MP-III-022 and SH-
053-2′F-R-CH3 in rat plasma and brain tissue was the same as in Obradović et al.16 
Grip strength 
Muscle strength was assessed by the grip strength meter (Ugo Basile, Milan, Italy, 
model 47105). When pulled by the tail, the rat grasps the trapeze connected to a 
force transducer, and the apparatus measures the peak force of experimenter’s 
pull (in grams) necessary to overcome the strength of the animal’s forelimbs grip. 
Six groups received one of the following treatments 20 minutes before testing: solvent, MP-
III-022 (1, 2.5, 10, 15 and 20 mg/kg). Each animal was given three consecutive trials, 
and the median value of three readings, normalized against body weight, was used for 
further statistics. 
Rotarod test 
Motor performance was assessed using an automated rotarod (Ugo Basile, Italy). Before 
testing, rats were trained for three days until they could remain for 180 s on the rod revolving 
at 15 rpm. On the fourth day, selection was made and rats fulfilling the given criteria were 
included in the experiment. Seven groups received one of the following treatments 20 minutes 
before testing: solvent, MP-III-022 (10, 15 and 20 mg/kg), SH-053-2′F-R-CH3 (200 mg/kg) 
and 15 mg/kg MP-III-022 in combination with XLi-093 (20 mg/kg) or flumazenil (15 mg/kg). 
Latency to fall from the rotarod was recorded automatically. 
Intravenous pentylenetetrazole infusion test 
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A butterfly cannula (needle size 25 G, ¾ in.) attached to a 20 ml syringe prefilled with 
pentylenetetrazole (PTZ) solution was used. The syringe was held in adjustable motor driven 
infusion pump (Stoelting Co., Wood Dale Illinois, USA). Before infusing PTZ, the rat’s tail 
vein was dilated with warm water. Single rat was then placed in the restrainer. A butterfly 
needle was inserted into the lateral tail vein and PTZ was infused at a constant rate of 0.5 
ml/min. The animal was observed throughout the infusion by two trained and blind observers. 
The threshold doses of PTZ (mg/kg) required to elicit clonic and tonic seizures were 
calculated using the following formula: volume of PTZ (ml) x concentration of PTZ 
(mg/ml)/body weight (kg). 
Spontaneous and amphetamine induced locomotor activity 
Activity of single rats in a clear Plexiglas chamber (40×25×35 cm) under dim red light (20 
lux) was recorded for a total of 45 min, without any habituation period but with 20 min 
acclimatization time. One of two doses of MP-III-022 (10 and 15 mg/kg) or solvent were 
applied 20 min before testing. The same apparatus was used for assessing the amphetamine-
induced locomotor activity, with an adapted protocol. Here, rats received the appropriate 
treatment (solvent, 1, 2.5 or 10 mg/kg MP-III-022) and were immediately placed in the 
tracking chamber. Behavior was recorded for 20 min and then rats were injected with saline 
or 0.5 mg/kg amphetamine and locomotor activity was recorded for an additional 60 min. 
Morris water maze  
Experiments were performed in a 2 m diameter circular pool filled to a height of 30 cm with 
water at 22 ± 1 °C. The escape platform (15 cm × 10 cm) was submerged 2 cm below the 
water surface. An indirect illumination in the experimental room was provided by white neon 
tubes and many distal cues were present. On each of the five consecutive days rats were given 
one swimming block, consisting of four trials. For each trial the rat was placed in the water at 
one of four pseudo–randomly determined starting positions. Once the rat has found and 
mounted the escape platform it was permitted to remain on the platform for 15 s. The rat was 
guided to the platform by the experimenter if it failed to locate it within 120 s. During the 
acquisition phase, treatments were applied once daily before the swimming block. On the 
sixth day, rats were given a treatment–free probe test (60 s) without the platform. In order to 
ensure that any spatial bias is a consequence of the spatial memory of escape location, rather 
than of a specific swim strategy, the probe test was started from the novel, most distant 
location.48 The pool was virtually divided into four quadrants, three concentric annuli and a 
target region consisting of the intersection of the platform quadrant and the platform (middle) 
annulus, as represented in Savić et al.29 Dependent variables chosen for tracking during the 
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acquisition trials were: escape latency (s), total distance traveled (m), path efficiency (the ratio 
of the shortest possible path length to actual path length), % of distance swam in the 
peripheral annulus and mean speed (m/s). The selected parameters in the probe test were the 
distance swam in the target zone (s) and % of the distance swam in the peripheral annulus. 
We tested the effects of 1, 2.5 and 10 mg/kg MP-III-022 and 2 mg/kg diazepam. 
Social novelty discrimination (SND) procedure  
SND experiments compared the social investigation times of an adult rat with a familiar and a 
novel juvenile rat. The procedure is replicated from previous studies.49,50 Testing consisted of 
two consecutive juvenile presentations periods to an adult subject: period 1 (P1) and period 2 
(P2). At the beginning of P1, one juvenile was placed into the adult home cage and the time 
spent by the adult investigating the juvenile (anogenital sniffing, licking, close pursuing and 
pawing) was recorded manually for 5 min. During P2, the same juvenile and a second, novel 
juvenile were placed in the cage together with the adult, and the times spent by the adult 
investigating each juvenile were measured independently for 3 min. A different pair of 
juvenile rats was presented to each adult tested. Manual scoring was conducted in a blinded 
manner. SND was impaired by the parametric manipulation applied, as there was 30 min 
delay between P1 and P2, and SND was expected to be low in control rats. The influence of 
MP-III-022 (1, 2.5 or 10 mg/kg) on such induced impairment in SND was examined. There 
were five groups of rats which received one of the following treatments 20 min before P1: 
solvent, 1.5 mg/kg diazepam and 1, 2.5 and 10 mg/kg MP-III-022. The amount of time 
investigating familiar (Tf) and novel (Tn) juvenile during P2 was manually scored, and 
discrimination indexes (Tn-Tf/Tn+Tf) was calculated. Total exploration time during P1 and 
P2 was also manually recorded. 
Three-chamber test 
The three-chamber test investigates the ability of the tested animal to discriminate between an 
object and another animal in the sociability trial, as well as to differentiate two animals in the 
social novelty trial. The procedure is replicated from a previous study.51 The test was 
performed in an apparatus consisting of three compartments, one central and two lateral 
chambers, with an overall dimension of 95×50×35 cm. The 10-minute habituation was 
performed in the central chamber immediately before the sociability trial. In the latter trial, an 
object was positioned in one of the lateral chambers, and an animal was placed in the opposite 
lateral chamber. The object was an empty cage identical to that used to enclose the rat in the 
other chamber. The investigation times of the tested rat were recorded. Time spent in each 
chamber, as well as the time spent exploring the novel rat or the novel object, were analyzed 
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automatically during 10 minutes. Immediately thereafter, the social novelty test began with 
introducing an additional, unfamiliar rat. This rat was placed in the empty wire cage. Time 
spent in each chamber and time spent sniffing each rat/wire cage was recorded during 10 
minutes. The rats which did not explore all three chambers during the sociability test were 
excluded from the statistical analysis. Since the social novelty test aims to evaluate the 
preference for social novelty and the formation of social memories, rodents that did not 
interact with both the familiar and the novel rat were also excluded from the analysis. The 
calculated parameters for the three-chamber test were a Sociability Index (SI) and, in an 
analogous manner, a Social Novelty Preference Index (SNI).51,52 
 
Statistics 
All numerical data presented in figures are given as the mean ± SEM. Pharmacokinetic 
parameters were calculated using PK Functions for Microsoft Excel software (by Joel 
Usansky, Atul Desai, and Diane Tang-Liuwere). In SND procedure the discrimination indexes 
were analyzed by one-sample t-test, and exploration times by paired-t test. The data from the 
acquisition days in the Morris water maze were averaged for each rat (total data/total number 
of trials per day) and analyzed using two–way ANOVA with repeated measures (factors: 
Treatment and Days) with Days as the repeated measure. In the case of significant interaction, 
separate one–way ANOVAs were conducted to assess the influence of treatment within 
individual levels of factor Days. The data from the probe test were assessed using one–way 
ANOVA. In SLA test one-way ANOVA (for overall effect) or two-way ANOVA with 
repeated measures (factors: Treatment and Time) with Time as the repeated measure (for 
effect during 5-min bins) were applied. For the binding study, as well as in the PTZ and 
rotarod test, one-way ANOVA were applied. Post hoc comparisons, where applicable, were 
performed using SNK test, with exception of the binding study, where Tukey test was 
applied. Statistical analysis was performed using SigmaPlot 11 (Systat Software Inc., 
Richmond, USA) software. Differences were considered significant when p < 0.05, while 0.1 
> p > 0.05 was considered as a trend toward significance. 
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HPLC and LCMS Spectra 
 
 
 
Figure S1. HPLC total ion chromatogram with associated LC-MS spectrum (positive ion 
mode) of MP-III-022 (Shimadzu Single Quadrupole Mass Spectrometer (2020)). 
433 
 
HRMS Report 
 
Figure S2. High-resolution-Mass spectrum of MP-III-022 (Shimadzu Ion Trap Time-of-
Flight) 
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Figure S3. The effects of 30 mg/kg SH-053-2′F-R-CH3 on (a) latency to platform, (b) total 
distance, (c) distance in the peripheral ring (%) and (d) path efficiency during acquisition 
trials in the water maze. Animals per treatment group were 8. SOL = solvent, SH-053-2′F-R-
CH3 30 = 30 mg/kg SH-053-2′F-R-CH3. The original data used for preparation of the figure 
were published in reference 19. 
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Figure S4. The effects of 30 mg/kg SH-053-2′F-R-CH3 on (a) distance in the target zone (m) 
and (b) distance in the peripheral ring (%) during probe trial in the water maze. Animals per 
treatment group were 8. SOL = solvent, SH-053-2′F-R-CH3 30 = 30 mg/kg SH-053-2′F-R-
CH3. Distance in the target zone (m): t(14) = -0.462, p = 0.651; distance in the peripheral ring 
(%): t(14) = -0.320, p = 0.754. The original data used for preparation of the figure were 
published in reference 19. 
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Table S1: Equilibrium binding constant (KD) for the different receptor subtypes  
α1β3γ2S α2β3γ2S α3β3γ2S α5β3γ2S 
7.2 ± 0.2 nM 2.9 ± 0.6 nM 4.1 ± 0.2 nM 2.2 ± 0.3 nM 
Legend: 
Membranes from HEK-293 cells transfected with the subunit combinations as indicated were 
incubated with various concentrations of 3H-Flunitrazepam in the absence or presence of 
either 5 µM diazepam (to determine unspecific binding). Results were analyzed using the 
equation Y=Bmax*X/(KD+X). KD values are presented as mean values ± SEM from 3-4 
independent experiments performed in duplicates. 
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Table S2. Measured positive modulation of GABA EC3-5 currents by MP-III-022 at rat 
recombinant α1-, α2-, α3,- and α5β3γ2 GABAA receptors 
 
  1 nM 10 nM 100 nM 1 µM 10 µM  
α1 
98 ± 3 100 ± 6 107 ± 3 123 ± 6 185 ± 7 
n=4 
α2 
108 ± 2 109 ± 6 150 ± 18 325 ± 47 454 ± 62 
n=4 
α3 
109 ± 9 107 ± 4 130 ± 8 231 ± 10 429 ± 28 
n=4 
α5  
104 ± 4 154 ± 10 354 ± 19 698 ± 70 825 ± 36 
n= 5 
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Table S3. The approximated % of GABA potentiation, read from Figure 1, for the estimated 
brain free concentrations of SH-053-2′F-R-CH3, in the dose range 10 mg/kg to 200 mg/kg, 
and MP-III-022, in the dose range 1 mg/kg to 10 mg/kg. 
 
 
SH-053-2′F-R-CH3 (dose 
(mg/kg) 
MP-III-022 (dose (mg/kg) 
 10 30  200 1  2.5  10  
Estimated brain free concentration (nmol/kg) 
 29.10 64.40 324.16 6.38 10.34 68.12 
Approximated % of GABA potentiation from Figure… 
α1β3γ2 102.14 108.27 130.99 102.74 104.99 107.25 
α2β3γ2 107.28 122.63 171.10 109.74 114.57 137.96 
α3β3γ2 106.29 120.72 154.70 108.30 111.99 123.74 
α5β3γ2 135.14 165.96 280.16 137.96 158.57 314.31 
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Metabolic stability in rat plasma 
Table S4. Estimated in vitro metabolic stability (total plasma concentration of MP-III-022 or 
SH-053-2′F-R-CH3 in 30, 60, 120 and 240 minutes). Mean ± SEM, n = 3 
MP-III-022 µM % 
SH-053-
2′F-R-
CH3 
µM % 
0 min 0.5556 100 0 min 0.5556 100 
30 min 0.5402 ± 0.0146 97.23 30 min 0.4258 ± 0.0042 76.64 
60 min 0.5403 ± 0.0193 97.25 60 min 0.3487 ± 0.0040 62.77 
120 min 0.5472 ± 0.0007 98.50 120 min 0.2126 ± 0.0036 38.27 
240 min 0.5374 ± 0.0063 96.74 240 min 0.0291 ± 0.0023 5.24 
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Table S5. The effects of 30 mg/kg SH-053-2′F-R-CH3 on the rat’s behavior in the MWM. 
Two-way repeated measures ANOVA and overall post hoc results for latency to platform (s), 
total distance (m), distance swam in the peripheral annulus (%) and path efficiency. SOL = 
solvent; SH = SH-053-2′F-R-CH3; ns = not significant.  
Factor 
Latency 
(s) 
Total distance 
(m) 
Distance in the 
peripheral 
ring (%) 
Path efficiency 
Treatment: F(1,14) 
p 
1.478 
0.244 
1.717 
0.211 
5.804 
0.030 
1.819 
0.199 
Days: F(4,56) 
p 
16.205 
< 0.001 
12.385 
< 0.001 
7.634 
< 0.001 
10.177 
< 0.001 
Interaction: F(4,56) 
p 
0.233 
0.919 
0.150 
0.962 
2.066 
0.097 
0.519 
0.722 
SNK post hoc for Treatment 
SOL vs. 30 mg/kg SH - - 0.030 - 
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Table S6. The raw data obtained in the three-chamber test 
YELLOW = excluded from T2 (sociability test) 
RED = excluded from T3 (social cognition test) 
MP-III-022 = 10 mg/kg MP-III-022, KET 15 = 15 mg/kg ketamine, SOL = solvent 
Sociability data 
Treatment Distance (m) Time RAT (s) Time OBJECT (s) Chamber RAT (s) Chamber OBJECT (s) Central chamber (s) 
KET 15 + MP-III-022 4.218 513.7 0 536.9 0 63.1 
KET 15 + MP-III-022 16.107 95.8 427.9 119.9 457.3 22.8 
KET 15 + MP-III-022 10.686 0 262.7 0 304.3 295.7 
KET 15 + MP-III-022 21.58 131.9 57.4 254.4 107.2 238.5 
KET 15 + MP-III-022 10.966 135.7 308.7 152.4 343.5 104.1 
KET 15 + MP-III-022 14.541 509.7 15.8 533 21.9 45.1 
KET 15 + MP-III-022 21.416 121.1 246.7 199.8 326 74.2 
KET 15 + MP-III-022 42.499 230.3 197.7 263.2 250.7 86.1 
KET 15 + MP-III-022 16.968 476.4 0 579.8 0 20.2 
KET 15 + MP-III-022 4.072 0 0 0 0 600 
KET 15 + MP-III-022 7.713 514 0 560.5 0 39.5 
KET 15 + MP-III-022 36.61 166.3 92.8 231.2 166.4 202.5 
KET 15 + MP-III-022 17.984 144 125.6 202.5 190.5 207.1 
KET 15 + MP-III-022 8.578 83.2 0 319.1 0 280.9 
KET 15 + MP-III-022 15.291 32.6 230.8 41 264.6 294.4 
KET 15 + MP-III-022 37.911 113.7 157.9 142.4 198.2 259.4 
KET 15 + MP-III-022 32.702 175.3 114.7 227.1 153.6 219.3 
KET 15 + SOL 6.338 11.1 35.3 13.6 48.9 537.5 
KET 15 + SOL 9.036 229.6 24.1 295.1 27.5 277.3 
KET 15 + SOL 10.092 262.7 233.1 313 258.8 28.3 
KET 15 + SOL 7.377 0 0 1.7 0 598.3 
KET 15 + SOL 11.279 260.1 0 296.9 0 303.1 
KET 15 + SOL 28.288 159.2 56.3 196.2 111.5 292.3 
KET 15 + SOL 17.606 147.6 135.6 183.5 207.2 209.3 
KET 15 + SOL 9.096 0 0 6.5 0 593.5 
KET 15 + SOL 16.866 154.8 174.9 210.9 273.2 115.9 
KET 15 + SOL 26.22 150.7 121.8 215 202.1 182.8 
KET 15 + SOL 15.671 416 0 547.9 0 52.1 
KET 15 + SOL 6.89 42.6 41.7 67.7 63.4 468.9 
KET 15 + SOL 3.992 0 0 0 0 600 
KET 15 + SOL 23.77 134.5 77.1 245.9 191.2 162.8 
SAL + MP-III-022 12.05 81.1 51.5 119.9 76.8 403.3 
SAL + MP-III-022 0.105 0 0 0 0 600 
SAL + MP-III-022 1.41 0 0 0 0 600 
SAL + MP-III-022 12.009 0 362.6 0 420.5 179.5 
SAL + MP-III-022 9.395 82.2 60.7 146.4 92.8 360.8 
SAL + MP-III-022 29.375 164.1 119 213.2 162.2 224.6 
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SAL + MP-III-022 19.902 158.2 88.4 270.6 163.5 165.9 
SAL + MP-III-022 11.167 99.7 38.1 148.4 49.5 402.2 
SAL + MP-III-022 19.627 28.4 314.4 55.2 390.4 154.4 
SAL + MP-III-022 5.805 47.3 39.2 51.4 72.5 476.1 
SAL + MP-III-022 22.779 123.9 98.4 181.4 146.3 272.3 
SAL + MP-III-022 12.731 86 55.3 103.6 88 408.3 
SAL + MP-III-022 19.011 0 278.1 0 411.3 188.7 
SAL + MP-III-022 25.034 169.7 31.9 333.7 77.4 188.9 
SAL + MP-III-022 14.893 88.4 41.6 105.3 75 419.7 
SAL + SOL 27.178 273.8 55 384.6 100.5 115 
SAL + SOL 22.189 175.3 51.2 234.3 92.6 273.1 
SAL + SOL 18.982 176.5 139.8 233 240.8 126.3 
SAL + SOL 28.474 172.7 100.8 272.7 184.2 143.1 
SAL + SOL 34.285 163.4 111.6 249.3 180.4 170.3 
SAL + SOL 30.795 140.5 106.5 230.4 177.1 192.5 
SAL + SOL 35.095 175.5 37.3 280.2 74.3 245.4 
SAL + SOL 25.778 224.1 105.9 314.5 165.4 120.1 
SAL + SOL 15.227 0 270.4 0 423.2 176.8 
SAL + SOL 24.576 172.3 126.6 281.3 197.9 120.7 
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Social cognition data 
Treatment Distance (m) Time NEW RAT (s) Time OLD RAT (s) Chamber NEW RAT (s) Chamber OLD RAT (s) Central chamber (s) 
KET 15 + MP-III-022 32.709 84.9 182 118 250.2 231.8 
KET 15 + MP-III-022 12.05 537.2 0 575.8 0.5 23.8 
KET 15 + MP-III-022 3.916 438.3 0 472.6 2.1 125.3 
KET 15 + MP-III-022 21.205 75.6 84.2 175.8 161.8 262.4 
KET 15 + MP-III-022 15.075 0 403.1 0 442.6 157.4 
KET 15 + MP-III-022 9.246 0 545.4 0 588.3 11.7 
KET 15 + MP-III-022 11.018 83.9 334 119.4 410.1 70.5 
KET 15 + MP-III-022 17.87 256.2 157.2 306.1 186.4 107.5 
KET 15 + MP-III-022 16.841 0 564.5 0 593.9 6.1 
KET 15 + MP-III-022 9.375 35.3 0 35.9 0 564.1 
KET 15 + MP-III-022 4.265 0 526.7 0 531.4 68.6 
KET 15 + MP-III-022 20.894 215.5 124.4 276.5 153.6 169.9 
KET 15 + MP-III-022 14.718 16.8 185 60.4 370 169.6 
KET 15 + MP-III-022 20.938 21.4 1.4 87.4 41.1 471.4 
KET 15 + MP-III-022 9.553 294.8 76.3 344.7 79.6 175.7 
KET 15 + MP-III-022 45.659 73 68.3 88.7 92.5 418.8 
KET 15 + MP-III-022 24.058 85.3 178.4 162.8 251.7 185.4 
KET 15 + SOL 23.125 122.3 178.6 210.4 271.9 117.7 
KET 15 + SOL 26.755 66.1 90.2 158.6 232.4 209 
KET 15 + SOL 4.058 99.5 456.5 124.8 458.4 16.8 
KET 15 + SOL 5.463 18 0 21.9 0 578.1 
KET 15 + SOL 3.895 0 586.7 0 598.5 1.5 
KET 15 + SOL 15.287 65.2 177.9 88.8 235.6 275.6 
KET 15 + SOL 19.23 298.7 88.2 320.1 120.5 159.4 
KET 15 + SOL 14.618 198 21.6 232.4 26.6 341 
KET 15 + SOL 9.795 207.1 54 344.5 84.3 171.2 
KET 15 + SOL 14.656 65.8 108 196.7 146.9 256.4 
KET 15 + SOL 12.412 134.1 52.2 293.1 131.4 175.5 
KET 15 + SOL 6.503 58.6 0 96.5 0 503.5 
KET 15 + SOL 0.02 0 0 0 0 1.9 
KET 15 + SOL 16.954 40.6 149.3 157.1 288.9 154 
SAL + MP-III-022 8.296 40.3 52.3 105.1 218.7 276.3 
SAL + MP-III-022 4.093 0 20.6 0 86.7 513.3 
SAL + MP-III-022 8.131 0.8 0.6 8.7 13.6 577.7 
SAL + MP-III-022 2.018 0 0 0 0 600 
SAL + MP-III-022 11.703 137.7 221.1 211.7 308.8 79.4 
SAL + MP-III-022 18.238 134.5 109.9 201.9 186.9 211.3 
SAL + MP-III-022 5.09 282.1 25.3 306.8 35.3 258 
SAL + MP-III-022 2.12 495.6 0 496.7 0 103.3 
SAL + MP-III-022 9.631 449.1 16.6 480.6 27.4 92 
SAL + MP-III-022 8.486 432.5 0 445.7 5.4 148.9 
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SAL + MP-III-022 119.499 0 0 202.3 101.7 296.1 
SAL + MP-III-022 22.394 63.8 58.5 165.8 141.6 292.7 
SAL + MP-III-022 11.452 32.9 88.8 67.6 151 381.4 
SAL + MP-III-022 20.354 108.6 21.6 224.9 108.7 266.4 
SAL + MP-III-022 13.514 24 62.9 94.7 271.2 234.2 
SAL + SOL 21.809 121.5 122.9 263.5 177.9 158.6 
SAL + SOL 10.42 67.3 52.3 139.3 178.7 282 
SAL + SOL 9.415 398.3 0 593.2 0 6.8 
SAL + SOL 16.768 164.3 144.9 211.6 216 172.4 
SAL + SOL 21.308 152.4 135.5 256.3 214.5 129.2 
SAL + SOL 29.802 63.6 133.4 152.4 234.5 213.1 
SAL + SOL 22.769 115.5 109.7 182.6 202.9 214.5 
SAL + SOL 21.576 144.2 170.1 228.4 249.9 121.7 
SAL + SOL 12.958 4.6 2.9 9.2 6.3 584.5 
SAL + SOL 17.74 78.6 18.4 209.5 116.7 273.8 
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APPENDIX G. Manuscript Prepared by Etienne Sibille, et al. on the Anti-
Depressant Effects of SH-053-2'F-R-CH3. 
 
Structure: 
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Highlights 
 Acute and chronic α5-PAM reduces anxiety- and depressive-like behavior induced by 
chronic mild stress in female mice 
 Neither acute nor chronic α5-PAM treatment affected anxiety- and depressive-like 
behavior induced by chronic mild stress in male mice.  
 Sex differences were not explained by differential pharmacokinetic or dose effects.  
 α5-PAM treatment increased Gabra5 expression in the hippocampus and prelimbic cortex 
of female, but not male mice.  
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Abstract    
Current treatments for Major Depressive Disorder (MDD) acting on monoaminergic systems take 
weeks to achieve a therapeutic effect and have poor response and low remission rates. Recent 
research has implicated the GABAergic system in the pathophysiology of depression, including 
deficits in interneurons targeting the dendritic compartment of pyramidal cells. The present study 
evaluates whether SH-053-2'F-R-CH3 (denoted "α5-PAM"), a positive allosteric modulator 
selective for α5-subunit containing GABAA receptors found predominantly on pyramidal cell 
dendrites, has anxiolytic- and/or antidepressant-like-like effects. Female and male C57BL6/J mice 
were exposed to unpredictable chronic mild stress (UCMS) for 10 weeks and treated with α5-
PAM acutely (30 minutes prior to assessing behavior) or chronically (weeks 3-10) before being 
assessed behaviorally (weeks 7-10). Acute and chronic α5-PAM treatments produce a pattern of 
decreased anxiety- and depressive-like behaviors (together denoted as “behavioral emotionality”) 
across various tests (elevated plus maze, open field, novelty suppressed feeding, and cookie test) 
only in females. Behavioral Z-scores across tests confirmed that both acute and chronic α5-PAM 
treatments produce significant decreases in behavioral emotionality in female but not male mice. 
Findings were replicated in independent cohorts. The characteristic behavioral responses to α5-
PAM could not be accounted for by the observed differences in brain disposition between female 
and male mice. In mice exposed to UCMS, expression of the Gabra5 gene was increased in the 
frontal cortex after acute treatment and in hippocampus after chronic treatment with α5-PAM in 
females only. Together, we showed that both, acute and chronic positive modulation of α5 
subunit-containing GABAA receptors may elicit anxiolytic- and antidepressant-like effects in a sex-
dependent manner, suggesting novel therapeutic modalities. 
 
Keywords: Gabra5, alpha5, depression, interneurons, PAM, GABA 
 
1. Introduction 
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 Major depressive disorder (MDD) is a debilitating disorder characterized by low mood, 
anhedonia, physiological disturbance, and increased self-focus and rumination (Ferrari et al, 
2013; Northoff and Sibille, 2014). Lifetime prevalence of MDD is higher in females than in males. 
Factors mediating this increase are still being investigated (Seney et al, 2013). Adding to the 
disease burden of MDD is the relative ineffectiveness of conventional antidepressant medications 
(roughly 30% remission rates), most of which act via the monoaminergic system (e.g. selective 
serotonin reuptake inhibitors – SSRIs) (Cipriani et al, 2009; Rush, 2010). Although drugs with 
rapid acting antidepressant effects have shown promise in preclinical studies and effectiveness 
in treating severely depressed individuals (Li et al, 2010; Zarate et al, 2012a; Zarate et al, 2012b) 
no existing antidepressant drug directly addresses the pathology observed in the depressed brain, 
providing a potential explanation for the limited efficacy of current antidepressants. 
 Converging evidence has long suggested a role for the inhibitory neurotransmitter gamma-
amino butyric acid (GABA) in the pathophysiology of depression (Krystal et al, 2002; Luscher et 
al, 2011). Studies using magnetic resonance spectroscopy show decreases in GABA levels in 
depression in brain regions critical for emotion regulation (dorsolateral prefrontal cortex (dlPFC), 
subgenual anterior cingulate cortex (sgACC)) (Bajbouj et al, 2006; Sanacora et al, 2004; 
Sanacora et al, 1999). At the cellular level, reduced density of calbindin-positive interneurons 
were reported in frontal cortex (Rajkowska et al, 2007). At the molecular level, we previously 
reported alterations in GABA-related gene expression in dlPFC, sgACC, and amygdala (Guilloux 
et al, 2012; Seney et al, 2014; Sibille et al, 2010; Tripp et al, 2011). Preclinical evidence has also 
implicated the GABA system in the development of anxiety- and depressive-like behaviors. Mice 
with reduced GABA signaling exhibit increased depressive-like behavior (Earnheart et al, 2007; 
Shen et al, 2010). Further, chronic stress paradigms that produce anxiety- and depressive-like 
behavior in rodents, cause GABAergic deficits in the frontal cortex, including decreases in major 
GABA synthesizing enzymes (Gilabert-Juan et al, 2013; Herman and Larson, 2001). 
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Interestingly, this alteration in GABAergic signaling in MDD subjects appears to be 
restricted to interneuron subtypes that project to the dendritic compartment of pyramidal cells, 
and that are characterized by the expression of somatostatin (SST), neuropeptide Y (NPY) and 
cortistatin (CORT) neuropeptides (and that co-express calbindin). Cells targeting the perisomatic 
compartment, such as parvalbumin (PV)-or cholecystokinin (CCK)- expressing GABA neurons 
appear only sparingly affected (Guilloux et al, 2012; Sibille et al, 2010; Tripp et al, 2011). Recent 
work in mice has demonstrated that cortical SST cells are also affected in the unpredictable 
chronic mild stress (UCMS) model which induces elevated behavioral emotionality, and that 
UCMS-induced anxiety- and depressive-like behavior can re recapitulated in mice lacking SST 
(Lin and Sibille, 2015). Together these findings suggest a causal link between low SST expression 
and elevated behavioral emotionality. The UCMS model has been used to assess potential drug 
targets for treating human depression, as it has good construct (stress precipitates the UCMS 
phenotype as well as MDD episodes and disrupts similar biological pathways), predictive (chronic 
treatment with SSRIs reverses the UCMS phenotype), and face validity (behavioral features 
replicated) (Edgar et al, 2011; Isingrini et al, 2012; Lin et al, 2015). 
 Importantly, the structured anatomical distribution of GABAA receptors in the cortex 
provides a potential means of directly addressing GABAergic dysfunction within a specific 
compartment. Specifically, α5-containing GABAA receptors are predominantly expressed on 
dendritic branches of pyramidal cells where they mediate dendritic inhibition in vitro (Ali and 
Thomson, 2008; Wainwright et al, 2000), whereas α1 and α2 containing GABAA receptors are 
found near the soma (Packer et al, 2013). This anatomical proximity suggests a functional link 
between dendrite-preferring SST cells and the extra-synaptic α5 containing GABAA receptors that 
mediate tonic inhibition in the cortex (Bonin et al, 2007; Brickley and Mody, 2012). Knowing that 
GABA signaling is decreased in MDD and similarly in the rodent UCMS model, we set out to test 
whether increasing GABAergic tone specifically at the dendritic compartment may reverse UCMS-
induced anxiety- and depressive-like behaviors. To directly test this hypothesis, we utilized the 
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GABAA receptor positive allosteric modulator (PAM), SH-053-2'F-R-CH3 (denoted further as α5-
PAM), which has high affinity for GABAA receptors containing the α5 subunit (Ki=95.2nM) and 
lower affinity for GABAA receptors containing the α1- (Ki=759.1nM), α2- (Ki=948.2nM), and α3-
subunits (Ki=768.8nM) (Savic et al, 2010). Based on the hypothesis that low GABA activity at the 
dendritic compartment following UCMS is involved in the expression of anxiety- and depressive-
like behaviors, we predicted that enhancing GABA tone with α5-PAM would reduce UCMS-
induced anxiety- and depressive-like behavior in female and male mice. 
 
2. Methods 
2.1. Animals.  C57BL/6J mice (Jackson Laboratories, Bar Harbor, Maine USA) were housed 
under standard conditions with a 12/12 light/dark cycle and ad libitum access to food and water 
in accordance with the University of Pittsburgh Institutional Animal Care and Use Committee.  
UCMS. Mice underwent 6 weeks of UCMS. Briefly, animals were exposed to 2-3 mild stressors 
each day throughout the light/dark cycle, including wet bedding, brief restraint, forced bath, no 
bedding, reduced space, and predator odor over a period of several weeks (see Lin et al. 2015 
and Edgar et al., 2011). In one experiment, UCMS was augmented with single-cage isolation 
starting at the fourth week until sacrifice.  
2.2. Drug treatment. Beginning on the third week of UCMS and continuing for ~50 days (including 
time for behavioral tests) until sacrifice, mice received daily i.p injections of vehicle (85% ddH2O, 
14% propylene glycol, 1% Tween 80) or 30mg/kg SH-053-2'F-R-CH3 (α5-PAM; synthesized in 
the laboratory of Dr. James M Cook) in a volume of 10mg/mL at least two hours prior to behavioral 
testing. Thirty minutes prior to behavioral testing, all animals received a second injection of either 
vehicle (for chronic α5-PAM treated animals and UCMS-vehicle treated animals) or α5-PAM 
acutely.  
2.3. Pharmacokinetic study of α5-PAM. Male and female C57BL/6J (Military Farm, Belgrade, 
Serbia) were divided into six groups corresponding to predetermined time intervals following a 
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single 30mg/kg α5-PAM injection (5, 10, 20, 40, 60 and 180 min). Blood samples were collected 
in heparinized syringes via cardiac puncture of mice anesthetized with ketamine (100mg/kg i.p.; 
10% Ketamidor, Richter Pharma Ag, Wels, Austria), and centrifuged at 2500rpm for 10min to 
obtain plasma. Thereafter, mice were decapitated and brains were weighed, homogenized in 2mL 
of methanol and centrifuged at 6000rpm for 20min. To determine the concentration of α5-PAM in 
plasma and supernatants of brain tissue homogenates, α5-PAM was extracted by solid phase 
extraction, using Oasis HLB cartridges (Waters Corporation, Milford, Massachusetts). The 
procedure of sample preparation and determination of α5-PAM by ultraperformance liquid 
chromatography–tandem mass spectrometry (UPLC–MS/MS) with Thermo Scientific Accela 600 
UPLC system connected to a Thermo Scientific TSQ Quantum Access MAX triple quadrupole 
mass spectrometer (Thermo Fisher Scientific, San Jose, California) equipped with electrospray 
ionization (ESI) source, is described in (Obradovic et al, 2014). 
2.4. Plasma protein and brain tissue binding studies. The rapid equilibrium dialysis assay used to 
determine free fraction of α5-PAM in mouse plasma and brain tissue was the same as in 
(Obradovic et al, 2014). 
2.5. Behavioral testing. After five weeks of UCMS, animals were assessed in a battery of 
behavioral tests including (each test separated by 24 hours, UCMS continued throughout 
behavioral testing): Elevated plus maze: under red light, animals were placed on a plus maze with 
two open and two closed arms (30x5cm). Number of entries into all arms as well as the time spent 
in the open arms was recorded for 10min. Open field test: The open field test was conducted in a 
43x43cm arena under bright (800lux) light. Using AnyMaze software (Stoelting, Wood Dale, IL 
USA), the center 50% of the arena was identified and animals were tracked for 10min. Novelty 
suppressed feeding test: Mice were food deprived for 24hours the day before testing. Testing 
occurred in brightly lit (~1000lux) open field arenas covered in bedding. A normal food pellet was 
placed into the brightly lit center and the latency for an animal to approach and bite the pellet was 
recorded over a 12min session. Immediately following the session, animals were placed into their 
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home cage and allowed to eat a weighed food pellet to assess hunger drive. Cookie test: The 
cookie test apparatus contains three identically sized chambers (40x20x20cm) separated by two 
offset dividers. The outer walls of each chamber were clear and the only difference between each 
was the color of the divider, with one divider shaded white and the other black. One week prior to 
experimentation, mice were habituated in their home cage to a piece (2±1g) of Keebler Fudge 
Stripe Cookie (Kellogg's Company, Battle Creek, MI USA). On the first and second day of testing, 
a piece of cookie (2±1g) was placed into the chamber separated by the black divider. Mice were 
then placed into the opposing chamber separated by the white divider and monitored for 10min. 
The latency for each mouse to bite the cookie was recorded. Data from day two of the cookie test 
are presented, after mice acclimated to the anxiogenic environment and their behavior is driven 
more prominently by reward-seeking, resulting in a decrease in latency to bite (Isingrini et al, 
2011; Soumier and Sibille, 2014).  
2.6. Tissue samples and micropunch procedure. 24hours after the final behavioral test, mice were 
injected with either an acute dose of α5-PAM or vehicle 30min prior to rapid perfusion (2ml 
4%PFA). Brains were rapidly dissected and flash frozen on dry ice and 160μm thick coronal 
sections were obtained using a cryostat. The prelimbic cortex and dorsal hippocampus was 
dissected with a 1mm diameter micropunch and tissue samples were then frozen at -80 ̊C. Total 
RNA was extracted with an RNAeasy FFPE kit (Qiagen, Germantown, MD USA). RNA 
concentration and quality (RIN) were then assessed using the Agilent RNA6000 Pico-Kit and 
Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA USA).  
2.7. Real-time quantitative PCR. ~90ng of total RNA was used to generate cDNA via the qScript™ 
cDNA Supermix synthesis kit (Quanta Biosciences, Gaithersburg, MD USA). Real-time 
quantitative polymerase chain (qPCR) reactions were carried out using SYBR green fluorescence 
signal (Invitrogen, Carlsbad, CA USA) and an Opticon Monitor DNA Engine (Bio-Rad, Berkeley, 
CA USA). Gene of interest was Gabra5, coding for the α5-subunit of the GABAA receptor. 
Samples were run in triplicate and ΔCt values were calculated by comparing the Ct values of 
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Gabra5 to the geometric mean of two reference genes, β-Actin and glyceraldehyde 3-phosphate 
dehydrogenase (Gapdh). Arbitrary signal intensity was calculated as 2-ΔCt*10000.  
2.8. Antibodies. The following antibodies and their dilutions were used in this study: rabbit 
polyclonal anti-α5 (1:750; ThermoFisher Scientific, MA, USA), rabbit monoclonal anti-β1-N+/K+-
ATPase (NK-ATPase) (1:1000; Abcam, MA, USA), and mouse monoclonal anti-β-actin (1:100; 
Abcam, MA, USA). 
2.9. Surface biotinylation. Dissected hippocampi were processed as described in (Pabba et al, 
2014) with minor modifications.  
2.10. Western blotting. Western blotting was performed using 5μg of protein resolved on 8% SDS-
PAGE and transferred onto PVDF membranes and developed using IR-Dye conjugated 
secondary antibody and detection using LI-COR (NE, USA). Quantification of bands was 
performed using Image Studio™ Software (LI-COR, NE, USA). We analyzed α5 surface 
biotinylation in vehicle versus drug treated mice (N=6 females and 4 males per group). Total α5 
band intensities were normalized to β-actin, whereas surface α5 band intensities were normalized 
to NK-ATPase.  
2.11. Z-score generation & statistical analysis. To assess the consistency of effects of stress and 
drug treatment on overall anxiety- and depressive-like behavior, we calculated test-specific z-
scores. These normalized scores integrate measures of behavioral emotionality over time and 
tests, yielding a combined measure of the UCMS-induced behavioral syndrome. For details, see 
(Guilloux et al, 2011).  Behavioral and gene expression data were analyzed with a two-way (sex 
x treatment) or one-way analysis of variance (ANOVA), unless otherwise noted. Fisher's LSD 
post-hoc test was used to determine group differences only following a significant main effect or 
interaction in the ANOVA model. In certain tests, a priori predictions for UCMS versus non-
stressed (NS) conditions lead to unpaired two-tailed t-tests being conducted. For western blot, 
statistical significance was determined using a two-tailed Student's t-test. 
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3. Results 
3.1. Systemic administration of α5-PAM leads to rapid increase in brain levels in female and male 
mice. 
 Free concentrations of α5-PAM were calculated by multiplying the total plasma and brain 
concentrations with the appropriate free fractions (7.44% for plasma and 2.73% for brain tissue) 
determined by rapid equilibrium dialysis. Two-way repeated measure ANOVA for total brain 
concentration revealed a statistically significant difference between female and male mice 
[F(1,4)=7.83, p<0.05], and between time points [F(5,20)=6.89, p<0.001] with no significant 
interaction [F(5,20)=1.05, p>0.05]. α5-PAM plasma concentration were higher in female than 
male mice [F(1,4)=16.54; p<0.05] with a significant effect of time [F(5,20)=12.27, p<0.001] and 
no interaction [F(5,20)=1.02, p>0.05]. Post-hoc comparisons revealed significant differences 
between female and male mice in plasma Cmax [t(4)=-3.04, p<0.05, Fig.1], confirming that higher 
concentrations were obtained in female mice. Furthermore, the AUC0-3 in brain is approximately 
1.25X higher for females (4910.13±1032.02) than males (3944.49±560.30), suggesting that a 
cumulative 25% more ligand available in brain of female mice, after the same dose. However, at 
30min, the amount of ligand in the brain of male and female mice was not statistically different 
(Fig.1). For this reason, we initially chose the 30mg/kg dose and 30min time point for evaluating 
the acute behavioral effects of α5-PAM in male and female mice.  
 
3.2. α5-PAM reduces the stress-induced elevated anxiety- and anhedonia-like behaviors in 
female, but not male mice 
 We first sought to examine whether acute or chronic α5-PAM treatment would reduce 
anxiety- and depressive- like behaviors induced by UCMS in female and male mice. Individual 
OFT and EPM tests revealed no significant group differences, although trends were observed for 
acute and chronic α5-PAM treatment to reduce anxiety-like behavior in the EPM in female mice, 
whereas chronic treatment in male mice produced a potential anxiogenic response (Fig.S1). 
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There was a positive correlation between individual EPM and OFT anxiety measures separately 
in males (blue linear fit; R=0.411, F(28)=5.721, p<0.05) and females (red linear fit; R=0.421, 
F(21)=4.527, p<0.05), suggesting consistent behavior across tests. Therefore we calculated Z-
anxiety scores encompassing both tests for each mouse (Fig.2A) and used those measures to 
assess group differences. ANOVA revealed a significant main effect of sex [F(1,48)=14.10, 
p<0.001] and an interaction between sex and treatment [F(2,48)=3.73, p<0.05]. Pairwise 
comparisons indicate that in female mice, both acute (p<0.05) and chronic (p<0.05) α5-PAM 
administration consistently decreased anxiety-like behaviors. By contrast, no difference in anxiety 
Z-scores were detected following α5-PAM in male mice (Fig.2B; p>0.05).  
The NSF and cookie tests were used to measure depressive-like behaviors. The cookie 
test also includes an anhedonia-like component. In the NSF, we again observed a significant 
interaction between sex and treatment [F(2,48)=3.930, p<0.05] and a similar pattern of behavior 
in female mice, with acute (p<0.01) and chronic (p<0.01) α5-PAM treatment reducing latency to 
bite the food pellet compared to UCMS-vehicle treated animals. Again, no effect of either acute 
or chronic α5-PAM was observed in male mice (Fig.2C; p>0.05). In the cookie test, two-way 
ANOVA indicated a significant main effect of treatment [F(2,48)=3.504, p<0.05]. Follow-up 
comparisons uncovered a significant decrease in latency to bite the cookie in female mice 
following chronic α5-PAM administration (p<0.01) and a trend for acute treatment to reduce 
latency to bite (p=0.086). No significant difference in latency to bite was observed in male mice 
after acute or chronic α5-PAM treatment (Fig.3D).  
Neither sex [F(1,48)=1.344, p>0.05] nor α5-PAM treatment [F(2,48)=1.721,p>0.05] altered 
the percentage of weight lost after 24 hours of food deprivation prior to the NSF test with no 
interaction between the two factors (Fig.3E; F(2,48)=1.775, p>0.05). Likewise, there was no effect 
of treatment on the amount of normal chow consumed in the home cage eight minutes after the 
NSF [Fig.3F; F(2,48)=1.441, p>0.05], though males did consume more relative to females 
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[F(1,48)=4.061, p<0.05]. Together, this suggests that differences in latency to bite are not due to 
a non-specific effect of treatment on hunger.  
Although not statistically significant at 30min, pharmacokinetic data indicate greater 
accumulation of α5-PAM in the brain of female compared to male mice during the first 30min post 
injection (Fig.1). Therefore we tested a 25% higher dose (37.5mg/kg) in males. We found it also 
failed to reduce UCMS-induced anxiety- and anhedonia-/depressive-like behavior (Fig.S2). 
Finally, for locomotor activity, a two-way ANOVA revealed no significant effect of sex [Fig.S1E; 
F(1,48)=1.747, p>0.05] or treatment [F(2,47)=2.94, p<0.05], and no interaction [F(2,48)=1.36, 
p>0.05] between the two factors.  
Together, these data indicate that acute and chronic treatments with α5-PAM result in a 
rapid reduction in stress-induced anxiety-like and anhedonia-like behaviors in female but not in 
male mice, without locomotion side–effects. 
 
3.3. α5-PAM reduces UCMS-induced emotionality-like behavior in female mice to control non-
stressed levels 
 The first studies tested whether treatment with α5-PAM has anxiolytic- or antidepressant-
like activity in UCMS-exposed mice. We next sought to confirm these findings in an independent 
cohort of female mice, and further test whether acute or chronic treatment with α5-PAM could 
reverse UCMS-induced emotionality behaviors to levels measured in non-stressed control mice. 
In the EPM, no significant effect of either stress or treatment was found for time spent in the open 
arms [Fig.3A; F(3,66)=2.416, p>0.05]. A significant effect of treatment was observed in the 
percentage of crosses an animal made into the open arms [F(3,66)=5.069, p<0.01]. Pairwise 
comparisons indicate that UCMS-vehicle treated animals spent a smaller percentage of time in 
the open arms compared to non-stressed vehicle animals (Fig.3B; p<0.001). In the OFT, mice 
treated chronically with α5-PAM spent more time (Fig.3C; p<0.001) and had a higher percentage 
of their total distance traveled (Fig.3D; p<0.01) in the center of the arena compared to vehicle-
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treated UCMS-exposed animals. A trend toward an increase in time spent in the center was also 
observed following acute α5-PAM treatment (Fig.3C; p=0.085).  
 In the NSF test, a significant effect of treatment was observed in the latency to bite the 
food pellet [F(3,66)=7.261, p<0.001]. Pairwise comparisons indicate that UCMS-vehicle treated 
animals took longer to bite the food pellet than non-stressed vehicle animals (p=0.010), and that 
both acute (p<0.001) and chronic (p<0.01) α5-PAM treatments reduced the latency to bite 
compared to UCMS-vehicle mice (Fig.3E). In the cookie test, there was a significant effect of 
treatment [F(3,66)=3.065, p<0.05] with post hoc comparisons revealing both acute (p<0.05) and 
chronic (p<0.05) α5-PAM treatment significantly reduced the latency to bite the cookie (Fig.3F). 
An overall Z-score was then calculated to assess the consistency of behaviors across tests. An 
effect of treatment on Z-emotionality score [F(3,66)=7.125, p<0.001] was observed, with pairwise 
comparisons highlighting an increase in emotionality behavior of UCMS-vehicle treated animals 
compared to non-stressed vehicle animals (p<0.001). Acute (p<0.001) and chronic (p<0.001) α5-
PAM treatment significantly reduced Z-emotionality scores compared to the UCMS-vehicle group, 
hence confirming the prior results in female mice (Fig.2). Neither group were statistically different 
from the non-stressed vehicle group (Fig.3G; p>0.05). 
 
3.4. α5-PAM fails to reduce anxiety- and depressive-like behaviors induced by combined isolation 
housing and UCMS in male mice 
 Given the inherent variability of the UCMS paradigm and the fact that the UCMS-induced 
phenotype can be more robust in female compared to male mice (Guilloux et al, 2011), we 
conducted an experiment in which male mice were single-housed during the final two weeks of 
UCMS, in order to potentiate the anxiety- and depressive-like UCMS-induced phenotypes (Ma et 
al, 2011). We detected a moderate positive correlation between Z-anxiety scores in these two 
tests (Fig.4A; R=0.273, F(34)=2.747, p=0.11), which combined show that UCMS-exposed and 
single–housed male mice exhibited a nearly-significant trend toward elevated anxiety-like 
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behavior (Fig.4B; t(22)=1.619, p=0.06). The combination of UCMS and social isolation also 
increased latency to bite a food pellet in the NSF (Fig.4C; t(22)=2.088, p<0.05), and latency to 
bite in the cookie test (Fig.4D; t(22)=2.075, p<0.05) relative to non-stressed vehicle-treated 
animals. Consistent with our prior observations, chronic treatment with α5-PAM did not alter the 
UCMS-induced behavioral phenotype of male mice in either the EPM, OFT, NSF or cookie test 
(Fig.4A-D; p>0.05). Emotionality z-scores indicated that combined UCMS and isolation housing 
robustly increases emotionality behavior in male mice compared to non-stressed controls (Fig.4E; 
t(22)=3.101, p<0.01), and confirmed the lack of effect of  chronic α5-PAM treatment in male mice 
(p>0.05). 
 
3.5. α5-PAM administration upregulates expression of the Gabra5 transcript in frontal cortex and 
hippocampus of female mice, but does not alter total or surface hippocampal Gabra5 protein 
levels   
To evaluate the possibility that differing α5-subunit expression at baseline might explain 
the sex-specific behavioral effects of treatment, we assessed levels of Gabra5 gene and protein 
expression within the frontal cortex and hippocampus of treated and untreated UCMS-exposed 
mice. Results show no difference in expression in either the prelimbic cortex or hippocampus as 
a factor of sex following UCMS exposure (Fig.5A-B, black bars; p>0.05). In frontal cortex, we 
observed a significant interaction between sex and treatment [F(2,32)=3.508, p<0.05], with post 
hoc comparisons indicating that acute α5-PAM treatment significantly increased Gabra5 transcript 
expression in female mice (Fig.5A; p<0.01). No effect of chronic treatment was observed in male 
or female mice, though a non-significant increase was observed in female mice relative to vehicle 
treatment (p=0.11). In hippocampus, we again observed an interaction between sex and 
treatment [F(2,26)=4.45, p<0.05], with pairwise comparisons highlighting an increase in Gabra5 
expression in females after chronic α5-PAM treatment (Fig.5B; p<0.01). No changes in Gabra5 
expression were observed in males after either acute or chronic α5-PAM treatment (p>0.05). We 
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next sought to determine whether changes in RNA expression corresponded to Gabra5 protein 
levels. We focused on the hippocampus due to high α5 levels in that region. We detected no 
difference in either total or surface Gabra5 protein expression following either acute or chronic 
α5-PAM treatment in female (Fig.6A-B; p>0.05) or male mice (Fig.6C-D; p>0.05).  
 
4. Discussion 
4.1. Treatment with α5-PAM reduces anxiety- and anhedonia-/depressive-like behavior in female, 
but not male mice 
We demonstrate that treatment with a GABAA receptor positive allosteric modulator with 
high affinity for α5 subunit-containing subtype (α5-PAM) (Savic et al, 2010) results in a rapid 
reduction in anxiety- and depressive-like behaviors in female mice exposed to UCMS (Fig.2&3). 
Moreover Z-normalization across tests suggests that both acute or chronic α5-PAM treatment 
was sufficient to reverse UCMS-induced anxiety- and depressive-like behaviors to WT levels, 
suggesting a rapid and sustained pharmacological effect (Fig.2&3). In contrast, treatment with α5-
PAM did not alter either anxiety- or depressive-like behaviors in male mice (Fig.2&4). Results in 
both female and male mice were observed in two consecutive and separate cohorts. Importantly, 
the fact that acute and chronic α5-PAM treatment were effective in blocking UCMS-induced 
behavioral emotionality in female mice (Fig.2&3) raises the possibility that targeting the α5-
containing GABAA receptors could have rapid anxiolytic and antidepressant effects.  
 Pharmacokinetic studies (Fig.1) show that the sex-specific behavioral differences were 
not explained by sex-dependent drug availability. Females displayed time-dependent elevated 
α5-PAM plasma levels compared to males (Fig.1). However, no effect of α5-PAM was observed 
in males at times when plasma levels were similar to females (30min; Fig.1) or when a 25% higher 
dose of α5-PAM was used (Fig. S2). Note that, even at Tmax, the estimated free brain 
concentrations in males (273nM) and females (313nM) were several times lower than the reported 
Ki values of α5-PAM at non-α5-GABAA receptors (Savic et al, 2010), thus demonstrating 
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selectivity of modulatory action of the ligand on mouse behavior in the used settings. Despite 
slight differences in the effect of acute versus chronic treatment (Fig.3A-D, S1), the data were 
qualitatively consistent across cohorts of mice in both sexes (Fig.2,3). 
 
4.2. Sex-dependent effects of α5-PAM treatment parallel human sex-dependent molecular deficits 
and highlight modulation of extrasynaptic GABAA as a potential novel therapeutic modality 
 The observed sex difference in preclinical testing is potentially clinically interesting since 
women are twice as likely than men to experience a single episode of depression (Kessler, 2003) 
and display higher morbidity risk (Piccinelli and Wilkinson, 2000). These differences are not 
explained by diagnostic criteria, suggesting a biological predisposition in women (Angst and 
Dobler-Mikola, 1984). Interestingly, evidence suggest that dysfunction in SST interneurons may 
be more robust in females. In two frontocortical regions critical for emotion regulation, the sgACC 
and dlPFC, decreases in markers of dendritic targeting interneurons were more pronounced in 
female MDD compared to male MDD subjects and their matched controls (Seney et al, 2013; 
Sibille et al, 2010; Tripp et al, 2011; Tripp et al, 2012). This decrease in SST expression spanned 
all cortical layers of the sgACC in MDD subjects with greater effect sizes and significance in 
female subjects, suggesting a cellular vulnerability affecting all cortical SST neurons in MDD and 
more robustly in females (Seney et al, 2014).  
In Lin & Sibille (2015), we showed that UCMS specifically affects expression of SST and 
GABA synthesizing molecules in SST neurons. The current pharmacological and behavioral 
results indicate that compounds that enhance α5-GABAAR mediated inhibition postsynaptic to 
SST cells may overcome or bypass the impact of the intrinsic vulnerability of SST cells to stress. 
That the potential therapeutic action of α5-PAM involves these cortical deficits is causally 
supported by our finding that acute treatment with α5-PAM upregulates expression of the Gabra5 
gene exclusively in female mice within the prelimbic cortex (homologous to the human sgACC). 
The lack of observed differences in α5 protein level may reflect the limitations and sensitivity of 
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the assays. In frontal cortex, low expression of total α5 protein precluded our ability to compare 
transcript and protein levels. In the hippocampus, where α5 mRNA and protein are highly 
expressed, we observed an increase in transcript expression following chronic α5-PAM treatment 
with no change in total or surface protein (Fig.5B & 6B), although a nominal non-significant 
increase was observed in males. Contributing to this discrepancy may be the 5-6 fold increase in 
protein half-life relative to mRNA, which results in much more dynamic mRNA regulation 
(Schwanhausser et al, 2011), or simply that at the time of sacrifice, translation of the α5 transcript 
was not elevated. It is worth noting that chronic α5-PAM treatment in female mice produced 
anhedonic- and anxiolytic-like effects with no down-regulation of the Gabra5 transcript, commonly 
observed following chronic benzodiazepine administration (Uusi-Oukari and Korpi, 2010), which 
potentially explains the development of drug tolerance to benzodiazepine-like pan-GABAA 
receptor modulators (Vinkers and Olivier, 2012). In fact, sustained upregulation of α5 protein has 
been reported after exposure to anesthetics that act primarily as GABAA receptor modulators 
(Zurek et al, 2014). These findings highlight the specificity of α5-PAM for α5-subunit containing 
GABAA receptors and may alleviate concerns regarding a decrease in efficacy following chronic 
treatment.  
Converging evidence from clinical data suggests an involvement of extrasynaptic GABAA 
receptors in psychiatric illness. Linkage studies have identified a susceptibility locus within the 
GABRA5 gene (15q11-q13) for bipolar depression (Kato, 2007; Otani et al, 2005). Post-mortem 
studies have further examined the link between GABRA5 gene expression and depression, with 
mixed findings. In the ACC and dlPFC, data suggest that expression of the GABRA5 gene is 
increased in cortical layers 2-6 of subjects with bipolar depression and those with MDD (Choudary 
et al, 2005). In post-mortem dlPFC tissue from depressed suicides, no difference in GABRA5 
expression was observed (Merali et al, 2004). Similarly, in the amygdala of female post-mortem 
subjects, where decreases in SST and other GABA interneuron markers are present, no change 
in GABRA5 gene expression was observed between MDD and matched controls (Guilloux et al, 
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2012). While this is the first study to demonstrate anxiolytic- and antidepressant-like effects of a 
selective α5-PAM compound, other studies have found that compounds with mixed α5 and α2 
specificity do have anxiolytic effects in rodents (Savic et al, 2008; Savic et al, 2010). Moreover a 
recent study in the amygdala suggests that generalization of fear and anxiety is mediated by α5-
subunit containing neurons in the central nucleus of the amygdala (Botta et al, 2015). Taken 
together, the data support a potential role for the α5-GABAA receptor in mood disorders, including 
anxiety and depression, though it is an area to study further, especially as it pertains to potential 
sex differences.  
 Data characterizing the expression of α5-GABAA receptors in a rodent model of 
depression are sparse, and our report is the first to examine potential sex-specific effects. 
Previous reports suggest that expression of the α5-subunit is increased in the frontal cortex 
following prolonged social isolation in male mice (Matsumoto et al, 2007). Expression of another 
extrasynaptic GABAA receptor subunit, the δ-subunit, is also increased after social isolation, a 
finding that correlates with increased tonic inhibition (Serra et al, 2006). A notable difference 
however is that the δ-subunit is not restricted to the dendritic compartment, as is the case for the 
α5-containing GABAA receptors (see Introduction). Interestingly, expression of extrasynaptic δ-
GABAA receptor is modulated across the estrous cycle and sensitive to the neurosteroid 
progesterone (Maguire et al, 2005). Expression of extrasynaptic GABAA receptors is decreased 
at parturition and increased postpartum, providing support for hormonal modulation of these 
extrasynaptic receptors. Together, these preclinical data support the involvement of extrasynaptic 
GABAA receptors in the stress response and indicate sex-specific regulation of receptor 
expression. 
 
4.3. Conclusions and therapeutic potential of targeting α5-containing GABAA receptors 
 Here we demonstrate that a GABAA α5-selective PAM can reverse anxiety- and 
depressive-like behavior induced by UCMS to non-stressed levels when administered acutely and 
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chronically to female mice (Fig.2 & 3). The effect on anxiety-like behaviors in females was mild 
and required behavioral z-score normalization across tests to identify consistent behavioral 
responses, but it was confirmed across two independent cohorts (Fig.2-3). By contrast, we 
observed a consistent lack of effect in male mice across separate cohorts and regardless of 
treatment regimen or dose (Fig.4 & S2). This lack of effect in males was not explained by 
pharmacokinetic differences (Fig.1). These data confirm previous reports that indicate a lack of 
anxiogenic/anxiolytic properties of α5-subunit modulation in male rodents either 
pharmacologically (Savic et al, 2008; Savic et al, 2010) or genetically (Collinson et al, 2002). 
Interestingly, a recent study in male rats found that two negative allosteric modulators (NAM) 
selective for the α5-subunit could reverse stress-induced anhedonia and deficits in AMPAR-
mediated synaptic transmission within the hippocampus (Fischell et al, 2015). While these 
findings appear at odds with the data presented here,  preclinical studies suggesting anxiogenic 
effects of α5-NAMs (Botta et al, 2015; Navarro et al, 2002), and of clinical and human post-mortem 
literature, they are in accordance with the actions of the rapid-acting antidepressant ketamine 
(Autry et al, 2011; Berman et al, 2000; Li et al, 2010). Together, these studies suggest that basal 
GABA tone or baseline cellular activity, for which sex may be a mediating factor, may influence 
which type of α5-modulator (positive or negative) may produce a therapeutic benefit. Support for 
this contention comes from the finding that while α5 GABAA receptor NAMs  enhance memory in 
young rats, positive modulation is necessary to improve memory in older rats with excessive 
hippocampal activity and decreases in α5 transcript expression (Haberman et al, 2011; Koh et al, 
2013). We believe that the same principle may exist in the UCMS condition, where animals are in 
a low GABA state due to dysfunction of SST cells, and potentially in MDD where low GABA 
content and dendritic targeting interneuron dysfunction is observed in analogous brain regions.   
 In summary, the present study supports the hypothesis that enhancing signaling 
specifically at α5-GABAA receptors may represent a novel therapeutic approach for mood 
disorders, including anxiety and depression, with the notable feature of rapid onset. Interestingly, 
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this treatment approach may be more beneficial to women, who are more severely affected by 
MDD. Future experiments should further explore the sex-dependent effects of treatment and 
propose the exact mechanism by which modulation of α5-GABAA receptors is exerting its effects 
in the UCMS condition.  
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Figure 1. Pharmacokinetic analysis of α5-PAM brain and plasma levels in female and male 
mice.  
Measured plasma (inset) and estimated brain (main figure) concentration–time profiles of α5-PAM 
(30mg/kg) after intraperitoneal administration (n=3 per time point) in female and male mice. 
*p<0.05 between female and male mice in different time-points, according to Tukey post hoc test 
after two-way repeated ANOVA. The calculated plasma and brain pharmacokinetic parameters 
of α5-PAM are tabularly presented on the right. *p<0.05 between female and male mice according 
to t-test. 
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Figure 2. Effect of α5-PAM on anxiety- and depressive-like behavior induced by UCMS in 
female and male mice  
A. Shown are significant positive correlations of Z-anxiety scores from the EPM and OFT. B. 
Female mice treated acutely and chronically with α5-PAM had reduced anxiety-like behavior 
across both tests while no effect of treatment was observed in male mice. C. Treatment with acute 
and chronic α5-PAM reduced latency to bite a food pellet in the NSF in female but not male mice. 
D. Chronic α5-PAM treatment reduced the latency to bite a piece of cookie in the cookie test in 
female mice, while a trend in the same direction was observed following acute treatment. No 
significant effect of α5-PAM was detected in males. E. No change in percentage of weight lost 
after 24 hour food deprivation after α5-PAM treatment. F. No change in amount of pellet 
consumed 5 minutes after the NSF test. *p<0.05, **p<0.01, ***p<0.001.  
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Figure 3. Treatment with α5-PAM normalizes anxiety- and depressive-like behavior induced 
by UCMS to non-stressed levels in female mice  
A-B. UCMS reduced time spent in the open arms of the EPM. C-D. Chronic treatment with α5-
PAM increased the amount of time spent and percentage of total distance traveled in the center 
of the open field, while a trend was observed for acute treatment to increase time in center. E. 
UCMS increased latency to bite in the NSF compared to NS-VEH treated animals, while both 
acute and chronic α5-PAM treatment reduced the increased latency following UCMS. F. Acute 
and chronic α5-PAM treatment reduced the latency to bite a piece of cookie in the cookie test 
compared to UCMS-VEH treated mice. G. Overall emotionality Z-score indicated an increase in 
emotionality in the UCMS-VEH treated mice that is normalized following acute and chronic α5-
PAM administration. #p<0.1, *p<0.05, **p<0.01, ***p<0.001. 
  
470 
 
 
 
Figure 4. Chronic treatment with α5-PAM is ineffective at reducing anxiety- and depressive-
like phenotypes induced by UCMS after the addition of isolation housing in male mice  
A. Positive correlation in Z-anxiety scores observed in the EPM and OFT. B. UCMS increased Z-
anxiety scores compared to NS-VEH animals, chronic α5-PAM treatment did not affect Z-anxiety 
scores. C. UCMS increases latency to bite in the cookie test relative to NS-VEH animals, no 
significant effect of α5-PAM administration. D. UCMS increases latency to bite a cookie while α5-
PAM does not reduce this increased latency. E. Overall emotionality Z-scores are increased 
following UCMS-VEH treatment compared to NS-VEH mice. α5-PAM treatment does not mediate 
the increased emotionality induced by UCMS in male mice. #p<0.1, *p<0.05, **p<0.01, 
***p<0.001. 
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Figure 5. Treatment with α5-PAM increases Gabra5 transcript expression in the frontal 
cortex and hippocampus of female, but not male mice  
 
A. Acute treatment with α5-PAM increases Gabra5 expression in the frontal cortex of female mice 
exposed to UCMS. No change in Gabra5 expression was observed following treatment in male 
mice. B. Chronic treatment with α5-PAM increases Gabra5 expression in the hippocampus of 
female mice exposed to UCMS and compared to animals treated with α5-PAM acutely. No change 
in Gabra5 expression was observed following either acute or chronic treatment in male mice. 
*p<0.05, **p<0.01. 
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Figure 6. No change in either α5 subunit total or surface protein level in the hippocampus 
of male and female mice 
A,C. Representative blots of two housekeeping proteins (NK-ATPase, β-Actin) as well as α5 at 
the surface and total protein levels following UCMS and either vehicle, acute, or chronic α5-
PAM treatment in female (A) or male (C) mice. The absence of Actin signal in the “surface” lane 
indicates the selective enrichment in membrane proteins. B,D. No significant effect of treatment 
observed on either total or surface α5 protein in female (B) or male (D) mice. 
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Introduction  
GABAA receptors are GABA-gated chloride channels which are expressed in neurons, glial 
cells and several non-neuronal cell types (Gladkevich et al., 2006; Olsen and Sieghart, 2008; 
Barragan et al., 2015; Mizuta et al. 2008; Wan et al., 2015) where they influence a variety of 
cellular processes through ligand-gated chloride flux. These receptors are pentamers of 
subunits that can belong to different subunit classes. The existence of six , three , three , 
the , , , , and three  subunits in mammalian systems gives rise to an enormous diversity 
of GABAA receptor subtypes with distinct subunit composition and different pharmacological 
properties (Olsen and Sieghart, 2008).  
GABAA receptors of the central nervous system (CNS) are the site of action of a variety of 
pharmacologically and clinically important drugs such as benzodiazepines, barbiturates, 
anesthetics and convulsants that allosterically modulate GABA-induced currents (Sieghart et 
al., 2012; Sieghart, 2015). In addition to these synthetic drugs, a wide range of natural 
products (Khom et al., 2010,  Lorenz et al., 2010; Hanrahan et al., 2011) as well as some 
endogenous agents, such as neuroactive steroids (Belelli and Lambert, 2005), the 
endocannabinoid 2-AG (Baur, Kielar, Richter, Ernst, Gerhard F Ecker, et al., 2013), 
histamine (Saras et al., 2008; Fleck et al., 2012) and dopamine (Hoerbelt et al., 2015) 
modulate GABAA receptors.  
The best characterized site of drug action on GABAA receptors is the benzodiazepine 
binding site located at the extracellular +/ interface of the receptors (Sigel and Lüscher, 
2011; Richter et al., 2012). Thus, their potency and efficacy is dependent on the subtype of 
both these subunits. In the CNS, benzodiazepine ligands exert mostly sedative-hypnotic, 
anxiolytic, ataxic, anticonvulsive and myo-relaxant properties (Sieghart, 2015). Studies on 
genetically modified mice carrying a point mutation at single types of  subunits, which 
renders the respective receptors insensitive to diazepam, revealed that benzodiazepine-
induced behavioral responses seem to be predominantly mediated by GABAA receptors 
containing specific  subunits in distinct neuronal circuits (Rudolph et al., 1999). Drugs 
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specifically interacting with certain GABAA receptor subtypes were thus expected to exhibit 
quite selective behavioral and pharmacological effects (Möhler, 2011). .  
Due to the high similarity between the and  subunits, the selective binding of 
compounds might not be attainable for all subtypes. However, the concept of efficacy- 
selectivity (also sometimes referred to as functional selectivity) has gained attention in recent 
years (Rudolph and Knoflach, 2011). This in turn has led to the development of ligands 
which bind to several subtypes with comparable affinity, but are “silent” allosteric modulators 
(SAM), or very weak allosteric modulators (near-SAM) at some subtypes, while acting as 
positive or negative allosteric modulators (PAM, NAM) at other subtypes (Rudolph and 
Knoflach, 2011). A pharmacophore based approach (He et al., 1999; Huang et al., 2000; 
Clayton et al., 2007, 2015; Harris et al., 2008) has led to an preferring chiral 
imidazobenzodiazepine SH-053-R-CH3 ((R)-ethyl-8-ethynyl-4-methyl-6-phenyl-4H-
benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate) with pronounced binding and functional 
preference for the 5 subtype (Clayton et al., 2007), and later a F-substituted analogue,  SH-
053-2'F-R-CH3 , was reported to display higher affinity (Savic et al. 2010).  
Clinically applied GABAA receptor targeting drugs are currently mainly used for their various 
effects on the human CNS (Sieghart, 2015); however, considerable interest in these 
receptors expressed in peripheral tissues as potential therapeutic targets has emerged 
((Gladkevich et al., 2006; Barragan et al., 2015; Wan et al., 2015; Mizuta et al. 2008 Yocum 
et al., 2015) Sengupta et al., 2014; Gallos et al., 2015). Here we focus on GABAA receptors 
expressed in airway smooth muscle and their ability to induce relaxation of an established 
contraction which could have enormous clinical implications in bronchoconstrictive diseases 
such as asthma. In these cells, a restricted panel of subunits has been found and includes 
 and (Mizuta et al., 2008) subunits. So far, the composition, 
stoichiometry and arrangement of GABAA receptors that are expressed in these cells have 
not been identified. It was shown recently, however, that the preferring chiral 
imidazobenzodiazepine SH-053-2'F-R-CH3 relaxes airway smooth muscle (ASM) and 
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enhances chloride currents in cultured ASM cells (Gallos et al., 2015), thus suggesting that 
benzodiazepine sensitive, containing receptors are present.  
Here we developed and characterized compounds with improved preference compared 
to SH-053-2'F-R-CH3; gained first insights on issues of their blood brain barrier (BBB) 
penetration; and tested their ability to relax airway smooth muscle in ex vivo preparations.  
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Materials and Methods  
Compounds 
(list of all IUPAC names, and other compounds used in all experiments)  
SH-053-2'F-R-CH3 ((R) stereoisomer of 8-ethynyl-6-(2-fluorophenyl)-4-methyl-4H-2,5,10b-
triaza-benzo[e] azulene-3-carboxylic acid ethyl ester);  
MP-III-004; 
MP-III-58; 
SH-053-2'F-R-CH3-acid; 
SH-I-048a ((S)-7-bromo-5-(2- fluorophenyl)-3-methyl-1H-benzo[e][1,4]diazepin-2(3H)-one); 
Hz-166 (8-ethynyl-6-(20-pyridine)-4H-2,5,10b- triaza-benzo[e]azulene-3-carboxylic acid ethyl 
ester) were designed and synthesized at the Department of Chemistry and Biochemistry, 
University of Wisconsin—Milwaukee. 
[3H]flunitrazepam (specific activity 83 Ci/mmmol) was purchased from Perkin Elmer NEN 
(New England Nuclear )(Waltham, Massachusetts, USA). Diazepam (7-chloro-1,3-dihydro-1-
methyl-5-phenyl-2H-1,4, benzodiazepine-2-one) from Nycomed (Opfikon, Switzerland). 
Standard chemicals came from Sigma-Aldrich (St. Louis, Missouri, USA) 
 
Culturing of human embryonic kidney 293 cells 
Human embryonic kidney (HEK) 293 cells (American Type Culture Collection ATCC® CRL-
1574TM) were maintained in Dulbecco’s modified Eagle medium (DMEM, high glucose, 
GlutaMAXTM supplement, Gibco 61965-059, ThermoFisher, Waltham, Massachusetts, USA) 
supplemented with 10% fetal calf serum (Sigma-Aldrich F7524, St. Louis, Missouria, USA), 
100 U/ml Penicillin-Streptomycin (Gibco 15140-122, ThermoFisher, Waltham, 
Massachusetts, USA) and MEM (Non-Essential Amino Acids Gibco 11140-035, 
ThermoFisher, Waltham, Massachusetts, USA) on 10 cm cell culture dishes (Cell+, Sarstedt, 
Nürnbrecht, Germany) at 37°C and 5% CO2. 
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HEK 293 cells were transfected with cDNAs encoding rat GABAA receptor subunits 
subcloned into pCI expression vectors. The ratio of plasmids used for transfection with the 
calcium phosphate precipitation method (Chen and Okayama, 1987) were 3 µg (1,2,3 or 5): 
3 µg 3 and 15 µg 2 per 10 cm dish. Medium was changed 4-6 hours after transfection. 
Cells were harvested 72 days after transfection by scraping into phosphate buffered saline. 
After centrifugation (10 min, 12000 g, 4°C) cells were resuspended in TC50 (50 mM Tris-
Citrate pH=7.1), homogenized with an ULTRA-TURRAX® (IKA, Staufen, Germany) and 
centrifuged (20 min, 50 000 g). Membranes were washed three times in TC50 as described 
above and frozen at -20°C until use. 
 
Radioligand binding assay 
Frozen membranes were thawed, resuspended in TC50 and incubated for 90 min at 4°C in a 
total of 500 µl of a solution containing 50 mM Tris/citrate buffer, pH=7.1, 150 mM NaCl and 2 
nM [3H]flunitrazepam in the absence of presence of either 5 µM diazepam (to determine 
non-specific binding) (dissolved in DMSO, final DMSO concentration 0.5%). Membranes 
were filtered through Whatman GF/B filters and the filters were rinsed twice with 4 ml of ice-
cold 50 mM Tris/citrate buffer. Filters were transferred to scintillation vials and subjected to 
scintillation counting after the addition of 3 ml Rotiszint Eco plus liquid scintillation cocktail. 
Non-specific binding determined in the presence of 5 µM diazepam was subtracted from 
total [3H]flunitrazepam binding to determine specific binding. 
In order to determine the equilibrium binding constant KD of [3H]flunitrazepam for the 
various receptor subtypes, membranes were incubated with various concentrations of 
[3H]flunitrazepam in the absence or presence of 5 µM diazepam. These results are shown in 
the Supplementary Table 1 (Stamenic, 2015, submitted). 
 
Data calculation 
Saturation binding experiments were analyzed using the equation Y=Bmax*X/(KD+X). 
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Nonlinear regression analysis of the displacement curves used the equation: log(inhibitor) 
vs. response - variable slope with Top=100% and Bottom=0% Y=100/(1+10^((logIC50-
x)*Hillslope)). Both analyses were performed using GraphPad Prism version 5.0a for Mac 
OS X, GraphPad Software, La Jolla California USA, www. graphpad.com. 
Drug concentrations resulting in half maximal inhibition of specific [3H]flunitrazepam binding 
(IC50) were converted to Ki values by using the Cheng-Prusoff relationship (Cheng and 
Prusoff, 1973) Ki= IC50/(1+(S/KD)) with S being the concentration of the radioligand (2 nM) 
and the measured KD values (Stamenic, 2015, submitted and Supplementary Table 1). 
 
Two-electrode voltage clamp electrophysiology 
The modulation of GABAA receptor subtypes by the imidazobenzodiazepines was analyzed 
with electrophysiology as described previously (Varagic et al., 2013). The cDNAs from the 
rat  and  subunits were linearized with restriction endonucleases. mRNA 
was prepared with in vitro transcription using the mMachine® T7 transcription kit (Ambion, 
TX, USA). The RNA was capped on the 5’ end and polyadenylated with yeast poly(A) 
polymerase.  
Stage 5-6 oocytes from decapitated Xenopus laevis frogs (Nasco, WI, USA) were isolated 
and singled with a platinum wire. xand mRNA were mixed in the ratio 1:1:5. An 
amount of 2.5 ng of the RNA mixture was injected into each cell. The cells were cultivated at 
18°C in a modified Barths’ medium (88 mM NaCl, 10 mM HEPES-NaOH (pH 7.4), 2.4 mM 
NaHCO3, 1 mM KCl, 0.82 mM MgSO4, 0.41 mM CaCl2, 0.34 mM Ca(NO3)2) with 100 U/ml 
penicillin and 100 µg/ml streptomycin. The cells were then defolliculated 2 to 4 days after 
injection and examined using the two-electrode voltage clamp method on expression days 3 
to 5. For current measurements the oocytes were impaled with two microelectrodes (1–3 
M) which were filled with 2 M KCl. The electrophysiological measurements were performed 
with a Warner OC-725C two-electrode voltage clamp (Warner Instrument, Hamden, CT, 
USA), a Dagan CA-1B Oocyte Clamp or a Dagan TEV-200A two-electrode voltage clamp 
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(Dagan Corporation, Mineapolis, MN, USA). Data were digitized, recorded and measured 
using a Digidata 1322A data acquisition system (Axon Instruments, Union City, CA, USA). 
Data were analyzed using GraphPad Prism. The cells were clamped at a holding potential of 
-60 mV. The perfusion medium was Xenopus Ringer (XR) solution (90 mM NaCl, 5 mM 
HEPES–NaOH (pH 7.4), 1 mM MgCl2, 1 mM KCl and 1 mM CaCl2). The application of buffer 
and compounds, respectively was done with gravity flow at 6 ml/min via a glass capillary 
placed directly above the cell. The compounds were applied with a GABA concentration 
which can elicit 3-5 % of maximal GABA current (GABA EC3-5 current) until the current 
trace reached the peak. Between each measurement the cells were washed for 3 min with 
buffer. Modulation of GABA EC3-5 currents was presented as % of the control current 
induced by the EC3-5 of GABA alone. 
 
Quantification in rat plasma and brain tissue 
Male outbred Wistar rats were supplied by Military Farm, Belgrade, Serbia. For each of four 
compounds tested, rats were divided into three dose groups, with three animals per group. 
All ligands were administered by intraperitoneal (i.p.) injection in a volume of 2 mL/kg. 
Compounds 1, 2 and 3 were dosed at 0.5, 2 and 10 mg/kg, while compound 4 was dosed at 
1, 2.5 and 10 mg/kg. Twenty minutes after treatment administration, the blood samples were 
collected in heparinized syringes via cardiac puncture of rats anesthetized with ketamine 
solution (10% Ketamidor, Richter Pharma Ag, Wels, Austria, dosed i.p. at 100 mg/kg), and 
centrifuged at 2500 rpm for 10 min to obtain plasma. Thereafter, rats were decapitated and 
brains were weighed, homogenized in 5 mL of methanol and centrifuged at 6000 rpm for 20 
min. To determine concentrations of the compounds 1, 2 and 3 in plasma and supernatants 
of brain tissue homogenates, compounds were extracted from these samples by solid phase 
extraction (SPE), using Oasis HLB cartridges (Waters Corporation, Milford, Massachusetts). 
The procedure of sample preparation and determination of the compounds by 
ultraperformance liquid chromatography–tandem mass spectrometry (UPLC–MS/MS) with 
Thermo Scientific Accela 600 UPLC system connected to a Thermo Scientific TSQ Quantum 
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Access MAX triple quadrupole mass spectrometer (Thermo Fisher Scientific, San Jose, 
California), equipped with electrospray ionization (ESI) source, has been already described 
in detail (Obradović et al., 2014). 
Even the modified protocols of SPE as a pretreatment procedure for UPLC–MS/MS could 
not yield satisfying results for compound 4. This could be due to the polarity and amphoteric 
qualities of this ligand. Instead, acetonitrile protein precipitation was used as preparation for 
UPLC–MS/MS. Plasma, brain supernatant, standard and internal standard solutions were 
prepared by the same way as before, for the standard SPE procedure. We then transferred 
250 µL of plasma or brain supernatant to microcentrifuge tubes and added 50 µL of standard 
solution for calibration or pure methanol for samples and 50 µL of internal standard solution. 
After vortexing the mixture for 1 min at 1,000 rpm, 1500 µL of acetonitrile was added, 
vortexed again for 1 min at 1000 rpm and centrifuged for 10 min at 13,000 rcf. Supernatants 
were transferred to vials for UPLC–MS/MS analysis. 
 
Plasma protein and brain tissue binding studies 
A 48-well rapid equilibrium dialysis (RED) device (Thermo Scientific) was used to determine 
the free fraction of compound 1, 2 and 3 in fresh rat plasma and brain tissue. The free 
fraction of compound 4 was determined only in plasma, as it was shown in the above 
mentioned experiment that this compound is not able to pass the BBB. The protocol used 
was the same as in Obradović et al., 2014. Free concentrations were calculated by 
multiplying the measured total plasma and brain concentrations with the appropriate 
estimated free fractions. 
 
Force Measurements in Guinea Pig Tracheal Rings 
All guinea pig protocols were approved by the Columbia University Animal Care and Use 
Committee. Studies were conducted as previously described (Gallos et al. 2015).  Briefly, 
male Hartley guinea pigs (∼400 g) were anesthetized with intraperitoneal pentobarbital (100 
mg/kg) and their tracheas dissected free of epithelium and suspended in physiological buffer 
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with 10uM indomethacin in organ baths at 37oC and continuously bubbled with 95% O2/5% 
CO2. Tracheal rings were placed under a resting tension of 1.0g and allowed to equilibrate 
for 1h with buffer exchanges every 15min.  Tracheal rings were pretreated with N-
vanillylnonanamide (10 μM) to activate and then deplete nonadrenergic, noncholinergic 
nerves contained within the tissue. After buffer exchanges the tracheal rings were subjected 
to two cycles of increasing cumulative concentrations of acetylcholine (0.1 μM to 0.1 mM). 
Following extensive buffer exchanges, pyrilamine (10 μM), and tetrodotoxin (1 μM) were 
added to the buffers to block confounding effects of released histamine or nerve 
depolarization on endogenous airway smooth muscle contractile force.  Tracheal rings were 
then contracted with 1uM substance P. After contractions achieved a steady-state plateau of 
increased force (typically 30 min), 50 M of the indicated GABAA ligand or the vehicle control 
(0.1% ethanol) was added to the buffers.  The maintenance of force was measured after 15 
min and was expressed as a percent of the initial contractile substance P-induced force for 
each ring and the resultant relaxation was compared to the vehicle control. 
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Results  
Scheme 1: Substitution pattern and numbering of chiral, - preferring 
imidazobenzodiazepines 
 
Investigated compounds 
 - selective 
Compound 
R8 R3 Lab code 
1 ethynyl ethyl ester SH-053-2'F-R-CH3 
2 ethynyl methyl ester MP-III-004 
3 Br methyl ester MP-III-058   
4 ethynyl -COOH SH-053-2'F-R-CH3-acid 
Control compound   
5 
Different chemotypes 
Hz-166 
6 SH-I-048a 
 
Ligand 1 is published (Cook et al., 2006) and is included here as a reference compound for 
receptor preference. The R3 position on the imidazole ring was varied to include the 
methyl ester and the charged acid in compound 4. The chemical synthesis and 
spectroscopic information on the newly synthesized ligands 2, 3 and 4 is provided as 
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supplementary information. Compounds 5 (ref) and 6 (ref) which are achiral and represent 
different chemotypes of benzodiazepine-site ligands were used as control compounds.   
 
Modulatory effects of compounds on GABA-induced chloride currents 
Ligand 1 is a published  - preferring chiral imidazobenzodiazepine (Fischer et al., 2010) 
which already has been shown to relax airway smooth muscle (Gallos et al., 2015). This 
compound possesses higher efficacy and affinity for the  receptor over  
(see Fig 1. and TABLE 1), but still significant residual activity in other subtypes and a rather 
narrow window of separation between allosteric modulation of the - and non-- subtypes. 
Here we investigate how different substituents on the imidazobenzodiazepine scaffold lead 
to alterations and improvements of the efficacy preference for the - subtype. 
The imidazobenzodiazepine MP-III-004 (compound 2) is the methyl ester analogue of 
compound 1. It exhibits a marked drop in efficacy in the non- subtypes compared to SH-
053-2'F-R-CH3, see Fig. 1. While 1 M SH-053-2'F-R-CH3 enhances EC3 (3% effective 
concentration) GABA currents to ~ 150 () and 200 ()%, the modulation by the same 
concentration of  compound 2 in the non- subtypes is less than  150%.  The compound 
with R8= Br, compound 3, has a fairly similar receptor preference profile as its R8= ethynyl 
analogue (compound 2), but a slightly higher apparent potency for the  subtype as it 
modulates the  receptors already at 100nM. Compound 4 is a charged compound 
with R3= COOH and displays very high efficacy, modulating the EC3 GABA current in the 
 subtype already by ~600% at only 100 nM compound concentration, see Fig. 1. At 
this low concentration, there is nearly no modulatory effect on the non- subtypes, see 
Fig. 1. At higher concentrations it modulates the other subtypes too, but due to the very good 
window of separation in the lower concentration range activation of these subtypes can be 
avoided by appropriate dosing. Thus, the three analogues of SH-053-2'F-R-CH3 all display a 
wider concentration range in which they act on -containing receptors exclusively 
compared to the parent compound. 
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Fig. 1. Mean relative potentiation above the EC3 GABA current at the indicated compound concentrations is 
displayed with SEM, n= 3 or higher from at least two batches of oocytes. Note the different Y-axis scale for the 
strong modulator compound 4.  
 
Binding selectivity 
To evaluate binding selectivity, receptors were expressed individually in HEK 
293 cells, and [3H]flunitrazepam displacement studies were performed with compounds 1-4 
to compare binding selectivity for  over non- containing receptors, see TABLE 1. The 
binding selectivity for  of the reference compound 1 is about ten-fold over the - 
receptor (give first ref). The best binding selectivity was found for the acidic/ charged 
analogue SH-053-2'F-R-CH3-acid, which is approximately 60-fold selective for  over  
containing receptors. All other tested compounds are equivalent or worse in - preference 
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compared to the parent compound 1, see TABLE 1. The binding data suggests together with 
the efficacy data (Fig. 1) that compound 4 possesses both binding- and efficacy- preference 
for the - containing receptor subtype, while compounds 2 and 3 feature mostly efficacy 
selective action.  
 
 
 
 
TABLE 1. Potency of [3H]flunitrazepam displacement in x receptors recombinantly expressed in HEK 293 
cells. Data is reported as mean ± SEM from three displacement curves done in duplicates.  
Cpd # Code Name Ki ± SEM in M  
     
1 SH-053-2'F-R-CH3 1.8 ± 0.2 3.7 ± 0.3 1.7 ± 0.2 0.22 ± 0.02 8 
2 MP-III-004 2.5 ± 0.2  3.2 ± 0.1 2.5 ± 0.3 0.4 ± 0.1 6 
3 MP-III-058 0.35 ± 0.06 0.69 ± 0.05 0.58 ± 0.05  0.10 ± 0.01 3.5 
4 SH-053-2'F-R-CH3-acid 1.9 ± 0.4 0.6 ± 0.1 1.1 ± 0.5 0.031 ± 0.005 61 
Legend to TABLE 1: Membranes from HEK 293 cells expressing the indicated subunit combinations x32 were 
incubated with 2 nM [3H]flunitrazepam in the presence of various concentrations of the test compound. The 
concentrations resulting in half maximal inhibition of specific binding (as determined in the absence or presence 
of 5 µM diazepam) were converted to Ki values using the Cheng-Prusoff relationship (see Methods).  
 
Free fraction and blood brain barrier penetration studies of the novel - preferring 
ligands 
Among the possible future applications of these compounds is the exploitation of an airway 
smooth muscle relaxing effect (reported for SH-053-2’F-R-CH3 in Gallos et al. 2015) for the 
treatment of asthma bronchialis. If a compound should be applied as an aerosol, a low blood 
brain barrier (BBB) penetration is desirable to avoid central nervous system side effects. 
Since the brain  receptor subtype is implicated in learning and memory (Soh and 
Lynch, 2015) and thought to be involved in tolerance development (van Rijnsoever et al., 
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2004) and the amnestic effects of positive modulators such as diazepam (Antkowiak, 2015), 
a compound that cannot pass the BBB would be the most appropriate for peripheral 
administration. The plasma and brain concentrations, total and (estimated) free, of 
compounds 1, 2 and 3 measured 20 min after intraperitoneal administration of 0.5, 2 and 10 
mg/kg doses are presented in TABLE 2. It is notable that among these three brain-penetrant 
compounds, the measured free brain fractions and estimated free brain concentrations of 
compound 3 were lowest (TABLE 2), which may translate into a very favorable low side 
effect profile. For the charged compound 4 the protocol of the kinetic study had to be 
adapted (see Methods section). The quantification of brain samples demonstrated that 
compound 4 is essentially unable to pass the BBB, while free plasma fraction was as high as 
18%, which may result in both, favorable central nervous system safety and good availability 
for eliciting pharmacological effects in peripheral tissues. 
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TABLE 2. Total and estimated free concentrations of SH-053-2’'F-R-CH3, MP-III-004 and MP-III-058 (dosed at 
0.5, 2 and 10 mg/kg) as well as SH-053-2’'F-R-CH3- acid (dosed at 1, 2.5 and 10 mg/kg) in rat plasma and brain 
samples 20 min after i.p. administration. 
Dose (mg/kg) 0.5 2 10 
SH-053-2'F-R-CH3 
Plasma (nmol/L) 
Total 
Free 
38.83  17.55 
26.62  12.03  
31.23  14.89 
21.41  10.21  
337.57  145.03 
231.41  99.41  
Brain (nmol/kg) 
Total 
Free 
43.88  18.47 
1.70  0.71 
66.59  34.13 
2.58  1.32  
552.72  241.70 
21.39  9.35 
MP-III-004 
Plasma (nmol/L) 
Total 
Free 
64.47  23.02 
22.78  8.13  
415.89  58.91 
146.93  20.81  
1182.49  546.09 
417.77  192.93 
Brain (nmol/kg) 
Total 
Free 
125.88  30.01 
7.89  1.88  
329.59  26.55 
20.66  1.66  
1696.44  269.70 
106.37  16.91  
MP-III-058 
Plasma (nmol/L) 
Total 
Free 
13.43  1.15 
8.65  0.74 
72.28  38.07 
46.55  24.52 
94.59  64.14 
60.91  41.30  
Brain (nmol/kg) 
Total 
Free 
55.17  4.98 
0.66  0.06  
268.15  11.03 
3.20  0.13  
902.94  395.01 
10.79  4.72  
SH-053-2'F-R-CH3-acid 
Dose (mg/kg) 1 2.5 10 
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Plasma (nmol/L) 
Total 
Free 
510.24  58.37 
91.75  10.50 
802.07  426.95 
144.22  76.77 
1511.03  814.51 
271.71  146.46 
 
Effect of - containing GABAA receptor subtype  selective compounds 2, 3 and 4 and 
control compounds in organ bath experiments on pre-contracted airway smooth 
muscle 
In experiments as described previously (Gallos et al., 2015), guinea pig airway smooth 
muscle was pre-contracted ex vivo by application of 1 M substance P and subsequently 
treated with the test compounds, see Fig. 2. 
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    A 
 
 
 
 
 
           B 
 
 
        
Fig. 2. Airway smooth muscle force relaxation in response to ligands with selectivity for 5 subunit containing 
GABAA receptors and the 2,3 selective ligand Hz-166 which is inactive in 5 subunit containing GABAA 
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receptors. (A) Representative airway smooth muscle force tracings of guinea pig tracheal rings suspended ex 
vivo in organ baths and contracted with 1 µM substance P. At a plateau in contractile force, rings were treated 
with 50 µM of the indicated compound or the vehicle (0.1% ethanol) at times indicated by the arrows to assay for 
induced relaxation.  There is a slow spontaneous decay in the substance P induced contraction but GABAA 5 
subunit-selective compounds induce active relaxation that is not seen with the ethanol vehicle or the GABAA 2,3 
subunit selective ligand Hz-166. (B) The amount of relaxation was measured 30 min after the addition of the test 
drug by comparing the remaining amount of contractile force at 30 min to the contractile force present just before 
test drug addition. ** and *** p< 0.01 and 0.001 compared to vehicle control, respectively; $$$ p< 0.001 
compared to SH-053, n = 6-17.   
 
All novel compounds with functional selectivity for the - containing receptors performed as 
well as, or better than the parent 1 in the tissue bath experiments. Compound 3 exerted the 
strongest relaxing effect among the - preferring test compounds and thus represents a 
considerably improved candidate for a future development towards a lead for an asthma 
medication compared to compound 1. Compound 4 displays comparable effects as than the 
parent 1, but offers the advantage of no blood brain barrier penetration, and thus also 
possibly represents an interesting follow up candidate. 
Two additional compounds were included to investigate the specificity of the test 
compounds. Although the identity of individual GABAA subunits expressed in airway smooth 
muscle is known (Mizuta et al. 2008), the specific composition and stoichiometry of GABAA 
receptors expressed by the ASM cells is unknown. It was tacitly assumed that ,  and  
subunits would co-assemble to produce receptors like those seen in the CNS (Olsen and 
Sieghart, 2008). This assumption is plausible, and consistent with the previously published 
effects of the benzodiazepine- type ligands SH-053-2'F-R-CH3 (Gallos et al., 2015) and the 
bretazenil analogues XHe-III-74 and CMD-54 (Yocum et al., 2015) on intact ASM and 
isolated ASM cells. If the ASM relaxing effects are elicited by benzodiazepine- type positive 
modulation of GABA-elicited chloride flux via the  (Gallos et al., 2015) and  
(Yocum et al., 2015) interfaces respectively, the compound Hz-166 which is an  
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selective benzodiazepine- site ligand (Rivas et al., 2009) should be inactive in the tissue 
bath experiments. Indeed, we found it to be inactive as hypothesized, see Fig. 2.  
Hz-166 is also an imidazobenzodiazepine. To seek further evidence for a benzodiazepine-
type mechanism by which the -selective ligands act in the ASM cells we included a 
compound which has a more distinct chemotype as additional control.  SH-I-048a, an 
unselective modulator in all tested subtypes, is a 1,4- benzodiazepine ligand (ref to 
appropriate item – structure in scheme 1 or in SI?) with very high potency for diazepam 
sensitive benzodiazepine sites, high efficacy in  receptors, but inactive in  
receptors (Obradović et al., 2014). In the tissue bath experiment at 50 M compound 
concentration it was as effective as the best - preferring test compound, see Fig. To 
nvestigate dose dependence of MP-III-058 and SH-I-048a, the tissue bath experiments were 
conducted at two additional lower concentrations. These experiments indicated that both 
compounds need to be present in the bath at concentrations higher than 10 M for the 
relaxant effect to occur at high significance, see Fig. 3 (or supplementary Figure?). However, 
the effect observed at 25 M was already approaching near saturation, see (see Fig 3. (or 
supplementary Figure?)).  Interestingly, even though the binding potency in recombinantly 
expressed receptors is different by three orders of magnitude (Ki of 100 nM for MP-III-058 
(TABLE 1) and 0.11 nM for Sh-I-048a (Obradović et al., 2014) respectively), in the tissue 
bath experiments no difference in apparent potency was detected (see Fig 3. (or 
supplementary Figure?)). The reason for this lack of difference in apparent potency likely 
must be ascribed to different tissue penetration properties of these compounds.  
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Figure X. Airway smooth muscle relaxation in response to ligands selective
(MP-III-58) or non-selective (SH-1-048a) for 5 subunit containing GABAA
channels.  Guinea pig airway smooth muslce was contracted ex vivo to
1uM substance P and at a plateau in contractile force treated with the
indicated ligand in 0.1% ethanol vehicle.  The remaining amount of
contractile force at 30 min was expressed as a percent of the initial
substance P-induced force.  ** p<0.01 and ***p < 0.001 compared to
vehicle control (0.1% ethanol).  n = 6-8.
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Discussion 
Subtype selective ligands of the benzodiazepine binding site subtypes would be highly 
desirable both as research tool compounds to study the role of individual receptor subtypes 
in CNS function (Drexler et al., 2013), and to selectively modulate these receptors in all 
tissues in which they are expressed. Due to the high homology of the six subunits, and 
particularly the four diazepam sensitive  subunits, truly selective compounds are still 
very sparse (Rudolph and Möhler, 2014). Here we present three derivatives of the - 
preferring compound SH-053-2'F-R-CH3 with improved properties.  Two compounds display 
enhanced functional selectivity (i.e. lower efficacy in non- receptors) (compounds 2 and 
3), while one displays enhanced binding selectivity (i.e. an approximately 60-fold higher 
affinity for the - subtype, the carboxylic acid compound 4). Free fraction and blood brain 
barrier penetrations studies after intraperitoneal application of these compounds suggest 
that compound 2 would be suitable for CNS applications, as it displays a better brain-
availability, and a better selectivity profile on central receptors compared to its parent 
compound 1. In contrast, the brain free fraction of compound 3 is rather low, and compound 
4 does not cross the BBB at all – making both these compounds very good candidates for 
peripheral applications.  
503 
 
A putative application of interest is as an aerosol to relax excessive contracted airway 
smooth muscle as it occurs in asthma bronchialis (Gallos et al. 2015). Airway smooth muscle 
cells express several GABAA receptor subunits. Among  subtypes, only the and  are 
expressed (Mizuta et al., 2008; Gallos et al., 2015; Yocum et al., 2015). It has been 
demonstrated previously, that targeting either of these subunits leads to relaxation of pre-
contracted ex vivo airway smooth muscle from guinea pig, mouse and human (Gallos et al., 
2015; Yocum et al., 2015), and that aerosol delivery of the - preferring benzodiazepine- 
type compound XHe-III-74 can prevent ASM contraction by methacholine in vivo (Yocum et 
al., 2015). While it was tacitly assumed so far that the ASM cells express GABAA receptors 
whose arrangement and stoichiometries correspond to those found in the CNS, this has so 
far not been investigated explicitly. However, the sensitivity of  and  positive ASM cells 
for benzodiazepine ligands (Gallos et al., 2015; Yocum et al., 2015) suggests that the 
receptors expressed by these cells contain “classical” benzodiazepine binding sites. More 
evidence for this hypothesis could be provided if the ASM relaxing effects of 
benzodiazepine- type compounds could be blocked by benzodiazepine- site antagonist 
compounds such as flumazenil. Unfortunately, these experiments are not feasible on cells 
that contain both  and  containing receptors, as flumazenil is a positive allosteric 
modulator of  receptors (Ramerstorfer et al., 2010). While an - preferring 
antagonist, XLi-093, has been published (Li et al., 2003), this compound also modulates 
 receptors in the concentration range that would be needed for the tissue bath 
experiments (unpublished observations). Thus, no known “benzodiazepine antagonist” is a 
true antagonist on both these receptor subtypes that are putatively expressed by ASM cells. 
To circumvent this practical limitation, we performed control experiments with a 
benzodiazepine- type compound that has nearly no efficacy in - containing receptors, 
namely the - preferring compound Hz-166 (Rivas et al., 2009). While it is structurally 
related to compounds 1, 2 and 3, and displays some overlapping CNS pharmacology 
(Fischer et al., 2010), we show it to be inactive in guinea pig trachea preparations. While the 
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chemically similar Hz-166 is inactive, suggesting a subtype specific effect that parallels the 
effects seen in recombinant receptors, a chemically more distinct compound, SH-048a, that 
unselectively modulates all four diazepam sensitive receptor subtypes (Obradovic et al. 
2014) was demonstrated here to also exert a pronounced relaxing effect in the tissue bath 
experiments with trachea ring preparations (see Figs 3 and 4).These observations together 
further support the working hypothesis that the receptors in the ASM cells that respond to 
our test compounds correspond to the CNS receptors, and that the compounds exert their 
effects by the classical benzodiazepine- mechanism and act on the  benzodiazepine 
site.  
It turned out not to be possible to correlate properties such as affinity data from recombinant 
receptors with dose dependence in ASM relaxation, or efficacy of modulation at GABA EC3 
with the degree of ASM relaxation. We tacitly attribute this to several possible causes that 
need further investigation in future experiments. Tissue penetration of the compounds is 
expected to steeply depend on physico-chemical properties such as electrostatics and 
lipophilicity of the compounds – the carboxylic acid compound 4 probably will not penetrate 
smooth muscle tissue very efficiently. Additionally, rapid degradation by tissue resident 
enzymes could be more limiting to the effects on ASM than apparent affinity or efficacy as 
seen in an isolated in vitro cell environment.  Thus, for the more promising compounds 3 and 
4 effective concentrations at several depths in the tissue samples should be investigated in 
future work. Furthermore, while the efficacy data obtained in recombinant receptors is 
obtained by applying a defined compound concentration, together with a known GABA 
concentration, directly to the receptors on the surface of the oocyte, the situation in the 
tissue bath experiment is profoundly different. Effective concentration of the compound is 
unknown, the level of tissue resident GABA is unknown, and furthermore, additional small 
molecules such as histamine or 2-AG that act on GABAA receptors also as allosteric 
modulators (Saras et al. 2008, Sigel et al. 2011)  may be present at unknown concentrations 
and change the interactions between benzodiazepine-type compounds and the receptors.  
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In order to move forward with this putatively promising novel application of benzodiazepine 
type compounds, we conclude that all candidates that display the desired profile in 
recombinant experiments should be given consideration in ex vivo and downstream 
experiments, and that a pre-selection based on data from recombinant receptors should be 
done only with respect to the subtype selective action.  
In conclusion, we present three novel chiral imidazobenzodiazepines derived from SH-053-
2'F-R-CH3 with a superior - selective profile. Two of these compounds, 3 and 4, show 
very favorable properties for peripheral application as ASM relaxants, while ligand 2 will 
possibly be suitable as a CNS-active selective agent featuring somewhat improved subtype 
selectivity compared to compound 1. Ex vivo experiments identified compound 3 as best 
performing in airway smooth muscle relaxant properties, and thus this compound should be 
selected with high priority for follow up experiments as a prospect for the treatment of 
bronchoconstriction in diseases such as asthma in subsequent experiments (Yocum et al., 
2015). The -subunit is also found in T cells and dendritic cells of the immune system 
(Barragan et al. 2015), in reproductive organs (Akinci and Schofield 1999) and in airway 
epithelium (Xiang et al. 2007).  ( The novel ligands presented here can be used also as 
tool compounds to study the function of - containing receptors in these cells, if they also 
form CNS-like benzodiazepine sensitive receptors there.  
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Supplemental material 
Supplementary Table 1. Equilibrium binding constant (KD) for the different receptor subtypes 
   
7.2 ± 0.2 nM 2.9 ± 0.6 nM 4.1 ± 0.2 nM 2.2 ± 0.3 nM 
Legend to Supplementary Table 1: Membranes from HEK 293 cells transfected with the subunit combinations as 
indicated were incubated with various concentrations of [3H]flunitrazepam in the absence or presence of either 5 
µM diazepam (to determine unspecific binding). Results were analyzed using the equation Y=Bmax*X/(KD+X). 
KD values are presented as mean values ± SEM from 3-4 independent experiments performed in duplicates. 
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APPENDIX I. Provisional Patent on α5 GABAA Selective Agonists for the 
Treatment of Depression and Related Disorders 
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TREATMENTS OF COGNITIVE AND MOOD SYMPTOMS IN NEURODEGENERATIVE 
AND NEUROPSYCHIATRIC DISORDERS WITH ALPHA5-CONTAINING 
GABAA SELECTIVE AGONISTS 
 
 
1. Summary  
 
Provided herein are novel compounds.  The compounds may include modulators of the 
GABAA receptor Alpha5 subunit.  The compounds may include positive allosteric modulators of 
GABAA receptor Alpha5 subunit.  Further provided are methods of making the compounds.  Further 
provided herein are compositions and formulations including one or more of the compounds.    
 
Further provided herein are methods of treating a disorder or condition.  Further provided are 
methods of cognitive and mood remediation in neurological disorders.  Further provided are methods 
of reversing stress-induced deficits in aspects of cognitive flexibility.  The disorder may be selected 
from Alzheimer’s Disease (AD), Major Depressive Disorder (MDD), cognitive deficits associated with 
Major Depressive Disorder (MDD), depression such as major depression and persistent depressive 
disorder and bipolar depression, schizophrenia, alcoholism, addiction, anxiety disorder, epilepsy, 
neuropathic pain, autism spectrum disorder, or a combination thereof.  Anxiety disorder is divided into 
generalized anxiety disorder, phobic disorder, and panic disorder; each has its own characteristics 
and symptoms and they require different treatment.  Particular examples of anxiety disorders include 
generalized anxiety disorder, panic disorder, phobias such as agoraphobia, social anxiety disorder, 
obsessive-compulsive disorder, post-traumatic stress disorder, separation anxiety and childhood 
anxiety disorders.  There are many different epilepsy syndromes, each presenting with its own unique 
combination of seizure type, typical age of onset, EEG findings, treatment, and prognosis. Exemplary 
epilepsy syndromes include, e.g., Benign centrotemporal lobe epilepsy of childhood, Benign occipital 
epilepsy of childhood (BOEC), Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE), 
Primary reading epilepsy, Childhood absence epilepsy (CEA), Juvenile absence epilepsy, Juvenile 
myoclonic epilepsy (JME), Symptomatic localization-related epilepsies, Temporal lobe epilepsy (TLE), 
Frontal lobe epilepsy, Rasmussen's encephalitis, West syndrome, Dravet's syndrome, Progressive 
myoclonic epilepsies, and Lennox-Gastaut syndrome (LGS). Genetic, congenital, and developmental 
conditions are often associated with epilepsy among younger patients. Tumors might be a cause for 
patients over age 40. Head trauma and central nervous system infections may cause epilepsy at any 
age.  Schizophrenia is a mental disorder characterized by a breakdown of thought processes and by 
poor emotional responsiveness.  Particular types of schizophrenia include paranoid type, disorganized 
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type, catatonic type, undifferentiated type, residual type, post-schizophrenic depression and simple 
schizophrenia.  Neuropathic pain encompasses a range of painful conditions of diverse origins 
including diabetic neuropathy, post-herpetic neuralgia and nerve injuries after surgery. It includes pain 
following paraplegia, hypersensitivity to non-painful stimuli (allodynia), for example after surgery or 
during migraine attacks, spontaneous pain, hyperalgesia and diffuse muscle tenderness of myofacial 
syndromes.  Autism spectrum disorder encompasses a range of phenotypes expressed during 
neurodevelopment, characterized by persistent deficits in social communication and interaction across 
various contexts.  The methods may include administering to a subject in need thereof a compound or 
composition as described herein.   
 
2. Introduction 
 
Neurological disorders as a whole, including neurodegenerative and neuropsychiatric 
disorders, represent the leading cause of disability and of years lost due to disability in the world. 
Currently there are no treatments for Alzheimer’s Disease (AD). Anticholinergic drugs are used for the 
cognitive deficits in AD but with very limited success. Current treatments for Major Depressive 
Disorder (MDD) acting on monoaminergic systems are all derived from mechanisms of actions of 
drugs that were discovered by chance over 60 years ago. Current antidepressants take weeks to 
achieve a therapeutic effect and have poor response and low remission rates. Indeed, despite their 
wide use, current antidepressant drugs only work at best in 50% of patients with depression. 
Moreover there are no treatments for cognitive deficits associated with MDD.  In addition, there are 
currently no drugs for the robust and early symptoms of depression in AD. MDD is often co-morbid 
with alcohol and addiction disorders, for which there are very limited treatment options as well.  
 
We and others have described evidence for reduced expression and function of somatostatin 
(SST)-positive inhibitory γ-aminobutyric acid (GABA) neurons in neurological disorders, including AD, 
schizophrenia, bipolar depression, and major depression. SST-positive GABA neurons are a subtype 
of inhibitory neurons which are characterized by inhibiting the dendritic compartment of glutamatergic 
pyramidal neurons, the main excitatory cells in the brain. Signaling through SST neurons regulate 
information and neural processes and has been specifically implicated in regulating cognition and 
mood. The main function of SST-positive neurons is mediated by the neurotransmitter GABA and by a 
specific subtype of GABAA receptors which contain the alpha5 subunit. Alpha5-containing GABAA 
receptors are localized on the dendrites of pyramidal cells, the cellular compartment targeted by SST-
positive neurons. Hence, the deficits in SST positive cells that is observed across neurological 
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disorders is postulated to result in reduced signaling though Alpha5-containing GABAA receptors. 
Targeting Alpha5-containing GABAA receptors may therefore have therapeutic value for cognitive and 
mood symptoms across brain disorders, and specifically in AD and MDD.  
 
3. Description 
 
The target for therapeutic intervention may include the inhibitory GABAA receptor Alpha5 
subunit, the pharmacological effect may include positive allosteric modulation (Alpha5-PAM), and the 
therapeutic indication may include cognitive and mood remediation in neurological disorders 
(Alzheimer’s disease, major depression, bipolar depression, schizophrenia, etc). Moreover, deficits in 
Alpha5-containing GABAA receptors have been reported in alcoholism and addiction, suggesting a 
therapeutic potential for alpha5-PAM in these disorders as well. 
 
Alpha5-PAM may reverse stress-induced deficits in aspects of cognitive flexibility.  Alpha5-
PAM represents a novel mechanism of cognitive remediation and antidepressant action that is 
informed by the pathology of the illness (i.e. decreased SST-positive GABA cell markers).  
 
We show in preclinical rodent models that drugs that augment signaling at Alpha5-containing 
GABAA receptors with an alpha5-PAM, can have antidepressant activity in rodent models of 
depression, and can reverse stress-induced deficits in aspects of cognitive flexibility, the ability of 
learning new rules, an important symptom dimension associated with neurological disorders.  In 
control animals (i.e. non-stressed baseline) we show that strong alpha5-PAM modulation (i.e. high 
dose) causes mild muscle relaxation, devoid of ataxia or sedation characteristic for non-selective 
benzodiazepines, and some spatial learning and memory deficits.  Finally, we show that mild alpha5-
PAM modulation in control animals improved social recognition and acquisition of spatial learning in 
control animals (i.e. baseline). 
 
Together this suggests that alpha5-PAM can remediate mood and cognitive symptoms in 
preclinical models of mood and cognitive disturbances (i.e., in disease states) with a mildly negative 
or positive behavioral profile in control animals (i.e., in non-disease states). 
 
The market of the use of Alpha5-PAM compounds is extremely broad. It includes Alzheimer’s 
disease (early stage; 10-30% of population between 65 and 85 years of age), late-life depression, 
adult depression (10% of population), treatment-resistant depression (5% of population) and other 
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categories of disorders characterized by reduced SST-positive GABA neurons and GABA inhibition 
(schizophrenia, bipolar disorders; 3% of the population). 
 
a. Behavioral Findings 
 
(1) Alpha5-PAM has antidepressant activity in rodent models of depression 
These results are described in the Piantadosi et al manuscript.  
This study was performed in mice and used the prototypical SH-053-2'F-R-CH3 alpha5-PAM, the 
parent compound of MP-III-022. Studies of antidepressant activity of MP-III-022 are on-going. 
 
(2) Alpha5-PAM can reverse stress-induced deficits in aspects of cognitive flexibility. 
These studies are described in Belzung and Sibille (See attached document). This study used MP-III-
022 in mice. 
 
3) Alpha5-PAM has mild myorelaxation and cognitive effects at high dose in control animals. 
These studies are described in Savic paper (Stamenic et al). This study used MP-III-022 in rats. 
 
(4) Alpha5-PAM has precognitive effects at mild doses in control animals. 
These studies are described in Savic paper (Stamenic et al). They show improved social recognition 
and acquisition of spatial learning in control animals. This study used MP-III-022 in rats. 
 
Together these results suggest that Alpha5-PAM represents a novel mechanism of cognitive 
remediation and antidepressant action. Patients with a range of brain diseases may benefit from 
Alpha5-PAM, including patients with AD, MDD, schizophrenia and bipolar disorders.   
 
On-going on future studies include pharmacokinetic and pharmacodynamics evaluation of 
compounds herein, including their effects on mood-related and cognitive behaviors in rodents (such 
as mice and rats). 
 
b. Compounds 
 
Definitions 
Definitions of specific functional groups and chemical terms are described in more detail 
below. For purposes of this invention, the chemical elements are identified in accordance with the 
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Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Ed., inside 
cover, and specific functional groups are generally defined as described therein. Additionally, general 
principles of organic chemistry, as well as specific functional moieties and reactivity, are described in 
Organic Chemistry, Thomas Sorrell, University Science Books, Sausalito, 1999; Smith and March 
March's Advanced Organic Chemistry, 5th Edition, John Wiley & Sons, Inc., New York, 2001; Larock, 
Comprehensive Organic Transformations, VCH Publishers, Inc., New York, 1989; Carruthers, Some 
Modern Methods of Organic Synthesis, 3rd Edition, Cambridge University Press, Cambridge, 1987; the 
entire contents of each of which are incorporated herein by reference. 
The term "acyl" refers to an alkylcarbonyl, cycloalkylcarbonyl, heterocyclylcarbonyl, 
arylcarbonyl or heteroarylcarbonyl substituent, any of which may be further substituted (e.g., with one 
or more substituents).  
The term "alkyl" refers to a straight or branched hydrocarbon chain, containing the indicated 
number of carbon atoms. For example, C1-C12 alkyl indicates that the alkyl group may have from 1 to 
12 (inclusive) carbon atoms, and C1-C4 alkyl indicates that the alkyl group may have from 1 to 4 
(inclusive) carbon atoms.  An alkyl group may be optionally substituted.  Examples of C1-C4 alkyl 
groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl and tert-butyl. 
The term "alkenyl" refers to a straight or branched hydrocarbon chain having one or more 
double bonds. Examples of alkenyl groups include, but are not limited to, allyl, propenyl, 2-butenyl, 3-
hexenyl and 3-octenyl groups.  One of the double bond carbons may optionally be the point of 
attachment of the alkenyl substituent.  An alkenyl group may be optionally substituted.   
The term "alkynyl" refers to a straight or branched hydrocarbon chain having one or more triple 
bonds. Examples of alkynyl groups include, but are not limited to, ethynyl, propargyl, and 3-hexynyl.  
One of the triple bond carbons may optionally be the point of attachment of the alkynyl substituent.  
An alkynyl group may be optionally substituted.   
The term "aryl" refers to an aromatic monocyclic, bicyclic, or tricyclic hydrocarbon ring system, 
wherein any ring atom capable of substitution can be substituted (e.g., with one or more substituents).  
Examples of aryl moieties include, but are not limited to, phenyl, naphthyl, and anthracenyl.   
The term "arylalkyl" refers to an alkyl moiety in which an alkyl hydrogen atom is replaced with 
an aryl group.  Arylalkyl includes groups in which more than one hydrogen atom has been replaced 
with an aryl group. Examples of arylalkyl groups include benzyl, 2-phenylethyl, 3-phenylpropyl, 9-
fluorenyl, benzhydryl, and trityl groups.  
The term "cycloalkyl" as used herein refers to nonaromatic, saturated or partially unsaturated 
cyclic, bicyclic, tricyclic or polycyclic hydrocarbon groups having 3 to 12 carbons (e.g., 3, 4, 5, 6 or 7 
carbon atoms). Any ring atom can be substituted (e.g., with one or more substituents).  Cycloalkyl 
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groups can contain fused rings. Fused rings are rings that share one or more common carbon atoms. 
Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, 
cyclohexyl, cyclohexenyl, cyclohexadienyl, methylcyclohexyl, adamantyl, norbornyl and norbornenyl. 
The term "halo" or "halogen" as used herein refers to any radical of fluorine, chlorine, bromine 
or iodine.  
The term "haloalkyl" as used herein refers to an alkyl in which one or more hydrogen atoms 
are replaced with a halogen, and includes alkyl moieties in which all hydrogens have been replaced 
with halogens (e.g., perfluoroalkyl such as CF3).  
The term "heteroaryl" as used herein refers to an aromatic 5-8 membered monocyclic, 8-12 
membered bicyclic, or 11-14 membered tricyclic ring system having 1-3 heteroatoms if monocyclic, 1-
6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms independently selected from 
O, N, S, P and Si (e.g., carbon atoms and 1-3, 1-6, or 1-9 heteroatoms independently selected from 
O, N, S, P and Si if monocyclic, bicyclic, or tricyclic, respectively). Any ring atom can be substituted 
(e.g., with one or more substituents). Heteroaryl groups can contain fused rings, which are rings that 
share one or more common atoms. Examples of heteroaryl groups include, but are not limited to, 
radicals of pyridine, pyrimidine, pyrazine, pyridazine, pyrrole, imidazole, pyrazole, oxazole, isoxazole, 
furan, thiazole, isothiazole, thiophene, quinoline, isoquinoline, quinoxaline, quinazoline, cinnoline, 
indole, isoindole, indolizine, indazole, benzimidazole, phthalazine, pteridine, carbazole, carboline, 
phenanthridine, acridine, phenanthroline, phenazine, naphthyridines and purines. 
The term "heterocyclyl" as used herein refers to a nonaromatic, saturated or partially 
unsaturated 3-10 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring 
system having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if 
tricyclic, said heteroatoms selected from O, N, S, Si and P (e.g., carbon atoms and 1-3, 1-6, or 1-9 
heteroatoms of O, N, S, Si and P if monocyclic, bicyclic, or tricyclic, respectively).  Any ring atom can 
be substituted (e.g., with one or more substituents). Heterocyclyl groups can contain fused rings, 
which are rings that share one or more common atoms. Examples of heterocyclyl groups include, but 
are not limited to, radicals of  tetrahydrofuran, tetrahydrothiophene, tetrahydropyran, piperidine, 
piperazine, morpholine, pyrroline, pyrimidine, pyrrolidine, indoline, tetrahydropyridine, dihydropyran, 
thianthrene, pyran, benzopyran, xanthene, phenoxathiin, phenothiazine, furazan, lactones, lactams 
such as azetidinones and pyrrolidinones, sultams, sultones, and the like.  
The term “hydroxy” refers to an –OH radical.  The term "alkoxy" refers to an –O-alkyl radical.   
The term “aryloxy” refers to an –O-aryl radical.  The term “haloalkoxy” refers to an –O-haloalkyl 
radical. 
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The term "substituent" refers to a group "substituted" on an alkyl, alkenyl, alkynyl, cycloalkyl, 
heterocyclyl, aryl, arylalkyl or heteroaryl group at any atom of that group.  Suitable substituents 
include, without limitation: acyl, acylamido, acyloxy, alkoxy, alkyl, alkenyl, alkynyl, amido, amino, 
carboxy, cyano, ester, halo, hydroxy, imino, nitro, oxo (e.g., C=O), phosphonate, sulfinyl, sulfonyl, 
sulfonate, sulfonamino, sulfonamido, thioamido, thiol, thioxo (e.g., C=S), and ureido.  In embodiments, 
substituents on a group are independently any one single, or any combination of the aforementioned 
substituents. In embodiments, a substituent may itself be substituted with any one of the above 
substituents.  
The above substituents may be abbreviated herein, for example, the abbreviations Me, Et and 
Ph represent methyl, ethyl and phenyl, respectively. A more comprehensive list of the abbreviations 
used by organic chemists appears in the first issue of each volume of the Journal of Organic 
Chemistry; this list is typically presented in a table entitled Standard List of Abbreviations. The 
abbreviations contained in said list, and all abbreviations used by organic chemists of ordinary skill in 
the art, are hereby incorporated by reference.  
For compounds, groups and substituents thereof may be selected in accordance with 
permitted valence of the atoms and the substituents, such that the selections and substitutions result 
in a stable compound, e.g., which does not spontaneously undergo transformation such as by 
rearrangement, cyclization, elimination, etc. 
Where substituent groups are specified by their conventional chemical formulae, written from 
left to right, they optionally encompass substituents resulting from writing the structure from right to 
left, e.g., -CH2O- optionally also recites -OCH2-. 
In accordance with a convention used in the art, the group: 
 
is used in structural formulas herein to depict the bond that is the point of attachment of the 
moiety or substituent to the core or backbone structure. 
In the context of treating a disorder, the term “effective amount” as used herein refers to an 
amount of the compound or a composition comprising the compound which is effective, upon single or 
multiple dose administrations to a subject, in treating a cell, or curing, alleviating, relieving or 
improving a symptom of the disorder in a subject. An effective amount of the compound or 
composition may vary according to the application.  In the context of treating a disorder, an effective 
amount may depend on factors such as the disease state, age, sex, and weight of the individual, and 
the ability of the compound to elicit a desired response in the individual.  In an example, an effective 
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amount of a compound is an amount that produces a statistically significant change in a given 
parameter as compared to a control, such as in cells (e.g., a culture of cells) or a subject not treated 
with the compound. 
 
It is specifically understood that any numerical value recited herein (e.g., ranges) includes all 
values from the lower value to the upper value, i.e., all possible combinations of numerical values 
between the lowest value and the highest value enumerated are to be considered to be expressly 
stated in this application.  For example, if a concentration range is stated as 1% to 50%, it is intended 
that values such as 2% to 40%, 10% to 30%, or 1% to 3%, etc., are expressly enumerated in this 
specification.  These are only examples of what is specifically intended. 
 
MP-III-022 has PAM activity at the alpha5-containing GABAA receptor and presents the best 
efficacy, potency, ADME and toxicity data compared to related compounds. 
 
Compounds may be of the following formula (I): 
 (I) 
or a salt thereof, wherein: 
X is selected from the group consisting of N, C-H, C-F, C-Cl, C-Br, C-I, and C-NO2; 
R1 is selected from the group consisting of –Br, C≡CH, -C≡C-Si(CH3)3, -cyclopropyl, and 
bicycle[1.1.1]pentane ( ); and 
 R10 and R11 are independently selected from H, C1-6 alkyl, cycloalkyl, or together may form a 
cycloalkyl ring. 
 
In some embodiments, X is N.  In some embodiments, X is CH.  In some embodiments, X is 
CF. In some embodiments, X is CCl. In some embodiments, X is CBr. In some embodiments, X is CI.  
In some embodiments, R1 is –Br.  In some embodiments, R1 is -C≡CH. In some embodiments, R1 is –
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C≡C-Si(CH3)3. In some embodiments, R1 is –cyclopropyl. In some embodiments, R1 is 
bicycle[1.1.1]pentane. 
 
Compounds may be of the following formula (II):  
 (II) 
or a salt thereof, wherein: 
X is selected from the group consisting of N, C-H, C-F, C-Cl, C-Br, C-I, and C-NO2; 
R1 is selected from the group consisting of –Br,  -C≡CH, -C≡C-Si(CH3)3, -cyclopropyl, and 
bicycle[1.1.1]pentane ( ); 
R3 is selected from the group consisting of -H, -CH3, -CH2CH3, -CH(CH3)2, -F, -Cl, -CF3, and -
CCl3; and 
R10 and R11 are independently selected from H, C1-6 alkyl, cycloalkyl, or together may form a 
cycloalkyl ring. 
 
In some embodiments, X is N.  In some embodiments, X is CH.  In some embodiments, X is 
CF. In some embodiments, X is CCl. In some embodiments, X is CBr. In some embodiments, X is CI.  
In some embodiments, R1 is –Br.  In some embodiments, R1 is -C≡CH. In some embodiments, R1 is –
C≡C-Si(CH3)3. In some embodiments, R1 is –cyclopropyl. In some embodiments, R1 is 
bicycle[1.1.1]pentane. In some embodiments, R3 is -H.  In some embodiments, R3 is –CH3. In some 
embodiments, R3 is –CH2CH3. In some embodiments, R3 is –CH(CH3)2. In some embodiments, R3 is 
F. In some embodiments, R3 is Cl. In some embodiments, R3 is –CF3. In some embodiments, R3 is –
CCl3. 
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Compounds may be of the following formula (III):  
 (III) 
or a salt thereof, wherein: 
X is selected from the group consisting of N, C-H, C-F, C-Cl, C-Br, C-I, and C-NO2; 
R1 is selected from the group consisting of –Br, -C≡CH, -C≡C-Si(CH3)3, -cyclopropyl, and 
bicycle[1.1.1]pentane ( ); 
R3 is selected from the group consisting of -H, -CH3, -CH2CH3, -CH(CH3)2, -F, -Cl, -CF3, and -
CCl3; and 
R10 and R11 are independently selected from H, C1-6 alkyl, cycloalkyl, or together may form a 
cycloalkyl ring. 
 
In some embodiments, X is N.  In some embodiments, X is CH.  In some embodiments, X is 
CF. In some embodiments, X is CCl. In some embodiments, X is CBr. In some embodiments, X is CI.  
In some embodiments, R1 is –Br.  In some embodiments, R1 is -C≡CH. In some embodiments, R1 is –
C≡C-Si(CH3)3. In some embodiments, R1 is –cyclopropyl. In some embodiments, R1 is 
bicycle[1.1.1]pentane. In some embodiments, R3 is -H.  In some embodiments, R3 is –CH3. In some 
embodiments, R3 is –CH2CH3. In some embodiments, R3 is –CH(CH3)2. In some embodiments, R3 is 
F. In some embodiments, R3 is Cl. In some embodiments, R3 is –CF3. In some embodiments, R3 is –
CCl3. 
 
Compounds may be of the following formula (IV): 
 (IV) 
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or a salt thereof, wherein: 
X is selected from the group consisting of N, C-H, C-F, C-Cl, C-Br, C-I, and C-NO2; 
R1 is selected from the group consisting of –Br, -C≡CH, -C≡C-Si(CH3)3, -cyclopropyl, and 
bicycle[1.1.1]pentane ( ); and 
 R13 is selected from the group consisting of H, C1-6 alkyl, and cycloalkyl. 
 
In some embodiments, X is N.  In some embodiments, X is CH.  In some embodiments, X is 
CF. In some embodiments, X is CCl. In some embodiments, X is CBr. In some embodiments, X is CI.  
In some embodiments, R1 is –Br.  In some embodiments, R1 is -C≡CH. In some embodiments, R1 is –
C≡C-Si(CH3)3. In some embodiments, R1 is –cyclopropyl. In some embodiments, R1 is 
bicycle[1.1.1]pentane. 
 
Compounds may be of the following formula (V):  
 (V) 
or a salt thereof, wherein: 
X is selected from the group consisting of N, C-H, C-F, C-Cl, C-Br, C-I, and C-NO2; 
R1 is selected from the group consisting of –Br, -C≡CH, -C≡C-Si(CH3)3, -cyclopropyl, and 
bicycle[1.1.1]pentane ( ); 
R3 is selected from the group consisting of -H, -CH3, -CH2CH3, -CH(CH3)2, -F, -Cl, -CF3, and -
CCl3; and 
R13 is selected from the group consisting of H, C1-6 alkyl, and cycloalkyl. 
 
In some embodiments, X is N.  In some embodiments, X is CH.  In some embodiments, X is 
CF. In some embodiments, X is CCl. In some embodiments, X is CBr. In some embodiments, X is CI.  
In some embodiments, R1 is –Br.  In some embodiments, R1 is -C≡CH. In some embodiments, R1 is –
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C≡C-Si(CH3)3. In some embodiments, R1 is –cyclopropyl. In some embodiments, R1 is 
bicycle[1.1.1]pentane. In some embodiments, R3 is -H.  In some embodiments, R3 is –CH3. In some 
embodiments, R3 is –CH2CH3. In some embodiments, R3 is –CH(CH3)2. In some embodiments, R3 is 
F. In some embodiments, R3 is Cl. In some embodiments, R3 is –CF3. In some embodiments, R3 is –
CCl3. 
 
Compounds may be of the following formula (VI):  
 (VI) 
or a salt thereof, wherein: 
X is selected from the group consisting of N, C-H, C-F, C-Cl, C-Br, C-I, and C-NO2; 
R1 is selected from the group consisting of –Br. -C≡CH, -C≡C-Si(CH3)3, -cyclopropyl, and 
bicycle[1.1.1]pentane ( ); 
R3 is selected from the group consisting of -H, -CH3, -CH2CH3, -CH(CH3)2, -F, -Cl, -CF3, and -
CCl3; and 
R13 is selected from the group consisting of H, C1-6 alkyl, and cycloalkyl. 
 
In some embodiments, X is N.  In some embodiments, X is CH.  In some embodiments, X is 
CF. In some embodiments, X is CCl. In some embodiments, X is CBr. In some embodiments, X is CI.  
In some embodiments, R1 is –Br.  In some embodiments, R1 is -C≡CH. In some embodiments, R1 is –
C≡C-Si(CH3)3. In some embodiments, R1 is –cyclopropyl. In some embodiments, R1 is 
bicycle[1.1.1]pentane. In some embodiments, R3 is -H.  In some embodiments, R3 is –CH3. In some 
embodiments, R3 is –CH2CH3. In some embodiments, R3 is –CH(CH3)2. In some embodiments, R3 is 
F. In some embodiments, R3 is Cl. In some embodiments, R3 is –CF3. In some embodiments, R3 is –
CCl3. 
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In some embodiments, for formulas (IV)-(VI), R13 is not C1-6 alkyl, particularly ethyl.  In some 
embodiments, for formulas (I)-(VI), the compound is not one or more of: 
, , ,  , or 
,. 
 
 
 
Compounds may be selected from the following:  
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Compounds may further include the following, wherein X = CH, CF, CCl, N; R4 = H, CH3; and 
R5 = H, CH3:   
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Compounds may further include the following:  
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c. Synthesis 
 
Scheme 1. Synthesis of SH-053-2’F-(R/S)-CH3.   
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Scheme 2. Synthesis of MP-III-022. 
 
 
 
Scheme 3. Synthesis of MP-II-065. 
 
 
 
 
8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxamide MP-II-065 (18) 
Ethyl ester 1 (1 g, 2.81 mmol) and calcium chloride (311 mg, 2.81 mmol) were placed inside a 
sealable vessel with a stir bar. Methanol (dry, 20 mL) was added and a septum was placed to seal the 
vessel. In a separate flask, ammonia (g) was bubbled into methanol (dry, 20 mL) until saturated, 
about 10 minutes. The ammonia-methanol solution was added to the vessel containing 1 and the 
vessel was sealed with a screw cap. The reaction mixed was heated and stirred at 85 oC for 18 hours. 
The reaction was allowed to cool and the methanol was removed under reduced pressure. The solid 
which remained was dissolved in ethyl acetate and filtered to remove the calcium chloride. The filtrate 
was washed with brine, dried (Na2SO4) and solvent removed under reduced pressure. The residue 
that remained was purified using a flash column chromatography (EtOAc with 1% methanol and 1% 
trimethylamine) to afford pure 18 as a white solid (661 mg, 72%); 1H NMR (300 MHz, CDCl3) δ 8.57 
(d, J = 4.6 Hz, 1H), 8.14 (d, J = 8.0 Hz, 1H), 7.84 (s, 2H), 7.81 – 7.73 (m, 1H), 7.61 – 7.51 (m, 2H), 
7.42 – 7.32 (m, 1H), 7.01 (s, 1H), 6.26 (s, 1H), 5.38 (s, 1H), 4.13 (s, 1H), 3.17 (s, 1H); 13C NMR (300 
MHz, CDCl3) δ 167.38, 164.71, 156.59, 148.59, 136.87, 136.52, 136.32, 135.53, 135.14, 133.29, 
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131.01, 127.14, 124.72, 124.04, 122.76, 121.07, 81.77, 79.35, 44.80; HPLC-MS (ESI) m/z (M+H) 
328.12.  
 
SCHEME 4. General synthetic route to carboxamides. 
 
 
SCHEME 5. General synthetic route to methylamides. 
 
 
SCHEME 6. General synthetic route to amides. 
 
 
SCHEME 7. General synthetic route to oxadiazoles. 
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4. Examples 
 
EXAMPLE 1 
 
Results - Effects of MP-III-022 on cognition in mice 
Mice (C57B6; n=10/group) were subjected to unpredictable chronic mild stress (UCMS), a 
validated paradigm to induce depressive-like behaviors in rodents. We previously showed that UCMS 
also induced molecular deficits in SST neurons (Lin and Sibille, 2015). The progression of the UCMS 
effects is monitored weekly by the progressive degradation of the fur coat quality. At the beginning of 
the 6th week of UCMS, mice are tested for cognitive functions including flexibility and inhibition of 
learned behavior using the cross water maze protocol. Groups included UCMS-exposed and control 
animals. Mice were treated during (following block1; see methods) to behavioral testing with MP-III-
022 (5 mg/kg) or vehicle. A control (non-stressed) group treated with MP-III-022 was not included as 
we separately showed no effect of the drug in that control group. 
 
Results indicated that UCMS induced a significant deficit in the ability to inhibit over-training, 
an aspect of cognitive flexibility following over-training in one task. This manifested as increased 
latency to perform the new rule and increased number of errors. 
MP-III-022 reversed those deficits in UCMS-exposed mice, as demonstrated by latency to switch 
strategy and number of errors being at control non-stress levels. See Yellow section of tests in figure 
below. 
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In a separate cohort, we assessed the effects of MPIII-022 on the cognitive performance of 
UCMS-exposed animals using the object recognition test. Acute administration of MPIII-022 (30 min 
before the test) increased the time that mice spent in the vicinity of the novel object compared to 
saline-treated UCMS-exposed mice. This translates as an increased percent discrimination novel 
versus familiar object (p<0.09), indicating that MP-III-022 increased the ability of mice to discriminate 
between a familiar or a novel object. 
 
 
 
 
 
 
 
 
 
 
 
 
50
55
60
65
70
75
80
Stress
MPIII-022Veh
Pe
rc
e
n
t 
D
is
cr
im
in
at
io
n
 
P=0.09
542 
 
Methods 
 
Unpredictable Chronic Mild Stress (UCMS)  
Mice were subjected to various stressors according to a “random” schedule for seven weeks. 
UCMS-exposed mice were maintained under standard laboratory conditions but were isolated in small 
individual cages (24x11x12cm) while non-stressed controls were group-housed in standard laboratory 
cages (42x28x18cm). The stressors were: altered bedding (sawdust change, removal or damp; 
substitution of sawdust with 21°C water, rat or cat feces); cage tilting (45°); cage exchange (mice 
positioned in the empty cage of another male); and altered length and time of light/dark cycle. Body 
weight and coat state were assessed weekly, as markers of the progression of the UCMS-evoked 
syndrome. The total score resulted from the sum of scores obtained from the head, neck, dorsal coat, 
ventral coat, tail, forepaws and hindpaws (0= well-groomed, 1= unkempt). 
 
Drug administration 
Half of the mice subject to the UCMS paradigm were injected with MP-III-022 at a dose of 5 
mg/kg i.p. or vehicle on the inhibition test day (see description below), right after the Block 1 trials. 
This time point also corresponds to 30min before the start of Block 2 trials since there is a 30min 
interval between blocks. 
 
Cross Water Maze Protocol 
 
 
Materials: 
- Water maze labyrinth composed of four arms perpendicular to each other, each 10 cm wide and 50 
cm long. North arm is thus distinguishable from South, East and West arms. Labyrinth is filled with 
about 15 cm of water (so mice cannot walk) to a temperature 21 ± 1°C (cold enough to motivate mice 
to move). 
- A movable platform submerged just below the water surface that can be positioned at the end of 
either arm in a variable manner 
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- To increase swimming difficulties, small lens (PVC capsules of 3mm) can be placed on the water 
surface. Some conditions need entire surface of the water maze covered by lens. 
 
Method: 
 
Learning 1 (Day 1) 
- Learning takes place through sessions that can also call blocks, within each block there is 5 trials. A 
mouse will do 5 trials to complete a Block. Then, when all mice did the Block 1, starts Block 2 and so 
on until Block 6. 
- In each block, the number of correct answers (arrive platform before 60 sec) is assessed, which can 
vary from 0 to 5. 
- Retrieve mouse on platform by 1 min between each trial. 
The time between 2 blocks is the time it takes to test all other mice in this block. 
Group 1: Clear water / go straight 
Group 2: Clear water / go to clue 
Group 3: Lens water / go straight 
Group 4: Lens water / go to clue 
 
Learning 2 (Day 2) 
- Procedure is similar to Learning 1, just change conditions of learning. 
Group 1: Lens water / go to clue 
Group 2: Lens water / go straight 
Group 3: Clear water / go to clue 
Group 4: Clear water / go straight 
 
Flexibility (Day 3) 
- After two days of learning, mice are participating in flexibility test. This test consists in alternate the 
two conditions learned. Similar to precedent days, this test consists of six blocks of five trials. Mice 
carry five trials with Learning 1 (Block 1). Then when all mice do Block 1, starts Block 2 (Learning 2), 
later Block 3 (Learning 1), Block 4 (Learning 2), Block 5 (Learning 1) and finally Block 6 (Learning 2). 
- On Flexibility test we measure: 
Swimming time is the time required to find platform on each trial.- 
Failures are defined by the mouse not directly reach to the platform. 
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Perseverance failures consist in the mouse fails to find the platform by using the precedent strategy. 
For example, if precedent block was "clear water go straight," and during current block (lens water go 
to clue), mouse goes straight, then we consider it a perseverance failure. 
Hesitations are defined when mouse is seeking its way in the central intersection of the maze, or 
when the mouse turned back at the entrance of an arm without fully enter. 
Group 1: Blocks 1, 3 and 5: Clear water / go straight. 
Blocks 2, 4 and 6: Lenses water / go to clue. 
Group 2: Blocks 1, 3 and 5: Clear water / go to clue. 
Blocks 2, 4 and 6: Lenses water / go straight. 
Group 3: Blocks 1, 3 and 5: Lenses water / go straight. 
Blocks 2, 4 and 6: Clear water / go to clue. 
Group 4: Blocks 1, 3 and 5: Lenses water / go to clue. 
Blocks 2, 4 and 6: Clear water / go straight. 
 
Overtraining (Day 4) 
- Procedure is similar to Learning 2. 
Group 1: Lens water / go to clue 
Group 2: Lens water / go straight 
Group 3: Clear water / go to clue 
Group 4: Clear water / go straight 
 
Inhibition (Day 5) 
- Mice start first Block with precedent learning (same condition of overtraining), and Blocks 2 to 6 will 
change condition for a new condition. Therefore, mice will have a spontaneous tendency to respond 
to learning in which they have been over-trained. During the test phase, we measure their ability to 
inhibit this response. 
- On Inhibition test we measure swim time, failures and perseverance as described above. We 
measure time spend in the wrong arms as an additional measure of cognitive deficit    
Group 1: Lens water / go straight 
Group 2: Clear water / go straight 
Group 3: Lens water / go to clue 
Group 4: Clear water / go to clue 
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Novel object recognition test 
Mice are habituated for 10 min to ~70x70 cm width and 33 cm height chamber and the presence of 2 
identical objects (30 cm appart, 17 cm from the walls of the arena) once a day for 3 sessions. The last 
session is recorded from above for 10 min. Two and a half hours after the last session, mice are 
injected with vehicle or MPIII-022.  Thirty minutes later, the mouse is placed back in the arena where 
one of the familiar object is replaced by a new one. This session also lasts for 10 min and is recorded. 
Since mice have a natural exploratory tendency and should remember the first object, animals should 
spend more time exploring the novel object. Time spent in proximity of the each object for each 
recorded session is measured using ANY-Maze tracking system. Object discrimination is determined 
as the percent time spent with the novel objet over the percent time spent with the both objects. 
 
EXAMPLE 2 
 
Assessment of MP-II-065 was assessed in the marble burying assay. Male NIH Swiss mice (n 
= 10) were dosed i.p. with vehicle (1% carboxymethyl cellulose) or MP-II-065 (10 or 30 mg/kg) 30 
minutes prior to being tested in the marble burying assay. Results were analyzed using ANOVA 
(Dunnett’s test: * P < 0.05). a Sedation-like effects were observed at 10 and 30 mg/kg.  Results are 
shown in the Figure below.   
 
 
MP-II-065 was assessed in the rotorod assay. Male NIH Swiss mice (n = 10) were dosed i.p. 
with vehicle (1% carboxymethyl cellulose) or MP-II-065 (10 or 30 mg/kg) 30 minutes prior to being 
tested on the rotorod. Mice were placed on a rod for two minutes at 4 revolutions per minute. Mice 
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that did not fall were designated a “Success”, while mice that fell once during the timing were given a 
“Partial” designation. Mice that fell twice failed the testing.  Results are shown in the Figure below.  
 
 
EXAMPLE 3 
 
The effects of MPIII-022 were examined in another cognitive task: the object recognition test.  
In a separate cohort, we assessed the effects of MPIII-022 on the cognitive performances of animals 
subjected to chronic stress using the object recognition test. 
 
Acute administration of MPIII-022 (30 min before the test) increased the ability of mice to 
discriminate between a familiar or a novel object. MPIII-022-treated mice spent more time in the 
vicinity of the novel object while mice only subjected to chronic unpredictable mild stress favored the 
familiar object. This translates as an increased percent discrimination novel versus familiar object 
(p<0.09) 
 
Methods: Mice are habituated for 10 min to ~70x70 cm width and 33 cm height chamber and 
the presence of 2 identical objects (30 cm appart, 17 cm from the walls of the arena) once a day for 3 
sessions. The last session is recorded from above for 10 min. Two and a half hours after the last 
session, mice are injected with vehicle or MPIII-022.  Thirty minutes later, the mouse is placed back in 
the arena where one of the familiar object is replaced by a new one. This session also lasts for 10 min 
and is recorded. Since mice have a natural exploratory tendency and should remember the first 
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object, animals should spend more time exploring the novel object. Time spent in proximity of the 
each object for each recorded session is measured using ANY-Maze tracking system. Object 
discrimination is determined as the percent time spent with the novel objet over the percent time spent 
with the both objects. 
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GABAERGIC LIGANDS AND THEIR USES  
CROSS-REFERENCE TO RELATED APPLICATIONS 
[0001] This application claims the benefit of U.S. Provisional Application Serial No. 
62/135,854, filed March 20, 2015, which is incorporated by reference herein. 
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
 
[0002] This invention was made with United States government support under NIH grant 
number RO1 NS076517, and NIH grant number RO1 MH09463. The United States government 
has certain rights to this invention.  
BACKGROUND 
[0003] Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the 
central nervous system.  GABA receptors are heteromeric, and are divided into three main 
classes: (1) GABAA receptors, which are members of the ligand-gated ion channel superfamily; 
(2) GABAB receptors, which may be members of the G-protein linked receptor superfamily; and 
(3) GABAC receptors, also members of the ligand-gated ion channel superfamily, but their 
distribution is confined to the retina.  Benzodiazepine receptor ligands do not bind to GABAB 
and GABAC receptors.  Since the first cDNAs encoding individual GABAA receptor subunits 
were cloned the number of known members of the mammalian family has grown to 21 including 
α, β, and γ subunits (6α, 4β, 4γ, 1δ, 1ε, 1π, 1θ, and 3ρ). 
[0004] A characteristic property of GABAA receptors is the presence of a number of 
modulatory sites, one of which is the benzodiazepine (BZ) site.  The benzodiazepine binding site 
is the most explored of the GABAA receptor modulatory sites, and is the site through which 
benzodiazepine-based anxiolytic drugs exert their effect.  Before the cloning of the GABAA 
receptor gene family, the benzodiazepine binding site was historically subdivided into two 
subtypes, BENZODIAZEPINE1 and BENZODIAZEPINE2, on the basis of radioligand binding 
studies on synaptosomal rat membranes.  The BENZODIAZEPINE1 subtype has been shown to 
be pharmacologically equivalent to a GABAA receptor comprising the α1 subunit in combination 
with a β subunit and γ2.  It has been indicated that an α subunit, a β subunit and a γ subunit 
constitute the minimum requirement for forming a fully functional Benzodiazepine/GABAA 
receptor.  
OTT1436    020871-9108-US00 
 550 
[0005] Receptor subtype assemblies for BZ-sensitive GABAA receptors include amongst 
others the subunit combinations α1β2/3γ2, α2β2/3γ2, α3 β2/3γ2, α4 β2/3γ2, and α5 β2/3γ2.  
Subtype assemblies containing an α1 subunit (α1β2γ2) are present in most areas of the brain and 
are thought to account for 40-50% of GABAA receptors in the rat.  Subtype assemblies 
containing α2 and α3 subunits respectively are thought to account for about 25% and 17% of 
GABAA receptors in the rat.  Subtype assemblies containing an α5 subunit (α5β3γ2) are 
expressed predominately in the hippocampus and cortex and are thought to represent about 5% 
of GABAA receptors in the rat.  Two other major populations are the α2β2/3γ2 and α3β2/3γ2 
subtypes as stated above.  Together these constitute approximately a further 35% of the total 
GABAA receptor population.  Pharmacologically this combination appears to be equivalent to the 
BENZODIAZEPINE2 subtype as defined previously by radioligand binding, although the 
BENZODIAZEPINE2 subtype may also include certain α5-containing subtype assemblies. 
[0006] The present pharmacology of agonists acting at the BZ site of GABAA receptors 
suggests that α1 containing receptors mediate sedation, anticonvulsant activity, ataxia, and 
anterograde amnesia, while α2 and/or α3 GABAA receptors mediate anxiolytic activity. α5 
containing GABAA receptors are involved in memory functions (U. Rudolph et al., Nature 1999, 
401, 796; K. Löw et al., Science 2000, 290, 131; McKernan Nature Neurosci. 2000, 3, 587; F. 
Crestani et al., Proc. Nat. Acad. Sci. USA 2002, 99, 8980; M.S. Chambers et al., J. Med. Chem. 
2003, 46, 2227).  
[0007] It is believed that agents acting selectively as benzodiazepine agonists at GABAA/α2, 
GABAA/α3, and/or GABAA/α5 receptors possess desirable properties.  Compounds which are 
modulators of the benzodiazepine binding site of the GABAA receptor by acting as 
benzodiazepine agonists are referred to hereinafter as “GABAA receptor agonists.”  The 
GABAA/α1-selective (α1β2γ2) agonists alpidem and zolpidem are clinically prescribed as 
hypnotic agents, suggesting that at least some of the sedation associated with known anxiolytic 
drugs which act at the Benzodiazepine 1 binding site is mediated through GABAA receptors 
containing the α1 subunit. Recently, two studies have shown that the majority of additive 
properties of diazepam are mediated by α1 subtypes (N. A. Ator et. al., J. Pharm. Exp. Thera. 
2010, 332, 4-16; K. R. Tan et. al., Nature, 463, 769-774). 
[0008] It is also known that some benzodiazepine derivatives, such as QH-ii-066, bind with 
high affinity to GABAA/α5 receptors (Ki<10 nM), intermediate affinity to GABAA/α2 and 
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GABAA/α3 (Ki<50 nM), and poorer affinity to GABAA/α1 receptors (Ki>70 nM), unlike 
diazepam which binds with high affinity to all four diazepam-sensitive GABAA receptors (Ki<25 
nM), as disclosed in Huang, et al., J. Med. Chem. 2000, 43, 71-95.  However, such 
benzodiazepine derivatives may contain ester linkages, and are thus sensitive to hydrolysis in 
vivo (e.g., by esterases).  What is needed are GABAergic receptor subtype selective ligands that 
lack ester linkages, and are less sensitive to hydrolysis in vivo by esterases.  
SUMMARY  
[0009] In one aspect, the invention provides a compound of formula (I):  
 (I) 
or a salt thereof, wherein: 
X is selected from the group consisting of N, C-H, C-F, C-Cl, C-Br, C-I, and C-NO2; 
R1 is selected from the group consisting of -C≡CH, -C≡C-Si(CH3)3, -cyclopropyl, and 
bicycle[1.1.1]pentane ( ); and 
R2 is selected from the group consisting of -H, -CH3, -CH2CH3 and -CH(CH3)2. 
[0010] In some embodiments of the compound of formula (I), R2 is -H. 
[0011] In another aspect, the invention provides a compound of formula (II):  
 (II) 
or a salt thereof, wherein: 
X is selected from the group consisting of N, C-H, C-F, C-Cl, C-Br, C-I, and C-NO2; 
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R1 is selected from the group consisting of  -C≡CH, -C≡C-Si(CH3)3, -cyclopropyl, and 
bicycle[1.1.1]pentane ( ); 
R2 is selected from the group consisting of -H, -CH3, -CH2CH3, and -CH(CH3)2; and 
R3 is selected from the group consisting of -H, -CH3, -CH2CH3, -CH(CH3)2, -F, -Cl, -CF3, 
and -CCl3. 
[0012] In some embodiments of the compound of formula (II), R2 is -H. 
[0013] In another aspect, the invention provides a compound of formula (III):  
 (III) 
or a salt thereof, wherein: 
X is selected from the group consisting of N, C-H, C-F, C-Cl, C-Br, C-I, and C-NO2; 
R1 is selected from the group consisting of -C≡CH, -C≡C-Si(CH3)3, -cyclopropyl, and 
bicycle[1.1.1]pentane ( ); 
R2 is selected from the group consisting of -H, -CH3, -CH2CH3, and  -CH(CH3)2; and 
R3 is selected from the group consisting of -H, -CH3, -CH2CH3, -CH(CH3)2, -F, -Cl, -CF3, 
and -CCl3. 
[0014] In some embodiments of the compound of formula (III), R2 is –H. 
[0015] In another aspect, the invention provides a method of treating a disorder selected from 
an anxiety disorder, depression, epilepsy, schizophrenia and neuropathic pain in a subject in need 
of treatment, comprising administering to the subject an effective amount of a compound of 
formula (I), (II), or (III).  
[0016] Other aspects and embodiments are encompassed by the disclosure and will become 
apparent in light of the following description. 
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BRIEF DESCRIPTION OF THE DRAWINGS 
[0017] FIG. 1 is a synthetic scheme for the synthesis of the bioisosteres.  
[0018] FIG. 2 are ORTEP views of the crystal structure of 7c (SH-I-85), 9a (KRM-II-81), 9c 
(KRM-II-18B), 10a, and 11a (displacement ellipsoids are at the 50% level).  
[0019] FIG. 3 are structures of compounds.  Shown in A) are the imidazobenzodiazepine-
bioisosteres, and shown in B) are structurally related compounds. 
[0020] FIG. 4 is a graph of dose versus inverted screen failures for KRM-II-81, HZ-166, and 
diazepam in the inverted screen assay. Male Sprague-Dawley rats (n = 5) were dosed i.p. 
(vehicle = 1% carboxymethyl cellulose) with diazepam (3, 10, or 30 mg/kg), KRM-II-81 (10, 30, 
or 60 mg/kg), or HZ-166 (30 mg/kg) 30 minutes prior to testing. Results were analyzed using 
ANOVA (Dunnett’s test: * P < 0.05). 
[0021] FIG. 5 are graphs showing results from the rotorod assay for A) HZ-166 and KRM-
II-81; B) MP-III-085, KRM-II-82 and KRM-II-18B; C) MP-III-080 and KRM-III-78; D) KRM-
III-59; E) KRM-III-66 and KRM-III-65; F) KRM-III-79 and KRM-III-67. Male NIH Swiss mice 
(n = 10) were dosed i.p. with vehicle (1% carboxymethyl cellulose) or one of the test compounds 
(10 or 30 mg/kg) 30 minutes prior to being tested on the rotorod. Mice were placed on a rod for 
two minutes at 4 revolutions per minute. Mice that did not fall were designated a “Success”, 
while mice that fell once during the timing were given a “Partial” designation. Mice that fell 
twice failed the testing.   
[0022] FIG. 6 is a graph of dose versus percent seizures, showing protection from MET-
induced seizures by KRM-II-81, HZ-166, and diazepam. Male CD-1 mice (n = 10) were dosed 
i.p. 30 minutes prior to being tested. Results were analyzed using ANOVA (Dunnett’s test versus 
vehicle: * P < 0.05). 
[0023] FIG. 7 is a graph of dose versus percent seizures, showing protection against scMET 
by KRM-II-81, HZ-166, and diazepam. Male Sprague-Dawley rats (n = 5) were dosed i.p. with 
KRM-II-81, HZ-166, or diazepam 30 minutes prior to testing. A 35 mg/kg subcutaneous dose of 
pentylenetetrazole was given and the percent outcome of seizure was recorded. Results were 
analyzed using ANOVA (Dunnett’s test: * P < 0.05). 
[0024] FIG. 8 is a graph of dose versus pentylenetetrazole (scMet), showing the threshold 
against scMET seizures by KRM-II-81, HZ-166, and diazepam. Male Sprague-Dawley rats (n = 
8) were dosed i.p. with KRM-II-81 or HZ-166 (3, 10, 30, or 60 mg/kg) or diazepam (0.1, 0.3, or 
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1 mg/kg) 30 minutes prior to infusion of PTZ until a convulsion is achieved.  Results were 
analyzed using ANOVA (Dunnett’s test: * P < 0.05). 
[0025] FIG. 9 are graphs showing the number of marbles buried for each dose of compound 
in the marble burying assay for A) HZ-166 and KRM-II-81; B) MP-III-085, KRM-II-82 and 
KRM-II-18B; C) MP-III-080 and KRM-III-78; D) KRM-III-59; E) KRM-III-66 and KRM-III-
65; F) KRM-III-79 and KRM-III-67. Male NIH Swiss mice (n = 10) were dosed i.p. with vehicle 
(1% carboxymethyl cellulose) or one of the test compounds (10 or 30 mg/kg) 30 minutes prior to 
being tested in the marble burying assay. Results were analyzed using ANOVA (Dunnett’s test: 
* P < 0.05). a Sedation-like effects were observed at 30 mg/kg. b Sedation-like effects were 
observed at 10 and 30 mg/kg. c Modest sedation-like effects were observed at 30 mg/kg. 
[0026] FIG. 10 is a graph of the concentration of KRM-II-81 versus percent of control for 
KRM-II-81 analyzed in the Vogel conflict procedure. After a baseline was established using a 
vehicle (1% 2-hydroxyethyl cellulose), male Sprague-Dawley rats (n = 6-8) were dosed i.p. with 
either KRM-II-81 (3, 10, 30, or 60 mg/kg) or chlordiazepoxide (20 mg/kg) 30 minutes prior to 
testing. Results were analyzed using ANOVA (Dunnett’s test: * P < 0.05; Student t-test: ** P < 
0.05). 
[0027] FIG. 11 is a graph of time versus withdrawal threshold for KRM-II-81, Gabapentin, 
and vehicle, showing the effect of KRM-II-81 on antihyperalgesia in the von Frey filament assay. 
Male Sprague-Dawley rats (n = 5) were dosed i.p. either vehicle, KRM-II-81 (30 mg/kg), or 
gabapentin (50 mg/kg) and tested in the von Frey filament assay after undergoing SNL 90 days 
prior. Results were analyzed using ANOVA (Dunnett’s test: * P < 0.05). 
[0028] FIG. 12 are graphs of compound concentration versus % MPE, showing that GABAA 
receptor PAMs, Midazolam (nonselective PAM), HZ166, KRM-II-18B, and KRM-II-81 dose-
dependently attenuated mechanical hyperalgesia in a CFA-induced inflammatory pain rat model. 
Raw data (paw withdrawal threshold, expressed in g of von Frey filament) was converted to a 
maximal possible effect value according the following equation: 
% MPE = [(test threshold (g)- control threshold (g) / (pre-CFA threshold – control threshold)] x 
100.   
[0029] FIG. 13 are graphs of compound concentration versus paw withdrawal threshold, 
showing that the benzodiazepine site antagonist flumazenil shifted the dose-effect curves of 
PAMs rightward, indicating the effect is modulated by the benzodiazepine receptor. 
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[0030] FIG. 14 are graphs of compound concentration or does versus % MPE in a three-
assay comparison, showing that midazolam produced antihyperalgesic, rate-suppressing, and 
muscle-relaxant activity at similar doses. The subunit-selective GABAA receptor PAMs HZ166, 
KRM-II-81, and KRM-II-18B seemed to selectively produce antihyperalgesic effect and produce 
rate-suppressing and muscle-relaxant activity at much larger doses.   
[0031] FIG. 15 is a graph of time versus concentration for male Sprague-Dawley rats (n = 3 
per time point) when given either a 1 mg/kg i.v. or 10 mg/kg i.p. dose.  The total plasma 
concentrations were taken at various time points.   
[0032] FIG. 16 is a graph of immobility illustrating the antidepressant effects of KRM-II-81 
assessed in the forced swim test. Male NIH Swiss mice (n = 7 – 8) were dosed i.p. with vehicle 
(1% HEC, 0.25% Tween 80, 0.05% antifoam), KRM-II-81 (3, 10, or 30 mg/kg), or imipramine 
(15 mg/kg) and assessed in the forced swim test.  Results were analyzed using ANOVA 
(Dunnett’s test * P < 0.05).   
DETAILED DESCRIPTION 
[0033] The present invention provides compounds that may be alpha 2, alpha 3, or 
alpha2/alpha3 GABAergic receptor subtype selective ligands, pharmaceutical compositions, and 
methods of use of such ligands and compositions in treatment of anxiety disorders, depression, 
epilepsy, schizophrenia and neuropathic pain.  In embodiments, such alpha 2, alpha 3 or 
alpha2/alpha3 GABAergic receptor subtype selective ligands lack ester linkages and are thus 
relatively insensitive to hydrolysis by esterases. 
Definitions 
[0034] Definitions of specific functional groups and chemical terms are described in more 
detail below. For purposes of this invention, the chemical elements are identified in accordance 
with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th 
Ed., inside cover, and specific functional groups are generally defined as described therein. 
Additionally, general principles of organic chemistry, as well as specific functional moieties and 
reactivity, are described in Organic Chemistry, Thomas Sorrell, University Science Books, 
Sausalito, 1999; Smith and March March's Advanced Organic Chemistry, 5th Edition, John Wiley 
& Sons, Inc., New York, 2001; Larock, Comprehensive Organic Transformations, VCH 
Publishers, Inc., New York, 1989; Carruthers, Some Modern Methods of Organic Synthesis, 3rd 
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Edition, Cambridge University Press, Cambridge, 1987; the entire contents of each of which are 
incorporated herein by reference. 
[0035] The term "acyl" refers to an alkylcarbonyl, cycloalkylcarbonyl, heterocyclylcarbonyl, 
arylcarbonyl or heteroarylcarbonyl substituent, any of which may be further substituted (e.g., 
with one or more substituents).  
[0036] The term "alkyl" refers to a straight or branched hydrocarbon chain, containing the 
indicated number of carbon atoms. For example, C1-C12 alkyl indicates that the alkyl group may 
have from 1 to 12 (inclusive) carbon atoms, and C1-C4 alkyl indicates that the alkyl group may 
have from 1 to 4 (inclusive) carbon atoms.  An alkyl group may be optionally substituted.  
Examples of C1-C4 alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl and 
tert-butyl. 
[0037] The term "alkenyl" refers to a straight or branched hydrocarbon chain having one or 
more double bonds. Examples of alkenyl groups include, but are not limited to, allyl, propenyl, 
2-butenyl, 3-hexenyl and 3-octenyl groups.  One of the double bond carbons may optionally be 
the point of attachment of the alkenyl substituent.  An alkenyl group may be optionally 
substituted.   
[0038] The term "alkynyl" refers to a straight or branched hydrocarbon chain having one or 
more triple bonds. Examples of alkynyl groups include, but are not limited to, ethynyl, propargyl, 
and 3-hexynyl.  One of the triple bond carbons may optionally be the point of attachment of the 
alkynyl substituent.  An alkynyl group may be optionally substituted.   
[0039] The term "aryl" refers to an aromatic monocyclic, bicyclic, or tricyclic hydrocarbon 
ring system, wherein any ring atom capable of substitution can be substituted (e.g., with one or 
more substituents).  Examples of aryl moieties include, but are not limited to, phenyl, naphthyl, 
and anthracenyl.   
[0040] The term "arylalkyl" refers to an alkyl moiety in which an alkyl hydrogen atom is 
replaced with an aryl group.  Arylalkyl includes groups in which more than one hydrogen atom 
has been replaced with an aryl group. Examples of arylalkyl groups include benzyl, 2-
phenylethyl, 3-phenylpropyl, 9-fluorenyl, benzhydryl, and trityl groups.  
[0041] The term "cycloalkyl" as used herein refers to nonaromatic, saturated or partially 
unsaturated cyclic, bicyclic, tricyclic or polycyclic hydrocarbon groups having 3 to 12 carbons 
(e.g., 3, 4, 5, 6 or 7 carbon atoms). Any ring atom can be substituted (e.g., with one or more 
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substituents).  Cycloalkyl groups can contain fused rings. Fused rings are rings that share one or 
more common carbon atoms. Examples of cycloalkyl groups include, but are not limited to, 
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, 
methylcyclohexyl, adamantyl, norbornyl and norbornenyl. 
[0042] The term "halo" or "halogen" as used herein refers to any radical of fluorine, chlorine, 
bromine or iodine.  
[0043] The term "haloalkyl" as used herein refers to an alkyl in which one or more hydrogen 
atoms are replaced with a halogen, and includes alkyl moieties in which all hydrogens have been 
replaced with halogens (e.g., perfluoroalkyl such as CF3).  
[0044] The term "heteroaryl" as used herein refers to an aromatic 5-8 membered monocyclic, 
8-12 membered bicyclic, or 11-14 membered tricyclic ring system having 1-3 heteroatoms if 
monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms 
independently selected from O, N, S, P and Si (e.g., carbon atoms and 1-3, 1-6, or 1-9 
heteroatoms independently selected from O, N, S, P and Si if monocyclic, bicyclic, or tricyclic, 
respectively). Any ring atom can be substituted (e.g., with one or more substituents). Heteroaryl 
groups can contain fused rings, which are rings that share one or more common atoms. Examples 
of heteroaryl groups include, but are not limited to, radicals of pyridine, pyrimidine, pyrazine, 
pyridazine, pyrrole, imidazole, pyrazole, oxazole, isoxazole, furan, thiazole, isothiazole, 
thiophene, quinoline, isoquinoline, quinoxaline, quinazoline, cinnoline, indole, isoindole, 
indolizine, indazole, benzimidazole, phthalazine, pteridine, carbazole, carboline, phenanthridine, 
acridine, phenanthroline, phenazine, naphthyridines and purines. 
[0045] The term "heterocyclyl" as used herein refers to a nonaromatic, saturated or partially 
unsaturated 3-10 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic 
ring system having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 
heteroatoms if tricyclic, said heteroatoms selected from O, N, S, Si and P (e.g., carbon atoms and 
1-3, 1-6, or 1-9 heteroatoms of O, N, S, Si and P if monocyclic, bicyclic, or tricyclic, 
respectively).  Any ring atom can be substituted (e.g., with one or more substituents). 
Heterocyclyl groups can contain fused rings, which are rings that share one or more common 
atoms. Examples of heterocyclyl groups include, but are not limited to, radicals of 
tetrahydrofuran, tetrahydrothiophene, tetrahydropyran, piperidine, piperazine, morpholine, 
pyrroline, pyrimidine, pyrrolidine, indoline, tetrahydropyridine, dihydropyran, thianthrene, pyran, 
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benzopyran, xanthene, phenoxathiin, phenothiazine, furazan, lactones, lactams such as 
azetidinones and pyrrolidinones, sultams, sultones, and the like.  
[0046] The term “hydroxy” refers to an –OH radical.  The term "alkoxy" refers to an –O-
alkyl radical.   The term “aryloxy” refers to an –O-aryl radical.  The term “haloalkoxy” refers to 
an –O-haloalkyl radical. 
[0047] The term "substituent" refers to a group "substituted" on an alkyl, alkenyl, alkynyl, 
cycloalkyl, heterocyclyl, aryl, arylalkyl or heteroaryl group at any atom of that group.  Suitable 
substituents include, without limitation: acyl, acylamido, acyloxy, alkoxy, alkyl, alkenyl, alkynyl, 
amido, amino, carboxy, cyano, ester, halo, hydroxy, imino, nitro, oxo (e.g., C=O), phosphonate, 
sulfinyl, sulfonyl, sulfonate, sulfonamino, sulfonamido, thioamido, thiol, thioxo (e.g., C=S), and 
ureido.  In embodiments, substituents on a group are independently any one single, or any 
combination of the aforementioned substituents. In embodiments, a substituent may itself be 
substituted with any one of the above substituents.  
[0048] The above substituents may be abbreviated herein, for example, the abbreviations Me, 
Et and Ph represent methyl, ethyl and phenyl, respectively. A more comprehensive list of the 
abbreviations used by organic chemists appears in the first issue of each volume of the Journal of 
Organic Chemistry; this list is typically presented in a table entitled Standard List of 
Abbreviations. The abbreviations contained in said list, and all abbreviations used by organic 
chemists of ordinary skill in the art, are hereby incorporated by reference.  
[0049] For compounds, groups and substituents thereof may be selected in accordance with 
permitted valence of the atoms and the substituents, such that the selections and substitutions 
result in a stable compound, e.g., which does not spontaneously undergo transformation such as 
by rearrangement, cyclization, elimination, etc. 
[0050] Where substituent groups are specified by their conventional chemical formulae, 
written from left to right, they optionally encompass substituents resulting from writing the 
structure from right to left, e.g., -CH2O- optionally also recites -OCH2-. 
[0051] In accordance with a convention used in the art, the group: 
 
is used in structural formulas herein to depict the bond that is the point of attachment of the 
moiety or substituent to the core or backbone structure. 
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[0052] In the context of treating a disorder, the term “effective amount” as used herein refers 
to an amount of the compound or a composition comprising the compound which is effective, 
upon single or multiple dose administrations to a subject, in treating a cell, or curing, alleviating, 
relieving or improving a symptom of the disorder in a subject. An effective amount of the 
compound or composition may vary according to the application.  In the context of treating a 
disorder, an effective amount may depend on factors such as the disease state, age, sex, and 
weight of the individual, and the ability of the compound to elicit a desired response in the 
individual.  In an example, an effective amount of a compound is an amount that produces a 
statistically significant change in a given parameter as compared to a control, such as in cells 
(e.g., a culture of cells) or a subject not treated with the compound. 
[0053] It is specifically understood that any numerical value recited herein (e.g., ranges) 
includes all values from the lower value to the upper value, i.e., all possible combinations of 
numerical values between the lowest value and the highest value enumerated are to be 
considered to be expressly stated in this application.  For example, if a concentration range is 
stated as 1% to 50%, it is intended that values such as 2% to 40%, 10% to 30%, or 1% to 3%, 
etc., are expressly enumerated in this specification.  These are only examples of what is 
specifically intended. 
Compounds 
[0054] Compounds may be of the following formula (I): 
 (I) 
or a salt thereof, wherein: 
X is selected from the group consisting of N, C-H, C-F, C-Cl, C-Br, C-I, and C-NO2; 
R1 is selected from the group consisting of -C≡CH, -C≡C-Si(CH3)3, -cyclopropyl, and 
bicycle[1.1.1]pentane ( ); and 
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R2 is selected from the group consisting of -H, -CH3, -CH2CH3 and -CH(CH3)2. 
[0055] In some embodiments, X is N.  In some embodiments, X is CH.  In some 
embodiments, X is CF. In some embodiments, X is CCl. In some embodiments, X is CBr. In 
some embodiments, X is CI.  In some embodiments, R1 is -C≡CH. In some embodiments, R1 is –
C≡C-Si(CH3)3. In some embodiments, R1 is –cyclopropyl. In some embodiments, R1 is 
bicycle[1.1.1]pentane. In some embodiments, R2 is -H. In some embodiments, R2 is –CH3. In 
some embodiments, R2 is –CH2CH3. In some embodiments, R2 is –CH(CH3)2.  In particular 
embodiments, in compounds of formula (I), R2 is H. 
[0056] Compounds may be of the following formula (II):  
 (II) 
or a salt thereof, wherein: 
X is selected from the group consisting of N, C-H, C-F, C-Cl, C-Br, C-I, and C-NO2; 
R1 is selected from the group consisting of  -C≡CH, -C≡C-Si(CH3)3, -cyclopropyl, and 
bicycle[1.1.1]pentane ( ); 
R2 is selected from the group consisting of -H, -CH3, -CH2CH3, and -CH(CH3)2; and 
R3 is selected from the group consisting of -H, -CH3, -CH2CH3, -CH(CH3)2, -F, -Cl, -CF3, 
and -CCl3. 
[0057] In some embodiments, X is N.  In some embodiments, X is CH.  In some 
embodiments, X is CF. In some embodiments, X is CCl. In some embodiments, X is CBr. In 
some embodiments, X is CI.  In some embodiments, R1 is -C≡CH. In some embodiments, R1 is –
C≡C-Si(CH3)3. In some embodiments, R1 is –cyclopropyl. In some embodiments, R1 is 
bicycle[1.1.1]pentane. In some embodiments, R2 is -H. In some embodiments, R2 is –CH3. In 
some embodiments, R2 is –CH2CH3. In some embodiments, R2 is –CH(CH3)2.  In some 
embodiments, R3 is -H.  In some embodiments, R3 is –CH3. In some embodiments, R3 is –
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CH2CH3. In some embodiments, R3 is –CH(CH3)2. In some embodiments, R3 is F. In some 
embodiments, R3 is Cl. In some embodiments, R3 is –CF3. In some embodiments, R3 is –CCl3. 
[0058] In particular embodiments, in compounds of formula (II), R2 is H. 
[0059] Compounds may be of the following formula (III):  
 (III) 
or a salt thereof, wherein: 
X is selected from the group consisting of N, C-H, C-F, C-Cl, C-Br, C-I, and C-NO2; 
R1 is selected from the group consisting of -C≡CH, -C≡C-Si(CH3)3, -cyclopropyl, and 
bicycle[1.1.1]pentane ( ); 
R2 is selected from the group consisting of -H, -CH3, -CH2CH3, and  -CH(CH3)2; and 
R3 is selected from the group consisting of -H, -CH3, -CH2CH3, -CH(CH3)2, -F, -Cl, -CF3, 
and -CCl3. 
[0060] In some embodiments, X is N.  In some embodiments, X is CH.  In some 
embodiments, X is CF. In some embodiments, X is CCl. In some embodiments, X is CBr. In 
some embodiments, X is CI.  In some embodiments, R1 is -C≡CH. In some embodiments, R1 is –
C≡C-Si(CH3)3. In some embodiments, R1 is –cyclopropyl. In some embodiments, R1 is 
bicycle[1.1.1]pentane. In some embodiments, R2 is -H. In some embodiments, R2 is –CH3. In 
some embodiments, R2 is –CH2CH3. In some embodiments, R2 is –CH(CH3)2.  In some 
embodiments, R3 is -H.  In some embodiments, R3 is –CH3. In some embodiments, R3 is –
CH2CH3. In some embodiments, R3 is –CH(CH3)2. In some embodiments, R3 is F. In some 
embodiments, R3 is Cl. In some embodiments, R3 is –CF3. In some embodiments, R3 is –CCl3. 
[0061] In particular embodiments, in compounds of formula (III), R2 is H. 
[0062] Compounds may be of the following formula (IV): 
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 (IV) 
or a salt thereof, wherein: 
X is selected from the group consisting of N, C-H, C-F, C-Cl, C-Br, C-I, and C-NO2; 
R11 is Br; and 
R12 is selected from the group consisting of -H, -CH3, -CH2CH3 and -CH(CH3)2. 
[0063] In some embodiments, X is N.  In some embodiments, X is CH.  In some 
embodiments, X is CF. In some embodiments, X is CCl. In some embodiments, X is CBr. In 
some embodiments, X is CI.  In some embodiments, R2 is -H. In some embodiments, R2 is –CH3. 
In some embodiments, R12 is –CH2CH3. In some embodiments, R12 is –CH(CH3)2.   
[0064] In particular embodiments, in compounds of formula (IV), R12 is H. 
[0065] Compounds may be of the following formula (V):  
 (V) 
or a salt thereof, wherein: 
X is selected from the group consisting of N, C-H, C-F, C-Cl, C-Br, C-I, and C-NO2; 
R11 is Br; 
R12 is selected from the group consisting of -H, -CH3, -CH2CH3, and -CH(CH3)2; and 
R13 is selected from the group consisting of -H, -CH3, -CH2CH3, -CH(CH3)2, -F, -Cl, -CF3, 
and -CCl3. 
[0066] In some embodiments, X is N.  In some embodiments, X is CH.  In some 
embodiments, X is CF. In some embodiments, X is CCl. In some embodiments, X is CBr. In 
some embodiments, X is CI.  In some embodiments, R12 is -H. In some embodiments, R12 is –
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CH3. In some embodiments, R12 is –CH2CH3. In some embodiments, R12 is –CH(CH3)2.  In some 
embodiments, R13 is -H.  In some embodiments, R13 is –CH3. In some embodiments, R13 is –
CH2CH3. In some embodiments, R13 is –CH(CH3)2. In some embodiments, R13 is F. In some 
embodiments, R13 is Cl. In some embodiments, R13 is –CF3. In some embodiments, R13 is –CCl3. 
[0067] In particular embodiments, in compounds of formula (V), R12 is H. 
[0068] Compounds may be of the following formula (VI):  
 (VI) 
or a salt thereof, wherein: 
X is selected from the group consisting of N, C-H, C-F, C-Cl, C-Br, C-I, and C-NO2; 
R11 is Br; 
R12 is selected from the group consisting of -H, -CH3, -CH2CH3, and  -CH(CH3)2; and 
R13 is selected from the group consisting of -H, -CH3, -CH2CH3, -CH(CH3)2, -F, -Cl, -CF3, 
and -CCl3. 
[0069] In some embodiments, X is N.  In some embodiments, X is CH.  In some 
embodiments, X is CF. In some embodiments, X is CCl. In some embodiments, X is CBr. In 
some embodiments, X is CI.  In some embodiments, R12 is -H. In some embodiments, R12 is –
CH3. In some embodiments, R12 is –CH2CH3. In some embodiments, R12 is –CH(CH3)2.  In some 
embodiments, R13 is -H.  In some embodiments, R13 is –CH3. In some embodiments, R13 is –
CH2CH3. In some embodiments, R13 is –CH(CH3)2. In some embodiments, R13 is F. In some 
embodiments, R13 is Cl. In some embodiments, R13 is –CF3. In some embodiments, R13 is –CCl3. 
[0070] In particular embodiments, in compounds of formula (VI), R2 is H. 
[0071] Suitable compounds include the following: 
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[0072] In some embodiments, the compound is not 
. 
 
[0073] For compounds of formula (I), (II), (III), (IV), (V), and (VI), groups and substituents 
thereof may be selected in accordance with permitted valence of the atoms and the substituents, 
such that the selections and substitutions result in a stable compound, e.g., which does not 
spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc. 
[0074] Compounds of formula (I), (II), (III), (IV), (V), and (VI) include compounds that 
differ only in the presence of one or more isotopically enriched atoms. For example, compounds 
may have the present structures except for the replacement of hydrogen by deuterium or tritium, 
or the replacement of a carbon by a 13C- or 14C-enriched carbon. 
[0075] A compound of formula (I), (II), (III), (IV), (V), or (VI) can be in the form of a salt, 
e.g., a pharmaceutically acceptable salt. The term "pharmaceutically acceptable salt" includes 
salts of the active compounds that are prepared with relatively nontoxic acids or bases, 
depending on the particular substituents found on the compounds.  Suitable pharmaceutically 
acceptable salts of the compounds of this invention include acid addition salts which may, for 
example, be formed by mixing a solution of the compound according to the invention with a 
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solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, 
methanesulfonic acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic 
acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.  Furthermore, where the 
compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts 
thereof may include alkali metal salts, e.g. sodium or potassium salts, alkaline earth metal salts, 
e.g. calcium or magnesium salts; and salts formed with suitable organic ligands, e.g. quaternary 
ammonium salts. 
[0076] Neutral forms of the compounds may be regenerated by contacting the salt with a 
base or acid and isolating the parent compound in a conventional manner.  The parent form of 
the compound differs from the various salt forms in certain physical properties, such as solubility 
in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for 
the purposes of this disclosure. 
[0077] In addition to salt forms, the present invention may also provide compounds of 
formula (I), (II) (III), (IV), (V), or (VI) that are in a prodrug form. Prodrugs of the compounds 
are those compounds that readily undergo chemical changes under physiological conditions to 
provide the compounds.  Prodrugs can be converted to the compounds of the present invention 
by chemical or biochemical methods in an ex vivo environment.  For example, prodrugs can be 
slowly converted to the compounds of the present invention when placed in a transdermal patch 
reservoir with a suitable enzyme or chemical reagent. 
[0078] Compounds of formula (I), (II) (III), (IV), (V), and (VI) can be, for example, an 
enantiomerically enriched isomer of a stereoisomer described herein. Enantiomer, as used herein, 
refers to either of a pair of chemical compounds whose molecular structures have a mirror-image 
relationship to each other.  For example, a compound may have an enantiomeric excess of at 
least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 
80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%.   
[0079] A preparation of a compound of formula (I), (II) (III), (IV), (V), or (VI) may be 
enriched for an isomer of the compound having a selected stereochemistry, e.g., R or S, 
corresponding to a selected stereocenter.  For example, the compound may have a purity 
corresponding to a compound having a selected stereochemistry of a selected stereocenter of at 
least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%.  A 
compound can, for example, include a preparation of a compound disclosed herein that is 
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enriched for a structure or structures having a selected stereochemistry, e.g., R or S, at a selected 
stereocenter. 
[0080] In some embodiments, a preparation of a compound of formula (I), (II) (III), (IV), (V), 
or (VI) may be enriched for isomers (subject isomers) which are diastereomers of the compound.  
Diastereomer, as used herein, refers to a stereoisomer of a compound having two or more chiral 
centers that is not a mirror image of another stereoisomer of the same compound.  For example, 
the compound may have a purity corresponding to a compound having a selected diastereomer of 
at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%.  
[0081] When no specific indication is made of the configuration at a given stereocenter in a 
compound, any one of the configurations or a mixture of configurations is intended.   
[0082] Compounds may be prepared in racemic form or as individual enantiomers or 
diastereomers by either stereospecific synthesis or by resolution. The compounds may, for 
example, be resolved into their component enantiomers or diastereomers by standard techniques, 
such as the formation of stereoisomeric pairs by salt formation with an optically active base, 
followed by fractional crystallization and regeneration of the free acid. The compounds may also 
be resolved by formation of stereoisomeric esters or amides, followed by chromatographic 
separation and removal of the chiral auxiliary. Alternatively, the compounds may be resolved 
using a chiral HPLC column. The enantiomers also may be obtained from kinetic resolution of 
the racemate of corresponding esters using lipase enzymes. 
[0083] A compound of formula (I), (II) (III), (IV), (V), or (VI) can also be modified by 
appending appropriate functionalities to enhance selective biological properties. Such 
modifications are known in the art and include those that increase biological penetration into a 
given biological system (e.g., blood, lymphatic system, central nervous system), increase oral 
availability, increase solubility to allow administration by injection, alter metabolism, and/or 
alter rate of excretion. Examples of these modifications include, but are not limited to, 
esterification with polyethylene glycols, derivatization with pivolates or fatty acid substituents, 
conversion to carbamates, hydroxylation of aromatic rings, and heteroatom substitution in 
aromatic rings. 
Synthesis of Compounds 
[0084] Compounds of formula (I), (II) (III), (IV), (V), and (VI) may be synthesized from 
commercially available starting materials.  Exemplary syntheses are illustrated below in the 
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Examples. The starting materials (1, 4, 9, and 14) in Schemes I, II, III, and IV have been 
previously synthesized (“Stereospecific anxiolytic and anticonvulsant agents with reduced 
muscle-relaxant, sedative-hypnotic and ataxic effects,” Cook, J.M.; Zhou, H.; Huang, S.; Sarma, 
P.V.V.S.; Zhang, C., U.S. Patent Publication No. 2006/0003995 A1, Published January 5, 2006). 
[0085] Relevant references include the following: 
van Leusen, A.M.; Hoogenboom, B.E.; Sideruis, H., “A novel and efficient synthesis of 
oxazoles from tosylmethylisocyanide and carbonyl compounds”, Tetrahedron Letters, 13, 2369-
2372, 1972; 
Webb, M.R.; Donald, C.; Taylor, R.J.K., “A general route to the Streptomyces-derived 
inthomycin family: the first synthesis of (+)-inthomycin B”, Tetrahedron Letters, 47, 549-552, 
2006; and 
Bull, J.A.; Balskus, E.P.; Horan, R.A.J.; Langner, M.; Ley, S.V., “Total synthesis of 
potent antifungal marine bisoxazole natural products bengazoles A and B”, Chem. Eur. J., 13, 
5515-5538, 2007 
[0086] Other methods of synthesizing the compounds of the formulae herein will be evident 
to those of ordinary skill in the art.  Synthetic chemistry transformations and protecting group 
methodologies (protection and deprotection) useful in synthesizing the compounds are known in 
the art and include, for example, those such as described in R. Larock, Comprehensive Organic 
Transformations, VCH Publishers (1989); T.W. Greene and P.G.M. Wuts, Protective Groups in 
Organic Synthesis, 2d. Ed., John Wiley and Sons (1991); L. Fieser and M. Fieser, Fieser and 
Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed., 
Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995), and subsequent 
editions thereof.  
Evaluation of compounds 
[0087] Compounds may be analyzed using a number of methods, including receptor binding 
studies and in vivo methods.   
[0088] For example, the GABAA subunit selectivity of compounds can be evaluated, for 
example, using competitive binding assays.  Such assays have been described (Choudhary et al. 
Mol Pharmacol. 1992, 42, 627-33; Savić et al. Progress in Neuro-Psychopharmacology & 
Biological Psychiatry, 2010, 34, 376–386).  The assays involve the use of a radiolabeled 
compound known to bind to GABAA receptors, such as [
3H]flunitrazepam.  Membrane proteins 
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can be harvested and incubated with the radiolabeled compound, and non-specific binding can be 
evaluated by comparing binding of the radiolabeled compound to another, non-labeled 
compound (e.g., diazepam).   Bound radioactivity can be quantified by liquid scintillation 
counting.  Membrane protein concentrations can be determined using commercially available 
assay kits (e.g., from Bio-Rad, Hercules, CA).   
[0089] Compounds can also be evaluated in electrophysiological assays in Xenopus oocytes.  
Compounds can be preapplied to the oocytes before the addition of GABA, which can 
then be coapplied with the compounds until a peak response is observed. Between 
applications, oocytes can be washed to ensure full recovery from desensitization. For 
current measurements, the oocytes can be impaled with microelectrodes, and 
recordings performed using voltage clamps. 
[0090] Compounds described herein may be GABAA receptor ligands which exhibit 
anxiolytic activity due to increased agonist efficacy at GABAA/α2, GABAA/α3, GABAA/α2/3 
and/or GABAA/α5 receptors.  The compounds may possess at least 2-fold, suitably at least 5-fold, 
and advantageously at least a 10-fold, selective efficacy for the GABAA/α2, GABAA/α3, and/or 
GABAA/α5 receptors relative to the GABAA/α1 receptors.  However, compounds which are not 
selective in terms of their agonist efficacy for the GABAA/α2, GABAA/α3, and/or GABAA/α5 
receptors are also encompassed within the scope of the present invention.  Such compounds will 
desirably exhibit functional selectivity by demonstrating anxiolytic activity with decreased 
sedative-hypnotic/muscle relaxant/ataxic activity due to decreased efficacy at GABAA/α1 
receptors. 
[0091] GABAergic receptor subtype selective compounds which are ligands of the GABAA 
receptors acting as agonists or partial agonists are referred to hereinafter as "GABAA receptor 
agonists" or "GABAA receptor partial agonists" or "agonists" or "partial agonists".  In particular 
these are compounds that are ligands of the benzodiazepine (BZ) binding site of the GABAA 
receptors, and hence acting as BZ site agonists or partial agonists.  Such ligands also include 
compounds acting at the GABA site or at modulatory sites other than the benzodiazepine site of 
GABAA receptors. 
[0092] GABAergic receptor subtype selective compounds act preferably by selectively or 
preferentially activating as agonists or partial agonists the GABAA/2 receptors, GABAA/3 
receptors, or GABAA/α2/3 as compared to the GABAA/1 receptors. A selective or preferential 
OTT1436    020871-9108-US00 
 586 
therapeutic agent has less binding affinity or efficacy to the GABAA/1 receptors compared to 
the GABAA/2, GABAA/3, or GABAA/α2/3 receptors. Alternatively, the agent binds to 
GABAA/1, GABAA/2 and GABAA/3 receptors with a comparable affinity but exerts 
preferential efficacy of receptor activation at GABAA/2, GABAA/3, GABAA/α2/3, or 
GABAA/α5 receptors compared to the GABAA/1 receptors. A selective agent of the present 
invention can also have a greater or lesser ability to bind or to activate GABAA/5 receptors 
relative to GABAA/2 and GABAA/3 receptors. The Bz/GABA agonists act at the 
benzodiazepine site of the respective GABAA receptors but are not restricted to this drug binding 
domain in its receptor interactions.   
[0093] Other methods for evaluating compounds are known to those skilled in the art.  For 
example, an assessment of anxiolytic effects of compounds can be accomplished objectively and 
quantitatively with operant-based conflict procedures, as described in Fischer et al. 
Neuropharmacology 59 (2010) 612-618.  Briefly, behavior which is positively reinforced can be 
suppressed in these procedures by response-contingent administration of a noxious stimulus such 
as mild electric shock.  If a compound has an anxiolytic effect it increases the rates of responding 
that are normally suppressed by response-contingent delivery of shock.  The strength of conflict 
procedures is their predictive validity with respect to expected therapeutic effects in humans.  
Results from the Fischer et al. indicate that benzodiazepine-like drugs that have pharmacological 
activity for α2GABAA and/or α3GABAA receptors and low receptor activity at α 1GABAA and 
α5GABAA receptors may be useful, particularly as non-sedating anxiolytics and agents to treat 
neuropathic pain.   
[0094] Anxiolytic activity and locomotor activity can evaluated in the light/dark box by a 
method developed by Crawley (Neurosci Biobehav Rev 1985, 9, 37-44).  The light/dark box is an 
extremely simple noninvasive test for anxiolytic activity. Mice or rats are administered new 
agents 15-30 minutes prior to testing and placed in the dark portion of the light/dark box. The 
amount of time it takes the animals to enter the light side and how long they stay versus controls 
(e.g., diazepam) are a measure of anxiolytic activity. The amount of exploration (or lack thereof) 
can be used as a preliminary measure of sedation.  
[0095] The marble burying assay (Deacon, Nat Protocols, 2006, 1, 122; Kinsey et al., 
Pharmacol Biochem Behav 2011, 98, 21) is another anxiolytic test. Mice or rats are pretreated 
the test compound 1 h before being placed in a cage filled with wood chip bedding. The rodents 
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are then timed  and the number of mables buried are counted. A reduction in marble burying 
compared to control is considered an anxiolytic effect. 
[0096] In the elevated plus maze (Savic et al. Pharmacol Biochem Behav 2004, 79, 279-290), 
test compounds can be administrated ip 15 minutes prior to testing at which time mice can be 
placed in the center of the maze under a bright light condition. The number of crosses as well as 
the time spent in the open and closed arms of the maze for the following 15 minutes can be 
recorded. Control values for the percentage of entries into the open arms, percentage of time 
spent in the open arms, and total entries can be correlated to values obtained with controls (e.g., 
diazepam).  Promising compounds may not suppress locomotor activity at up to 100 mg/kg and 
may be anxiolytic. 
[0097] For evaluation of potential to treat schizophrenia, compounds may be tested using a 
mouse model as described in Gill et al. Neuropsychopharmacology 2011, 36: 1903-1911.  This 
mouse model of schizophrenia arises from a development disturbance induced by the 
administration of a DNA-methylating agent, methylazoxymethanol acetate (MAM), to pregnant 
dams on gestational day 17.  The MAM-treated offspring display structural and behavioral 
abnormalities, consistent with those observed in human patients with schizophrenia. Antagonism 
or genetic deletion of the α5GABAA receptor (α5GABAA R) leads to behaviors that resemble 
some of the behavioral abnormalities seen in schizophrenia, including prepulse inhibition to 
startle and impaired latent inhibition. The MAM model can be used to show the effectiveness of 
a benzodiazepine-positive allosteric modulator (PAM) compound selective for the α5 subunit of 
the GABAAR.  In Gill et al., the pathological increase in tonic dopamine transmission in the 
brain was reversed, and behavioral sensitivity to psychostimulants observed in MAM rats was 
reduced.  The data suggests that such compounds would be effective in alleviating dopamine-
mediated psychosis. 
[0098] Compounds selective for GABAA receptor subunits can be tested for the ability to 
suppress seizures in several standard rat and mouse models of epilepsy, as described in U.S. 
Patent Application Publication No. US 2011/0261711. Anticonvulsant activity of compounds can 
be compared to diazepam. The standard models incorporated into anticonvulsant screening 
include the maximal electroshock test (MES), the subcutaneous Metrazol test (scMet), and 
evaluations of toxicity (TOX). The data for each condition can be presented as a ratio of either 
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the number of animals protected or toxic (loss of locomotor activity) over the number of animals 
tested at a given time point and dose.  
[0099] The MES is a model for generalized tonic-clonic seizures and provides an indication 
of a compound's ability to prevent seizure spread when all neuronal circuits in the brain are 
maximally active. These seizures are highly reproducible and are electrophysiologically 
consistent with human seizures. For all tests based on MES convulsions, 60 Hz of alternating 
current (50 mA in mice, 150 in rats) is delivered for by corneal electrodes which have been 
primed with an electrolyte solution containing an anesthetic agent (0.5% tetracaine HCL). For 
Test 1, mice are tested at various intervals following doses of 30, 100 and 300 mg/kg of test 
compound given by ip injection of a volume of 0.01 mL/g. In Test 2, rats are tested after a dose 
of 30 mg/kg (po) in a volume of 0.04 mL/g. Test 8 uses varying doses administered via i.p. 
injection, again in a volume of 0.04 ml/g. An animal is considered "protected" from MES-
induced seizures upon abolition of the hindlimb tonic extensor component of the seizure 
(Swinyard, E. A., et al. in Antiepileptic Drugs, Levy, R. H. M., et al., Eds.; Raven Press: New 
York, 1989; pp 85-102; White, H. S., et al., Ital J Neurol Sci. 1995a, 16, 73-7; White, H. S., et al., 
in Antiepileptic Drugs, Levy, R. H. M., Meldrum, B. S., Eds.; Raven Press: New York, pp 99-
110, 1995b).  
[00100] Subcutaneous injection of the convulsant Metrazol produces clonic seizures in 
laboratory animals. The scMet test detects the ability of a test compound to raise the seizure 
threshold of an animal and thus protect it from exhibiting a clonic seizure. Animals can 
pretreated with various doses of the test compound (in a similar manner to the MES test, 
although a dose of 50 mg/kg (po) is the standard for Test 2 scMet). At the previously determined 
TPE of the test compound, the dose of Metrazol which will induce convulsions in 97% of 
animals (CD.sub.97: 85 mg/kg mice) is injected into a loose fold of skin in the midline of the 
neck. The animals can be placed in isolation cages to minimize stress (Swinyard et al. J. Physiol. 
1961, 132, 97-0.102) and observed for the next 30 minutes for the presence or absence of a 
seizure. An episode of clonic spasms, approximately 3-5 seconds, of the fore and/or hindlimbs, 
jaws, or vibrissae is taken as the endpoint. Animals which do not meet this criterion are 
considered protected.  
[00101] To assess a compound's undesirable side effects (toxicity), animals may monitored 
for overt signs of impaired neurological or muscular function. In mice, the rotorod procedure 
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(Dunham, M. S. et al. J. Amer. Pharm. Ass. Sci. Ed. 1957, 46, 208-209) is used to disclose 
minimal muscular or neurological impairment. When a mouse is placed on a rod that rotates at a 
speed of 6 rpm, the animal can maintain its equilibrium for long periods of time. The animal is 
considered toxic if it falls off this rotating rod three times during a 1-min period. In rats, minimal 
motor deficit is indicated by ataxia, which is manifested by an abnormal, uncoordinated gait. 
Rats used for evaluating toxicity are examined before the test drug is administered, since 
individual animals may have peculiarities in gait, equilibrium, placing response, etc., which 
might be attributed erroneously to the test substance. In addition to MMI, animals may exhibit a 
circular or zigzag gait, abnormal body posture and spread of the legs, tremors, hyperactivity, lack 
of exploratory behavior, somnolence, stupor, catalepsy, loss of placing response and changes in 
muscle tone. 
[00102] To further characterize the anticonvulsant activity of compounds, a hippocampus 
kindling screen can be performed. This screen is a useful adjunct to the traditional MES and 
scMet tests for identification of a substance potential utility for treating complex partial seizures. 
[00103] Benzodiazepines can be highly effective drugs in certain treatment paradigms. They 
are routinely employed for emergency situations such as status epilepticus and other acute 
conditions. But their use in chronic convulsant diseases has been limited due to side effects such 
as sedation and with high doses respiratory depression, hypotension and other effects. Further it 
has long been purported that chronic administration of this class of drugs can lead to tolerance to 
the anticonvulsant effects. This has limited their utility as first line treatment for chronic 
anticonvulsant conditions. Discovery of a potent BDZ with a decreased side effect profile and 
efficacy over extended treatment periods would be highly desirable.  
[00104] In order to assess the effects of tolerance of compounds, whether tolerance could be 
detected using a chronic (5 day) dose of the candidate drug can be studied. With typical 
benzodiazepines (for example diazepam), tolerance to the anticonvulsant effects of the drug are 
evident before 5 days have passed, consequently studies can be done for only 5 days. The dose to 
be used may be the predetermined ED50 against the scMet seizure model.  
Compositions and Routes of Administration 
[00105] In another aspect, the invention provides pharmaceutical compositions comprising 
one or more compounds of this invention in association with a pharmaceutically acceptable 
carrier.  Such compositions may be in unit dosage forms such as tablets, pills, capsules, powders, 
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granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, 
ampoules, auto-injector devices or suppositories; for oral, parenteral, intranasal, sublingual or 
rectal administration, or for administration by inhalation or insufflation.  It is also envisioned that 
compounds may be incorporated into transdermal patches designed to deliver the appropriate 
amount of the drug in a continuous fashion.  For preparing solid compositions such as tablets, the 
principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting 
ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, 
dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid 
preformulation composition containing a homogeneous mixture for a compound of the present 
invention, or a pharmaceutically acceptable salt thereof.  When referring to these preformulation 
compositions as homogeneous, it is meant that the active ingredient is dispersed evenly 
throughout the composition so that the composition may be easily subdivided into equally 
effective unit dosage forms such as tablets, pills and capsules.  This solid preformulation 
composition is then subdivided into unit dosage forms of the type described above containing 
from 0.1 to about 500 mg of the active ingredient of the present invention.  Typical unit dosage 
forms contain from 1 to 100 mg, for example, 1, 2, 5, 10, 25, 50, or 100 mg, of the active 
ingredient.  The tablets or pills of the novel composition can be coated or otherwise compounded 
to provide a dosage form affording the advantage of prolonged action.  For example, the tablet or 
pill can comprise an inner dosage and an outer dosage component, the latter being in the form of 
an envelope over the former.  The two components can be separated by an enteric layer, which 
serves to resist disintegration in the stomach and permits the inner component to pass intact into 
the duodenum or to be delayed in release.  A variety of materials can be used for such enteric 
layers or coatings, such materials including a number of polymeric acids and mixtures of 
polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate. 
[00106] The liquid forms in which the compositions of the present invention may be 
incorporated for administration orally or by injection include aqueous solutions, suitably flavored 
syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed 
oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles.  
Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural 
gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, 
methylcellulose, polyvinylpyrrolidone or gelatin.  
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[00107] Suitable dosage level is about 0.01 to 250 mg/kg per day, about 0.05 to 100 mg/kg 
per day, or about 0.05 to 5 mg/kg per day.  The compounds may be administered on a regimen of 
1 to 4 times per day, or on a continuous basis via, for example, the use of a transdermal patch. 
[00108] Pharmaceutical compositions for enteral administration, such as nasal, buccal, rectal 
or, especially, oral administration, and for parenteral administration, such as intravenous, 
intramuscular, subcutaneous, peridural, epidural or intrathecal administration, are suitable. The 
pharmaceutical compositions comprise from approximately 1% to approximately 95% active 
ingredient, or from approximately 20% to approximately 90% active ingredient.  
[00109] For parenteral administration including intracoronary, intracerebrovascular, or 
peripheral vascular injection/infusion preference is given to the use of solutions of the subunit 
selective GABAA receptor agonist, and also suspensions or dispersions, especially isotonic 
aqueous solutions, dispersions or suspensions which, for example, can be made up shortly before 
use. The pharmaceutical compositions may be sterilized and/or may comprise excipients, for 
example preservatives, stabilizers, wetting agents and/or emulsifiers, solubilizers, viscosity-
increasing agents, salts for regulating osmotic pressure and/or buffers and are prepared in a 
manner known per se, for example by means of conventional dissolving and lyophilizing 
processes.  
[00110] For oral pharmaceutical preparations suitable carriers are especially fillers, such as 
sugars, for example lactose, saccharose, mannitol or sorbitol, cellulose preparations and/or 
calcium phosphates, and also binders, such as starches, cellulose derivatives and/or 
polyvinylpyrrolidone, and/or, if desired, disintegrators, flow conditioners and lubricants, for 
example stearic acid or salts thereof and/or polyethylene glycol. Tablet cores can be provided 
with suitable, optionally enteric, coatings. Dyes or pigments may be added to the tablets or tablet 
coatings, for example for identification purposes or to indicate different doses of active 
ingredient. Pharmaceutical compositions for oral administration also include hard capsules 
consisting of gelatin, and also soft, sealed capsules consisting of gelatin and a plasticizer, such as 
glycerol or sorbitol. The capsules may contain the active ingredient in the form of granules, or 
dissolved or suspended in suitable liquid excipients, such as in oils.   
[00111] Transdermal application is also considered, for example using a transdermal patch, 
which allows administration over an extended period of time, e.g. from one to twenty days.  
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Methods of Treatment 
[00112] Compounds may be used in methods of treatment or prevention of anxiety disorders, 
depression, epilepsy, schizophrenia, and/or neuropathic pain.   
[00113] Anxiety disorder is a term covering several different forms of a type of mental illness 
of abnormal and pathological fear and anxiety. Current psychiatric diagnostic criteria recognize a 
wide variety of anxiety disorders. Recent surveys have found that as many as 18% of Americans 
may be affected by one or more of them.  The term anxiety covers four aspects of experiences an 
individual may have: mental apprehension, physical tension, physical symptoms and dissociative 
anxiety.  Anxiety disorder is divided into generalized anxiety disorder, phobic disorder, and 
panic disorder; each has its own characteristics and symptoms and they require different 
treatment. The emotions present in anxiety disorders range from simple nervousness to bouts of 
terror.  Standardized screening clinical questionnaires such as the Taylor Manifest Anxiety Scale 
or the Zung Self-Rating Anxiety Scale can be used to detect anxiety symptoms, and suggest the 
need for a formal diagnostic assessment of anxiety disorder. 
[00114] Particular examples of anxiety disorders include generalized anxiety disorder, panic 
disorder, phobias such as agoraphobia, social anxiety disorder, obsessive-compulsive disorder, 
post-traumatic stress disorder, separation anxiety and childhood anxiety disorders. 
[00115] Depression is a state of low mood and is generally caused by genetic, psychological 
and social factors. Depression can leave those affected feeling down and unable to enjoy 
activities. Approximately 4.3% of the world population suffers from depression, while lifetime 
prevalence ranges from 8-12%. Particular examples of depression are major depressive disorder, 
persistent depressive disorder and bipolar disorder, which itself has extreme lows as a 
characteristic. 
[00116] Epilepsy is a common chronic neurological disorder that is characterized by recurrent 
unprovoked seizures. These seizures are transient signs and/or symptoms due to abnormal, 
excessive or synchronous neuronal activity in the brain. There are many different epilepsy 
syndromes, each presenting with its own unique combination of seizure type, typical age of onset, 
EEG findings, treatment, and prognosis. Exemplary epilepsy syndromes include, e.g., Benign 
centrotemporal lobe epilepsy of childhood, Benign occipital epilepsy of childhood (BOEC), 
Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE), Primary reading epilepsy, 
Childhood absence epilepsy (CEA), Juvenile absence epilepsy, Juvenile myoclonic epilepsy 
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(JME), Symptomatic localization-related epilepsies, Temporal lobe epilepsy (TLE), Frontal lobe 
epilepsy, Rasmussen's encephalitis, West syndrome, Dravet's syndrome, Progressive myoclonic 
epilepsies, and Lennox-Gastaut syndrome (LGS). Genetic, congenital, and developmental 
conditions are often associated with epilepsy among younger patients. Tumors might be a cause 
for patients over age 40. Head trauma and central nervous system infections may cause epilepsy 
at any age. 
[00117] Schizophrenia is a mental disorder characterized by a breakdown of thought 
processes and by poor emotional responsiveness.  It most commonly manifests itself as auditory 
hallucinations, paranoid or bizarre delusions, or disorganized speech and thinking, and it is 
accompanied by significant social or occupational dysfunction.  The onset of symptoms typically 
occurs in young adulthood, with a global lifetime prevalence of about 0.3–0.7%.  Diagnosis is 
based on observed behavior and the patient's reported experiences.  Genetics, early environment, 
neurobiology, and psychological and social processes appear to be important contributory factors. 
Current research is focused on the role of neurobiology, although no single isolated organic 
cause has been found.  Particular types of schizophrenia include paranoid type, disorganized type, 
catatonic type, undifferentiated type, residual type, post-schizophrenic depression and simple 
schizophrenia. 
[00118] Neuropathic pain encompasses a range of painful conditions of diverse origins 
including diabetic neuropathy, post-herpetic neuralgia and nerve injuries after surgery. It 
includes pain following paraplegia, hypersensitivity to non-painful stimuli (allodynia), for 
example after surgery or during migraine attacks, spontaneous pain, hyperalgesia and diffuse 
muscle tenderness of myofacial syndromes. Back pain, cancer pain and AIDS associated pain 
also qualify as neuropathic pain. Currently prescribed drugs for neuropathic pain are often 
addictive, are not effective for all patients and have various side effects including tolerance, 
addiction, sedation, liver toxicity. The financial burden from the loss of productivity in the US 
alone numbers in the billions of dollars notwithstanding the misery these patients suffer. 
[00119] In another aspect, the invention provides a method of treating a disorder selected from 
an anxiety disorder, depression, epilepsy, schizophrenia and neuropathic pain, in a subject in 
need of treatment, comprising administering to the subject an effective amount of a compound of  
[00120] In an aspect, the invention provides a method of treating an anxiety disorder in a 
subject in need of treatment, comprising administering to the subject an effective amount of a 
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compound of formula (I), (II) (III), (IV), (V), or (VI).  In embodiments, the anxiety disorder is 
selected from the group consisting of generalized anxiety disorder, panic disorder, phobias such 
as agoraphobia, social anxiety disorder, obsessive–compulsive disorder, post-traumatic stress 
disorder, separation anxiety and childhood anxiety disorders.   
[00121] In an aspect, the invention provides a method of treating depression in a subject in 
need of treatment, comprising administering to the subject an effective amount of a compound of 
formula (I), (II) (III), (IV), (V), or (VI).   
[00122] In an aspect, the invention provides a method of treating schizophrenia in a subject in 
need of treatment, comprising administering to the subject an effective amount of a compound of 
formula (I), (II) (III), (IV), (V), or (VI).  In embodiments, the schizophrenia may be selected 
from the group consisting of paranoid type, disorganized type, catatonic type, undifferentiated 
type, residual type, post-schizophrenic depression and simple schizophrenia. 
[00123] In an aspect, the invention provides a method of treating epilepsy in a subject in need 
of treatment, comprising administering to the subject an effective amount of a compound of 
formula (I), (II) (III), (IV), (V), or (VI).  In another aspect, the invention provides a method of 
treating seizures in a subject in need of treatment, comprising administering to the subject an 
effective amount of a compound of formula (I), (II) (III), (IV), (V), or (VI).   
[00124] In an aspect, the invention provides a method of treating neuropathic pain in a subject 
in need of treatment, comprising administering to the subject an effective amount of a compound 
of formula (I), (II) (III), (IV), (V), or (VI).   
[00125] The following non-limiting examples are intended to be purely illustrative of some 
aspects and embodiments, and show specific experiments that were carried out in accordance 
with the disclosure. 
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EXAMPLES 
Example 1. Compound Syntheses 
Scheme I. Synthesis of KRM-II-81 (3). 
 
8-Ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carbaldehyde (2)  
[00126] The ethyl ester of 2'-pyridylbenzimidazodiazepine 1 (1.5 g, 4.21 mmol) was placed in 
an oven dried two neck round bottom flask and was then dissolved in dry THF. The reaction 
mixture was stirred at 0oC and LiAlH4 (320 mg, 8.42 mmol) was added to the reaction mixture at 
0 oC.  After 10 min the reaction mixture was stirred at rt for up to 45 min under an argon 
atmosphere. After 45 min at rt analysis of the mixture by TLC (silica gel 1: 9 MeOH/EtOAc) 
indicated the absence of starting ester 1. The reaction mixture was slowly quenched with an aq 
saturated sodium sulfate solution (20 mL) at 0oC and then the reaction mixture was diluted with 
ethyl acetate (50 mL). After this the mixture was filtered through a small bed of Celite. Water 
was added to the filtrate and it was extracted with ethyl acetate (3x 30 mL). The combined 
organic layers were washed with water and brine successively and dried (Na2SO4). After this the 
solvent was removed under reduced pressure to furnish the mixture of alcohols (imine alcohol 
40% and reduced imine alcohol 60%, via analysis by H1NMR spectroscopy) as a yellow solid. 
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This mixture of alcohols was used directly in the next step. The mixture of 2'-pyridylalcohols 
(4.45 g, 4.61 mmol) were dissolved in dry DCM (60 mL) under an argon atmosphere, and 
activated MnO2 (4.01 g, 46.10 mmol) and Na2CO3 were added to the reaction mixture at 0
oC. The 
mixture was stirred at room temperature for 12 hours. After completion of the reaction as 
indicated by TLC (complete conversion of alcohol to aldehyde), the reaction mixture was diluted 
with DCM (50 mL) and it was filtered through a small pad of Celite. The solvent was removed 
under reduced pressure to get the crude 2'-pyridyl aldehyde along with some other byproducts by 
TLC (1:9 MeOH/EtOAc). This material was purified by flash column chromatography using 
EtOAc/DCM (2:1 and 1 mL MeOH + 1 mL TEA for 100 mL) to afford the pure 2' pyridyl 
aldehyde 2 as a white solid (650 mg, 49.2% over two steps); mp: 238-240oC; 1H NMR (500 
MHz, CDCl3)  10.05 (s, 1H), 8.56 (d, J = 5.0 Hz, 1H), 8.08 (d, J = 7.5 Hz, 1H), 7.97 (s, 1H), 
7.78 (ddd, J = 1.5, 6.0 Hz, 1H), 7.77 (dd, J = 1.5, 7.0 Hz, 1H), 7.55-7.57 (m, 2H), 7.38 (ddd, J = 
1.5, 5.0 Hz,  1H), 6.00 (br s, 1H), 4.17 (br s, 1H), 3.16(s, 1H): 13C NMR (75 MHz, CDCl3)  
186.9, 167.7, 156.2, 148.6, 137.7, 137.1, 136.7, 136.3, 135.4, 135.3, 135.0, 127.1, 124.9, 124.0, 
122.8, 121.5, 81.5, 79.7, 44.4. (ESI) MS: m/z 313 (M+H)+. 
5-(8-Ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-yl)oxazole (3, 
KRM-II-81) 
[00127] The toluenesulfonylmethyl isocyanide (TosMIC, 640 mg, 3.30 mmol) was placed in a 
dry two neck round bottom flask and dissolved in dry MeOH (50 mL) under an argon 
atmosphere. At room temperature, K2CO3 (1.30 g, 9.99 mmol) was added as well as 2' 
pyridyldiazepine carboxaldehyde 2 (650 mg, 2.08 mmol) to the reaction mixture and it was 
heated to reflux for 3 to 4 h. After completion of the reaction on analysis by TLC (silica gel, 1:10 
MeOH and EtOAc) which indicated the absence of aldehyde starting material and complete 
conversion into an oxazole of lower Rf. The reaction mixture was then quenched with cold water. 
After this, 1/3 of the solvent was removed under reduced pressure and the work up followed with 
ethyl acetate (3x30 mL). The combined organic layers were washed with water and brine 
successively and dried (Na2SO4). The solvent was then removed under reduced pressure and the 
residue was purified by silica gel flash chromatography to give the pure 2' pyridyldiazepine 
oxazole as a white solid (510 mg, 72%); mp: 220-222 oC 1H NMR (300 MHz, CDCl3)  8.62 (d, 
J = 4.2 Hz, 1H), 8.12 (s, 1H), 8.06 (d, J = 7.8 Hz, 1H), 7.96 (s, 1H), 7.85 (ddd, J = 1.8, 6.0 Hz, 
1H), 7.79 (dd, J = 1.8, 6.6 Hz, 1H), 7.62 (d, J = 8.4 Hz, 1H), 7.55 (d, J = 1.5 Hz, 1H), 7.53 (s, 
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1H), 7.41 (ddd, J = 1.5, 4.8 Hz, 1H), 5.78 (d, J = 12.9 Hz, 1H), 4.31 (d, J = 12.9 Hz, 1H). 13C 
NMR (75 MHz, CDCl3)  167.9, 156.7, 149.9, 149.0, 146.6, 137.0, 136.4, 135.8, 135.5, 135.3, 
129.8, 127.5, 127.0, 124.9, 124.0, 122.8, 122.7, 121.0, 81.8.7, 79.5, 45.3; HRMS (ESI m/z) for 
C21H13N5O calcd 352.1188, found 352.1193 (M+H)
+.  
Scheme II. Synthesis of KRM-II-18B (8). 
 
 
8-Bromo-6-(2-fluorophenyl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carbaldehyde (5)  
[00128] A solution of diisobutylaluminumhydride (6.25 mL of 1.2 M solution in toluene, 20% 
w/v) was added dropwise to a vigorously stirred solution of the ester 4 (1.5 g, 3.51 mmol) in 
anhydrous dichloromethane (40 mL) under an argon atmasphere at –78oC (dry ice-ethyl acetate). 
After this, the reaction mixture was stirred for an additional 2-3 h at –78oC, and was monitored 
by TLC every 30 min after 1 h. The temperature must not get above –78oC. If the temperature 
gets above –78oC  or if the reaction continues more than 3  h at –78oC other byproducts are 
formed (imine reduced aldehyde and ester to alcohol). After completion of the reaction, excess 
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DIBAL-H was quenched by careful addition of dry methanol (5 mL), followed by 5% aq HCl 
(10 mL). After this the resulting mixture was allowed to warm to room temperature. If the 
reaction mixture formed an aluminum-related emulsion, a saturated aq solution of Rochelle's salt 
and DCM (50 mL) were added to the reaction mixture. It was then filtered through a small pad of 
Celite and then the organic layer was separated. The aq layer which remained was extracted with 
DCM (2x30 mL). The combined organic layers were washed with brine and dried (Na2SO4). The 
solvent was removed under reduced pressure to afford the crude aldehyde. This residue was 
purified by flash chromatography (2:1 ethyl acetate/hexane) to afford the pure diazepine 
aldehyde 5 as a white solid (1.0 g, 74.6%); mp 120-122oC; 1H NMR (300 MHz, CDCl3)  10.07 
(s, 1H), 8.01 (s, 1H), 7.80 (dd, J = 1.8, 6.6 Hz, 1H), 7.67 (ddd, J = 1.5, 6.0 Hz, 1H), 7.45-7.52 (m, 
3H), 7.25-7.30 (m, 1H), 7.04 (t, J = 9.3 Hz, 1H), 6.02 (br s, 1H), 4.15 (br s, 1H). LCMS: m/z 385 
(M+H). 
General synthetic procedure for oxazole containing benzimidazodiazepines.  
5-(8-Bromo-6-(2-fluorophenyl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-yl)oxazole (6) 
[00129] The toluenesulfonylmethyl isocyanide (TOSMIC, 300 mg, 1.56 mmol) was placed in 
a dry two neck round bottom flask and dissolved in dry MeOH (30 mL) under an argon 
atmosphere. At room temperature, K2CO3 (649 mg, 1.53 mmol) was added as well as the 2'fluoro 
diazepine carboxaldehyde 5 (647 mg, 1.62 mmol) to the reaction mixture and it was heated to 
reflux for 3 to 4 h. After completion of the reaction on analysis by TLC (silica gel, 2:1 EtOAc 
and hexane), which indicated the absence of aldehyde starting material and complete conversion 
to the oxazole of lower Rf, the reaction mixture was then quenched with cold water. After this, 
1/3 of the solvent was removed under reduced pressure and the work up followed with ethyl 
acetate (3x40 mL). The combined organic layers were washed with water, brine successively and 
dried (Na2SO4). The solvent was then removed under reduced pressure and the residue was 
purified by silica gel flash chromatography to give the pure 2' 2'fluorodiazepine oxazole 6 as 
white solid (550 mg, 76.7 % yield); mp:190-192 oC;  1H NMR (300 MHz, CDCl3)  8.01 (s, 1H), 
7.92 (s, 1H), 7.77 (dd, J = 2.1, 6.6 Hz, 1H), 7.77 (ddd, J = 1.5, 6.0 Hz, 1H), 7.52 (s, 1H), 7.46-
7.52 (m, 3H), 7.23-7.28 (m, 1H), 7.04 (t, J = 8.4 Hz, 1H), 5.75 (br s, 1H), 4.26 (br s, 1H). 13C 
NMR (300 MHz, CDCl3)  165.0, 161.8, 158.5, 149.8, 146.5, 135.1, 134.9, 133.6, 133.3, 132.5, 
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131.1, 130.4, 129.7, 127.6, 124.6, 124.0, 122.6, 120.9, 116.4, 116.1, 45.3; HRMS (ESI-TOF m/z) 
for C20H12N4OFBr calcd 423.0263, found 423.0251 (M+H)
+. 
5-(6-(2-Fluorophenyl)-8-((trimethylsilyl)ethynyl)-4H-benzo[f]imidazo[1,5-a][1,4] diazepin-
3-yl)oxazole (7) 
[00130] The 2'fluorodiazepine diazepine bromide 6 (100 mg, 0.23 mmol) and 
bis(triphenylphosphine)-palladium (II) acetate (10 mg, 0.011 mmol) were added to an oven dried 
two neck round bottom flask, after which the round bottom flask was fitted with a rubber septum. 
It was then evacuated under vaccum and back filled with argon. After this, a mixed dry solvent 
system of CH3CN:TEA (1:2 ratio) and trimethylsilylacetylene (0.04 mL, 0.26 mmol) were added 
to the round bottom flask with a syringe under a positive pressure of argon. The round bottom 
flask was fitted with a reflex condenser and the reaction mixture was degased under vaccum and 
argon, the process was repeated three times, after which the reaction mixture was slowly heated 
to 90oC. After stirring for 10 h, the reaction mixture was diluted with ethyl acetate and filtered 
through a bed of Celite. The organic layer was washed with brine and dried (Na2SO4). The 
solvent was then removed under reduced pressure to furnish a crude solid. This material was 
purified by flash chromatography (3:1 ethyl acetate/hexane) to afford the pure 
trimethylsilylacetylene 2'fluorodiazepine intermediate as a light brown solid 7 (90 mg, 92.6% 
yield). 1H NMR (300 MHz, CDCl3)  8.02 (s, 1H), 7.92 (s, 1H), 7.60-7.74 (m, 3H), 7.40-7.57 (m, 
3H), 7.23-7.28 (m, 1H), 7.04 (t, J = 9.0 Hz, 1H), 5.73 (br s, 1H), 4.24 (br s, 1H), 0.24 (s, 9H); 
HRMS (ESI-TOF m/z) for C25H21N4OFSi calcd 441.1543, found 441.1541 (M+H)
+. 
5-(8-Ethynyl-6-(2-fluorophenyl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-yl)oxazole 
KRM-II-18B (8) 
[00131] A solution of 2'-fluorodiazepine trimethylsilylacetylene 7 (90 mg, 0.20 mmol) was 
dissolved in dry THF and kept at 0°C after which tetrabutylammonium iodide (0.05 mL, 024 
mmol) was added slowly to the reaction mixture at 0°C. After 10 min the reaction mixture was 
stirred at room temperature for 2 h under an argon atmosphere. After TLC (silica gel) indicated 
the absence of starting material, this reaction mixture was quenched by slow addition of ice cold 
water and the combined layers were extracted with ethyl acetate (320 mL). The combined 
organic layers were washed with water and brine. This solution was dried (Na2SO4) and the 
solvent was removed under reduced pressure to furnish a solid. This material was then purified 
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by flash chromatography (4:1 ethyl acetate/hexane) to afford the pure 8-acetyleno-2'-
fluorodiazepine oxazole 8 as a white solid (80 mg, 88% yield); mp 212-214; 1H NMR (300 MHz, 
CDCl3)  8.03 (s, 1H), 7.93 (s, 1H), 7.75 (d, J = 7.8 Hz, 1H), 7.57-7.63 (m, 2H), 7.44-7.53 (m, 
3H), 7.23-7.28 (m, 1H), 7.04 (t, J = 9.0 Hz, 1H), 5.74 (br s, 1H), 4.26 (br s, 1H), 3.16 (s, 1H). 13C 
NMR (300 MHz, CDCl3)  165.5, 161.9, 158.5, 149.8, 146.5, 135.4, 135.0, 134.3, 132.3, 131.1, 
129.8, 128.9, 127.8, 127.5, 124.5, 122.6, 121.6, 116.4, 116.1, 81.4, 79.6, 45.0; HRMS (ESI-TOF 
m/z) for C22H13N4OF calcd 369.1144, found 369.1146 (M+H)
+. 
 
Scheme III. Synthesis of KRM-II-82 
 
8-Bromo-6-phenyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carbaldehyde (10) 
[00132] A solution of diisobutylaluminumhydride (8.5 mL of 1.2 M solution in toluene, 20% 
w/v) was added dropwise to a vigorously stirred solution of the ester 9 (2.7 g, 6.58 mmol) in 
anhydrous dichloromethane (50 mL) under an argon atmasphere at –78oC (dry ice-ethyl acetate). 
After this the reaction mixture was stirred for an additional 2-3 h at –78oC, and was monitored by 
TLC every 30 min after 1 h. The temperature must not get above –78oC. If the temperature gets 
above –78oC  or if the reaction continues more than 3  h at –78oC other byproducts are formed 
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(imine reduced aldehyde and ester to alcohol). After completion of the reaction, excess DIBAL-
H was quenched by careful addition of dry methanol (5 mL), followed by 5% aq HCl (10 mL). 
After this the resulting mixture was allowed to warm rt. If the reaction mixture forms an 
aluminum-related emulsion, a saturated aq solution of Rochelle's salt and DCM (50 mL) were 
added to the reaction mixture. It was then filtered through a small pad of Celite and then the 
organic layer was separated. The aq layer which remained was extracted with DCM (2x30 mL). 
The combined organic layers were washed with brine and dried (Na2SO4). The solvent was 
removed under reduced pressure to afford the crude aldehyde. This residue was purified by flash 
chromatography (2:1 ethyl acetate/hexane) to afford the pure diazepine aldehyde 10 as a white 
solid (2.0 g, 76%); mp 192-194oC; 1H NMR (300 MHz, CDCl3)  10.06 (s, 1H), 8.01 (s, 1H), 
7.84 (d, J = 8.4 Hz, 1H), 7.62 (s, 1H), 7.47-7.54 (m, 4H), 7.39-7.44 (m, 2H), 5.98 (d, J = 12.6 Hz, 
1H), 4.02 (d, J = 12.3 Hz, 1H). LCMS: m/z 367 (M+2). 
5-(8-Bromo-6-phenyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-yl)oxazole (11) 
[00133] The reaction was performed following the same procedure for 6 employing TosMIC 
(350 mg, 1.79 mmol), K2CO3 (7.4 g, 6.90 mmol) and diazepine aldehyde 10 (720 mg, 2.30 
mmol). This afforded the crude compound which was purified by flash silica gel chromatography 
(4:1 ethyl acetate/hexane) to give a white solid 11 (601 mg, 78.0 % yield): mp 225-227 oC; 1H 
NMR (300 MHz, CDCl3)   8.05 (s, 1H), 7.92 (s, 1H), 7.81 (dd, J = 1.8, 6.6 Hz, 1H), 7.82 (d, J = 
8.4 Hz, 1H), 7.53-7.57 (m, 3H), 7.43-7.49 (m, 2H), 7.39-7.43 (m, 2H), 5.75 (d, J = 12.6 Hz, 1H), 
4.24 (d, J = 12.6 Hz, 1H). 13C NMR (300 MHz, CDCl3)  167.9, 156.7, 149.9, 148.9, 146.6, 
137.0, 136.4, 135.8, 135.4, 135.3, 129.8, 127.5, 127.0, 124.9, 124.0, 122.8, 122.6, 121.0, 45.3; 
HRMS (ESI-TOF m/z) for C20H13N4OBr calcd 405.0349, found 405.0345 (M+H)
+. 
5-(6-Phenyl-8-((trimethylsilyl)ethynyl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-yl)oxazole 
(12) 
[00134] The trimethylsilylacetylenodiazepine 12 was prepared according to the method 
described for 7, employing the bromodiazepine oxazole 11 (700 mg, 1.72 mmol), 
bis(triphenylphosphine)palladium(II)acetate (64 mg, 0.0864 mmol) and trimethylsilyl acetylene 
(0.3 mL, 2.07 mmol). The residue which resulted was purified by silica gel flash column 
chromatography (3:1 ethyl acetate/hexane) to give a light yellow solid 12 (650 mg, 89.6% yield); 
mp 107-109 oC; 1H NMR (300 MHz, CDCl3)   8.05 (s, 1H), 7.92 (s, 1H), 7.81 (dd, J = 1.8, 6.6 
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Hz, 1H), 7.82 (d, J = 8.4 Hz, 1H), 7.53-7.57 (m, 3H), 7.43-7.49 (m, 2H), 7.39-7.43 (m, 2H), 5.75 
(d, J = 12.6 Hz, 1H), 4.24 (d, J = 12.6 Hz, 1H), 0.25 (s, 9H); HRMS (ESI-TOF m/z) for 
C25H22N4OSi calcd 423.1638, found 423.1636 (M+H)
+. 
5-(8-Ethynyl-6-phenyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-yl)oxazole KRM-II-82 (13) 
[00135] The acetylenodiazepine oxazole 13 was prepared, according to the method described 
for 8, which employed the TMS-acetylenodiazepine oxazole 12 (500 mg, 1.18) and TBAF (0.5 
mL, 1.76 mmol). After workup, the residue was purified by silica gel flash column 
chromatography (4:1 ethyl acetate/hexane) to afford acetylenodiazepine oxazole 13 as a white 
solid (370 mg, 90% yield); mp 120-122 oC. 1H NMR (300 MHz, CDCl3)  8.08 (s, 1H), 7.93 (s, 
1H), 7.81 (dd, J = 1.8, 6.6 Hz, 1H), 7.81 (d, J = 8.4 Hz, 1H), 7.53-7.57 (m, 3H), 7.43-7.49 (m, 
2H), 7.39-7.43 (m, 2H), 5.75 (d, J = 12.9 Hz, 1H), 4.24 (d, J = 12.9 Hz, 1H), 3.18 (s, 1H).13C 
NMR (300 MHz, CDCl3)  167.9, 156.7, 149.9, 148.9, 146.6, 137.0, 136.4, 135.8, 135.4, 135.3, 
129.8, 127.5, 127.0, 124.9, 124.0, 122.8, 122.6, 121.0, 81.8, 79.5, 45.2; HRMS (ESI-TOF m/z) 
for C22H14N4O calcd 351.1246, found 351.1240 (M+H)
+. 
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Scheme IV. Alternate Synthetic Route to KRM-II-81 (3). 
 
 
8-Bromo-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxaldehyde(15)  
[00136] The ethyl ester of 2'-pyridylbenzimidazodiazepine 14 (500 mg, 1.22 mmol) was 
placed in an oven dried two neck round bottom flask and was then dissolved in dry THF. The 
reaction mixture was stirred at 0oC and LiAlH4 (93 mg, 2.43 mmol) was added to the reaction 
mixture at 0 oC.  After 10 min the reaction mixture was stirred at rt up to 45 min under an argon 
atmosphere. After 45 min at rt analysis of the mixture by TLC (silica gel 1: 9 MeOH/EtOAc) 
indicated the absence of starting ester 14. The reaction mixture was slowly quenched with a 
saturated aq solution of sodium sulfate (10 mL) at 0oC and then the reaction mixture was diluted 
with ethyl acetate (30 mL). After this the mixture was filtered through a small pad of Celite and 
then the filtrate was extracted with ethyl acetate (3x 30 mL). The combined organic layers were 
washed with water and brine successively. After this, the solvent was removed under reduced 
pressure to furnish the mixture of alcohols (imine alcohol 60% and reduced imine alcohol 40%, 
via analysis by H1NMR spectroscopy) as a yellow solid. This mixture of alcohols was used 
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directly in the next step. The mixture of 2'-pyridylalcohols (455 mg, 1.22 mmol) were dissolved 
in dry DCM (30 mL) under an argon atmosphere, and activated MnO2 (278 mg, 14.4 mmol) was 
added to the reaction mixture at 0oC. The mixture was stirred at rt overnight. After completion of 
the reaction as indicated by TLC (complete conversion of alcohol to aldehyde), the reaction 
mixture was diluted with DCM/EtOAc (30 mL) and was filtered through a small pad of Celite. 
The solvent was removed under reduced pressure to get the crude 2'-pyridyl aldehyde along with 
some other byproducts by TLC (1:9 MeOH/EtOAc). This material was purified by flash column 
chromatography using EtOAc/DCM (2:1 and 1 mL MeOH + 1 mLTEA for 100 mL) to afford 
the pure 2' pyridyl aldehyde 15 as a white solid (289 mg, 56.7% over two steps); mp: 220-222 oC. 
1H NMR (300 MHz, CDCl3)  10.07 (s, 1H), 8.56 (d, J = 2.4 Hz, 1H), 8.13 (d, J = 7.8 Hz, 1H), 
7.96 (s, 1H), 7.80-7.86 (m, 2H), 7.62 (s, 1H), 7.49 (d, J = 8.4 Hz, 1H), 7.40 (t, J = 7.2 Hz, 1H), 
6.10 (br s, 1H), 4.15 (br s, 1H). LCMS: m/z 368 (M+2)+. 
5-(8-Bromo-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-yl)oxazole (16) 
[00137] The 2' pyridyldiazepine oxazole 16 was prepared according to the method described 
for 6 employing TosMIC (160 mg, 0.81 mmol), K2CO3 (223 mg, 18.46 mmol) and 2' 
pyridyldiazepine carboxaldehyde 15 (200 mg, 1.62 mmol). This afforded the crude oxazole 
which was purified by flash silica gel chromatography (silica gel, 1:10 MeOH and EtOAc) to 
give pure 2' pyridyldiazepine oxazole 16 as a white solid (160 mg, 73%); mp:226-228 oC; 1H 
NMR (500 MHz, CDCl3)  8.62 (d, J = 4.5 Hz, 1H), 8.24 (s, 1H), 8.08 (d, J = 8.0 Hz, 1H), 7.96 
(s, 1H), 7.82-7.87 (m, 2H), 7.57-7.59 (m, 2H), 7.40-7.43 (m, 1H), 5.78 (d, J = 12.5 Hz, 1H), 4.32 
(d, J = 12.5 Hz, 1H), (ESI) MS: m/z 368 (M+H)+. )+. 13C NMR (300 MHz, CDCl3)  167.2, 
155.9, 150.1, 148.7, 145.4, 137.2, 135.3, 135.2, 134.4, 133.3, 129.6, 128.3, 126.9, 125.1, 124.5, 
124.1, 123.4, 120.8, 44.9; HRMS (ESI-TOF m/z) for C19H12N5OBr calcd 406.0299, found 
406.0298 (M+H)+. 
5-(6-(Pyridin-2-yl)-8-((trimethylsilyl)ethynyl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-
yl)oxazole (17) 
[00138] The 2'pyridyltrimethylsilylacetylenodiazepine 17 was prepared, according to the 
method described for 7, which employed the 2' pyridyldiazepine bromide 16 (160 mg, 0.394 
mmol) bis(triphenylphosphine)palladium(II)acetate (15.0 mg, 0.02 mmol) and trimethylsilyl 
acetylene (0.3 mL, 2.07 mmol). After work up, the residue which resulted was purified by silica 
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gel flash column chromatography (4:1 ethyl acetate/DCM and 1 mL MeOH and 1 mL TEA for 
100 mL) to give a light brown solid 17 (133 mg, 80%). 1H NMR (300 MHz, CDCl3)  8.63 (d, J 
= 4.1 Hz, 1H), 8.26 (s, 1H), 8.06 (d, J = 8.0 Hz, 1H), 7.97 (s, 1H), 7.82-7.88 (m, 2H), 7.57-7.59 
(m, 2H), 7.40-7.43 (m, 1H), 5.78 (d, J = 12.1 Hz, 1H), 4.32 (d, J = 12.1 Hz, 1H), 0.24 (s, 9H). 
5-(8-Ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-yl)oxazole KRM-II-
81 (3) 
[00139] The 2'-pyridyl-8-acetylenediazepines oxazole 3 was prepared, according to the 
method described for 8, employing the 2'-pyridyltrimethylsilylacetylene diazepine 17 (600 mg, 
1.4 mmol), and TBAF (0.48 mL, 1.7 mmol). After workup the residue was purified by flash 
chromatography (4:1 ethyl acetate/DCM, 1 mL MeOH and 1 mL TEA for 100 mL) to afford the 
pure 2'-pyridyl-8-acetylenediazepines oxazole 3 as a white solid (410 mg, 82%); mp: 230-232 
oC; 1H NMR (300 MHz, CDCl3)  8.62 (d, J = 4.2 Hz, 1H), 8.12 (s, 1H), 8.06 (d, J = 7.8 Hz, 1H), 
7.96 (s, 1H), 7.85 (ddd, J = 1.8, 6.0 Hz, 1H), 7.79 (dd, J = 1.8, 6.6 Hz, 1H), 7.62 (d, J = 8.4 Hz, 
1H), 7.55 (d, J = 1.5 Hz, 1H), 7.53 (s, 1H), 7.41 (ddd, J = 1.5, 4.8 Hz, 1H), 5.78 (d, J = 12.9 Hz, 
1H), 4.31 (d, J = 12.9 Hz, 1H). 13C NMR (300 MHz, CDCl3)  167.9, 156.7, 149.9, 149.0, 146.6, 
137.0, 136.4, 135.8, 135.5, 135.3, 129.8, 127.5, 127.0, 124.9, 124.0, 122.8, 122.7, 121.0, 81.8.7, 
79.5, 45.3; HRMS (ESI-TOF m/z) for C21H13N5O calcd 352.1188, found 352.1193 (M+H)
+.  
Example 2. Compound Assays 
Explanation of Terms  
[00140] EC3: A concentration of GABA eliciting 3% of the maximal GABA-elicited current 
amplitude of the individual oocyte. 
[00141] log[M]: Represents the logarithm of molar concentration 
Assays Of Competitive Binding To αxβ3γ2 GABAA Receptors 
[00142] The GABAA subunit selectivity of several compounds prepared as described above 
were determined using competitive binding assays.  Competition binding assays were 
performed in a total volume of 0.5 mL at 4°C for 1 h using [3H]flunitrazepam as the 
radioligand (Savić, M. M.; Cook, J. M. et al. Progr. Neuro. Psychopharm. Biol. Psy. 2010, 34, 
376-386). A total of 6 μg of cloned human GABAA receptor DNA containing desired α 
subtype along with β2 and γ2 subunits were used for transfecting HEK 293T cell line 
using Fugene 6 (Roche Diagnostic) transfecting reagent. Cells were harvested 48 h 
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after transfection, washed with Tris–HCl buffer (pH 7.0) and Tris Acetate buffer (pH 7.4) 
and resulting pellets were stored at -80°C until assayed. On the day of the assay, 
pellets containing 20-50 μg of GABAA receptor harvested with hypotonic buffer (50 mM 
Tris–acetate, pH 7.4, at 4°C) was incubated with the radiolabel as previously described. 
Non-specific binding was defined as radioactivity bound in the presence of 100 μM 
diazepam and represented less than 20% of total binding. Membranes were harvested 
with a Brandel cell harvester followed by three ice-cold washes onto polyethyleneimine-
pretreated (0.3%) Whatman GF/C filters. Filters were dried overnight and then soaked 
in Ecoscint A liquid scintillation cocktail (National Diagnostics; Atlanta, GA). Bound 
radioactivity was quantified by liquid scintillation counting. Membrane protein 
concentrations were determined using an assay kit from Bio-Rad (Hercules, CA) with 
bovine serum albumin as the standard. 
Electrophysiological experiments 
[00143] Oocytes will be injected according to a standard method (Savic et al. Prog. 
Neuropsychopharmacol. Biol. Psychiatry 2010, 34(2):376-386) with different combinations of 
cDNA's comprised of different α-GABAergic cDNA's in combination with β3 and γ2 
GABAergic cDNAs to express the different GABAA ion channels (Savic et al. Prog. 
Neuropsychopharmacol. Biol. Psychiatry 2010, 34(2):376-386). These will be used for the 
oocyte studies, applying an EC3 of GABA and then the drug being tested.  For 
electrophysiological recordings, oocytes will be placed on a nylon-grid in a bath of Xenopus 
Ringer solution (XR, containing 90 mM NaCl, 5 mM HEPES-NaOH (pH 7.4), 1 mM MgCl2, 1 
mM KCl and 1 mM CaCl2). The oocytes will be constantly washed by a flow of 6 ml/min XR 
which could be switched to XR containing GABA and/or drugs. Drugs were diluted into XR 
from DMSO-solutions resulting in a final concentration of 0.1 % DMSO perfusing the oocytes. 
Drugs will be preapplied for 30 sec before the addition of GABA, which will be coapplied with 
the drugs until a peak response was observed. Between two applications, oocytes will be washed 
in XR for up to 15 min to ensure full recovery from desensitization. For current measurements 
the oocytes will be impaled with two microelectrodes (2–3 mΩ) which were filled with 2 mM 
KCl. All recordings will be performed at room temperature at a holding potential of –60 mV 
using a Warner OC-725C two-electrode voltage clamp (Warner Instruments, Hamden, CT). Data 
will be digitized, recorded and measured using a Digidata 1322A data acquisition system (Axon 
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Instruments, Union City, CA). Results of concentration response experiments will be fitted using 
GraphPad Prism 3.00 (GraphPad Software, San Diego, CA).  
[00144] The equation to be used for fitting concentration response curves will be 
Y=Bottom + (Top-Bottom)/(1+10^((LogEC50-X)*HillSlope)); X represents the logarithm of 
concentration, Y represents the response; Y starts at Bottom and goes to Top with a sigmoid 
shape. This is identical to the "four parameter logistic equation." 
[00145] Concentration–effect curves can be prepared for various compounds tested on α1β3γ2, 
α2β3γ2, α3β3γ2, andα5β3γ2 GABAA receptors, using an EC3 GABA concentration.   
Metabolic Stability for GABAA Receptor Ligands Using Human Liver Microsomes  
[00146] The metabolic stability of GABAA receptor ligands using human liver microsomes 
will be studied. The test articles will be incubated at two concentrations (1 and 10 μM) and 
aliquots (100 μL) were removed at various time points (0, 15, 30, and 60 minutes), and analyzed 
by LC-MS/MS.  
Example 3. Binding and Brain Fractions 
[00147] KRM-II-81 was shown to have a great affinity in the nanomolar range for the α3-
subtype (0.97 μM), complemented by a low affinity for the α1-subtype (testing was halted at 
greater than 20 μM). This α3 binding is comparable to the nonsedating anxiolytic, HZ-166 (0.84 
μM).  In a 10 mg/kg oral dose in rats, a concentration of 644 ng/g of KRM-II-81 was found 
unbound in the brain, indicating a great pharmacokinetic-profile. In addition, KRM-II-81 was not 
found to be a substrate of CYP3A4, CYP2D6, or CYP2C9; all of which are responsible for the 
metabolism of many other clinically used drugs. 
Example 4. Marble Burying Assay 
[00148] The marble burying assay is designed to measure the anxiolytic-effect of a compound. 
When mice are nervous, they will bury marbles. As there becomes a decrease in amount of 
marbles buried, the better anxiolytic effect of a compound.  Herein, KRM-II-81 is shown to be a 
better anxiolytic than HZ-166, which is a published anxiolytic (Fischer et al. 
Neuropharmacology, 2010, 59, 612). KRM-II-81 also displayed less sedative effects than HZ-
166 based on the rotarod assay, which implies that it have little to no amnesic or addictive 
properties.   
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Example 5. Pharmacokinetics 
[00149] A 10 mg/kg P.O. dose was given for each of the compounds; however, HZ-166 used 
mice while KRM-II-81 used rats. Although these are different species, the numbers can still be 
compared. Data are summarized in TABLE 1.   
TABLE 1: Highest concentration of compound, Cmax, found in blood at time Tmax. 
HZ-166 KRM-II-81 
Cmax 4.11 ng/mL 1746 ng/mL 
Tmax 5.58 hours 1.3 hours 
 
[00150] This data shows that the concentration of KRM-II-81 is nearly 500-times more 
concentrated in the blood than HZ-166. This leads to a higher concentration of the compound 
getting into the brain, which leads to a more effective compound. This data coupled with the 
brain unbound concentration ([brain]u) of 644 ng/g and an 18% free fraction gives KRM-II-81 an 
exceptional profile.  This is also superior to MP-III-080, which was also evaluated for the brain 
concentrations one hour after a 10 mg/kg oral dose.  MP-III-080 produced a [brain]u of 340 ng/g 
and an 11% free fraction.   
[00151] In vitro metabolism studies were done in mouse, rat, human, and dogs cells (TABLE 
2). 
TABLE 2: Percent of compound metabolized by in individual species. 
Mouse % Metabolized Rat % Metabolized Human % Metabolized Dog % Metabolized 
10.1 9.6 8.6 5.9 
 
[00152] In summary, the max concentration of the nonsedating anxiolytic/anticonvulsant/ 
antinociceptive agent HZ-166 in rodents was 4.11 ng/mL; while KRM-II-81 came in at 1746 
ng/mL. KRM-II-81 was found in the blood at nearly a 500-times higher concentration. 
 
Example 6. Synthesis of Compounds 
[00153] Compounds shown in FIG. 3 were synthesized according to the scheme shown in 
FIG. 1, with intermediates further shown in FIG. 2.   
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8-Bromo-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carbaldehyde (6a), 
Method 1 
[00154] The ethyl ester of 2'-pyridyl benzimidazodiazepine 5a (500 mg, 1.21 mmol) was 
placed in an oven dried two neck round bottom flask and was then dissolved in dry THF. The 
reaction mixture was stirred at 0oC and LiAlH4 (50 mg, 1.34 mmol) was added to the reaction 
mixture at 0oC.  After 10 min the reaction mixture was stirred at room temperature up to 45 min 
to 1 h under an argon atmosphere. After 45-60 min at room temperature analysis of the mixture 
by TLC (silica gel 1: 9 MeOH/EtOAc) indicated the absence of starting ester 5a. The reaction 
mixture was slowly quenched with a saturated aqueous solvent of sodium sulfate (10 mL) at 0°C 
and then the reaction mixture was diluted with ethyl acetate (30 mL). After this, the mixture was 
filtered through a small pad of Celite and then the filtrate was extracted with ethyl acetate (3 x 30 
mL). The combined organic layers were washed with brine and dried over Na2SO4. The solvent 
was then removed under reduced presser to furnish the mixture of alcohols (imine alcohol 60% 
and reduced imine alcohol 40%, via analysis by H1NMR spectroscopy) as a yellow solid. This 
mixture of alcohols was used directly in the next step. The mixture of 2'-pyridylalcohols (455 mg, 
1.22 mmol) was dissolved in dry DCM (30 mL) under an argon atmosphere, after which Na2CO3 
(384 mg, 3.66 mmol) and activated MnO2 (278 mg, 14.4 mmol) were added to the reaction 
mixture at 0°C. The mixture was stirred at room temperature overnight. After completion of the 
reaction as indicated by TLC, the reaction mixture was diluted with DCM (30 mL) and was 
filtered through a small pad of Celite. The solvent was removed under reduced pressure to give 
the crude 2'-pyridyl aldehyde along with some other byproducts by TLC (1:9 MeOH/EtOAc). 
This material was purified by flash column chromatography using EtOAc/DCM/Hexane (2:1:1 
and 1 mL MeOH + 1 mLTEA for 100 mL) to afford the pure 2' pyridyl aldehyde 6a as a white 
solid (180 mg, 39.8% over two steps); mp: 220-222 oC.  1H NMR (300 MHz, CDCl3)  10.07 (s, 
1H), 8.56 (d, J = 2.4 Hz, 1H), 8.13 (d, J = 7.8 Hz, 1H), 7.96 (s, 1H), 7.80-7.86 (m, 2H), 7.62 (s, 
1H), 7.49 (d, J = 8.4 Hz, 1H), 7.40 (t, J = 7.2 Hz, 1H), 6.10 (br s, 1H), 4.15 (br s, 1H). (ESI) MS: 
m/z 368 (M+H)+.  13C NMR (75 MHz, CDCl3)  186.7, 167.6, 156.3, 148.5, 137.7, 137.1, 136.8, 
136.4, 135.5, 135.4, 135.0, 127.1, 124.9, 124.1, 122.9, 121.6, 81.5, 79.8, 44.3; HRMS (ESI-TOF 
m/z) for C17H11BrN4O calcd 367.0176 found 367.0189 (M+H)+. 
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8-Bromo-6-phenyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carbaldehyde (6b), Method 2 
[00155] A solution of diisobutylaluminum hydride (8.5 mL of 1.0 M solution in hexane) was 
added dropwise to a vigorously stirred solution of the ester 5b (2.7 g, 6.58 mmol) in anhydrous 
dichloromethane (50 mL) under an argon atmasphere at –78°C (dry ice-ethyl acetate). The 
reaction mixture was stirred for an additional 2-3 h at –78°C, and was monitored by TLC every 
30 min. The temperature cannot be allowed to above –78°C. If the temperature gets above –78°C 
other byproducts are formed (imine reduced aldehyde and alcohols). After completion of the 
reaction excess DIBAL-H was quenched by careful addition of dry methanol (5 mL), followed 
by 5% aq HCl (10 mL). After this the resulting mixture was allowed to warm to room 
temperature. If the reaction mixture forms an aluminum emulsion, a saturated solution aqueous 
solution of Rochelle's salt and DCM (50 mL) were added to the reaction mixture. It was then 
filtered through a pad of Celite and then the organic layer was separated. The aqueous layer 
which remained was extracted with DCM (2x30 mL). The combined organic layers were washed 
with brine and dried (Na2SO4). The solvent was removed under reduced pressure to afford the 
crude aldehyde. This residue was purified by flash chromatography (2:1 ethyl acetate/hexane) to 
afford the pure diazepine aldehyde 6b as a white solid, (2.0 g, 78%); mp 192-194oC. 1H NMR 
(300 MHz, CDCl3)  10.06 (s, 1H), 8.01 (s, 1H), 7.84 (d, J = 8.4 Hz, 1H), 7.62 (s, 1H), 7.47-7.54 
(m, 4H), 7.39-7.44 (m, 2H), 5.98 (d, J = 12.6 Hz, 1H), 4.02 (d, J = 12.3 Hz, 1H). 13C NMR (75 
MHz, CDCl3)  186.6, 168.2, 138.9, 138.3, 136.7, 135.2, 135.0, 134.8, 134.1, 130.9, 129.8, 
129.3, 128.4, 124.2, 121.1, 44.2; HRMS (ESI-TOF m/z) for C18H12BrN3O calcd 366.0230 found 
366.0236 (M+H)+.  
8-Bromo-6-(2-fluorophenyl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carbaldehyde (6c) 
[00156] The aldehyde 6c was prepared according to the method described for pyridine 6b, 
employing the 2'-F ethyl ester 5c (1.5 g, 3.51 mmol) and DIBAL-H (6.25 mL of 1.2 M solution 
in toluene, 20% w/v), to afford the pure aldehyde 6c as a white solid (1.0 g, 74.6%); mp 120-
122oC. 1H NMR (300 MHz, CDCl3):  10.07 (s, 1H), 8.01 (s, 1H), 7.80 (dd, J = 1.8, 6.6 Hz, 1H), 
7.67 (ddd, J = 1.5, 6.0 Hz, 1H), 7.45-7.52 (m, 3H), 7.25-7.30 (m, 1H), 7.04 (t, J = 9.3 Hz, 1H), 
6.02 (br s, 1H), 4.15 (br s, 1H). 13C NMR (75 MHz, CDCl3)  186.6, 165.6, 161.8, 158.5, 137.8, 
136.8, 135.4, 135.2, 134.1, 133.5, 132.6, 132.4, 131.3, 129.2, 127.6, 127.5, 122.5, 122.1, 116.4, 
116.1, 44.2. HRMS (ESI-TOF m/z) for C18H11BrFN3O calcd 384.0145 found 384.0142 (M+H)+.  
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General synthetic procedure for oxazole containing benzimidazodiazepines through Van 
Leusen reaction via Baldwin's rules 
5-(8-Bromo-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-yl)oxazole (7a) 
[00157] The 2' pyridyldiazepine carboxaldehyde 6a (200 mg, 0.54 mmol) was placed in a dry 
two neck round bottom flask and dissolved in dry MeOH (30 mL) under an argon atmosphere. 
At rt, toluenesulfonylmethyl isocyanide (TosMIC, 130 mg, 0.65 mmol) was added as well as 
K2CO3 (225 mg, 1.6 mmol), The reaction mixture was heated to reflux for 3 to 4 h. After 
completion of the reaction on analysis by TLC (silica gel, 1:10 MeOH and EtOAc) this indicated 
the absence of aldehyde starting material and complete conversion to an oxazole of lower Rf. The 
reaction mixture was then quenched with cold water. After this 33% of the solvent was removed 
under reduced pressure and the solution was extracted with ethyl acetate (3x40 mL). The 
combined organic layers were washed with water and brine successively and dried (Na2SO4). 
The solvent was then removed under reduced pressure and the residue was purified by silica gel 
flash chromatography using EtOAc/DCM/Hexane (2:1:1 and 1 mL MeOH + 1 mLTEA for 100 
mL) to give the pure 2' pyridyldiazepine oxazole as white solid (170 mg, 77%); mp: 226-228 oC. 
1H NMR (500 MHz, CDCl3)  8.62 (d, J = 4.5 Hz, 1H), 8.24 (s, 1H), 8.08 (d, J = 8.0 Hz, 1H), 
7.96 (s, 1H), 7.82-7.87 (m, 2H), 7.57-7.59 (m, 2H), 7.40-7.43 (m, 1H), 5.78 (d, J = 12.5 Hz, 1H), 
4.32 (d, J = 12.5 Hz, 1H), (ESI) MS: m/z 368 (M+H)+. )+. 13C NMR (300 MHz, CDCl3)  167.2, 
155.9, 150.1, 148.7, 145.4, 137.2, 135.3, 135.2, 134.4, 133.3, 129.6, 128.3, 126.9, 125.1, 124.5, 
124.1, 123.4, 120.8, 44.9; HRMS (ESI m/z) for C19H12BrN5O calcd 406.0299, found 406.0298 
(M+H)+. 
5-(8-Bromo-6-phenyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-yl)oxazole (7b) 
[00158] The reaction was performed following the same procedure for 7a, employing 
diazepine aldehyde 6b (720 mg, 1.9 mmol), TosMIC (460 mg, 2.36 mmol) and K2CO3 (977 mg, 
7.08 mmol). This afforded the crude oxazole which was purified by flash silica gel 
chromatography (4:1 ethyl acetate/hexane) to give a white solid 7b (601 mg, 78 % yield); mp 
225-227 oC.  1H NMR (300 MHz, CDCl3)   8.05 (s, 1H), 7.92 (s, 1H), 7.81 (dd, J = 1.8, 6.6 Hz, 
1H), 7.82 (d, J = 8.4 Hz, 1H), 7.53-7.57 (m, 3H), 7.43-7.49 (m, 2H), 7.39-7.43 (m, 2H), 5.75 (d, 
J = 12.6 Hz, 1H), 4.24 (d, J = 12.6 Hz, 1H). 13C NMR (300 MHz, CDCl3)  167.9, 156.7, 149.9, 
148.9, 146.6, 137.0, 136.4, 135.8, 135.4, 135.3, 129.8, 127.5, 127.0, 124.9, 124.0, 122.8, 122.6, 
121.0, 45.3; HRMS (ESI m/z) for C20H13N4OBr calcd 405.0349, found 405.0345 (M+H)
+. 
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5-(8-Bromo-6-(2-fluorophenyl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-yl)oxazole (7c) 
[00159] The 2'-F oxazole 7c was prepared according to the method described for 7a 
employing 2'-F diazepine aldehyde 6c (649 mg, 1.53 mmol), TosMIC (330 mg, 1.68 mmol) and 
K2CO3 (640 mg, 4.60 mmol). This afforded the crude oxazole which was purified by flash silica 
gel chromatography (3:1 ethyl acetate/hexane) to give 2'-F oxazole 7c as a white solid (550 mg, 
76.7 % yield); mp:190-192 oC.1H NMR (300 MHz, CDCl3)  8.01 (s, 1H), 7.92 (s, 1H), 7.77 (dd, 
J = 2.1, 6.6 Hz, 1H), 7.77 (ddd, J = 1.5, 6.0 Hz, 1H), 7.52 (s, 1H), 7.46-7.52 (m, 3H), 7.23-7.28 
(m, 1H), 7.04 (t, J = 8.4 Hz, 1H), 5.75 (br s, 1H), 4.26 (br s, 1H). 13C NMR (300 MHz, CDCl3)  
165.0, 161.8, 158.5, 149.8, 146.5, 135.1, 134.9, 133.6, 133.3, 132.5, 131.1, 130.4, 129.7, 127.6, 
124.6, 124.0, 122.6, 120.9, 116.4, 116.1, 45.3; HRMS (ESI-TOF m/z) for C20H12N4OFBr calcd 
423.0263, found 423.0251 (M+H)+. 
5-(8-Bromo-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-yl)-4-methyloxazole 
(7d) 
[00160] The 2'-N methyl oxazole 7d was prepared according to the method described for 7a, 
employing 2'-N aldehyde 6a (300 mg, .815 mmol), 1-((1-isocyanoethyl)sulfonyl)-4-
methylbenzene (α-methyl TosMIC, 196 mg, 0.978 mmol) and K2CO3 (340 mg, 2.44 mmol). This 
afforded the crude oxazole which was purified by flash silica gel chromatography EtOAc/DCM 
(1:1 and 1 mL MeOH + 1 mLTEA for 100 mL) to give 2'-N methyl oxazole 7d as a half white 
solid (250 mg, 73 % yield); mp  228-230 oC. 1H NMR (500 MHz, CDCl3)  8.60 (d, J = 3.6 Hz, 
1H), 8.07 (d, J = 7.5 Hz, 1H), 7.96 (s, 1H), 7.77-7.86 (m, 3H), 7.57 (s, 1H), 7.47 (d, J = 8.7 Hz, 
1H), 7.38 (t, J = 5.4 Hz, 1H), ), 5.71 (d, J = 11.7 Hz, 1H), 4.28 (d, J = 12.3 Hz, 1H), 2.52 (s, 3H); 
13C NMR (300 MHz, CDCl3)  167.0, 156.4, 148.7, 140.6, 136.9, 135.2, 134.9, 134.8, 132.7, 
129.8, 128.4, 128.1, 124.8, 124.1, 123.8, 120.1, 45.2, 12.37; HRMS (ESI-TOF m/z) for 
C20H14N5OBr calcd 420.0450, found 420.0456 (M+H)
+. 
5-(8-Bromo-6-phenyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-yl)-4-methyloxazole (7e) 
[00161] The methyl 2'-H methyl oxazole compound 7e was prepared according to the method 
described for 7a, employing the 2'-H aldehyde 6b (500 mg, 1.366 mmol), 1-((1-
isocyanoethyl)sulfonyl)-4-methylbenzene (α-methyl TosMIC, 342 mg, 1.6 mmol) and K2CO3 
(565 mg, 4.0mmol). This afforded the crude solid which was purified by flash chromatography 
(4:1 ethyl acetate/hexane) to give a half white 2'-H methyl oxazole as a solid 7e (450 mg, 78 % 
yield); mp 236-238 oC. 1H NMR (300 MHz, CDCl3)   7.99 (s, 1H), 7.85 (s, 1H), 7.80 (dd, J = 
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3.0, 8.4 Hz, 1H), 7.58 (d, J = 2.1 Hz, 1H), 7.47-7.53 (m, 3H), 7.37-7.42 (m, 3H), 5.67 (d, J = 
13.2 Hz, 1H), 4.20 (d, J = 12.6 Hz, 1H), 2.52 (s, 3H). 13C NMR (75 MHz, CDCl3)  168.0, 148.6, 
140.6, 139.3, 135.0, 134.9, 134.8, 134.4, 132.7, 130.6, 130.3, 129.6, 129.3, 128.4, 128.2, 124.1, 
120.2, 45.1, 12.3; HRMS (ESI-TOF m/z) for C21H15N4OBr calcd 419.0500, found 419.0502 
(M+H)+. 
5-(8-Bromo-6-(2-fluorophenyl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-yl)-4-
methyloxazole (7f) 
[00162] The 2'-F methyl oxazole 7f was prepared according to the method described for 7a, 
employing the 2'-F aldehyde 6c (300 mg, 0.782 mmol), 1-((1-isocyanoethyl)sulfonyl)-4-
methylbenzene (α-methyl TosMIC, 196 mg, 0.938 mmol) and K2CO3 325 mg, 2.34 mmol). This 
afforded the crude solid which was purified by flash chromatography (4:1 ethyl acetate/hexane) 
to give a half white 2'-F methyl oxazole as a solid 7f (260 mg, 76 % yield); mp 138-140 oC. 1H 
NMR (500 MHz, CDCl3)  8.04 (s, 1H), 7.84 (s, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.77 (t, J = 7.0 
Hz, 1H), 7.46-7.52 (m, 3H), 7.23-7.28 (m, 1H), 7.05 (t, J = 8.5 Hz, 1H), 5.72 (br s, 1H), 4.24 (br 
s, 1H), 2.53 (s, 3H); 13C NMR (75 MHz, CDCl3)  164.8, 161.8, 158.5, 148.75, 140.65, 135.1, 
134.7, 133.7, 133.2, 132.8, 132.4, 132.3, 131.2, 131.1, 130.4, 129.9, 128.2, 127.6, 127.5, 124.5, 
124.1, 120.7, 116.4, 116.1, 45.3, 12.3. HRMS (ESI-TOF m/z) for C21H14N4OFBr calcd 437.0403 
found 437.0408 (M+H)+. 
General synthetic procedures for Sonogashira coupling 
5-(6-(Pyridin-2-yl)-8-((trimethylsilyl)ethynyl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-
yl)oxazole (8a) 
[00163] The 2'-N bromide 7a (200 mg, 0.50 mmol) and bis(triphenylphosphine)-palladium 
(II) acetate (18 mg, 0.024 mmol) were added to an oven dried two neck round bottom flask, after 
which the round bottom flask was fitted with a rubber septum. It was then evacuated under 
vaccum and back filled with argon three times. After this, a mixed dry solvent system of 
CH3CN:TEA (1:2 ratio) and trimethylsilylacetylene (0.3 mL, 2.07 mmol) were added to the 
round bottom flask with a syringe under a positive pressure of argon. The round bottom flask 
was fitted with a reflex condenser and the reaction mixture was degased under vaccum and argon, 
the process was repeated two to three times, after which the reaction mixture was slowly heated 
to 90°C. After stirring for 10 h, the reaction mixture was filtered through a bed of Celite. The 
organic layer was washed with brine and dried (Na2SO4). The solvent was then removed under 
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reduced pressure to furnish a crude solid. This material was purified by flash chromatography 
using EtOAc/DCM/Hexane (2:1:1 and 1 mL MeOH + 1 mLTEA for 100 mL) to afford the pure 
2'-N trimethylsilylacetylene intermediate as a light brown solid (170 mg, 80.6% yield); mp 208-
210 oC. 1H NMR (300 MHz, CDCl3)   8.63 (d, J = 4.1 Hz, 1H), 8.26 (s, 1H), 8.06 (d, J = 8.0 Hz, 
1H), 7.97 (s, 1H), 7.82-7.88 (m, 2H), 7.57-7.59 (m, 2H), 7.40-7.43 (m, 1H), 5.78 (d, J = 12.3 Hz, 
1H), 4.32 (d, J = 12.3 Hz, 1H), 0.22 (s, 9H); 13C NMR (75 MHz, CDCl3)  167.6, 149.8, 146.5, 
139.5, 135.3, 134.8, 132.1, 131.9, 131.6, 130.5, 130.2, 129.3, 128.6, 128.3, 127.8, 127.1, 122.5, 
122.4, 122.2, 102.5, 97.4, 44.9, -.0.22; HRMS (ESI-TOF m/z) for C24H21N5OSi calcd 424.1816, 
found 424.1810 (M+H)+. 
5-(6-Phenyl-8-((trimethylsilyl)ethynyl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-yl)oxazole 
(8b) 
[00164] The 2'-H trimethylsilylacetylenediazepine oxazole 8b was prepared according to the 
method described for 8a, employing the 2'-H bromodiazepine oxazole 7b (700 mg, 1.72 mmol), 
bis(triphenylphosphine)palladium(II)acetate (64 mg, 0.0864 mmol) and trimethylsilylacetylene 
(0.3 mL, 2.07 mmol). The residue which resulted was purified by silica gel flash column 
chromatography (4:1 ethyl acetate/hexane) to give a white solid 8b (650 mg, 89.6% yield); mp 
126-128 oC. 1H NMR (300 MHz, CDCl3)  8.00 (s, 1H), 7.93 (s, 1H), 7.81 (dd, J = 1.5, 8.4 Hz, 
1H), 7.65-7.72 (m, 1H), 7.51-7.57 (m, 4H), 7.38-7.47 (m, 4H), 5.70 (d, J = 12.6 Hz, 1H), 4.19 (d, 
J = 12.6 Hz, 1H), 0.25 (s, 9H); 13C NMR (300 MHz, CDCl3)  168.8, 149.8, 146.5, 139.5, 135.3, 
134.8, 132.1, 131.9, 131.6, 130.5, 130.2, 129.3, 128.6, 128.3, 127.8, 127.1, 122.5, 122.4, 122.2, 
102.5, 97.4, 44.9, -0.23; HRMS (ESI-TOF m/z) for C25H22N4OSi calcd 423.1630, found 
423.1636 (M+H)+. 
5-(6-(2-Fluorophenyl)-8-((trimethylsilyl)ethynyl)-4H-benzo[f]imidazo[1,5-a][1,4] diazepin-
3-yl)oxazole (8c) 
[00165] The 2'-F trimethylsilylacetylenediazepine oxazole 8c was prepared according to the 
method described for 8a, employing the 2'-F bromodiazepine oxazole 7c (100 mg, 0.23 mmol) 
bis(triphenylphosphine)palladium(II)acetate (10 mg, 0.011 mmol) and trimethylsilylacetylene 
(0.04 mL, 0.26 mmol). After work up the residue which resulted was purified by silica gel flash 
column chromatography (4:1 ethyl acetate/hexane) to give a light brown solid 8c (90 mg, 92.6% 
yield). 1H NMR (300 MHz, CDCl3)  8.02 (s, 1H), 7.92 (s, 1H), 7.60-7.74 (m, 3H), 7.40-7.57 (m, 
3H), 7.23-7.28 (m, 1H), 7.04 (t, J = 9.0 Hz, 1H), 5.73 (br s, 1H), 4.24 (br s, 1H), 0.24 (s, 9H). 13C 
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NMR (75 MHz, CDCl3)  165.6, 161.9, 158.4, 148.7, 140.7, 135.4, 134.7, 134.3, 133.7, 132.7, 
132.1, 131.1, 131.3, 129.9, 128.8, 128.3, 128.1, 124.4, 122.4, 116.5, 116.2, 102.5, 97.2, 45.1, -
0.23; HRMS (ESI-TOF m/z) for C25H21N4OFSi calcd 441.1543, found 441.1541 (M+H)
+. 
4-Methyl-5-(6-phenyl-8-((trimethylsilyl)ethynyl)-4H-benzo[f]imidazo[1,5-a][1,4] diazepin-
3-yl)oxazole (8e) 
[00166] The 2'-H trimethylsilylacetylenediazepine methyl oxazole 8e was prepared according 
to the method described for 8a, employing the bromo 2'-H trimethylsilylacetylenediazepine 
methyl oxazole 7e (250 mg, 1.72 mmol), bis(triphenylphosphine)palladium(II)acetate (17 mg, 
0.0238 mmol) and trimethylsilyl acetylene (0.074 mL, 0.52 mmol). The residue which resulted 
was purified by silica gel flash column chromatography (4:1 ethyl acetate/hexane) to give a light 
brown solid 8b (188 mg, 90 % yield); mp130-132°C. 1H NMR (300 MHz, CDCl3)  8.00 (s, 1H), 
7.93 (s, 1H), 7.81 (dd, J = 1.5, 8.4 Hz, 1H), 7.65-7.72 (m, 1H), 7.51-7.57 (m, 4H), 7.38-7.47 (m, 
4H), 5.70 (d, J = 12.6 Hz, 1H), 4.19 (d, J = 12.6 Hz, 1H), 0.25 (s, 9H); 13C NMR (300 MHz, 
CDCl3)  168.8, 149.8, 146.5, 139.5, 135.3, 134.8, 132.1, 131.9, 131.6, 130.5, 130.2, 129.3, 
128.6, 128.3, 127.8, 127.1, 122.5, 122.4, 122.2, 102.5, 97.4, 44.9, -0.23; HRMS (ESI-TOF m/z) 
for C26H24N4OSi calcd 437.1638, found 437.1636 (M+H)
+. 
5-(6-(2-Fluorophenyl)-8-((trimethylsilyl)ethynyl)-4H-benzo[f]imidazo[1,5-a][1,4] diazepin-
3-yl)-4-methyloxazole (8f) 
[00167] The 2'-F trimethylsilylacetylenediazepine methyl oxazole 8f was prepared according 
to the method described for 8a, employing the bromo 2'-F trimethylsilylacetylenediazepine 
methyl oxazole 7f (900 mg, 2.059 mmol), bis(triphenylphosphine)palladium(II)acetate (77 mg, 
0.103 mmol) and trimethyl silylacetylene (0.321 mL, 2.65 mmol). The residue which resulted 
was purified by silica gel flash column chromatography (4:1 ethyl acetate/hexane) to give a 
brown solid 8f (800 mg, 87 % yield); mp 209-211 oC. 1H NMR (300 MHz, CDCl3)  8.03 (s, 1H), 
7.83 (s, 1H), 7.71 (dd, J = 1.8, 8.1 Hz, 1H), 7.63 (td, J = 1.8, 7.5 Hz, 1H), 7.40-7.53 (m, 3H), 
7.23-7.28 (m, 1H), 7.04 (t, J = 10.2 Hz, 1H), 5.69 (br s, 1H), 4.21 (br s, 1H), 2.53 (s, 3H), 0.25 (s, 
9H); 13C NMR (75 MHz, CDCl3)  165.4, 161.9, 158.5, 148.6, 140.7, 135.3, 134.6, 134.2, 133.7, 
132.7, 132.1, 131.0, 131.2, 129.9, 128.8, 128.2, 128.0, 124.4, 122.4, 116.4, 116.1, 102.6, 97.1, 
45.1, 12.3, -0.23; HRMS (ESI-TOF m/z)  for C26H23N4OFSi calcd 455.1690, found 455.1698 
(M+H)+. 
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5-(8-Ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-yl)oxazole (9a) 
[00168] A solution of 2'-N trimethylsilylacetylene oxazole intermediate 8a (150 mg, 0.35 
mmol) was dissolved in dry THF and kept at 0°C after which tetrabutylammonium iodide (0.12 
mL, 0.39 mmol) was added slowly to the reaction mixture at 0°C. After 10 min the reaction 
mixture was stirred at room temperature for 2 h under an argon atmosphere. After TLC on silica 
gel indicated the absence of starting material, this reaction mixture was quenched by slow 
addition of ice cold water and the combined layers were extracted with ethyl acetate (330 mL). 
The combined organic layers were washed with water and brine. This solution was dried over 
Na2SO4 and the solvent was removed under reduced pressure to furnish a solid. This material 
was then purified by flash chromatography using EtOAc/DCM/Hexane (2:1:1 and 1 mL MeOH 
+ 1 mLTEA for 100 mL) to afford the pure 2'-N acetyleno oxazole 9a as a white solid (101 mg, 
82% yield); mp 220-222 oC. 1H NMR (300 MHz, CDCl3)  8.62 (d, J = 4.2 Hz, 1H), 8.12 (s, 1H), 
8.06 (d, J = 7.8 Hz, 1H), 7.96 (s, 1H), 7.85 (ddd, J = 1.8, 6.0 Hz, 1H), 7.79 (dd, J = 1.8, 6.6 Hz,  
1H), 7.62 (d, J = 8.4 Hz, 1H), 7.55 (d, J = 1.5 Hz, 1H), 7.53 (s, 1H), 7.41 (ddd, J = 1.5, 4.8 Hz, 
1H), 5.78 (d, J = 12.9 Hz, 1H), 4.31 (d, J = 12.9 Hz, 1H). 13C NMR (75 MHz, CDCl3)  167.9, 
156.7, 149.9, 149.0, 146.6, 137.0, 136.4, 135.8, 135.5, 135.3, 129.8, 127.5, 127.0, 124.9, 124.0, 
122.8, 122.7, 121.0, 81.8.7, 79.5, 45.3; HRMS (ESI-TOF m/z) for C21H13N5O calcd 352.1188, 
found 352.1193 (M+H)+. 
5-(8-Ethynyl-6-phenyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-yl)oxazole (9b) 
[00169] The 2'-H acetyleno oxazole 9b was prepared according to the method described for 
7a, employing the 2'-H trimethylsilylacetylenodiazepine oxazole 8b (500 mg, 1.18) and TBAF 
(0.5 mL, 1.76 mmol). After workup, the residue was purified by silica gel flash column 
chromatography (4:1 ethyl acetate/hexane) to afford 2'-H acetyleno oxazole 9b as a white solid 
(370 mg, 90% yield); mp 120-122°C. 1H NMR (300 MHz, CDCl3)  8.08 (s, 1H), 7.93 (s, 1H), 
7.81 (dd, J = 1.8, 6.6 Hz, 1H), 7.81 (d, J = 8.4 Hz, 1H), 7.53-7.57 (m, 3H), 7.43-7.49 (m, 2H), 
7.39-7.43 (m, 2H), 5.75 (d, J = 12.9 Hz, 1H), 4.24 (d, J = 12.9 Hz, 1H), 3.18 (s, 1H).13C NMR 
(300 MHz, CDCl3)  167.9, 156.7, 149.9, 148.9, 146.6, 137.0, 136.4, 135.8, 135.4, 135.3, 129.8, 
127.5, 127.0, 124.9, 124.0, 122.8, 122.6, 121.0, 81.8, 79.5, 45.2; HRMS (ESI-TOF m/z) for 
C22H14N4O calcd 351.1246, found 351.1240 (M+H)
+. 
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5-(8-Ethynyl-6-(2-fluorophenyl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-yl)oxazole (9c) 
[00170] The 2'-F acetyleno oxazole 9c was prepared according to the method described for 9a, 
employing the 2'-F TMS-acetyleno-2'-fluorodiazepine oxazole 8c (90 mg, 0.20 mmol), and 
TBAF (0.05 mL, 024 mmol). After workup the residue was purified by silica gel flash column 
chromatography (4:1 ethyl acetate/hexane) to give the 2'-F acetyleno oxazole 9c as a white solid 
(80 mg, 88% yield); mp 212-214°C. 1H NMR (300 MHz, CDCl3)  8.03 (s, 1H), 7.93 (s, 1H), 
7.75 (d, J = 7.8 Hz, 1H), 7.57-7.63 (m, 2H), 7.44-7.53 (m, 3H), 7.23-7.28 (m, 1H), 7.04 (t, J = 
9.0 Hz, 1H), 5.74 (br s, 1H), 4.26 (br s, 1H), 3.16 (s, 1H). 13C NMR (300 MHz, CDCl3)  165.5, 
161.9, 158.5, 149.8, 146.5, 135.4, 135.0, 134.3, 132.3, 131.1, 129.8, 128.9, 127.8, 127.5, 124.5, 
122.6, 121.6, 116.4, 116.1, 81.4, 79.6, 45.0; HRMS (ESI-TOF m/z) for C22H13N4OF calcd 
369.1144, found 369.1146 (M+H)+. 
5-(8-Ethynyl-6-phenyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-yl)-4-methyloxazole (9e) 
[00171] The 2'-H acetyleno methyl oxazole 9e was prepared according to the method 
described for 9a, employing the TMS-acetyleno-2'-H methyl oxazole 8c (250 mg, 0.573 mmol), 
and TBAF (0.19 mL, 0.68 mmol). After workup the residue was purified by silica gel flash 
column chromatography (4:1 ethyl acetate/hexane) to give the 2'-H acetyleno methyl oxazole 9e 
as a white solid (190 mg, 91% yield); mp 228-230°C. 1H NMR (300 MHz, CDCl3)  8.01 (s, 1H), 
7.85 (s, 1H), 7.77 (dd, J = 1.8, 8.4 Hz, 1H), 7.56-7.60 (m, 2H), 7.49-7.53 (m, 2H), 7.37-7.46 (m, 
3H), 5.67 (d, J = 12.9 Hz, 1H), 4.20 (d, J = 12.9 Hz, 1H), 3.17 (s, 1H), 2053 (s, 3H); 13C NMR 
(300 MHz, CDCl3)  168.5, 148.7, 140.6, 139.5, 135.9, 135.8, 135.3, 134.5, 132.8, 130.5, 130.3, 
129.3, 128.3, 128.2, 128.0, 122.6, 121.0, 81.5, 79.6, 45.3, 12.3; HRMS (ESI-TOF m/z) for 
C23H16N4O calcd 365.1400 found 365.1397 (M+H)
+. 
5-(8-Ethynyl-6-(2-fluorophenyl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-yl)-4-
methyloxazole (9f) 
[00172] The 2'-F acetyleno methyl oxazole 9e was prepared according to the method 
described for 9a, employing the TMS-acetyleno-2'-H methyl oxazole 8c (500 mg, 1.147 mmol), 
and TBAF (0.390 mL, 1.37 mmol). After workup the residue was purified by silica gel flash 
column chromatography (4:1 ethyl acetate/hexane) to give the 2'-F acetyleno methyl  oxazole 9f 
as a white solid (395 mg, 90 % yield); mp 145-147°C. 1H NMR (300 MHz, CDCl3)  8.03 (s, 
1H), 7.84 (s, 1H), 7.74 (d, J = 7.8 Hz, 1H), 7.55-7.65 (m, 2H), 7.46 (s, 2H), 7.22-7.28 (m, 1H), 
7.03 (t, J = 8.1 Hz, 1H), 5.70 (br s, 1H), 4.25 (br s, 1H), 3.16 (s, 1H), 2.53 (s, 3H). 13C NMR (75 
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MHz, CDCl3)  165.4, 161.9, 158.5, 148.7, 140.6, 135.4, 134.6, 134.2, 132.8, 132.2, 132.1, 
131.2, 131.1, 129.9, 128.9, 128.3, 127.9, 127.8, 124.5, 124.4, 122.5, 121.4, 116.4, 116.1, 81.5, 
79.9, 45.1, 12.3; HRMS (ESI-TOF m/z) for C23H15N4OF calcd 383.1300 found 383.1303 
(M+H)+. 
General synthetic procedures for Sonogashira coupling and desilylation 
Ethyl-8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate 
(10a) 
[00173] The 2'-N bromide ethyl ester 5a (17.0 g, 41.2 mmol) and bis(triphenylphosphine)-
palladium (II) acetate (1.50 g, 2.06 mmol) were added to an oven dried two neck round bottom 
flask, after which the round bottom flask was fitted with a rubber septum. It was then evacuated 
under vaccum and back filled with argon three times. After this, a mixed dry solvent system of 
CH3CN:TEA (1:2 ratio) and trimethylsilylacetylene (6.4 mL, 45.40 mmol) were added to the 
round bottom flask with a syringe under a positive pressure of argon. The round bottom flask 
was fitted with a reflex condenser and the reaction mixture was degased under vaccum and argon, 
the process was repeated two to three times, after which the reaction mixture was slowly heated 
to 90°C. After stirring for 10 h, the reaction mixture was filtered through a bed of Celite. The 
organic layer was washed with brine and dried (Na2SO4). The solvent was then removed under 
reduced pressure to furnish a crude solid. This material was purified by flash chromatography 
using EtOAc/DCM/Hexane (2:1:1 and 1 mLTEA for 100 mL) to afford the pure 2'-N 
trimethylsilyl acetyleno intermediate (14.12 g, 80 % yield) as a light brown solid. And this 
intermediate (14.12 mg, 3.30 mmol) was dissolved in dry THF and kept at 0°C after which 
tetrabutylammonium iodide (10.30 mL, 3.62 mmol) was added slowly to the reaction mixture at 
0°C. After 10 min the reaction mixture was stirred at room temperature for 2 h under an argon 
atmosphere. After TLC on silica gel indicated the absence of starting material, this reaction 
mixture was quenched by slow addition of ice cold water and the combined layers were extracted 
with ethyl acetate (2150 mL). The combined organic layers were washed with water and brine. 
This solution was dried over Na2SO4 and the solvent was removed under reduced pressure to 
furnish a solid. This material was then purified by flash chromatography using 
EtOAc/DCM/Hexane (2:1:1 and 1 mLTEA for 100 mL) to afford the pure 2'-N acetyleno ethyl 
ester 10a as a white solid (9.63 g, 82 % yield); mp 248-250°C. 1H NMR (300 MHz,  CDCl3)   
8.58 (d, J = 4.8 Hz, 1H), 8.07 (d, J = 7.8 Hz, 1H), 7.92 (s, 1H), 7.82 (td, J = 1.8, 7.8 Hz, 1H), 
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7.57-7.59 (dd, J = 1.5, 8.4 Hz, 1H), 7.54-7.57 (m, 2H), 7.37 (td, J = 0.9, 4.8 Hz, 1H), 6.14 (d, J = 
9.9 Hz, 1H), 4.42 (q, J = 3.9, 7.2 Hz, 2H), 4.16 (d, J = 10.2 Hz, 1H), 3.17 (s, 1H), 1.44 (t, J = 7.2 
Hz, 1H); 13C NMR (75 MHz, CDCl3)  167.5, 162.9, 156.2, 148.6, 138.3, 137.1, 136.1, 135.4, 
135.3, 134.5, 129.2, 127.0, 124.9, 124.1, 122.9, 121.3, 81.6, 79.5, 60.8, 45.0, 14.4; HRMS (ESI-
TOF m/z) for C21H16N4O calcd 357.1340, found 357.1346 (M+H)
+. 
Ethyl 8-ethynyl-6-phenyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate (10b) 
[00174] The 2'-H acetyleno ethyl ester 10b was prepared according to the method described 
for 10a, employing the 2'-H bromodiazepine ethyl ester 5b (10.0 g, 24.40 mmol), 
bis(triphenylphosphine)palladium(II)acetate (913 mg, 1.22 mmol) and trimethylsilylacetylene 
(3.82 mL, 26.84 mmol). The residue was purified by flash chromatography (3:1 ethyl 
acetate/hexane) to afford the 2'-H trimethylsilyl acetyleno intermediate (9.48 mg, 91.0% yield). 
And this intermediate (9.48 mg, 22.20 mmol). was treated with tetrabutylammonium iodide (7.0 
mL, 24.42 mmol), this resulting material was purified by flash column chromatography using 
EtOAc/Hexane (4:1) to afford the pure 2'-H acetyleno ethyl ester 10b as a white solid (7.33 mg, 
93.0% yield); mp 237-239 oC. 1H NMR (300 MHz, CDCl3)  8.00 (s, 1H), 7.81 (dd, J = 1.8, 8.3 
Hz, 1H), 7.65-7.72 (m, 2H), 7.51-7.57 (m, 3H), 7.38-7.47 (m, 2H), 6.11 (d, J = 12.6 Hz, 1H), 
4.41-4.48 (m, 2H), 4.19 (d, J = 12.6 Hz, 1H), 3.20 (s, 1H), 1.44 (t, J = 7.3 Hz, 3H); 13C NMR (75 
MHz, CDCl3)  168.3, 138.8, 138.4, 136.7, 135.3, 135.0, 134.8, 134.1, 130.9, 129.8, 129.2, 
128.3, 124.2, 121.1, 81.3, 80.0, 60.6, 44.2, 14.7; HRMS (ESI-TOF m/z) for C22H17N3O2 calcd 
356.1390 found 356.1394 (M+H)+.  
Ethyl-8-ethynyl-6-(2-fluorophenyl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate 
(10c) 
[00175] The 2'-F acetyleno ethyl ester 10c was prepared according to the method described 
for 10a, employing the 2'-F bromodiazepine ethyl ester 5c (7 g, 16.35 mmol), 
bis(triphenylphosphine)palladium(II)acetate (612 mg, 0.817 mmol) and trimethylsilylacetylene 
(2.56 mL, 18.0 mmol). The residue was purified by flash chromatography (3:1 ethyl 
acetate/hexane) to afford the 2'-F trimethylsilyl acetyleno intermediate (6.47 g, 89.0% yield). 
And this intermediate (6.47 g, 14.55 mmol) was treated with tetrabutylammonium iodide (4.54 
mL, 16.0 mmol), this resulting material was purified by flash column chromatography using 
EtOAc/Hexane (4:1) to afford the pure 2'-F acetyleno ethyl ester 10c as a white solid (4.89 g, 
90.0% yield); mp 232-234 oC. 1H NMR (300 MHz, CDCl3)  7.97 (s, 1H), 7.64 (dd, J = 1.5, 8.1 
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Hz, 1H), 7.65 (td, J = 1.8, 7.5 Hz, 1H), 7.57 (d, J = 8.4 Hz, 1H), 7.42-7.48 (m, 2H), 7.23-7.28 (m, 
1H), 7.02 (t, J = 9.9 Hz, 1H), 6.11 (br s, 1H), 4.43 (q, J = 3.6, 6.9 Hz, 2H), 4.14 (br s, 1H), 3.16 
(s, 1H), 1.43 (t, J = 6.9 Hz, 3H); 13C NMR (300 MHz, CDCl3)  165.5, 162.8, 161.8, 158.5, 
138.3, 135.5, 135.3, 134.5, 134.3, 134.1, 134.0, 132.3, 132.2, 131.2, 129.4, 129.0, 127.7, 127.5, 
124.4, 122.7, 121.9, 116.3, 116.0, 81.3, 79.8, 60.7, 44.8, 14.8; HRMS (ESI-TOF m/z) for 
C22H16N3O2F calcd 374.1290, found 374.1299 (M+H)
+. 
8-Ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carbaldehyde (11a), 
Method 1 
[00176] The reaction was performed following the same procedure for 6a, employing the 2'-
pyridyl ethyl ester (HZ-166) 10a (3.0 g, 8.42 mmol) and LiAlH4 (360 mg, 9.27 mmol). This 
afforded the crude mixture of alcohols (1:0.4 ratio); this mixture of alcohols was used directly in 
the next step. The mixture of 2'-pyridylalcohols (2.5 g, 8.00 mmol) was dissolved in dry DCM 
(200 mL) under an argon atmosphere, after which Na2CO3 (2.8 g, 24 mmol) and activated MnO2 
(10.5 g, 120 mmol) were added to the reaction mixture at 0oC. The mixture was stirred at room 
temperature overnight. After 12-14 h, the reaction mixture was diluted with DCM (50 mL) and 
was filtered through a pad of Celite. The desired aldehyde 11a was purified by flash silica gel 
chromatography (2:1:1 ethyl acetate/DCM/hexane and 1 mL MeOH + 1 mLTEA for 100 mL) to 
give a white solid 11a (1.02 g, 40 % yield for 2 steps); mp 238-240°C. 1H NMR (500 MHz, 
CDCl3)  10.05 (s, 1H), 8.56 (d, J = 5.0 Hz, 1H), 8.08 (d, J = 7.5 Hz, 1H), 7.97 (s, 1H), 7.78 
(ddd, J = 1.5, 6.0 Hz, 1H), 7.77 (dd, J = 1.5, 7.0 Hz, 1H), 7.55-7.57 (m, 2H), 7.38 (ddd, J = 1.5, 
5.0 Hz,  1H), 6.00 (br s, 1H), 4.17 (br s, 1H), 3.16 (s, 1H): 13C NMR (75 MHz, CDCl3)  186.9, 
167.7, 156.2, 148.6, 137.7, 137.1, 136.7, 136.3, 135.4, 135.3, 135.0, 127.1, 124.9, 124.0, 122.8, 
121.5, 81.5, 79.7, 44.4 HRMS (ESI-TOF m/z) for C19H12N4O calcd 113.1080 found 313.1084 
(M+H)+.  
8-Ethynyl-6-phenyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carbaldehyde (11b) 
Method 2 
[00177] The aldehyde 11b was prepared according to the method described for pyridine 6b, 
employing the 2'H 8-ethynyl ethyl ester 10b (4.5 g, 12.6 mmol) and DIBAL-H (22.5 mL of 1.2 
M solution in toluene, 20% w/v), to afford the pure compound 11b as a white solid (3.15 g, 
80.0%); mp 117-119 oC. 1H NMR (300 MHz, CDCl3)  10.07 (s, 1H), 8.01 (s, 1H), 7.80 (dd, J = 
1.8, 8.1 Hz, 1H), 7.58-7.62 (m, 2H), 7.46-7.53 (m, 3H), 7.36-7.43 (m, 2H), 5.98 (d, J = 12 Hz,  
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H), 4.13 (d, J = 12 Hz, 1H). 3.20 (s, 1H).13C NMR (75 MHz, CDCl3)  186.7, 168.3, 138.8, 
138.4, 136.7, 135.3, 135.0, 134.8, 134.1, 130.9, 129.8, 129.2, 128.3, 124.2, 121.1, 81.3, 80.0, 
44.2; HRMS (ESI-TOF m/z) for C20H13N3O calcd 312.0231 found 312.0236 (M+H)+.  
8-Ethynyl-6-(2-fluorophenyl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carbaldehyde 
(11c) 
[00178] The aldehyde 11c was prepared according to the method described for pyridine 6b, 
employing the 2'F 8-ethynyl ethyl ester 10c (770 mg, 2.06 mmol) and DIBAL-H (4 mL of 1.2 M 
solution in toluene, 20% w/v), to afford the pure aldehyde 11c as a white solid (530 mg, 78.0%); 
mp 190-192 oC. 1H NMR (300 MHz, CDCl3)  10.08 (s, 1H), 8.04 (s, 1H), 7.77 (d, J = 8.4 Hz, 
1H), 7.67 (t, J = 7.5 Hz, 1H), 7.60 (d, J = 8.4 Hz, 1H), 7.44-7.50 (m, 2H), 7.25-7.30 (m, 1H), 
7.04 (t, J = 9.0 Hz, 1H), 6.00 (br s, 1H), 4.13 (br s, 1H), 3.18 (s, 1H). 13C NMR (75 MHz, 
CDCl3)  186.7, 165.7, 161.8, 158.5, 137.8, 136.8, 135.4, 135.2, 134.1, 133.7, 132.5, 132.4, 
131.2, 129.2, 127.5, 127.4, 122.6, 122.2, 116.4, 116.1, 81.3, 80.0, 44.2; HRMS (ESI-TOF m/z) 
for C20H12FN3O calcd 330.1030 found 330.1037 (M+H)+.  
General synthetic procedure for oxazole containing benzimidazodiazepines through Van 
Leusen reaction via Baldwin's rules. 
5-(8-Ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-yl)oxazole (9a) 
[00179] The 2'-N aldehyde 11a (1.1 g, 3.52 mmol) was placed in a dry two neck round bottom 
flask and dissolved in dry MeOH (100 mL) under an argon atmosphere. At rt, TosMIC (825 mg, 
4.23 mmol) was added as well as K2CO3 (1.30 g, 9.75 mmol) to the reaction mixture and it was 
allowed to heat reflux for 2 to 3 h. After completion of the reaction on analysis by TLC (silica 
gel, 1:10 MeOH and EtOAc) which indicated the absence of aldehyde starting material and 
complete conversion of oxazole of lower Rf. The reaction mixture was then quenched with cold 
water. After this 33% of the solvent was removed under reduced pressure and the work up 
followed with ethyl acetate (3x30 mL). The combined organic layers were washed with water 
and brine successively and dried (Na2SO4). The solvent was then removed under reduced 
pressure and the residue was purified by silica gel flash chromatography to give the pure 2'-N 
oxazole 9a as a white solid (910 mg, 73.4%); mp: 220-222oC. 1H NMR (300 MHz, CDCl3)  
8.62 (d, J = 4.2 Hz, 1H), 8.12 (s, 1H), 8.06 (d, J = 7.8 Hz, 1H), 7.96 (s, 1H), 7.85 (ddd, J = 1.8, 
6.0 Hz, 1H), 7.79 (dd, J = 1.8, 6.6 Hz, 1H), 7.62 (d, J = 8.4 Hz, 1H), 7.55 (d, J = 1.5 Hz, 1H), 
7.53 (s, 1H), 7.41 (ddd, J = 1.5, 4.8 Hz, 1H), 5.78 (d, J = 12.9 Hz, 1H), 4.31 (d, J = 12.9 Hz, 1H). 
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13C NMR (75 MHz, CDCl3)  167.9, 156.7, 149.9, 149.0, 146.6, 137.0, 136.4, 135.8, 135.5, 
135.3, 129.8, 127.5, 127.0, 124.9, 124.0, 122.8, 122.7, 121.0, 81.8.7, 79.5, 45.3; HRMS (ESI-
TOF m/z)  for C21H13N5O calcd 352.1188, found 352.1193 (M+H)
+. 
5-(8-Ethynyl-6-phenyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-yl)oxazole (9b) 
[00180] The 2'-H oxazole compound 9b was prepared according to the method described for 
9a, employing the 2'-H aldehyde 11b (3.30 g, 10.61 mmol), TosMIC, 2.50 g, 12.7 mmol) and 
K2CO3 (4.3 g, 31.80 mmol). This afforded the crude solid which was purified by flash 
chromatography (4:1 ethyl acetate/hexane) to give a white solid 9b (2.90 g, 78% yield); mp 120-
122 oC. 1H NMR (300 MHz, CDCl3)  8.08 (s, 1H), 7.93 (s, 1H), 7.81 (dd, J = 1.8, 6.6 Hz, 1H), 
7.81 (d, J = 8.4 Hz, 1H), 7.53-7.57 (m, 3H), 7.43-7.49 (m, 2H), 7.39-7.43 (m, 2H), 5.75 (d, J = 
12.9 Hz, 1H), 4.24 (d, J = 12.9 Hz, 1H), 3.18 (s, 1H).13C NMR (300 MHz, CDCl3)  167.9, 
156.7, 149.9, 148.9, 146.6, 137.0, 136.4, 135.8, 135.4, 135.3, 129.8, 127.5, 127.0, 124.9, 124.0, 
122.8, 122.6, 121.0, 81.8, 79.5, 45.2; HRMS (ESI-TOF m/z) for C22H14N4O calcd 351.1246, 
found 351.1240 (M+H)+. 
5-(8-Ethynyl-6-(2-fluorophenyl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-yl)oxazole (9c) 
[00181] The 2'-F oxazole 9c was prepared according to the method described for 9a, 
employing the 2'-N aldehyde 11c (500 mg, 1.51 mmol), TosMIC, 366 mg, 1.82 mmol) and 
K2CO3 (629 mg, 4.56 mmol). This afforded the crude solid which was purified by flash 
chromatography (4:1 ethyl acetate/hexane) to give 2'-F oxazole as a white solid 9b (446 mg, 
80% yield); mp 212-214°C. 1H NMR (300 MHz, CDCl3)  8.03 (s, 1H), 7.93 (s, 1H), 7.75 (d, J = 
7.8 Hz, 1H), 7.57-7.63 (m, 2H), 7.44-7.53 (m, 3H), 7.23-7.28 (m, 1H), 7.04 (t, J = 9.0 Hz, 1H), 
5.74 (br s, 1H), 4.26 (br s, 1H), 3.16 (s, 1H). 13C NMR (300 MHz, CDCl3)  165.5, 161.9, 158.5, 
149.8, 146.5, 135.4, 135.0, 134.3, 132.3, 131.1, 129.8, 128.9, 127.8, 127.5, 124.5, 122.6, 121.6, 
116.4, 116.1, 81.4, 79.6, 45.0; HRMS (ESI-TOF m/z) for C22H13N4OF calcd 369.1144, found 
369.1146 (M+H)+. 
5-(8-Ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-yl)-4-methyloxazole 
(9d) 
[00182] The 8-ethynyl 2'-N methyl oxazole 9d was prepared according to the method 
described for 9a, employing 2'-N aldehyde 11a (700 mg, 2.23 mmol), α-methyl TosMIC (560 
mg, 2.683 mmol) and K2CO3 (925 mg, 6.709 mmol). This afforded the crude oxazole which was 
purified by flash silica gel chromatography EtOAc/DCM (1:1 and 1 mL MeOH + 1 mLTEA for 
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100 mL) to give 8-ethynyl 2'-N methyl oxazole 9d as a half white solid (600 mg, 74% yield); mp  
209-211°C. 1H NMR (500 MHz, CDCl3)  8.60 (d, J = 4.5 Hz, 1H), 8.04 (d, J = 7.5 Hz, 1H), 
7.98 (s, 1H), 7.86 (s, 1H), 7.81 (t, J = 7.5 Hz, 1H), 7.76 (dd, J = 1.5, 8.5 Hz, 1H), 7.57 (d, J = 8.5 
Hz, 1H), 7.54 (d, J = 1.0 Hz, 1H), 7.37 (t, J = 7.5 Hz, 1H), ), 5.70 (d, J = 12.0 Hz, 1H), 4.28 (d, J 
= 12.5 Hz, 1H), 3.16 (s, 1 H), 2.53 (s, 3H); 13C NMR (75 MHz, CDCl3)  167.6, 156.7, 148.8, 
148.7, 140.7, 136.8, 136.2, 135.9, 135.3, 134.8, 132.8, 129.8, 128.2, 126.9, 124.7, 123.9, 122.7, 
120.7, 81.8, 79.2, 45.3, 12.3; HRMS (ESI-TOF m/z) for C22H15N5O calcd 366.1340 found 
366.1349 (M+H)+. 
5-(8-Ethynyl-6-phenyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-yl)-4-methyloxazole (9e) 
[00183] The 8-ethynyl 2'-H methyl oxazole 9e was prepared according to the method 
described for 9a, employing the 2'-H aldehyde 11b (250 mg, 0.803 mmol), α-methyl TosMIC 
(201 mg, 0.967 mmol) and K2CO3 (332 mg, 2.4 mmol). This afforded the crude solid which was 
purified by flash chromatography (4:1 ethyl acetate/hexane) to give half white 8-ethynyl 2'-H 
methyl oxazole as a solid 9e (242 mg, 82% yield); mp 228-230°C. (300 MHz, CDCl3)  8.01 (s, 
1H), 7.85 (s, 1H), 7.77 (dd, J = 1.8, 8.4 Hz, 1H), 7.56-7.60 (m, 2H), 7.49-7.53 (m, 2H), 7.37-7.46 
(m, 3H), 5.67 (d, J = 12.9 Hz, 1H), 4.20 (d, J = 12.9 Hz, 1H), 3.17 (s, 1H), 2053 (s, 3H); 13C 
NMR (300 MHz, CDCl3)  168.5, 148.7, 140.6, 139.5, 135.9, 135.8, 135.3, 134.5, 132.8, 130.5, 
130.3, 129.3, 128.3, 128.2, 128.0, 122.6, 121.0, 81.5, 79.6, 45.3, 12.3; HRMS (ESI-TOF m/z) for 
C23H16N4O calcd 365.1400 found 365.1397 (M+H)
+. 
5-(8-Ethynyl-6-(2-fluorophenyl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-yl)-4-
methyloxazole (9f) 
[00184] The 8-ethynyl 2'-F methyl oxazole 9f was prepared according to the method 
described for 9a, employing the 8-ethynyl 2'-F aldehyde 11c (500 mg, 1.52 mmol), α-methyl 
TosMIC (381 mg, 1.82 mmol) and K2CO3 (630 mg, 4.55 mmol). This afforded the crude solid 
which was purified by flash chromatography (4:1 ethyl acetate/hexane) to give a half white 8-
ethynyl 2'-F methyl oxazole as a solid 9f (450 mg, 78 % yield); mp 145-147°C; 1H NMR (300 
MHz, CDCl3)  8.03 (s, 1H), 7.84 (s, 1H), 7.74 (d, J = 7.8 Hz, 1H), 7.55-7.65 (m, 2H), 7.46 (s, 
2H), 7.22-7.28 (m, 1H), 7.03 (t, J = 8.1 Hz, 1H), 5.70 (br s, 1H), 4.25 (br s, 1H), 3.16 (s, 1H), 
2.53 (s, 3H). 13C NMR (75 MHz, CDCl3)  165.4, 161.9, 158.5, 148.7, 140.6, 135.4, 134.6, 
134.2, 132.8, 132.2, 132.1, 131.2, 131.1, 129.9, 128.9, 128.3, 127.9, 127.8, 124.5, 124.4, 122.5, 
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121.4, 116.4, 116.1, 81.5, 79.9, 45.1, 12.3; HRMS (ESI-TOF m/z) for C23H15N4OF calcd 
383.1300 found 383.1303 (M+H)+. 
 
Example 7. In Vitro Analysis 
FLIPR Binding 
[00185] The FLIPR functional assay is used to determine the EC50 at the α1 and α3 GABAA 
receptor subtypes. A high EC50 for the α1 subtype would indicate a low chance of adverse effects, 
including sedation, ataxia, and muscle relaxation. A low α3 EC50 would indicate potential 
effectiveness as an anxiolytic, antihyperalgesic, and likely an anticonvulsant. See, for example, 
Liu et al. (Assay. Drug. Dev. Technol. 2008, 6, 781-6) and Joesch et al. (J. Biomol. Screen. 2008, 
13, 218-28).   
[00186] Compounds tested were synthesized internally and solubilized in DMSO at a 10 mM 
concentration. GABA was purchase from Sigma (#A2129) and prepared at 100 mM in water.   
[00187] HEK-293 cells were stably transfected with the α1, β3, γ2 GABA A receptor subunits 
(GenBank accession numbers NM_000806.3, NM_000814.5, and NM_198904.1, respectively) 
or α3, β3, γ2 (NM_000808 for α3) where obtained from ChanTest Co. (Catalog # CT6216 and 
CT6218, respectively). 
[00188] Cells were cultivated in Dulbeco’s Modified Eagle’s Medium (DMEM, Sigma 
D5796) supplemented with 10 % Fetal Bovine Serum (FBS, Gibco 16000), 0.5 mg/mL Geneticin 
(Gibco), 0.04 mg/mL Hygromycin B (Gibco), 0.1 mg/mL Zeocin (Gibco) and 20 mM HEPES  
(Sigma). Cells were grown at 37ºC in a humidified atmosphere of 5% CO2. In the experiments 
described here frozen cells were used. For this purpose, cells were gown and maintained under 
confluency during 2-3 weeks and then frozen down at different cell densities using Recovery™ 
Cell Culture Freezing Medium (Gibco).   
[00189] 18 hours prior to the experiment, cells were quickly thawed at 37ºC and seeded on 
Poly-D-Lys 384 plates (Corning 356663) at a density of 25,000 cells/well and in 25 µL of 
complete cell medium as described above. 
[00190] Membrane potential changes induced by the flux of ions through the receptor were 
measured as relative fluorescence units (RFU) using the Fluorometric Imaging Plate Reader 
(FLIPR Tetra®, Molecular Devices) and the FLIPR Membrane Potential Blue Assay kit 
(Molecular Devices). Prior to the addition of the compounds the medium was removed and cells 
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were loaded with 20 µL of dye prepared in assay buffer composed of Hank’s Balanced  Salt 
Solution (HBSS with Ca+2 and Mg+2; Gibco 14025) with 20 mM Hepes. After 1 hour of 
incubation at room temperature (RT), the plate was placed into the FLIPR instrument and 
experiments were run adding first 10 µL from the 1st addition plate (compound plate) and after a 
3 minutes incubation adding 20 µL of the 2nd addition or agonist plate. The response to this last 
GABA addition was monitored for another 3 minutes. 
[00191] 1st addition plates or compound plates. First addition plates containing the 
compounds to be tested were prepared as follows: compounds in 10 mM dimethyl sulfoxide 
(DMSO) stock were serially diluted from column 3 to 12 and 13 to 22 in 100 % DMSO using 
Corning 3657 plates and a Tecan Freedom Evo ® platform. Then, compounds were further 
diluted 1:100 in assay buffer. A GABA EC0 (assay buffer alone) and EC100 (150 or 100 µM final 
GABA concentration after 1st addition for α1 or α3-containing receptor cell lines, respectively) 
were also included in these plates and used as minimum and maximum response controls, 
respectively, to analyse any possible compound agonist response.  
[00192] 2nd addition plate or agonist plate. Second addition plates were generated using a 
GABA EC20 to test potentiation profile of the compounds. EC20 and EC100 GABA (final assay 
concentrations) were used as minimum and maximum response controls, respectively. EC20 was 
2 or 1.2 µM final GABA concentration for α1 or α3-containing receptor cell lines, respectively. 
[00193] Data analysis. The difference between the maximum and the minimum (Max-Min) 
fluorescence reached during the first addition or read interval and the second read interval were 
used for data analysis (agonist and potentiation, respectively). Data was normalized according to 
the following formula: 
 
 
 
wherein “Test well” refers to those that contain test compounds. 
 
[00194] EC50 and maximum stimulation values were determined from concentration-response 
curves at 10 distinct concentrations. The four-parameter logistic model was used to fit each data 
set.   
[00195] All compounds (HZ-166, MP-III-085, MP-III-080, KRM-II-81, KRM-II-82, KRM-II-
18B, KRM-II-97, KRM-II-73, and SH-I-085) displayed a α1 EC50 above 20 µM (the highest 
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concentration tested) while also exhibiting α3 activity, with EC50 in, or near, the nanomolar 
range (TABLE 3). 
Liver Microsomal Stability Studies 
[00196] In vitro liver microsomal studies were completed to measure the stability of the 
compounds against degradation in various species’ liver microsomes.  
[00197] Compound was incubated in hepatic microsomes over a 30-minute incubation period 
at 37ºC. Incubations both with and without NADPH (2 mM) were performed in a 96-well plate 
format. The reaction was initiated with the addition of substrate and was terminated by protein 
precipitation. All incubations were performed using a final substrate concentration of 4 μM in 50 
mM sodium phosphate buffer, pH 7.4. The final organic solvent content was 0.5 % acetonitrile 
and 0.02% DMSO. The amount of enzyme present was fixed at 1.11 mg/mL protein irrespective 
of the species of microsomes used. Samples were analyzed by LC/MS-MS to determine the 
percent loss in the NAPDH incubations relative to the NADPH free incubations.   
[00198] Although HZ-166 and other BZDs had been shown to be stable against human liver 
microsomes, short half lives in in vivo studies indicated poor stability in rodents, which can be a 
hindrance in fully evaluating compounds in preclinical studies in rodents.  Results are shown in 
TABLE 3. 
 
TABLE 3. Compound binding affinities (α1 and α3) and liver microsomal stability. 
Compound 
α1 Binding α3 Binding Human Dog Mouse Rat 
EC50 (µM) 
Liver microsome stability (reported in % 
remaining) 
Conditions: 37oC, 4 µM compound, 30 minutes 
HZ-166 > 20 0.844 80 97 54 50 
MP-III-085 > 20 5.15 81 93 85 93 
MP-III-080 > 20 3.02 91 97 92 94 
KRM-II-81 > 20 0.937 91 94 90 90 
KRM-II-82 > 20 0.0321 74 86 73 72 
KRM-II-18B > 20 0.0112 78 87 79 68 
KRM-II-97 > 20 0.629 94 85 86 75 
KRM-II-73 > 20 0.115 78 89 70 77 
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SH-I-085 > 20 0.0249 62 77 67 61 
 
Example 8. Motor Impairment 
Inverted Screen 
[00199] The inverted screen test is used to measure whether or not a test compound induces 
muscle relaxation. When a test subject is placed on a wire screen which is then inverted, the 
reaction is to climb to the opposite side so they are no longer hanging upside down. If a 
compound promotes muscle relaxation, the test subjects will either fall off, or hang onto the 
screen without being able to climb to the opposite side.  
[00200] Male Sprague-Dawley rats (n = 5) were dosed i.p. (vehicle = 1% carboxymethyl 
cellulose) with diazepam (3, 10, or 30 mg/kg), KRM-II-81 (10, 30, or 60 mg/kg) or HZ-166 (30 
mg/kg) 30 minutes prior to testing. Rats were placed onto the top of a wire screen, which was 
then inverted so that the rats were hanging upside down. Rats were observed for 60 seconds, at 
which point they were score (0 = climbed over; 1 = hanging onto screen; 2 = fell off).  Results 
were analyzed using ANOVA (Dunnett’s test: * P < 0.05). 
[00201] Neither HZ-166 nor KRM-II-81 induced significant muscle relaxation (FIG. 4); 
however, signs of muscle relaxation began to appear at 30 mg/kg for HZ-166, while the same 
slight signs occurred at 60 mg/kg for KRM-II-81.  Non-dosed rats were able to climb to the top 
of the screen when inverted (score of 0.4 + 0.4).  Diazepam but not KRM-II-81 or HZ-166 
produced full motor impairment. 
Rotorod 
[00202] The rotorod assay (FIG. 5) is used to determine the ataxic effects, generally 
stemming from the α1 subtype, that compounds have in test subjects. Mice are trained to run on a 
slow, rotating cylinder for two minutes, and failure to stay on the rod may be due to ataxia. HZ-
166 has previously been shown to have no ataxic complications in doses over 100 mg/kg. Each 
set of compounds were tested against a vehicle.  
[00203] Male NIH Swiss mice (n = 10/group) were trained on a rotorod (Ugo Basile 7650) at 
4 r.p.m. for two minutes per training session prior to testing. On test day, mice were dosed i.p. 
with either vehicle (1% carboxymethyl cellulose) or one of the test compounds (10 or 30 mg/kg) 
30 minutes prior to testing. Once placed on the rotorod, mice were observed for falling. Mice 
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that did not fall off during testing were given a “success” designation, while mice that fell off 
once during the 2 minutes of testing were scored as “partial.”  Mice that fell twice failed the trial. 
[00204] The majority of compounds tested well at 10 mg/kg, while KRM-II-82, KRM-II-18B, 
and KRM-III-69 failed multiple times at 30 mg/kg.   
[00205] KRM-II-81 still appeared to be the best compound in rotarod assays as it exhibited no 
significant ataxic concerns (rotarod) without observed signs of sedation.   
 
Example 9. Anticonvulsant Activity 
Maximal Electroshock (MES)-induced convulsion protection 
[00206] The maximal electroshock (MES) assay is designed to determine how well a test 
compound can prevent seizures induced by applying a voltage stimuli to a mouse. HZ-166 has 
previously been shown to be effective in this assay, as well as giving protection against scMET-
induced seizures.  
[00207] Male CD (n = 10) were pretreated i.p. with vehicle (1% carboxymethyl cellulose), 
KRM-II-81 (3, 10, 30 mg/kg), or HZ-166 (3, 10, 30 mg/kg).  Mice were subjected to electrical 
induced tonic seizures and examined for anticonvulsant effects 30 minutes after treatment. Mice 
were then given a 7mA electroshock using a Wahlquist Model H for 0.2 seconds and observed 
for the presence or absence of seizure activity. Each mouse is tested only once and euthanized 
immediately following the test. 
[00208] KRM-II-81 is shown to display greater effectiveness than HZ-166 (FIG. 6).  Both 
diazepam and KRM-II-81 fully protected against seizure induction, whereas HZ-166 (up to 60 
mg/kg) did not. 
scMET-induced seizure protection 
[00209] A subcutaneous (sc) injection of pentylenetetrazol (PTZ), also known as metrazole 
(MET), is known to induce clonic and tonic seizures, demonstrated by loss of righting (inability 
to orient itself in an upright position). Test subjects were given a test compound, followed by a 
35 mg/kg dose of MET and observed for convulsions (FIG. 7). 
[00210] Male Sprague-Dawley rats (n = 5) were dosed i.p. (vehicle = 1% carboxymethyl 
cellulose) with either diazepam (3 or 10 mg/kg), KRM-II-81 (10, 30 or 60 mg/kg), or HZ-166 
(30 mg/kg) 30 minutes prior to testing. Pentylenetetrazole (in saline) was dosed at 35 mg/kg i.p., 
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and rats were observed for 30 minutes for signs of seizures. Results were analyzed using 
ANOVA (Dunnett’s test: * P < 0.05). 
[00211] Mice were then dosed i.p. with 5, 10, 25, or 50 mg/kg of KRM-II-81. 30 minutes later, 
a subcutaneous dose of pentylenetetrazole was administered, and the mice were observed for 
seizures. KRM-II-81 performed very well (TABLE 4), protecting most mice, with an ED50 of 
10.94 mg/kg at the half hour time point. 
[00212] Diazepam achieved significant protection at 10 mg/kg, KRM-II-81 at 30 mg/kg, 
while previously shown anticonvulsant HZ-166 had little effect at 30 mg/kg. This indicates that 
KRM-II-81 has greater therapeutic potential against convulsions than HZ-166. 
 
TABLE 4. Assessment of KRM-II-81 in the scMET test for anticonvulsant activity.* 
Dose (mg/kg) 5 10 25 50 
Protected 0/8 5/8 7/8 8/8 
* ED50 = 10.94 mg/kg 
 
PTZ-induced seizure threshold 
[00213] Following the evaluation of protection against scMET (35 mg/kg), KRM-II-81, HZ-
166, and diazepam were tested to determine at what threshold of scMET each compound can 
protect against seizures at various concentrations. After a pretreatment of test compound, MET 
was intravenously administered to a test subject until a convulsions were observed. 
[00214] Male Sprague-Dawley rats (n = 8; from Harlan Sprague Dawley, Indianapolis, IN) 
were dosed i.p. (vehicle = 1% carboxymethyl cellulose) with diazepam (0.1, 0.3, or 1 mg/kg) or 
a test compound (3, 10, 30, or 60 mg/kg) 30 minutes prior to testing. Pentylenetetrazole was 
administered i.v. to each group (10 mg/mL at 0.5 mL/minute) until each animal exhibited a 
clonic convulsion, or for four minutes. Each animal was used only once and was euthanized post 
testing. Results were analyzed using ANOVA (Dunnett’s test: * P < 0.05). 
[00215] HZ-166 displayed little protection against MET (35 mg/kg) at concentrations varying 
from 3 mg/kg to 60 mg/kg, while KRM-II-81 began to exhibit a significant protection against 
seizures, requiring a 71 mg/kg dose of MET when pretreated with 10 mg/kg of KRM-II-81 (FIG. 
8).  Both diazepam and KRM-II-81 significantly increased the seizure threshold to PTZ with 
KRM-II-81 producing larger maximal effect. 
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Example 10. Anxiolytic Activity 
Anxiolytic Marble Burying Assay 
[00216] The marble burying assay is used to determine the anxiolytic activity of a given 
compound. Mice are placed in a tub containing 20 marbles placed over a bed of sawdust. 
Defensive burying (Broekkamp 1986) is the natural reaction for the mice. When given an 
anxiolytic, such as diazepam, the mice are less likely to defensively bury the marbles.  
[00217] Experiments were carried out by the methods described in Li et al. (Life Sciences 
2006, 78, 1933-1939).  Separate groups of mice were used in these experiments and were 
conducted in a dimly lit testing room.  After 60 min acclimation to the experimental room, mice 
were placed in a 17 x 28 x 12 cm high plastic tub with 5 mm sawdust shavings (Harlan Sani-
Chips, Harlan-Teklad, Indianapolis, IN, USA) on the floor, which was covered with 20 blue 
marbles (1.5 cm diameter) placed in the center.  Mice were left in the tub for 30 min.  The 
number of marbles buried (2/3 covered with sawdust) was counted and submitted to inter-
observer reliability assessment. 
[00218] All compounds are shown to display a significant reduction in marbles buried at 30 
mg/kg (FIG. 9), while MP-III-080 and KRM-III-69 show a reduction at 10 mg/kg.  However, 
sedation was also observed in these three compounds, which likely led to the reduction in marble 
burying (both at 10 and 30 mg/kg) for MP-III-080, and KRM-III-69. 
[00219] KRM-II-81 still appeared to be the best compound in the marble burying assay as it 
had good activity in the marble burying without observed signs of sedation.   
Vogel conflict model for anxiety 
[00220] The Vogel conflict procedure is used to determine the anxiolytic effects a compound 
exerts on a test subject, and HZ-166 has previously been shown to be effective in rhesus 
monkeys. Subjects are withheld from water prior to testing. Once given water during testing, 
they will either be unpunished, where they are free to drink without consequence, or punished, 
where a small electrical shock is applied after every 20th lick. In vehicle punished, is it is 
expected that the rats hesitate from drinking due to the anxiousness of being shocked. When 
given an anxiolytic, the mice will continue to drink water despite the electrical shock.  
[00221] Experiments were conducted as described in the protocol of Alt et al. 
(Neuropharmacology 2007, 52, 1482-1487).  Experimentally-naive adult male Sprague-Dawley 
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rats (Harlan Industries, Indianapolis, IN), weighing between 200 and 300 g, were used as 
subjects. The rats were housed in Plexiglas cages (4 per cage) and given free access to Lab Diet 
#5001 for rodents (PMI Nutrition International Inc., St. Louis, MO). Water was withheld for 20-
24 hours prior to the first training session. A 12-hr light/dark cycle was maintained, and all 
experimental sessions were conducted during the light phase of the cycle at about the same time 
each day.  All experiments were conducted in accordance with the NIH regulations of animal 
care covered in “Principles of Laboratory Animal Care”, NIH publication 85-23, and were 
approved by the Institutional Animal Care and Use Committee. 
[00222] Apparatus. The experiments were conducted using operant behavior test chambers 
ENV-007 (Med Associates Inc., Georgia, Vermont, USA), 30.5 x 24.1 x 29.2 cm.  The test 
chambers were contained within light and sound attenuating shells. On the front wall of the 
chamber, a food trough was mounted 2 cm off the grid floor on the centerline.  Two response 
levers were centered 8 cm off the centerline and 7 cm off the grid floor.  Three lights were 
located above each response lever at 15 cm off the grid floor.  Responding on the levers was 
without consequences for all sessions. On the rear of the chamber, a sipping tube was mounted 3 
cm off the grid floor and 3 cm from the door.  The sipping tube was wrapped with electrical tape 
to prevent the circuit from being completed if the animals were holding/touching the tube. All 
events were controlled and licking data was recorded by a Compaq computer running MED-PC 
Version IV (Med Associates Inc., Georgia, Vermont, USA). 
[00223] Sipper tube training.  Rats were put into the chamber on day 1 and 2 with white noise 
and the houselight illuminated, and allowed to drink for a total of six minutes after the first lick 
was made.  The six minutes was broken into two components, the first three minutes was 
recorded as the unpunished component and the second three minutes were recorded as the 
punished component.  During the two training days no shock was delivered in the punished 
component.  After training, animals were returned to the home cage and given access to water for 
30 minutes.  For the second and third tests for each group, water was withheld for 24 hours 
before the training session.  Animals were re-trained for one day.  After training, animals were 
returned to the home cage and given access to water for 30 minutes. 
[00224] Sipper tube testing. On day 3, animals were weighed and injected with either vehicle 
or compound and returned to the home cage.  Thirty minutes after injection, animals were placed 
into the test chamber.  The session was identical to the training session except that during the 
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punishment  component the sipper tube delivered a brief electrical shock (100 milliseconds, 0.5 
mA) after every 20th lick (FR20). 
[00225] Data Analysis.  The mean number of licks for both the unpunished and punished 
components were analyzed.  In addition, data were also expressed as a percent of control values.  
The calculation was done using the mean number of licks for the control group in both 
components. Individual animal means (percent control) were calculated for animals receiving 
drug utilizing the formula: number of licks divided by mean number of licks by control group 
times 100 for each respective component.  Dose-effect functions were analyzed by ANOVA 
followed by post-hoc Dunnett’s test with vehicle treatment as the control standard.  The 
proportion of animals exhibiting specified numbers of responses was analyzed by Fisher’s exact 
probability test comparing vehicle control to drug values.  Statistical probabilities < 0.05 were 
considered significant. 
[00226] As shown in FIG. 10, KRM-II-81 exhibited a significant increase in punished licking 
as compared to control at 10 mg/kg, indicating a powerful anxiolytic effect. Chordiazepoxide 
was run as a positive control.  Both the anxioltyic, chlordiazepoxide, and KRM-II-81 increased 
punished licking. 
 
Example 11. Antihyperalgesic Activity 
Tactile hypersensitivity in spinal nerve ligated (SNL) rats 
[00227] The von Frey filament test is used to test for antihyperalgesia, or an increased 
sensitivity to pain. HZ-166 has been shown to perform well in this assay. The von Frey filaments 
are used to apply pressure to the forelimbs of test subjects at set amounts. When pressure 
becomes too great, the forelimb is withdrawn and the amount of force applied recorded. The 
spinal nerve ligation induced hyperalgesia, reducing the amount of force a limb can take before 
being withdrawn.  
[00228] Test compounds were given to test the effectiveness of combating the hyperalgesic 
effect of SNL. Male Sprague-Dawley rats went through SNL at least 90 days prior to the von 
Frey testing. Rats were first tested without given an injection to determine a baseline. Following 
baseline establishment, rats (n = 5 for all groups) were dosed i.p. with vehicle (1% 
carboxymethyl cellulose), KRM-II-81 (30 mg/kg), or gabapentin (50 mg/kg). Subjects were then 
tested every hour for four hours to determine the antihyperalgesic effect of the test compounds.  
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For testing, pressure using von Frey filaments was applied to the forelimb of the rat.  Pressure 
was increased until the limb was withdrawn, and the amount of pressure was recorded. 
[00229] In FIG. 11, rats given vehicle were only able to withstand an average of 5-6 grams of 
force before the forelimb is withdrawn. Both gabapentin (50 mg/kg) and KRM-II-81 (30 mg/kg) 
were active as antihyperalgesics, increasing the amount of force that can be handled before 
forelimb withdrawal.  However, KRM-II-81 (at one hour) was able to reach significance, while 
gabapentin was not. This indicates that KRM-II-81 is a potential therapeutic for the treatment for 
neuropathic pain.  With vehicle, rats were able to withstand ~5 g. of force before removing paw. 
KRM and gabapentin increase this pain threshold to ~12 g. of force from 1-2 hours, with KRM 
slightly more effective (doses unknown).  The results indicate that KRM-II-81 was able to 
reverse the effects of hyperalgesia, allowing rats to withstand more force in the von Frey 
filament test after SNL surgery. 
 
Example 12. GABA-A Receptor PAM 
Model of Pain 
[00230] Complete Freund’s adjuvant (CFA) contains Mycobacterium butyricum, inducing 
inflammation and an increase in paw thickness. 0.1 mL of CFA was injected in the right hind 
paw of Sprague Dawley male rats under isoflurane anaesthesia. 
[00231] Food-maintained operant responding (rate response).  Rats (n=7) were placed in a 
chamber consisting of two (one active) levers. Rats were trained to press a lever (left) for a food 
pellet under a multiple-cycle procedure. Each cycle started with a 15 min inactive period (dark 
chamber and no programmed consequence), followed by a 5 min active period (cue light above 
the active lever lit up). The active period was set on a FR10 schedule and rats could receive a 
maximum of 5 food pellets. The cue light was terminated either after 5 minutes or once 5 food 
pellets were delivered. After each active period (every 20 minutes), rats received the next dose of 
drug for a duration of 2 hours.  Data (rate per minute) was collected using Graphic State 3.03 
software and interface (Coulbourn Instruments Inc.) 
[00232] Mechanical hyperalgesia.  Mechanical hyperalgesia was measured 3 days after CFA 
treatment.  Rats (n=6) were placed in elevated boxes with a mesh floor. Von Frey filaments 
(expressed in g) were applied perpendicularly to the hindpaws, starting with the lowest filament 
(1.4 g) then increased until hindpaw withdrawal was observed. After each measurement, rats 
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received the next dose of drug (every 20 min) until the maximum threshold (26 g) was observed. 
For the antagonist study, rats were pretreated with the benzodiazepine site antagonist flumazenil 
(10 min) and then received the next dose of drug (every 20 min) until the pre-CFA threshold was 
observed. 
[00233] Horizontal wire test.  Rats (n=10) were lifted by the tail and allowed to grasp a 
horizontally strung wire with their forepaws and released. The inability to complete this task 
(within 3 seconds) was recorded 20 minutes after each injection of drug. 
[00234] Drugs.  The following drugs were used: HZ166, KRM-II-18B, and KRM-II-81, and 
were dissolved in a mixture containing 20% Dimethyl sulfoxide (DMSO), 10% Emulphor-620 
(Rhodia Inc.), and 70% of 0.9% saline. Flumazenil (purchased from Cayman Chemical Company, 
MI) was dissolved in a mixture containing 10% ethanol, 40% propylene glycol, and 50% sterile 
water. Midazolam (Akorn, Inc.) was dissolved in 0.9% saline. Doses were expressed as the 
weight of the drug in milligrams per kilogram of body weight and drugs were administered 
intraperitoneally. 
[00235] Results.  Results are shown in FIG. 12, FIG. 13, and FIG. 14.  This data 
demonstrated that KRM-II-81 and KRM-II-18B are much more active against hyperalgesia in the 
von Frey filament assay and on par with the performance of midazolam. 
 
Example 13. Pharmacokinetics and concentrations in brain of KRM-II-81 
administered to rats by IV and IP 
[00236] The single-dose pharmacokinetics were determined in femoral artery/vein cannulated 
Sprague-Dawley rats. The rats received a 1 mg/kg intravenous and 10 mg/kg oral gavage dose of 
compound. Blood samples were collected at 0.08 (IV only), 0.25, 0.5, 1, 2, 4, 8, 12, and 24 hours 
after initiation of compound administration.  Plasma was obtained via centrifugation. Plasma 
samples were then analyzed by LC-MS, and pharmacokinetic parameters calculated using 
Watson (version 7.4; Thermo Fisher Scientific). Calculated parameters include clearance (Cl), 
volume of distribution (Vdss), area-under-the-curve (AUC), half-life (T1/2), maximum plasma 
concentration (Cmax), time of maximum concentration (Tmax), and bioavailability (%F).   
[00237] Male Sprague-Dawley rats were given either a 1 mg/kg oral dose or 10 mg/kg i.p. 
dose. Plasma concentrations were taken at 0.08, 0.25, 0.5, 1.0, 2, 4, 8, 12, and 24 hours (three 
rats per time point for each dose). The time-plasma concentration profiles are shown in FIG. 15.   
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[00238] Following a 1 mg/kg IV dose in rat, KRM-II-81 had a mean clearance of 21.7 
mL/min/kg with a mean Vdss of 1.4 L/kg and a mean T ½ of 1.4 hours.  Following a 10 mg/kg 
IP dose in rat, the mean AUC was 16500 nM*hrs with a Cmax of 3090 nM occurring at 2.0 
hours.  The mean IP T ½ was 3.1 hours and the mean bioavailability was 69%.  The 1 hour brain 
concentration following a 10 mg/kg IP dose was 6630 nM with a Kp,uu of 0.53.  The 4 hour 
brain concentration was 2050 nM with a Kp,uu of 0.67.  
 
Example 14.  Forced Swim Test 
[00239] The forced swim test is used as a primary screen for the antidepressant nature of a test 
compound. Mice are placed in a cylinder filled with a small amount of water. Mice that are more 
mobile after a dosing of a compound are determined to be less depressed.  
[00240] The experiment was carried out as described by Porsolt et al. (Arch. Int. 
Pharmacodyn. Ther. 1977, 229, 327-366). Male NIH Swiss mice (n = 7 – 8) were dosed i.p. with 
vehicle (1% HEC, 0.25% Tween 80, 0.05% antifoam), KRM-II-81 (3, 10, or 30 mg/kg), or 
imipramine (15 mg/kg) and assessed in the forced swim test.  Mice were placed individually in 
clear plastic cylinders (10 cm in diameter x 25 cm in height) filled to 6 cm with 22 – 25oC water 
for 6 minutes. The duration of immobility was recorded during the last 4 minutes of a 6-minute 
trial. A mouse was regarded as immobile when floating motionless or making only those 
movements necessary to keep its head above the water. 
[00241] Results are shown in FIG. 16.  Results were analyzed using ANOVA (Dunnett’s test 
* P < 0.05).  KRM-II-81 demonstrated antidepressant effects at 10 and 30 mg/kg.  Imipramine 
was used as a positive control. 
 
[00242] All patents, publications and references cited herein are hereby fully incorporated by 
reference.  In case of conflict between the present disclosure and incorporated patents, 
publications, and references, the present disclosure should control. 
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CLAIMS 
 
1. A compound of formula (I):  
 (I) 
or a salt thereof, wherein: 
X is selected from the group consisting of N, C-H, C-F, C-Cl, C-Br, C-I, and C-NO2; 
R1 is selected from the group consisting of -C≡CH, -C≡C-Si(CH3)3, -cyclopropyl, and 
bicycle[1.1.1]pentane ( ); and 
R2 is selected from the group consisting of -H, -CH3, -CH2CH3 and -CH(CH3)2. 
 
2. A compound of formula (II):  
 (II) 
or a salt thereof, wherein: 
X is selected from the group consisting of N, C-H, C-F, C-Cl, C-Br, C-I, and C-NO2; 
R1 is selected from the group consisting of  -C≡CH, -C≡C-Si(CH3)3, -cyclopropyl, and 
bicycle[1.1.1]pentane ( ); 
R2 is selected from the group consisting of -H, -CH3, -CH2CH3, and -CH(CH3)2; and 
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R3 is selected from the group consisting of -H, -CH3, -CH2CH3, -CH(CH3)2, -F, -Cl, -CF3, 
and -CCl3. 
 
3. A compound of formula (III):  
 (III) 
or a salt thereof, wherein: 
X is selected from the group consisting of N, C-H, C-F, C-Cl, C-Br, C-I, and C-NO2; 
R1 is selected from the group consisting of -C≡CH, -C≡C-Si(CH3)3, -cyclopropyl, and 
bicycle[1.1.1]pentane ( ); 
R2 is selected from the group consisting of -H, -CH3, -CH2CH3, and  -CH(CH3)2; and 
R3 is selected from the group consisting of -H, -CH3, -CH2CH3, -CH(CH3)2, -F, -Cl, -CF3, 
and -CCl3. 
 
4. The compound of any of claims 1-3, wherein R1 is -C≡CH. 
 
5. The compound of any of claims 1-4, wherein the compound has the following formula: 
. 
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6. A compound of formula (IV): 
 (IV) 
or a salt thereof, wherein: 
X is selected from the group consisting of N, C-H, C-F, C-Cl, C-Br, C-I, and C-NO2; 
R11 is Br; and 
R12 is selected from the group consisting of -H, -CH3, -CH2CH3 and -CH(CH3)2,  
with the proviso that the compound is not . 
 
7. A compound of formula (V): 
 (V) 
or a salt thereof, wherein: 
X is selected from the group consisting of N, C-H, C-F, C-Cl, C-Br, C-I, and C-NO2; 
R11 is Br; 
R12 is selected from the group consisting of -H, -CH3, -CH2CH3, and -CH(CH3)2; and 
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R13 is selected from the group consisting of -H, -CH3, -CH2CH3, -CH(CH3)2, -F, -Cl, -CF3, 
and -CCl3. 
 
8. A compound of formula (VI): 
 (VI) 
or a salt thereof, wherein: 
X is selected from the group consisting of N, C-H, C-F, C-Cl, C-Br, C-I, and C-NO2; 
R11 is Br; 
R12 is selected from the group consisting of -H, -CH3, -CH2CH3, and  -CH(CH3)2; and 
R13 is selected from the group consisting of -H, -CH3, -CH2CH3, -CH(CH3)2, -F, -Cl, -CF3, 
and -CCl3. 
 
9. The compound of any of claims 1-8, wherein R2 is -H. 
 
10. The compound of any of claims 1-9, wherein X is N. 
 
OTT1436    020871-9108-US00 
 640 
11. A compound selected from the group consisting of: 
, ,
, ,
, ,
, ,
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, ,
, and . 
 
12. A compound selected from the group consisting of: 
,        
 
,        , 
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. 
 
13. A pharmaceutical composition comprising a compound according to any of claims 1-12; 
and a carrier. 
 
14. A pharmaceutical composition comprising a compound according to Formula IV and a 
carrier, wherein the compound of Formula IV is 
 (IV) 
or a salt thereof, wherein: 
X is selected from the group consisting of N, C-H, C-F, C-Cl, C-Br, C-I, and C-NO2; 
R11 is Br; and 
R12 is selected from the group consisting of -H, -CH3, -CH2CH3 and -CH(CH3)2.. 
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15. The pharmaceutical composition of claim 14, wherein the compound is selected from the 
group consisting of: 
       , , 
 
,        , 
 
,       , 
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16. A method of treating a disorder selected from an anxiety disorder, depression, epilepsy, 
schizophrenia and neuropathic pain in a subject in need of treatment, comprising administering 
to the subject an effective amount of a compound of any of claims 1-12 or a composition of 
claims 13-15. 
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17. A method of treating a disorder selected from an anxiety disorder, depression, epilepsy, 
schizophrenia and neuropathic pain in a subject in need of treatment, comprising administering 
to the subject an effective amount of a compound according to Formula IV: 
  (IV) 
or a salt thereof, wherein: 
X is selected from the group consisting of N, C-H, C-F, C-Cl, C-Br, C-I, and C-NO2; 
R11 is Br; and 
R12 is selected from the group consisting of -H, -CH3, -CH2CH3 and -CH(CH3)2.. 
 
18. The method according to claim 17, wherein the compound is selected from the group 
consisting of: 
       , , 
 
,        , 
 
OTT1436    020871-9108-US00 
 666 
,       , 
 
 
, 
 
      , , 
 
OTT1436    020871-9108-US00 
 667 
,      , 
 
  ,    , 
 
, 
 
    ,   , 
OTT1436    020871-9108-US00 
 668 
 
      , , 
 
   ,  , 
 
, 
 
 
 
OTT1436    020871-9108-US00 
 669 
 ,      , 
 
   ,    , 
 
       , , 
 
, 
OTT1436    020871-9108-US00 
 670 
 
       
 
 ,      , 
 
    ,    , 
 
OTT1436    020871-9108-US00 
 671 
, 
 
 ,     , 
 
 ,       , 
 
,          , and 
OTT1436    020871-9108-US00 
 672 
 
. 
 
 
 
 
OTT1436    020871-9108-US00 
 673 
ABSTRACT 
 
Described herein are α3 or α2 or α2/α3 GABAergic receptor subtype selective ligands, 
pharmaceutical compositions, and methods of use of such ligands and compositions in treatment 
of anxiety disorders, epilepsy and schizophrenia with reduced sedative and ataxic side effects.  In 
embodiments, such as α3 or α2 or α2/α3 GABAergic receptor subtype selective ligands lack 
ester linkages and may be thus relatively insensitive to hydrolysis by esterases. 
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APPENDIX K. Crystal Structures (from Jeff Deschampes) 
List of Figures: 
1. HZ-166 (cook152) 
2. MP-II-050 (cook153) 
3. KRM-II-81 (1)* 
4. KRM-II-81 (2) 
5. KRM-II-81 (3) 
6. KRM-II-81 (4) 
7. KRM-II-81 (5) 
8. SH-I-085 (KRM-I-100; cook128) 
9. KRM-II-18B 
* The code number for KRM-II-81 is cook149 
List of Tables (data for KRM-II-81): 
1. Crystal data and structure refinement for KRM-II-81 (cook149). 
2. Atomic coordinates (x 104) and equivalent isotropic displacement parameters (Å2x 103) for 
KRM-II-81 (cook149). U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
3. Bond lengths [Å] and angles [°] for KRM-II-81 (cook149). 
4. Anisotropic displacement parameters (Å2x 103) for KRM-II-81 (cook149). The anisotropic 
displacement factor exponent takes the form: -2π2[ h2a*2U11 + ... + 2 h k a* b* U12] 
5. Hydrogen coordinates (x 104) and isotropic displacement parameters (Å2x 103) for KRM-II-81 
(cook149). 
6. Torsion angles [°] for KRM-II-81 (cook149). 
7. Hydrogen bonds for KRM-II-81 (cook149) [Å and °].
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Table 1. Crystal data and structure refinement for KRM-II-81 (cook149). 
 
Empirical formula  C21H13N5O 
Formula weight  351.36 
Temperature  150(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P21/n 
Unit cell dimensions a = 17.6247(13) Å = 90°. 
 b = 8.2158(7) Å = 102.499(5)°. 
 c = 23.1472(17) Å  = 90°. 
Volume 3272.3(4) Å3 
Z 8 
Density (calculated) 1.426 Mg/m3 
Absorption coefficient 0.749 mm-1 
F(000) 1456 
Crystal size 0.115 x 0.100 x 0.010 mm3 
θ range for data collection 2.871 to 68.957°. 
Index ranges -21<=h<=20, -9<=k<=6, -27<=l<=27 
Reflections collected 17063 
Independent reflections 5806 [R(int) = 0.0579] 
Completeness to θ = 67.679° 96.8 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7456 and 0.5364 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5806 / 0 / 495 
Goodness-of-fit on F2 1.023 
Final R indices [I>2σ(I)] R1 = 0.0628, wR2 = 0.1596 
R indices (all data) R1 = 0.1158, wR2 = 0.1894 
Largest diff. peak and hole 0.302 and -0.275 e.Å-3 
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Table 2. Atomic coordinates (x 104) and equivalent isotropic displacement parameters (Å2x 103) for 
KRM-II-81 (cook149). U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
O(1A) 8188(1) 6079(4) 4697(1) 55(1) 
C(2A) 8979(2) 6002(6) 4859(2) 57(1) 
N(3A) 9337(2) 6371(4) 4461(2) 56(1) 
C(4A) 8737(2) 6737(5) 3969(2) 44(1) 
C(5A) 8049(2) 6547(4) 4113(2) 39(1) 
C(6A) 7246(2) 6713(4) 3803(2) 35(1) 
N(7A) 6651(2) 5935(3) 4000(1) 38(1) 
C(8A) 6016(2) 6323(4) 3616(1) 35(1) 
N(9A) 6161(1) 7288(3) 3172(1) 34(1) 
C(10A) 6957(2) 7575(4) 3294(2) 34(1) 
C(11A) 7298(2) 8680(4) 2913(2) 37(1) 
N(12A) 7233(2) 7964(3) 2322(1) 36(1) 
C(13A) 6548(2) 7842(4) 2002(2) 34(1) 
C(14A) 5812(2) 8368(4) 2165(2) 34(1) 
C(15A) 5616(2) 8035(4) 2705(1) 32(1) 
C(16A) 4886(2) 8448(4) 2802(2) 37(1) 
C(17A) 4366(2) 9294(4) 2373(2) 38(1) 
C(18A) 4571(2) 9755(4) 1848(2) 36(1) 
C(19A) 4084(2) 10791(5) 1420(2) 41(1) 
C(20A) 3750(2) 11719(5) 1069(2) 47(1) 
C(21A) 5275(2) 9212(4) 1742(2) 35(1) 
C(22A) 6474(2) 7118(4) 1395(2) 35(1) 
C(23A) 7042(2) 7366(4) 1073(2) 41(1) 
C(24A) 6949(2) 6617(5) 526(2) 49(1) 
C(25A) 6311(2) 5666(5) 324(2) 50(1) 
C(26A) 5772(2) 5512(5) 671(2) 48(1) 
N(27A) 5835(2) 6217(4) 1195(1) 39(1) 
C(1B) 1719(2) 6428(5) 352(2) 45(1) 
N(2B) 920(2) 6201(4) 202(1) 50(1) 
C(3B) 772(2) 5342(5) 622(2) 48(1) 
O(4B) 1402(1) 4961(3) 1054(1) 45(1) 
C(5B) 2011(2) 5689(4) 867(2) 36(1) 
C(6B) 2787(2) 5522(4) 1222(1) 34(1) 
N(7B) 3399(2) 6258(3) 1024(1) 36(1) 
C(8B) 4021(2) 5888(4) 1422(1) 34(1) 
N(9B) 3850(1) 4974(3) 1874(1) 30(1) 
C(10B) 3052(2) 4722(4) 1744(1) 32(1) 
C(11B) 2692(2) 3691(4) 2136(1) 35(1) 
N(12B) 2774(1) 4440(3) 2724(1) 35(1) 
C(13B) 3458(2) 4484(4) 3044(1) 31(1) 
________________________________________________________________________________ 
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Table 2. (continued) 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
 
C(14B) 4183(2) 3862(4) 2879(1) 32(1) 
C(15B) 4383(2) 4209(4) 2337(1) 30(1) 
C(16B) 5115(2) 3768(4) 2247(2) 35(1) 
C(17B) 5630(2) 2915(4) 2676(2) 35(1) 
C(18B) 5409(2) 2431(4) 3194(2) 34(1) 
C(19B) 5887(2) 1406(4) 3621(2) 37(1) 
C(20B) 6230(2) 473(5) 3971(2) 46(1) 
C(21B) 4701(2) 2964(4) 3295(2) 33(1) 
C(22B) 3565(2) 5164(4) 3657(1) 32(1) 
C(23B) 2986(2) 5037(4) 3974(2) 39(1) 
C(24B) 3128(2) 5581(5) 4550(2) 46(1) 
C(25B) 3833(2) 6261(5) 4793(2) 46(1) 
C(26B) 4381(2) 6361(4) 4446(2) 43(1) 
N(27B) 4259(1) 5836(3) 3887(1) 37(1) 
________________________________________________________________________________
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Table 3. Bond lengths [Å] and angles [°] for KRM-II-81 (cook149). 
____________________________________________________________________ 
O(1A)-C(2A)  1.364(4) O(1A)-C(5A)  1.374(4) 
C(2A)-N(3A)  1.261(5) C(2A)-H(2A)  0.9500 
N(3A)-C(4A)  1.408(5) C(4A)-C(5A)  1.336(4) 
C(4A)-H(4A)  0.9500 C(5A)-C(6A)  1.447(4) 
C(6A)-C(10A)  1.373(5) C(6A)-N(7A)  1.389(4) 
N(7A)-C(8A)  1.310(4) C(8A)-N(9A)  1.366(4) 
C(8A)-H(8A)  0.9500 N(9A)-C(10A)  1.390(4) 
N(9A)-C(15A)  1.420(4) C(10A)-C(11A)  1.481(4) 
C(11A)-N(12A)  1.471(4) C(11A)-H(11C)  0.9900 
C(11A)-H(11D)  0.9900 N(12A)-C(13A)  1.277(4) 
C(13A)-C(14A)  1.490(4) C(13A)-C(22A)  1.505(5) 
C(14A)-C(21A)  1.391(5) C(14A)-C(15A)  1.395(4) 
C(15A)-C(16A)  1.394(4) C(16A)-C(17A)  1.384(5) 
C(16A)-H(16A)  0.9500 C(17A)-C(18A)  1.392(5) 
C(17A)-H(17A)  0.9500 C(18A)-C(21A)  1.390(4) 
C(18A)-C(19A)  1.441(5) C(19A)-C(20A)  1.175(5) 
C(20A)-H(20A)  0.88(5) C(21A)-H(21A)  0.9500 
C(22A)-N(27A)  1.344(4) C(22A)-C(23A)  1.386(4) 
C(23A)-C(24A)  1.387(5) C(23A)-H(23A)  0.9500 
C(24A)-C(25A)  1.366(5) C(24A)-H(24A)  0.9500 
C(25A)-C(26A)  1.375(5) C(25A)-H(25A)  0.9500 
C(26A)-N(27A)  1.326(4) C(26A)-H(26A)  0.9500 
C(1B)-C(5B)  1.337(5) C(1B)-N(2B)  1.387(4) 
C(1B)-H(1B)  0.9500 N(2B)-C(3B)  1.274(5) 
C(3B)-O(4B)  1.360(4) C(3B)-H(3B)  0.9500 
O(4B)-C(5B)  1.378(4) C(5B)-C(6B)  1.441(4) 
C(6B)-C(10B)  1.366(5) C(6B)-N(7B)  1.397(4) 
N(7B)-C(8B)  1.307(4) C(8B)-N(9B)  1.373(4) 
C(8B)-H(8B)  0.9500 N(9B)-C(10B)  1.388(4) 
N(9B)-C(15B)  1.411(4) C(10B)-C(11B)  1.482(4) 
C(11B)-N(12B)  1.471(4) C(11B)-H(11A)  0.9900 
C(11B)-H(11B)  0.9900 N(12B)-C(13B)  1.271(4) 
C(13B)-C(22B)  1.498(4) C(13B)-C(14B)  1.500(4) 
C(14B)-C(21B)  1.387(4) C(14B)-C(15B)  1.404(4) 
C(15B)-C(16B)  1.399(4) C(16B)-C(17B)  1.382(5) 
C(16B)-H(16B)  0.9500 C(17B)-C(18B)  1.397(4) 
C(17B)-H(17B)  0.9500 C(18B)-C(21B)  1.388(4) 
C(18B)-C(19B)  1.427(5) C(19B)-C(20B)  1.183(5) 
C(20B)-H(20B)  0.93(4) C(21B)-H(21B)  0.9500 
C(22B)-N(27B)  1.342(4) C(22B)-C(23B)  1.385(4) 
C(23B)-C(24B)  1.378(5) C(23B)-H(23B)  0.9500 
C(24B)-C(25B)  1.368(5) C(24B)-H(24B)  0.9500 
C(25B)-C(26B)  1.385(5) C(25B)-H(25B)  0.9500 
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Table 3. (continued) 
____________________________________________________________________ 
 
C(26B)-N(27B)  1.337(4) C(26B)-H(26B)  0.9500 
C(2A)-O(1A)-C(5A) 103.8(3) N(3A)-C(2A)-O(1A) 115.5(3) 
N(3A)-C(2A)-H(2A) 122.3 O(1A)-C(2A)-H(2A) 122.3 
C(2A)-N(3A)-C(4A) 103.6(3) C(5A)-C(4A)-N(3A) 109.6(3) 
C(5A)-C(4A)-H(4A) 125.2 N(3A)-C(4A)-H(4A) 125.2 
C(4A)-C(5A)-O(1A) 107.4(3) C(4A)-C(5A)-C(6A) 135.0(3) 
O(1A)-C(5A)-C(6A) 117.6(3) C(10A)-C(6A)-N(7A) 110.6(3) 
C(10A)-C(6A)-C(5A) 128.1(3) N(7A)-C(6A)-C(5A) 121.3(3) 
C(8A)-N(7A)-C(6A) 105.1(3) N(7A)-C(8A)-N(9A) 112.4(3) 
N(7A)-C(8A)-H(8A) 123.8 N(9A)-C(8A)-H(8A) 123.8 
C(8A)-N(9A)-C(10A) 106.9(3) C(8A)-N(9A)-C(15A) 128.1(3) 
C(10A)-N(9A)-C(15A) 124.7(3) C(6A)-C(10A)-N(9A) 105.0(3) 
C(6A)-C(10A)-C(11A) 134.7(3) N(9A)-C(10A)-C(11A) 120.3(3) 
N(12A)-C(11A)-C(10A) 110.4(3) N(12A)-C(11A)-H(11C) 109.6 
C(10A)-C(11A)-H(11C) 109.6 N(12A)-C(11A)-H(11D) 109.6 
C(10A)-C(11A)-H(11D) 109.6 H(11C)-C(11A)-H(11D) 108.1 
C(13A)-N(12A)-C(11A) 116.4(3) N(12A)-C(13A)-C(14A) 126.5(3) 
N(12A)-C(13A)-C(22A) 116.9(3) C(14A)-C(13A)-C(22A) 116.6(3) 
C(21A)-C(14A)-C(15A) 117.7(3) C(21A)-C(14A)-C(13A) 117.6(3) 
C(15A)-C(14A)-C(13A) 124.6(3) C(16A)-C(15A)-C(14A) 120.8(3) 
C(16A)-C(15A)-N(9A) 118.6(3) C(14A)-C(15A)-N(9A) 120.6(3) 
C(17A)-C(16A)-C(15A) 119.9(3) C(17A)-C(16A)-H(16A) 120.0 
C(15A)-C(16A)-H(16A) 120.0 C(16A)-C(17A)-C(18A) 120.4(3) 
C(16A)-C(17A)-H(17A) 119.8 C(18A)-C(17A)-H(17A) 119.8 
C(21A)-C(18A)-C(17A) 118.5(3) C(21A)-C(18A)-C(19A) 119.3(3) 
C(17A)-C(18A)-C(19A) 122.3(3) C(20A)-C(19A)-C(18A) 173.7(4) 
C(19A)-C(20A)-H(20A) 179(4) C(18A)-C(21A)-C(14A) 122.3(3) 
C(18A)-C(21A)-H(21A) 118.9 C(14A)-C(21A)-H(21A) 118.9 
N(27A)-C(22A)-C(23A) 123.0(3) N(27A)-C(22A)-C(13A) 115.8(3) 
C(23A)-C(22A)-C(13A) 121.1(3) C(22A)-C(23A)-C(24A) 118.0(3) 
C(22A)-C(23A)-H(23A) 121.0 C(24A)-C(23A)-H(23A) 121.0 
C(25A)-C(24A)-C(23A) 119.5(3) C(25A)-C(24A)-H(24A) 120.3 
C(23A)-C(24A)-H(24A) 120.3 C(24A)-C(25A)-C(26A) 118.3(4) 
C(24A)-C(25A)-H(25A) 120.8 C(26A)-C(25A)-H(25A) 120.8 
N(27A)-C(26A)-C(25A) 124.2(4) N(27A)-C(26A)-H(26A) 117.9 
C(25A)-C(26A)-H(26A) 117.9 C(26A)-N(27A)-C(22A) 117.0(3) 
C(5B)-C(1B)-N(2B) 109.7(3) C(5B)-C(1B)-H(1B) 125.2 
N(2B)-C(1B)-H(1B) 125.2 C(3B)-N(2B)-C(1B) 104.3(3) 
N(2B)-C(3B)-O(4B) 114.7(3) N(2B)-C(3B)-H(3B) 122.6 
O(4B)-C(3B)-H(3B) 122.6 C(3B)-O(4B)-C(5B) 103.7(3) 
C(1B)-C(5B)-O(4B) 107.5(3) C(1B)-C(5B)-C(6B) 133.4(3) 
O(4B)-C(5B)-C(6B) 119.1(3) C(10B)-C(6B)-N(7B) 110.9(3) 
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Table 3. (continued) 
____________________________________________________________________ 
 
C(10B)-C(6B)-C(5B) 130.7(3) N(7B)-C(6B)-C(5B) 118.4(3) 
C(8B)-N(7B)-C(6B) 105.0(3) N(7B)-C(8B)-N(9B) 112.0(3) 
N(7B)-C(8B)-H(8B) 124.0 N(9B)-C(8B)-H(8B) 124.0 
C(8B)-N(9B)-C(10B) 107.2(3) C(8B)-N(9B)-C(15B) 127.1(2) 
C(10B)-N(9B)-C(15B) 125.1(3) C(6B)-C(10B)-N(9B) 104.9(3) 
C(6B)-C(10B)-C(11B) 135.0(3) N(9B)-C(10B)-C(11B) 120.1(3) 
N(12B)-C(11B)-C(10B) 111.0(3) N(12B)-C(11B)-H(11A) 109.4 
C(10B)-C(11B)-H(11A) 109.4 N(12B)-C(11B)-H(11B) 109.4 
C(10B)-C(11B)-H(11B) 109.4 H(11A)-C(11B)-H(11B) 108.0 
C(13B)-N(12B)-C(11B) 116.2(3) N(12B)-C(13B)-C(22B) 118.1(3) 
N(12B)-C(13B)-C(14B) 126.5(3) C(22B)-C(13B)-C(14B) 115.3(3) 
C(21B)-C(14B)-C(15B) 118.2(3) C(21B)-C(14B)-C(13B) 118.3(3) 
C(15B)-C(14B)-C(13B) 123.4(3) C(16B)-C(15B)-C(14B) 120.0(3) 
C(16B)-C(15B)-N(9B) 119.0(3) C(14B)-C(15B)-N(9B) 121.0(3) 
C(17B)-C(16B)-C(15B) 120.5(3) C(17B)-C(16B)-H(16B) 119.8 
C(15B)-C(16B)-H(16B) 119.8 C(16B)-C(17B)-C(18B) 120.0(3) 
C(16B)-C(17B)-H(17B) 120.0 C(18B)-C(17B)-H(17B) 120.0 
C(21B)-C(18B)-C(17B) 118.8(3) C(21B)-C(18B)-C(19B) 119.2(3) 
C(17B)-C(18B)-C(19B) 122.0(3) C(20B)-C(19B)-C(18B) 174.5(4) 
C(19B)-C(20B)-H(20B) 178(3) C(14B)-C(21B)-C(18B) 122.2(3) 
C(14B)-C(21B)-H(21B) 118.9 C(18B)-C(21B)-H(21B) 118.9 
N(27B)-C(22B)-C(23B) 122.3(3) N(27B)-C(22B)-C(13B) 116.5(3) 
C(23B)-C(22B)-C(13B) 121.2(3) C(24B)-C(23B)-C(22B) 119.2(3) 
C(24B)-C(23B)-H(23B) 120.4 C(22B)-C(23B)-H(23B) 120.4 
C(25B)-C(24B)-C(23B) 119.3(3) C(25B)-C(24B)-H(24B) 120.4 
C(23B)-C(24B)-H(24B) 120.4 C(24B)-C(25B)-C(26B) 118.2(3) 
C(24B)-C(25B)-H(25B) 120.9 C(26B)-C(25B)-H(25B) 120.9 
N(27B)-C(26B)-C(25B) 123.7(3) N(27B)-C(26B)-H(26B) 118.2 
C(25B)-C(26B)-H(26B) 118.2 C(26B)-N(27B)-C(22B) 117.4(3) 
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Table 4. Anisotropic displacement parameters (Å2x 103) for KRM-II-81 (cook149). The anisotropic 
displacement factor exponent takes the form: -22[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
O(1A) 33(1)  83(2) 49(2)  8(2) 9(1)  -1(1) 
C(2A) 34(2)  86(3) 47(2)  7(2) 2(2)  -1(2) 
N(3A) 32(2)  70(2) 67(2)  14(2) 12(2)  1(2) 
C(4A) 31(2)  54(3) 50(2)  4(2) 12(2)  6(2) 
C(5A) 33(2)  41(2) 43(2)  -1(2) 8(2)  2(2) 
C(6A) 25(2)  36(2) 45(2)  -4(2) 10(1)  1(1) 
N(7A) 33(2)  36(2) 47(2)  3(1) 11(1)  -2(1) 
C(8A) 30(2)  36(2) 41(2)  0(2) 10(2)  -2(2) 
N(9A) 22(1)  35(2) 44(2)  0(1) 8(1)  -2(1) 
C(10A) 26(2)  33(2) 46(2)  -6(2) 12(1)  -2(1) 
C(11A) 27(2)  36(2) 49(2)  3(2) 10(1)  -4(2) 
N(12A) 28(1)  34(2) 48(2)  3(1) 12(1)  -3(1) 
C(13A) 25(2)  30(2) 49(2)  3(2) 10(2)  0(1) 
C(14A) 25(2)  31(2) 45(2)  -5(2) 7(1)  -3(1) 
C(15A) 25(2)  27(2) 42(2)  -4(2) 5(1)  -3(1) 
C(16A) 27(2)  39(2) 48(2)  -5(2) 14(2)  -5(2) 
C(17A) 20(2)  38(2) 55(2)  -5(2) 8(2)  2(2) 
C(18A) 25(2)  33(2) 49(2)  -3(2) 6(2)  0(1) 
C(19A) 31(2)  38(2) 51(2)  -6(2) 5(2)  2(2) 
C(20A) 45(2)  44(3) 52(2)  -3(2) 7(2)  3(2) 
C(21A) 26(2)  34(2) 43(2)  -2(2) 7(1)  -4(1) 
C(22A) 24(2)  32(2) 49(2)  1(2) 9(1)  3(1) 
C(23A) 32(2)  41(2) 52(2)  7(2) 14(2)  1(2) 
C(24A) 39(2)  60(3) 51(2)  9(2) 22(2)  8(2) 
C(25A) 43(2)  61(3) 47(2)  -7(2) 11(2)  0(2) 
C(26A) 40(2)  54(3) 51(2)  -7(2) 13(2)  -5(2) 
N(27A) 30(1)  43(2) 47(2)  -5(2) 11(1)  -5(1) 
C(1B) 40(2)  47(2) 49(2)  -1(2) 7(2)  -6(2) 
N(2B) 35(2)  54(2) 57(2)  -1(2) -1(2)  6(2) 
C(3B) 24(2)  57(3) 59(2)  -9(2) 1(2)  8(2) 
O(4B) 26(1)  53(2) 54(2)  -1(1) 5(1)  -1(1) 
C(5B) 28(2)  33(2) 48(2)  -4(2) 8(2)  1(2) 
C(6B) 26(2)  36(2) 39(2)  -4(2) 6(1)  0(1) 
N(7B) 32(1)  34(2) 42(2)  -1(1) 7(1)  -1(1) 
C(8B) 25(2)  34(2) 43(2)  2(2) 9(1)  -1(1) 
N(9B) 19(1)  31(2) 40(2)  -2(1) 7(1)  -1(1) 
C(10B) 22(2)  32(2) 44(2)  -7(2) 10(1)  -4(1) 
C(11B) 23(2)  37(2) 45(2)  0(2) 9(1)  -3(1) 
N(12B) 24(1)  35(2) 45(2)  1(1) 9(1)  -3(1) 
C(13B) 25(2)  25(2) 45(2)  2(2) 13(1)  -3(1) 
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Table 4. (continued) 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
 
C(14B) 23(2)  29(2) 43(2)  -4(2) 6(1)  -3(1) 
C(15B) 23(2)  27(2) 37(2)  -3(2) 4(1)  -1(1) 
C(16B) 26(2)  36(2) 45(2)  -2(2) 11(1)  -2(1) 
C(17B) 20(2)  36(2) 49(2)  -5(2) 8(1)  2(1) 
C(18B) 24(2)  32(2) 45(2)  -6(2) 7(1)  1(1) 
C(19B) 29(2)  38(2) 45(2)  0(2) 9(2)  5(2) 
C(20B) 37(2)  48(3) 53(2)  -1(2) 9(2)  5(2) 
C(21B) 26(2)  30(2) 43(2)  -1(2) 9(1)  1(1) 
C(22B) 24(2)  30(2) 43(2)  4(2) 10(1)  2(1) 
C(23B) 27(2)  45(2) 46(2)  2(2) 12(1)  1(2) 
C(24B) 39(2)  53(3) 53(2)  4(2) 22(2)  0(2) 
C(25B) 48(2)  49(2) 44(2)  -2(2) 14(2)  4(2) 
C(26B) 35(2)  42(2) 51(2)  -5(2) 10(2)  -3(2) 
N(27B) 27(1)  37(2) 50(2)  -3(1) 10(1)  -2(1) 
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Table 5. Hydrogen coordinates (x 104) and isotropic displacement parameters (Å2x 103) for KRM-II-81 
(cook149). 
________________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________________ 
 
H(2A) 9243 5692 5246 68 
H(4A) 8811 7070 3592 53 
H(8A) 5511 5974 3643 42 
H(11C) 7023 9739 2877 44 
H(11D) 7852 8878 3096 44 
H(16A) 4747 8149 3161 45 
H(17A) 3866 9562 2437 45 
H(21A) 5393 9425 1368 41 
H(23A) 7483 8029 1224 49 
H(24A) 7326 6764 292 58 
H(25A) 6241 5125 -46 60 
H(26A) 5327 4858 526 58 
H(1B) 2014 7018 124 54 
H(3B) 261 4994 633 58 
H(8B) 4532 6213 1402 40 
H(11A) 2134 3538 1956 42 
H(11B) 2943 2607 2179 42 
H(16B) 5260 4058 1888 42 
H(17B) 6134 2658 2618 42 
H(21B) 4568 2705 3660 39 
H(23B) 2495 4579 3796 47 
H(24B) 2741 5484 4777 56 
H(25B) 3945 6654 5188 55 
H(26B) 4872 6829 4615 51 
H(20B) 6510(20) -240(60) 4250(20) 79(15) 
H(20A) 3500(30) 12390(60) 800(20) 97(19) 
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Table 6. Torsion angles [°] for KRM-II-81 (cook149). 
____________________________________________________________________________ 
C(5A)-O(1A)-C(2A)-N(3A) 0.7(5) O(1A)-C(2A)-N(3A)-C(4A) -0.2(5) 
C(2A)-N(3A)-C(4A)-C(5A) -0.4(5) N(3A)-C(4A)-C(5A)-O(1A) 0.8(4) 
N(3A)-C(4A)-C(5A)-C(6A) -178.9(4) C(2A)-O(1A)-C(5A)-C(4A) -0.9(4) 
C(2A)-O(1A)-C(5A)-C(6A) 178.9(3) C(4A)-C(5A)-C(6A)-C(10A) -20.5(7) 
O(1A)-C(5A)-C(6A)-C(10A) 159.8(3) C(4A)-C(5A)-C(6A)-N(7A) 158.4(4) 
O(1A)-C(5A)-C(6A)-N(7A) -21.3(5) C(10A)-C(6A)-N(7A)-C(8A) 0.1(4) 
C(5A)-C(6A)-N(7A)-C(8A) -179.0(3) C(6A)-N(7A)-C(8A)-N(9A) 1.1(4) 
N(7A)-C(8A)-N(9A)-C(10A) -1.8(4) N(7A)-C(8A)-N(9A)-C(15A) -175.1(3) 
N(7A)-C(6A)-C(10A)-N(9A) -1.2(4) C(5A)-C(6A)-C(10A)-N(9A) 177.8(3) 
N(7A)-C(6A)-C(10A)-C(11A) 176.0(3) C(5A)-C(6A)-C(10A)-C(11A) -5.0(6) 
C(8A)-N(9A)-C(10A)-C(6A) 1.8(4) C(15A)-N(9A)-C(10A)-C(6A) 175.3(3) 
C(8A)-N(9A)-C(10A)-C(11A) -176.0(3) C(15A)-N(9A)-C(10A)-C(11A) -2.4(5) 
C(6A)-C(10A)-C(11A)-N(12A) 115.3(4) N(9A)-C(10A)-C(11A)-N(12A) -67.8(4) 
C(10A)-C(11A)-N(12A)-C(13A) 68.2(4) C(11A)-N(12A)-C(13A)-C(14A) 0.7(5) 
C(11A)-N(12A)-C(13A)-C(22A) 179.7(3) N(12A)-C(13A)-C(14A)-C(21A) 135.5(4) 
C(22A)-C(13A)-C(14A)-C(21A) -43.5(4) N(12A)-C(13A)-C(14A)-C(15A) -46.3(5) 
C(22A)-C(13A)-C(14A)-C(15A) 134.6(3) C(21A)-C(14A)-C(15A)-C(16A) 3.9(5) 
C(13A)-C(14A)-C(15A)-C(16A) -174.3(3) C(21A)-C(14A)-C(15A)-N(9A) -175.2(3) 
C(13A)-C(14A)-C(15A)-N(9A) 6.7(5) C(8A)-N(9A)-C(15A)-C(16A) 28.9(5) 
C(10A)-N(9A)-C(15A)-C(16A) -143.3(3) C(8A)-N(9A)-C(15A)-C(14A) -152.1(3) 
C(10A)-N(9A)-C(15A)-C(14A) 35.8(5) C(14A)-C(15A)-C(16A)-C(17A) -4.3(5) 
N(9A)-C(15A)-C(16A)-C(17A) 174.8(3) C(15A)-C(16A)-C(17A)-C(18A) -0.9(5) 
C(16A)-C(17A)-C(18A)-C(21A) 6.1(5) C(16A)-C(17A)-C(18A)-C(19A) -172.9(3) 
C(17A)-C(18A)-C(21A)-C(14A) -6.6(5) C(19A)-C(18A)-C(21A)-C(14A) 172.5(3) 
C(15A)-C(14A)-C(21A)-C(18A) 1.6(5) C(13A)-C(14A)-C(21A)-C(18A) 179.9(3) 
N(12A)-C(13A)-C(22A)-N(27A) 145.7(3) C(14A)-C(13A)-C(22A)-N(27A) -35.2(4) 
N(12A)-C(13A)-C(22A)-C(23A) -33.6(5) C(14A)-C(13A)-C(22A)-C(23A) 145.5(3) 
N(27A)-C(22A)-C(23A)-C(24A) -1.4(5) C(13A)-C(22A)-C(23A)-C(24A) 177.9(3) 
C(22A)-C(23A)-C(24A)-C(25A) -0.3(6) C(23A)-C(24A)-C(25A)-C(26A) 1.2(6) 
C(24A)-C(25A)-C(26A)-N(27A) -0.7(6) C(25A)-C(26A)-N(27A)-C(22A) -0.9(6) 
C(23A)-C(22A)-N(27A)-C(26A) 1.9(5) C(13A)-C(22A)-N(27A)-C(26A) -177.4(3) 
C(5B)-C(1B)-N(2B)-C(3B) -0.5(4) C(1B)-N(2B)-C(3B)-O(4B) 0.4(4) 
N(2B)-C(3B)-O(4B)-C(5B) -0.1(4) N(2B)-C(1B)-C(5B)-O(4B) 0.5(4) 
N(2B)-C(1B)-C(5B)-C(6B) 179.5(4) C(3B)-O(4B)-C(5B)-C(1B) -0.2(4) 
C(3B)-O(4B)-C(5B)-C(6B) -179.4(3) C(1B)-C(5B)-C(6B)-C(10B) -178.8(4) 
O(4B)-C(5B)-C(6B)-C(10B) 0.2(5) C(1B)-C(5B)-C(6B)-N(7B) 0.6(6) 
O(4B)-C(5B)-C(6B)-N(7B) 179.6(3) C(10B)-C(6B)-N(7B)-C(8B) 0.5(4) 
C(5B)-C(6B)-N(7B)-C(8B) -179.0(3) C(6B)-N(7B)-C(8B)-N(9B) -1.0(4) 
N(7B)-C(8B)-N(9B)-C(10B) 1.1(4) N(7B)-C(8B)-N(9B)-C(15B) 172.0(3) 
N(7B)-C(6B)-C(10B)-N(9B) 0.2(4) C(5B)-C(6B)-C(10B)-N(9B) 179.6(3) 
N(7B)-C(6B)-C(10B)-C(11B) -176.6(3) C(5B)-C(6B)-C(10B)-C(11B) 2.8(7) 
C(8B)-N(9B)-C(10B)-C(6B) -0.8(3) C(15B)-N(9B)-C(10B)-C(6B) -171.9(3) 
C(8B)-N(9B)-C(10B)-C(11B) 176.7(3) C(15B)-N(9B)-C(10B)-C(11B) 5.5(5) 
____________________________________________________________________________ 
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Table 6. (continued) 
____________________________________________________________________________ 
 
C(6B)-C(10B)-C(11B)-N(12B) -118.0(4) N(9B)-C(10B)-C(11B)-N(12B) 65.6(4) 
C(10B)-C(11B)-N(12B)-C(13B) -69.3(4) C(11B)-N(12B)-C(13B)-C(22B) -177.2(3) 
C(11B)-N(12B)-C(13B)-C(14B) 0.5(5) N(12B)-C(13B)-C(14B)-C(21B) -135.6(3) 
C(22B)-C(13B)-C(14B)-C(21B) 42.1(4) N(12B)-C(13B)-C(14B)-C(15B) 47.6(5) 
C(22B)-C(13B)-C(14B)-C(15B) -134.6(3) C(21B)-C(14B)-C(15B)-C(16B) -5.2(5) 
C(13B)-C(14B)-C(15B)-C(16B) 171.5(3) C(21B)-C(14B)-C(15B)-N(9B) 173.6(3) 
C(13B)-C(14B)-C(15B)-N(9B) -9.6(5) C(8B)-N(9B)-C(15B)-C(16B) -26.0(5) 
C(10B)-N(9B)-C(15B)-C(16B) 143.3(3) C(8B)-N(9B)-C(15B)-C(14B) 155.1(3) 
C(10B)-N(9B)-C(15B)-C(14B) -35.5(5) C(14B)-C(15B)-C(16B)-C(17B) 3.5(5) 
N(9B)-C(15B)-C(16B)-C(17B) -175.4(3) C(15B)-C(16B)-C(17B)-C(18B) 2.5(5) 
C(16B)-C(17B)-C(18B)-C(21B) -6.5(5) C(16B)-C(17B)-C(18B)-C(19B) 173.4(3) 
C(15B)-C(14B)-C(21B)-C(18B) 1.1(5) C(13B)-C(14B)-C(21B)-C(18B) -175.8(3) 
C(17B)-C(18B)-C(21B)-C(14B) 4.7(5) C(19B)-C(18B)-C(21B)-C(14B) -175.1(3) 
N(12B)-C(13B)-C(22B)-N(27B) -152.5(3) C(14B)-C(13B)-C(22B)-N(27B) 29.6(4) 
N(12B)-C(13B)-C(22B)-C(23B) 30.2(5) C(14B)-C(13B)-C(22B)-C(23B) -147.8(3) 
N(27B)-C(22B)-C(23B)-C(24B) -1.6(5) C(13B)-C(22B)-C(23B)-C(24B) 175.6(3) 
C(22B)-C(23B)-C(24B)-C(25B) 1.2(6) C(23B)-C(24B)-C(25B)-C(26B) -0.6(6) 
C(24B)-C(25B)-C(26B)-N(27B) 0.3(6) C(25B)-C(26B)-N(27B)-C(22B) -0.6(5) 
C(23B)-C(22B)-N(27B)-C(26B) 1.3(5) C(13B)-C(22B)-N(27B)-C(26B) -176.1(3) 
____________________________________________________________________________ 
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Table 7. Hydrogen bonds for KRM-II-81 (cook149) [Å and °]. 
____________________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________ 
 C(8A)-H(8A)...N(27B) 0.95 2.40 3.314(4) 162.5 
 C(8B)-H(8B)...N(27A) 0.95 2.45 3.361(4) 161.9 
 C(11B)-H(11A)...O(4B) 0.99 2.50 3.173(4) 125.4 
 C(26B)-H(26B)...N(2B)#1 0.95 2.61 3.518(5) 161.0 
____________________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
#1 x+1/2,-y+3/2,z+1/2  
 
710
APPENDIX L. Results from the Psychoactive Drug Screening Program 
 
Table 1. Primary Results 
Note: The PDSP has a low threshold for “hits” at primary assays. They perform a large number 
of secondary assays using a relatively low threshold in order not to miss potential high-affinity 
compounds. The likelihood of an actual, high-affinity, “hit” is still very low. Thus, one should 
not over-interpret results from primary assays. 
 
Data represent mean % inhibition (n = 4 determinations) for compound tested at receptor 
subtypes. Significant inhibition is considered > 50%. In cases where negative inhibition (-) is 
seen, this represents a stimulation of binding. Occasionally, compounds at high concentrations 
will non-specifically increase binding. 
 
The default concentration for primary binding experiments is 10 µM. 
 
Legend: 
1° Assay 
Scheduled Complete 
2° Assay 
Scheduled 2° Assay or Functional Completed 
Redo 
In 
Progress Pending Approval  
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CMPD Code Name 5-HT1A 5-HT1B 5-HT1D 5-ht1e 5-HT2A
473 JY-XHe-053 42 53 45 -15 1
962 HZ-166
1031 XHe-II-053
30605 MP-III-024 12.2 20.1 5.7 13.1 -3
30606 MP-II-064 0.5 11.6 22.6 8 -5.6
30607 MP-II-068 -2.9 2.2 14.3 7.5 14
30608 MP-III-002 5.4 17 12.5 4.8 -1.5
30609 MP-II-075 55 19 18.5 -1.6 -12.1
30611 SH-053-2'F-R-CH3 18 9.3 16.4 -8.8 -10.7
30612 SH-053-2'F-S-CH3 8.5 4.8 12.8 -4.6 19.4
30613 MP-III-004 37.5 0.6 32.5 -3.3 9.4
30614 MP-III-021 18.8 3.3 34.4 -12.5 -0.9
30615 MP-III-019.A -1.4 2.1 37 -9.5 -9.6
30616 MP-III-018.A 8.3 2.4 23.1 -5.8 38.5
30617 MP-III-022 1.7 0.9 9.6 -2 8.8
30618 MP-III-023 6.9 2.3 20.1 -0.3 12.4
30619 SH-I-085 22.9 9.4 14 -12 7
30620 KRM-I-56 2.8 4.3 17.5 -9.1 8.8
30621 KRM-I-55 0.3 -2.3 2.6 -8 6.8
37713 MP-III-068 2.4 5.6 -0.7 3.1 -20
37714 MP-III-080 18.8 11 -3.5 2.2 -11.7
37715 MP-III-085 7.3 2.8 2.4 3.5 -16
37717 SH-053-2'F-R-CH3-Acid 0.8 5.4 -2.3 1.6 -7.2
37718 SH-053-2'F-S-CH3-Acid 7.1 14.2 -2.9 -1 4.8
37719 MP-III-018.B 12 3.1 -2.5 1.6 -0.2
37720 MP-III-019.B 1.5 14.2 -9.2 2.7 17.3
37721 MP-IV-004 8.7 8.2 -7 0.7 32.8
37723 MP-IV-005 19.6 17.3 2.2 -1.1 18.9
37725 MP-IV-010 19.4 28.7 6 -6.7 -0.6
37728 SH-I-085 43.4 28.8 13.9 -9.6 -3.1
37729 KRM-II-18B 51.2 27.6 16 -2.9 3.5
37730 KRM-II-73 43.4 29.3 15.7 -6.8 -3.7
37731 KRM-II-82 56.6 38.8 20.1 -2.7 7.7
37732 KRM-II-97 22.9 5.9 -0.4 -3.3 16.8
37733 KRM-II-81 29.5 -1.6 -0.3 4.9 16
37734 KRM-II-68 15.5 -5.2 3.6 10 20.1
37735 KRM-II-08 9.6 3.6 9.2 1.1 -2.3
37736 KRM-II-3B 17.8 1.2 6.9 -2.7 11
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Code Name 5-HT2B 5-HT2C 5-HT3 5-ht5a 5-HT6 5-HT7 Alpha1A Alpha1B
JY-XHe-053 1 -2 23 14 9 13 12.3
HZ-166
XHe-II-053
MP-III-024 14.5 1.1 -1.3 2.3(AVE) 9.7 1.3 2.8 34.9
MP-II-064 -5.2 2.9 -0.2 7.8(AVE) 43.9 -9.8 0.3 -22.1
MP-II-068 -5.6 29.5 -4.4 13.4(AVE) 36.4 14.4 0.9 6.6
MP-III-002 16.3 27.3 -4.7 -1.3(AVE) 9.5 -4.8 3.1 -8.6
MP-II-075 17.8 11.6 -6 -2.6(AVE) 10.0 5.7 2 -4.1
SH-053-2'F-R-CH3 17.3 17.4 -3.8 11.5(AVE) 16.8 8.2 4.8 -3.7
SH-053-2'F-S-CH3 20.4 23.4 -10.7 4.9(AVE) 8.6 7.9 3.9 -7.1
MP-III-004 44.2 24.5 36.6 -3.9(AVE) 11.1 24.4 7.7 2.4
MP-III-021 36.6 14.6 1.1 1.4(AVE) 4.1 47.8 1.7 -7
MP-III-019.A 50 19.6 -6.5 7.7(AVE) 18.5 32.9 1.3 -4.7
MP-III-018.A 47.3 17.2 -2.9 11.6(AVE) 4.8 38.2 2 -3.6
MP-III-022 10.4 15.8 -1.7 3.5(AVE) 14.1 -1.8 -5.3 39.6
MP-III-023 44.5 35 6.1 9.5(AVE) 20.3 3.2 -11.4 23.4
SH-I-085 54.7 14.8 -5.3 12.2(AVE) 18.8 18.6 -11 22
KRM-I-56 23 5.2 -8.5 10.7(AVE) 13 18.7 -8.8 4
KRM-I-55 66.1 28.1 5.3 10.0(AVE) -4.7 4.8 2 23.4
MP-III-068 -16.8 -4.7 -15.3 -9.2 -15.2 2.6 15.3 15.8
MP-III-080 1.3 92.6 -11.4 11.9 -17.6 18.9 11 3.5
MP-III-085 -6.4 -3.7 -6.6 -0.9 2.8 14.7 5.1 -5.6
SH-053-2'F-R-CH3-Acid -9.7 8.6 -14.4 -1.1 -9.6 0 11.1 -17.4
SH-053-2'F-S-CH3-Acid -8.9 -0.6 -1.2 -6.8 -5 -7.1 2.2 -15.2
MP-III-018.B -8.4 10.2 6.3 3.7 11.2 -1.9 9.3 12.3
MP-III-019.B 0.8 14 0.9 9.4 2.2 4.5 16.7 -3.9
MP-IV-004 -8.2 10.4 0.8 12.2 21.1 3.1 12.9 1.5
MP-IV-005 1.4 11.2 -0.3 11.8 21.6 7 13.2 8.3
MP-IV-010 0.2 -1.9 12.8 11.3 21.2 -5.4 2.1 14.6
SH-I-085 5.9 24.1 3.9 14.6 -0.3 10.2 4.2 27
KRM-II-18B -8.5 21.8 4.9 18.4 8.2 -4.5 4.3 26.1
KRM-II-73 -8.9 24.2 17.3 18.9 -1.7 8.1 -0.2 18.7
KRM-II-82 -11.3 16.4 11.5 14 -5.4 1.8 2.2 27.4
KRM-II-97 -5.5 21.9 13.3 8.1 -1.5 5.4 5.2 17.8
KRM-II-81 -1.5 17.3 6.7 9.4 -1.3 4.3 -9.6 22.3
KRM-II-68 -3.1 10.7 12.5 3.9 7.3 1.7 7.4 9.7
KRM-II-08 8 15.3 18 17.6 11.6 10.9 10.2 27.9
KRM-II-3B 88.9 65.9 -6.7 26.3 20.8 13 2.5 8.1
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Code Name Alpha1D Alpha2A Alpha2B Alpha2C Beta1 Beta2
JY-XHe-053 67 59.3 74.7 9.4 4.3
HZ-166
XHe-II-053
MP-III-024 15.6(AVE) -3 24.3(AVE) -7.4(AVE) 26.8(AVE) 11.4
MP-II-064 5.3(AVE) 12.2 7.0(AVE) 1.2(AVE) 26.3(AVE) 26.5
MP-II-068 -0.8(AVE) 10.3 16.9(AVE) -1.2(AVE) 19.9(AVE) 17.7
MP-III-002 -9.9(AVE) 11.7 9.9(AVE) 1.7(AVE) 1.9(AVE) 0.6
MP-II-075 -6.3(AVE) 14.2 55.0(AVE) 23.5(AVE) 14.9(AVE) 4.3
SH-053-2'F-R-CH3 13.6(AVE) 9.4 9.6(AVE) 18.2(AVE) 30.6(AVE) -1.2
SH-053-2'F-S-CH3 10.7(AVE) 16.6 18.9(AVE) 18.9(AVE) 19.4(AVE) -1.8
MP-III-004 7.5(AVE) 14.4 13.6(AVE) 19.3(AVE) 14.5(AVE) 16.8
MP-III-021 5.4(AVE) 8 10.5(AVE) 1.7(AVE) 21.4(AVE) 22.9
MP-III-019.A 8.5(AVE) -4.8 3.3(AVE) -4.3(AVE) 21.4(AVE) 31.1
MP-III-018.A 12.8(AVE) 11.6 17.1(AVE) 2.9(AVE) 42.9(AVE) 19
MP-III-022 6.7(AVE) 1.9 0.7(AVE) 1.8(AVE) 32.2(AVE) 18
MP-III-023 -1.2(AVE) -1.0 4.3(AVE) 27.5(AVE) 26.5(AVE) 5.6
SH-I-085 26.8(AVE) 8.5 28.3(AVE) 12.8(AVE) 19.2(AVE) 5.2
KRM-I-56 6.1(AVE) 10.5 15.7(AVE) 23.9(AVE) 36.5(AVE) 9.4
KRM-I-55 5.3(AVE) 14.4 9.6(AVE) 10.9(AVE) 25.1(AVE) 16.5
MP-III-068 2.5 5 23.8 -5.2 -19.4 29.4
MP-III-080 -10.5 23 35 1.2 -19.9 8.2
MP-III-085 -18.4 11.7 23.8 -7.3 -16.7 -8.2
SH-053-2'F-R-CH3-Acid -17.9 13.4 -1.7 -10.4 13.2 93.6
SH-053-2'F-S-CH3-Acid -9.1 21.2 16.2 0.9 -5.9 19.7
MP-III-018.B -8.9 5 21.1 -5.3 -14.1 19.2
MP-III-019.B -4.6 29.4 18.3 19.3 -2.1 3.1
MP-IV-004 4.5 22 9.7 3.8 -3.7 7.8
MP-IV-005 5.9 30.5 20.5 20.9 5.6 22.2
MP-IV-010 9 14.1 28.8 30.9 6.4 20.5
SH-I-085 3.6 14.9 37.8 11 -17.1 26.7
KRM-II-18B 12 13.4 23.7 2.6 11.6 -8.2
KRM-II-73 8.6 17 50 20 6.9 -18
KRM-II-82 6.8 16.3 36.3 13.1 -6.6 -10.5
KRM-II-97 13.5 15 79.5 17.6 -4.6 -18.7
KRM-II-81 0.1 20.9 55 0.1 -12.2 -28.4
KRM-II-68 -6.1 14.7 12.2 4.2 -9.6 -12.2
KRM-II-08 -11.6 27.7 2.6 -6.7 -13.3 -7.2
KRM-II-3B -4.7 37.1 26.2 23.7 -6.1 -5.2
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Code Name Beta3 BZP Rat Brain Site Calcium Channel CB1 D1
JY-XHe-053 30.3 59 22
HZ-166
XHe-II-053
MP-III-024 6.0(AVE) 80.2(AVE) 9.4
MP-II-064 -21.1(AVE) 68.9(AVE) 13.6
MP-II-068 19.7(AVE) 95.5(AVE) 28.7
MP-III-002 -5.5(AVE) 90.9(AVE) 6.8
MP-II-075 -3.9(AVE) 97.9(AVE) 35.1
SH-053-2'F-R-CH3 -7.2(AVE) 83.7(AVE) 12.3
SH-053-2'F-S-CH3 0.3(AVE) 91.5(AVE) 11.2
MP-III-004 -12.4(AVE) 76.3(AVE) 16
MP-III-021 -11.0(AVE) 87.3(AVE) 33.2
MP-III-019.A 1.0(AVE) 49.0(AVE) 15.2
MP-III-018.A 7.9(AVE) 93.1(AVE) 14.2
MP-III-022 0.2(AVE) 93.5(AVE) 9.7
MP-III-023 18.5(AVE) 97.0(AVE) 2.4
SH-I-085 15.7(AVE) 98.2(AVE) 26.7
KRM-I-56 15.1(AVE) 97.5(AVE) -5.4
KRM-I-55 0.1(AVE) 96.0(AVE) -6.1
MP-III-068 -2.5 87.6 -4.6
MP-III-080 15.4 88.2 11.1
MP-III-085 -1.3 81.7 4
SH-053-2'F-R-CH3-Acid -6.5 93.4 -10.4
SH-053-2'F-S-CH3-Acid -16.2 92.9 -4.3
MP-III-018.B 6.5 96.6 4.9
MP-III-019.B 16.6 94.1 10
MP-IV-004 14.8 63.4 9.3
MP-IV-005 29.6 67.7 20.5
MP-IV-010 38.2 64.1 27.8
SH-I-085 -0.5 97 19.5
KRM-II-18B -1.4 96.8 12.9
KRM-II-73 -8.5 96.9 26.4
KRM-II-82 -2.9 94.6 18
KRM-II-97 -5.8 93.4 8.1
KRM-II-81 -14 85.6 14.3
KRM-II-68 -7.4 74.8 0.6
KRM-II-08 -12.4 94.8 5.5
KRM-II-3B 5.9 69.4 25.3
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Code Name D2 D3 D4 D5 DAT DOR
JY-XHe-053 9 -36 -5 -1 -8 43.8
HZ-166
XHe-II-053
MP-III-024 3.2(AVE) 3.9(AVE) 14 9.7(AVE) 4.4(AVE) 15.4(AVE)
MP-II-064 4.5(AVE) -8.0(AVE) 34.8 20.1(AVE) 39.9(AVE) 16.8(AVE)
MP-II-068 1.8(AVE) -4.7(AVE) 2.9 19.2(AVE) 31.4(AVE) 22.2(AVE)
MP-III-002 6.6(AVE) 2.4(AVE) 7.6 5.8(AVE) 27.0(AVE) 7.5(AVE)
MP-II-075 17.0(AVE) 16.9(AVE) 14.1 23.6(AVE) 27.6(AVE) 19.1(AVE)
SH-053-2'F-R-CH3 9.6(AVE) 2.4(AVE) 23.1 5.9(AVE) 35.3(AVE) 22.4(AVE)
SH-053-2'F-S-CH3 7.9(AVE) 6.8(AVE) 3.1 25.1(AVE) 38.1(AVE) 25.2(AVE)
MP-III-004 22.7(AVE) 9.6(AVE) -5.5 19.6(AVE) 32.3(AVE) 21.0(AVE)
MP-III-021 20.1(AVE) 7.5(AVE) 4.9 21.7(AVE) 36.9(AVE) 20.2(AVE)
MP-III-019.A 14.3(AVE) -9.8(AVE) 42.5 20.6(AVE) 65.4(AVE) 13.6(AVE)
MP-III-018.A 3.7(AVE) 12.9(AVE) -7.4 8.1(AVE) 34.0(AVE) 27.1(AVE)
MP-III-022 12.6(AVE) 11.1(AVE) -7.1 1.0(AVE) 48.6(AVE) 16.9(AVE)
MP-III-023 14.8(AVE) 6.2(AVE) -15.7 14.1(AVE) 41.6(AVE) 15.0(AVE)
SH-I-085 13.6(AVE) 4.2(AVE) 2 13.9(AVE) 33.6(AVE) 35.2(AVE)
KRM-I-56 0.1(AVE) 6.1(AVE) -15.6 16.1(AVE) 43.4(AVE) 21.7(AVE)
KRM-I-55 4.8(AVE) 9.0(AVE) -21.7 10.8(AVE) 27.5(AVE) 17.9(AVE)
MP-III-068 -10.3 -5 -4.7 -17.2 7.8 18.7
MP-III-080 -5.8 12.1 -0.3 11.7 -6.4 0
MP-III-085 5.7 -0.3 -3.1 -17.2 -2.9 -3.9
SH-053-2'F-R-CH3-Acid -14.8 -4.3 -4.6 -16.2 -1.5 -3.9
SH-053-2'F-S-CH3-Acid -8.4 -2.8 -3.7 -13.3 3.6 17.6
MP-III-018.B 1.3 2.3 -6.5 -9.1 11 9.7
MP-III-019.B -4.8 20.4 -6.2 -0.4 21.8 -9.9
MP-IV-004 -1.1 6.9 -2.9 11.6 32.2 9.8
MP-IV-005 -0.8 10 4.7 30.7 26.6 23.4
MP-IV-010 25.1 15 4.8 28.7 13.5 5.1
SH-I-085 29.4 1.5 -4.5 13.3 17.8 11
KRM-II-18B 13.9 4.6 -1.8 5.9 18.9 20.1
KRM-II-73 21.6 3.3 5 9 19.3 31.7
KRM-II-82 15.4 9.4 7.6 1 20.3 19.6
KRM-II-97 23.6 9.9 3.2 14 21.3 8.3
KRM-II-81 13.6 6.6 -2.8 -7 26.9 15.2
KRM-II-68 16.4 11.2 -1 -8.7 39.5 -6
KRM-II-08 19.1 17 4.3 5.1 -15.2 -7.2
KRM-II-3B -1.7 35.8 -12 -2.9 -17.7 11.9
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Code Name GABA a1 GABAA H1 H2 H3 H4 HERG
JY-XHe-053 99 -12.4 26.2 7.4 -13.8
HZ-166 92.6
XHe-II-053 99
MP-III-024 -14.0(AVE) 36.3 -1.1 4.2 -9.0(AVE)
MP-II-064 -6.5(AVE) 32.4 -14.3 -15.2 -6.4(AVE)
MP-II-068 -12.6(AVE) 48.0 -12 -7.9 16.0(AVE)
MP-III-002 -13.0(AVE) 50.4 -36.6 2.2 25.2(AVE)
MP-II-075 -25.1(AVE) 56.5 3.2 16.2 25.6(AVE)
SH-053-2'F-R-CH3 -12.2(AVE) 35.6 1 -2.6 9.7(AVE)
SH-053-2'F-S-CH3 -12.6(AVE) 50.0 -7 0.4 13.9(AVE)
MP-III-004 -6.0(AVE) 44.5 -9 -6.6 12.9(AVE)
MP-III-021 -13.4(AVE) 44.8 -5.8 -1.8 12.1(AVE)
MP-III-019.A -11.1(AVE) 59.5 8.6 -19.1 20.5(AVE)
MP-III-018.A -10.4(AVE) 53.7 -2.7 -1.2 16.5(AVE)
MP-III-022 -19.5(AVE) 25.5 5.5 12.5 10.4(AVE)
MP-III-023 -24.4(AVE) 17.3 -3.2 12 14.1(AVE)
SH-I-085 -17.7(AVE) 3.2 -5.5 4.8 -6.3(AVE)
KRM-I-56 -5.8(AVE) -9.3 -4.7 9.4 3.1(AVE)
KRM-I-55 -2.9(AVE) -9.3 -10.2 15.5 -4.5(AVE)
MP-III-068 9.4 24.9 12.4 2.3 -3.2
MP-III-080 -0.6 89.3 2.6 7.9 7.1
MP-III-085 -18.2 90.2 -1.9 -5.9 -3.1
SH-053-2'F-R-CH3-Acid -15.2 86.7 -5.4 -1.3 14
SH-053-2'F-S-CH3-Acid -3.8 78 7.7 8 -7.6
MP-III-018.B -14.4 71.3 1.2 3 -1.1
MP-III-019.B -19.4 58.3 -0.8 -0.2 -0.1
MP-IV-004 -8.5 44.1 -6.9 -5.5 8.4
MP-IV-005 -5.6 20.8 0.7 -1.2 5.6
MP-IV-010 -7.6 19 28.2 -17.9 5.7
SH-I-085 -1.2 19.3 11.6 16.2 15.5
KRM-II-18B -11.2 5.1 9.6 22.2 19
KRM-II-73 -17.5 -8.1 0.7 16.6 14.8
KRM-II-82 -15.3 -11.3 19.6 13.1 32.8
KRM-II-97 -14.8 -32.6 -4.7 2.4 15.2
KRM-II-81 -7.9 -13.5 -11.7 8.6 11.7
KRM-II-68 -0.6 4.2 79.1 -1 4.9
KRM-II-08 -19.8 89 1.7 -11.4 20.5
KRM-II-3B -16.1 42.9 -0.7 -6.8
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Code Name HERG binding KOR M1 M2 M3 M4 M5
JY-XHe-053 26 -4.2 12.3 21.8 30.6 6.4
HZ-166
XHe-II-053
MP-III-024 -0.0 40.0(AVE) -10.6 -5.7 12.0(AVE) 3.3(AVE) -1.4
MP-II-064 8.1 35.5(AVE) 5.7 -1.5 -5.7(AVE) -3.5(AVE) 21.7
MP-II-068 -6.9 82.8(AVE) -10.7 16.5 -14.6(AVE) 21.9(AVE) 4.9
MP-III-002 1.1 12.6(AVE) -7.2 11.2 6.8(AVE) -1.6(AVE) -2.6
MP-II-075 14.7 84.1(AVE) -8.4 23.8 16.2(AVE) 4.4(AVE) 2.1
SH-053-2'F-R-CH3 10.6 90.9(AVE) -4.9 17.9 26.1(AVE) 7.7(AVE) 0
SH-053-2'F-S-CH3 15.3 95.7(AVE) -8.5 11.7 12.8(AVE) 12.6(AVE) -1.9
MP-III-004 21.7 80.3(AVE) -7.8 -0.7 7.9(AVE) 1.0(AVE) 3.6
MP-III-021 16.1 97.5(AVE) -6.2 2.9 9.3(AVE) 5.8(AVE) 0.8
MP-III-019.A 15 45.5(AVE) -4.5 2.1 1.7(AVE) 9.2(AVE) 6
MP-III-018.A 27.6 71.1(AVE) -7.2 -3.2 2.3(AVE) 43.3(AVE) 8.3
MP-III-022 25.3 87.0(AVE) -11.4 4.7 -0.9(AVE) -3.9(AVE) 5.7
MP-III-023 9.4 96.1(AVE) -2.2 10 9.1(AVE) -2.3(AVE) 2.6
SH-I-085 4.1 95.6(AVE) -10.2 0.6 10.8(AVE) 1.4(AVE) 2.4
KRM-I-56 37.6 7.6(AVE) -2 -2.6 14.5(AVE) 0.3(AVE) 6.3
KRM-I-55 -10.8 2.7(AVE) -5.2 0.3 19.7(AVE) 1.6(AVE) 6
MP-III-068 -10.5 28.5 7.2 19.5 15.4 18.2 -2.7
MP-III-080 5.3 46.6 4 25.9 7.8 26.6 11.5
MP-III-085 -6.4 40.2 6.2 16.3 3.3 29.4 -5.9
SH-053-2'F-R-CH3-Acid 0.7 16.4 11.9 21.1 8.6 29 -3.9
SH-053-2'F-S-CH3-Acid -4.4 20.1 5.8 20.7 12.3 20.7 -0.1
MP-III-018.B 0.4 50.9 10.6 50 16.7 29.7 6.6
MP-III-019.B 2 62.1 4.2 50 8.1 28.6 14.1
MP-IV-004 18.6 86 -9.8 26.5 -5.5 27.7 12.4
MP-IV-005 18.5 89.3 -11.3 22.3 7.3 22.2 12
MP-IV-010 28.8 93.6 -11.2 10.5 -0.4 8.4 26.2
SH-I-085 17.8 91.3 -3.4 17.1 -3.9 14.2 28.2
KRM-II-18B 17.6 88.9 -1.4 4.9 7.7 9 30.5
KRM-II-73 17.9 83.1 -4.5 6.6 4.9 15.4 50
KRM-II-82 16.3 77.9 -4.3 0 3.8 13.5 33.5
KRM-II-97 20 61.6 10.1 3.5 6.7 12 38.3
KRM-II-81 -16.4 45.9 3.2 2.4 -8.9 11.2 37.5
KRM-II-68 6.1 20.3 6.9 0.1 -8.3 12.8 26.2
KRM-II-08 3 80.2 11.8 3.5 -0.1 18 25.4
KRM-II-3B -9.2 54.7 -5 -1.3 15.2 -7.5 10.3
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Code Name mGlur5 MOR NET NMDA Oxytocin PBR SERT
JY-XHe-053 5 46 -7.2(AVE) 103.0
HZ-166
XHe-II-053
MP-III-024 -1.8 -5.4(AVE) -1.6 20.4 20.8(AVE) -1.3
MP-II-064 -19.8 -1.4(AVE) 2.5 14.3 38.4(AVE) 8.9
MP-II-068 36.5 10.0(AVE) -3.6 4.5 59.5(AVE) -13.2
MP-III-002 10.1 7.4(AVE) -11 8.1 24.0(AVE) -7.4
MP-II-075 -18.5 8.4(AVE) -0.1 24.1 81.8(AVE) -11.5
SH-053-2'F-R-CH3 31.7 15.7(AVE) -11.3 13.9 12.3(AVE) -14.3
SH-053-2'F-S-CH3 24.8 15.6(AVE) -5.5 18.1 18.2(AVE) -9.5
MP-III-004 4.8 -2.2(AVE) -14.2 42.1 30.1(AVE) -12.5
MP-III-021 -5.1 2.1(AVE) -11.8 16.8 25.5(AVE) -9
MP-III-019.A -7.3 2.7(AVE) -22 15.9 22.5(AVE) -4.2
MP-III-018.A 54.4 8.8(AVE) -6.4 7.6 1.9(AVE) 5.4
MP-III-022 29.1 4.1(AVE) -11.4 12.5 16.6(AVE) -6.1
MP-III-023 -0.6 -5.7(AVE) 7.9 21.8 15.1(AVE) -10
SH-I-085 28.6 10.8(AVE) -26.8 30.2 60.4(AVE) 1.1
KRM-I-56 39 9.0(AVE) 60.4 37 11.1(AVE) -11.8
KRM-I-55 -16.9 2.7(AVE) 39.8 55.3 -2.6(AVE) -9.9
MP-III-068 24.8 -11.3 61.8 -12.7
MP-III-080 -1.1 -3.4 84.8 -13.4
MP-III-085 -4.3 -17.8 75.2 40.7
SH-053-2'F-R-CH3-Acid -9.2 11.4 12.8 -26.8
SH-053-2'F-S-CH3-Acid -2.5 38.9 17.7 2.1
MP-III-018.B 2 38.5 22.3 -5.4
MP-III-019.B 2 32.8 34.4 -2
MP-IV-004 7 19 47.6 10.9
MP-IV-005 20.6 27.2 38.2 13.3
MP-IV-010 32.7 -2.2 27.7 21.7
SH-I-085 10.9 -12.1 80.3 6.4
KRM-II-18B 10.9 -2.2 38.4 11.5
KRM-II-73 10.5 16.6 67.9 3.5
KRM-II-82 5.4 9.8 42.7 21.1
KRM-II-97 18.1 26.6 93.4 0.7
KRM-II-81 6.5 41.1 93.1 -9.1
KRM-II-68 6.1 37.3 37.8 -3.7
KRM-II-08 5 38.3 81.6 7.7
KRM-II-3B -12.3 39.4 66.5 33.4
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Code Name Sigma 1 Sigma 2 V1A V1B V2
JY-XHe-053 -6 -18 -13
HZ-166
XHe-II-053
MP-III-024 16.5(AVE) -22.7(AVE) 7.2 10.5 4.6
MP-II-064 9.1(AVE) 0.1 10.6 18.1 3.7
MP-II-068 -2.0(AVE) 2.3 13.8 -7.4 6
MP-III-002 6.4(AVE) -15.9(AVE) 6.7 18.6 8.3
MP-II-075 4.3(AVE) -18.4 11.7 24.1 17.9
SH-053-2'F-R-CH3 -5.3(AVE) -2.8 9.2 31.3 2
SH-053-2'F-S-CH3 -3.0(AVE) -5.0 10.7 32.3 7.5
MP-III-004 7.5(AVE) -7.1 4.7 18.1 5.6
MP-III-021 8.9(AVE) 5.5 9.7 13.2 9.1
MP-III-019.A 3.2(AVE) -22.5(AVE) 7.1 10 6.6
MP-III-018.A -0.7(AVE) -8.4 17.4 -2.5 8.6
MP-III-022 -8.1(AVE) -7.6 5.4 17.9 15.7
MP-III-023 -15.3(AVE) -9.9 10 23.1 14.1
SH-I-085 -12.7(AVE) 30.3 14.6 44.7 4.2
KRM-I-56 9.8(AVE) -1 18.4 48 8
KRM-I-55 -5.6(AVE) -5.1 8.8 26.8 9.3
MP-III-068 25.5 -16.6
MP-III-080 36.3 24.1
MP-III-085 25 59.1
SH-053-2'F-R-CH3-Acid 0.5 -3.3
SH-053-2'F-S-CH3-Acid 12.6 -3.8
MP-III-018.B 18.5 11.6
MP-III-019.B 28 26.2
MP-IV-004 22.2 62.4
MP-IV-005 25.3 63.2
MP-IV-010 34.9 64.2
SH-I-085 11.6 44.8
KRM-II-18B -1.5 45.8
KRM-II-73 6.3 58.1
KRM-II-82 -5.5 47.5
KRM-II-97 -13.1 30.7
KRM-II-81 -14.9 34.5
KRM-II-68 -8.2 14.9
KRM-II-08 -6.3 41.5
KRM-II-3B 17.5 54.6
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Table 2. Secondary Results 
Unless otherwise indicated (see Note), data represent Ki (nM) values obtained from non-linear 
regression of radioligand competition binding isotherms. Ki values are calculated from best fit 
IC50 values using the Cheng-Prusoff equation. 
 
Note: When the Hill coefficient (nH) is significantly different from -1 (assessed by F test), the 
IC50 and nH are reported instead of the Ki. 
A * next to a value denotes IC50. 
 
Legend: 
Complete 
2° Assay 
Scheduled 
1° Assay 
<50% Redo 
In 
Progress Pending Approval 
Under 
Review  
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CMPD Code Name 5-HT1A 5-HT1B 5-HT2B 5-HT2C
473 JY-XHe-053 >10000
962 HZ-166
1031 XHe-II-053
30605 MP-III-024
30606 MP-II-064
30607 MP-II-068
30608 MP-III-002
30609 MP-II-075 2,062.00
30611 SH-053-2'F-R-CH3
30612 SH-053-2'F-S-CH3
30613 MP-III-004
30614 MP-III-021
30615 MP-III-019.A >10,000
30616 MP-III-018.A
30617 MP-III-022
30618 MP-III-023
30619 SH-I-085 >10,000
30620 KRM-I-56
30621 KRM-I-55 3,665.00
37713 MP-III-068
37714 MP-III-080 1,319.0(AVE)
37715 MP-III-085
37717 SH-053-2'F-R-CH3-Acid
37718 SH-053-2'F-S-CH3-Acid
37719 MP-III-018.B
37720 MP-III-019.B
37721 MP-IV-004
37723 MP-IV-005
37725 MP-IV-010
37728 SH-I-085
37729 KRM-II-18B 3,372.0(AVE)
37730 KRM-II-73
37731 KRM-II-82 2,383.7(AVE)
37732 KRM-II-97
37733 KRM-II-81
37734 KRM-II-68
37735 KRM-II-08
37736 KRM-II-3B 852.5(AVE) 1,066.5(AVE)
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Code Name Alpha2A Alpha2B Alpha2C Beta1 Beta2
JY-XHe-053 3,484.00 3,975.00 2,105.00
HZ-166
XHe-II-053
MP-III-024
MP-II-064
MP-II-068
MP-III-002
MP-II-075 1,760.00
SH-053-2'F-R-CH3
SH-053-2'F-S-CH3 7,214.00
MP-III-004
MP-III-021 >10,000
MP-III-019.A >10,000
MP-III-018.A >10,000
MP-III-022
MP-III-023 >10,000
SH-I-085
KRM-I-56 >10,000
KRM-I-55
MP-III-068
MP-III-080
MP-III-085
SH-053-2'F-R-CH3-Acid >10,000
SH-053-2'F-S-CH3-Acid
MP-III-018.B
MP-III-019.B
MP-IV-004
MP-IV-005
MP-IV-010
SH-I-085
KRM-II-18B
KRM-II-73 4,565.7(AVE)
KRM-II-82
KRM-II-97 834.3(AVE)
KRM-II-81 2,876.7(AVE)
KRM-II-68
KRM-II-08
KRM-II-3B
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Code Name BZP Rat Brain Site CB1 DAT GABA a1 H1 H2
JY-XHe-053 4,771.00 47.4
HZ-166
XHe-II-053
MP-III-024 277
MP-II-064 590 >10,000
MP-II-068 42 >10,000
MP-III-002 109 7,603.00 >10,000
MP-II-075 21 >10,000
SH-053-2'F-R-CH3 379 >10,000
SH-053-2'F-S-CH3 111 >10,000 >10,000
MP-III-004 445
MP-III-021 219
MP-III-019.A 3,246.00 6,482.00 >10,000
MP-III-018.A 139 5,857.00 >10,000
MP-III-022 83 >10,000
MP-III-023 37 >10,000
SH-I-085 11 >10,000
KRM-I-56 2.8 >10,000
KRM-I-55 29
MP-III-068 244.7(AVE)
MP-III-080 263.3(AVE) 9,156.7(AVE)
MP-III-085 339.0(AVE) 10,000.0(AVE)
SH-053-2'F-R-CH3-Acid 32.3(AVE) 10,000.0(AVE)
SH-053-2'F-S-CH3-Acid 52.7(AVE) 10,000.0(AVE)
MP-III-018.B 27.7(AVE) 924.3(AVE)
MP-III-019.B 88.3(AVE) 10,000.0(AVE)
MP-IV-004 941.0(AVE)
MP-IV-005 710.0(AVE)
MP-IV-010 1,051.0(AVE)
SH-I-085 10.8(AVE)
KRM-II-18B 38
KRM-II-73 56.0(AVE)
KRM-II-82 134.7(AVE)
KRM-II-97 150.3(AVE)
KRM-II-81 382.0(AVE)
KRM-II-68 475.7(AVE) 3,516.00
KRM-II-08 6.4(AVE) 9,333.3(AVE)
KRM-II-3B 1,114.0(AVE) 1.2
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Code Name KOR M2 M4 M5 mGlur5
JY-XHe-053
HZ-166
XHe-II-053
MP-III-024
MP-II-064
MP-II-068 550
MP-III-002
MP-II-075 547
SH-053-2'F-R-CH3 240
SH-053-2'F-S-CH3 90
MP-III-004 599
MP-III-021 122
MP-III-019.A 3,367.00
MP-III-018.A 1,182.00 >10,000 1,358.0(AVE)
MP-III-022 381
MP-III-023 119
SH-I-085 162
KRM-I-56
KRM-I-55
MP-III-068
MP-III-080
MP-III-085
SH-053-2'F-R-CH3-Acid
SH-053-2'F-S-CH3-Acid
MP-III-018.B 3,072.0(AVE) 10,000.0(AVE)
MP-III-019.B 2,621.0(AVE) 10,000.0(AVE)
MP-IV-004 637.0(AVE)
MP-IV-005 379.5(AVE)
MP-IV-010 149.0(AVE)
SH-I-085 219.5(AVE)
KRM-II-18B 375.5(AVE)
KRM-II-73 900.5(AVE) 10,000.0(AVE)
KRM-II-82 1,084.0(AVE)
KRM-II-97 2,102.5(AVE)
KRM-II-81
KRM-II-68
KRM-II-08 713.0(AVE)
KRM-II-3B 3,627.0(AVE)
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Code Name NET Oxytocin PBR SERT Sigma 2
JY-XHe-053 >10000
HZ-166
XHe-II-053
MP-III-024
MP-II-064
MP-II-068 1,671.00
MP-III-002
MP-II-075 439
SH-053-2'F-R-CH3
SH-053-2'F-S-CH3
MP-III-004
MP-III-021
MP-III-019.A
MP-III-018.A
MP-III-022
MP-III-023
SH-I-085 1,226.00
KRM-I-56 644
KRM-I-55 >10,000
MP-III-068 2,501.3(AVE)
MP-III-080 943.5(AVE)
MP-III-085 2,241.5(AVE) 6,994.3(AVE)
SH-053-2'F-R-CH3-Acid
SH-053-2'F-S-CH3-Acid
MP-III-018.B
MP-III-019.B
MP-IV-004 1,730.0(AVE)
MP-IV-005 2,054.3(AVE)
MP-IV-010 2,070.5(AVE)
SH-I-085 1,338.0(AVE)
KRM-II-18B
KRM-II-73 3,318.0(AVE) 1,579.7(AVE)
KRM-II-82
KRM-II-97 311.0(AVE)
KRM-II-81 560.0(AVE)
KRM-II-68
KRM-II-08 1,055.0(AVE)
KRM-II-3B 3,757.7(AVE) 3,061.3(AVE)
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